,ticker,content
0,ISRG,abaxis abax have relative strength rs rating upgrade monday proprietary rating track market leadership used worst best score identify stock price action last week match rest market decade market research show best perform stock tend have rs rating north begin biggest run look best stock buy watch start hereabaxis have rise more past entry first stage consolidation meaning now proper buy range look stock offer new chance pick share week tight pullback day week move average top bottom line growth moved higher last quarter earning be compare prior report revenue increase abaxis hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
1,ISRG,american century growth fund twcgx be feel oat fund be year go thursday thank part gain aerospace giant boee ba year video game provider activision blizzard atvi robotic surgical system maker intuitive surgical isrg fund gain be better double year average annual gain top average year large cap growth rival track morningstar direct well gain information technology consumer staple be fund first fifth largest sector nov weighting respectively reflect outlook expressed manager gregory woodham justin brown note commentary growth prospect appear strong tech valuation consumer staple be compelling factor matter manager seek invest company fundamental be strong improve share price performance do not fully reflect trait activision be fund tech holding so be facebook fb apply material amat latter happen be member ibd list top perform growth stock facebook be also member leaderboard ibd premium service spotlight play play move top stock trading facebook share be so far year ibd reader see facebook be buy range prior flat base buy point big volume nov slide be bad sign stock be hold so far number daily active facebook user have climb facebook grow mobile platform be pull bulk company total advertising revenue manager activision video game publisher think continue benefit ongoing shift online subscription model away reliance console base video game shift subscription model tend boost business margin american century research show capital spending semiconductor company be rise apply material be semiconductor equipment provider be see rapid growth due increase demand chip used artificial intelligence big datum application growth fund manager tell shareholder ibd take apple alphabet google microsoft other be race develop artificial intelligence hardware software bookmark ibd ai page follow latest development consumer staple fund manager note dollar tree dltr be buck trend weakness brick mortar retailer dollar tree benefit focuse lower income consumer manager say company have boost result due acquisition family dollar chain dollar tree share be so far year earning share grow past quarters wal mart store wmt earning share inched modest past quarters reflect competitive challenge face brick mortar retailer general compete online retailer such amazon amzn be also hold american century fund wal mart sale rise past stanzas yet wal mart share be so far year such bullishness investor third quarter report last month wal mart commerce sale jump gross merchandise volume leap company appear be learn compete online ibd recently report wal mart acquisition jet com have beef online capability acquisition such modcloth bonobos moosejaw be help megastore build indie fashion cred enabled firm beat forecast last month give upbeat holiday quarter guidance wal mart also announce last month start sell lord taylor department store product walmart com broaden assortment product fashionable apparel ibd have report american century growth appear poise continue run aim leadership stock largest holding have ibd composite rating so do top new buy third top new buy have comp rating ibd composite rating be score scale stock poise move higher often have comp rating higher related new tax bill affect need much retirement saving age income
2,ISRG,important metric look stock be higher relative strength rating hill hrc now clear threshold jump friday ibd proprietary rating identify market leadership worst best score rating show stock price movement last week hold other stock database decade market research show best stock typically have rs rating launch biggest price move look best stock buy watch start herehill have climb more past entry second stage cup handle meaning now proper buy zone look stock create new chance pick share week tight pullback day week move average company show earning growth latest quarterly report sale growth come company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
3,ISRG,index other major average hit record high wave earning weaker dollar greenback rebound somewhat netflix nflx sky-rocket blowout subscriber growth bullish outlook celgene celg buy juno therapeutic juno intel intc surge earning outlook texas instrument txn other top chip fail impress quarterly financial apple aapl continue lag grow chorus concern regard iphone sale production airline stock plunge unite airline ual say expand rapidly set stage renew price war index dow industrial nasdaq rally solidly hit fresh record high earning season heated fall dollar have act tailwind multinational stock profit rebound year lows thursday president trump say expect stronger greenback netflix nflx be big earning winner intel intc also do texas instrument txn lam research lrcx be several lead chip stock struggle earning airline stock plunge unite airline ual apple aapl iphone related stock sell several analyst cite evidence weaker iphone demand share rocket record high netflix nflx add stream subscriber worldwide crush fourth quarter target internet tv stream giant end total stream subscriber analyst predict netflix subscriber gain come netflix implement price hike service plan europe netflix credit hit original content such tv series stranger thing crown movie bright subscriber gain period march quarter netflix be predict add net new subscriber chipmaker intel intc maxim integrate product mxim stm xilinx xlnx beat december quarter target get mixed reviews investor texas instrument txn post line result share be punish sector continue wrestle concern chip cycle have ebb top chip gear maker lam research lrcx kla tencor klac beat view sell news meanwhile xilinx joined nvidia nvda amd amd benefit sale high performance chip mining bitcoin other cryptocurrency related intel beat fourth quarter target offer cheery outlookbiotech merger heated celgene celg agree pay car drug developer juno therapeutic juno didn already own sanofi sny reach deal biogen biib hemophilia spinoff bioverativ bivv celgene acquisition come prepare lose exclusivity cancer drug revlimid juno rival gilead science gild novartis nvs make car drug treat blood cancer sanofi deal follow fail merger early wednesday novartis nvs report core earning share sale respective constant currency basis easily beating consensus thursday biogen biib report sale grow top consensus adjust earning grow be short also thursday celgene beat lower analyst view abbvie abbv friday top expectation adjust profit sale climb sale unite airline ual send airline stock tailspin carrier tell analyst plan expand flight coverage investor fear move do part regain relevance smaller city unite once abandon risk more competition cheaper fare help passenger threaten profit american airline aal earning call signale wouldn change profit growth target base unite ambition now southwest airline luv jetblue jblu alaska air alk also report general electric ge miss earning disclose sec probe core unit do well ge keep outlook industrial member dow industrial caterpillar cat mmm unite technology utx report strong earning guidance insurer traveler trv consumer product giant procter gamble pg also beat earning view verizon vz miss ep top revenue johnson johnson jnj top view fall patent ruling vs blockbuster arthritis fighter remicade president trump slap tariff import large washing machine part solar panel tax washing machine decrease then expire year duty solar cell module phase year solar technology provider suniva solarworld charge china be provide unfair subsidy financing solar producer whirlpool whr complain korean maker be dump washing machine excessively low price whirlpool also report quarterly earning rally first solar fslr initially pop close less china base daqo new energy dq lose crude top barrel brent edge briefly oil inventory continue drop oilfield service provider halliburton hal crushed quarterly forecast international growth outpace domestic growth share shot clear buy point baker hughe bhge edge past earning estimate be upbeat spending customer share fall nearly market price possibility ge fully spin business northrop grumman noc raytheon rtn general dynamic gd top profit forecast raytheon general dynamic miss revenue northrop give strong guidance lift dividend raytheon gd say order backlog be strong defense firm surge record high lockheed martin lmt boee ba report next week steel dynamic stld earning rise top view modestly sale climb rank company ibd steel producer industry group say be shape be good year thank more moderate inventory level improvement global demand pricing incremental investment drive tax cut specialty steel producer allegheny technology atus nearly double profit estimate revenue grow fuel high performance material jet engine freeport mcmoran fcx benefit higher copper price boost earning ahead estimate revenue grow negotiation indonesia ownership massive grasberg mine be progress haven erased uncertainty company outlook casino operator wynn resort wynn la vegas sand lvs put result beat top bottom line help rebound macau world largest gaming market sand ceo sheldon adelson cite acceleration mass gaming market chinese administrative region only area nation gamble be legal wynn share plunge friday erase nearly weekly gain report allegation serious sexual misconduct ceo steve wynn ford motor see ep climb cent revenue grow analyst have expect ep cent sale accord zack investment research ford be buy mobility startup autonomic transloc share extend sell prior week ford outlook disappoint investor fiat chrysler fcau deliver strong result generally affirm ambitious financial target send share fresh week high new oriental education edu logged ep growth short view sale gain narrowly beat fiscal estimate student enrollment grow china base school education provider offer guide sale view higher share tumble recoup loss end week tal education tal meanwhile surge nearly thursday retake day ep jump revenue growth tal enrollment swell td ameritrade amtd trade financial etfc beat top bottom line fiscal earning share jump td ameritrade revenue expand see full year earning exclude item vs expectation td ameritrade also say allow customer buy sell certain etfs day week trade report ep revenue ll also acquire retail brokerage account capital financial cof asset share online broker fall modestly week millennial focuse free investing app robinhood let person buy sell bitcoin other cryptocurrency commission intuitive surgical isrg report adjust income share sale rise respective metric top expectation robot surgery gear maker give cautious guidance homebuilder nvr nvr miss earning sale view share tumble crash week line first time more year huge volume doj subpoena mortgage unit lennar len bigger expect new home sale decline other homebuilder also suffer notable decline
4,ISRG,many same exchange trade fund perform best last year continue lead broader market so far year continue xprospect wall street new year likely depend largely effect tax overhaul potentially higher interest rate rate hike year next year be appropriate cleveland federal reserve bank president loretta mester say thursday slightly faster pace fed official prefer speaking fed senate democrat agree temporary bridge measure government shutdown be poise go effect midnight friday list top perform etfsark invest ceo catherine wood bitcoin tech stockstop etf pick tax overhaul likely boost economy be already run full capacity say richard turnill blackrock global chief investment strategist lower taxe capital spending incentive lead more consumer business spending overhaul tax code include supply side reform inject significant term demand stimulus economy run full employment note recent commentary faster grow accelerate global growth result rise inflation higher treasury yield steeper yield curf overall see strong earning momentum home head like financial technology dividend grow stock let take look last year winner be do note re only few week new year etfs be rank performance instead year date so year date return be more tell now last year diversify stock winner continue outperform past month top etf ishare edge msci usa momentum factor mtum return ytd innovator ibd ffty come second be close gain pair ark invest fund ark innovation arkk ark web arkw top sector fund category last year gain accord morningstar direct ve also continue outperform broader market jan arkk arkw post ytd return respectively vs be first etfs significant exposure bitcoin investment trust gbtc make top holding last year investment trust have suffer steep decline year be longer fund biggest name arkk top include tesla tsla stratasys ssys juno therapeutic juno arkw top holding include amazon amzn twitter twtr nvidia nvda global robotic artificial intelligence botz place sixth last year boast biggest ytd return jan fund track indxx global robotic artificial intelligence thematic index target company involved industrial robotic automation nonindustrial robot autonomous vehicle japan account botz asset greater asia region north america make greater europe botz biggest holding be japan yaskawa electric fanuc keyence well graphic chip designer ai player nvidia intuitive surgical isrg make da vinci surgical robot robotic focuse etf robo global robotic automation robo have return year fund have greater exposure north america nearly greater asia represent japan greater europe make rest top holding include roomba maker irobot irbt laser company ipg photonic ipgp yaskawa fanuc foreign stock arena kraneshare csi china internet kweb see biggest ytd gain score second best performance category last year return last year fund emqq emerge market internet ecommerce emqq be close gain year related alternative etfs help hedge portfolio market riskmoney manager play offense defense favor sector
5,ISRG,nasdaq composite outperformed friday uneventful session see dow jone industrial lag mostly due weakness ibm ibm american express axp report earning ibm gap fall report rise sale news be offset gross margin operate margin come view american express meanwhile lose nearly report earning announce suspend share buyback program first half nasdaq end shorten week trading gain nearly picked dow add major stock index extend weekly streak shrug threat possible government shutdown small cap be star day russell jump not far crack level dollar be weak again year low year treasury yield add basis point fang name amazon com amzn give back early gain still rise news raise monthly prime membership netflix nflx meanwhile get flurry price target hike ahead earning report monday close share rise less ahead result stock market today nvidia nvda be nice gainer nasdaq help positive comment bofa lynch share rise late stage base be work well so far biotech space share acorda therapeutic acor jump news be acquisition target biogen biib earning biogen be still buy range buy point be due thursday open outperformance growth stock start year have be sight behold ibd be driver seat again friday nearly half name list more leaderboard name ibd component floor decor fnd hit time high rise more breakout basis be sparse retailer big lot big pass muster rise end week well buy range entry earning season start kick gear report due netflix intuitive surgical isrg lam research lrcx well dow component johnson johnson jnj traveler trv related ibm turn corner result concern profit arisenetflix intuitive surgical set report earning season ramp upapple iphone end life predict production cut see
6,ISRG,idexx laboratory idxx have relative strength rs rating upgrade wednesday welcome improvement still short higher score prefer see exclusive rating investor business daily identify market leadership worst best score grade show stock price performance last week stack other stock database history reveal stock go make biggest gain typically have rs rating early stage move see idexx laboratory continue show renew price strength clear threshold look best stock buy watch start hereidexx laboratory be still buy zone move past buy point consolidation once stock move higher initial entry consider proper buy zone earning growth decline most recent report sale moved higher look next report feb company earn rank peer medical system equipment industry group intuitive surgical isrg be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
7,ISRG,welcome move steris ste see relative strength rating improve tuesday proprietary rating measure market leadership show stock price action last week compare other stock database decade market research show best stock typically have rs rating least early stage move see steris continue rebound hit benchmark see ibd help make more money stockssteris be build flat base buy point see stock break heavy volume earning growth fall last quarter revenue moved higher company be expect report latest performance number feb steris earn rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd cutera cutr be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
8,ISRG,dow marked new record high thursday stock extend early gain apple aapl remain track end day slide spdr dow jone industrial average dium spdr spy powershare qqq trust qqq be small cap lead ishare core small cap ijr ishare russell iwm soar respectively apple climb continue find support day move average have clear flat base buy point dec pull back iphone maker report quarterly result feb close energy homebuilder retail be top sector fund gainer stock market today oil etfs surge west texas intermediate oil price rise barrel spdr oil gas exploration production xop leap vaneck vector oil service oih add xop be highest level nearly month oih be trading best level april gold play also gain underlie commodity future real estate utility consumer staple lag bitcoin extend loss accord coindesk digital currency be earlier rise bitcoin investment trust gbtc sank poise extend decline fourth straight session south korea bitcoin biggest market say work bill ban cryptocurrency trading robot artificial intelligence be longer science fiction fantasy company irobot irbt nvidia nvda be practically household name investor look own share such company take look robo global robotic automation robo exchange trade fund be extend mid december rebound day move average remain potential buy range flat base entry robo have advanced recent pullback day prior share rise mid july bounce support line nov intraday high year old fund track robo global robotic automation index have attract north america account biggest regional weighting jan nearly asset accord morningstar direct greater asia be next japan represent more third region greater europe make remain top holding stock portfolio include laser maker ipg photonic ipgp offshore oil gas outfit oceaneering international oii clean robot maker irobot irbt japan fanuc daifuku further list be name such zebra technology zbra intuitive surgical isrg graphic chip designer nvidia component be roughly equal weight ibd take make money catch etf uptrend require knowledge read chart learn ibd university nvidia be big winner last year score gain notch return so far year santa clara base company make splash early week consumer electronic show la vegas announce uber self drive partner well new deal volkswagen vklay baidu bidu fund be lead broader market so far year return jan vs robo year gain year average annual return also beat benchmark index clock respective advance period etf carry expense ratio robotic play global robotic artificial intelligence botz be also buy range flat base entry ideal buy point be fund be featured etf column jan stage solid rebound day line share be support line botz top holding jan include nvidia fanuc intuitive surgical daifuku related apple wal mart be just buy point flash key warningchina hit stock buffett vs bitcoin new high cannabis stock market close record high be bitcoin longer fraud robotic etf tap growth manufacturing drone other areasai bitcoin radar niche etf help
9,ISRG,relative strength rs rating omnicell omcl moved new percentile monday get lift proprietary rating track market leadership used worst best score indicate stock price performance trail week compare rest market decade market research show best perform stock often have better rs rating early stage move see omnicell continue show renew price strength clear threshold look winning stock try simple routineomnicell be build cup handle buy point see stock clear price volume least average take look top bottom line number omnicell have post rise ep growth last report sale growth have also increase same time frame omnicell earn rank peer medical system equipment industry group cantel medical cmd cutera cutr intuitive surgical isrg be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
10,ISRG,be orderly day trading major stock index monday perfectly fine performance bull nasdaq composite jump last week higher volume so call fang name facebook fb amazon com amzn netflix nflx alphabet googl outperformed gain range facebook
11,ISRG,monday lead drugmaker abbvie abbv announce positive phase trial result psoriasis treatment risankizumab tuesday ibd big cap be fractionally potential new buy zone result ongoing study show nearly half risankizumab patient achieve complete skin clearance pasi vs
12,ISRG,perhaps not well know ibd big cap member intuitive surgical isrg maker da vinci surgical system cantel medical cmd share ranking robot assist surgery pioneer medical system equipment industry group xcantel medial provide infection prevention product service specialize endoscopy water purification filtration health care disposable
13,ISRG,intuitive surgical isrg pop record high friday frigid investor warm third quarter sale earning beat come partially back defer revenue tax benefit xby close bell stock market today intuitive climb finish earlier rise much late thursday follow earning release intuitive sank more crush sale earning expectation quarter intuitive report sale adjust earning share easily top consensus grow respective vs year period sale however benefit revenue defer customer trade program adjust income be bulk cent tax benefit cent benefit trade program even benefit sale earning still have beat estimate firm also raise procedure gross margin guidance rbc analyst brandon henry write note client year intuitive see gross margin certain item earlier view see growth procedure ibd take earning season be kick earnest next week number stock keep tab day action visit ibd investing action plan henry boost price target intuitive keep sector perform rating overall intuitive surgical continue aggressively spending accelerate development work several pipeline technology expand total addressable market allow company remain premium player surgical robotic market new upcoming competition write quarter system placement be better expect globally write note client worldwide intuitive place system internationally analyst view respectively morgan stanley analyst david lewis note expectation be high go quarter intuitive surgical deliver even adjust deferral time tax benefit firm beat top bottom line expectation write note client greatest source upside quarter be system placement margin say evidence inflection be clear gross system placement growth last quarters be time prior quarter rate guidance procedure growth imply top end year year growth fourth quarter lewis say likely conservative give momentum procedure especially hernia outside say note client intuitive stock be likely depress late thursday management margin commentary lewis say firm expect flat margin next year intuitive outperformed sale expectation drive higher expect margin reflect conservatism company preserve flexibility invest growth also potentially avoid repeat last year disconnect consensus earning expectation lead management used accelerate share repurchase bridge difference say related intuitive surgical rocket top earning salesdow component pop top view pharma surgical hold lesson not be
14,ISRG,intuitive surgical isrg be late thursday report third quarter sale crushed view adjust earning share beat expectation more xin hour trading stock market today intuitive be volatile initially rocket fall break even point share be hour trade end regular session be unclear be suppress share company do include defer revenue result third quarter end intuitive report adjust income share rise year year top consensus sale come beating analyst view grow part sale beat be due defer revenue customer trade program intuitive offer customer first quarter defer revenue sale still have beat expectation grow intuitive ship da vinci surgical system quarter system use robotic help surgeon perform operation just few incision globally number da vinci procedure grow drive growth general surgery worldwide urologic procedure revenue instrument accessory grow intuitive say news release be drive growth da vinci procedure volume service revenue rise system revenue increase approximately intuitive note increase include revenue related customer trade program related hottest stock busiest day earning investing action plandow component pop top view pharma surgical hold lesson not be
15,ISRG,welcome move natus medical baby see relative strength rating improve wednesday exclusive rating investor business daily identify market leadership worst best score grade show stock price behavior trail week compare other stock database history reveal best stock typically have rs rating least early stage move see natus medical continue rebound clear threshold look winning stock try simple routinenatus medical be work flat base buy point see clear price volume least average company see earning sale growth rise last quarter earning share increase revenue rise natus medical hold rank peer medical system equipment industry group cutera cutr cantel medical cmd intuitive surgical isrg be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
16,ISRG,fidelity investment need new manager otc fund focpx september didn need look far boston base mutual fund behemoth tap own sonu kalra kalra be manager fidelity market beating blue chip growth fbgrx help lead stock alibaba group baba paypal pypl blue chip growth gain year nov outperform large cap growth rival track morningstar direct well be also manager early mid otc now remain helmsman blue chip growth lead manager otc kalra be track guide fund ibd best mutual fund award winner status dec fund have outperformed time period year date trail year need join elite club maintain outperformance year end talk ibd office boston year old kalra discuss investment strategy early mentor fidelity shareholder not fear be stretched too thin add otc workload more ibd nearly double asset management take otc fund do know handle fund large kalra have get question few time be couple reason not spread too thin biggest reason be have co manager otc christopher lin be integral part growth team here research analyst tech sector list mutual fund month leadersbest perform mutual fund categoriessome mutual fund get boost value stock stock be top fund manager buy bond fund decline november turn tide so cover larger growth stock technology sector company apple aapl facebook fb amazon amzn company have be key contributor strong performance otc blue chip growth fund come co manager make possible manage not be stretched too thin reason be run otc so familiar product overall asset otc own blue chip growth ibd be fund run same way kalra be lot overlap portfolio nature fund differ individual stock level risk profile be different be similar name different weighting be growth fund mandate differ blue chip growth be more large cap steady eddie growth fund otc be more aggressive have more smaller name well younger faster grow company blue chip growth be benchmark russell growth otc be benchmark nasdaq composite otc have larger tech component give nasdaq larger tech component ibd summarize overall investment approach fund sonu kalra try find company market be not only mispricing absolute rate growth also sustainability growth think long term investor try take advantage market myopic short term focus ibd do think growth stock same kalra try look bucket be business model company make money company potential generate free cash flow end day value company be future cash flow discount backward company get misprice investor potential generate free cash flow future second pay attention company incremental business opportunity be go be better be today be deteriorate last focus revenue growth number make really try find company grow regardless happen economy ibd latest disclosure tell hold alibaba fund kalra ve own blue chip growth time introduce otc september take be leader china commerce commerce be grow overall retail sale happen china online higher retail infrastructure be not develop china so don have compete entrench brick mortar competitor ibd take alibaba have agree let netflix nflx globally distribute popular detective drama series own youku be own alibaba ibd have build blue chip share count paypal kalra investment thesis be online growth commerce provide payment mechanism make easy purchase online hide gem be venmo peer peer payment mechanism let person share payment social twist appeal millennial go together dinner friend venmo other almost become verb eventually paypal begin monetize now re piggybac growth online commerce guess be re still few year away venmo make material impact parent company monetization ibd be name ve be build be secret sauce fact sell product less audience kalra hit nail head brick mortar store have difficulty do work be have great value proposition enable company drive traffic store have price point say have iphone case power cord charger be beneficiary spinner fad school more story have fast supply chain spot trend quickly come market fast provide unbelievable value consumer have differentiate store model also store rollout be grow square footage more year so show healthy top bottom line growth ibd do way facebook be develop new platform kalra start medium analyst fidelity first thing learn be advertising dollar follow eyeball facebook have be key contributor beneficiary change past year person spend time various medium facebook be core platform also have instagram whatsapp have audience spending more time application drive ad dollar ibd otc also have stock be not household name atlassian team thesis kalra provide project management collaboration software software service go public late software let team work project seamlessly collaborate organization re show strong revenue growth excess year past year re underpenetrated market be leader ibd make introduce intuitive surgical isrg otc fairly recently kalra use technology change way surgery be do system enable doctor do surgery robot outcome be better fewer injury safer more cost efficient hospital well everyone hospital patient ibd fidelity manager have be mentor kalra feel fortunate be organization history great investor be able learn watch work run giant fidelity contra fcntx advisor new insight fniax steve wymer manager fidelity growth company fdgrx have be wonderful mentor ve watch work ethic ability identify great growth company early stick long term ve work closely steve wymer ve be same growth team here ve travele together visit company attend trade show same ve be part same team be tech analyst start year be part research team focuse tech so support guy robert stansky run fidelity growth company now magellan fund fmagx wymer so ve work high profile manager here fidelity identify great company related find income take big risk
17,ISRG,friday cantel medical cmd get upgrade relative strength rs rating ibd unique rating measure market leadership worst best score grade show stock price performance trail week compare other stock database year market history reveal top perform stock typically have higher rs rating begin new price run look best stock buy watch start herecantel medical have rise more past entry first stage flat base meaning now proper buy range look stock create new chance get week tight pullback day week move average cantel medical report ep growth last quarter sale growth come company earn rank peer medical system equipment industry group intuitive surgical isrg cutera cutr be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
18,ISRG,cantel medical cmd be trading buy range next quarterly earning report due dec trading approximately buy point first stage flat base understand buy just stock report be risky don know stock report market react don have enough time build profit cushion reduce risk wait see company report market react look winning stock try simple routinewhile company bottom line growth drop last quarter sale grow prior report consensus analyst estimate call earning share growth quarter growth full year annual growth estimate be recently revise lower company have composite rating earn rank peer medical system equipment industry group intuitive surgical isrg cutera cutr be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
19,ISRG,earning season caterpillar cat have second best earning growth big cap company have already report xearning grow share third quarter only vertex pharmaceutical vrtx top performance vertex grow quarterly earning however many investor pass vertex point
20,ISRG,natus medical baby have relative strength rs rating upgrade thursday welcome improvement still shy better score look ibd proprietary rating measure share price performance worst best score grade show stock price behavior trail week stack other stock database history reveal best stock often have rs rating begin biggest run see natus medical continue rebound clear threshold look winning stock try simple routinenatus medical be build consolidation entry see stock break heavy trading top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase natus medical hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
21,ISRG,intuitive surgical isrg see ibd smartselect composite rating rise monday day revise score mean stock currently top other stock term key performance metric technical strength intuitive surgical be not currently proper buy zone look stock form break new base see ibd help make more money stock have ep rating mean recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post ep growth top line growth rise prior report mark quarter accelerate revenue growth intuitive surgical earn rank peer medical system equipment industry group cantel medical cmd be rank stock group related company be now outperform stock
22,ISRG,get ready earning season look stock potential buy zone ahead next report such company be cantel medical cmd expect release latest number dec trading buy point first stage flat base be aware buy stock just report be risky disappointing number send sharply lower minimize risk wait see actual number market reaction see ibd help make more money stocksearning growth slow most recent quarter sale moved higher analyst be look ep growth quarter growth full year annual growth estimate be recently revise lower cantel medical have composite rating hold rank peer medical system equipment industry group intuitive surgical isrg cutera cutr be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
23,ISRG,relative strength rs rating omnicell omcl jump new percentile thursday get lift exclusive rating investor business daily track price movement worst best score rating show stock price performance last week compare other stock database history show best stock typically have higher rs rating early stage move see omnicell continue show renew price strength hit benchmark look winning stock try simple routinewhile omnicell be not proper entry right now see manage form break proper chart pattern take look revenue profit performance company have post quarters rise earning growth sale gain have also moved higher same time frame omnicell hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
24,ISRG,here investing action plan thursday need know investor come day week earning frenzy hit crescendo tomorrow only handful company report be high performer boast top notch ibd composite rating include paypal pypl atlassian team winnebago wgo intuitive surgical isrg
25,ISRG,dow component johnson johnson jnj surpass wall street third quarter expectation early tuesday strength pharmaceutical unit boost guidance prompt share pop premarket trade xby close bell stock market today stock jump finish share break flat base buy point oct third quarter report sale adjust income share respective vs year earlier quarter metric top consensus analyst poll zack investment research sale share earning rbc analyst glenn novarro attribute sale beat upside pharma unit global sale be forecast consensus pharma revenue top novarro estimate medical device sale lag worldwide pharma sale increase year year basis key product include cancer drug darzalex imbruvica zytiga latter beating novarro view sale new actelion brand be novarro model ibd take isn alone report quarterly result week earning season kick earnest keep tab ibd investing action plan deck day medical device sale grow include shortfall be slightly novarro view orthopedic vision care revenue be light respectively write note client consumer unit grow be just ahead rbc estimate operational basis counter beauty sale grow other category fall highlight continue pressure segment firm also raise guidance sale see adjust income share vs earlier expectation novarro write analyst have modeled sale share earning disclose medical device segment sustain negative impact basis point follow hurricane texas florida puerto rico be number firm manufacturing facility puerto rico investor have be wary effect storm negative impact be attribute lose surgery day area affected stormwater write leerink analyst geoffrey porge note client be supply disruption firm site puerto rico be open generator power run different capacity porge note result extend other biotech space give reliance puerto rico pharmaceutical manufacturing lack disclosure regard demand supply impact be increasingly confident company biopharma coverage not experience material storm related headwind say rbc novarro be bit less bullish result point continue soft market trend medical device diagnostic say exclude acquisition divestiture medical device diagnostic unit grow just year year overall hospital admission be basis point surgical procedure basis point year year basis novarro write orthopedic sale be short weak performance knee spine segment weak knee performance be blame negative impact india implant pricing legislation write estimate sale impact quarter worldwide knee revenue decline year year revenue hip product grow pricing decline likely lose share stryker syk knee product unit novarro say global spine product sale decline lose share spine product segment benefit nuvasive nuva group also suggest continue weak growth quarter spine product market separately look lose share trauma product market stryker worldwide sale grow intuitive surgical isrg medtronic mdt be take piece surgery unit novarro say related be time buy dow dividend machine dow flirt buy point bullish pre earning reportthese medtech player be flail hurricane related headwind
26,ISRG,relative strength rs rating idexx laboratory idxx moved higher percentile friday get lift ibd proprietary rating identify price performance worst best score score show stock price behavior trail week compare other stock database decade market research reveal market biggest winner typically have rs rating least early stage move see idexx laboratory continue show renew price strength clear threshold see ibd help make more stock be work flat base entry see stock clear price volume least higher normal company show ep growth last quarter revenue rise keep eye company next round number nov idexx laboratory earn rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
27,ISRG,point sale payment specialist square sq have rare distinction move buy range same time monday stock clear buy point week pattern be see cup flat base rise slightly next week trade sideway
28,ISRG,haemonetic hae see welcome improvement relative strength rs rating thursday upgrade ibd unique rating identify price action worst best score grade show stock price performance last week hold other stock database history reveal best stock often have better rs rating early stage move see ibd help make more money be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week move average ep growth fall last quarter revenue rise company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg fonar fonr be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
29,ISRG,wednesday natus medical baby get positive adjustment relative strength rs rating proprietary rating identify technical performance show stock price action last week measure other stock database decade market research reveal market biggest winner often have rs rating least early stage move look winning stock try simple routinenatus medical be work entry see clear price heavy volume earning grow last quarter prior report revenue also increase natus medical earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg fonar fonr be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
30,ISRG,wednesday haemonetic hae get upgrade relative strength rs rating ibd proprietary rating measure price movement worst best score rating show stock price performance trail week hold other stock database history show best stock typically have rs rating early stage move look best stock buy watch start herehaemonetic have moved more past entry first stage flat base meaning now proper buy range look stock create new buy opportunity week tight pullback day week move average ep growth drop last quarter top line rise haemonetic hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg fonar fonr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
31,ISRG,important metric look stock be higher relative strength rating varian medical system var clear benchmark monday jump monday ibd proprietary rating identify market leadership worst best score score show stock price movement last week compare other stock database decade market research show market biggest winner often have better rs rating begin biggest climb look winning stock try simple routinevarian medical system break earlier have fall back prior entry flat base stock re watch climb buy point then fall more original entry price consider fail base best stock form new base also understand latest consolidation be later stage base make riskier establish new position add share exist take look top bottom line number varian medical system have post rise ep growth last report revenue growth have be different story come last quarter company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg fonar fonr be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
32,ISRG,important metric look stock be higher relative strength rating haemonetic hae clear benchmark friday jump friday unique rating track market leadership used worst best score show stock price action trail week match rest market year market history show market biggest winner tend have higher rs rating early stage move see ibd help make more have moved more past entry first stage flat base meaning now proper buy range look stock offer new buy opportunity week tight pullback day week line haemonetic see earning sale growth rise last quarter earning share increase revenue rise haemonetic hold rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
33,ISRG,idexx laboratory idxx see positive improvement relative strength rs rating thursday rise ibd proprietary rating track price action worst best score rating show stock price performance last week compare other stock database history reveal market biggest winner tend have rs rating north early stage move see idexx laboratory continue show renew price strength clear threshold look winning stock try simple stock be build flat base entry see break volume least average company post earning growth latest quarterly report sale growth come company be expect report latest earning sale number nov company earn rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
34,ISRG,consider name put watch list look stock higher rs rating omnicell omcl just meet criterium new score ibd unique rs rating track technical performance used worst best score show stock price action trail week match other publicly trade company year market history show stock go make biggest gain typically have better rs rating begin biggest price move look winning stock try simple routineomnicell be not currently show potential buy point see stock go build chart pattern spark new run term fundamental omnicell have post quarters accelerate earning growth sale gain have also moved higher same period company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg fonar fonr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
35,ISRG,relative strength rs rating natus medical baby moved higher percentile tuesday get lift ibd proprietary rs rating identify market leadership used worst best score show stock price action trail week compare other publicly trade company history reveal stock go make biggest gain typically have rs rating north launch biggest price move see natus medical continue rebound clear threshold look best stock buy watch start herenatus medical be work consolidation entry see stock clear price heavy volume company see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
36,ISRG,hill hrc be form base entry next quarterly report set nov current formation be second stage cup handle understand buy stock just ahead earning involve risk typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look best stock buy watch start herehill post ep growth latest quarterly report sale growth come consensus analyst estimate call ep growth quarter growth full year annual growth estimate be recently revise lower hill have composite rating hold rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
37,ISRG,cantel medical cmd see welcome improvement relative strength rs rating monday rise exclusive rating investor business daily track market leadership worst best score rating show stock price behavior trail week stack other stock database year market history reveal top perform stock tend have rs rating north launch biggest run look winning stock try simple routinecantel medical be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week move average earning growth decline company most recent report top line rise company hold rank peer medical system equipment industry group fonar fonr intuitive surgical isrg be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
38,ISRG,haemonetic hae see welcome improvement relative strength rs rating monday upgrade ibd unique rating identify price action worst best score score show stock price movement last week compare other stock database history reveal best perform stock typically have better rs rating early stage move see haemonetic continue rebound hit benchmark look best stock buy watch start herewhile haemonetic be not proper buy zone right now see manage form break proper consolidation haemonetic see earning sale growth rise last quarter earning share increase revenue rise company earn rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
39,ISRG,thursday nevro nvro receive positive adjustment relative strength rs rating ibd proprietary rating track market leadership worst best score score show stock price behavior last week hold other stock database decade market research show top perform stock typically have rs rating north begin largest price move see nevro continue show renew price strength clear threshold look best stock buy watch start herenevro be work double bottom buy point see stock break volume least higher normal keep mind later stage consolidation entail more risk company report ep growth latest quarterly report sale gain come company earn rank peer medical system equipment industry group fonar fonr cantel medical cmd intuitive surgical isrg be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
40,ISRG,dow industrial rally strongly thank ibm ibm turnaround johnson johnson jnj several other blue chip earning general electric ge be big miss adobe system adbe also be big winner bullish outlook netflix nflx hit new high boom subscriber growth ipos be hot dow industrial rise week fuel ibm predict return revenue growth johnson johnson unitedhealth unh be also notable blue chip contributor general electric crash big ep miss have little impact price weight dow rise nasdaq help senate first step big tax cut adobe system soar outlook paypal pypl beat netflix pull back record high high subscriber gain unite airline ual crash carrier have few answer question few new ipos impressed internet television network netflix cheer investor third quarter subscriber addition trounce expectation earning growth miss view sign net new stream subscriber third quarter beating wall street target december quarter netflix expect add new subscriber edge consensus view end september quarter stream subscriber worldwide netflix share hit record high tuesday morning sank week remain buy range related netflix stock fall third quarter subscriber beatadobe system share surge record high maker digital medium marketing software announce upbeat sale earning target fiscal san jose calif base adobe be target adjust earning share year year sale wall street be modele related adobe system rocket outlookibm share soar tech icon report quarterly earning beat estimate indicated sale growth return first time more year ibm do not provide formal quarterly guidance management indicated revenue snap quarter string revenue decline related ibm get price target hike earning report outlookgeneral electric earn just cent share far cent expect revenue rise more expect organic industrial revenue dip industrial operate margin shrank ge power business be big drag industrial cash flow operate activity plunge adjust due weakness power business ge slash full year earning cash flow guidance raise concern dividend cut ge share fall soon friday open close related ge earning miss badly cash flow dive add dividend fearsunited airline tumble more management carrier third quarter earning call be unable provide detail longer term plan drive profit lack clarity lead analyst believe carrier be walking back target outlined last year grow earning higher expect cost be also concern drop fare compete ultra low cost carrier morgan stanley ms top estimate help strong stable wealth management business rival investment bank goldman sachs gs also beat analyst raise concern result be help more volatile capital intensive line business goldman trading result continue struggle morgan outperformed other big bank morgan stanley rise retake buy point goldman sachs climb dow component johnson johnson top wall street view report adjust earning share sale pharmaceutical sale jump worldwide medical device revenue rise miss estimate abbott laboratory narrowly beat expectation early wednesday lion share beat come abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product share rise clear buy point hit record high abbott advanced also time best related dow component pop top view pharma strengthqudian qd china base online credit firm backed alibaba baba rise debut raise pricing expect range singapore base online gaming company sea backed chinese internet giant tencent tcehy edge higher debut raise upsized ipo mongodb mdb provide open source database software platform business pop ipo top just raise price range qudian be profitable sea be poise start make money related sea upsized ipo raise millionmongodb price high qudian strong debut play new ipostop semiconductor industry player deliver generally upbeat report september quarter past week taiwan semiconductor manufacturing tsm beat target third quarter sale earning guide higher current quarter sale maxim integrate product mxim beat wall street target earning sale be tad short however maxim guide earning sale december quarter be well view chip gear vendor lam research lrcx beat view guide higher current quarter rival asml asml beat sale earning target third quarter revenue guidance be light unitedhealth group unh share vault record high tuesday then keep climb insurer report earning growth cent ahead estimate show enviable strategic position have exit obamacare exchange unitedhealth say benefit president trump executive order make low cost plan more widely available amazon com amzn want enter retail prescription business analyst say unitedhealth be ideal partner company signale willing meanwhile anthem antm insurer follow example unitedhealth announce broaden offer include pharmacy benefit management anthem share near buy point news dump express script esrx utilize cvs health cvs process retail distribution start related anthem jump prescription business amazon speculation signal openness amazon partnership earning beatpaypal report september quarter profit revenue top view forecast current quarter sale estimate send share commerce payment processor paypal say adjust earning be cent share year revenue rise current quarter paypal forecast revenue growth midpoint guidance gaap profit cent vs consensus estimate cent paypal jump friday new record high related paypal earning revenue top expectation share slb say friday investment demand north america be moderate baker hughe bhge warn challenge year end customer remain cautious spending due volatile oil price suggest shale other operator be rein production growth plan schlumberger meet ep view gain baker hughe report first quarter merger general electric oil gas unit july crude price hold barrel inventory fall yet again production plunge due gulf shutdown hurricane nate charle schwab schw trade etfc beat wall street consensus third quarter earning schwab miss revenue trade meet expectation schwab report ep cent revenue trade post earning cent share revenue schwab undercut buy point report sharp fall trading revenue share rebound friday trade share fall be still buy range past entry ebay ebay meet third quarter earning estimate revenue be slightly forecast online marketplace fourth quarter ep outlook fall short estimate share sank close day move average recent buy point undercut intraday thursday related ebay meet earning view share tumble weak outlooksap sap report quarterly earning top estimate german enterprise software giant raise guidance year base cloud compute strength bombardier bdrbf agree sell stake struggle series jet airbus eadsy commerce department call tariff narrow body jet deliver boee ba accuse canadian company receive unfair government subsidy gilead science gild win fda approval car drug dub yescarta treat aggressive form hodgkin lymphoma yescarta come gilead recent kite pharma deal gilead rise thursday be little change weekcelgene celg scrap trial crohn disease drug win start third cite internal futility review celgene fall friday intuitive surgical isrg top expectation late thursday report sale adjust profit share share rise friday atlassian team surge maker project management software report fiscal first quarter sale profit handily top estimate atlassian up full year revenue guidance midpoint guidance earlier forecast share surge nearly verizon communication vz add more postpaid wireless phone subscriber expect revenue also top estimate proofpoint pfpt report earning revenue top estimate fiscal outlook disappoint share rise friday video game publisher electronic art ea disappoint news be delay star war action adventure game have be set release fiscal run april march do not give new release time frame ea share be so far week rv maker winnebago wgo exceed forecast profit growth cent share revenue increase company also approve share buyback share close american express axp exceed earning estimate longtime ceo kenneth chenault retire stephen squeri set take place feb unite rental uri steamrolled estimate cent share ep rise revenue boost hurricane rebuild be reason nation largest equipment rental company boost guidance capital spending plan procter gamble pg profit grow share top view cent organic sale rise just result follow narrow proxy fight trian fund management nelzon peltz share fall friday unilever report weak sale thursday european consumer food product giant fall week related stock buy watch top ipos big small cap growth stockslooking best stock buy watch start here
41,ISRG,rule keep individual investor harm way improper understand rule create problem example most case investor take profit stock rise ideal buy point important exception build statement investor buy ideal buy
42,ISRG,nevro nvro see welcome improvement relative strength rs rating thursday rise exclusive rating investor business daily measure share price action worst best score rating show stock price performance trail week stack other stock database decade market research reveal market biggest winner typically have rs rating north early stage move see nevro continue show renew price strength clear threshold nevro be try complete double bottom buy point see clear price heavy trading be aware stage base later stage pattern work have greater failure rate point stock have already rise significantly nevro report ep growth most recent report revenue rise nevro earn rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
43,ISRG,medtech space lead intuitive surgical isrg varian medical system var steris ste have prove be safe haven ride drug pricing fear have weigh big pharma biotech stock xanalyst say economy job number have improve allow patient finally go pseudo deferrable
44,ISRG,nevro nvro see positive improvement relative strength rs rating monday rise ibd proprietary rating track price movement worst best score rating show stock price behavior last week stack other stock database decade market research reveal best perform stock often have rs rating early stage move see nevro continue show renew price strength hit benchmark nevro be build double bottom buy point see stock clear price volume least higher normal keep mind later stage consolidation entail more risk company show ep growth last quarter sale increase company hold rank peer medical system equipment industry group fonar fonr cutera cutr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
45,ISRG,thursday intuitive surgical isrg receive upgrade relative strength rs rating ibd unique rating identify market leadership worst best score rating show stock price behavior last week stack other stock database year market history reveal best perform stock tend have rs rating north early stage move intuitive surgical have rise more past entry first stage cup handle meaning now proper buy zone look stock offer new chance get week tight pullback day week move average intuitive surgical show earning growth last quarter sale increase intuitive surgical hold rank peer medical system equipment industry group cutera cutr be top rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
46,ISRG,wednesday haemonetic hae get upgrade relative strength rs rating ibd proprietary rating measure share price action worst best score rating show stock price movement trail week hold other stock database decade market research show market biggest winner tend have rs rating north launch largest run see haemonetic continue show renew price strength hit benchmark haemonetic break earlier have fall back prior entry flat base stock re tracking clear buy point then fall more original entry price consider fail base stock set new base entry price also understand latest pattern be later stage base make riskier establish new position add share exist top bottom line growth moved higher last quarter earning be compare prior report revenue increase haemonetic earn rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
47,ISRG,major average turn narrowly mixed finish tuesday weak company earning strong economic news left stock battle stalemate nasdaq composite dip day powerful performance apple aapl slip fraction red dow jone industrial average end session cling faint gain preliminary datum show overall volume be quiet lower nyse nasdaq relative monday action stock receive positive stroke economic news better expect july retail sale growth surge new york region manufacturing growth business inventory outpaced estimate june national association homebuilder home price index rebound august month high have help apple pull gain fang name facebook fb rise amazon com amzn google parent alphabet googl lose netflix nflx drop approach buy point dow see big move direction apple american express axp cisco system csco climb respectively home depot hd command dow downside fall nearly earning revenue comfortably top second quarter estimate increase comparable sale guidance suggest slow latter half year loss send share week move average heavy trade trigger sell signal few winner rise earning result china base holisys automation technology holi churn gain weak fiscal fourth quarter report late monday gain moved share further right side month cup base overwhelming majority company report quarterly result suffer loss dick sporting good dks advanced auto part aap coach coh post decline photronic plab take headline hit tech name nasdaq retailer post session heaviest loss bed bath bbby drop ulta beauty ulta scratch lead nasdaq intuitive surgical isrg rattle third straight gain move extend territory rebound support week move average ibd stock see good bad tuesday top list zebra technology zbra kick gain leave just buy point cup handle base also list realpage rp national beverage fizz alibaba group baba rise more apiece bottom ibd china yy yy dive stock offer plan nova measure instrument nvmi shed more slip back week line support related networking firm share jump month highwill cisco explain telco pact aren provide relief cisco target report other buy zone investing action planarista network smash estimate stock soar hour
48,ISRG,china base stock continue act well face thursday market sell positive earning surprise have become solid catalyst stock make move new high market leader alibaba baba surge new high thursday report strong earning result earlier morning join china base peer earning beat
49,ISRG,consider name put watch list look stock higher rs rating varian medical system var now meet criterium increase monday proprietary rating identify market leadership show stock price action last week measure other stock major index decade market research reveal market biggest winner typically have rs rating north early stage move varian medical system be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average company top line growth fall last quarter earning share grow prior report varian medical system hold rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
50,ISRG,monday haemonetic hae earn positive adjustment relative strength rs rating exclusive rating investor business daily track share price action worst best score score show stock price behavior last week stack other stock database history reveal best perform stock typically have rs rating least launch biggest run see haemonetic continue show renew price strength hit benchmark haemonetic break earlier have fall back prior entry flat base stock re tracking clear buy point then decline more original entry price consider fail base best stock form new consolidation also keep mind latest pattern be later stage base involve more risk earning grow last quarter prior report revenue also increase company earn rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
51,ISRG,welcome move varian medical system var see relative strength rating rise thursday exclusive rating investor business daily track share price action worst best score score show stock price movement last week compare other stock database year market history show best stock typically have better rs rating early stage move see varian medical system continue show renew price strength hit benchmark varian medical system be not currently potential buy zone see stock go form base launch new move company top line growth fall last quarter earning share grow previous report company earn rank peer medical system equipment industry group cutera cutr fonar fonr intuitive surgical isrg be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
52,ISRG,wednesday cutera cutr get upgrade ibd smartselect composite rating revise score mean stock currently top other stock term key performance metric technical strength market biggest winner often have higher rating early stage new price run cutera be now buy range breaking buy point flat base keep mind thinly trade stock average daily dollar volume weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show heavy buy institutional investor last week company report ep growth sale growth rise prior report mark quarters increase revenue gain cutera hold rank peer medical system equipment industry group fonar fonr intuitive surgical isrg be also group highest rate stock related company be now outperform stock
53,ISRG,rule regard shape bullish chart pattern be strict solid cup handle pattern take minimum week more form flat base need least week week cup wrong answer time true market leader stage run new high need time weather market pullback profit take shareholder stock need time bottom regain upward price momentum get right position rally new high research major market winner decade ibd have discover many best stock build cup pattern take month even more year form so find cup pattern only week length have just spot subtle top pattern ibd take be common pattern best growth company create stock market break go new high stock be new high long holder be happy learn more key pattern cup handle other investor corner sell signal call sharp pullback recovery new high first introduce ibd chart school workshop now featured home study course available investor com constitute offense related sell signal help nail profit top even stock be rise be several variety pattern long run stock fall hard straight week then rush higher next week new high eventually peak case be week week simply big weekly drop big week matter combination re try spot excessively volatile action sharp pullback follow fast surge new high ground suggest late fund manager individual investor be desperately buy share throw caution wind nice see stock shoot quickly back new high result shape base pattern tend bear higher risk failure contrast sudden run sound base be exactly see let say re view week cup base handle form cup high slant gently lower handle action indicate few remain frustrated shareholder buy high price have finally exit stock investor deep pocket suddenly start buy share heavily spike demand send price scream higher intuitive surgical isrg break long base buy point heavy volume april market be decent uptrend time july year excellent report sunnyvale calif base firm send stock catapult new high monstrous volume time earning share rocket year level sale climb tax margin be stock offer several chance add share such mild pullback week move average june javelin spike late june late october intuitive rise week gain climactic jump week end oct intuitive carved week week base post new high intuitive quickly reversed fall fast next month stock form jagged cup base featured week accumulation shape be not march intuitive share plummet peak column originally run jan edition ibd related know sell rule largest single session point drop heavy turnoverknow sell rule ii shape cup base usually spell troublewhat individual investor learn october market crash
54,ISRG,roughly week stock market condition switch uptrend pressure confirm uptrend sound familiar july ibd weekly big cap column note investor increase exposure testlike fashion buy stock be breaking see work do work give
55,ISRG,idexx laboratory idxx be form base buy point get ready report earning aug current formation be first stage flat base buy stock just ahead earning be risky typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure idexx laboratory report earning growth last quarter revenue rise consensus analyst estimate call ep growth quarter growth full year idexx laboratory have composite rating hold rank peer medical system equipment industry group hill hrc intuitive surgical isrg be also group highest rate stock note date earning report be estimate subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
56,ISRG,intuitive surgical isrg be hamstrung psychological barrier share analyst argue friday stock topple robot surgeon maker sale earning beat late thursday number simply weren good enough pull stock evercore analyst vijay kumar say stock market today intuitive surgical stock tumble close share have climb half year close mark thursday hit high intuitive surgical inched hour follow second quarter earning report headline revenue procedure overall system beat point life be good intuitive surgical key question investor be number be enough drive stock higher potentially break psychological barrier kumar say ibd take intuitive surgical be fend robotic advance alphabet googl google medtronic mdt fare offering rival come fruition visit ibd datum story procedure proxy overall health company continue be healthy write note client say procedure guidance imply slowdown second half year first half guidance growth high end imply growth second half year vs see first year write rbc analyst brandon henry doesn see same psychological barrier up price target intuitive surgical stock keep sector perform rating stock henry also increase sale view respectively call adjust profit come respective share meanwhile intuitive surgical be work maintain lead robotic be aim have lung biopsy system launch face robotic competition like google parent alphabet medtronic robotic competition be come intuitive surgical be make necessary investment expand total addressable market remain premium player surgical robotic market write note client related robot surgeon maker best sale profit view
57,ISRG,intuitive surgical isrg inched late thursday robot surgeon maker top wall street second quarter sale profit view report nearly growth shipment da vinci surgical system year year basis sale advanced adjust profit share grow metric top analyst expectation period intuitive surgical ship da vinci surgical system firm also launch next generation model da vinci lower cost version robotic assist technology worldwide da vinci procedure grow vs year earlier quarter intuitive surgical say news release ibd take google alphabet googl medtronic mdt other be try crack robot assist surgery space intuitive surgical dominate intuitive surgical stock top stock term key growth metric grab more ibd datum story growth procedure be drive primarily growth general surgery procedure worldwide urologic procedure intuitive surgical say hour trading stock market today intuitive surgical stock rise less share close regular trading session related medtronic undercut robot surgeon maker
58,ISRG,wall street analyst friday raise price target share software giant microsoft msft chipmaker skywork solution swks credit card company visa drugmaker abbott laboratory robotic surgery leader intuitive surgical isrg report quarterly earning thursday xmicrosoft crushed wall street target fiscal fourth quarter end june redmond wash base company earn cent share exclude item year year sale analyst be expect ep cent sale microsoft give cautious revenue guidance current quarter least analyst raise price target microsoft stock earning news piper jaffray be most bullish analyst alex zukin reiterate overweight rating microsoft up price target microsoft report very strong end fiscal year beating segment metric punctuate commercial cloud booking growth accelerate azure growth improve gross margin zukin say report other firm raise price target microsoft include bmo capital market canaccord genuity cfra research cowen deutsche bank jeffery keybanc capital market raymond james stifel ub microsoft stock close stock market today apple aapl chip supplier skywork solution earn share revenue fiscal third quarter analyst be expect ep sale skywork result marked third straight quarter accelerate earning growth skywork receive price target increase least investment bank cowen mizuho security needham mizuho analyst vijay rakesh be most optimistic stock maintain buy rating skywork increase price target skywork share close hit morning action cowen analyst george mihalos raise price target visa maintain outperform rating visa report third consecutive quarter outperformance drive solid global volume trend sustainable line item lower tax rate additional buyback mihalos say report san francisco base visa earn cent share sale fiscal third quarter analyst be look ep cent sale share be hit record intraday visa be still buy range buy point north chicago ill base abbott earn cent share sale second quarter analyst be modele cent rbc capital market analyst glenn novarro reiterate outperform rating abbott raise price target abbott stock dip cent sunnyvale calif base intuitive surgical earn share sale second quarter analyst have expect least investment bank up price target company barclay cantor fitzgerald rbc barclay keep overweight rating intuitive surgical up price target cantor stick hold rating raise price target rbc stay sector perform bump price target intuitive surgical share fall
59,ISRG,internet television network netflix nflx receive wave price target hike analyst tuesday big second quarter beat late monday elsewhere chipmaker advanced micro device amd be smack downgrade financial technology stock paypal pypl square sq nab price target hike xnetflix receive least price target hike stock monster second quarter outperformance los gatos calif base company add net new subscriber wall street be expect also guide subscriber add view morgan stanley rbc capital market be most bullish netflix up price target netflix stock soar hit record intraday stock market today netflix share clear flat base form past week buy point future be look bright netflix rbc analyst mark mahaney say note client execution continue improve flywheel come motion wedbush security analyst michael pachter be most bearish maintain underperform rating up price target rosenblatt security upgrade netflix buy neutral moved price target amd share fall receive downgrade investment bank barclay barclay lower rating graphic compute chipmaker underweight equal weight price target also cut rating cirrus logic crus underweight equal weight price target barclay analyst blayne curtis say be unconvinced amd latest processor gain enough traction support company current valuation keybanc capital market tuesday up price target bunch payment process company include highly rate paypal square keybanc analyst josh beck reiterate overweight rating stock hike price target paypal square paypal rise square be be now extend last week breakout paypal be currently rank ibd list top perform growth stock rbc capital market play catch surgical robot maker intuitive surgical isrg tuesday raise price target stock be currently trading rbc analyst brandon henry reiterate sector perform rating intuitive surgical increase price target stock intuitive surgical fall sunnyvale calif base company be likely see continue momentum system such area hernia repair colorectal surgery thoracic surgery say report
60,ISRG,large cap fund be set potential breakout stock market remain time high xfirst be ishare edge msci min vol usa usmv be just shy flat base buy point briefly clear prior flat base entry late april pull back buy point bounce day move average en route gain fund track msci usa minimum volatility index comprise domestic stock tend be less volatile broader equity market carry expense ratio usmv biggest sector weighting be health care july just asset information technology follow nearly consumer staple financial health care name account half top becton dickinson bdx johnson johnson jnj stryker syk unitedhealth group unh intuitive surgical isrg fund top name make less total asset usmv also help limit volatility keep hold less have relatively low annual turnover year date gain july be line accord morningstar inc etf outpaced benchmark index past year vs slightly underperform past year vs have dividend yield flexshare quality dividend index fund qdf track northern trust quality dividend index be buy point flat base fund launch december target stock sustainable yield lead profitable company have ability keep pay dividend top holding july include procter gamble pg boee ba pfizer pfe apple aapl merck mrk top stock account asset annual turnover be qdf have lag year past year annualize yield be well benchmark index average yield expense ratio be tuesday be good day many foreign etfs include international equity fund dwm ishare msci hong kong ewh dwm be still buy range entry ewh flat base buy point stock market pare early gain wednesday leave only dow jone industrial average positive territory earning fuel jump apple aapl spdr dow jone industrial average dium hold only gain spdr spy slip powershare qqq trust qqq edge lower stock sell board telecom retail real estate lead decline spdr telecom xtl fall slip day line first time week vaneck vector oil service oih reversed advance west texas intermediate crude price early reversed higher barrel few sector buck decline industrial select sector spdr xli rise utility select sector spdr xlu climb vaneck vector gold miner gdx be vaneck vector junior gold miner gdxj give powershare db gold fund dgl spdr gold trust gld ishare gold trust iau hold small gain related dow keep streak alive foreign play breaking dow hit new high techs give gain apple focusdow mark record high check solid play buy pointsfind happen stock market today
61,ISRG,nasdaq composite index hit new high techs continue reassert market leadership netflix nflx amazon com amzn facebook fb microsoft msft hit record high netflix soar subscriber gain amazon sell kenmore appliance sear shld send latter sharply higher hit several retailer include dow home depot hd dow jone industrial average also be hit general electric bank blue chip visa american express axp continue good news payment stock nasdaq composite rise hit record high week rise straight session thursday netflix other fang stock such facebook amazon contribute index climb also hit fresh high week dow industrial fall weigh goldman sachs gs general electric ge home depot internet television network netflix add net new subscriber june quarter vs wall street consensus estimate also guide higher current quarter forecast net new subscriber top consensus view bull point strong subscriber growth bear voiced caution ballooning video content obligation include original tv series stranger thing glow netflix end subscriber worldwide include foreign market netflix international stream subscriber top first time netflix sky-rocket record high week sear sell alexa enabled kenmore appliance amazon send share soar thursday give most gain friday whirlpool whr major seller appliance home depot lowe low best buy bby be hit home improvement chain home depot lowe have be see amazon proof least amazon resistant best buy have bounce back recent year amazon initial onslaught be hurt earlier month news amazon be create geek squad rival amazon appear be get more government attention size scope grow ftc probe antitrust rumbling software giant microsoft earn cent exclude item june fiscal fourth quarter year year well view cent revenue rise forecast microsoft credit demand cloud compute service azure office well acquisition linkedin dow component give cautious guidance current quarter share dip friday remain buy range related microsoft crush earning estimate stock dip outlookgeneral electric fall friday say full year ep be trend low end target cite oil gas weakness ge report smaller earning revenue decline analyst cite weakness headline figure fellow industrial conglomerate honeywell international hon also beat top bottom line guide full year estimate slightly higher honeywell share rise friday retake buy point related general electric stock dife earning outlookamerican express beat top bottom line provision loss jump due loan portfolio growth rise rate lend off visa earning also top strong cross border travel help stronger dollar global payment volume drive result accord mizuho analyst thomas company also hike full year revenue growth outlook view visa american express dow component rise respectively still buy range td ameritrade amtd stock break long consolidation july online broker beat top bottom line even industry trading fee stock etfs have plunge year charle schwab schw day match view share fall buy point have clear late june trade etfc share gap make new week high friday company score overall beat thursday share be now buy range chip gear maker asml asml wireless communication chipmaker qualcomm qcom be first major semiconductor industry player report june quarter earning year asml rise record high post better expect sale earning second quarter qualcomm disappoint current quarter profit outlook come short view even beat estimate fiscal apple aapl chip supplier skywork swks report better expect fiscal sale earning guide higher current period drug giant novartis nvs johnson johnson jnj report better expect earning tuesday dow component report adjust income share top view cent sale be light novartis share exclude various item sale top analyst view drug stock rise week be still buy range friday close goldman sachs fix income trade revenue plunge second straight quarter trading heavy bank say misread market weaker trading net interest income also hurt bank america bac fed rate hike have help bank say expect net interest income rise morgan stanley ms report trading revenue fall less so rival jpmorgan jpm citigroup have also signale caution slow loan growth longer term bond yield indicate flagging confidence chance long term economic gain morgan stanley clear buy point goldman undercut day day move average check point software chkp report better expect second quarter earning thursday give weak guidance current check point tumble day fall day move average check point wednesday briefly top buy point close trigger so do other cybersecurity stock day stock proofpoint pfpt retreat modestly check point warning unite airline ual tuesday offer disappointing third quarter unit revenue forecast airline competition pick head further summer send share plunge delta air line dal american airline aal have remain bullish key metric fall significantly well unite say take least several month plan expand service different part rollout cheaper basic economy fare pay health insurer earning share rise top forecast revenue grow roughly line be smallest gain quarters unitedhealth unh have exit obamacare exchange big player medicare medicaid coverage optum service unit see revenue rise unitedhealth now see adjust full year profit share analyst have expect result unitedhealth rise republican health care struggle also influence share insurer hospital related unitedhealth raise full year target earning jump top rail company top quarterly forecast csx csx say crude oil train shipment have fall hint return shareholder be more cautious union pacific unp predict nearly flat volume coal shipment stabilize still see second half volume improve first half kansa city southern ksu benefit auto production energy market reform mexico csx fall week union pacific lose kansa city southern edge vertex pharmaceutical vrtx stock rocket time high wednesday strong phase datum trial cystic fibrosis treatment triple drug combo aim treat genetic disease underlie cause intuitive surgical isrg easily top analyst second quarter view thursday adjust income share sale share maker robot surgical system fall friday afternoon chipotle grill cmg share tumble year low report fast casual chain temporarily close restaurant virginia follow report diner have get sick once trendy fast casual burrito eatery have be try mend reputation sale food bear illness scare begin harley davidson hog cut motorcycle shipment outlook unit dealer year drop prior guidance flat modest decline iconic motorcycle brand report ep decline be better estimate sale slide retail sale new motorcycle tumble weak industry condition share fall
62,ISRG,thursday check point software technology chkp report better expect earning apple aapl iphone chipmaker skywork solution swks tap tonight check point be cybersecurity stock verge breakout tuesday night include fortinet ftnt proofpoint pfpt palo alto network panw cross buy point intraday meanwhile skywork provide clue apple business other iphone chipmaker broadcom avgo just entry point wednesday session nasdaq composite rise index hit record high dow jone industrial average advanced future index dow jone industrial average rise vs fair value early thursday morning so do nasdaq future israeli base check point software report second quarter earning share exclude various item gain revenue analyst have expect share profit rise revenue nearly accord zack investment research check point fall thursday premarket action wednesday stock market trading check point software rise high trading flat base entry much session share close just buy point stock tend move group still be striking many cybersecurity play act check point fortinet fireeye feye imperva impv palo alto network clear entry intraday only close just level proofpoint close session high move position possible be valid entry point fortinet proofpoint report quarterly result next week skywork solution report fiscal third quarter earning late thursday skywork be earlier chipmaker report very first apple iphone chipmaker do so qualcomm qcom report late wednesday ongoing royalty feud apple doesn make great bellwether iphone ecosystem skywork be expect report earning share vs year earlier be ep gain revenue be yearly gain match fiscal skywork rise wednesday close entry cup base skywork retook day move average last friday apple share finally regain day line tuesday ve rise straight session now apple be near flat base entry apple supplier broadcom be much closer skywork apple broadcom rise wednesday now entry base base pattern apple release quarterly result aug addition check point skywork slew big earning report be due thursday visa sap sap ebay ebay intuitive surgical isrg microsoft msft related dow giant buy range ahead earning investing action big picture market send signal invest growththese techs hammer new high nasdaq rally
63,ISRG,here investing action plan thursday need know investor come day xdow jone industrial average heavyweight microsoft msft visa be buy territory investor get ready result share ebay ebay intuitive surgical isrg be record high ahead
64,ISRG,here weekly investing action plan need know investor come day xearning season really take come week report netflix nflx microsoft msft general electric ge lockheed martin lmt johnson johnson jnj remain bank giant also come well
65,ISRG,google parent alphabet googl medtronic mdt other be try challenge dominance intuitive surgical isrg robot assist surgery space so far have fail disrupt market leader maker da vinci surgery system see ibd smartselect composite rating jump tuesday day revise score mean intuitive surgical now top other stock term key performance metric technical strength best stock tend have better grade begin launch significant move intuitive surgical have climb buy point cup handle clear february tuesday moved past follow buy point week tight pattern intuitive pull back session high close positive territory weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week company report earning share gain prior report revenue growth increase intuitive surgical hold rank peer medical system equipment industry group idexx laboratory idxx be rank stock group related company be now outperform stock
66,ISRG,be upside intuitive surgical isrg guidance analyst suggest tuesday investor be already pay downgrade stock likelihood subdue demand asia canaccord analyst jason mill also see medtronic mdt know make heart valve replacement rival edward lifescience ew stout competitor surgery robotic year date intuitive surgical stock be phenomenal year canaccord analyst jason mill write note client intuitive end year sale growth earning growth cash health care sector have be top performer so far intuitive surgical have be lead charge mill say however investor exuberance company strong performance past few year have drive stock unprecedented valuation level mill downgrade intuitive surgical stock hold rating buy year keep price target close stock market today intuitive surgical be expect intuitive surgical deliver solid result believe risk reward setup tilt too much former present say stock hasn trade valuation be now premium own year average ibd take intuitive surgical stock have ibd composite rating best possible rank fourth ibd company medical system equipment industry group idexx laboratory idxx stock lead group cr look group setup head ibd stock checkup guidance have play big role intuitive surgical stock mill say company typically offer conservative guidance easily outperform thus investor expect positive guidance revision balance not be case easter weekend tailwind first quarter become headwind second quarter outside business be slow mill write procedure growth be expect be subdue japan moderate china think be upside current guidance think re already pay write meantime competition be loom say intuitive surgical make robotic assist perform surgery medtronic reiterate earning call last week plan launch surgical robotic outside april fiscal medtronic competitive approach seem be center ability target customer myriad surgical spectrum also deduce conversation management target cost side equation well mill say medtronic not become much competitor late early domestic launch creep closer intuitive surgical investor begin account upcoming competition multiple afford share say related robot surgeon maker launch record high strong
67,ISRG,fast food restaurant operator yum brand yum be upgrade buy drug giant pfizer pfe be downgrade sell wall street analyst tuesday goldman sachs initiate coverage host medical pharmaceutical company rating baxter international bax intuitive surgical isrg buy abbott laboratory hold argus research upgrade yum brand stock buy hold yum operate franchise kfc pizza hut taco bell restaurant yum stock rise stock market today break cup base buy point remain buy zone hit record regular session trading high louisville ky base yum report better expect revenue earning first quarter thank strong sale taco bell citigroup downgrade share pfizer sell stock be tuesday pfizer stock have form saucer handle chart pattern buy point past week new york base pfizer report mixed first quarter result earning top view sale come short goldman initiate coverage baxter buy rating price target start surgical robot maker intuitive surgical buy price target begin coverage abbott lab hold rating price target baxter rise hit fresh time high intuitive surgical rise climb also set record high abbott lab fall related baxter raise guidance hospital market rebound stock hit highpfizer follow baxter get slam subpoena related saline shortagerobotic surgeon maker launch record high strong
68,ISRG,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
69,ISRG,intuitive surgical isrg stock rocket time high wednesday medical tech player report procedure growth first quarter unveil upgrade robotic surgeon platform intuitive surgical stock close stock market today announce first quarter result late tuesday share lead ibd company medical system equipment industry group broadly rise evercore analyst vijay kumar call result especially strong such big name generally high growth high price earning value name intuitive surgical number have be pretty solid sustain multiple kumar say think intuitive surgical manage put enough satisfy elevated expectation procedure growth launch first quarter follow change guideline testing prostate specific antigen preventive service task force group now encourage man age sign symptom talk doctor regard potential benefit harm screening man age not be screen potential benefit don outweigh harm intuitive robotic tool be used number urologic gynecologic setting recent society american endoscopic surgeon conference expert say hernia treatment be likely grow change psa testing guideline task force think procedure trend midteen range intuitive surgical kumar say tuesday intuitive guide procedure growth earlier view ibd take intuitive surgical be leader medtech world get again head investor corner more system update be somewhat mixed intuitive surgical plan delay single port launch quarters also unveil da vinci upgrade sit da vinci si da vinci xi third fourth generation platform da vinci leverage many benefit xi provide hospital entry point intuitive surgical advanced technology wedbush analyst tao levy write note client meanwhile delay submit single port fda be disappointment rbc analyst brandon henry say have expect slow rollout single port tech anyway shouldn detract otherwise strong start intuitive surgery henry boost price target intuitive surgical stock keep outperform rating wedbush levy up price target intuitive stock have outperform rating stock related robotic surgeon maker pop smash consensus view
70,ISRG,intuitive surgical isrg stock pop late tuesday medtech player top wall street first quarter sale profit view worldwide growth procedure robotic surgical tool call da vinci hour intuitive surgical stock be follow announcement share close regular session intuitive surgical stock be now extend buy point achieve february cup handle formation first quarter intuitive surgical report sale grow year year basis top consensus analyst poll yahoo adjust earning rise share beating view company ship da vinci surgical system compare year earlier quarter growth da vinci procedure be drive growth general surgery procedure worldwide urologic procedure intuitive surgical say news release be pleased broad base da vinci procedure growth first quarter be encourage trend key global market surgery business chief executive gary guthart say prepared statement procedure grow outside procedure grow procedure growth be strongest have see so far evercore analyst vijay kumar say note client follow earning release growth benefit timing element help give intuitive surgical solid start year ibd take intuitive surgical be leader basis lead again head investor corner deep dive stock management see procedure grow earlier guidance company expect interest lease da vinci system rather buy grow subsequently pricing purchase be likely drop intuitive surgical didn give sale profit guidance conference call analyst expect sale adjust earning share second quarter year year basis sale be profit rise related come robot race
71,ISRG,stock rac commendable gain light trade monday haul dow jone industrial average further day move average session open boost saturday announcement more long term deal manufacturer saudi arabia set bargain time correspond president trump first trip saudi arabia news lift defense play lead boee ba lockheed martin lmt raytheon rtn well national oilwell varco nov other boee lockheed martin end nearly ford hold early gain end monday more announce have replace chief executive mark field jim hackett former ceo steelcase scs have head ford smart mobility experimental operation unit field hold ceo seat year ford share have be month decline nasdaq composite lead more nasdaq stock climb more autodesk adsk lead nasdaq more new high add gain post last week fiber optic telecom stock post session best gain industry boost handful analyst report acacia communication acia apply optoelectronic aaoi finisar fnsr gain more maker medical software also score high skewer higher gain thinly trade polarityte cool group leader veeva system veev be extend peer cerner cern be trading just buy point week tight pattern dow jone industrial average scale cisco system csco lead index rebound look salvage support week move average diving gale force volume last week loss blue chip be generally modest pfizer pfe fall hardest dow industrial score gain jack daniel distiller brown forman bfb run list gain clear prior high august chipmaker qorvo qrvo sped higher intuitive surgical isrg jump take new high defense consultant booz allen hamilton bah spiked possibly aid saturday announcement more saudi defense deal also report first quarter earning revenue expectation host full year revenue guidance past consensus target gap gain lift share just buy point flat base related dow jone industrial average dow stock news housing stock buy point investing action plan
72,ISRG,corporate earning result grab front center stage be help propel equity higher late afternoon trading tuesday major index be padding last week nice gain dow jone industrial average boost better expect result several component include caterpillar cat ep dupont dd ep rise more better gain nasdaq composite dow jone industrial be now nearly jan nasdaq composite breaking first time be ahead nearly gain big cap techs select consumer oriented stock have help nasdaq cause keep monitoring earning result see more money flow blue chip type large cap outside tech realm caterpillar also notch surprise gain revenue first year year increase quarters last time construction mining gear titan see top line lift come third quarter cat share vault past flat base buy point gap open enjoy heavy institutional buy share see triple normal turnover stock open day proper buy zone follow tuesday russell rally more volume be run firmly higher vs same time monday main exchange sign heavy institutional demand equity crude oil future meanwhile rebound get hammer monday wti future rise barrel be still more year date gold mining stock other defensive play lead market downside newmont mining nem sank nearly heavy volume mining giant grow first quarter profit cent share pickup revenue month clear institutional investor be favore certain industrial sector other good news stock picker here be stock addition high growth name ibd sector leader show more mature fundamental be turnaround situation have potential beat nvidia nvda market value leader graphic processor have step nicely new growth market include self drive automobile ai artificial intelligence nvidia nearly be try retake key day move average get slam bearish analyst comment april stock be huge leader rise cup handle back march year nvidia sport solid earning share rating scale earning april end fiscal first quarter be see rise impressive cent share top gain year quarter keep mind next quarters nvidia face absolutely steep year year comp profit rise respectively give giant gain nvidia current correction be very respectable fall more time high celgene celg market value highly respect biotech pioneer treatment chronic difficult disease include multiple myeloma stock jump find vital support day line slightly earlier cup handle entry street see full year earning rise share chipotle grill cmg former large cap burrito taco chain report result close tuesday watch expect positive change comparable restaurant sale see restaurant level operate margin show stability improve intuitive surgical isrg robotic surgery firm recently post double digit top bottom line growth be more jan bolt base late february intuitive get rock solid composite rating ibd stock checkup top ibd medical system equipment industry group group be rank industry group subgroup month relative price performance watch potential new buy point emerge form new base gentle pullback week move average see weekly chart case stock not fall back day line find support week line so crucial study stock price action daily weekly chart related case future new bull market goldearning result today chipotle lead big report closestock market today be time buy hasbro now rite aid sink more income investor top perform stock large dividend yield
73,ISRG,xu stock index revert indefinite trend friday small loss follow thursday big gain nasdaq fall blue chip dow jone industrial average drop respectively volume fall major exchange small cap russell fall positive sign market be
74,ISRG,nasdaq composite remain driver seat afternoon trading wednesday help strong earning report chip equipment maker lam research lrcx intuitive surgical isrg dow jone industrial lag fall weigh weakness ibm ibm crash nearly weaker expect sale lose volume nasdaq be tracking slightly higher tuesday level nyse volume be tracking close tuesday new york mercantile exchange benchmark crude oil settle barrel crude stockpile fall second straight week gasoline supply show first weekly increase month financial try get go morgan stanley ms report strong earning didn have much luck financial select sector spdr xlf only manage gain morgan stanley gap be session low late trading share still rise help earning beat news fix income revenue nearly double dow component jpmorgan jpm goldman sachs gs lose respectively stock market today lam research be top gainer ibd rise company report surge quarterly profit sale jump ibd component group peer apply material amat also do well rise intuitive surgical isrg gap level soar company report earning sale accelerate procedure growth rise first quarter company also unveil upgrade robotic surgical platform leaderboard name dycom industry dy be big mover dycom do lot growth stock have be have hard time do lately follow share surge nearly tuesday breaking past buy point downside maker fiber optic component take heat renew fear slow demand china finisar fnsr lumentum lite fall hardest respectively economic news fed beige book report be release et nutshell report show economic activity fed district increase modest pace low inflation close watch earning report ebay ebay unite rental uri csx corp csx related chip gear stock be soar here whyrobotic surgeon maker launch record high strong finisar optical stock sell china worry
75,ISRG,stock be mixed midday wednesday upside earning surprise buoy nasdaq dow jone industrial average struggle thin loss ibm ibm weigh nasdaq composite rally rise dow jone industrial average be flat negative small cap outperformed russell volume be mixed tracking lower nyse higher nasdaq stock market today vs same time tuesday chip bank automobile related industry group lead upside gold miner fiber optic utility lag ibm gap tumble heavy trade month low stock have be consolidate past month undercut day move average close tuesday big blue report mixed result beat earning miss sale maintain outlook full year ep least analyst expect share top blue chip gainer include intel intc visa unitedhealth group unh apple aapl add rapid trade hold day line just buy point week tight pattern iphone maker be slate report quarterly result close morgan stanley ms rise fast turnover earning revenue beat street estimate investment bank stock have be consolidate early march be day line intuitive surgical isrg surge big volume time high share be well extend prior week tight entry be still play late tuesday robotic surgery system maker deliver result top view top bottom line thank growth procedure da vinci tool ibd lam research lrcx rally new high chip equipment maker late tuesday beat raise quarterly report several analyst raise price target dycom industry dy add follow tuesday past buy point related ibm beat bottom line miss revenue restructure surgeon maker pop smash consensus earning view
76,ISRG,stock open mainly higher help wave positive earning news counter heavy undertow ibm ibm tumble earning report late tuesday dow jone industrial average be flat rise nasdaq climb american express axp rise dow industrial ahead first quarter result close coca cola ko climb open credit suisse upgrade stock outperform neutral apple aapl run higher be just buy point week tight pattern earning drive bulk early action ibm dive first quarter revenue fall more expect earning rise expectation revenue company target core strategic imperative rise ibm share have be consolidate early march morgan stanley ms muscle report earning gain rise revenue number be analyst projection stock be work new base adtran adtn marched higher early trade optical network system maker report late tuesday sale earning easily beat expectation share rise day move average remain correction intuitive surgical isrg add early trade maker da vinci robotic surgical system report tuesday close earning rise revenue climb number analyst target stock gap find support week move average chip equipment maker lam research lrcx surge fiscal earning revenue gain top analyst target raise guidance view ibd stock be extend more buy point abbott laboratory climb open solidly beating analyst first quarter revenue earning target stock rebound find support week move average monday work first weekly gain week consolidation oil price bob trade essentially flat west texas intermediate hold just barrel ahead energy information administration weekly inventory report due et boston federal reserve bank president eric rosengren be schedule speak et federal reserve release april beige book report et related dow face point drag commerce giant be buy range stock basis ahead earning investing action plan
77,ISRG,stock market have be bit complacent recent week tumbleweed have be blow earning landscape change come week promise earning firework top rate growth stock latest week didn offer much way earning option play heavyweight financial citigroup jpmorgan jpm
78,ISRG,dow jone industrial average rally midweek wo president trump top aide signale tax cut other key agenda item be track dow credit card giant visa american express axp charge higher ibm ibm goldman sachs gs netflix nflx subscriber growth underwhelm even internet tv giant be hit user facebook fb tout augment reality developer conference dow jone industrial average fall month low wednesday follow weaker expect result ibm goldman sachs johnson johnson jnj blue chip index rebound thursday leave dow modestly higher week still day line index retook day line thursday return support friday nasdaq rally fuel chip gear stock facebook netflix predict reach milestone stream video subscriber worldwide weekend netflix miss forecast first quarter subscriber growth guide analyst higher customer addition current period internet television network expect end subscriber worldwide netflix fall tuesday close week virtually unchanged related ibm stock plunge big blue report straight quarter year year decline ibm revenue fall miss consensus time tech icon continue struggle multiyear transition ep rise share modestly beating related goldman sachs gs show surprise weakness first quarter trading bank chalk estimate miss result more re-serve market trump agenda stutter european election approach ultimately didn navigate market well deputy cfo martin chavez say quarter define franchise compound goldman wo rival morgan stanley ms beat goldman fix income trading revenue analyst estimate overall meanwhile bank america bac beat higher rate fed kick say fall treasury yield hurt result further related facebook ceo mark zuckerberg make augment reality centerpiece keynote presentation company annual facebook developer conference be also see strike snapchat snap operator snap be also push augment reality zuckerberg say mainstream augment reality platform future be not headset glass smartphone related strong result semiconductor equipment maker lam research lrcx spark rally already hot chip gear sector rival asml asml beat first quarter sale earning target disappoint guidance wireless chip maker qualcomm qcom post better expect fiscal second quarter sale earning guide analyst lower current quarter qualcomm warn potential revenue earning shortfall ongoing legal clash major customer apple aapl related crude future week barrel concern shale production offset opec effort rein global supply saudi arabia say several top oil producer have agree extend output cut help reduce global inventory energy information administration say inventory drop barrel smaller drop expect gasoline inventory rise barrel crude output continue rise schlumberger slb meet ep view drop revenue rise first increase revenue year fall short wall street view oilfield service giant say deploy more idled north american equipment see difficult year international business related unite airline ual turn strong first quarter share initially sell close slightly higher management defend plan expand flight reclaim call natural market share executive unite earning call repeatedly expressed need improve security forcibly remove passenger be tell give seat sell flight refuse additional policy change related incident management say present result review april meanwhile hawaiian airline parent hawaiian holding also report result top estimate send share soar friday related verizon report first quarter profit revenue fall even more lower expectation dow component lose surprising postpaid subscriber intense price competition verizon say buy least optical fiber wiring corning glw deploy wireless service installation firm dycom dy surge news fiber optic stock fall china demand concern verizon be set june takeover close yahoo yhoo report better expect earning revenue growth verizon ceo lowell mcadam say open strategic talk wide range company include comcast cmcsa fellow dow component walt disney cbs cbs related steel stock show sign life boost thursday executive order president trump lead new protectionist measure positive earning guidance nucor nue steel dynamic stld trump order launch promise be quick investigation import steel be hurt national security order potentially pave way trade restriction trade expansion act meanwhile nucor steel dynamic expect preannounce march report strong first quarter earning signale be also shape be good help stronger steel consumption nonresidential construction improve energy sector demand related trump turbocharge thursday top perform stock groupgeneral electric ge report flat earning share cent revenue less vs year earlier be better expect ge aviation power segment lead way dow stock sank friday undercut day line organic revenue climb organic order climb honeywell earning rise exclude divestiture sale edge lower honeywell hon rise friday hit record high intraday briefly top buy point related ge beat view lead aviation power honeywell topsebay stock tumble thursday keep fall friday even commerce giant receive several price target hike wake first quarter result meet revenue forecast beat bottom line revenue rise ep rise cent value good sell site quarter reach ebay guidance be light related dow component unitedhealth unh earn share first quarter year cent ahead expectation revenue grow top estimate unitedhealth also raise full year guidance be be help pullback obamacare exchange meanwhile large fast grow optum health service unit set unitedhealth apart other insurer expand reach acquisition surgical care affiliate related unitedhealth rise blowout surgical isrg stock launch record high wednesday report procedure growth first quarter sale rise year year top consensus adjust earning share rise beating dime related charle schwab schw logged most quarterly account opening year top forecast ep revenue growth ongoing online broker war have take trading fee major player schwab report growth retail brokerage account march end quarter meanwhile rival trade etfc handily beat cent ep sale td ameritrade amtd post mixed result visa result beat estimate cent ep revenue full year revenue guidance growth also top visa share initially soar record high friday close flat be still week american express axp also top forecast softer expect earning sale decline share leap thursday american express lose card partnership costco cost last year be midst premium credit card war jpmorgan chase jpm csx report first quarter earning revenue well wall street estimate operate metric also strong show csx be improve even ceo president hunter harrison take helm march csx also raise dividend cent share say buy back stock csx share surge thursday then add close buy point canadian pacific railway cp harrison previously be ceo also top view late wednesday rise thursday pare gain friday kansa city southern ksu narrowly top view friday morning fall sharply more then offset thursday advance union pacific unp gain thursday tick higher friday related drug medical product giant johnson johnson jnj abbott laboratory diverged first quarter earning sale be light drug revenue advance just adjust ep do top view abbott crushed view dow component fall week abbott lab rise related horton dhi report better expect quarterly earning revenue order cancellation rise share initially retook buy point quickly reversed fall thursday several other builder also reversed exist home sale rise year high march national association realtor report friday earlier week housing start fall more expect march homebuilder sentiment sank be still longtime high related
79,ISRG,dow jone industrial average lead downside afternoon trading tuesday hurt weakness goldman sachs gs johnson johnson jnj dow fall loss nasdaq composite be volume nyse nasdaq be tracking higher monday level stock market hold relatively well sharp loss london paris overnight paris cac swoon uncertainty outcome france presidential election meanwhile london ftse slump prime minister theresa say ll seek early election june strengthen hand head brexit talk year treasury yield continue bleed fall basis point bond market continue seem odd fed fed current economic outlook stock market today earning report financial sector remain focus goldman sachs gs slump be poise test day move average currently bank america bac reversed lower strong start share be rise early charle schwab schw have lot good news earning report include earning sale beat well highest number new quarterly account year headline didn help stock much share fall cardinal health cah crash company announce plan buy medtronic mdt medical supply unit cardinal also lower full year earning outlook ibd telecom infrastructure firm dycom industry dy clear base buy point share be afternoon trading verizon inked fiber optic cable deal corning glw dycom provide engineering construction maintenance installation service telecom provider intuitive surgical isrg give back ahead earning report close growth have slow dramatically medical device maker best know da vinci robotic surgical system minimally invasive procedure stock continue hold high company sell da vinci system fourth quarter year quarter related uk prime minister call snap election european stock fallgoldman sack wall street giant blame politic trading wo dow verizon buy corning fiber cable tv acquisition hold
80,ISRG,stock open lower tuesday feel drag overseas britain prime minister call early election pare initial loss dow jone industrial average be nasdaq composite british prime minister theresa call june vote move mean bolster political support go negotiation britain exit european union announcement come just ahead sunday first round presidential election france be see many facto vote country also exit european union london blue chip ftse dive cac paris be frankfurt dax be afternoon trade earning news rolled big bite late monday early tuesday johnson johnson jnj be nearly harley davidson hog drop more goldman sachs gs sank first quarter result miss view revenue earning line management raise quarterly dividend cent cent stock have be consolidate early march be now lowest level nov bank america bac edge squarely beating first quarter performance target earning rise revenue climb total expense be flat stock have be consolidate week line mid march unite airline ual scratch gain late monday carrier report first quarter earning less expect forecast revenue gain company project passenger revenue available seat mile second quarter share be rise support day move average unitedhealth group unh rac advance open health insurer report surprise surge first quarter earning revenue gain raise full year guidance consensus target share end monday session buy point flat base netflix nflx fall open follow first quarter report late monday earning soar top analyst expectation revenue growth meet view company add stream video subscriber quarter consensus projection new set eyeball netflix have be find support week move average mid february sporting good retailer cabela cab reel gain open construct deal capital financial cof buy credit card business synovus financial snv buy cabela bank deposit move clear path bass pro shop acquire cabela previously announce transaction facebook fb trade slightly lower ahead start day conference software developer chief executive mark zuckerberg launch confab keynote speech morning facebook share have pull back tight test support week move average set possible follow buy opportunity close ibm ibm yahoo yhoo lam research lrcx intuitive surgical isrg be company schedule report result new housing start be weaker expect march commerce department report run annualize pace february number be revise higher rate start economist project pace march build permit provide view upcoming activity be issue annualize rate february projection new permit kansa city federal reserve bank president george speak federal reserve industrial production number be due et related facebook dow stock report investing action homebuilder score new high industry perform well
81,ISRG,get robot be come drone warfare self checkout line grocery store change be clear sale automate industrial robot rise year year reach annual record unit accord international federation robotic unit be value more year
82,ISRG,stock be show impressive rebound monday open sell nasdaq composite turn loss gain nasdaq reflect resilience large megacap techs rise dow jone industrial average be turn drop nearly loss just fall more last week early monday dow jone industrial average briefly clip day move average first time fall south side key support resistance line back then take nearly month stock dow rebound back day line help dow be dupont dd be sole component rise point more diversify manufacturer be legitimate leader stock market today jan share also be recent nov past flat base buy point be less ibd best mutual fund award view winner categoryamong new issue snap snap be get plenty attention back positive comment analyst new buy rating share stride more higher possibly set highest close more week market debut snapchat social medium site operator leap past share ipo finish then catapult high come earth next session snap slide low normal cup double bottom base decline usually run more high low base ibd research big winner past bull bear market cycle so snap case decline be heavy side especially give fact gain share ipo do not exceed more recent positive wall street comment snap be course lose money consensus estimate net loss cent share still stock deserve close watch rebound continue stock get peak most excellent cup handle pattern stock tend form handle last final shakeout uncommitted holder big new high trading more week time high trump support american health care act never see light day friday investor continue watch lead name medical health care service industry group celgene celg intuitive surgical isrg regeneron pharmaceutical regn be day biggest point winner celgene rank big cap see whole list latest ibd weekly page failure american health care act future change former president obama affordable care act be unlikely suppress demand superior medicine treat patient deadly disease such multiple myeloma celgene be field also be become force treatment chronic illness such psoriasis celgene get wonderful ep rating ibd stock checkup due consistent pattern long term profit increase solid gain short term well past quarters earning share rise vs year level average ep gain be outstanding company market cap higher celgene have market value share outstanding be large not excessively so point comparison pfizer pfe have share outstanding street see fiscal year profit rise share lift revenue revenue rise vs year level prior year intuitive meanwhile remain top hill field robotic surgery system wall street see earning rise share current quarter accelerate increase see sale be see rise growth intuitive present buy point so far feb stock spurt past cup base entry volume expand nearly day average sign healthy demand mutual fund large investment adviser pension insurer go daily chart ll also see very narrow handle form jan feb create hard see early buy point add cent highest price handle obtain handle entry point notice daily chart stock gap huge volume jan reaction decent fourth quarter result ep revenue intuitive currently get solid composite rating better regeneron score watch see regeneron muster strength rise back day day line create space key resistance line earnest start form right side new base pattern related invest add week line pullback trading invest key great cup handle basestock market today do lead chipmaker deserve spot watch list ibd do big winner have common tech news ibd snap be get love wall street
83,ISRG,field robotic have capture imagination other industry company develop machine once be stuff science fiction today robotic be expand manufacturing first get foothold military drone be now battalion be used naval warfare robo global robotic automation robo etf capture wave innovation portfolio company develop used robotic technology company include name printing health care energy consumer product other industry such large portfolio many etf component be only partially involved robotic other be regard pure play firm say fund consist bellwether company be lead robotic company rest be firm enable robotic automation grow revenue contribution example nvidia nvda be make stride field self drive car main business be graphic chip intuitive surgical isrg pioneer robotic assist surgery have be better perform stock etf year irobot irbt be best know vacuum clean pool clean robot aerovironment avav make drone industrial military use have other business such electric car charger cognex cgnx make electronic vision equipment industrial inspection advance robotic be accelerate digital technology make increasingly possible automate function computer market robotic automation be expect grow accord research note robo global expert also see compound annual growth rate service consumer robotic robo global robotic automation be sole etf product robo global etfs dalla base firm component be equal weighting market capitalization portfolio be make big cap company midcap small cap be not only robotic etf however global robotic artificial intelligence botz be newer etf start trading september have fewer stock many be robo global robotic etf start trading october have surge more low february break base december be now have trouble maintain support day move average related cloud compute etf be load fang stock
84,ISRG,big cap techs be have superb first quarter so far just look nasdaq tech heavy index cover largest nonfinancial firm electronic exchange be end last year growth investor know strong market leader tend get stronger market show sign tip other
85,ISRG,thematic etfs be many thing many investor not good thing tend not be be dull chase fad other be underpin sound strategy exchange trade fund base specific theme begin investment process identify macroeconomic trend tesla tsla mobileye mbly top perform thematic etfs give exposure stock related stock share same underlie driver growth consumer want electric vehicle eye environment pocketbook also want mobile device allow always stay connect broader world trend be unlikely disappear anytime soon be benefit company mine refine use lithium metal power electric car smartphone battery global lithium battery tech lit target global company benefit lithium demand include tesla samsung panasonic etf jump march tesla steam ahead report vehicle delivery march be more robust expect alphabet googl self drive car amazon amzn alexa apple aapl siri put consumer friendly face machine learn artificial intelligence ai however robot ai automation have widespread industrial commercial used global robotic artificial intelligence botz seize company stand gain most trend stock holding include mobileye intuitive surgical isrg irobot irbt etf advanced march share mobileye spiked news acquisition chip giant intel intc mobileye israeli technology firm develop vision safety software make road safer lit botz be year date respectively vs gain latter be relatively new etf be trade care thematic etfs appeal investor seek beat absolute return benchmark long term accord global fund have shortcoming too track index stock be just loosely affiliated investment theme accord morningstar report make hairy ride global uranium ura be year sit feb high investor pay specialize investment lit example have expense ratio related be go etf market
86,ISRG,stock charge ahead tuesday follow last week big gain advance show good breadth once again plastic hospital fiber optic automaker chip equipment stock jump highest yet buy be strong defensive area wall street well confectionery gas distribution long term medical care stock also rally more rally add last week rise fourth weekly gain row dow jone industrial average lift nearly nasdaq composite almost russell popular small cap benchmark rolled more higher be now jan volume edge slightly higher nyse vs friday rise little more sharply nasdaq such turnover increase be impressive consider friday be witching day weekly monthly option expire tend boost turnover winner thump loser nyse more margin tuesday nasdaq margin be still bullish roughly confidence economy corporate earning continue encourage flow money big cap home depot hd report yet quarter double digit ep growth january end quarter rise be now past saucer handle entry revenue rise repeating increase fiscal third quarter end october note earning review ibd news reporter bill peter home depot be able increase profit faster rate sale thank continue shareholder friendly action heavily buy back share management also hike cash payout shareholder cent quarter approve new share buyback plan meanwhile advanced micro device amd priceline group pcln intuitive surgical isrg be also rise further past recent proper entry point advanced micro fierce rival intel intc personal computer core processor space gap tuesday open roar higher nearly clear week pause stock market cap putt squarely midcap big cap range have act very well propel past low price base notice daily chart amd find bullish buy support nearly week fast rise day move average amd lose money wall street expect turnaround earning cent then cent amd rs rating be maximum scale intuitive pioneer robotic surgery rise heavy trading rolled mildly past cup base buy point also see daily chart stock form narrow day handle start jan yielding early entry give intuitive slower move vs hypergrowth year mid not surprising see rs rating be middling rs line still recent high however middling rs be vast improvement lowly just week rs mean intuitive be now outperform third company ibd stock database past month rs rating put greater weighting latest month worth action also company continue post steady top bottom line growth past quarters sale have rise vs year level revenue eclipse mark meanwhile intuitive medical system equipment group rank not too shabby industry group month relative price performance see entire list industry group here go ibd datum table section stock list investor com apple aapl top perform megacap stock so far add rise further past cup handle buy point break initially dull volume jan apple have lead way batter blue chip name breaking end deep decline build constructive bottom base pattern apple be also more clear initial cup handle entry holder not be wrong take least profit base sell rule help savvy investor capture gain stock upside course supreme conviction apple decide be patient hold longer indeed lead name be capable rise stage significant price correction correction be genesis new basis confirm market uptrend equity be not rise alone chinese stock have rise sharply past few session tuesday trade mainland china focuse shanghai composite gain nearly straight session composite stand hearty year date fear escalate tension north korea neighbor continue nuclear test japan nikkei index bounce day move average past session stage overnight tuesday related big picture current price pattern major index right now home depot be sharing spoil invest be trump delay fiduciary rule boon bank invest apple form bottom base pattern
87,ISRG,hawaiian holding steel dynamic stld meet earning forecast late tuesday intuitive surgical isrg texas instrument txn beat estimate estimate fourth quarter ep jump revenue company parent hawaiian airline be see rise result ep revenue outlook capacity rise unit cost ex fuel full year capacity stock hawaiian slip hour share close stock market today hover just buy range related delta unite american declare mission accomplish delta air line see market share pressure atlanticunite beat cost surge csx mixedestimate analyst expect chip company report fourth quarter earning share cent revenue increase result ep revenue outlook ep cent include cent benefit vs view cent revenue midpoint just consensus stock ti dip late share end nearly year high still buy range breaking monday related stock close lower texas instrument break key company post fourth quarter earning share analyst see maker robotic surgical device grow revenue result ep revenue da vinci surgical shipment rise year stock intuitive surgical add late share close be work handle cup base buy point estimate wall street expect steel maker fourth quarter ep increase nearly fold cent revenue be see climb result adjust ep cent revenue stock steel dynamic be flat hour share finished be currently flat base buy point related ak steel allegheny earning top steel stock bend wayssteel dynamic be second steel maker profit day
88,ISRG,same day atomic scientist doomsday clock spread worry possible global catastrophe venture capital firm launch robot fear index track public concern range automation take job full scale robot apocalypse thursday member bulletin atomic scientist reset symbolic doomsday clock closest time midnight year say world be closer catastrophe due threat such nuclear weapon climate change donald trump election president also thursday loup venture debut robot fear index be base survey consumer attitude automation artificial intelligence robotic scale meaning fear robot meaning widespread extreme fear robot robot fear index have initial score robot fear index value suggest balance re cautiously comfortable robot andrew murphy loup venture manage partner say blog post robot fear index very well rise example expect index value increase follow fatal crash involve self drive car faulty surgical procedure perform robotic assistance consumer familiarity ai robotic technology have increase significantly recent year person frequently ask virtual assistant apple aapl siri amazon amzn alexa speak question also use self checkout kiosk grocery store robotic vacuum cleaner irobot irbt ve grow comfortable idea robotic surgery tool intuitive surgical isrg self drive car tesla motor tsla other however person be still concern ai robotic technology be head fear ll replace job somehow overthrow be blunt fear be valid murphy say quantify consumer say robot make nervous related amazon alexa dominate voice command tech ce nvidia ceo detail bold plan push self drive carsrobot push fight backer work company cause robot apocalypse
89,ISRG,stock index sail new high late afternoon trade wednesday volume picked second straight day build sector stir dow jone industrial average pop clear mark first time history nasdaq rise respectively small cap moved form russell add volume nyse nasdaq be tracking higher tuesday level stock market today ibd industry group build related stock such homebuilder heavy construction wood product cement be lead way day biggest loser include steel maker gold miner dow outlandish sound number have little meaning mileage marker do complement market bullish mood most stock dow jone industrial average be score gain more boee ba lead gain caterpillar cat be second gain attract heavy volume suggest institutional buy be move caterpillar break flat base clear buy point caterpillar release result thursday morning boee report quarterly result open beat street consensus estimate sale earning ibd take david ryan william neil protege comment current stock market breakout include datum storage firm seagate technology stx electronic part provider te connectivity tel intuitive surgical isrg martin marietta mlm parker hannifin ph nasdaq breakout include chip designer marvell technology mrvl contract manufacturer flex flex ibd proprietary growth stock screen also featured breakout include insurer essent group esnt computer peripheral maker logitech international logi other breakout include illinois tool work itw exchange trade fund ishare home construction itb vanguard mid cap vo related trump wall stock caterpillar material firm breaking outu crude oil output hit month highstarbuck growth expect be slowest year
90,ISRG,stock index barely stir thursday market sit day sizable gain nasdaq be flat slip blue chip dow jone industrial average rise volume fall major exchange accord preliminary datum pause day solid gain appear natural factor
91,ISRG,stock market open higher wednesday nasdaq dow jone industrial average reach new high dow reach elusive mark trade higher nasdaq rise fang stock amazon amzn facebook fb be trading slightly higher open breaking cup handle basis amazon be just entry facebook be hope continue momentum yesterday entry cisco system csco edge higher late tuesday cisco announce buy appdynamic appdynamic be expect price ipo wednesday night top target valuation vs prior private valuation freeport mcmoran fcx drop more miss top bottom line estimate fourth quarter result copper miner leaderboard member break cup handle base daily chart be hold just entry seagate technology stx share soar follow better expect second quarter result intuitive surgical isrg gain exceed fourth quarter earning sale estimate texas instrument txn moved follow fourth quarter earning sale beat company also guide first quarter earning street view unite technology utx drop miss fourth quarter sale estimate company say plan buy back share year boee ba add nearly surpass fourth quarter earning sale view ebay ebay qualcomm qcom network ffiv la vegas sand lvs be stock report earning today market close overseas market europe be trading higher particularly germany dax be trading japan nikkei gain hang seng hong kong rise related texas instrument beat target guide higher unite tech earning meet sale light see buyback
92,ISRG,stock market push time high close tuesday broad base rally capped lead rise russell nasdaq rally reach new time high dow jone industrial average follow gain move blue chip index striking distance volume be tracking much higher nyse nasdaq accord preliminary figure dupont dd lead industrial higher report earning beat monday market close miss revenue estimate stock gain reach new week high downside verizon communication vz drop follow quarterly earning release alibaba baba gain be much premarket hour chinese commerce giant report blowout earning sale earlier morning stock be build right side base miner construction stock be act particularly well stock market today freeport mcmoran fcx leaderboard member soar gapping cup handle buy point see daily chart copper mining company report quarterly earning wednesday market open mastec mtz surge nearly reclaim day line have be fight support last several week stock be now away short cup shape base entry meanwhile lag sector be medical merck mrk pfizer pfe johnson johnson jnj fall johnson johnson provide cautious outlook earning revenue fall short street estimate lead growth stock ibd be very positive close only stock red broadcom avgo continue recent dominance be lead stock ibd tack recent gain stock be now extend flat base entry downside healthequity hqy be volatile close minor change lead health saving account provider be now top buy range stock break flat base entry surge volume stock be initiate overweight rating keybanc monday close hawaiian holding steel dynamic stld other report quarterly result close hawaiian holding parent hawaiian airline meet quarterly earning estimate be ep surpass revenue estimate share fall almost hour steel dynamic steel producer have not announce be estimate report ep cent intuitive surgical isrg top earning sale estimate share rise texas instrument txn beat expectation top bottom line estimate share edge lower seagate stx quarterly earning exceed street view earning sale figure share gain additional rise regular market hour related alibaba crush earning estimate raise guidancej hcv dip virtually mirror gilead view air steel dynamic texas instrument report closeseagate easily beat bottom line sale also top estimate
93,ISRG,stock open modestly higher tuesday dollar continue higher mining stock rise include break base dow jone industrial average be fraction rise nasdaq add new administration president donald trump launch first week office secretary state nominee rex tillerson receive senate foreign relation committee approval monday confirmation full senate be expect next week senate approve rep mike pompeo kan head central intelligence agency also monday president withdraw tran pacific partnership trade agreement mining stock jump copper price continue climb rio rio be nearly announce sell coal ally industry business australia yancoal bhp billiton bhp vale vale climb nearly cliff natural resource clf rise more freeport mcmoran fcx gain breaking past buy point cup handle base long list earning report also drive premarket action verizon communication vz fall fourth quarter earning miss analyst estimate revenue fall slightly less expect verizon have be hold support week move average work cup handle base yahoo yhoo climb online content provider late monday report stronger forecast acceleration earning sale growth company also say acquisition verizon be delay second quarter alibaba group holding baba muscle open china base online retailer report solid improvement include increase cloud base revenue stock be climb right side cup base corning glw post gain open glass maker performance easily top expectation share be form flat base buy point lockheed martin lmt slump weak full year earning guidance overshadowed better expect result homebuilder horton dhi climb nearly healthy board beat fiscal result stock be trading week move average month long consolidation tuesday busy hour report schedule include result due alcoa aa seagate technology stx steel dynamic stld logitech logi intuitive surgical isrg stock market today get few piece economic news london base researcher markit deliver manufacturing purchasing manager index january et national association realtor exist home sale december be due et richmond federal reserve bank manufacturing index january be tap etoil future rise west texas intermediate add trade just barrel gold slip ounce copper jump almost dollar continue rebound bond slip leave year yield basis point overseas china benchmark hong kong shanghai rise tokyo nikkei fall europe market trade moderately higher afternoon action related fang facebook amazon form handle alphabet hit high
94,ISRG,intuitive surgical isrg be trading buy zone next quarterly report tap sometime jul trading buy point second stage flat base buy stock just ahead earning involve risk typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look best stock buy watch start heretop bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase analyst be look earning share growth quarter growth full year annual ep estimate be recently revise upward intuitive surgical have composite rating hold rank peer medical system equipment industry group omnicell omcl abaxis abax be also group highest rate stock note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
95,ISRG,nasdaq composite outperformed afternoon trading friday dow jone also hold impressive gain solid job report fuel positive sentiment session yielded several strong mover include alibaba baba share rise china name moved conviction price level be still buy range entry veeva system veev newest member leaderboard reclaim entry share rise nasdaq composite show noteworthy price action rise level conviction volume nasdaq be tracking close thursday level stock market result today dow russell add gain volume nyse be tracking higher thursday level economic news economy add job jobless rate fall wage growth tick annual rate line expectation enterprise software name hubspot hub look poise extend winning streak session share be late trading week clear early entry be just conventional entry elsewhere share intuitive surgical isrg pop nearly good flat base entry stock be strong food drug administration clear da vinci sp robot assist surgery device expand use vmware vmw jump nearly gap cup handle buy point be still buy range solid earning report be catalyst fang stock google parent alphabet googl be strongest gainer alphabet be only high breaking trend line thursday share facebook fb add clear buy point thursday volume thursday be average well level previous many day related option trading new issue mongodb carve base ahead earning reportfang stock fend critic fundamental intact healthy chartmassive beat raise quarter drife lululemon stock higher
96,ISRG,be year date not savory number index investor nasdaq composite rise ibd gain list premier growth company have outperformed large cap benchmark nearly fourfold have individual name do even better bet use ibd timesave screen pick great stock right time know make ibd mean company have top notch fundamental wonderful relative strength ibd remain watch list not buy list do mean let chart analysis bottom mini chart ibd weekly be compass stock be breaking permissible buy range analysis say so not then stay alert follow buy point such additional entry point include first second rebound week move average stock thrust week tight pattern let consider viper energy partner vnom intuitive surgical isrg svb financial sivb trade desk ttd tal education tal make ibd week feb february be pivotal month so far suffer first correction february yet company flex strength also help stock trader importance be nimble viper energy finished week end feb tiny gain trail rebound then oil gas play fall week row surface sound bad right well not necessarily be careful analysis viper weekly chart come play stock do fall week row limit overall decline skimpy stingy loss check week end march viper bound lows week cut loss just be tight weekly close tight weekly close base matter viper have lot treat subtle clue institutional investor be not willing dump share texas base firm uncoiled base past april volume wasn hissing quietly share exchange hand day average big price move big volume good result usually follow viper be now trading past proper entry intuitive surgical note stock day ibd social medium coverage hit new high jan then begin fall few day major index do share basically floated relatively tight trading range april stock character change report strong result earning revenue biggest top line jump more year intuitive jam week base be valid entry point robotic surgery system pioneer have not gain lot then medical stock leader have stretched advance early february svb financial tal trade desk have also clear new basis recent week be spanking year date return trade ibd efficiently innovator ibd etf ffty innovator capital follow david saito chung twitter ibd_dchung related be week tight pattern help investor make moneyglobal leader stock market todayipo leader
97,ISRG,globus medical gmed be top medical stock watch ibd member abiom abmd inogen ingn stock medical product industry group have highest possible composite rating composite rating mean stock be outperform stock
98,ISRG,here weekly investing action plan need know investor come week earning appetizer market sample past few week shift rich meaty entree heavyweight alphabet googl alibaba baba microsoft msft intel intc boee ba mcdonald mcd starbucks sbux chevron cvx report quarterly result president trump
99,ISRG,barclay analyst geoff meacham thursday say expect gilead science gild outlook be hinder limit hepatitis sale also see merck mrk alexion pharmaceutical alxn issue sluggish view be more bullish biogen biib johnson johnson jnj rbc capital wednesday say much same gilead also be more bullish biogen well amgen amgn hepatitis drug prescription dip quarter quarter accord market tracker im gilead make sovaldi harvoni combat hepatitis merck alexion meanwhile guide decline metric heavier spending new management respectively meacham predict argue be widely anticipate meacham say research report see biogen offer upside guidance spinraza launch ionis pharmaceutical ion johnson leverage cost control offer better view ibd take hepatitis sale fall gilead go check ibd industry theme full scoop biotech biggest be expect do ahead pharma earning season start next week report company such stryker syk intuitive surgical isrg meacham boost price target incyte incy stock note company phase tumor effort merck duo be testing immunotherapy keytruda epacadostat tumor meacham expect incyte earning conference call give color jakafi trial graft vs host disease well tumor effort merck bump price target incyte stock incycte hasn yet set date earning report incyte stock last week touch month high just shy rally close stock market today consensus analyst poll thomson reuter expect incyte report sale cent earning share third respectively vs year earlier quarter merck spending be likely ramp keytruda be grant priority review last week combination eli lilly lly chemotherapy alimta treat squamous small cell lung cancer nsclc patient high expression pdl gene keytruda alimta be phase testing datum be strong merck open larger patient population vs patient pdl expression keytruda be already approve monotherapy high express pdl patient nsclc related merck biogen lilly top approval fda slumptrump disastrous pharma view doesn rattle jpmorgan drug trump break republican push major drug reform
100,ISRG,stock index post moderate gain midday tuesday nasdaq gun sixth consecutive day nasdaq pop dow jone industrial average add respectively small cap have lag major index past session thrust higher volume stock market today be run higher nyse lower nasdaq nasdaq have not have day yet blue chip dow american express axp be leader american express have be bob week tight entry mediocre volume tuesday stock punch higher volume average american express have bullish volume ratio best possible ibd accumulation distribution rating figure point institutional support american express be fifth biggest hold warren buffett berkshire hathaway brka portfolio other payment processor also be do well tuesday mastercard rise quiet volume stock be work flat base financial dfs advanced volume average be extend november visa shift sideway slow turnover stock be work flat base ibd take earning preview stock be expect post higher growth quarter ibd collection top stock fundamental technical winner lead loser ratio health saving account provider healthequity hqy be leader surge heavy volume biotech stock illumina ilmn jump huge volume company announce new human genome sequence treatment day winner nasdaq show variety apparel retailer urban outfitter urbn rise china base internet content provider baidu bidu advanced yahoo yhoo add work flat base robotic surgery equipment maker intuitive surgical isrg pop ibd industry group metal ore steel airline be day leader laggard group such soap food show sizable loss related price target raise facebook alphabetis build stock get ready break small business optimism soar year high
101,ISRG,intuitive surgical isrg stock weigh medical sector wednesday tank sell zone slow growth procedure use robotic surgery product company late tuesday post massive sale earning beat stock market today intuitive surgical stock fall earlier fall low put stock nearly entry point achieve flat base investor be advise sell stock fall buy point ibd company medical system equipment industry group intuitive surgical lead term market cap fall nearly wednesday be fourth worst perform group track ibd take intuitive surgical stock lead group term market cap cantel medical group be term key growth metric have ibd composite rating meaning perform top stock keep tab stock checkup best stock bet total procedure rise intuitive surgical say tuesday firm say urology procedure da vinci prostatectomy equipment slow low single digit growth patrick clingan company vice president finance sale say growth level be consistent overall rate new prostate cancer diagnosis meanwhile gynecology procedure grow modestly year year lead malignant benign complex hysterectomy general thoracic surgery remain strong lead hernia repair cholecystectomy surgery decline growth multiport procedure be offset decline single site procedure clingan tell analyst company earning conference call late tuesday evercore analyst vijay kumar be bullish late tuesday intuitive surgical stock consumable revenue procedure grow prior quarter be first time metric top say print reaffirm view xi upgrade cycle be nice adoption cycle higher consumable revenue procedure be very positive sign write research report be order timing think mix contribute well kumar blame stock decline investor go result high multiple stock fine tooth comb cause volatility earning say nothing have change company medium term outlook kumar reiterate buy rating stock boost price target related top view buoy intuitive surgical say surgical earning revenue beat
102,ISRG,success mind stock investor desire sell stock top investor be also human impossible be perfect yet don need be perfect bag large chunk profit best stock be ibd investor corner column have publish hundred article best rule selling big winning stock rule involve properly draw trend line used trend line identify serious decline be spur active institutional selling practice anyone draw proper trend line weekly chart good stock break properly draw trend line heavy volume usually time sell best stock tend pull back numerous time long run make higher high higher lows nevertheless watch pullback carefully be sell kill rally trend line start low first pullback week line proper base such cup handle flat base trend line extend lows subsequent pullback draw line weekly chart span least week line draw daily chart draw shorter period compel sell too early trend line method be not design trigger sell right top be repeatedly show work growth stock investor also consider overall market health stock fundamental other chart signal decide time sell big picture column help understand market health be aware general reaction individual stock follow corporate earning report too intuitive surgical isrg pioneer maker da vinci robotic surgical system break buy point cup handle base july company turn year net loss strong profit year unleashed torrid run intuitive climb next year half peak jan then spend next month form new base year be good stock intuitive break again rise week end march surpass new buy point long base resemble shallow double bottom handle next month medical tech firm climb steadily find support rise week move average then share really take nearly jump week end july trend line be draw first point be low week used logarithmic chart second third point trend line be connect lows week end oct nov total time period first point third point trend line week january intuitive change character stock trade volatile manner then fall week row second third week decline stock slide combine price action violate properly draw trend line time sell intuitive make giant rebound week move average month later go complete new base be wide loose thus flaw past deep handle lack power send intuitive hit new high faulty late stage basis also flash valuable sell signal alert shareholder late november lehman brother bankruptcy subprime debt meltdown intuitive drop low peak editor note column originally publish edition ibd related be stock make lot share split be time exitwhy shape base mean time sell
103,ISRG,early tuesday johnson johnson jnj post better expect earning include double digit sale growth advanced surgery evercore analyst vijay kumar say prove boon intuitive surgical isrg stock however have diverged close bell stock market today johnson johnson finished day intuitive surgical stock close gain share intuitive surgical be set report earning close tuesday share try gain traction breaking flat base ibd take johnson johnson be face upcoming rivalry pharmaceutical unit celgene gilead science galapago biogen be also work drug treat crohn disease johnson johnson report sale earning share item respective vs last year metric top consensus analyst poll thomson reuter sale fall huge consumer segment other hand pharmaceutical medical device sale grow respectively pull still small advanced surgery device unit general seem be bode well intuitive surgical kumar write research report intuitive surgical be know da vinci robot surgery system analyst expect intuitive surgical report ep ex item sale ep dip sale climb related be google plan surgical strike intuitive da vinci
104,ISRG,intuitive surgical isrg report third quarter earning close tuesday company da vinci system be leader robotic assist minimally invasive surgery quarters more year year growth ep ex item earning be expect fall tad comparison get tougher sale growth be expect remain fairly steady johnson johnson jnj early tuesday post solid rise advanced surgery device business be good sign rival intuitive estimate ep ex item be see fall revenue growth accord analyst poll thomson reuter result ep ex item revenue ship da vinci surgical system prior quarter ep ex item rise sale jump biggest increase quarters company say ship da vinci surgical system stock intuitive surgical rise stock market today share be nearly hour earning release stock clear buy point flat base just barely stock have do little hit buy point do touch record high oct relative strength line be new high related boost intuitive surgical chart look good not good
105,ISRG,stock market open mixed turn modestly higher early wednesday oil stock rally earning morgan stanley ms other major company influenced early trading nasdaq erased tiny loss rise dow jone industrial average add hold gain volume be tracking slightly lower board energy sector lead price crude future rise more barrel lower inventory sign decline output china drill exploration oilfield service oil machinery be oil gas industry group top today trading google parent alphabet googl follow yesterday add almost heavy volume earning continue sway wall street major financial technology health care company be day docket morgan stanley climb nearly bank beat profit expectation be latest investor please quarterly report major bank revenue also top view surge bond trading help quarter stock be slightly buy point intel intc slide nearly erase gain buy point early september also gap day move average heavy volume put stock perilous position chipmaker guidance be weak report result late tuesday intuitive surgical isrg fall nearly company sale earning beat expectation operate earning be share revenue increase stock slide much buy point intuitive have difficulty climb stock also pierce day move average heavy volume leave share compromise wednesday canaccord genuity analyst jason mill raise price target cite expand margin increase procedure spike revenue procedure ibd homebuilding industry group edge other construction related industry group fall mixed industry report housing start annualize september be slowest pace march economist have expect slight increase pace drop be due volatile multifamily start single family start jump september highest february build permit gauge future activity climb pace highest november related morgan stanley profit soar bond trading revenue surgesintel investor cash chip guidance start dive month low single family activity strong
106,ISRG,new high be fine individual investor already have position stock other new high be actionable only stock be clear valid base stock be flirt new high not quite able break too be useful possibility be new high volume new high reverse lower be case new high communicate trouble tuesday market have bit everything rv maker thor industry tho gap new high torrid volume stock be too extend buy point ditto computer networking company gigamon gimo heart device maker abiom abmd online marketplace operator amazon com amzn also be extend stock rise new high volume average spike be generally consider minimum level bullish action amazon size make less issue spike be quite good mammoth stock other stock peg new high average volume include telecom play lumentum lite health account operator healthequity hwy network equipment maker arista network anet online food delivery restaurant order facilitator grubhub grub ibd take intuitive surgical stock chart look good be flaw fundamental side use ibd stock checkup do fast yet comprehensive research company fundamental technical institutional sponsorship strength be critical make true stock market winner stock mentioned here robot surgery aid intuitive surgical isrg probably have most invite chart situation technically stock clear buy point stock close only cent entry individual investor watch better volume be only average weekly chart show net accumulation pattern relative strength line be new high be bullish intuitive be only group stock checkup related fedex stock rise againgrubhub call long term winner food delivery
107,ISRG,intuitive surgical isrg intel intc hawaiian holding yahoo yhoo top earning forecast close tuesday estimate earning share vs year earlier revenue result ep revenue stock share rally late stock have consolidated flat base then couple effort break past buy point estimate earning share cent revenue result ep cent revenue outlook revenue midpoint consensus charge stock share sank late intel share recently clear flat base base pattern intel stock be buy range estimate earning share vs year earlier be third straight quarter decelerate growth revenue rise be fourth straight quarter accelerate growth result ep revenue outlook capacity growth full year capacity growth stock hawaiian airline parent stock break cup handle base buy point share rise late tuesday estimate adjust ep cent revenue result ep cent revenue outlook full year revenue stock share edge hour web portal cancele conference call wake pending acquisition verizon communication vz fallout massive datum hack verizon say last week reasonable basis declare datum breach yahoo email account material verizon purchase open door renegotiate term scuttle acquisition altogether telecom july agree buy yahoo nearly include employee compensation cost
108,ISRG,key investing success be always keep build watch list even market come selling pressure have recently best stock be typically first move uptrend regain strength want be prepared act happen list feature top rate stock intuitive surgical ticker
109,ISRG,here investing action plan tuesday need know investor come day earning season kick high gear slew big name company tap include intel intc domino pizza dpz unitedhealth unh goldman sachs gs hawaiian holding also report tuesday several company be proper
110,ISRG,google parent alphabet googl vow create future surgery verb surgical joint venture johnson johnson jnj intuitive surgical isrg da vinci system remain clear leader robotic assist minimally invasive operation fiercebiotech report last month verb surgical be aim develop next generation system incorporate robotic advanced visualization machine learn datum
111,ISRG,mom have tell never judge person look do stock be especially case be individual investor professional advisor wish use chart full advantage do have sharp eye do want improve chart read skill do ll be able improve return stock market avoid stock form shape base harbor big gain stock carve faulty pattern then know market have present gift insight ibd research stock be very close peak thus be sell investor be discriminate basis be shape not only do shape cup pattern differ greatly winning cup basis also bring other sell signal just stock strong fundamental shape base doesn mean automatic buy still have pore stock chart decipher good bad price volume action shape base initially look good action stock stage fast recovery selling sometimes type action be akin be too fast too furious be not healthy shape basis don allow stock go more natural correction sharp pullback good see stock consolidate week wear remain weak holder create better foundation result shape pattern cup cup handle base be short week respectively basis biggest stock market winner have take month more form qualcomm qcom clear month cup handle january stage astronomical run sunpower spwr blast month cup handle pattern more quadruple top sometimes shape base stock fall hard couple week then rally couple week gain new high ground fast recovery new high be sell signal mean stock be top time pullback send stock week move average typically heavy volume week week sell signal generally occur long uptrend keep watch variation sell signal sometimes be week follow week new high late october intuitive surgical isrg fall straight week find support week move average point decline look normal be fine start potential new base volume latter week cool good sign lead maker robotic surgical system then rise week row result faulty shape base be week long week short week minimum length cup pattern good time didn last intuitive surgical soon reversed lower slump next few week get support week line have buy stock clear shape cup keep loss small have avoid serious pain portfolio so always cut loss short maximum stock action doesn look right mean sell more quickly editor note piece originally publish april edition ibd
112,ISRG,someday po be take fast food restaurant order cook burger fry instead save galaxy star war say have bad feel consider current business technology trend political push raise minimum wage nationwide hour have motivated many restaurant other business low skilled worker think replace human staff automation robot same time such technology be improve leap bound cost be come ibd take always be good stock top fundamental breakout ibd stock spotlight flag learn domino make current list already restaurant chain mcdonald mcd wendy wen be add self service kiosk take order payment customer thousand location domino dpz be testing wheel pizza delivery robot drive home unlock storage compartment smartphone mcdonald stock rise stock market friday company post better expect earning domino stock restaurant industry rare top performer touch record high fourth straight day end trading wendy stock rise friday help positive mcdonald earning report restaurant kitchen be next area automation take hold industry expert say silicon valley entrepreneur be take restaurant automation next level eatsa fast food restaurant chain have location san francisco berkeley southern california woodland hill be fully automate front end customer place order ipad kiosk pick food vending machine cubicle see human worker eatsa serve vegetarian quinoa bowl variety topping kitchen staffer prepare meal back room andy puzder ceo cke restaurant holding tell business insider last march be inspire visit eatsa explore more automation cke chain include carl jr hardee san francisco base startup momentum machine have build machine crank make order hamburger hour robot grill patty add topping assemble wrapped burger help human momentum plan open restaurant soon san francisco mountain view calif base startup zume pizza be used robot make pizza realm food service innovation engineer also have create robot make cook burritos bratwurst noodle sushi other eat cost be big driver labor cost rise business pass increase consumer look way reduce overhead raise price consumer lead reduce sale quick service restaurant be turn technology improve efficiency lower cost just other industry have automation have go atm banking self service airport kiosk self checkout grocery aisle amazon com amzn famously automate much fulfillment warehouse acquisition kiva system restaurant automation be happen even pressure cause fight movement jeff burnstein president trade group association advance automation tell ibd manufacturing other business company be look better way do thing improve productivity lower cost burnstein say industry expert say fight movement have accelerate automation push term automation have benefit restaurant industry lower cost dan kara practice director robotic abi research tell ibd benefit include avoid worker injury prevent food contamination say move more automation quick service restaurant business be early stage automate order take cashier function be easy part kara say next generation customer kiosk move touchscreen order take speech recognition simplify speed process say person be more accept now self service automation technology retail wendy mcdonald today get own soda now time somebody do kara say travis brigg ceo partner robo global be keep eye workforce automation movement investment opportunity firm create robo global robotic automation index etf robo consist more stock focuse robotic automation year old fund hit time high earlier month be friday person component restaurant business be extremely expensive brigg say just natural area more automation re move stage interesting novelty new era necessity robo index include industrial automation firm abb abb hollysys automation holi asset tracking specialist zebra technology zbra machine vision firm cognex cgnx automate drive technology firm mobileye mbly speech recognition tech firm nuance communication nuan robotic surgery pioneer intuitive surgical isrg even restaurant shift more automation ll still need human worker robot break go make hamburger sushi burnstein say employment shift low wage burger flipper higher wage technician engineer service maintain restaurant system say related wendy serve big kiosk expansion wage hike hit fast foodmcdonald ceo dodge harsh fast food wage realityblame minimum wage not carl jr ceo automate top job robot steal human
113,ISRG,third quarter earning season have kick full gear come week be busiest yet several blue chip name nasdaq titan release result blue chip investor be watch report caterpillar cat dupont dd early week report tuesday open caterpillar be recently still buy range
114,ISRG,major stock index hold solid gain early afternoon trading tuesday help round mostly healthy earning report nasdaq composite lead way rise just add dow jone industrial average lag rise unitedhealth unh goldman sachs gs outperformed dow strong earning wall street frown earning dow component ibm ibm johnson johnson jnj stock market today alphabet googl jump more good volume modest pullback owner google be back buy point still buy range credit suisse monday reiterate outperform rating raise price target netflix nflx surge nearly quarterly profit cent share double consensus estimate sale growth accelerate third straight quarter rise leaderboard name domino pizza dpz jump also strong earning intuitive surgical isrg continue hold well ahead earning report close share rise slightly money weekly call option strike price recently offer premium present trade reasonable downside risk just ibd take used option earning be less risky buy stock ahead earning week ibd earning preview column delve strategy provide potentially actionable name strong mover ibd include pra health science prah match group mtch gain more related domino pizza earning beat comp sale jump takeaway netflix earning surprise stock surge
115,ISRG,stock hold decent gain hour left session tuesday advance have be fuel large part positive earning result market closely watch news more company report close include robotic surgery firm intuitive surgical isrg ep estimate share hawaiian airline operator hawaiian holding ep intel intc nasdaq composite hold day move average run more higher session high nasdaq slightly outperformed nyse composite gain dow jone industrial lag gain volume be higher exchange vs same time monday restaurant stock be show life continue wo burrito taco chain chipotle grill cmg edge be time high wall street expect chipotle third quarter profit fall share contrast del taco taco lake forest calif fast food chain bolt higher fifth straight gain small cap dine play have market value much smaller chipotle market cap however del taco be rise sharply report gain earning cent share sale grow remain single digit mode del taco tax margin jump year quarter systemwide same store sale rise del taco management news release cite progress unfreshing believable campaign highlight use fresh ingredient restaurant level margin grow basis point gaap basis stock launch long deep bottom style cup handle breaking past buy point stock be extend entry note weekly chart share have encounter upside resistance thus more pivot point develop del taco be only company ibd member retail restaurant industry group relative strength rating higher del taco rs have middling composite rating maximum likely improve quickly tuesday big gain domino pizza dpz part ibd leaderboard surge more get extend follow buy point second test buy support day move average domino earn rs rating domino first enter leaderboard leader list elite growth company feb year industry peer jack box jack operator qdoba eat fast casual chain rise nearly just shy rise north side day line lead stock be nearly jan wall street see earning jump cent share company be likely report september end fiscal result november elsewhere stock market today tesla motor tsla rebound nearly briefly undercut recent low monday share ev maker be still swimming fall day move average ceo elon musk postpone new product announcement wednesday monday related be bottom base domino make lot dough tesla score big third quarter order need more cash health care firm lead stock market unitedhealth break
116,ISRG,third quarter earning season have kick gear come week isn short decent technical setup market uptrend pressure continue suffer sign institutional selling remain issue recent month column have focuse option strategy introduce ibd minimize risk earning rather buy stock
117,ISRG,global market starve growth lead manager justin kelly think mainstay large cap growth fund mlaax be feast shark school tasty fish lose more twice much ground first quarter average large cap growth rival track morningstar inc fund double peer group gain so far quarter be ahead vs peer mutual fund go thursday so fund sudden burst speed market have tilt back type stock favore fund include stock unitedhealth group unh be year lead manager justin kelly think party growth stock be still ramp growth stock underperform year vs call safety stock kelly say safety stock do best year bond be decline yield be utility staple telecom reit do well first half year june fund have be tear fund focus stock grow faster broad market current global market growth overall be slow stock manage generate average growth be greater demand kelly say happen growth stock do better value fund rip key fund maneuver various market phase adjust allocation type growth stock manager seek bucket contain stock fund see long term sustainable earning grower second bucket contain quality cyclical grower third hold stock newer industry rapid growth sustainable grower have competitive advantage let grow year year unitedhealth group be example revenue provider health care coverage benefit service have grow double digit pace quarters row broadcom avgo be fund cyclical have radio frequency filter be highly desirable best market allow mobile phone jump frequency kelly say give pricing power few other vendor semiconductor industry have broadcom filter kelly add enable phone work network different country user move cell tower facebook fb be bucket stock newer industry rapid growth top hold june rapid growth come market share gain advertising return investment advertiser be better get other platform television print kelly say more advertiser shift dollar higher facebook think growth continue year intuitive surgical isrg be also rapid growth bucket intuitive robot system be start catch new surgical market especially hernia case kelly say have become widely used prostatectomy hysterectomy growth have lag heyday estimate earning growth be street perhaps current slow growth economic environment manager think best prospect be company fast steady earning sale growth see best opportunity newer faster grow company kelly say also consistent growth be substantially overweight newer faster grow company consistent grower be underweight cyclical still manager clark patrick burton also run fund don hibernate market tilt away strategy take advantage broader pullback market spring kelly say fund start position intuitive surgical also fund increase stake unitedhealth top hold be take market share medicare advantage medicaid market say steve hamill health care analyst capital fund subadvisor optum health service business have be tremendous growth business hamill say generate unitedhealth earning other holding activision blizzard atvi earning share jump past quarters company be shift online gaming away reliance console base video game boost margin kelly say next growth come sport turn video gaming sport spectator such person go madison square garden watch other gamer say zimmer biomet zbh be newcomer portfolio fund begin current stake spring thesis here be be steady grower hamill say re lead company orthopedic implant related surgical category fundamental slide merger zimmer biomet close june due redundant sale force other inefficiency hamill say now company have cut cost surgeon zimmer biomet product hamill add earlier year many wall street analyst expect company continue lose share especially hip knee market think grow least fast market hamill say think company growth be even better spine trauma market revenue growth margin expansion be key driver add fund institutional share mlaix carry load expense ratio minimum investment be meet plan brokerage level related john roth equal top perform fidelity new insight fundjanus manager bet proven champ comer calculate risk hot hodge mutual fund shine several lead stock holding climbwhy winning mfs fund prefer stock durable growth fastest growth
118,ISRG,handful new high involved breakout wednesday give bullish investor buy candidate caterpillar cat break shallow base base pattern volume be average move be good enough week high stock still be face overhead supply decline begin july analyst expect caterpillar earning drop year then rebound not be enough turnaround attract discipline investor base base pattern often form response shaky market stock fail gain least then consolidate second consolidation often sketch lowest pattern high previous pattern market turn more bullish base base deliver big gain june initial public offer mindbody mb break cup base stock marked new high drawback cast shadow stock first daily average dollar volume be putt stock thin side second pattern be third stage be third stage problem stock rise pause consolidate breakout first basis be more likely work later base mindbody develop software health sector worthington industry wor break base base pattern volume almost triple usual pace pattern be second stage worthington be steel processor tucow tcx break volume more average pattern be see cup handle cup larger consolidation stock be thinly trade tucow provide internet telecom service intuitive surgical isrg continue flirt stock have sketch base base pattern hasn be able break intuitive make robotic surgery equipment assist surgery
119,ISRG,stock make solid stride tuesday main index seek keep moderate uptrend right track nasdaq lead increase wipe away monday loss chip internet stock class be well represent composite layer claim day best perform industry group amazon com amzn winner ibd
120,ISRG,make money buy good stock hold go then sell say roger doesn go don buy own way roger point fallacy buy low sell high investment myth low be low high be high parameter re flail dark roger start right buy good stock good probably already know outstanding earning sale growth recent quarters past year solid accumulation institution sweet margin return equity new product service take country storm do buy low mean bargain hunting investor do well approach don end apple aapl intuitive surgical isrg major winner initially break high share price then keep go higher more likely bargain hunting approach lure buy someone else problem date technology wane customer base stiffer competition patent expiration worst world have moved bargain company ll pick favor airline stock solar energy sure maybe future right now stock be deep toilet be afraid pay higher price earning ratio be real bargain be buy high sell higher be end great winner look baidu bidu china lead search engine baidu be lead market uptrend bottom first base stock trade split adjust february monthly chart be show time ratio be still finished long deep base break week high contract still high baidu rally then go correction worst panic selling baidu fall share ratio rebound stock form new basis hit new high so see ratio fall company earning catch optimistic projection remember too es rise stock price break build big gain editor note column originally publish march edition ibd
121,ISRG,conventional wisdom sometimes advise caution boldness be require example stock gap base natural think too late buy ll hear remark ve buy last week today big gain way too late buy kind think paralyze many investor ibd be momentum investing then too late argument be valid investor buy junky mediocre stock simply big price gain be assume more risk be prudent sometimes ll see stock weak fundamental notch big gap gain often sloppy base move seldom hold not too surprising stock have weak fundamental reason buy certain condition be meet market be confirm uptrend stock have strong fundamental industry group be market leader stock break base heavy volume condition be meet then huge gap gain be least risky stock buy yes think buy stock ve buy much cheaper day earlier exactly do let consider few example gain be calculate close price gap rather ideal entry stock skip case market be confirm uptrend year ipo mastercard gap clear base volume be average month stock rise additional composite rating be day next day green mountain coffee roaster gap huge volume stock rise further month composite rating be july intuitive surgical isrg gap surely be too much consider buy not stock advanced additional month composite rating be priceline group pcln gap aug quiet trip day line stock rise further month composite rating be editor note column originally publish feb edition ibd green mountain coffee roaster later change corporate name keurig green mountain be acquire march
122,ISRG,medical stock particularly drugmaker play key role buoy challenged market first half year year date tuesday ibd medical sector industry group show average loss biotechs ethical drugmaker be hardest respectively have left medical group rank
123,ISRG,intuitive surgical isrg maker robotic surgery system late tuesday post earning revenue handily beat wall street expectation send share rise hour earning share item rise year earlier quarter sale rise analyst poll thomson reuter have expect maker da vinci surgical system minimally invasive surgery didn provide guidance earning release analyst expect ep ex item quarter sale intuitive surgical stock be nearly hour trading company release result share rise fraction tuesday regular session intuitive stock hit time high july move flat base buy point june so share remain buy range da vinci success have spawn more competition alphabet googl verily unit formerly google life science have team johnson johnson jnj advanced surgical robot early tuesday post earning beat johnson johnson stock hit record high tuesday close medtronic mdt make big move field acquisition last year covidien company say number da vinci procedure rise nearly vs ship da vinci system vs pre earning research note leerink analyst richard newitter say intuitive be increasingly benefit next leg growth da vinci xi system launch
124,ISRG,buyer maintain upper hand late afternoon trading wednesday dow jone industrial average poise ninth straight gain dow component microsoft msft gap top long consolidation strong earning facebook fb meanwhile break base buy point ahead earning report next week facebook volume be slightly average signale lack institutional buy nasdaq gap open help several strong earning report be clear leader hour left go session add dow rise volume stock market today be tracking slightly higher nyse nasdaq tuesday level much current market uptrend confirm june growth stock be act better help scant sign institutional selling july good environment stock make headway always good see plenty breakout early stage confirm uptrend market deliver plenty wednesday ibd china base new oriental education edu reversed higher report strong earning open clear cup handle base buy point share jump nearly new oriental be top rate stock consumer service education group china base name be see be ibd stock checkup biotech ligand pharmaceutical lgnd add still buy range handle buy point see daily chart intuitive surgical isrg gap solid report share soar nearly head wednesday session be still buy range buy point extend now elsewhere papa john pzza gain strong earning news bode well domino pizza dpz report thursday open domino rise briefly top buy point ibd take domino briefly clear cup handle buy point wednesday see daily chart learn more recognize bullish chart pattern visit ibd university new york mercantile exchange west texas intermediate crude oil august delivery add barrel year treasury yield rise basis point
125,ISRG,new high list expand nicely wednesday several top rate growth name lead charge monolithic power system mpwr add ahead earning report monday close volume be slightly average chip designer be slightly extend cup handle base week end buy point be
126,ISRG,stock make positive open wednesday aid raft heavyweight earning report dow industrial be almost flat add nasdaq lead gain small cap russell future be microsoft msft climb stock market today intuitive surgical isrg new oriental education technology edu be other stock move earning microsoft rise open bell late tuesday microsoft report surprise increase adjust fiscal earning revenue azure cloud business double past year management revenue guidance be view microsoft share be build right side consolidation go back end last year intuitive surgical climb maker da vinci robotic surgical system report earning share gain revenue rise late tuesday intuitive surgical share have be buy range clear entry point flat base late june morgan stanley ms rise report broad second quarter beat earning share slip better consensus expectation decline revenue also decrease less forecast ibd stock new oriental education fall premarket trading announce result give weak outlook be nearly flat early trading valeant pharmaceutical vrx jump open food drug administration late tuesday approve use valeant relistor constipation tablet steel distributor ryerson hold ryi tumble chicago base metal processor price follow offer common share tuesday close price ryerson be more february low topple monday announce offer cinta cta jump top fiscal fourth quarter earning revenue target raise full year earning guidance analyst estimate cincinnatus ohio base provider uniform end tuesday session buy point retake buy point late june ibd global leader stock yirendai yrd climb open bell online consumer lend operation be extend cup base buy point only significant item wednesday economic calendar be energy information administration report weekly oil inventory eastern time weekly datum american petroleum institute tuesday show inventory barrel week end june line expectation accord oilprice com surprise build gasoline inventory send oil price lower late tuesday oil price downshift early wednesday west texas intermediate drop nearly barrel brent crude be gold slip more ounce dollar rise vs euro yen be outpaced rise pound year treasury yield add basis point china market capped mixed session hong kong hang seng index tokyo nikkei slip stock europe turn mixed afternoon trade cac france trim gain germany dax be ftse london slip gain
127,ISRG,stock rally wednesday fuel strong earning report lead dow fresh time high microsoft msft lead blue chip jump nasdaq score gain thank also big move facebook fb intuitive surgical isrg tech heavy index close best level nearly month follow advance dow jone industrial average add volume be higher board vs tuesday accord preliminary datum leisure software medical related stock take lead stock market today gold miner food steel stock lag gold future fall ounce west texas intermediate oil climb barrel hour ebay ebay jump sharply online marketplace post upside surprise top bottom line raise full year guidance rise regular session intel intc fall close revenue miss share be close mattel mat regular session trade leap extend trading narrower expect quarterly loss microsoft gap gain triple normal trade xbox surface tablet maker post big quarterly earning revenue beat hour tuesday share get close new time high session intuitive surgical gap soar new high healthy trade close tuesday surgical system maker report result top view share be now extend past buy point initially clear june stock be sharply extend trading facebook rise clear flat base buy point average volume analyst expect jump profit social network report next week ligand pharmaceutical lgnd rise breaking past handle point fast turnover biotech share remain buy zone ibd new oriental education edu stage sharp upward reversal finish jump heavy volume share chinese educator report solid quarterly result open rushed past buy point still buy range economic report due thursday include weekly jobless claim philly fed business outlook survey july exist home sale june chipotle grill cmg general motor gm starbucks sbux be company report quarterly result thursday
128,ISRG,stock rise midday wednesday dow jone industrial average hit new high strong earning report volume picked nasdaq rise add dow jone industrial average climb volume be run higher nyse nasdaq compare tuesday facebook fb rise clear buy point flat base volume be run well normal facebook be try third straight gain get support day move average however stock accumulation distribution rating be neutral indicate standoff buyer seller microsoft msft jump heavy volume software giant report gain profit latest quarter cent share well wall street estimate sale slip microsoft be face resistance medical stock be best performer stock market today intuitive surgical isrg jump heavy volume maker robotic surgical system post strong result intuitive surgical be extend buy point flat base medical software stock medidata solution mdso soar month high heavy volume post better expect gain profit cent share sale rise medidata solution be buy range entry cup handle base meanwhile eagle material exp rise heavy volume breaking past flat base buy point most ibd stock be higher lead chinese education stock new oriental education technology edu erased early loss climb more follow quarterly earning report volume be heavy stock clear buy point cup handle base
129,ISRG,dow jone industrial average ride longest streak march be look ninth straight advance stock future signal higher open fuel strong earning microsoft msft other meanwhile facebook fb threaten hit buy point dow industrial future be point vs fair value stock market today future be point higher nasdaq future be point tuesday dow rise dip nasdaq composite lose microsoft rise premarket trading late tuesday microsoft report surprise increase adjust earning share azure cloud business double past year microsoft share be build right consolidation go back end last year stock have potential buy point intuitive surgical isrg climb nearly intuitive surgical maker da vinci robotic surgical system report ep gain revenue rise late tuesday intuitive surgical share have be buy range clear entry point flat base late june stock look set be extend wednesday open ibd take buy stock earning enjoy big gain big loss here be strategy limit downside risk ibd stock new oriental education edu fall new oriental education profit chinese private language test prep provider report wednesday morning profit cent share penny wall street view revenue rise slightly view give weak revenue guidance new oriental have form flat base buy point appear likely fall day move average open meanwhile social networking giant facebook rise buy point flat base pattern facebook chart be not flaw facebook report earning july market close intel intc qualcomm qcom network ffiv be company report earning check earning preview intel qualcomm network
130,ISRG,share microsoft msft unite airline ual intuitive surgical isrg get bump hour stock market today company release strong quarterly result financial service dfs meanwhile edge estimate fiscal fourth quarter earning share cent revenue edge result microsoft earn cent share vs year earlier revenue rise first gain quarters sale company intelligent cloud segment grow revenue azure company cloud compute platform surge company productivity business process segment rise office commercial revenue jump tech giant have place bigger bet cloud service concern legacy business have top microsoft last month say buy professional networking site linkedin lnkd microsoft share rise hour action share close estimate ep drop revenue unite airline month say expect consolidated passenger unit revenue decline quarter better earlier forecast result unite earn share revenue slightly top view consolidated passenger unit revenue fall due strong dollar weaker travel demand competition weaker demand pricier airfare other factor company say carrier also forecast capacity growth year forecast give april unite expect capacity grow consolidated passenger unit revenue fall airline face prospect higher fuel cost cut profit concern expansion lower airfare competitive market be hurt financial result unite airline stock rise early hour action reversed lower trade unveil share repurchase program share close higher estimate ep year earlier revenue result ep rise beating cent net revenue be just view total loan rise day delinquency net charge rate inched quarter concern persist consumer borrow reach more fragile height bank jpmorgan jpm bank america bac report solid borrower credit quality financial stock fall late share close ibd take financial be close buy point be highest late july financial have be meeting resistance recent day approach bullish consolidation investor do thorough review company fundamental technical consider buy take detailed look ibd stock checkup estimate ep sale increase company make da vinci robotic surgical system result intuitive surgical earn share ex item sale rise intuitive stock jump hour action share close
131,ISRG,many medical stock have be have tough year maker medical device system have be popular lately especially large cap name offer stability uncertain time week biggest name show performance justify investor trust report late tuesday robotic surgery specialist intuitive surgical isrg be expect continue recent growth rebound slower pace year year comparison have be make tougher strong analyst currently expect earning sale grow year earlier quarter grow respectively july preview second half year leerink analyst richard newitter write ll be watch continue uptake da vinci xi surgical system launch help intuitive surgical turn rough couple year importantly see intuitive surgical turn point transition next leg growth general surgery outside expansion stabilization urology gynecology franchise increasingly begin benefit xi new product cycle newitter write intuitive surgical stock hit time high july move flat base june intuitive rise fractionally stock market today wednesday morning medical device titan abbott laboratory company process acquire st jude medical stj be due report earning company have struggle growth department recent quarters st jude top line have be accelerate estimate abbott do not grow previous quarters be expect report single digit percentage growth top bottom line global footprint company hit foreign exchange headwind rbc capital market analyst glenn novarro expect continue report give stronger dollar especially several emerge market currency be lower sale forecast abbott report constant currency novarro write july preview note greater fx headwind expect management reaffirm revenue guidance low single digit report mid single digit constant currency ep guidance range abbott have also say buy diagnostic company alere alr close have be doubt company have admit accounting problem last week alere report preliminary financial leave analyst believe deal go doubt be interested abbott management have say conference call abbott share shave penny close day st jude share inched cent alere slip ibd take medical device stock have lately be mainstay ibd big cap stock choose strong potential gain volatility smaller growth stock see else be big cap list finally late thursday orthopedic giant stryker syk be set report modest accelerate growth estimate sale rise be highest stryker be have gangbuster stock more ibd composite rating putt top stock stryker have be grow top line range last couple year see momentum continue next several year reconstructive volume be stable hospital capital spending be stable recent tuck acquisition drive faster sale growth corporate average analyst novarro write preview note friday raise estimate price target stryker furthermore company be gain share core segment orthopedic medsurg neurotechnology spine styker stock end trading
132,ISRG,quiet stretch earning front upcoming week be lot busier several top performer schedule report latest week yum brand yum be featured potential option play ahead earning work well thank solid quarter bullish forecast parent company kentucky fried chicken taco
133,ISRG,stock index turn higher afternoon trading wednesday be sign strength riskier play nasdaq stage positive reversal late morning be now be much dow jone industrial average also turn higher afternoon dow small cap russell lead advance volume be run lower nyse modestly higher nasdaq compare previous session conservative stock struggle dow jone utility average retreat ibd big cap currently feature many conservative dividend stock growth play be beating income stock day top gainer big cap edward lifescience ew ulta beauty ulta boston scientific bsx intuitive surgical isrg none pay dividend edward lifescience rise ulta beauty boston scientific intuitive surgical climb meanwhile worst performer be dividend payer such verizon communication vz real estate investment trust venta vtr feature annualize dividend yield more verizon venta have hit record high recent day post brexit defensive play bull welcome shift more growth oriented stock be way know represent change be merely day minor adjustment year treasury yield edge hit record lows earlier west texas intermediate crude oil rise more barrel tumble tuesday spdr gold share gld exchange trade fund gap nearly more highest level march gold etf be so far year
134,ISRG,several top rate growth stock have be move higher recent day thank strong earning report come week see more same latest week featured stock space be buy point ahead earning deliver nice option win intuitive surgical isrg soar earning beat slight acceleration
135,ISRG,dow jone industrial average jump time high late morning trade wednesday microsoft msft gap higher facebook fb try break pizza stock papa john international pzza domino pizza dpz get unusual upgrade microsoft msft lead dow higher downgrade walt disney be drag microsoft jump close late december time high report fiscal fourth quarter earning close tuesday cent share whip estimate cent revenue come vs estimate several analyst raise price target microsoft walt disney fall disney be downgrade buy hold stifel analyst benjamin mogil say share be fully value maintain price target nasdaq rise gain stock market today dow be volume be tracking higher same time tuesday nyse nasdaq exchange facebook fb rise clear buy point flat base facebook volume be strong sign institutional buy analyst keybanc upgrade papa john sector weight overweight diner concern civil political unrest stay home order pizza deliver rather go dinner papa john clear resistance climb domino break cup handle base rise domino report earning thursday have buy point intuitive surgical isrg gap furious volume be trading nearly higher late tuesday intuitive surgical report ep vs estimate sale be compare estimate
136,ISRG,stock be mixed late afternoon trading tuesday dow jone industrial average be lead mcdonald mcd johnson johnson jnj netflix nflx weigh nasdaq dow add nasdaq composite lose ease distribution day be take shape nasdaq hold be tech index first confirm new uptrend june volume nyse be tracking slightly lower monday level mcdonald rise breaking past buy point double bottom base johnson johnson rise report earning open bell stock market today lockheed martin lmt rise maker report second quarter earning share increase year earlier cent estimate sale rise company increase guidance lockheed rise morning then reversed briefly turn negative concern cash burn await government payment ibd facebook fb add top flat base entry elsewhere new oriental education edu rise nearly work cup handle base buy point new oriental education report quarterly earning wednesday couple retailer moved higher heavy volume ollie bargain outlet olli gain try clear first stage double bottom base buy point meanwhile allen interior eth add still buy range base base buy point downside netflix crash company report earning late monday netflix top ep view subscription gain fall short view intuitive surgical isrg fall ahead earning report due close be hold gain reclaim buy point light volume slightly money weekly call option july expiration strike price currently offer premium offer trade downside risk check latest earning preview column learn more used option earning
137,ISRG,stock close mixed tuesday positive housing datum earning report continue roll netflix nflx hit nasdaq lockheed martin lmt score gain regular session microsoft msft jump big hour dow jone industrial average hold gain give nasdaq fall volume be also mixed accord preliminary figure run slightly lower nyse higher nasdaq vs monday metal miner movie related stock oil driller lead downside stock market today west texas intermediate crude price slide barrel paper solar ship transport stock advanced close microsoft jump fiscal earning sale beat business software titan xbox maker earn cent share revenue view cent respectively fall regular session ahead earning report share be week high base tuesday close intuitive surgical isrg fractionally regular trading jump extend trading result also top forecast tuesday close share be buy range flat base entry netflix gap sank heavy volume report mixed result close monday earning top view revenue subscriber growth disappoint share subscription stream service fall day line be week high super micro computer smci gap plunge year low massive trade server system maker cut fiscal earning sale guidance late monday upside lockheed martin settle gain soar much record best then fall nearly cash concern wait government contract fighter jet maker report earning revenue top view ibd facebook fb add approach top flat base buy point other gainer include fabless chipmaker silicon motion technology simo new high new oriental education technology edu add nearly brisk trade economic news june housing start rise annualize rate beating forecast build permit climb more ahead view economic report tap wednesday include mortgage banker association weekly mortgage application energy information administration weekly crude oil stockpile datum earning be due american express axp ebay ebay intel intc mattel mat morgan stanley ms
138,ISRG,volatility surprising many member big cap list large cap growth stock be extend new high most have defensive flavor such smucker sjm brave day sell follow brexit vote barely hiccup then rocket new high recovery
139,ISRG,handful top quality stock clear buy point en route new high thursday volume be lack several move furniture maker herman miller mlhr rise follow better expect quarterly earning report volume be heavy stock retook buy point cup handle base ibdchart symbol mlhr type daily size full position leftchart
140,ISRG,pause broad market past week be still pocket strength big cap leader investor keep eye discount retailer big cap dollar general dg dollar tree dltr hit new high well receive fiscal first quarter earning report offer similar model dollar tree offer
141,ISRG,company provide high end highly technical equipment hospital other care provider have be something roll recently aid pronounce recovery customer spending much medical hardware industry have diversify recent string megamerger small hot group medical system maker have be get more focuse late
142,ISRG,medical sector bury slumping drugmaker still have few big capitalization stock have be shine biotechs be more year ethical drug maker be more generic drug company nearly worry pricing power have contribute bad sentiment pharmaceutical other segment medical sector be fare much
143,ISRG,varian medical system var get mostly favorable reception wall street tuesday announce late monday spin imaging component business separate company varian say complete spinoff year end tax free distribution turn imaging unit stand alone company business be fundamentally different varian core business radiation oncology varian ceo dow wilson say statement so be better apart varian say incur charge financial guidance year be otherwise unchanged varian management say spinoff bring synergy remain company mostly increase general administrative expense couple year be offset combination cost cut service agreement company rbc capital market analyst brandon henry give thumb raise price target varian stock affirm sector perform rating varian imaging component business have weigh company topline growth last quarters henry write research note cite slow customer demand competitive pricing pressure however expect imaging component return low single digit year year growth fiscal year varian revenue growth have be stick single digit last year most recent quarter be flat henry see spinoff opportunity remain company broaden reach cancer market do not expect management like keep relatively conservative balance sheet write however expect slightly more topline growth go forward be tuck past varian stock finished trading fraction stock market today stock hold decent ibd composite rating help partly be highest rank medical group system equipment currently stand ibd ranking industry group top stock group include intuitive surgical isrg masimo masi cantel medical cmn
144,ISRG,market face shortage challenge buildup distribution day settle back negative territory year nasdaq diving support converge day move average technical challenge be be underscored development vacuum leadership technology industry tech industry group have entirely exit
145,ISRG,number stock medical equipment industry group be trace bullish pattern make group watch closely group have be market leader rank top ibd group several week investor find attractive mix stock buy range still form basis cantel medical ticker
146,ISRG,clue way fight current market take look investment strategy mutual fund have outperformed long haul american century ultra fund twcux beat large cap growth rival track morningstar inc past week go friday past year fund average annual gain top peer averaged averaged fund seek highly profitable company look poise keep grow aim large industry lead company have sustainable accelerate earning growth positive price momentum do fund expect best odd find such company look fund portfolio weighting offer clue march manager lee michael li jeff bourke have key overweight information technology health care sector tech fund be find opportunity internet software service service communication equipment fund top holding reflect tilt tech health care apple aapl alphabet googl amazon amzn facebook fb be top feb top also include health care name unitedhealth group unh gilead science gild celgene celg social networking giant facebook be still buy range buy point gapping april strong earning recent action stock market be not perfect ibd accumulation distribution rating have improve worst possible weak rating be still sign more recent selling buy mutual fund past week earning share growth have sped go quarters past frame respectively stock ibd composite rating be solid composite rating combine ibd performance rating include ep relative strength rating be highest manage health care service provider unitedhealth ep rebound growth most recent stanza fall previous quarter share be past week even fall nearly thursday federal judge rule obama administration be spending federal money fund obamacare share many key health care stock go decision district judge rosemary collyer ruling be house republican bring legal challenge government be slate pay year health insurer lower copayment lower income person robotic surgical system developer intuitive surgical isrg be health care name be unharmed obamacare ruling share rise nearly thursday re more past week stock ep grow respective past quarters bank america lynch recently say intuitive be stock soon start pay dividend cite company low debt compare industry least market cap come cash stable earning trend ep growth prior fiscal year well growth expect current year
147,ISRG,stock ve easily find excuse go friday index keep cool nasdaq add rise ibd jump volume fall major exchange be normal day day holiday market be close monday memorial day market be look excuse
148,ISRG,rain grab umbrella manager oppenheimer discovery mid cap growth fund oegax be apply adage find shelter storm mutual fund blah macroeconomic environment ve be bet few company capable generate superior growth be increasingly attractive investor be stock be aim accord march commentary hasbro have world second largest publicly trade toy company be key contributor fund performance first quarter be help holiday season sale toy base big success star war force awaken film be release december sale rise earning share climb hasbro have quicken pace revenue rise drive ep surge ep have grow quarters row share be so far year go friday stock have dividend yield composite rating ibd stock get powerful free advertising recent day texas mom candace payne don mask depict star war character chewbacca emit wookiee trademark growl time payne open mouth video payne laugh hysterically mask growl dub happy chewbacca be post facebook fb draw view tuesday ibd report piper jaffray say video drive sale unit more mask generate cent term ep hasbro kohl kss post video payne family further promote hasbro product then payne appear cbs cbs late late show recreate viral video hit host james corden star war director abram also wear hasbro make mask highest comp rating be comp rating combine ibd performance rating include ep relative strength rating stock poise move higher often have high comp rating fund top holding march have comp rating higher so do fund top new buy trading top hold acuity brand ayi be extend earlier entry alternate entry ibd market team point stock have comp rating dividend yield
149,ISRG,now work new flat base buy point accumulation distribution be neutral rating be offset strong volume ratio supplier light product be see strong demand april acuity report earning share february end fiscal second quarter share nicely analyst consensus estimate sale rise analyst be modele ulta salon ulta top hold be so far year
150,ISRG,ulta have comp rating hour trading ulta jump big box cosmetic retailer report fiscal profit rise share increase sale wall street be look share profit revenue ep grow previous quarters ulta rise new high regular session have climb buy range follow march past buy point previously beauty segment have be laud amazon amzn proof analyst cite strength ulta sephora loyalty program fact customer sample cosmetic person intuitive surgical isrg top new buy be suturing gain medical sector company be debt free ep shrank quarters grow just have grow double digit pace frame then revenue grow past stanzas intuitive surgical be not hurt district court ruling upheld bar government payment billion dollar insurance company participate obamacare enable insurer reduce customer pocket cost such deductible low income person share many insurance oriented health care stock go decision ronald zibelli jr take fund helm june justin livengood have be job early fund be ibd best mutual fund award winner midcaps outperform year period end dec fund average annual gain decade go thursday rank top midcap growth rival track morningstar inc peer averaged averaged past year fund outperformed peer so far year loss top direct competitor
151,ISRG,load player market seem give treat nearly type investor wednesday perhaps utility stockholder key index rally unison fortify surprising advance begin wild reversal nasdaq composite smallcap logged gain volume be mixed
152,ISRG,hunting best stock put watch list start top rate stock be potential buy point be member top rank industry group cantel medical cmd be name fit bill new jersey base company be stock medical system equipment industry group ahead cynosure ticker
153,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
154,ISRG,look index hugger stock market be shift direction favor active manager stock picker say rowe price fund manager ann holcomb boost prospect stock mutual fund help run portfolio holding include lead stock intuitive surgical isrg red hat rht mastercard fund have already do well variety past market have outperformed calendar well year end dec only diversify stock fund least asset pull feat make winner ibd best mutual fund award winner market be rotate benefit active manager stock picker heighten volatility say holcomb manager rowe price capital opportunity prcox institutional clone institutional structure research trisx holcomb fund bear additional distinction holcomb co manager jason polun tom watson oversee portfolio keep eye big picture rowe price let team analyst make buy sell decision fund analyst run own sleeve segment portfolio professional sport team coach oversee team player score play defense delegate much responsibility analyst be rare stock mutual fund world get newsletter deliver inbox more info product service privacy policy term useholcomb be year old discuss fund investment approach ibd office baltimore md ibd do market environment impact capital opportunity holcomb ve have year low volatility high correlation stock performance compress dispersion challenge stock picker extra reward good stock pick stock move together now volatility be increase correlation be go continue interest rate rise help active manager addition stock picker re one take advantage mispricing vs underlie stock value analyst ibd do rise rate cause dispersion holcomb re not necessarily cause help company have be support free low cost money now get somewhat take market high quality company take market share ibd fund be only rowe price portfolio let analyst make buy sell decision use approach be mind be better holcomb be idea current ceo bill stromberg become director research late analyst be expert bill want showcase stock pick have manage portfolio risk controlled framework limit much industry sector weight deviate ibd left portfolio manager do holcomb have call oversight committee consist name pms portfolio specialist jennifer martin decide analyst join team also look much analyst cover monitor overall profile portfolio daily come form risk monitoring look component active risk tilt develop term look more growthy valuey re also analyze analyst performance re also ensure be consistency position portfolio advocate other fund engage large institutional client well also manage monthly rebalance process position be outside risk limit be bring back line ibd intuitive surgical have be volatile november long uptrend drive holcomb fundamental continue improve analyst have raise estimate company deliver sometimes take time market catch ve have big position time analyst jon wood have very favorable view bet computer assist robotic surgery bet become more mainstream be adopt urology gynecology analyst see be used more general surgery ibd take learn intuitive surgical hit record high report first quarter result ibd fund have trim exposure red hat do still holcomb red hat be prime beneficiary increase use open source software drive cloud compute have leadership linux so red hat have strong core be successfully expand cloud software analyst change position many reason trimming position red hat remain overweight fund relative weight analyst ken allen used source fund reduce underweight oracle orcl due analyst view prospect be improve ibd hold mastercard well visa do more other holcomb be largely do same thing look mastercard analyst jon friar see sustainable mid high teen earning share grower company benefit movement payment cash check electronic have high incremental margin pricing power strong free cash flow conversion regard mastercard have willingness invest next generation product such acquisition last year base payment technology company vocalink mastercard have very attractive business model high barrier entry ibd have fund trim stake paypal pypl holcomb analyst prioritize own sleeve paypal thesis have be materially outperform due monetize venmo asset used balance sheet buy back share accretive have core business surprise trim paypal be valuation be not attractive other name used source fund more attractive name long term see paypal characteristic still be play so still portfolio ibd earning share growth svb financial sivb have accelerate quarters row thesis stock holcomb generally svb do well head federal reserve money tighten cycle re market have not fully value deposit strength re look potential pay dividend usually pay dividend open investor base so start position march ibd do prefer global index business rating business holcomb do have lot business be compounder grow earning share double digit pace improve margin cost cut price increase rating business have market lead share be return capital shareholder also tax rate fall implementation tax reform financial crisis regulation space increase just make more difficult competitor get business deepen moat business paypal red hat mastercard global be leader be pull further ahead rival re also shift recur revenue model make financial less lumpy lift valuation revenue be recur vs less year ibd thesis salesforce com crm holcomb pioneer saas software service application remain far biggest company market benefit large ecosystem software hardware service partner make product more valuable make market position even larger re company recur revenue model ibd do diamondback energy fang fit growth portfolio holcomb well re core portfolio exposure sector include energy diamondback be lead operation permian basin ve get lot low cost acreage grow production faster better result lot competitor have low financial leverage execution last several quarters have be excellent ibd give example please play be not part holcomb worldpay wp be re combination merchant acquirer payment processor be vantiv takeover worldpay early year have best collection asset public merchant acquirer grow earning share mid double digit pace extend time also want be millionaire here encourage newsyou need much retirement saving age income
155,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
156,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
157,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
158,ISRG,build watch list focus stock higher rs rating cutera cutr now meet criterium increase monday re research best stock buy watch keep close eye relative price strength exclusive rating investor business daily identify price action worst best score score show stock price behavior last week stack other stock database history reveal stock go make biggest gain tend have better rs rating begin biggest climb look best stock buy watch start herewhile cutera be not ideal buy range right now see go form break proper base cutera show ep growth last quarter sale growth come company hold rank peer medical system equipment industry group intuitive surgical isrg iradime irmd abaxis abax be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
159,ISRG,get ready earning season look stock potential buy range ahead next quarterly report such company be intuitive surgical isrg expect report jan stock be approximately buy point second stage flat base be aware buy close stock report be risky don know stock report market react don have enough time build profit cushion reduce risk wait see company report market react see ibd help make more money stockstop bottom line growth moved higher last quarter earning be compare prior report revenue increase consensus analyst estimate call ep growth quarter growth full year annual growth estimate be recently revise higher company have composite rating hold rank peer medical system equipment industry group cantel medical cmd cutera cutr be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
160,ISRG,relative strength rs rating varian medical system var climb new percentile thursday get lift look best stock buy watch keep close eye relative price strength ibd unique rs rating measure technical performance show stock price movement last week measure other stock database year market history show market biggest winner typically have higher rs rating early stage move see varian medical system continue rebound clear threshold look winning stock try simple routinevarian medical system be not currently potential buy area see stock go form base kick new price move varian medical system post earning growth latest quarterly report sale growth come varian medical system earn rank peer medical system equipment industry group cantel medical cmd iradime irmd intuitive surgical isrg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
161,ISRG,cantel medical cmd be trading buy zone get ready report earning jun trading buy point first stage cup handle be aware buy just stock report be risky disappointing number send sharply lower minimize exposure wait see company report market react way minimize risk post earning sell be use option strategy see ibd help make more money stockstop bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase analyst expect earning growth quarter growth full year earning share estimate full year be recently revise higher company have composite rating hold rank peer medical system equipment industry group intuitive surgical isrg iradime irmd be also group highest rate stock note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
162,ISRG,relative strength rs rating idexx laboratory idxx enter new percentile monday increase look best stock buy watch factor watch closely be relative price strength unique rating identify technical performance show stock price action last week measure other stock major index year market history show top perform stock often have higher rs rating launch biggest price move look best stock buy watch start hereidexx laboratory break earlier have fall back prior entry cup handle stock re watch clear buy point then retreat more original entry price consider fail base best stock form new consolidation also keep mind most recent pattern be later stage base involve more risk regard fundamental company have post quarters accelerate earning growth sale growth have also rise same period company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg abaxis abax be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
163,ISRG,american century ultra fund twcux get right wabtec wab also know air brake portfolio be underweight industrial manager nonetheless make room locomotive equipment maker start wabtec fit quality durable growth philosophy base management team track record business strong operate margin average last year client portfolio manager kevin lewis tell ibd further company have sustainable growth opportunity aftermarket sale be high margin also due strong demand active safety improve emission product produce news agreement merge diesel locomotive business dow jone industrial veteran general electric ge deal wabtec be full steam ahead monday chug forward nearly share retreat tuesday lose wednesday be thursday morning left stock ahead year wabtec shareholder own combine company lewis say believe structure merger make sense view favorably wabtec management remain control be lead merged company fund manager hope hit similar jackpot other holding lead stock such netflix nflx amazon com amzn abiom abmd stock have gain respectively year overall fund aim invest company fundamental be strong get better growth be not fully reflect share price get newsletter deliver inbox more info product service privacy policy term useultra fund success strategy be reflect gain month go wednesday outperformed large cap growth rival track morningstar inc ultra be bottom portfolio invest stock stock buy sell be not dictate sector macro factor still be broad theme make industry more likely pond manager reel catch be technology sector manager see lot growth stock story information technology end portfolio largest overweight continue find strong growth opportunity bottom fundamental analysis manager lee michael li jeffrey bourke tell shareholder latest commentary first quarter fund add stake facebook fb paypal pypl netflix have ibd highest possible composite rating stock composite rating higher be consider leader netflix offer tv show movie subscription customer internet netflix be most watch stream service view respondent year accord recent report morgan stanley ms original programming be main draw netflix amazon prime video be third most watch stream service now capture viewer poll morgan stanley be year amazon earning share be flat then grow most recent quarters trading share be just buy point paypal tech name fund add november agree sell consumer credit business synchrony financial syf last week paypal agree buy sweden izettle be biggest acquisition be spun ebay ebay potential new investor have balk paypal high level stock base compensation accord morgan stanley analyst james faucette health care be sector manager find lot growth story fund overweight health care vs russell growth index benchmark be second largest overweight march valuation drug medical supply company have correct see opportunity earning growth be drive innovation manager say commentary potential measure control drug pricing drug pipeline be robust ample clinical trial readout maker cardiac pump device abiom be stock ibd best possible composite rating trading share be extend buy point late stage base stock rank ibd medical product industry group turn group rank very strong group leader strong industry get way show superior earning growth sale abiom get top industry group part grow earning share straight year post year ep growth rate addition abiom holding include intuitive surgical isrg unitedhealth group unh also maximize social security benefit need much retirement saving age income
164,ISRG,look best stock buy watch focus rise relative price strength stock fit bill be mazor robotic mzor have relative strength rs rating upgrade tuesday try find best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily measure share price movement worst best score rating show stock price behavior trail week compare other stock database year market history show top perform stock often have rs rating begin biggest climb look best stock buy watch start herewhile stock be not ideal entry right now see manage form break proper consolidation earning growth increase last quarter sale fall company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg iradime irmd be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
165,ISRG,welcome move mazor robotic mzor see relative strength rating rise friday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price performance worst best score score show stock price movement trail week hold other stock database history show stock go make biggest gain typically have better rs rating launch largest price move see mazor robotic continue show renew price strength clear threshold see ibd help make more money stocksmazor robotic be not currently show potential buy point see stock go build base ignite new run earning growth picked last quarter sale fall company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg iradime irmd be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
166,ISRG,intuitive surgical isrg see ibd smartselect composite rating rise thursday day new score indicate company be now outperform stock term most important fundamental technical stock pick criterium winning stock often have higher grade early stage new price run intuitive surgical be trading entry flat base see ibd help make more money stock sport ep rating meaning recent quarterly annual earning growth be outpace stock accumulation distribution rating show moderate buy institutional investor last week company report ep growth top line growth climb prior quarter mark quarter accelerate revenue gain company next quarterly report be expect jan intuitive surgical earn rank peer medical system equipment industry group cantel medical cmd cutera cutr be also group highest rate stock related company be now outperform stock
167,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
168,ISRG,stock index head first clear loss day big loser be disparate dog breakfast ibd industry group defensive play such food soap slide midday wednesday semiconductor stock nasdaq plop lower dow jone industrial average retreat respectively volume today stock market be run flat lower vs same time previous session upside pocket strength include airline bank saving loan gold miner bank be move strong volume jpmorgan chase jpm report earning friday rise heavy volume score week high bank new york mellon bk rattle higher strong volume morgan stanley ms advanced twice usual volume saving loan space bofi hold bofi pop higher heavy volume stock be climb right side month base airline stock be mostly improve outlook unite continental ual american airline aal stock surge respectively breakout midday wednesday include medical stock intuitive surgical isrg regional bank hancock hbhc banking service provider fidelity national information service fis intuitive surgical break year then rise month recently stock sketch flat base offer new entry stock gap hold buy point midday action wednesday street expect intuitive earning growth roll then slow growth year economic news china shake market news slow halt purchase treasury report be base anonymous source decline stock index ve be drive china rumor market be make natural retreat day row nasdaq meanwhile mortgage banker association report mortgage application rise week end jan related american join unite raise key succeed warren buffett
169,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
170,ISRG,idexx laboratory idxx see welcome improvement relative strength rs rating monday increase look best stock buy watch factor watch closely be relative price strength ibd unique rs rating identify market leadership show stock price action last week compare other stock database history show market biggest winner tend have higher rs rating begin new price run look best stock buy watch start ibd stock be trading buy range clear buy point cup handle once stock move higher original entry consider buy range relative strength have enter new high ground sign stock be outperform general market term price performance take look revenue profit performance idexx laboratory have post rise ep growth last report top line growth have also moved higher same period company earn rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd iradime irmd be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
171,ISRG,friday dexcom dxcm get positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength ibd unique rs rating identify technical performance show stock price action last week compare other stock database history reveal market biggest winner typically have better rs rating begin new climb look winning stock try simple routinewhile dexcom be not ideal buy zone right now see be able form break proper chart pattern top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company earn rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd cutera cutr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
172,ISRG,relative strength rs rating nevro nvro climb higher percentile wednesday get lift look best stock buy watch keep close eye relative price strength ibd proprietary rs rating measure technical performance used worst best score indicate stock price performance last week match other stock history show market biggest winner typically have higher rs rating early stage move see nevro continue show renew price strength hit benchmark see ibd help make more money stocksnevro have moved more past entry third stage cup handle meaning now proper buy range look stock create new chance pick share week tight pullback day week line nevro see earning sale growth rise last quarter earning share increase revenue rise look next report nevro hold rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd fonar fonr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
173,ISRG,re try build earning season watch list look stock set base ahead next quarterly report here fit bill intuitive surgical isrg expect release latest number jan be currently buy point pattern be second stage flat base understand buy stock just ahead earning involve risk typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look winning stock try simple surgical see earning sale growth rise last quarter earning share increase revenue rise analyst expect ep growth quarter growth full year annual growth estimate be recently revise higher intuitive surgical have composite rating hold rank peer medical system equipment industry group cantel medical cmd be rank stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
174,ISRG,nevro nvro see welcome improvement relative strength rs rating monday upgrade look best stock buy watch factor watch closely be relative price strength ibd proprietary rating identify share price action worst best score rating show stock price performance trail week stack other stock database decade market research show market biggest winner typically have better rs rating early stage move see nevro continue rebound clear threshold look winning stock try simple routinenevro have climb more past entry third stage cup handle meaning now proper buy zone look stock offer new chance get week tight pullback day week move average top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase look next report nevro hold rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd cutera cutr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
175,ISRG,stock market be shaky knee tuesday positive reversal show still have good cartilage tendon apple aapl earning close give market reason cheer nasdaq composite erased loss close higher philadelphia semiconductor index leap index bounce
176,ISRG,stock end firmly higher thursday help part rebound fang stock final trading day first quarter close nasdaq composite rise add dow jone industrial average rise preliminary datum show volume nyse nasdaq come lower thursday not surprising ahead long holiday weekend top gainer dow include intel intc exxon mobil xom boee ba nasdaq nvidia nvda lam research lrcx intuitive surgical isrg outperformed gain stock market today facebook fb bounce back strength do little repair damage do stock recent day still wall street like news company plan scale back ad target offering get newsletter deliver inbox more info product service privacy policy term useamazon com amzn meanwhile pare loss plunge intraday share fall sharply early go president trump tweet online retailer do not pay enough taxe amazon show resilience end session high netflix nflx reversed higher just day move average share rise more ipo news baidu bidu spinoff iqiyi iq price last night right midpoint propose range share open close leaderboard name lululemon athletica lulu follow wednesday bullish gain earning share jump wednesday rise thursday ibd well half name index rise more top gainer include arista network anet casa system casa mks instrument mksi other reminder stock market be close friday observance good friday related quarterly result cloudera ollie impress tough market here investor do market correctionwhich stock just come ibd top stock list
177,ISRG,relative strength rs rating hill hrc climb higher percentile friday get lift re research best stock buy watch keep close eye relative price strength ibd unique rs rating identify market leadership used worst best score identify stock price performance trail week stack other stock database year market history show market biggest winner tend have better rs rating early stage move see hill continue show renew price strength clear threshold see ibd help make more money stockshill be build cup handle entry see stock clear price heavy volume company report earning growth most recent report sale growth come hill earn rank peer medical system equipment industry group cantel medical cmd cutera cutr intuitive surgical isrg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
178,ISRG,relative strength rs rating nevro nvro jump higher percentile friday get lift look best stock buy watch factor watch closely be relative price strength ibd unique rating track market leadership worst best score rating show stock price movement trail week stack other stock database decade market research reveal best stock often have rs rating north begin biggest run see nevro continue show renew price strength hit benchmark see ibd help make more money stocksnevro be buy range breaking past buy point cup handle proper buy range extend initial entry once stock move range best set buy opportunity earning grow last quarter prior report revenue also increase company earn rank peer medical system equipment industry group cantel medical cmd cutera cutr intuitive surgical isrg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
179,ISRG,chip china name lead stock strong start friday earning report stir early trade investor weigh fourth quarter gdp datum commerce department dow jone industrial average open aim press new high intel intc nike nke handled early heavy lift nasdaq pop trading wednesday high intel maxim integrate product mxim trip chip rally jd com jd head advance lead china base stock add russell be early trade economic news fourth quarter gdp rise accord initial estimate commerce department be gain third quarter economist consensus view advance consumer spending surge big jump third quarter estimate beating forecast gain december durable good order be better expect nearly double november increase clobber expectation rise transportation be primary factor beat transport good order rise month well november rise line expectation intel power ahead almost lead dow nasdaq heel fourth quarter report clean beat include dividend increase upgrade outlook stock have be struggle news security lapse affected nearly product make past year news kill attempt send stock lower early january stock have be fight hold support week move average lead chip developer maxim integrate jump almost late thursday report show line earning revenue fiscal second quarter third quarter guidance top consensus view stock have pull back just buy point flat base other chipmaker see buy spillover xilinx xlnx advanced micro device amd rise more apple aapl open lower amazon com amzn lead fang stock tech leader gain many china name moved higher hong kong market end strong week alibaba group holding baba weibo wb trade stock have end thursday buy zone online retail giant jd com vault breaking buy point bloomberg report jd com plan enter market be seek finance expansion part deal shareholder tencent holding tcehy buy logistic unit tencent rise open trade post strong advance china market friday drugmaker abbvie abbv punch nearly clear analyst revenue earning target wide margin fourth quarter result share be extend flat base buy point intuitive surgical isrg drop early action fourth quarter revenue earning well analyst forecast late thursday report also show charge related re-form tax rule intuitive end thursday buy point flat base starbucks sbux dive coffee house chain late thursday report beat earning miss revenue guide earning consensus view founder chief executive howard schultz chat future cryptocurrency conference call investor heavy volume loss drive share back buy point month saucer handle base trade financial etfc slump top fourth quarter earning sale estimate announce plan acquire retail brokerage account capital financial cof trade share have be trading tight high december asia stock market be sharply mixed friday tokyo nikkei slip dollar continue dive vs yen china hong kong hang seng index power apparently help morgan stanley report boost price target china bank due higher net interest margin improve asset quality accord south china morning post nikkei end week hang seng finished seventh straight weekly gain european market extend early gain afternoon trade cac paris london ftse ahead frankfurt dax show gain other important market news friday big picture blue chip advance breakout sparse lesson today volatile action china name buy range find strength flaw intel beat fourth quarter target offer cheery outlook
180,ISRG,welcome move hill hrc see relative strength rating improve monday look best stock buy watch keep close eye relative price strength ibd proprietary rs rating measure technical performance used worst best score indicate stock price performance last week stack other stock database decade market research show top perform stock tend have higher rs rating begin largest climb see hill continue rebound hit benchmark look best stock buy watch start herehill be build cup handle buy point see break heavy volume company post ep growth last quarter revenue rise company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
181,ISRG,nevro nvro see positive improvement relative strength rs rating monday rise look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track market leadership worst best score rating show stock price behavior trail week stack other stock database year market history reveal market biggest winner typically have better rs rating begin biggest price move see nevro continue rebound hit benchmark look best stock buy watch start herenevro be still buy range move past buy point cup handle once stock move higher initial entry consider buy range nevro see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
182,ISRG,hill hrc have relative strength rs rating upgrade wednesday welcome improvement still better score prefer see look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price action worst best score score show stock price behavior last week compare other stock database year market history show stock go make biggest gain often have rs rating north begin largest price move see hill continue rebound hit benchmark see ibd help make more money stockshill be work flat base entry see clear price heavy volume company post earning growth latest quarterly report sale growth come hill hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
183,ISRG,welcome move hill hrc see relative strength rating rise thursday look best stock buy watch factor watch closely be relative price strength ibd proprietary rating track share price performance worst best score rating show stock price behavior trail week compare other stock database decade market research reveal top perform stock often have rs rating north begin largest price move see hill continue show renew price strength hit benchmark look winning stock try simple routinehill be work flat base buy point see break heavy trading company report ep growth last quarter sale gain come hill hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
184,ISRG,stock market erased loss index close mostly higher nasdaq give first sign market have bottom nasdaq make bullish price reversal close back day move average day nasdaq index largest nonfinancial company composite make similar show support day line suggest market have exhaust selling market risk remain higher normal climb dow jone industrial average fall small cap shine russell leap close volume fall nasdaq nyse accord preliminary number second straight day wall street contract news president trump impose tariff steel aluminum import yet sector etf spdr industrial xli represent area economy feel more pain higher steel price fall less day top industry group include couple defensive play such hospital generic drug other health care consumer technology group be more stock ibd leaderboard average gain retail sector be split home furnishing specialty mail order group laggard department store be best group friday market restaurant rise more mcdonald mcd gap lowest level rbc cut same store sale estimate cite lackluster sale new dollar menu oil stock be mainly higher price crude be little change close dow transport rise fractionally airline be modestly major storm force hundred flight cancellation atlanta airport busiest nation most noteworthy stock move nvidia nvda reversed higher dip day move average put chip leader potential follow buy area day move average week move average nvidia be late long term advance nvidia be ibd other stock make similar move day line watch weibo wb china lodging htht asml holding asml intuitive surgical isrg related new investor corner mcdonald be dow jone biggest loser tough start dollar trump steel tariff policy spark economic clash china xi jinp delta flight cancellation threaten revenue georgia threaten follow day spark market bottom century
185,ISRG,interactive broker ibkr asml hold asml atlassian team deliver solid earning report latest week asml be only meaningful upside mover deliver call option buyer more earning report be tap present actionable call option trade have yellow flag form
186,ISRG,thursday hill hrc receive positive adjustment relative strength rs rating ibd proprietary rating measure price action worst best score grade show stock price movement trail week compare other stock database year market history show stock go make biggest gain typically have rs rating north begin biggest climb see hill continue rebound clear threshold look best stock buy watch start herewhile stock be not ideal buy range right now see go form break proper consolidation hill show ep growth most recent report sale growth come hill earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
187,ISRG,relative strength rs rating steris ste moved higher percentile thursday get lift ibd unique rs rating track technical performance used worst best score indicate stock price action trail week compare other publicly trade company history show top perform stock tend have higher rs rating begin biggest climb see steris continue rebound hit benchmark see ibd help make more money stockssteris be try complete flat base entry see stock break heavy volume earning grow last quarter prior report revenue also increase steris earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
188,ISRG,major stock index be spook early go wednesday news china think debt be less attractive other asset class moment fuel speculation world second largest economy start slow bond purchase nasdaq composite re-cover late afternoon trading intraday drop give back dow jone industrial average ease volume nyse nasdaq be tracking close tuesday level stock market today jump basis point tuesday year treasury yield get close wednesday be back late trading financial lead ibd higher essent group esnt leaderboard name svb financial sivb grupo supervielle supv show gain department store operator be top performer airline also do well delta air line dal jump ahead earning report thursday open recent buy point didn make much headway delta continue hold comfortably entry earning news lennar len reversed higher inauspicious start rise earning miss make early headline cause share drop intraday wall street change tune perhaps focuse nice sale beat instead late october lennar announce plan acquire calatlantic caa just meanwhile enterprise software name workday wday surge help positive comment morgan stanley daily chart interpret workday latest pattern cup handle not case handle be too short still workday price action be bullish clear level elsewhere intuitive surgical isrg gap cup shape base buy point rise nearly company announce bullish preliminary result now see sale well consensus estimate doubt growth investor be see plenty bullish chart pattern important recognize stock be still early stage run later stage breakout late stage basis work be generally more prone fail example later stage basis now include tal education tal arista network anet nvidia nvda crude oil future settle barrel weekly inventory datum show larger expect decline stockpile related here berkshire warren buffett think price stay crude production inventory droprobot surgeon break top financial hit new high
189,ISRG,brief sell general market early wednesday few top growth stock be hit new week high include strong medical name meanwhile financial stock continue outperform robot surgeon intuitive surgical isrg surge past flat base entry rise intraday high early wednesday
190,ISRG,get ready earning season focus stock potential buy range ahead next quarterly report cantel medical cmd currently fit bill expect report mar stock be buy point first stage flat base be aware buy just stock report be risky don know stock report market react don have enough time build profit cushion reduce exposure wait see actual number market reaction see ibd help make more money company show earning share growth last quarter sale gain come consensus analyst estimate call earning share growth quarter growth full year annual growth estimate be recently revise upward company have composite rating earn rank peer medical system equipment industry group intuitive surgical isrg cutera cutr be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
191,ISRG,year ibd showcased just company gigantic medical sector look back copy remember be do well memory be photographic be unite therapeutic uthr ibd biotech group patient datum monitoring gear expert masimo masi medical
192,ISRG,steris ste see positive improvement relative strength rs rating friday increase ibd proprietary rs rating identify market leadership show stock price action last week compare other stock database history show best stock tend have rs rating north launch largest run see steris continue rebound hit benchmark see ibd help make more money stockssteris break earlier be now prior entry flat base stock re tracking climb buy point then retreat more original entry price consider fail base best stock form new consolidation also keep mind most recent consolidation be later stage base make riskier establish new position add share exist top bottom line growth moved higher last quarter earning be compare prior report revenue increase company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
193,ISRG,welcome move steris ste see relative strength rating improve monday ibd proprietary rs rating measure technical performance show stock price action last week compare other stock database history reveal top perform stock often have rs rating north launch largest climb see steris continue show renew price strength clear threshold see ibd help make more money stocksnow be not ideal time jump isn proper buy zone see stock be able offer clear proper buy point top bottom line growth moved higher last quarter earning be compare prior report revenue increase company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
194,ISRG,wall street kick new year apple aapl nvidia nvda lead tech stock higher emerge market surge bitcoin climb powershare qqq trust qqq rise spdr spy advanced spdr dow jone industrial average dium climb emerge market outperformed ishare msci emerge market eem surge ge ge walt disney lead dow industrial respective gain apple add testing day move average share get lift couple bullish analyst report iphone maker be flat base buy point first clear dec semiconductor retail biotech etfs be top sector fund gainer stock market today utility real estate consumer staple lag graphic chip designer nvidia rise try retake day line gold fund continue recent hot streak spdr gold share gld ishare gold trust iau add track extend advance consecutive session bitcoin padded early gain rise accord coindesk slip earlier bitcoin investment trust gbtc climb other cryptocurrency such ethereum ripple have be steal bitcoin thunder start ethereum leap new record high tuesday ripple be nearly top perform exchange trade fund tap hot artificial intelligence stock nvidia soon offer chance buy share global robotic artificial intelligence botz return year date dec lead etfs launch fund have be testing day move average early december solid rebound support line present new buy opportunity botz advanced prior bounce day line early september nov high fund begin trading have amassed asset track indxx global robotic artificial intelligence thematic index be make company benefit rise adoption use robotic ai include autonomous vehicle technology account portfolio dec accord morningstar direct industrial health care make remain respectively asia primarily japan represent biggest region weighting follow nearly north america greater europe ibd take be bitcoin ethereum other digital currency real investment speculator game individual investor be extremely cautious diving new area read feature bitcoin risk possible gain first breakdown vs stock be cash top holding dec include japan yaskawa electric keyence fanuc mitsubishi electric santa clara calif base graphic chip designer nvidia sunnyvale calif base intuitive surgical isrg also make top see accompany table other top young etfs make big splash name include amplify online retail ibuy innovator ibd ffty etfmg prime mobile payment ipay top exchange trade fund share technology growth focus friday pick spdr gold share gld ishare gold trust iau extend streak straight session gold price have be rise bitcoin other cryptocurrency have be generate daily headline bitcoin investment trust gbtc aim track digital currency price sky-rocket end year highly volatile week related bitcoin ai stay hottest market trend gold extend streak bitcoin dife ai stock buy bitcoin reverse gold keep rise apple test support again
195,ISRG,pocket health care sector be ailing other have perked right ishare medical device ihi bound week high thursday eye fourth straight weekly gain relative strength line gauge performance vs be bolt higher defiance overall stock market mood market uptrend have come pressure week ihi be target bet health care niche invest company manufacture distribute medical device edward lifescience ew be top rate ibd stock industry group base measure technical fundamental health such earning sale growth ihi count edward top holding give portfolio weighting edward stock have jump past month california base company be battle top spot heart valve market sapien receive fda approval treatment high risk patient suffering severe symptomatic aortic stenosis chief rival be medtronic mdt hold ihi portfolio edward report quarterly result april close wall street stock analyst track thomson reuter expect gain earning quarter year
196,ISRG,major stock hold ihi report week late tuesday surgical robot maker intuitive surgical isrg beat earning estimate stock hit new high wednesday receive series price target hike wednesday orthopedic giant stryker syk also beat expectation raise guidance stryker intuitive stock have fall then volatile trade ihi also have smaller weighting cantel medical cmn steris ste cynosure cyno device specialist top notch ibd composite rating respectively steris provide product prevent infection control contamination report jump sale latest report quarter help buyout base synergy health small cap cantel medical be also infection control prevention business cynosure develop treatment system hair removal skin rejuvenation ihi have relative strength rating mean outperformed other stock etfs ibd database last month accumulation distribution rating point healthy institutional demand share etf see net inflow first quarter asset have grow year year date april ihi have advanced vs broadly diversify health care select sector spdr xlv xlv largest health care etf have be hurt year hefty combine stake underperform pharmaceutical biotech industry past year xlv produce annual average gain vs ihi
197,ISRG,robotic surgery specialist intuitive surgical isrg beat wall street earning estimate late tuesday stock be hour trading intuitive surgical earning totale share year earlier quarter top analyst consensus share accord thomson reuter sale gain vs analyst intuitive surgical be highest rate stock medical system group be collectively do well ibd ranking industry group share hit lifetime high last wednesday have hover mark then stock close fraction regular trade stock market today intuitive surgical be second hot medical stock report earning week earlier tuesday johnson johnson jnj hit new high beat estimate raise full year guidance due diminish foreign exchange headwind stryker syk also hit new high early tuesday give back gain later be due report earning wednesday close
198,ISRG,surgical robot maker intuitive surgical isrg receive multiple price target hike wall street stock hit new high wednesday follow earning report late tuesday ibd report intuitive surgical earning beat estimate really interested analyst be quarter procedure growth intuitive surgical normally sell only pricey da vinci robotic system quarter so surgical procedure used company consumable accessory service be key steady revenue management raise procedure growth guidance year previous operate expense increase intuitive surgical management also raise opex guidance year revenue previously however likewise raise gross margin guidance intuitive surgical be ibd big cap else make grade intuitive surgical impressive procedure growth be consistent recent positive general surgeon check write rbc capital market analyst brandon henry raise price target maintain sector perform rating intuitive surgical be accelerate operate expense spend believe investment drive increase future robotic adoption help company maintain superior position robotic market upcoming competition company have competitor present medtronic mdt transenterix trxc johnson johnson jnj partner alphabet googl verily division be develop own robotic surgery system leerink analyst richard newitter lift intuitive surgical price target maintain outperform rating now stronger outlook urology gyn general surgery give management confidence raise procedure guidance newitter write research note also management seem be talk more aggressively da vinci use thoracic procedure area think be corner emerge growth driver piper jaffray analyst matt brien raise price target rate stock neutral intuitive surgical stock hit record high early stock market today push year morning trading share be
199,ISRG,intel intc report earning cent share top ep view cent revenue rise fall short forecast share fall late intel announce restructure effort intend accelerate evolution pc company power cloud billion smart connect compute device move result job cut employee mid say company yahoo yhoo report drop first quarter earning share cent beating estimate penny revenue fall top view number paid click fall quarter meanwhile bid part company continue roll reportedly send letter say be sale yahoo revenue guidance be view share rise late intuitive surgical isrg top estimate ep rise sale grow share rise late tuesday close fraction regular session stock hit time high last wednesday vmware vmw come ahead wall street forecast first quarter flat year year earning cent revenue growth analyst poll thomson reuter have expect cent share sale vmware also share buyback virtualization software pioneer midst complicate dell takeover parent emc emc rise late close manhattan associate manh report earning share time item rise cent top estimate cent supply chain management software developer revenue grow vs forecast manhattan associate ceo eddie capel cite investment omni channel retail store distribution management software growth driver manhattan association see full year ep vs analyst estimate share rise late close highest point early march image provide shutterstock related intuitive surgical beat estimate stock hover high
200,ISRG,medical giant johnson johnson jnj beat estimate raise guidance tuesday morning send stock fifth recent record high report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise match consensus say foreign exchange impact knock percentage point sale growth nonetheless forex headwind finally seem be abate cite improve forex outlook reason be raise full year sale guidance also add cent ep guidance now ibd take johnson johnson rate group cr be iffy pharmaceutical business continue deliver impressive level growth have steady improvement consumer business be see momentum medical device business be fuel optimism full year ahead ceo alex gorsky say statement stock be early trading stock market today touch record high intraday stock be more year so far be first medical stock be hit new high be report week other be intuitive surgical isrg evening stryker syk late wednesday morning continue growth momentum company have see recent quarters again deliver organic sale growth acceleration second consecutive quarter double digit ep growth adjust operational basis write leerink analyst danielle antalffy research note note exclude impact foreign exchange activity shrink sale hepatitis drug olysio be make obsolete gilead science gild release harvoni late sale rise operate ep growth be just credit suisse analyst vamil divan write pharma sale beat be drive immunology franchise remicade simponi stelara well stroke prevention treatment xarelto top seller diabetes drug invokana miss consensus investor have be wonder invokana take hit eli lilly lly jardiance last september prove dramatically cut death heart failure didn get sale bump
201,ISRG,medical industry have lot prove upcoming earning season last round earning guidance didn do much reassure investor be already nervous other reason however major stock sector have be hit new high lately especially hardware side group here be such company report earning week johnson johnson jnj take traditional place head line report earning early tuesday first big drug company report cycle growth be expect be modest due gigantic size foreign exchange headwind have be drag global company earning year analyst poll thomson reuter estimate revenue rise year earlier quarter earning be estimate share muted growth johnson johnson stock hit record high trading friday close day fraction have maintain ibd relative strength rating last week mood wall street go quarter seem bullish late thursday rbc capital market analyst glenn novarro raise estimate base read drug prescription foreign exchange trend im im script trend several key drug suggest strong pharma quarter year year ex fx olysio novarro write olysio be hepatitis treatment additionally analysis currency movement begin year suggest negative fx impact full year result be less initially expect novarro note likely topic conversation conference call be month fda approval pfizer pfe inflectra biosimilar version blockbuster immunology drug remicade robotic surgery specialist intuitive surgical isrg be due report close tuesday analyst estimate earning rise last year share sale intuitive surgical have also be top perform stock lately company have be make comeback financially rollout da vinci xi surgical system improve procedure growth intuitive surgical stock hit new high wednesday more year boast excellent ibd composite rating close friday head key question investor be stock be baking too much optimism be start new product cycle evercore isi analyst vijay kumar write email client friday expect procedure volume be healthy growth general surgery lead way extra day leap year also help similar concern optimistic market seem be dog orthopedic giant stryker syk be due report close wednesday stock have also be roll wednesday hit new high be wound last year share close friday stryker stock keep climb last week even robert baird downgrade neutral barclay resume coverage underweight latter write stryker valuation appear be full go face more competition rejuvenate zimmer biomet zbh analyst cover stryker estimate sale rise quarter earning share
202,ISRG,stock stage mostly mild decline monday drowsy action masked excellent upside action few name largest most important sector market namely medical fall give back half friday advance nasdaq also be miserly mood follow solid start new
203,ISRG,ibd smartselect composite rating intuitive surgical isrg rise tuesday revise score mean stock currently top other stock term key performance metric technical strength history show top market performer tend have higher score launch major climb intuitive surgical be currently form flat base buy point see stock break heavy trade least average look winning stock try simple stock sport ep rating mean recent quarterly annual earning growth top stock accumulation distribution rating show roughly equal amount buy selling institutional investor last week get newsletter deliver inbox more info product service privacy policy term company post ep growth top line growth climb prior quarter mark quarter rise revenue increase intuitive surgical earn rank peer medical system equipment industry group cantel medical cmd be top rank stock group related company be now outperform stock see stock just come ibd top stock list
204,ISRG,intuitive surgical isrg break record high friday food drug administration approve surgical robot company stock market today intuitive surgical share surge close stock begin form flat base april buy point conjunction share medical product company pop late thursday fda approve da vinci single port platform allow surgeon perform complex procedure single incision body meant work intuitive surgical other surgical robot system chief executive gary guthart say prepared statement da vinci sp complement da vinci da vinci xi system enable surgeon access narrow workspace maintain high quality vision precision control surgeon have come trust da vinci system say get newsletter deliver inbox more info product service privacy policy term system include multus jointed wrist instrument well high definition camera instrument camera emerge single thin tube piece work together avoid external instrument collision occur narrow space evercore analyst vijay kumar say approval new surgical robot be line expectation intuitive surgical file approval december company also say look expand approval new system other used kumar note intuitive surgical try keep expectation low initial launch come earlier intuitive surgical flexible catheter analyst expect flexible catheter also drive system sale past intuitive surgical have temper expectation initial launch say think make sense give system do not yet have broad applicability be interested learn company be plan price system related ibd stock be buy range nowwhat be inflation do matter fed sell great stock take profit regularly mostly stock be show rise relative strength
205,ISRG,big gain stock market friday lower volume result nicely expand new high list session be curiously light breakout common theme recent week intuitive surgical isrg rise close just entry wasn much conviction buy volume rise thursday level
206,ISRG,health etfs perked tuesday follow better expect report nation largest health insurer gold price surge boost gold stock material sector help cross keenly watch level first time early december spdr spy post fresh high stock market today highest level dec stock gain follow steadying oil price key earning hearten investor health care select sector spdr xlv jab higher unitedhealth unh earning revenue beat forecast health insurer raise full year forecast strong organic growth good customer retention level xlv slice day move average monday first time health care sector be laggard year trail only financial unitedhealth first health insurer report first quarter be now have report scrutinize clue health care industry be fare company announce remain only handful obamacare public exchange next year state exchange currently unitedhealth stock jump more strong volume johnson johnson jnj also beat earning estimate tuesday revenue match forecast medical product maker add nearly raise full year forecast johnson johnson be hold xlv stock portfolio unitedhealth be medical peer ibd leaderboard stock edward lifescience ew report april meanwhile robotic surgery specialist intuitive surgical isrg report close beat earning estimate stock rise hour orthopedic giant stryker syk be report close wednesday material select sector spdr xlb carved gain tuesday hit fresh high etf have rise session xlb gain come soar gold price boost gold stock include portfolio member newmont mining nem market vector gold miner gdx gap add nearly gdx have soar year date hand profit etf investor buy day global silver miner sil streak ahead highest level more year ishare silver trust slv commodity etf flash more higher highest level june key outside market be bullish posture precious metal tuesday dollar index be weaker crude oil price be higher kitco senior technical analyst jim write tuesday weaker expect housing report give more price upside gold market say here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
207,ISRG,number big cap name be buy range be more testament slow progress rather fresh setup price retailer tjx tjx break more week be still only away buy point stock break flat base increase volume beating earning estimate spend
208,ISRG,major average remain higher late afternoon trading friday lead blue chip stock volume be run well thursday level dow jone industrial average be nasdaq climb turnover jump more nyse be nearly higher nasdaq compare thursday friday be expiration day often boost volume medical leisure transportation stock fared best oil stock fall crude price slip due rise oil rig count intuitive surgical isrg maker robotic surgical system jump more retook buy point however volume be run only average bit lower desirable meanwhile starwood hotel resort hot pop heavy volume spurn offer marriott international mar buy hotel operator instead starwood say consider higher offer group investor lead china insurance marriott rise most ibd stock be higher growth stock finally appear gain traction market dominate recently defensive stock such utility chip designer nvidia nvda rise more clear buy point cup handle base argus initiate coverage buy rating nvidia supplier apple aapl tesla tsla be leader graphic process chip used personal computer game console mobile device also move emerge virtual reality market
209,ISRG,so call fang stock facebook fb amazon amzn netflix nflx google parent alphabet googl be bare tooth move aggressively expand market share core industry enter new one tech titan be have most success generate continue growth year sale growthdriven mark zuckerberg successful pivot mobile right mobile advertising start skyrocket facebook lead pack metric year annual sale growth rate follow netflix amazon alphabet worth note here ceo jeff bezos say growth amazon web service cloud unit be outpace commerce business reach sale year year ep growthnetflix edge facebook top spot category year annual earning share growth rate compare social medium giant pace alphabet rank distant third rate pre tax profit marginfacebook alphabet dominate fang family term annual pre tax profit margin netflix amazon trail far high level profitability be allow facebook make multus dollar bet instagram whatsapp oculus vr well invest heavily mobile advertising new apps facebook messenger also allow google parent alphabet explore so call moon shot project include verb surgical joint venture verily unit johnson johnson jnj develop advanced surgical robotic compete intuitive surgical isrg earning sale growthamazon bounce back drone blaze deliver gain earning easily top facebook alphabet netflix sale side facebook defange competition increase year year netflix amazon alphabet post solid gain accumulation distribution accumulation distribution rating show fund manager other institutional investor have be heavily buy selling stock trail week netflix rating show moderate institutional buy be only fang stock currently get pass grade facebook amazon have lowest possible rating point heavy selling last month week alphabet be only little better still get fail grade rating composite composite rating range worst best provide overall grade stock show stack term technical fundamental strength other stock market facebook alphabet earn highest possible score meaning re outperform other stock amazon rating have be move higher now stand netflix have decidedly mediocre score top stock industry group ibd stock checkup show top rate stock industry group fang stock only facebook alphabet member internet content group earn distinction amazon rank retail internet group stamp com stmp alibaba baba hold spot respectively netflix come peer leisure movie related industry group excerpt ibd extra newsletter image provide shutterstock
210,ISRG,monday tepid rally produce few new high fresh breakout most case volume be miss new oriental education technology edu be case point complete cup handle base buy point volume be only average stock rise close chinese company provide english instruction
211,ISRG,intuitive surgical isrg be ibd stock day robot surgery pioneer be show resilience stock market volatility index component be worth keep close eye near buy point rare base base base chart pattern base base pattern be powerful especially market be struggle base base pattern choppy trading environment show stock have hold recent win give back gain instead set again intuitive surgical have form third flat base trot be work entry relative strength line compare stock price performance be also time high get newsletter deliver inbox more info product service privacy policy term useshare rise stock market today stock boast impressive ibd composite rating composite rating combine several ibd proprietary rating single score time stock winner often have composite rating least start big run however intuitive surgical have miss earning view last quarters have also miss revenue quarters nasdaq list intuitive surgical be summit medical system equipment group sit second place infection prevention system specialist cantel medical cmd also be interested base base breakout yield big gain square flirt buy zone againrelative strength line have clue stock healthwhich stock be show rise relative strength invest stock market start simple routine
212,ISRG,growth stock base be sort mattress new high quality one have good bounce spring old mattress tend lose strength support need good night rest late stage base be old mattress don want be lie finally give growth investor learn count basis correctly be able avoid pitfall big loss be once hot perform stock late stage base be third fourth even fifth base appear chart even third stage base be push envelope point stock uptrend be get old count basis be crucial even good stock peter go deep correction finishing just basis stock make fourth fifth stage base perhaps only handful bull market be almost always very best term profit sale growth expand institutional sponsorship quality product service sometimes tell just scanning ibd smartselect rating strength stock checkup evaluation short re market longtime leader get newsletter deliver inbox more info product service privacy policy term become complacent often prelude nasty surprise hard work ve do sifting stock tracking price moment break shame be miss flaw most often case most stock reset base count end nasty bear market such one point new bull emerge base count reset everything be fresh new isn much difficulty count basis do do stock have break look minimum rally proper buy point look second base emerge base base pattern count single base upper base form stock have advanced ibd research have discover second way stock reset base count midst long term market uptrend fail send stock downward spiral stock decline far enough undercut most recent base lowest price then reset base count consider longtime market favorite intuitive surgical isrg count basis cup high handle base appear february july accompany chart be monthly please go marketsmith link home page investor com view historical weekly chart cup handle april july double bottom august october be best see daily weekly chart vast cup handle february march last pattern most dramatic be say have be failure stock triple buy point now look action december april robot operate room pioneer form month cup handle break april reversed lower ultimately fall apart huge decline reset base count let fast forward today stock have show enough strength actually emerge new leader yet bull market such instance be rare new bull run tend produce brand new set solid winner don ignore truly great company somehow continue find way keep grow stay top respective industry major market bottom march intuitive have become rare big cap have become leader again growth metric have certainly slow still succeed achieve mild double digit gain earning share revenue past year july september intuitive create shallow flat base then clear buy point week rally heavy volume adjust split october last year however rally lack oomph big cap member ibd medical system equipment group fall sharply fourth quarter last year undercut flat base low base count go back yet intuitive fought way back intuitive breakout continue be winner include move month early stage saucer base week end feb share have gain more have climb only same time frame version column be originally publish dec edition ibd follow saito chung twitter ibd_dchung additional commentary chart growth stock financial market related find great chart pattern learn cup handlestock buy chart pattern pump big gain stock portfoliowhere be stock market head right now read column best growth stock start simple routine
213,ISRG,intuitive surgical isrg pop late tuesday crush wall street first quarter expectation grow demand robotic surgical system call da vinci share spiked hour trading stock market today stock end regular session intuitive stock be consolidate buy point meanwhile medical product stock broadly rise close bell first quarter intuitive report adjust profit share revenue grow respectively vs year earlier period metric easily top consensus adjust income share sale evercore analyst vijay kumar note intuitive be expect report solid quarter company do not disappoint get newsletter deliver inbox more info product service privacy policy term use impressive top line be mostly drive system sale contribute third revenue beat system come consensus kumar say note client remain third beat come higher instrument accessory consumable revenue worldwide intuitive ship da vinci surgical system year earlier quarter number procedure perform used da vinci system grow year year basis drive growth surgical urologic procedure lion share growth stem system sale increase biggest chunk sale come instrument accessory revenue grow service revenue also rise instrument accessory revenue procedure come be seasonally strong kumar say number procedure grow international sale dip investor likely look update system performance china japan say intuitive didn offer guidance analyst have modeled adjust profit share sale related do spot major market top easy look heavy distributionnew option strategy limit risk buy stock ahead earning report
214,ISRG,intuitive surgical isrg be form base show entry get ready report earning apr chart pattern be second stage consolidation keep mind buy close stock report be risky don know stock report market react don have enough time build profit cushion reduce exposure wait see company report market react look best stock buy watch start hereintuitive surgical post earning growth latest quarterly report sale growth come analyst expect ep growth quarter growth full year annual growth estimate be recently revise upward company have composite rating hold rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd be also group highest rate stock note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
215,ISRG,re try build earning season watch list look stock set base ahead earning here fit bill intuitive surgical isrg expect release latest number apr be currently approximately entry chart pattern be second stage consolidation buy stock just ahead earning be risky typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look best stock buy watch start hereintuitive surgical report ep growth last quarter sale growth come analyst expect earning growth quarter growth full year earning share estimate full year be recently revise higher intuitive surgical have composite rating earn rank peer medical system equipment industry group cutera cutr intuitive surgical isrg be also group highest rate stock note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
216,ISRG,first sign stock market overcome trade war fatigue stock market friday dash ahead open never look back nasdaq jump dow jone industrial average climb respectively small cap add volume fall major
217,ISRG,be wild week nasdaq composite index dow jone industrial average fang stock facebook fb lead top growth stock be still trading just buy zone salesforce stock intuitive surgical stock upland software stock join facebook stock facebook salesforce crm upland software upld be top growth stock earn highest possible ibd composite rating intuitive surgical isrg be right best composite rating rank stock key fundamental technical metric earning sale growth roe price performance time stock winner often have composite rating least start big run facebook close week handle buy point share fall week volume facebook have be somewhat muted compare past several month strong volume signal institutional buy next resistance level fang stock be mark facebook rise stock market today close just chase zone get newsletter deliver inbox more info product service privacy policy term usesalesforce initially break past flat base entry run much past buy point demand business software pioneer moved back buy range briefly close friday just chase zone salesforce stock have fared well even many top software stock have stumble salesforce latest earning report fuel recent stock gain salesforce rise monday become more extend intuitive surgical be trading flat base buy point base base pattern volume initial be strong have fade still intuitive surgical stock have be able find support day line intuitive surgical climb monday upland software be extend buy point rebound day line past week point upland software stock nearly round trip gain never want double digit gain turn loss however rally day line be buy point be chance add share position upland have strong fundamental fellow top growth stock trading volume be thin side upland software stock be further extend buy zone get instant access more trading idea exclusive stock list ibd proprietary rating only also be interested stock future rise tech titan buy zonestock market forecast next month expect stock buy watch top ipos big small cap top growth market direction affect portfolio
218,ISRG,second quarter earning season be begin bull be hope get respect time first quarter be triumph financial result disappointment stock market reaction stock beat estimate generally didn find much traction do happen thing overshadowed report season concern president trump trade war flatten yield curve unfortunately neither factor have be resolve bull be hope strong earning season do time fail do last time shove market news drive creature earning drive beast get newsletter deliver inbox more info product service privacy policy term usewell fargo wfc jpmorgan chase jpm citigroup give earning season unofficial start july last time major bank turn sideway story stock market lackluster result later month stock recently appear big cap report quarterly result street expect netflix nflx grow earning company report july close leisure sector play match expectation first quarter report april close stock gap next day netflix be more hold vs sell decision right now chart be not offer legitimate buy point online platform twitter twtr be expect report result open july street estimate earning come cent share improvement vs year quarter profit cent share be twitter second biggest profit least quarters ep cent cent previous quarters twitter be extend stock form new base be third stage research show first second stage breakout be more likely work later stage basis facebook fb report close july analyst expect facebook increase earning pop be smallest quarters last time facebook beat consensus view earning stock rally next week invisible brace provider align technology algn report also july close street expect earning grow first quarter align top consensus view intuitive surgical isrg report quarterly result july close analyst estimate earning increase share top year growth rate stock clear flat pattern june couldn rise buy zone intuitive test find support week line past couple week get instant access more trading idea exclusive stock list ibd proprietary rating only related second chance buy stock rebound take profit hold guidelinesare trump tariff stock market
219,ISRG,dow jone index nasdaq composite rally last week strong stock market gain friday follow just right job report week choppy trading not many stock be set investor focus market lead stock facebook fb twitter twtr etsy etsy intuitive surgical isrg recent ipo stitch fix sfix be ibd stock list relative strength new high relative strength stock list include top stock relative strength line new high relative strength line track stock performance vs index stock list here have have rise rs line past several month facebook stock co also run dow jone nasdaq composite last week facebook stock twitter stock etsy stock boast best possible composite rating intuitive surgical stock have composite rating stitch fix stock hold cr time stock winner often have composite rating better start big run intuitive surgical stitch fix close friday buy zone former moved slightly extend monday morning etsy stitch fix be niche commerce firm face competition amazon com amzn facebook twitter be social medium giant be rise profit estimate list several stock be relative strength rise profit list not surprising give earning ultimately drive share price performance get newsletter deliver inbox more info product service privacy policy term usefacebook share clear buy point volume be average large part trading activity have be so heavy cambridge analytica scandal facebook stock hasn have higher volume day share rise high then pull back buy range facebook stock last week close friday hit new intraday peak nearly extend entry point facebook stock rise soon open monday stock market trading short message social site clear cup handle buy point late twitter stock shot mid june year high then share have consolidated briefly find support fast rise day line twitter stock pop almost last week june peak theory twitter stock form flat base need least week proper consolidation form twitter fall monday morning follow report company suspend fake suspicious account june alone art craft commerce specialist gap consolidation buy point feb strong earning then continue gradually advance etsy stock gap june company raise revenue guidance raise fee seller share hit record june then etsy stock much twitter have consolidated short shallow consolidation share rise last week etsy stock be monday morning just record high intuitive surgical break june high volume share clear buy point flat base be really part base base base formation intuitive surgical stock have stay buy range aside close just entry june share robotic surgical system maker climb last week top buy range intuitive surgical stock rise just top chase zone stitch fix stock soar friday triple normal volume blast past high handle buy point share close just chase zone end stock pop soon monday open reversed trade stitch fix stock have more double november ipo price stitch fix be online personal styling service customer submit size style preference human stylist decide clothe be send package fix customer get day return clothe discount keep time get instant access more trading idea exclusive stock list ibd proprietary rating only also market direction improve stock aim lead rallythree new high rise relative strength get carl icahn boostdon discount top stock buy leader qualys rebound sell many top growth stock be form basis now ibd stock day near new buy point run
220,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
221,ISRG,market have be advance feb follow day be disappointing slim investor rally have be lead defensive stock such utility food staple tobacco household product usually fast move growth stock have be left gate raise question validity rally money manager win
222,ISRG,tech titan alphabet googl facebook fb have venture far core business search social medium continue battle more market share mobile advertising space already dominate do compare term key fundamental recent chart action alphabet drive mostly google oversee
223,ISRG,stock market end week decidedly positive note stock open nicely higher strengthen close nasdaq marked fourth straight weekly price gain nasdaq gain rally dow jone industrial average picked small cap outperformed russell more preliminary datum show nyse nasdaq volume come lower thursday level stock market today stock follow lead european market rise sharply overnight germany dax soar paris cac gain london ftse add stock market strong gain friday session be curiously light breakout intuitive surgical isrg barely clear buy point light volume share rise alaska air alk clear cup handle buy point share jump nearly solid trade handle area be see daily chart not weekly chart ideally good see clear handle daily weekly chart earning news nasdaq component ulta beauty ulta soar report strong earning give bullish guidance late thursday china base stock also do well nasdaq jd com jd baidu bidu ctrip com ctrp rise more elsewhere fast grow china lodging group htht jump nearly work right side cup shape base approach buy point new york mercantile exchange april crude oil settle barrel cent week rise cap fourth straight weekly price gain fed day meeting start tuesday decision interest rate be due wednesday et accord cme group fedwatch odd rate hike be image provide shutterstock
224,ISRG,market confirm uptrend still look good many front doesn mean easy environment make money growth stock growth name mellanox technology mlnx stamp com stmp texas roadhouse txrh be act well recent breakout other breakout like tal education xrs ross store rost other be face
225,ISRG,stock see early gain fade friday turn slightly higher early afternoon trade nasdaq add rise dow jone industrial average picked volume nyse nasdaq be tracking higher thursday level economic news gdp growth be revise upward meanwhile personal income spending datum january come slightly better expect ibd several name outperformed include try reclaim day move average recent pullback ligand pharmaceutical lgnd jump acuity brand ayi rise biggest gain stock market today come herbalife hlf nutritional supplement company say talk ftc potential resolution investigation ftc start hedge fund manager bill ackman be still heavily short herbalife call pyramid scheme intuitive surgical isrg continue trade well hold high share rise bounce back nicely mostly light volume hit low earlier month elsewhere monster beverage mnst lose fizz fall disappointing earning new york mercantile exchange wti april crude oil pare gain still rise barrel year treasury yield add basis point image provide shutterstock
226,ISRG,wesson swhc broadcom avgo break several leader set stock market close higher third straight week see top holding warren buffett berkshire hathaway bkrb oil exploration firm be next takeover target also take look top name ibd big cap be close potential buy point also available itune video audiosee current leader buy point free trial leaderboard ibd extra newsletter be apple stock healthy again check telltale clue
227,ISRG,stock make list fastest grow company
228,ISRG,lesson legendary investor time buy darvas boxattend ibd workshop level begin strategy successful investing
229,ISRG,level intermediate strategy successful link outlook brighten growth stock
230,ISRG,ibd stock analysis alphabet medtronic new rival intuitive surgical
231,ISRG,ibd stock analysis major retailer stand amazon online store
232,ISRG,mutual fund see top mutual fund paypal verizon
233,ISRG,technology be facebook ready unleash multus dollar opportunity download checklist buy checklist download pdf see work
234,ISRG,base checklist download pdf see find top big cap stock view latest ibd big cap
235,ISRG,seek plush ride rough market scan ibd big cap top holding recent buy warren buffett berkshire hathaway warren buffett have be investing withdraw money
236,ISRG,warren buffett stock be solid dividend stock leader
237,ISRG,be warren buffett make next mega acquisition take free trial leaderboard
238,ISRG,ibd print eibd digital editionattend ibd investing workshop find level topic right send feedback questionsemail email protected
239,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
240,ISRG,artificial intelligence now firmly entrench many hospital operate room field robotic surgery be start get competitive giant company alphabet googl johnson johnson jnj medtronic mdt be training sight intuitive surgical isrg king robotic surgery company analyst say boom medical technology segment have lot room run robotic surgery be area grow billion dollar more machine be used treat patient intuitive command space annual sale signature da vinci robotic surgeon however be limit type procedure handle multus limb da vinci be used variety procedure include cardiac colorectal gynecological head neck thoracic urologic surgery only long re minimally invasive big market be be still unclear yet analyst agree potential have yet be tap so more player be move quickly get newsletter deliver inbox more info product service privacy policy term use think investor need understand robotic ai artificial intelligence revolution be happen touch sector economy say jeremie capron director research manage partner robo global index advisory firm specialize robotic industry investment be technological revolution investor afford miss analyst say march auris health become first company formidable threat intuitive catheter base monarch platform gain approval intuitive counterpunch seek approval flexible catheter similar auris device likely year rbc analyst brandon henry say recent report meanwhile other be work area intuitive surgical doesn have foothold nephew snn have robotic assistant knee replacement stryker syk have robotic joint replacement system mazor robotic mzor zimmer biomet zbh have robotic offering brain spinal surgery mazor alone see sale just system player have long way go take intuitive surgical throne intuitive have market cap today worth nearly capron call intuitive amazing stock think investment community have be scratch head try figure impact new entrant intuitive surgical tell investor business daily feel pretty relax size be big enough small player come share medical tech company have be relatively insulate wo frustrate biotech pharmaceutical stock late stock medical equipment maker such intuitive mazor have collectively spiked year date intuitive blowout quarter april help spur excitement evercore analyst vijay kumar say recent note client recent investor day medtronic be help drive frenzy robotic surgery be topic currently medtech blowout quarter intuitive surgical hint pace manual robotic transition be pick kumar say topic competition elicit various response investor intuitive surgical stock be year climb kumar expect intuitive surgical competition become more apparent next month intuitive da vinci surgical system now boast patient count da vinci system be also move deeper hernias be see early stage adoption bariatric surgery perform induce weight loss myriam curet executive vice president chief medical officer intuitive note email ibd estimate prostatectomy be perform robotic assist surgery same be true malignant hysterectomy general surgery be fastest grow specialty be still early stage adoption procedure such ventral inguinal hernia repair colorectal bariatric surgery say believe be substantial opportunity expand robotic usage category be develop additional tool technology do so year intuitive guide first quarter earning conference call growth number procedure perform system year follow many consider strong fourth quarter recur revenue include instrument accessory da vinci system grow recur revenue represent sale pie still even intuitive surgical see early innings expect robotic surgery present huge total addressable market number da vinci procedure perform year grow nearly other robotic surgery company intuitive closest competitor auris doesn trade publicly recently be stealth mode kumar say medical technology company sign agreement division agreement come month auris monarch system grab approval monarch be flexible catheter surgeon thread patient mouth lung remote control approval investor believe credible competitor intuitive be year away kumar say monarch get approval month ahead view intuitive surgical plan seek approval own flexible catheter later year auris say monarch first target be lung cancer expert estimate half lung biopsy be perform year surgeon also use flexible catheter urinary tract procedure number roughly procedure year intuitive isn sweat competition auris chief executive interestingly be frederic moll founder intuitive surgical intuitive current ceo gary guthart joined medical technology firm take ceo have build technology make decision architecture base first principle not look shoulder other person be do really engage customer deeply understand clinical need guthart say recent earning call rbc henry note auris monarch have larger catheter intuitive allow camera intuitive see benefit smaller catheter move deeper lung henry write recent report allow surgeon potentially use remove diseased tissue meanwhile have team google company call verb surgical analyst be unsure system team be create do expect enter robotic surgery market same time medtronic be partner mazor medtronic also expect own robotic surgery system launch not unreasonable suggest intuitive keep market evercore kumar tell ibd new robotic surgery company have differentiate have straightforward too product say investor have put pretty punchy marketable valuation intuitive surgical re still early stage robotic conversation add market be big enough sustain multiple player company mazor zimmer biomet make system call rosa come have system surgeon use brain spinal procedure other mazor ceo ori hadomi say sizing opportunity robotic surgery company be difficult surgeon use mazor system spinal surgery company renaissance system perform spinal brain surgery cost disposable instrument material comprise mazor revenue hadomi tell ibd surgery perform mazor list price be term disposable item estimate half procedure generate stakeholder expect spine procedure grow rapidly person be be more more active say meaning suffer more injury require surgery more often procedure become less invasive safer procedure become more patient be willing interested be treat be operated benefit robotic surgery be plentiful hadomi say revision surgery surgery correct mistake tweak prior surgery be significantly lower robot assist precision robot help curb potential error say last october mazor unveil result patient study find fivefold reduction complication surgery perform mazor robotic surgery technology notably be also sevenfold reduction revision surgery compare freehand lumbar fusion surgery doubt patient perspective not consider go surgery robot know chance go revision surgery be time higher say revision surgery be also costly hospital face reimbursement hurdle agree robotic surgery win replace human surgeon hadomi liken system other toolbox surgeon be simply medical technology tool make operate easier surgeon safer patient say benefit be also grow investor say robo global capron really exciting be fact be inflection point technology enable robotic surgery price point be attractive say now lot action medtronic see confirmation be substantial addressable market related look best stock buy watch start herecan crispr small biotechs cure disease amazon vs walmart locking horn battle retail futurechart read basic buy point mark time real marijuana industry overtake beer legalization spur innovation
241,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
242,ISRG,intuitive surgical isrg break past buy point heavy volume hit record high wednesday knock park once again first quarter analyst say share intuitive jump close stock market today stock break consolidation begin form late january buy point intuitive also joined investor business daily leaderboard sign point strong canaccord analyst jason mill say note client firm continue produce best class result large cap medtech knock park once again first quarter say lion share first quarter metric handily eclipse expectation get newsletter deliver inbox more info product service privacy policy term analyst be more split procedure growth expectation quarter number procedure used intuitive da vinci surgical system rise intuitive cite grow demand general surgery worldwide urologic procedure number da vinci procedure perform grow growth be rest world intuitive raise bottom line outlook growth procedure placement new da vinci system hospital also be highlight grow year year ultimately procedure growth remain key focus investor procedure volume growth have historically be lead indicator additional system placement mill say intuitive expect still early innings large hernia repair market mill say hernia general surgery be expect be biggest procedure volume bucket mill see intuitive fire cylinder evercore analyst vijay kumar note intuitive didn raise top end outlook procedure volume procedure grow say note client question come valuation intuitive stock kumar say hospital be fact purchasing da vinci system anticipation future procedure demand then lofty price earning ratio be justified however give historical comment procedure be lead indicator system placement procedure come line expectation argue greater time price earning ratio capital expenditure revenue beat say maintain high valuation also depend intuitive maintain standing predominant player market kumar say auris health recently launch monarch platform lung biopsy same time dow jone component johnson johnson jnj medtronic mdt be move robotic surgery market investor be more comfortable pay premium price earning ratio asset perceive have monopoly power say other entrant come make case sustenance monopoly power bull argue intuitive have technological lead rival debate be likely come head next month kumar say meantime kumar say be stay sideline canaccord mill up price target intuitive keep hold rating related much volume look stock look best stock buy watch start basic analyze stock cup handle
243,ISRG,tech stock be pressure early trade wednesday stock future steer positive start future dow jone industrial average be fair value ibm ibm drag early action future nose nasdaq future scratch gain ibm intuitive surgical isrg lam research lrcx railroad csx csx unite airline ual be lead name active early trading medical tech stock have power market tuesday major index seize powerful gain rise trade netflix nflx goldman sachs gs unitedhealth unh post first quarter result carry element upside surprise investor send more stock news high session past week get newsletter deliver inbox more info product service privacy policy term dow nasdaq climb day move average tuesday session technical line have present possible barrier market week old uptrend test remainder week be benchmark index be able maintain new level support top tech stock early motion intuitive surgical bolt higher maker da vinci robotic surgical system report ep gain rise revenue first quarter late tuesday number surgical system ship soar quarter procedure perform used da vinci system rise intuitive share rise regular trade tuesday stock best session january share be more month new base close tuesday less potential buy point lam research tumble late action largely positive fiscal third quarter report chip equipment leader earning revenue jump be consensus target guidance also surpass expectation lam be first chip sector name report result season investor be feel flighty chip stock general lam share surge tuesday regular trade stock have be consolidate nearly week unite climb premarket trade first quarter revenue earning squeak past analyst target second quarter guidance be positive company quarterly conference call be set et today unite share be consolidate have long way go reach valid buy point dow ibm dive tuesday close legacy tech brand post stronger expect result report second straight quarter year year revenue growth first time more year full year earning guidance be just shy consensus view however stock have have little success attempt climb month consolidation ibd issue interactive broker ibkr edge premarket trade greenwich conn base online broker report larger forecast sale earning gain tuesday close stock close tuesday buy range buy point flat base morgan stanley ms asml hold asml bancorp usb be name report result early wednesday wednesday session also offer simple calendar economic release homebuilding stock aren likely see much reaction weekly mortgage application datum due mortgage banker association open later morning energy stock oil price now hover year high respond weekly oil inventory news energy information administration afternoon federal reserve release march beige book related big picture nasdaq take command fuel stocksthese dow stock be just buy flash bullish signalgoldman sachs crush ahead leader be set upuse trend line buy growth stock rule help avoid lose stock
244,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
245,ISRG,nasdaq re-cover nicely wednesday drop intraday growth investor weren happy bunch several top rate growth name china stock face more selling pressure dow jone industrial average end modestly higher nasdaq composite ease less ibd underperform fall
246,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
247,ISRG,dow struggle straight close bell wednesday mark mixed finish market gain narrow late trade still major index hold gain ground day move average dow jone industrial average end run home depot hd afternoon rally blue chip energy name help dow hold ground vs ibm ibm slide ease advance less textron txt csx csx intuitive surgical isrg power index much session hold ground early breakout rally airline energy stock share several index top gain nasdaq close session high intuitive surgical csx american airline aal lead nasdaq quarterly result send chip equipment maker lam research lrcx low end nasdaq trigger broader loss chip sector apple aapl shed afternoon gain close fang stock tech leader give ground hold amazon com amzn jump stock be buoy agreement best buy bby sell smart television set power amazon fire tv operate system best buy share end higher get newsletter deliver inbox more info product service privacy policy term energy issue be drive factor afternoon trade unite continental holding ual report mixed bag first quarter result outlook flat lower cost expand route help hoist share stock be fight build right side month consolidation american air soar delta air line dal jump southwest airline luv jetted higher emergency landing aircraft tuesday engine disintegrate cruise altitude passenger be kill incident crude oil price spiked more send bench mark crude well barrel first time december dow chevron cvx exxon mobil xom end respectively devon energy dvn snatch top advance stock gain growth stock wildhorse resource development wrd jump eighth straight advance ibd stock venom energy vnom pop also eighth session row stock be extend cup basis csx intuitive surgical textron score gap breakout stock market today csx be break past buy point month long base fuel healthy first quarter result remain play buy range extend base be second stage pattern be good stock relative strength line have be trend higher february make new high time stock be base intuitive surgical swell gain move also drive positive earning left stock still buy range entry intuitive relative strength line break cleanly new high good sign textron close hold ground maker cessna aircraft report strong earning beat sale tool unit remain buy range buy point stock have form multiple second stage basis climb less consolidation intuitive textron rs line punch new high gap open today be reinforce signal stock move new high ebay ebay bolt state gate wednesday advance stock meet resistance day move average pare gain close morgan stanley upgrade stock hoist price target cite new payment program development ebay be attempt build right side double bottom base buy point be be interested big picture nasdaq take command fuel stocksafter hour tech stock dive transportation name soara stock specialty tool relative strength lineintel stock near buy point price target soar strong earning guidance
248,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
249,ISRG,intuitive surgical isrg tumble friday issue underwhelm guidance beating wall street fourth quarter sale adjust profit expectation late thursday share dip close stock market today share earlier topple much make intuitive surgical biggest intraday decline early december rbc analyst brandon henry blame lackluster guidance stock plunge earlier month intuitive surgical pre announce fourth quarter sale procedure growth so investor be key guidance intuitive surgical initial guidance underwhelm give heighten investor expectation henry say note client year firm expect procedure growth range drive general surgery procedure outside first quarter be expect be weakest due year year headwind timing good friday capital sale be ultimately drive procedure growth catalyze hospital establish expand robotic system capacity say calvin darling intuitive surgical senior director finance investor relation earning conference call ibd take intuitive surgical be longtime market favorite manage show enough strength emerge new leader bull market get more intuitive surgical history include stock pattern visit investor corner firm also project modestly lower gross profit margin base higher cost associate new product pro operate expense be see grow level tax rate be likely be range give heighten investor expectation believe intuitive surgical higher expect operate expense growth guidance slightly lower expect gross margin guidance underwhelm rbc henry say call procedure growth gross margin guidance prudently conservative note operate expense growth allow intuitive surgical continue aggressively reinvest international growth technology henry raise estimate sale be year year expect intuitive surgical accelerate investment continue drive topline growth also expect adjust profit grow share base higher revenue lower tax rate partially offset higher operate expense growth evercore analyst vijay kumar note intuitive surgical have long runway replace older da vinci si robotic surgery system new da vinci product be intuitive surgical low end system price tag da vinci launch have be very successful kumar say note client many system be place europe be si system potentially be available upgrade next few year related biopharma behemoth soon become acquisitivewhy insurer haven win push back rare disease drugscelgene reverse fourth quarter otezla sale rebound
250,ISRG,robot surgeon maker intuitive surgical isrg top street fourth quarter sale adjust earning guidance share fall late thursday firm report expense related new tax law hour trading stock market today intuitive surgical stock topple rise regular session share break flat base earlier month be now extend point fourth quarter intuitive report adjust profit share rise vs year earlier period top view share sale advanced year year beating consensus estimate intuitive also post loss income tax expense related tax cut job act firm say news release ibd take intuitive have ibd composite rating best possible meaning perform top stock term key growth metric still not rank first ibd medical system equipment industry group see stock outrank intuitive visit ibd stock checkup quarter worldwide procedure used intuitive da vinci system grow drive growth general surgery procedure worldwide urologic procedure firm ship system year earlier period related biogen revenue top spinraza ms drug deliver upsidecelgene reverse fourth quarter otezla sale reboundwhy valeant climb month make sense
251,ISRG,california base intuitive surgical isrg get boost last week new study show patient undergo procedure da vinci surgical system experience fewer complication subject undergo conventional operation be welcome news leader robotic assist surgery help settle long run debate merit minimally invasive quite expensive da vinci equipment compare
252,ISRG,load player result new study announce monday show patient undergo procedure da vinci robotic surgical system intuitive surgical isrg experience fewer complication subject undergo conventional abdominal other operation california base medical device maker note better outcome be observed increase complexity patient robotic assist group welcome
253,ISRG,stock market be confirm uptrend rowe price growth stock prgfx be still way late high year go tuesday lot growth oriented mutual fund so fund do position future resume outperformance chart helmsman joe fath take tiller little more year become manager early then reshape portfolio reflect strategy fath guide fund gain top large cap growth rival mutual fund track morningstar inc peer group averaged gain edge be increasingly hard find growth fath say year end commentary durable grower be crucial good performance want use market volatility find good grower price get knock too low relative long term prospect top holding dec have strong composite rating ibd higher already see gain name ross store rost apparel accessory footwear home fashion discounter be jan low trading share tuesday rise buy point ahead company close earning report analyst be expect gain fiscal
254,ISRG,close ross report gain fiscal earning cent share beat analyst expectation company guide lower fiscal sale full year earning share continue higher hour tuesday paypal pypl top new buy fund be year be jan low trading digital mobile payment provider share be still buy range early entry conventional buy point lie stock average daily volume be almost share more enough attract institutional sponsorship several fund ibd month rating addition growth stock own stock intuitive surgical isrg be feb low stock be year trading share be cup handle entry robotic procedure be gain market share surgical field company be debt free manage health care provider unitedhealth group unh be so far year jan low trading be pivot point stock market news tuesday unitedhealth qualcomm qcom launch program offer financial incentive worker meeting specific walking goal wear monitor track distance autozone azo have be reinvent serve more car repair shop auto part retailer top analyst consensus quarterly earning expectation tuesday solid same store sale gain benefit upbeat industry trend higher margin autozone earning share rev net sale rise match view same store sale climb year earlier gross profit percentage sale widen prior year drive higher merchandise margin
255,ISRG,alphabet googl release earning february tech giant reveal last year spend so call moonshot project range self drive car extend human lifespan potential payoff initiative be year away investor profit sooner stock break current base take stock alphabet initiative alphabet
256,ISRG,come surgery intuitive surgical isrg chief executive gary guthart seek follow old camper motto leave campsite be ever trauma involved open patient end be almost damage difficult recover ailment surgery aim remove thus
257,ISRG,similar theme play stock market monday major average turn session constructive price action be also day leadership come lag group steel oil coal stock outperformed blue chip be favor dow jone industrial average rise nasdaq swoon afternoon
258,ISRG,day follow nasdaq tuesday give ibd reader proverbial green light deploy capital fresh new leader question be bright be green light indeed ibd style growth investor know thing not follow through be same success breadth breakout high quality stock ultimately determine quality follow right bat new uptrend be hampered much smaller pool stock be towering ep sale growth well price strength small list stock make weekly review reflect clearly nevertheless market rally heat spring always follow winter watch see comeback crude oil price better expect fourth quarter result other positive external event help provide spark keep close eye weekly review list change do grow size week come yes positive jan edition just name make stringent screen only company score ep rating rs rating trading week high make cut jan list show stock quick scan today ywr show quite few different industry sector get represent only handful stock less company be true leader specific industry nich win find many stock hail medical sector today list intuitive surgical isrg ep rs make grade fall recent day still trade not so far high hit recent have yet come better system robotic surgery ross store rost truly excel buy excess inventory department store chain selling merchandise deep discount clean well lit atmosphere stock be not far handle buy point fiserv fisv reilly automotive orly public storage psa also be top field
259,ISRG,frank caruso helm mid february almost exactly year ab large cap growth fund apgax have top peer track morningstar inc jan fund notch average annual gain time vs direct rival garner month performance rating ibd meaning performance be top mutual fund time lately mutual fund have show outperform ugly market well beautiful one lose less peer broad market turbulent past month fund rank top category fall last month little better average diversify stock fund decline caruso be year old be member ab fund complex last year change name caruso lead manager fund discuss ibd manhattan office team invest ibd have achieve outperformance bad market well good caruso focus great business obsession fundamental integrity holding way manage risk look datum march dec month time be rd percentile peer month be percentile beating peer risk adjust performance portfolio be extremely good ibd business cycle be not focus right caruso don want person associate overarch concern business cycle look consistent performance particularly important growth stock investing company want need have kind business have long runway invest high return earn return excess cost capital so combination persistence duration create unleash power compound rather say look high grow company look return look really good business ibd be look company meet requirement several year right caruso window be year company russell ve get high teen number earning forecast year next then fall cliff get fewer estimate year variability forecast increase lot longer time horizon lead inefficiency growth stock investing ibd other word have longer time horizon most other investor easier find company be price inefficiently caruso be absolutely ibd recent example please caruso most investor look nike nke see most efficiently price stock market change longer term provocative be ve be experiment new manufacturing technology weave technology most person say nike biggest cost be labor not shipping tariff duty eliminate lot localize manufacturing weave technology let do instead need lot low paid worker cut bang stitching glue coloring pack product have smaller factory world decrease shipping tariff duty cost so model nike push profitability hundred basis point give confidence long term inform want behave short term volatility ibd manager pay little attention short term re do well short term luck design caruso fact stock go doesn impact way manage portfolio have say year have have good consistent performance last year start see lot risk exposure momentum stock spend entire year manage more conservative level have see reversion mean ibd recent month volatility have trim have add caruso part ve do well be market continue be concern earning portfolio be deliver ve reduce size excess winner last year redeploy more not defensive more edgy controversial company have not be leadership stock intuitive surgical isrg be name ibd fang do own have trim caruso don own amazon com amzn netflix nflx have facebook fb google alphabet googl haven trim ve be more incline trim discretionary stock take profit reduce position starbucks sbux nike thought moment be pretty fully value welcome opportunity build back volatility disney be trim monster mnst staple spls have be phenomenal performer be trim ve add last summer be basically market weight health care little overweight be put grinder late summer early fall emerge correction start increase exposure add intuitive surgical last summer rebalance biogen biib introduce position edward lifescience ew do number thing tech introduce adobe adbe cognizant ctsh do add longer term position such servicenow now ibd do intuitive surgical caruso company have unbelievable return have enterprise cash debt re see utilization robotic ever increase number procedure company long term see more surgeon adoption robotic re see stock suffer fair amount past couple year stick knit add stake re start see contribution fund performance stock ibd weren facebook ipo buy many other be flee thesis caruso be controversial buyer rest street be puke re proud go back ipo summer banker buy have year forecast model be terminal year now current forecast be higher be back then point be fundamental overachievement be really hard model facebook have potential drive tremendous excess performance ibd go back monster beverage do trim caruso be verge deploy lot capital be able sell overseas then coke ko take strategic position company shareholder appreciate many other monster not have spend become global company be able leverage coke best planet global distribution platform get profit thought see year growth opportunity be increase exponentially so sizing decision be really starbucks type decision have be unbelievably successful stock valuation get little uncomfortable short term so reduce exposure diminution long term conviction ibd boost current stake cognizant september november attraction caruso bring level expertise software service mobility solution company be try figure get architecture next level position key technology interest cognizant be stock talk end step away more recently start build back ibd adobe post earning share gain quarters suffering ep decline prior stanzas crux thing be work caruso used put product shrink wrapped box sell ve switch subscription model allow be consistent upgrade be manage deploy customer don have upgrade model be destine compress up down business lower volatility result be good valuation point view model let manage risk piracy more head fashion so long term value subscription model be more attractive old model ibd be investor start alphabet more company bring ruth porat cfo caruso yes become excited bring porat morgan stanley ms google have great business focuse search used cash flow fund variety initiative many case didn appear make lot sense appearance strong cfo hope be finally adult room bring financial discipline way thought allocate capital so far do now ve get company basically be focuse advertising youtube be grow economically handsome property search then ve get essentially call option driverless car robotic ve be deploy capital build telecom network city so portfolio early stage company acquire nurtured ready prime time need more incubation split company let investor have more transparency properly value business
260,ISRG,medical system maker ibd stock intuitive surgical isrg beat analyst estimate late thursday report sale line pre announcement last week intuitive earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter consensus however have not be update reflect intuitive preliminary sale number announce previous week be wall street estimate amount increase year sale full year earning climb share sale intuitive partner hill holding hrc also say fda have clear latest accessory intuitive da vinci xi robotic surgery system call integrate table motion allow operate room team reposition table robotic arm be dock intuitive say have place da vinci system xi earlier version quarter procedure used da vinci system increase drive urologic general surgery procedure company say intuitive didn provide overall sale ep guidance say expect procedure increase conference call discuss earning intuitive executive say equipment sale likely be more seasonal last year be slowest quarter operate expense be forecast rise gross profit margin tax rate consensus have expect gross margin intuitive stock be more hour trading stock market today company release result share rise fraction regular session close rare stock intuitive stock touch nearly year high jan positive pre announcement big revenue beat system placement have take surprise print intuitive surgical still manage surprise upside massive ep beat drive gross margin improvement impressive operate leverage write evercore isi analyst vijay kumar email client follow amy reeve twitter ibd_areeve facebook
261,ISRG,load player stock rollick ahead friday volume once again step nasdaq surge dow jone industrial average add respectively ibd gain volume fall board few leader do anything dazzling generally action be upbeat intuitive surgical isrg pop early
262,ISRG,petm express pet break saucer handle base buy point friday show solid volume day upward run stock rise move come prior earning be announce monday market open analyst be look cent share increase year earlier online dog cat
263,ISRG,alphabet world internet search leader be prospect core business strike success health care world company glucose monitoring contact lens diabetic be inch closer drugstore shelve sale self stabilize spoon design help person uncontrollable hand tremor eat comfortably top first month google restructure last year become largest operate unit new parent alphabet googl buy biotech company lift lab just few month health focuse startup begin product sale point broaden emphasis other health medical advancement alphabet last month rename google life science division verily life science division bring together clinician scientist be focuse understand improve chronic condition impact massive number person health issue include cardiovascular disease diabetes cancer disease mental health be development health care think be far reach be long last be see period convergence technology company health care company california life science association trade group ceo sara radcliffe tell ibd say change drive health care tech firm partnership include explosion big datum result demand way manage patient information growth access datum internet cloud mobile technology such fitbit fit wearable be shift health care maintain tracking health rather simply treat disease say company team uprecent notable health tech partnership include alphabet verily division team last month johnson johnson jnj develop surgical robot news follow september announcement google life science spinoff calico have enter year collaboration north chicago ill base pharmaceutical firm abbvie abbv research age related disease verily have partner too medical device firm dexcom link verily create new class disposable glucose monitoring system be faster cheaper smaller product be currently available johnson johnson verily announce last year have create verb surgical develop new surgical robotic device smaller less expensive intuitive surgical isrg da vinci system now control minimally invasive surgery segment other look join force health tech divide include medical device maker medtronic mdt be collaborate big datum solution provider ibm ibm watson health analyze wave information glean diabetes insulin pump datum vs be not only tech heavyweight seek blend medical altruism big datum big moneymaking plan apple aapl microsoft msft other be also used deep technology expertise create medical related product service year apple introduce health tracking tool monitor user footstep heart rate sleep activity microsoft samsung already offer number so call wearable device also allow person monitor daily movement advance mobile compute artificial intelligence new analytic software be drive effort recent year have be increase interest health care application company traditionally be see be consumer focuse company say iain simpson drug delivery specialist cambridge consultant company such google apple facebook fb amazon com amzn have build consumer focuse business base creation compelling sustainable user experience now simpson say various tech company be head health drive increase relevance capability market create new high value business opportunity particularly work collaboration establish health care player such pharma medical device company health care spending weigh project reach accord california health care foundation profit potential be obvious incentive other factor be also work part reason alphabet focus move needle parkinson treatment be personal google co founder now alphabet president sergey brin mother eugenia have parkinson brin be diagnosed carry mutation lrrk gene have be associate higher rate degenerative disorder central nervous system generally pace medical research be glacial compare used internet brin tell wire interview google amplify process be look lot place collect lot information see pattern lead somewhere legislative change be factor have help open door tech firm put massive compute muscle health care datum drive medicine be key element affordable care act federal law ushered president barack obama health care reform be major force center boom new health technology law provide major financial incentive doctor hospital prove care be effective value base payment rule be spark demand new software track analyze patient datum say lynne dunbrack research vice president idc health insight patient prescribe example dunbrack say hospital be find cheaper send medicare patient have congestive heart failure home weight scale electronic tablet connect app rather risk too many readmission day discharge result hospital get federal reimbursement rate cut have be real financial incentive health care organization purchase use technology be then help drive demand be company be now see new opportunity dunbrack say shift value base care other top area focus health care industry include sequence human genome digitize health care datum say cowen co analyst john blackledge september report alphabet health care strategy health care trend be not occur vacuum be be accommodate technology advance area such social mobile analytic cloud compute be area google expertise blackledge say swirl change tech advance be also help fuel medical ambition tech heavyweight apple annual worldwide developer conference june apple introduce new healthkit app monitor user heart rate sleep weight blood pressure other health related measurement let home health device such heart monitor fitness monitor exchange datum healthkit allow clinician mayo clinic send health information user app turn transmit datum user physician healthkit be logical extension apple exist product digital ecosystem keep user engage increase apple app store business also keep apple product service relevant grow increasingly competitive consumer health market say simpson cambridge consultant apple tech framework researchkit let person want remotely participate clinical medical trial do so used specially design apps iphone instead have show person march apple display apps say help diagnose range condition diabetes heart disease apple say win see datum transmit person opt sharing researcher want researchkit help address few problem medical research current state such limit patient participation infrequent datum sampling apple jeff william now chief operate officer say time person sign single medical study stanford university first hour release researchkit apple ceo tim cook tell cnbc march put perspective stanford have tell have take normally medical center entire year sign many participant so researchkit be absolute game changer say cook call discover cure disease push life expectancy much longer currently be alphabet google have own initiative call fit include developer tool online platform collect datum connect michele chandler twitter ibd_mchandler facebook
264,ISRG,fall stock market have whittle weekly review fraction bull market self make list stock need earning share relative price strength rating least list make ibd index healthy market stock make cut publication market have fall recent week not enough stock be highly enough rate category fill list list be sort industry group highest ranking group close top few group solid representation be real estate investment trust group stock make cut constellation brand stz make distribute beer such corona wine such make robert mondavi spirit such make black velvet stock continue be winner trading time high bounce north side day move average extend base remember only first pullback day line be safe secondary entry jan company report earning year earlier stock gap new high day have give back gain chuy holding chuy make cut break base buy point give back good part gain recent day operate more tex mex restaurant state upbeat funky eclectic somewhat irreverent atmosphere stock have quarters good earning growth analyst expect year year decline next report intuitive surgical isrg be back leader report accelerate earning sale past several quarters company make da vinci robotic surgical system stock build cup handle base attempt wednesday reversed day be fall buy point
265,ISRG,stock settle small gain thursday wobble back forth much conviction nasdaq draft gain take almost trip direction dow jone industrial average rise respectively ibd slide volume fall nasdaq rise nyse so far best
266,ISRG,san francisco medical equipment maker intuitive surgical isrg st jude medical stj be move opposite direction stock market wednesday issue preliminary result
267,ISRG,intuitive maker da vinci robotic surgery system say revenue be year earlier quarter beating analyst consensus do not provide guidance overall say expect procedure used da vinci system increase company be slate report full result jan
268,ISRG,intuitive press release do not provide much color company be plan presentation jp morgan healthcare conference thursday san francisco analyst however be positive news
269,ISRG,procedure continue show momentum highlight be magnitude strength system placement write evercore isi analyst vijay kumar research note procedure guidance fy be slightly estimate believe reflect amount conservatism give recent trend procedure come estimate
270,ISRG,intuitive stock rise year high early trading stock market today close share be fraction day
271,ISRG,st jude meanwhile say sale be fraction year earlier quarter short consensus earning be share line estimate
272,ISRG,speaking conference wednesday st jude ceo michael rousseau admit exclude last year acquisition thoratec maker device heart failure therapy business have decline say foreign exchange headwind be particularly bad last year cardiac rhythm management business shrank company be lull product cycle
273,ISRG,competitor medtronic mdt last year win approval first implantable cardioverter defibrillator safe mri scan already launch mri safe pacemaker st jude start roll similar product europe japan last year be disadvantage medtronic product be clear rousseau say start first half year
274,ISRG,thoratec meanwhile outperformed wall street expectation growth constant currency basis
275,ISRG,st jude didn offer guidance be expect earning conference call schedule jan leerink analyst danielle antalffy write guidance likely be conservative possibly leave room estimate raise year
276,ISRG,follow amy reeve twitter ibd_areeve facebook san francisco medical equipment maker intuitive surgical isrg st jude medical stj be move opposite direction stock market wednesday issue preliminary result intuitive maker da vinci robotic surgery system say revenue be year earlier quarter beating analyst consensus do not provide guidance overall say expect procedure used da vinci system increase company be slate report full result jan intuitive press release do not provide much color company be plan presentation jp morgan healthcare conference thursday san francisco analyst however be positive news procedure continue show momentum highlight be magnitude strength system placement write evercore isi analyst vijay kumar research note procedure guidance fy be slightly estimate believe reflect amount conservatism give recent trend procedure come estimate intuitive stock rise year high early trading stock market today close share be fraction day st jude meanwhile say sale be fraction year earlier quarter short consensus earning be share line estimate speaking conference wednesday st jude ceo michael rousseau admit exclude last year acquisition thoratec maker device heart failure therapy business have decline say foreign exchange headwind be particularly bad last year cardiac rhythm management business shrank company be lull product cycle competitor medtronic mdt last year win approval first implantable cardioverter defibrillator safe mri scan already launch mri safe pacemaker st jude start roll similar product europe japan last year be disadvantage medtronic product be clear rousseau say start first half year thoratec meanwhile outperformed wall street expectation growth constant currency basis st jude didn offer guidance be expect earning conference call schedule jan leerink analyst danielle antalffy write guidance likely be conservative possibly leave room estimate raise year follow amy reeve twitter ibd_areeve facebook
277,ISRG,most other large cap growth mutual fund american century ultra fund have little show term return year american century ultra be year go tuesday market have be challenge loss year be broad market benchmark worst trading day start year history
278,ISRG,seller have be driver seat pretty much start year have firm grip steering wheel again wednesday stock suffer smackdown nasdaq fall weigh weakness netflix nflx biotech stock lose hurt weakness railroad trucking airline stock dow jone industrial average give dow jone transportation index shed volume nyse nasdaq be tracking slightly higher tuesday level stock market today west texas intermediate crude oil future edge lower barrel year treasury yield fall basis point day mover chipotle cmg be few bright spot share jump renew confidence fast casual chain be able bounce back recent coli outbreak restaurant regain trust customer intuitive surgical isrg gap cup handle base rise company release preliminary result open earlier month morgan stanley upgrade share equal weight overweight webmd wbmd soar time high rise nearly stock continue perform well be downgrade sun trust robinson humphrey earlier week neutral buy reit space datum center operator qts realty trust qts give close work cup handle base buy point other reit bullish setup be topic thursday income investor column connect ken shreve twitter ibd_kshreve facebook
279,ISRG,market be back uptrend be still trading high be easy see month struggle market reflect ibd blue chip big cap list fully stock current list qualify defensive name utility include southern energy so consolidated edison ed wec energy group wec be defensive price consumer be generally lock customer have little choice use product also stock typically offer healthy dividend factor utility be segment mutual fund work maintain minimum level investment rotate choppy market demand hold share price steady even drive higher general market correct other hand stock list qualify solid growth stock cognizant technology ctsh equinix eqix intuitive surgical isrg mcdonald mcd carry combine trait defensive growth stock give interesting leg current market fast food chain turnaround new chief executive steve easterbrook have make stock growth contender regard number fundamental technical attribute earning growth same store sale relative strength accumulation distribution mcdonald still fall short standard punch list slim element turnaround have make stock much more attractive investor look healthy dividend name double threat defensive play mcdonald fall list monday be extend last week bounce week move average october dollar general dg be double threat growth defensive stock re entry public market november july now merged competitor family dollar dollar tree dltr be grab market share wal mart wmt buy smaller regional chain dollar general ep growth be forecast healthy year end january revenue growth have slow high single digit reilly automotive orly torqu nearly october october period market be choppy correction auto part chain be see dual growth defensive play be consolidate gain market share benefit consumer hold car longer have past reilly announce result feb be forecast remain camp full ep growth forecast revenue growth be see slow analyst consensus put ep growth sale growth big cap stock tend be stable healthy performer be not list pick play buy opportunity investor need look carefully fundamental make sure understand company value proposition sudden change market direction generate significant change company list
280,ISRG,relative strength rs rating mazor robotic mzor enter new percentile thursday increase look best stock buy watch factor watch closely be relative price strength proprietary rating measure technical performance show stock price action last week compare other stock major index decade market research reveal market biggest winner typically have higher rs rating early stage move look best stock buy watch start herewhile mazor robotic be not ideal buy point right now see be able form break proper chart pattern earning growth moved company most recent report top line fall look next report aug company hold rank peer medical system equipment industry group intuitive surgical isrg omnicell omcl abaxis abax be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
281,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
282,ISRG,stock strengthen afternoon trading tuesday monday drubbing see lead growth stock come heavy selling pressure don give bull market yet shortage market leader still boast bullish chart leaderboard name netflix nflx rebound monday haircut be far best performer fang stock other top gainer nasdaq include ibd name align technology algn intuitive surgical isrg amazon com amzn apple aapl
283,ISRG,apple be testing support day move average intuitive surgical be hold nicely still buy range recent flat base entry nasdaq composite lead way rise add dow jone industrial average picked volume nyse nasdaq be tracking lower monday level oil gas stock outperformed oil price surge crude oil future jump more barrel pressured ally stop import oil iran stock market result today akamai akam gap day move average fall nearly company forecast second quarter earning sale low end prior guidance retailer home home gap new high rise more morgan stanley upgrade share overweight equal weight stitch fix sfix re-cover more half monday decline new issue chart be still intact trade just recent high plenty liquid average daily volume share annual earning growth be expect slow year fall cent share company earn cent couple china base ibd name bounce back monday drubbing see ibd index drop baozun bzun rally nearly pay visit day line monday zto express zto picked come close day line monday get newsletter deliver inbox more info product service privacy policy term usegold lose ground again dollar strengthen hit high april spdr gold share gld be nearly exchange trade fund fall tuesday still hold december low also homebuilder stock soar demolish earning viewsthese stock just come ibd stock liststrump say harley move abroad be begin end
284,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
285,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
286,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
287,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
288,ISRG,look best stock buy watch focus rise relative price strength stock fit bill be mazor robotic mzor have relative strength rs rating upgrade monday look best stock buy watch factor watch closely be relative price strength unique rating measure market leadership used worst best score identify stock price performance last week match other stock history reveal stock go make biggest gain typically have rs rating early stage move see ibd help make more money stocksmazor robotic be work consolidation buy point see break volume least average later stage pattern investor be aware be less likely lead significant gain earning growth picked last quarter revenue gain fall company hold rank peer medical system equipment industry group intuitive surgical isrg iradime irmd abaxis abax be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
289,ISRG,here weekly investing action plan need know investor come week trump trade war china see biggest salvo date market get update tesla tsla model production job datum highlight busy week economic report fed minute reveal policymaker deliberation
290,ISRG,mazor robotic mzor see positive improvement relative strength rs rating wednesday rise try find best stock buy watch keep close eye relative price strength proprietary rating identify technical performance show stock price movement last week compare other stock database decade market research reveal best perform stock typically have rs rating least early stage move see mazor robotic continue show renew price strength clear threshold look best stock buy watch start herewhile mazor robotic be not ideal entry right now see go form break proper consolidation earning growth picked last quarter sale fall mazor robotic hold rank peer medical system equipment industry group intuitive surgical isrg iradime irmd abaxis abax be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
291,ISRG,think oldest mutual fund have figured now beat benchmark consistent basis be right rowe price growth stock fund prgfx notch top result hold lead growth stock amazon com amzn book holding bkng alibaba group holding baba microsoft msft google parent alphabet googl growth stock fund open april have beaten index year year year year year annualize period year accord morningstar com inception fund have post average annual return compare return first month year fund be vs large cap growth mutual fund be direct rival joe fath manage fund say holding amazon book alibaba microsoft alphabet share key trait re look innovative disruptor fath say unique time re go powerful information revolution massive platform business be be build top powerful technology build powerful network effect user platform get newsletter deliver inbox more info product service privacy policy term usefath seek large cap become megacaps growth be accelerate very big base business google be good example fath say refer google parent alphabet ve be able grow top line annually long period time continue even company become much larger other big thing be don rest profit pool ve create continue invest break barrier new area so far year alphabet be amazon be gain alibaba book microsoft range fund be large cap focuse more mostly domestic only foreign stock march still fund have additional international exposure large cap stock many have multinational operation bring stock fund fath need see double digit growth earning free cash flow year year fath assess company total addressable market ask be area ripe disruption be new entrant look stock market appreciate speed pace durability company growth online retailer amazon be fund top hold perfect example innovative disruptor go many different direction same time disrupt many different part marketplace fath say biggest area be commerce drive prime membership second be cloud offer amazon web service have other iron fire biggest be advertising hardware amazon be do more advertising third party merchant use amazon storefront also move home device alexa speaker system compete google apple aapl fath say book online travel agent run book com have powerful business model say accumulate inordinate amount supply europe add lot brand independent hotel well alternative vacation home bed breakfast say put pressure aggregator travel site such trivago be more efficient marketing spend drive person own site big hold be alibaba chinese commerce giant fath say have probably best business model be very cash flow generative epicenter take advantage china rise middle class buy more more good service intuitive surgical isrg have see share rise more past year first quarter earning share jump revenue profit top expectation company make robotic da vinci surgical system profitability be base classic razor razor blade business model make money robotic surgical system then create recur revenue stream additional profit sale service contract disposable item surgical blade other instrument accessory fath also like nike nke have be favor competitor adida addyy hustle way resurgence say nike be begin ramp innovation engine soon pump number product include react sneaker line go forward fath say feel very good fundamental also need much retirement saving age incomenew etf aim provide steady annual distribution rate
292,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
293,ISRG,welcome move natus medical baby see relative strength rating improve monday look best stock buy watch factor watch closely be relative price strength ibd unique rating identify market leadership worst best score score show stock price movement trail week stack other stock database decade market research reveal top perform stock often have rs rating begin biggest climb see natus medical continue rebound hit benchmark look winning stock try simple routinewhile natus medical be not ideal buy zone right now see be able form break proper consolidation company report earning growth last quarter revenue gain come look next report apr natus medical earn rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd cutera cutr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
294,ISRG,medtronic mdt share sank early tuesday firm suggest first used surgical robot hugo human likely be push analyst say share drop come medical device maker top wall street quarterly expectation diabetes business revenue handily beat consensus medtronic put production issue rearview mirror rbc analyst brandon henry write note client stock market today medtronic sank close robotic issue previously medtronic have say competitor intuitive surgical isrg begin operate patient end fiscal full launch fiscal call firm say software hardware integration testing be take longer expect believe commentary suggest first human case medtronic surgical robot slip fiscal henry say believe slippage medtronic surgical robot timeline be slight positive intuitive transenterix trxc ibd take hard identify start uptrend simply rely headline so do savvy trader look uptrend head investor corner key tip operate resurgent market delay medtronic give transenterix longer second mover advantage henry say transenterix gain approval october senhance surgical robotic system sell first system hospital system florida november intuitive surgical gain close transenterix gain cent fiscal third quarter medtronic report adjust income share sale third quarter rise respectively vs year period analyst have call adjust profit share sale rbc analyst glenn novarro note segment contribute upside cardiac vascular sale rise constant currency basis restorative therapy minimally invasive therapy diabetes sale grow respectively get ibd market prep tech report newsletter free edward jone analyst john boylan credit sale beat diabetes group bring worldwide handily beating estimate evercore analyst vijay kumar say consensus have project diabetes sale revenue beat be drive broad strength board standout mind be diabetes drug eluting stent pain therapy kumar say note drug eluting stent grow midteen percentage pain therapy rise medtronic reiterate guidance adjust earning grow year year imply share edward jone boylan write consensus have modeled share sale be expect grow constant currency basis consensus be modele sale fiscal year end april related be explosive year biotech biotech stock need anesthesia collapse nearly abbott laboratory jump boost quarterly dividend
295,ISRG,thursday natus medical baby receive positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength ibd proprietary rating measure price movement worst best score rating show stock price behavior trail week hold other stock database history reveal best perform stock often have rs rating north launch largest climb see natus medical continue show renew price strength hit benchmark look winning stock try simple routinewhile now be not ideal time buy share see stock manage offer clear appropriate buy point company report ep growth most recent report sale growth come next quarterly result be expect apr natus medical earn rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd cutera cutr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
296,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
297,ISRG,relative strength rs rating nevro nvro moved new percentile monday get lift look best stock buy watch factor watch closely be relative price strength ibd unique rating measure price action worst best score grade show stock price performance trail week compare other stock database year market history show stock go make biggest gain typically have higher rs rating launch largest climb see nevro continue rebound clear threshold see ibd help make more money stocksnevro be now consider extend buy range clear buy point third stage cup handle see stock form new chart pattern follow buy opportunity week tight pullback day week move average earning grow last quarter prior report revenue also increase look next report company hold rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
298,ISRG,apple aapl sell badly friday touch day move average first time mid february stock market bear also send major index trip day move average friday first time week nasdaq composite slide nearly dow jone industrial average yet major index still manage march higher second week row wake key follow take place april square sq meanwhile offer fresh proof remain true market leader share run more stretch year date advance more square be huge winner well addition square transunion tru charle schwab schw trade financial etfc western alliance bancorp wal show bullish action blast gain more schwab continue work new base etrade be now extend recently retake entry point week cup handle yield benchmark treasury year bond continue soar rise high practically eclipse feb year date high higher interest rate help boost net interest profit margin bank other financial firm square san francisco base digital transaction business analytic innovator rise climb high average turnover large cap tech be likely middle form new base base wall street see jack dorsey lead tech firm grow full year profit cent share year square have ramp higher clear tightly wound flat base buy point april get newsletter deliver inbox more info product service privacy policy term base base pattern be awesome generator price gain only selling pressure overall market ease stock market be confirm uptrend april follow improve stock market outlook raise market correction confirm uptrend square show excellent composite rating scale ibd stock checkup nasdaq composite sank nearly get go then stretched loss more follow rally last week volume be lower thursday level accord preliminary datum lead index still cling weekly gain roughly be jan so tech center index be still week close key day move average nasdaq tracking powershare qqq trust qqq etf fall too slip mildly day move average first time nearly week hand tool shoe paper numerous defensive industry group pace downside see weekly gain slim prior week large cap benchmark rally turnover climb roughly higher vs same time thursday nyse overall trading volume have be hold day average nasdaq least straight week nyse trading have be muted nearly week row typically best follow through give alert investor chance hunt breakout leadership quality stock term excellent fundamental relative stock price strength fund sponsorship take place day day new rally attempt also occur much later home depot hd be sole stock component dow jone industrial average initially gain point more share retreat just fraction volume be usual level home depot diy home improvement chain have be correction mode striking new high jan peak come right first year intermediate market correction stock hasn fall much lose just market value well range normal decline say cup handle base saucer base chart pattern be common dow industrial type issue home depot have pound steady not rip roar profit growth earning share have lift vs year level past quarters street see fiscal profit rise share consumer tech titan apple gap day move average sign weakness iphone ipad giant stock fall more hit intraday low intense turnover apple be now tickle long term day move average be trading time high apple have already rally burst cup handle way back jan so due rest keep watch base complete note new click tech blog post morgan stanley analyst katy huberty trim price target consumer electronic digital service firm cite concern iphone sale however huberty also reportedly advise client buy share price weakness apple report fiscal sale march end quarter close point slice price target do not amount much term market value stock market value be apple have share outstanding google operator alphabet googl lose just weak turnover still manage post stout weekly gain nearly watch see hold day move average paint red ibd daily chart megacap tech be form new double bottom base middle peak stock first second lows be stock continue rebound set potential cent middle peak alphabet be expect increase first quarter profit share follow ep gain prior quarters name currently leaderboard new entrant intuitive surgical isrg cool second straight day normal fashion big cap medical play remain buy range entry shallow cup handle share ease average volume go back transunion credit report agency financial datum expert have hold spot leaderboard watch list more week friday stock gap open jump share get high easily surpass buy point shallow cup handle base be better view flat base entry cent left side high case transunion be proper buy range right open price flat base entry expert consumer financial datum post jump first quarter earning cent share spanking thomson reuter consensus estimate nearly issue biggest year year increase quarters revenue grow mark third quarter row accelerate top line growth transunion also announce acquisition base callcredit skecher skx get body slam gapping more finishing session sell wipe month worth gain volume soar past share more quarter total float share stock day average turnover be share day company report rise earning cent share sharply undercut wall street expectation sale rise ease top line increase move faster pace year quarter weak rise net margin edge basis point lower decline suggest shoe giant feel price pressure competition see cost climb please follow saito chung twitter ibd_dchung more commentary analysis lead growth stock buy point sell signal financial market related stock be move sharply right now trigger buy sell signal find stock be new ibd top screen check herestock buy latest investor cornera peek ibd be leader recent breakout fare lately be still golden rule investing
299,ISRG,index dow jone industrial average nasdaq composite rise strongly early week then erased most gain friday close netflix nflx soar subscriber growth guidance energy stock bust higher crude oil price keep rise alcoa aa american express axp unitedhealth unh jump report offset weak outlook taiwan semiconductor manufacturing tsm chip gear giant lam research lrcx asml asml broader chip sector apple aapl come pressure index dow jone nasdaq composite be more thursday friday close be major average rally wednesday netflix nflx earning oil fuel energy stock stock pull back taiwan semiconductor manufacturing tsm warn rest cite weak smartphone demand already pressured weak asml asml lam research lrcx guidance chip stock sell apple aapl also come heavy pressure thursday friday iphone demand concern year treasury yield jump year high internet television network netflix nflx add stream subscriber first quarter beating target end march quarter subscriber worldwide netflix expect add subscriber top wall street target netflix also top ep sale figure guide higher metric subscriber number benefit new original content such science fiction series alter carbon fresh season comic book series marvel jessica jone comedy grace frankie share shot record high taiwan semiconductor manufacturing tsm cut sale outlook rest year largely softer smartphone demand slam chip stock apple aapl taiwan semi be world largest contract chipmaker count apple nvidia nvda qualcomm qcom customer meanwhile chip gear maker lam research lrcx asml hold asml pressured semiconductor stock day earlier weak outlook lam equipment shipment view rest year come light asml forecast lower gross profit margin current quarter get newsletter deliver inbox more info product service privacy policy term useu oil future rise barrel hit fresh multiyear high opec russia likely stay course output cut meeting jeddah saudi arabia friday president trump blast opec crude hold domestic crude stockpile fall barrel last week energy information administration say defy view small gain oil production climb fresh high barrel day schlumberger slb meet view energy stock be big winner yet again more oil play breaking set charle schwab schw interactive broker ibkr trade financial etfc report better expect quarterly earning schwab share reclaim day move average build right side flat base interactive broker moved buy zone just earning then pull back slightly trade moved buy range late thursday report bank america bac first quarter earning top expectation rebound trading lead estimate beating result goldman sachs gs morgan stanley ms extra client activity goldman reversed lower say say likely pause buyback second quarter meanwhile comerica cma sank other super regional bank weak loan growth treasury yield soar financial stock rise weekly lows southwest airline luv flight head dalla new york make emergency landing philadelphia jet left engine explode burst window kill female passenger result passenger jennifer riordan be pronounce dead hospital unite airline ual say inspect engine boee ba type plane experience engine failure follow recent faa bulletin unite share jump carrier narrow expansion plan year ahead stay upbeat sale trend bristol myer squibb bmy plunge report drug combination opdivo yervoy reduce risk lung cancer progression death be lower merck regimen keytruda chemotherapy cut risk death similar group lung cancer patient merck mrk stock climb nearly commerce department ban domestic firm selling component chinese telecom gear maker zte spark sell optical device maker acacia communication acia oclaro oclr lumentum holding lite government determine zte violate term settlement involve illegally ship networking gear iran acacia garner sale zte oclaro analyst say ciena cien compete zte optical system get lift year ban be not lift unitedhealth group unh cruised past wall street first quarter earning estimate net share cent view revenue grow manage care enrollment gain come medicare advantage medicaid meanwhile unitedhealth fast grow optumhealth service unit grow revenue deliver care related service person share rise week approach buy point alcoa aa stock break past buy point record alumina price strong earning blowout profit guidance aluminum giant earning rise revenue grow alcoa expect full year adjust ebitda range offer january expect industry supply shortage year trump administration sanction unite co rusal impose month bar ban entity do business russian aluminum giant top steel maker steel dynamic stld nucor nue edge past first quarter earning estimate issue moderately positive comment outlook nucor expect sustainable strength steel market not quite bullish steel investor have expect late february president trump initially call tariff steel import exemption then more half steel import have be exempt general electric ge report smaller expect adjust ep decline revenue rise more expect aviation health care be solid ge power remain drag ge reaffirm full year ep guidance say have plan cut dividend again ge stock rise friday atlassian team report adjust fiscal profit cent share revenue jump top estimate maker project management collaborative software guide low current quarter ep share tumble friday amazon com amzn ceo jeff bezos disclose amazon prime have more member worldwide first time online sale leader have give specific membership figure be higher expect intuitive surgical isrg break wednesday robot surgical system maker report adjust ep gain sale grow beating view textron txt sell tool test business segment emerson electric cash maker cessna jet bell helicopter also report jump ep cent share rise revenue beating analyst view announce share buyback program textron soar gapping past buy point ibm ibm beat first quarter estimate stock tumble weak margin slower growth key area ebay ebay shot morgan stanley upgrade stock boost price target more cite recent partnership payment processor adyen move away paypal pypl abbott laboratory beat expectation wednesday adjust income cent share sale share dip pharmaceutical sale come expectation johnson johnson jnj top estimate share edge lower share fall wednesday news kentucky be sue allegation run deceptive marketing scheme related painkiller consumer electronic retailer best buy bby amazon com amzn announce partnership best buy use amazon fire tv operate system insignia brand television replace roku roku software best buy also sell tvs amazon american express axp jump thursday report better expect earning wednesday ep rise revenue climb nearly rail giant csx csx gap wednesday beating earning day report ep cent revenue operate income increase skecher skx crash friday give weak earning sale outlook athleisure shoe maker meet ep estimate rise modestly beat sale view gain be interested look best stock buy watch start invest stock market start simple routine
300,ISRG,stock market be higher wednesday morning earning news drive bulk early action market look add tuesday bullish action dow jone industrial average edge hold back ibm ibm steep post earning decline nasdaq composite add index extend gain csx csx ebay ebay intuitive surgical isrg haul nasdaq higher textron txt csx post widest gain stock chip equipment maker lam research lrcx ibm chalk largest decline stock market today issue textron intuitive surgical gap past buy point mark start bell railroad csx also narrowly top buy point quickly retreat back entry get newsletter deliver inbox more info product service privacy policy term usecrude oil price pulse nearly higher early wednesday bench mark crude climb barrel put price penny friday high marked oil strongest level november american petroleum institute tuesday report slightly smaller expect draw crude inventory prior week also report surprise barrel draw gasoline supply vs expectation takeout api number be generally consider preliminary weekly supply datum energy information administration datum be due et et federal reserve release march beige book report ebay vault early trade morgan stanley raise price target stock more also raise rating notch overweight underweight note base upgrade ebay recent announcement be develop new payment system netherlands base adyen ebay share be rebound support week line month consolidation dow home depot hd caterpillar cat stake early lead respectively caterpillar be work second weekly advance rebound support week line ibm founder early trade legacy tech brand late tuesday post stronger expect result first quarter also report second straight quarter year year revenue growth first time more year full year earning guidance be just shy consensus view however stock have have little success attempt climb month consolidation earning news drive lion share wednesday premarket session action stock future sharply divide report addition ibm early loss chip equipment maker lam research asml hold asml drop respectively cable system maker adtran adtn tumble upside morgan stanley ms rise unite airline ual surge csx throttle interactive broker group ibkr gain follow quarterly result intuitive surgical trim early gain pull back buy point maker da vinci robotic surgical system report gain earning share rise revenue first quarter late tuesday number surgical system ship soar quarter procedure perform used da vinci system rise defense contractor textron power stock market today score big beat first quarter revenue earning premarket move imply start bell buy point month flat base premarket move stock future do not always carry regular trade be interested big picture nasdaq take command fuel stocksafter hour tech stock dive transportation name soara stock specialty tool relative strength lineintel stock near buy point price target soar strong earning guidance
301,ISRG,tuesday premarket trading receive several shot arm first be netflix nflx surge report strong first quarter result late monday then cohort blue chip name kick post early advance follow expectation quarterly result result future dow jone industrial average vault trade fair value nasdaq future pressed higher netflix be premarket trading powerhouse more easily largest gainer nasdaq stock merck mrk bolster dow early trade follow analyst upgrade drugmaker quickly surrender lead investor wade early batch blue chip earning report goldman sachs gs johnson johnson jnj unitedhealth group unh positive premarket trading poise week old uptrend hurdle resistance uptrend be good standing carry distribution day day move average remain key test major index dow fail hold day line monday nasdaq have yet break back critical level support get newsletter deliver inbox more info product service privacy policy term usepremarket action suggest dow open day line keep mind future drive premarket trading do not always translate action regular session dow unitedhealth rolled early gain first quarter result be stronger expect stock retook day line support gain monday attempt start right side month consolidation also dow merck buzz ahead morgan stanley upgrade stock overweight equal weight drugmaker surge heavy trade monday company lung cancer treatment outperformed competitor clinical trial merck be early april low overall dow index stand poise test resistance day move average further list early dow advancer johnson johnson trim early gain medical product leader report first quarter result earning revenue top analyst target full year guidance meet beat expectation goldman sachs reversed early loss step clobber first quarter earning expectation raise quarterly dividend nearly stock have spend day fight resistance day move average ibd leaderboard stock churn strong early move draft netflix early advance stream entertainment leader report first quarter sale earning only narrowly consensus target blowout beat subscriber growth surprised investor launch share higher premarket trading netflix share remain extend rebound support week move average planet fitness plnt pop ahead open gym network end monday bit more buy point second stage flat base leader peer lululemon athletica lulu pare early surge back premarket trading company late monday name patrick guido chief financial officer effective april stock have jump past week china base stock be mixed market hong kong shanghai end lower tuesday datum show country gdp expand first quarter retail sale surge investment education soar china commerce ministry also announce impose tariff sorghum import ministry say investigation find grain be unfairly subsidize government march ipo iqiyi iq jump premarket trading share netflix platform advanced past session rise march ipo price housing start jump march annualize rate commerce department report be healthy uptick february disappointing rate home start startling economist have project rate new project build permit gauge upcoming activity post even larger increase annualize rate february permit clock pace economist have expect march permit issue rate industrial production number federal reserve be set release et busy slate tuesday hour session include quarterly report railroad csx csx intuitive surgical isrg unite airline ual lam research lrcx also report close kick first quarter report season chip sector be interested big picture strength sector be good lam research ibm earning due investing action planamazon report send cvs walgreen drug distributor soar
302,ISRG,stock index fail overcome resistance area friday market ignore big bank earning beat slip nasdaq dow jone industrial average slide volume fall major exchange bull perspective friday be half loaf session lower volume help index avoid
303,ISRG,relative strength rs rating nevro nvro moved higher percentile wednesday get lift re research best stock buy watch be sure pay attention relative price strength unique rating identify technical performance used worst best score identify stock price action last week match other stock year market history reveal market biggest winner typically have rs rating begin biggest run see nevro continue show renew price strength clear threshold look winning stock try simple routinewhile stock be not ideal buy zone right now see go form break proper consolidation company see earning sale growth rise last quarter earning share increase revenue rise look next report company hold rank peer medical system equipment industry group cutera cutr intuitive surgical isrg cantel medical cmd be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
304,ISRG,here investing action plan tuesday need know investor come day health insurance giant unitedhealth unh goldman sachs gs ibm ibm unite airline ual big cap chip gear maker lam research lrcx be big gun report quarterly result earning season heat meanwhile electronic brokerage firm interactive broker ticker
305,ISRG,dirty little secret investing sort study show pretty woman handsome man be more likely be hire someone be ugly stock be different stock be forgive chart flaw more readily fundamental be not just good beautiful different rule different folk well yes say life be fair netflix nflx be good example beautiful stock earning grow last year be expect surge year stock break january then advanced more march high meanwhile nasdaq score intraday high day netflix high nasdaq then correct netflix fall almost stock have so so fundamental then bigger average pullback be regard serious flaw hot growth stock sharper correction be accept quicker rebound be expect get newsletter deliver inbox more info product service privacy policy term usethere more netflix decline stop day move average stock bounce line tuesday add nice cushion be netflix first trip day line january bounce provide secondary entry do volume be quiet rebound wednesday turnover be average be spike volume sufficient create buy area many investor say yes netflix fundamental be beautiful share have continue climb netflix return equity gauge financial efficiency be almost last year best year annual sale jump year growth rate street expect sale jump year netflix report result monday close market new uptrend create more buy candidate bull corral netflix be other big cap several stock be well position possible buy let look chart fundamental cloud base tech software developer servicenow now be tough read chartwise stock have make multiple trip day line july however chart reader interpret consolidation oct mid december flat base then recent trip day line be first prudent interpretation be treat stock extend servicenow grow earning past year other stock show promise be online brokerage trade financial etfc robotic surgery equipment maker intuitive surgical isrg drugmaker zoetis zts annual ep growth stock be good not pretty related millionaire be more common daysold advice be true advice follow rule investingwhen sell great stock make money
306,ISRG,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
307,ISRG,here weekly investing action plan need know investor come week earning season pick momentum result due netflix nflx goldman sachs gs general electric ge ibm ibm score other airline stock get rattle further unite airline ual report give update expansion plan
308,ISRG,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
309,ISRG,stock be try rebound tuesday earning season get underway let take look stock be form basis near buy point ahead quarterly report week starbucks sbux intuitive surgical isrg eght traveler trv rockwell collin col starbucks have ibd composite rating
310,ISRG,wall street be settle first earning season calendar year long weekend ibd stock starbucks sbux intuitive surgical isrg be set disclose quarterly result coffee giant starbucks report result close thursday be expect experience earning growth cent share revenue rise accord analyst poll thomson reuter growth mark slowdown previous quarters company remain bullish expand market share china even country experience market volatility less rapid economic growth starbucks plan open store goal open store china ceo howard schultz say china have potential become company biggest market other retailer flounder starbucks have remain bright spot share fall stock market friday gain week broader market dip be currently trading day line intuitive surgical also report thursday robotic surgery leader release preliminary result wednesday say revenue climb vs wall street view growth analyst expect earning rise share company say expect procedure used da vinci system grow share edge friday week new oriental education technology edu be expect break even report earning tuesday cent share last year revenue be see rise share edge week ibd counterpart tal education xrs experience sharper decline week end jan tal report earning jan earning be see fall cent share revenue be expect jump new oriental tal be trading day move average alaska air alk announce result thursday be see logging ep growth revenue growth stock receive downgrade neutral credit suisse earlier month american airline aal receive upgrade outperform firm share be essentially flat friday stumble week fellow carrier currently occupy seat ibd table hawaiian holding announce earning jan wall street anticipate ep more double cent revenue dip share rise friday dip week end follow elaine low twitter ibd_elow related do good stock threaten round surgical try get turn awayintuitive surgical st jude prelim starbucks expand china become biggest be good get airline
311,ISRG,market continue downward march new high be become scarcer intuitive surgical isrg attempt buck trend stage cup handle wednesday intuitive surgical be leader robotic surgery dominant da vinci system robot assist surgical procedure allow surgeon greater precision quicker recovery patient
312,ISRG,stock market kick stub toe intuitive surgical isrg get upgrade overweight morgan stanley maker da vinci surgical system try buck downturn break first stage base intuitive surgical be clear leader robotic surgery platform enable surgeon perform precise minimally
313,ISRG,stock future power friday open boost rally overseas market sharp uptick oil price dow future steer more point fair market value future gain nasdaq future be ahead stock market today take early strength oil price perked back barrel more broad range factor include potential eurozone stimulus terrorist attack libyan oil site cold weather europe lift price appear scare short seller position economic news start preliminary estimate january manufacturing researcher markit et december exist home sale number be due national association realtor also conference board report lead economic indicator index december baker hughe bhi report weekly oil rig count oil earning report be friday strongest early influence stock company selling generator emergency supply also receive early boost weather forecaster project record breaking snowfall mid atlantic begin friday afternoon emergency generator maker generac gnrc jump home depot hd rise more dow stock be generally positive nike nke chevron cvx top index gain premarket trade american express axp slip lowest earning revenue decline less expect general electric ge boee ba trade slightly lower ge report quarter result boee say late thursday take charge oil energy related play post most big gain william wmb marathon oil mro freeport mcmoran fcx vault irish drugmaker mallinckrodt mnk lap pack gain stock be consolidate week move average deep month correction constellation brand stz muscle nearly stock remain extend august multiple touchback week move average starbucks sbux slip almost open report fiscal result late thursday intuitive surgical isrg add conference call also thursday close move imply open back buy point stock have be catch premarket move do not always carry regular trade linkedin lnkd hammer premarket gain professional networking site end thursday loss week fall past week overseas rise oil price possible stimulus action europe help boost china market shanghai composite rise hong kong hang seng jump left shanghai half point hang seng week japan tokyo nikkei bolt higher biggest move month rise oil price weaken yen possible new stimulus measure europe be factor so be speculation bank japan adopt fresh monetary aid action meeting next week accord reuter nikkei end week loss europe market rocked higher frankfurt dax london ftse ahead more midday cac paris surge week cac be tracking gain ftse be ahead dax be steering gain
314,ISRG,dennis lynch investing be family affair year old lead manager morgan stanley growth be follow footstep father be money manager co founder lynch mayer start elder lynch also name dennis be proud morgan stanley growth be best perform diversify stock fund outperformed peer mutual fund track morningstar inc past year gain fourth quarter top direct rival lynch be again top perform mutual fund manager lynch helm mid fund have focuse manager best idea rather overdiversify have aim security stock market benefit competitive advantage such network effect site visitor steady flow subscription base revenue industry employ battalion analyst be expert diving detail earning report key member lynch team be futurist job be spot emerge investment trend year generate revenue profit lynch talk ibd investment approach office manhattan ibd dennis fund have outperformed long term be middle pack go fund approach year lynch try add value stock pick identify think be misprice undervalue company company be undervalue investor don understand quality business grow time way be period specific idea be not work market be not agreement idea have challenge period back part year do poorly give large allocation facebook fb come public lot public enthusiasm then go vicious challenge period stock price more halved actually add position challenge period then later benefit stock price rebound generally have up down relative market peer group sometimes re go period market think re wrong also make mistake time time ibd concentrated portfolio be flip side long term approach right lynch yes do well give year reflect decision make previous year rather anything do current year amazon com amzn be company ve own continuously roughly year reason get involved be combination online advantage make tough beat offer inventory don necessarily possess have access same time ve slowly build very large logistical infrastructure physical world target increasingly technology amazon web service ibd be anything disrupt juggernaut facebook lynch don have worry social network get bigger highly unlikely be something take person attention away virtual reality other technology still early stage now absence something unlikely facebook network effect be challenged anytime soon ibd linkedin lnkd third quarter profit jump nice rebound be network effect play isn lynch holding have strong network effect user connect other have user cross connect hard displace even have core make money different way so re not expose same end market even same spending pattern earlier year linkedin make change workforce surprised person quarter result have see fruit linkedin longer term think ibd key monster beverage mnst be deal coke ko give shot foreign expansion right lynch coca cola become substantial owner open opportunity distribution become more efficient increase chance capture more global share ve have less success outside ibd be salesforce com crm subscription revenue company lynch provide customer relationship management service past be sell high license fee basis have novel approach offer service subscription format rather require large upfront fee be costly give customer ability benefit upgrade whole system rather have buy new version software upgrade cycle result build high recur revenue business annual basis revenue renewal be so give revenue lot visibility be figure meet other important need large organization re expand marketing ibd have athenahealth athn share price be choppy recently lynch athenahealth be dominant provider doctor get reimburse insurer way system work doctor learn method improve insurance reimbursement experience other doctor platform once figure apply new rule doctor doctor benefit so hard doctor not join network be inherent network effect penetration be still less overall doctor market so ve get lot room growth ve diversify electronic health record once get lot doctor join provide other service draw more doctor ibd rough patch intuitive surgical isrg earning share growth be accelerate again be improvement real lynch rough period be be transition first generation platform next generation razor razor blade model be lot consumable need be reorder time so high recur revenue model continue take share company have upgrade cycle customer wonder order old system new sale slow happened couple year now thing be head back right direction ibd dennis do team differ rival lynch thing try emphasize talk person be think put money fund be skin game do person run product have here re not go do well quarter month be period thing go badly morgan stanley defer compensation program vast majority team pay be defer most go product have significant personal exposure co ownership client product make ibd tell person team job be ahead emerge trend disruptive new technology lynch yes addition expert work meeting company look financial statement conventional activity ve dedicate person research topic have potential be disruptive industry sector ibd be change researcher look day lynch more recently be focuse bitcoin virtual reality be potentially powerful emerge theme disruptive trend ibd be disruptor expert lynch stan delaney ibd do other manager fund david cohen sam chainani norton jason yeung armistead nash divide workload be manager responsible different industrial sector example lynch act generalist outside everyone have sector industry expertise sam follow internet financial david follow consumer sound industry be really jason follow health care consumer staple armistead follow business service software alex do technology think technology differently internet company use internet create be not selling semiconductor software alex focus kind business model thing industrial dad manage large midcap growth stock start time manager tend be generalist today person tend be expert category lack perspective know multiple category be able compare believe benefit take generalist approach leverage expert
315,ISRG,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
316,ISRG,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
317,ISRG,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
318,ISRG,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
319,ISRG,housing related stock get bad news november pending home sale drop unexpectedly
320,ISRG,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
321,ISRG,fang stock facebook fb amazon amzn netflix nflx google parent alphabet googl have logged notable loss lately old leadership fade new leadership rotate ai robotic automation field become new fang stock accord bill studebaker robo global re definitely new world order fang company clearly be past growth studebaker president cio robo global tell investor business daily etfs conference earlier year think call raai robotic automation artificial intelligence be future fang add fang company be raai ambassador use ai robotic automation many aspect business be liken investing pick shovel gold rush accord studebaker example amazon google be used ai smart home device amazon also used robot warehouse be several robotic automation ai focuse etf offering market include robo global robotic automation robo global robotic artificial intelligence botz get newsletter deliver inbox more info product service privacy policy term robo top holding include zebra technology zbra irobot irbt intuitive surgical isrg rockwell automation rok abb abb tech sector general hasn perform well late doesn mean win see turnaround time soon studebaker say investor devote portfolio robotic ai automation group watch video learn more raai space studebaker call massive ai robotic arm race also be interested gold vs cryptocurrency re not suitable alternativesas top tech sector name rotate favor be fang trade finally dead stock buy watch top ipos big small cap growth stock
322,ISRG,nevro nvro have relative strength rs rating upgrade wednesday look best stock buy watch be sure pay attention relative price strength ibd unique rating identify market leadership worst best score rating show stock price movement trail week hold other stock database decade market research show market biggest winner often have rs rating north early stage move look winning stock try simple routinenevro break earlier have fall back prior entry cup handle case stock break then fall more entry price consider fail happen best new pattern take shape also keep mind most recent consolidation be later stage base make riskier establish new position add share exist nevro see earning sale growth rise last quarter earning share increase revenue rise nevro hold rank peer medical system equipment industry group cantel medical cmd cutera cutr intuitive surgical isrg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
323,ISRG,putt together watch list look stock higher rs rating dexcom dxcm be stock just reach mark now earn score look best stock buy watch factor watch closely be relative price strength ibd unique rs rating track technical performance used worst best score show stock price action trail week match rest market decade market research reveal market biggest winner typically have better rs rating begin biggest climb look winning stock try simple routinewhile not currently ideal time invest see stock manage establish enter buy zone heavy trade earning grow last quarter prior report revenue also increase next quarterly result be expect company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg cutera cutr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
324,ISRG,future index dow jone industrial average nasdaq fall modestly tuesday morning monday index dow nasdaq composite close solid gain notable stock reclaim support day move average ll take look few dow component visa square sq salesforce com crm intuitive surgical isrg steel spdr biotech xbi monday rally build friday solid rebound follow index intraday test day move average be better be still stock market correction further evidence rebound jump back follow action major average lead stock read stock market today column big picture day create watch list look top rate stock high relative strength line find support key level visa square other stock discuss article come play index future fall vs fair value dow jone future lose nasdaq future retreat vs fair value just couple good market day don confirm uptrend day wouldn doom rally attempt so long major average hold last friday intraday lows visa share rise monday trading comfortably retake day move average volume be normal relative strength line track stock performance vs index have be trend gradually end visa rs line blue line chart be time high visa peer mastercard have be fare even better mastercard never close day line rs line be record high square edge just creep day line volume be well normal square rebound friday just close higher continue pattern month underperform index push rs line lower square have quasi climax run november reflect payment firm tangential bitcoin ty take stock recover such blowoff move not always ibd take burn bitcoin ibd hold cryptocurrency webinar tuesday chief content officer chris gessel reporter elaine low ll show use chart bitcoin ethereum more buy profit digital currency register now free slot salesforce stock climb volume be just average follow bounce friday rs line be not record high not far intuitive surgical rise quiet trade monday rs line have be trend stock peaked jan just ahead earning night stock market jan top steel shot trade be normal rs line be still late january peak month best steelmaker rally monday president trump unveil infrastructure plan involve federal fund kick start private state local project biotech etf gain monday regain day line easily xbi edge higher friday plunge intraday rs line be modestly october year high xbi main rival ishare nasdaq biotech advanced monday retake day line xbi ibb be biotech etfs perform well also be interested big picture stock jump again hurdle remainwhy stock market sell do nowthese defense stock stand market correctionnike microsoft lead dow stock hold market correction
325,ISRG,dexcom dxcm see welcome improvement relative strength rs rating thursday increase look best stock buy watch factor watch closely be relative price strength ibd unique rating identify share price action worst best score grade show stock price movement trail week hold other stock database history reveal stock go make biggest gain often have rs rating north launch largest run see dexcom continue show renew price strength clear threshold see ibd help make more money stock be not proper buy point right now see go form break proper chart pattern earning grow last quarter prior report revenue also increase dexcom earn rank peer medical system equipment industry group cantel medical cmd cutera cutr intuitive surgical isrg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
326,ISRG,lead medical device maker cantel medical cmn be testing key line support continue work early stage base new jersey base company be currently stock medical system equipment industry group cynosure cyno ahead intuitive surgical isrg idexx laboratory idxx hill hrc cantel develop device
327,ISRG,week ibd list top rate growth stock add business social network linkedin lnkd computer networking company arista network anet also join be paycom software payc cloud base payroll hr company raft biotech medical technology firm strong growth also make ibd tough sector leader screen arista be new kid block sport best ep rating best year sale growth ibd company computer networking industry cloud compute trend putt network switch work datum center paycom be enterprise software industry group rank group ibd track meanwhile linkedin also leaderboard stock be sporting double digit ep revenue growth rate internet content group more tech company clamber ibd week biotech celgene celg unite therapeutic uthr musculoskeletal implant maker globus medical gmed robotic surgery system maker intuitive surgical isrg laser manufacturer ipg photonic ipgp monday biggest mover new ibd tech stock be arista network gap fifth straight trading day rise celgene give back last week rally related resolution patent dispute blood cancer blockbuster drug revlimid stock paycom be most so far year cumulative performance ibd be gain so far year index be flat follow donna howell twitter ibd_dhowell related ibd tech stock alibaba add web shopping jump
328,ISRG,alphabet world internet search leader be prospect core business strike success health care world company glucose monitoring contact lens diabetic be inch closer drugstore shelve sale self stabilize spoon design help person uncontrollable hand tremor eat comfortably top first month google restructure last year become largest operate unit new parent alphabet googl buy biotech company lift lab just few month health focuse startup begin product sale point broaden emphasis other health medical advancement alphabet last month rename google life science division verily life science division bring together clinician scientist be focuse understand improve chronic condition impact massive number person health issue include cardiovascular disease diabetes cancer disease mental health be development health care think be far reach be long last be see period convergence technology company health care company california life science association trade group ceo sara radcliffe tell ibd say change drive health care tech firm partnership include explosion big datum result demand way manage patient information growth access datum internet cloud mobile technology such fitbit fit wearable be shift health care maintain tracking health rather simply treat disease say company team uprecent notable health tech partnership include alphabet verily division team last month johnson johnson jnj develop surgical robot news follow september announcement google life science spinoff calico have enter year collaboration north chicago ill base pharmaceutical firm abbvie abbv research age related disease verily have partner too medical device firm dexcom link verily create new class disposable glucose monitoring system be faster cheaper smaller product be currently available johnson johnson verily announce last year have create verb surgical develop new surgical robotic device smaller less expensive intuitive surgical isrg da vinci system now control minimally invasive surgery segment other look join force health tech divide include medical device maker medtronic mdt be collaborate big datum solution provider ibm ibm watson health analyze wave information glean diabetes insulin pump datum vs be not only tech heavyweight seek blend medical altruism big datum big moneymaking plan apple aapl microsoft msft other be also used deep technology expertise create medical related product service year apple introduce health tracking tool monitor user footstep heart rate sleep activity microsoft samsung already offer number so call wearable device also allow person monitor daily movement advance mobile compute artificial intelligence new analytic software be drive effort recent year have be increase interest health care application company traditionally be see be consumer focuse company say iain simpson drug delivery specialist cambridge consultant company such google apple facebook fb amazon com amzn have build consumer focuse business base creation compelling sustainable user experience now simpson say various tech company be head health drive increase relevance capability market create new high value business opportunity particularly work collaboration establish health care player such pharma medical device company health care spending weigh project reach accord california health care foundation profit potential be obvious incentive other factor be also work part reason alphabet focus move needle parkinson treatment be personal google co founder now alphabet president sergey brin mother eugenia have parkinson brin be diagnosed carry mutation lrrk gene have be associate higher rate degenerative disorder central nervous system generally pace medical research be glacial compare used internet brin tell wire interview google amplify process be look lot place collect lot information see pattern lead somewhere legislative change be factor have help open door tech firm put massive compute muscle health care datum drive medicine be key element affordable care act federal law ushered president barack obama health care reform be major force center boom new health technology law provide major financial incentive doctor hospital prove care be effective value base payment rule be spark demand new software track analyze patient datum say lynne dunbrack research vice president idc health insight patient prescribe example dunbrack say hospital be find cheaper send medicare patient have congestive heart failure home weight scale electronic tablet connect app rather risk too many readmission day discharge result hospital get federal reimbursement rate cut have be real financial incentive health care organization purchase use technology be then help drive demand be company be now see new opportunity dunbrack say shift value base care other top area focus health care industry include sequence human genome digitize health care datum say cowen co analyst john blackledge september report alphabet health care strategy health care trend be not occur vacuum be be accommodate technology advance area such social mobile analytic cloud compute be area google expertise blackledge say swirl change tech advance be also help fuel medical ambition tech heavyweight apple annual worldwide developer conference june apple introduce new healthkit app monitor user heart rate sleep weight blood pressure other health related measurement let home health device such heart monitor fitness monitor exchange datum healthkit allow clinician mayo clinic send health information user app turn transmit datum user physician healthkit be logical extension apple exist product digital ecosystem keep user engage increase apple app store business also keep apple product service relevant grow increasingly competitive consumer health market say simpson cambridge consultant apple tech framework researchkit let person want remotely participate clinical medical trial do so used specially design apps iphone instead have show person march apple display apps say help diagnose range condition diabetes heart disease apple say win see datum transmit person opt sharing researcher want researchkit help address few problem medical research current state such limit patient participation infrequent datum sampling apple jeff william now chief operate officer say time person sign single medical study stanford university first hour release researchkit apple ceo tim cook tell cnbc march put perspective stanford have tell have take normally medical center entire year sign many participant so researchkit be absolute game changer say cook call discover cure disease push life expectancy much longer currently be alphabet google have own initiative call fit include developer tool online platform collect datum connect michele chandler twitter ibd_mchandler facebook
329,ISRG,santa claus rally fizzle later part december oil rout fed long await rate bump rise fourth quarter edge december nasdaq gain last quarter year fall christmas month stock mutual fund follow same track december manager nation top fund past month have be gathering medical stock such icon iclr allergan agn centene cnc akorn akrx intuitive surgical isrg latest report period also top fund buy list be china biologic product cbpo be rank ibd best list ibd personal finance action plan year end edition best perform fund gaming chipmaker nvidia nvda light system provider acuity brand ayi southwest airline luv cosmetic retailer ulta beauty ulta be few standout several financial reit be strong performer include public storage psa extra space storage exr equity lifestyle property el ibd note top rate fund buy constellation brand stz investing estimate latest report period mfs growth fund own big stake firm victor base firm make market alcoholic beverage most popular beer brand include corona pacifico modelo especial constellation wine portfolio include robert mondavi clos du franciscan estate recent global market sell do not rain constellation parade stock shot time high thursday report robust third quarter fiscal result earn share revenue stock fall friday company beer segment specifically corona extra modelo especial boost company third quarter profit keep beer buzz go constellation announce plan build new brewery mexicali mexico cost also expand production exist brewery mexico support growth beer business aerospace defense contractor northrop grumman noc also see heavy buy best perform fund stock have be trading flat base past week seesaw market volatility trading just week high sell sidelead fund have be take profit general electric ge latest report period hit week high
330,ISRG,stock index resume torrid selling friday raise odd nasdaq reach bear market territory nasdaq dive dow jone industrial average splash lower ibd drop volume rise board option expiration probably play part higher volume thursday big gain
331,ISRG,so far year big cap stock have be outperform big cap russell have lose small cap russell have lose make sense market turn rocky have recent month expect investor avoid more speculative issue favor big well know name long track record success so
332,ISRG,market sag last week diversify stock fund lose week end dec be second straight weekly setback investor be jittery widely expect rate rise week federal reserve be also worry stock market news concern slumping oil price weak commodity price weakness technology sector share fed oil be big problem say erik ristuben russell investment chief investment strategist history provide potential silver line dark cloud week market blahs market often show weakness rate rise ristuben say often recover right rise oil weakness stem price war saudi arabia be determine protect market share so be push opec partner keep production high saudis expect low price drive north american producer business ristuben say good news be outside energy sector economy be moderately good shape fuel part low energy price eventually market see past fed rate increase see economic growth be likely continue even modestly add earning growth drive stock price expect mid single digit return equity next year not anything spectacular mutual fund lose ground get good start strong job report many investor see sealing deal rate hike week dedicate short bias fund do best category diversify stock mutual fund gain just market capitalization style group large cap growth fund do best rise only category post gain small cap value fund do worst lose stock fund more asset don do lot shorting hedge borrow transamerica growth opportunity be week top performer gain latest disclosure hold intuitive surgical isrg rise week robotic surgical system maker have good ibd composite rating composite rating combine ibd stock performance rating include ep rs rating be highest intuitive earning share rise past quarters lend club lc rise week provider online marketplace borrower lender have comp rating ep rise past quarters morgan stanley institutional mid cap growth gain week latest disclosure hold ulta beauty ulta cosmetic chain look pretty rise week ulta have strong comp rating also ulta be ibd new america index catalyst dynamic alpha rise hold netease nte latest disclosure chinese provider online gaming rise week stock have comp rating ep rise past quarters ligand pharmaceutical lgnd have comp rating rise week commodity precious metal fund lead sector week gain european region fund lead world equity fund category lose least week taxable bond fund overall be average treasury fund be strongest taxable category tax exempt fund gain average follow paul katzeff twitter ibd_pkatzeff
333,ISRG,doctor prescribe first quarter earning trio medical related company perform strongly other examination disappoint analyst amgen amgn earn share year earlier crush cent estimate analyst poll thomson reuter be best gain quarters amgen revenue rise
334,ISRG,medical giant johnson johnson jnj announce friday have enter collaboration tech titan google develop surgical robotic company press release didn give many detail say ethicon device business google googl bring together capability intellectual property expertise create innovative robotic assist surgical platform capable integrate advanced technology goal improve health care delivery operate room financial term be not disclose deal raise prospect real competition intuitive surgical isrg da vinci system dominate business high end robotic surgery only few small startup intrude domain analyst have time speculate acquire intuitive surgical have suffer financial slowdown last couple year google deal suggest company intend develop own technology johnson johnson stock be fraction early trading stock market today so be intuitive surgical stock google stock be fraction follow amy reeve twitter ibd_areeve
335,ISRG,stock take mild loss quiet trading early wednesday earning report center action
336,ISRG,dow jone industrial average dip nasdaq fall loss boee ba chipotle grill cmg illumina ilmn intuitive surgical isrg weigh early trading
337,ISRG,volume be mixed stock market today shade higher nyse nasdaq compare same time tuesday
338,ISRG,morning economic news be good
339,ISRG,housing price rise february accord federal housing finance agency housing price index gain be better double january advance best view
340,ISRG,exist home sale jump annualize rate march national association realtor report well february upwardly revise pace sale also stomp expectation sale
341,ISRG,stock mcdonald mcd lead dow surge announce generally weak result pledge announce turnaround plan detail say share
342,ISRG,visa also help bolster dow gain
343,ISRG,tesla motor tsla broadcom brcm lead nasdaq more
344,ISRG,tesla jump note deutsche bank say energy storage system company plan launch april represent significant opportunity bank maintain stock buy rating price target tesla share have be rise late march month dive
345,ISRG,lead stock stage positive open ibd stock advance early trade gain loss be generally mild drugmaker grab early upside lead horizon pharma hznp akorn akrx more stock be trading just tuesday high akorn be also just cup base buy point
346,ISRG,list low end genetic test equipment maker illumina ilmn slump report generally positive result late tuesday full year guidance be mixed stock be form double bottom base buy point stock take mild loss quiet trading early wednesday earning report center action dow jone industrial average dip nasdaq fall loss boee ba chipotle grill cmg illumina ilmn intuitive surgical isrg weigh early trading volume be mixed stock market today shade higher nyse nasdaq compare same time tuesday morning economic news be good housing price rise february accord federal housing finance agency housing price index gain be better double january advance best view exist home sale jump annualize rate march national association realtor report well february upwardly revise pace sale also stomp expectation sale stock mcdonald mcd lead dow surge announce generally weak result pledge announce turnaround plan detail say share visa also help bolster dow gain tesla motor tsla broadcom brcm lead nasdaq more tesla jump note deutsche bank say energy storage system company plan launch april represent significant opportunity bank maintain stock buy rating price target tesla share have be rise late march month dive lead stock stage positive open ibd stock advance early trade gain loss be generally mild drugmaker grab early upside lead horizon pharma hznp akorn akrx more stock be trading just tuesday high akorn be also just cup base buy point list low end genetic test equipment maker illumina ilmn slump report generally positive result late tuesday full year guidance be mixed stock be form double bottom base buy point
347,ISRG,francis pulizzi wouldn think scrimp pet health care even bit pricey new york city native owner chihuahuas figure spend minimum time take dog veterinarian recent visit vet month old puppy sebastian take even bigger bite cash flow cost pulizzi exam various test medication pulizzi isn squawking ll go go dinner make sure pet have proper health care tell ibd be priority have child judge performance high rate idexx laboratory idxx pulizzi have plenty company idexx manufacture develop diagnostic information technology base product service companion animal veterinary livestock poultry water testing dairy market revenue come companion animal group division provide diagnostic product service vet practice say raymond james analyst nichola jansen livestock poultry dairy segment provide diagnostic health monitoring product market product selling company vast lineup include clinic diagnostic solution comprise vetlab suite clinic chemistry hematology analyzer well associate proprietary consumable product test supply chemistry analyzer include product such catalyst dx catalyst be used vet measure level certain enzyme other substance blood urine offer be vetconnect cloud base technology let vet access analyze patient datum idexx diagnostic modality revenue come outside idexx deliver good news investor wednesday pre announce result fourth quarter report jan company say see record total placement premium chemistry hematology analyzer globally fourth quarter america see increase vs year earlier placement catalyst analyzer rise premium hematology analyzer also see record total premium instrument quarterly placement international placement premium analyzer grow fourth quarter result capped year excellent progress reflect full year catalyst placement gain include growth international say ceo ayer press release company also raise guidance full year organic revenue exclude impact distribution change channel inventory related transition direct product distribution model companion animal group diagnostic range prior guidance gain wednesday upbeat report come wake move hybrid direct product distribution model america companion animal group diagnostic product element become fully operational fourth quarter move be announce last july sale go directgo direct mean idexx have drop distributor used past be selling group diagnostic product directly own sale force direct approach idexx take order ship product invoice receive payment recognize revenue rapid assay test kit instrument consumable align direct model instrument reference lab service other companion animal group product ayer add change allow significant expansion direct sale coverage capacity include estimate increase veterinary diagnostic consultant field sale role customer field call frequency ayer say cut distributor also mean idexx keep margin have be pay jansen say be controversy be mixed performance transition idexx lose little share competitor say wednesday announcement allay concern distribution change appear be have very little impact company business momentum seem risk primary concern idexx share write jansen research note follow announcement acknowledge currency headwind only get bigger give recent exchange rate volatility believe underlie fundamental be strengthen guidance reaffirmedalso wednesday company reinforce guidance organic revenue growth outlook reflect expectation organic revenue growth exclude benefit margin capture associate direct sale product distribution strategy company say statement idexx stock hit new high wednesday close give back little thursday company have be enjoy nice run earning have grow double digit past quarters analyst poll thomson reuter expect fourth quarter earning slip cent share report ep be not go be relevant metric fourth quarter company be impact transition direct model weigh report margin say jansen normalizes everything be back normal analyst expect full year earning rise share lift jansen say idexx primary strength be innovation be fuel spending spending represent industry diagnostic product say package strength add be fact idexx offer complete solution diagnostic product service bundle idexx have razor razor blade model say jansen not only sell diagnostic equipment also develop sell test consumable equipment analyze once place system vet animal hospital have highly recur revenue stream say jansen overall landscape business have be improve post great recession say jansen now unemployment consumer confidence translate more spending person pet say jansen diagnostic be faster growth area pet spending idexx be part ibd medical system equipment industry group be strong performer ranking group track idexx get score possible ibd composite rating metric factor thing such earning growth stock gain group also include steris ste cantel medical cmn have composite rating intuitive surgical isrg be group largest firm market cap have composite rating
348,ISRG,look alphabet googl google soon disclose more plan medical robotic partnership johnson johnson jnj eventually pressure intuitive surgical isrg stock share sunnyvale calif base intuitive surgical lead maker medical robotic system be nearly intuitive stock be flat early trading stock market
349,ISRG,ve ever wonder just buy stock price currently trading re not alone actuality buy stock matter price re try maximize upside potential lead stock get proper buy point be best bet try buy point be premature ibd chairman founder william neil write make money stock many case stock never get point rather stall actually decrease price stock need time consolidate gain particularly big advance follow move often form base common base pattern include cup cup handle double bottom flat base ideal time buy assume company fundamental stock price volume action well overall market check be stock cross proper buy point even don get precise buy point don fret be chase zone give investor chance buy stock be consider extend threshold risk become elevated so best secondary entry future bounce day week move average new base form buy more past precise buy point be buy late more likely get catch next price correction neil write be exception buy range breakaway gap rare occasion lead stock gap open soar right past buy point end well prior session high proper entry instance company report upside earning surprise close stock gap next open such breakaway gap be sign unusual strength so investor consider buy normal chase zone intuitive surgical isrg clear series flat basis back gap base july earning report then trigger week hold rule next day advance share begin consolidate late august close oct surgical gear maker report earning surge top view wide margin also raise full year guidance stock gap soar next day blow past buy point chase zone extend case general rule thumb be buy close open price possible intuitive sport solid fundamental include composite earning share relative strength accumulation distribution rating medical system industry group be rank well share rally buy point less week trigger week hold rule january intuitive rally diving new price correction
350,ISRG,surgeon predict big increase robot assist surgery next year especially colorectal hernia procedure accord survey rbc capital market surgery today involve use robot figure hit year year survey indicate most surgeon be quite satisfied
351,ISRG,artificial intelligence sweep technology sector robotic usage manufacturing soar say lynch page study note japanese company such alphabet apple aapl be lead charge ai apple recently acquire ai startup perceptio vocaliq company alphabet googl ibm ibm have high exposure ai say bank america report robotic bofa stock pick include rockwell automation rok intuitive surgical isrg ai japanese company have be lead way include effort apple facebook fb google hitachi ibm intel intc linkedin lnkd nec yahoo yhoo twitter twtr other last year say report bil market more be invest ai company say bofa worldwide market ai base analytic grow say report apple alphabet be explore ai application self drive vehicle accord report facebook have look application virtual reality oculus product robot be likely be perform manufacturing task vs today say bofa report estimate robot ai solution market grow comprise robot robotic ai base analytic say report adoption robot ai boost productivity many industry cut manufacturing labor cost company bofa stock pick include switzerland abb abb japan fanuc mitsubishi electric yaskawa electric omron china shenzhen inovance technology say bloomberg report bofa expect robotic usage jump aerospace include drone auto financial service health care industrial setting anticipate fast growth like agribot ai automation care bot cobot drone commercial military fintech industrial robot medical robot computer assist surgery self drive car service robot software telehealth say report apple culture secrecy be hamper ai research development say bloomberg report ibd leaderboard stock alphabet facebook currently get best possible composite rating ibd linkedin apple have intuitive surgical intel have rockwell automation ibm yahoo twitter abb composite rating be lower follow reinhardt krause twitter ibd_rkrause
352,ISRG,stock shift lower monday open oil price slump global investor reposition follow sunday referendum vote greece
353,ISRG,dow jone industrial average fall nasdaq be trimming loss volume be stock market today rise nyse nasdaq compare very light pre holiday trade thursday
354,ISRG,global market show moderate recalculation risk follow vote greece oil price have be much more reactive west texas intermediate crude trade just barrel early action monday oil natural gas related stock show worst loss early trade
355,ISRG,economic datum be not cooperate researcher markit report purchasing manager service index drop june disappointing view mild downtick output growth staff hire slow sector june report say uptick new work suggest increase client spending
356,ISRG,institute supply management june manufacturing index rise month previous month line forecast
357,ISRG,stock nasdaq stock drop start bell intuitive surgical isrg fall furthest almost ebay ebay be holdout rise less
358,ISRG,aetna aet drop bottom open bell manage care giant announce friday pay acquire peer humana hum monday humana trim annual earning outlook humana share rise
359,ISRG,ibd stock china base athm drop nearly loss drive provider online automotive information service back day move average heavy trade
360,ISRG,consumer lend operation santander consumer usa sc backed fast trade stock be just june high extend second rebound week support follow april stock shift lower monday open oil price slump global investor reposition follow sunday referendum vote greece dow jone industrial average fall nasdaq be trimming loss volume be stock market today rise nyse nasdaq compare very light pre holiday trade thursday global market show moderate recalculation risk follow vote greece oil price have be much more reactive west texas intermediate crude trade just barrel early action monday oil natural gas related stock show worst loss early trade economic datum be not cooperate researcher markit report purchasing manager service index drop june disappointing view mild downtick output growth staff hire slow sector june report say uptick new work suggest increase client spending institute supply management june manufacturing index rise month previous month line forecast stock nasdaq stock drop start bell intuitive surgical isrg fall furthest almost ebay ebay be holdout rise less aetna aet drop bottom open bell manage care giant announce friday pay acquire peer humana hum monday humana trim annual earning outlook humana share rise ibd stock china base athm drop nearly loss drive provider online automotive information service back day move average heavy trade consumer lend operation santander consumer usa sc backed fast trade stock be just june high extend second rebound week support follow april
361,ISRG,stock finished lower wednesday re-cover somewhat high profile earning report rattle market early nasdaq fared worst loss hurt earning weakness tech giant apple aapl microsoft msft fall dow jone industrial average slip
362,ISRG,small cap shine stock market today russell add volume be higher board accord preliminary datum
363,ISRG,close cirrus logic crus be sharply response earning sale smash analyst expectation regular session cirrus logic fall disappointing report apple hurt cirrus other apple supplier
364,ISRG,infinera infn be modestly hour trading report share earning cent ahead analyst expectation cent
365,ISRG,residential commercial build group be top performer wednesday help bullish datum national association realtor exist home sale lennar len nvr nvr climb better lennar retook buy point cup handle nvr extend gain past flat base buy point
366,ISRG,restaurant medical system equipment also lead lift strong earning move chipotle grill cmg intuitive surgical isrg stock finished lower wednesday re-cover somewhat high profile earning report rattle market early nasdaq fared worst loss hurt earning weakness tech giant apple aapl microsoft msft fall dow jone industrial average slip small cap shine stock market today russell add volume be higher board accord preliminary datum close cirrus logic crus be sharply response earning sale smash analyst expectation regular session cirrus logic fall disappointing report apple hurt cirrus other apple supplier infinera infn be modestly hour trading report share earning cent ahead analyst expectation cent residential commercial build group be top performer wednesday help bullish datum national association realtor exist home sale lennar len nvr nvr climb better lennar retook buy point cup handle nvr extend gain past flat base buy point restaurant medical system equipment also lead lift strong earning move chipotle grill cmg intuitive surgical isrg
367,ISRG,stock drag weak start wednesday earning result center early trading action
368,ISRG,nasdaq swoon hobble apple aapl high volume decline dow jone industrial average dip apiece russell hover just fractional decline
369,ISRG,stock market today receive first real dose economic datum week
370,ISRG,federal housing finance agency report housing price index rise be level april upwardly revise number line consensus projection
371,ISRG,exist home sale bump annualize rate unit june accord national association realtor outpace expectation increase unit nar revise sale estimate downward pace
372,ISRG,stock apple drop powerful volume set tone tempo early trade cupertino giant report better expect fiscal sale earning revenue guidance be bit soft investor worry apple watch sale iphone demand china loss haul share stock week move average interrupt climb month consolidation
373,ISRG,response ripple broad swathe apple supplier qorvo qrvo tank arm holding armh fall also report mixed result cirrus logic crus crumble skywork solution swks shed
374,ISRG,thicket early earning report send stock direction
375,ISRG,appliance maker whirlpool whr muscle aerospace heavyweightb aerospace beav topple
376,ISRG,intuitive surgical isrg soar second quarter revenue earning soar past consensus projection canaccord genuity raise stock buy hold lift price target heavy volume move lift share past buy point shallow base
377,ISRG,chipotle grill cmg leap post mixed second quarter result late tuesday base restaurant chain earning squeak past consensus estimate revenue growth stop just short forecast same store sale be lower expect huge volume gap gain blast stock past early buy point first stage base stock drag weak start wednesday earning result center early trading action nasdaq swoon hobble apple aapl high volume decline dow jone industrial average dip apiece russell hover just fractional decline stock market today receive first real dose economic datum week federal housing finance agency report housing price index rise be level april upwardly revise number line consensus projection exist home sale bump annualize rate unit june accord national association realtor outpace expectation increase unit nar revise sale estimate downward pace stock apple drop powerful volume set tone tempo early trade cupertino giant report better expect fiscal sale earning revenue guidance be bit soft investor worry apple watch sale iphone demand china loss haul share stock week move average interrupt climb month consolidation response ripple broad swathe apple supplier qorvo qrvo tank arm holding armh fall also report mixed result cirrus logic crus crumble skywork solution swks shed thicket early earning report send stock direction appliance maker whirlpool whr muscle aerospace heavyweightb aerospace beav topple intuitive surgical isrg soar second quarter revenue earning soar past consensus projection canaccord genuity raise stock buy hold lift price target heavy volume move lift share past buy point shallow base chipotle grill cmg leap post mixed second quarter result late tuesday base restaurant chain earning squeak past consensus estimate revenue growth stop just short forecast same store sale be lower expect huge volume gap gain blast stock past early buy point first stage base
378,ISRG,stock split share especially manner more often mark top regular reader column know too many large stock split offer alert investor timely sell signal
379,ISRG,market also offer subtle change nowadays be fewer split
380,ISRG,company manager think nothing let stock run share even small subset lead stock encounter extreme share split
381,ISRG,sharp increase share outstanding have long term consequence stock fundamental technical be very strong not be negative effect term
382,ISRG,here dramatic statistic ibd later become ibd be unveil april not single issue trade century mark highest price stock be ebay ebay trade
383,ISRG,fast forward ibd publish july name be price regeneron pharmaceutical regn be just north
384,ISRG,original trade teen only most recent ibd stock trade
385,ISRG,amazon com amzn late be typical usually happen stock split time bull market second split january stock shot week price december high not surpass year
386,ISRG,also dot com boom qualcomm qcom split last week nov stock split news ultimate high first trading day stock rocket top precisely
387,ISRG,more recent example be baidu bidu be trading split stock rise week then build month base baidu break again advanced more year top chinese search engine then correct year breaking again september
388,ISRG,apple aapl split june seem have little effect stock marched higher month split seem tailor make apple fit comfortably dow jone industrial average
389,ISRG,now come netflix nflx announce split effective july shareholder record july june announcement have little impact stock be interesting see happen
390,ISRG,growth company have show little interest split priceline group pcln see share rise split sight intuitive surgical isrg rise nearly have never split
391,ISRG,ibd founder chairman william neil write make money stock prefer see company split share rather conduct more extreme split company add often split stock extravagantly end bull market
392,ISRG,say stock be likely top second third time stock split neil own study winning stock show only have split year make big move stock split share especially manner more often mark top regular reader column know too many large stock split offer alert investor timely sell signal market also offer subtle change nowadays be fewer split company manager think nothing let stock run share even small subset lead stock encounter extreme share split sharp increase share outstanding have long term consequence stock fundamental technical be very strong not be negative effect term here dramatic statistic ibd later become ibd be unveil april not single issue trade century mark highest price stock be ebay ebay trade fast forward ibd publish july name be price regeneron pharmaceutical regn be just north original trade teen only most recent ibd stock trade amazon com amzn late be typical usually happen stock split time bull market second split january stock shot week price december high not surpass year also dot com boom qualcomm qcom split last week nov stock split news ultimate high first trading day stock rocket top precisely more recent example be baidu bidu be trading split stock rise week then build month base baidu break again advanced more year top chinese search engine then correct year breaking again september apple aapl split june seem have little effect stock marched higher month split seem tailor make apple fit comfortably dow jone industrial average now come netflix nflx announce split effective july shareholder record july june announcement have little impact stock be interesting see happen growth company have show little interest split priceline group pcln see share rise split sight intuitive surgical isrg rise nearly have never split ibd founder chairman william neil write make money stock prefer see company split share rather conduct more extreme split company add often split stock extravagantly end bull market say stock be likely top second third time stock split neil own study winning stock show only have split year make big move
393,ISRG,ibd industry group biggest mover lately be medical system equipment group currently rank sit low month group have get lift few different front range boost hospital admission expect affordable care act obamacare positive impact
394,ISRG,ibd industry group biggest mover lately be medical system equipment group currently rank sit low month group have get lift few different front range boost hospital admission expect affordable care act obamacare positive impact
395,ISRG,flabby year thing be shape fat bust technology developer zeltiq aesthetic zeltiq zltq offer person way get rid unwanted fat nonsurgical coolsculpt procedure selectively reduce bulge problem area used patented cool technology coolsculpt do physician office be base principle fat cell be more sensitive
396,ISRG,stock edge quietly higher monday aid general uptick global market
397,ISRG,dow jone industrial average moved nasdaq inched
398,ISRG,volume backed stock market today be nasdaq nyse compare action same time friday
399,ISRG,brazil related stock surge exchange sunday election shake ballot country presidential race challenger marina silva drop list leave incumbent dilma rousseff face aecio neve oct runoff election country slip recession year many blame rousseff leftist approach economic policy neve have run platform government cut business friendly economic measure
400,ISRG,state own oil producer petrobra pbr surge open banco bradesco bbd soar itau unibanco hold itub leap
401,ISRG,hewlett packard hpq lock morning headline gain more fast trade announce divide publicly trade company advance hoist share back day move average stock remain august high
402,ISRG,liberty interactive linta spiked take head nasdaq list multimedium hold company say friday board have approve return company tracking stock format cable shopping business qvc group other digital commerce liberty digital commerce
403,ISRG,intuitive surgical isrg pop strong trade upgrade buy neutral goldman sachs report give maker robotic surgical instrument price target share be low
404,ISRG,chip designer ambarella amba spark lead ibd list brokerage stifel nicolaus maintain buy rating stock raise price target stock be buy point stock edge quietly higher monday aid general uptick global market dow jone industrial average moved nasdaq inched volume backed stock market today be nasdaq nyse compare action same time friday brazil related stock surge exchange sunday election shake ballot country presidential race challenger marina silva drop list leave incumbent dilma rousseff face aecio neve oct runoff election country slip recession year many blame rousseff leftist approach economic policy neve have run platform government cut business friendly economic measure state own oil producer petrobra pbr surge open banco bradesco bbd soar itau unibanco hold itub leap hewlett packard hpq lock morning headline gain more fast trade announce divide publicly trade company advance hoist share back day move average stock remain august high liberty interactive linta spiked take head nasdaq list multimedium hold company say friday board have approve return company tracking stock format cable shopping business qvc group other digital commerce liberty digital commerce intuitive surgical isrg pop strong trade upgrade buy neutral goldman sachs report give maker robotic surgical instrument price target share be low chip designer ambarella amba spark lead ibd list brokerage stifel nicolaus maintain buy rating stock raise price target stock be buy point
405,ISRG,stock hit fresh session high late thursday be track fourth straight gain
406,ISRG,help internet computer hardware stock nasdaq rally dow jone industrial average be volume be tracking modestly higher major exchange stock market today
407,ISRG,tata motor ttm stretched gain earlier stock clear buy point double bottom base heavy trading indian carmaker have composite rating highest auto manufacturer group tata be mentioned international leader earlier month
408,ISRG,armour ua rally regain day line fast trade stock be flat base larger pattern telsey advisory group upgrade share outperform market perform wednesday
409,ISRG,downside microsemi mscc reversed fall ahead fiscal earning close chipmaker be expect earn cent share year mark second straight quarter accelerate growth microsemi be work potential base
410,ISRG,intuitive surgical isrg kla tencor klac skywork solution swks starbucks sbux also be report earning close stock hit fresh session high late thursday be track fourth straight gain help internet computer hardware stock nasdaq rally dow jone industrial average be volume be tracking modestly higher major exchange stock market todaytata motor ttm stretched gain earlier stock clear buy point double bottom base heavy trading indian carmaker have composite rating highest auto manufacturer group tata be mentioned international leader earlier month armour ua rally regain day line fast trade stock be flat base larger pattern telsey advisory group upgrade share outperform market perform wednesday downside microsemi mscc reversed fall ahead fiscal earning close chipmaker be expect earn cent share year mark second straight quarter accelerate growth microsemi be work potential base intuitive surgical isrg kla tencor klac skywork solution swks starbucks sbux also be report earning close
411,ISRG,regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm
412,ISRG,jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak
413,ISRG,ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market
414,ISRG,pre emptive drug price war
415,ISRG,everyone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline
416,ISRG,be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter
417,ISRG,paz comment seem allude widespread perception street pcsk be basically similar
418,ISRG,regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just
419,ISRG,schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not
420,ISRG,regeneron eylea sale bright
421,ISRG,presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus
422,ISRG,also guide expense item tend do lieu earning be heavily affected option expense
423,ISRG,range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation
424,ISRG,regeneron stock rise nearly intraday reversed overall market close day move average
425,ISRG,separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation
426,ISRG,expect isrg share move higher morning continue believe worst be isrg henry write note market open
427,ISRG,be right first part intuitive surgical rise intraday stock retreat afternoon close regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market pre emptive drug price wareveryone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter paz comment seem allude widespread perception street pcsk be basically similar regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not regeneron eylea sale brightat presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus also guide expense item tend do lieu earning be heavily affected option expense range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation regeneron stock rise nearly intraday reversed overall market close day move average separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation expect isrg share move higher morning continue believe worst be isrg henry write note market open be right first part intuitive surgical rise intraday stock retreat afternoon close
428,ISRG,intuitive surgical isrg stock jump wednesday company say shipment da vinci surgical system rise higher expect growth robotic surgery procedure intuitive be nearly afternoon trading stock market today more month high sunnyvale calif base company late tuesday report
429,ISRG,wall street split defender skeptic intuitive surgical isrg day robot surgery firm warn sale fall short expectation stock be morning trading stock market today intuitive stock hit week high thursday late tuesday intuitive say revenue fall
430,ISRG,stock keep tight trading range wednesday market head final hour action nasdaq be dow jone industrial average ease volume be run previous session pace major exchange be perch just previous high close new high index be regard bullish market be mostly breadth be unimpressive nyse winner lead loser ratio nasdaq advancer barely lead decline issue still large cap more dozen stock rise more include robotic medical company intuitive surgical isrg biotech market cap biogen idec biib staffing provider robert half international rhi online social platform facebook fb volume be strong stock downside chip designer xilinx xlnx suffer day biggest percentage loss stock gap tremendous volume tuesday close san jose calif base company report quarterly result top view earning miss revenue crusher be weaker expect guidance fiscal end september
431,ISRG,intuitive surgical isrg announce tuesday fda have clear new version da vinci robot surgery system send intuitive stock more month high early trading stock market today
432,ISRG,new da vinci xi be more versatile able do more complex surgery previous edition accord company
433,ISRG,da vinci xi system new overhead architecture mean multus quadrant surgery be perform repositioning system innovation long seek surgeon perform complex procedure intuitive ceo gary guthart say company press release
434,ISRG,approval be widely expect be positive intuitive surgical nonetheless isi group analyst vijay kumar say email client
435,ISRG,note new system be specifically design general surgery procedure particular complex colorectal case require multus quadrant approach write
436,ISRG,kumar estimate colorectal opportunity translate placement least new system perhaps greater number abroad
437,ISRG,sale da vinci system have decline double digit last few quarters partly due age product cycle also due bad publicity last summer safety cost effectiveness da vinci surgery bring stock more last july tuesday marked first time intuitive stock crack then intuitive be trading tuesday morning
438,ISRG,follow amy reeve twitter ibd_areeve intuitive surgical isrg announce tuesday fda have clear new version da vinci robot surgery system send intuitive stock more month high early trading stock market today new da vinci xi be more versatile able do more complex surgery previous edition accord company da vinci xi system new overhead architecture mean multus quadrant surgery be perform repositioning system innovation long seek surgeon perform complex procedure intuitive ceo gary guthart say company press release approval be widely expect be positive intuitive surgical nonetheless isi group analyst vijay kumar say email client note new system be specifically design general surgery procedure particular complex colorectal case require multus quadrant approach write kumar estimate colorectal opportunity translate placement least new system perhaps greater number abroad sale da vinci system have decline double digit last few quarters partly due age product cycle also due bad publicity last summer safety cost effectiveness da vinci surgery bring stock more last july tuesday marked first time intuitive stock crack then intuitive be trading tuesday morning follow amy reeve twitter ibd_areeve
439,ISRG,lead apple aapl microsoft msft nasdaq climb wednesday upside volume perk second straight day be trading new high approach
440,ISRG,nasdaq rise gain dow jone industrial average be less
441,ISRG,tech giant post earning close tuesday cheer investor apple rise more near time high have correct company beat earning estimate be light revenue iphone ipad sale flag fan pant pending release new product fall
442,ISRG,microsoft rise ep fall be estimate revenue surge company say commercial cloud sale double purchase nokia nok asset cut profit
443,ISRG,stock market today dow be shackle boee ba mcdonald mcd coca cola ko intel intc lower boee beat earning miss revenue
444,ISRG,ibd stock be be star day be biogen biib beat earning expectation fuel sale multiple sclerosis treatment stock break cup handle base
445,ISRG,lift biotech stock last week federal reserve say have valuation be stretched
446,ISRG,intuitive surgical isrg maker da vinci robotic surgical system soar report decline ep revenue nonetheless beat expectation lead apple aapl microsoft msft nasdaq climb wednesday upside volume perk second straight day be trading new high approach nasdaq rise gain dow jone industrial average be less tech giant post earning close tuesday cheer investor apple rise more near time high have correct company beat earning estimate be light revenue iphone ipad sale flag fan pant pending release new product fall microsoft rise ep fall be estimate revenue surge company say commercial cloud sale double purchase nokia nok asset cut profit stock market today dow be shackle boee ba mcdonald mcd coca cola ko intel intc lower boee beat earning miss revenue ibd stock be be star day be biogen biib beat earning expectation fuel sale multiple sclerosis treatment stock break cup handle base lift biotech stock last week federal reserve say have valuation be stretched intuitive surgical isrg maker da vinci robotic surgical system soar report decline ep revenue nonetheless beat expectation
447,ISRG,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
448,ISRG,stock future be narrowly higher early high ahead wednesday open
449,ISRG,dow future trade point fair market value nasdaq future be point higher future hold tight point gain
450,ISRG,stock market today receive little input economic datum ahead busy report session schedule thursday friday
451,ISRG,stock tubemogul tube rocket higher flip profit second quarter notch second straight quarter triple digit revenue gain
452,ISRG,provider online ad buy technology also raise full year guidance well consensus projection july new issue end tuesday sixth week ipo base high ipo price
453,ISRG,aruba network arun spiked premarket action wi fi base network access security software developer fiscal earning top consensus view penny revenue jump well expectation management also report basis point gain gross margin year guide margin higher fiscal
454,ISRG,aruba end tuesday back week support work fourth weekly advance climb right side month consolidation
455,ISRG,filtration manufacturer donaldson dci shot fiscal report earning clear narrow margin revenue surge past expectation management report strong sale gain asia europe south america sharp drop gas turbine category
456,ISRG,tif climb more blue box jeweler top consensus earning revenue forecast easily post strong gross margin gain revenue growth outpaced cost heavy investment information technology system
457,ISRG,stock have be scoop shallow consolidation early july
458,ISRG,wesson holding swhc dive mixed fiscal report earning beat expectation penny revenue miss wide mark more important management carved earning guidance cent vs cent consensus view put revenue guidance consensus expectation be management cite industry wide inventory glut peer sturm ruger rgr drop bell
459,ISRG,overseas china market tag mixed finish tokyo nikkei pull very thin advance stock europe be quiet sticking close start point midday stock future be narrowly higher early high ahead wednesday open dow future trade point fair market value nasdaq future be point higher future hold tight point gain stock market today receive little input economic datum ahead busy report session schedule thursday friday stock tubemogul tube rocket higher flip profit second quarter notch second straight quarter triple digit revenue gain provider online ad buy technology also raise full year guidance well consensus projection july new issue end tuesday sixth week ipo base high ipo price aruba network arun spiked premarket action wi fi base network access security software developer fiscal earning top consensus view penny revenue jump well expectation management also report basis point gain gross margin year guide margin higher fiscal aruba end tuesday back week support work fourth weekly advance climb right side month consolidation filtration manufacturer donaldson dci shot fiscal report earning clear narrow margin revenue surge past expectation management report strong sale gain asia europe south america sharp drop gas turbine category tif climb more blue box jeweler top consensus earning revenue forecast easily post strong gross margin gain revenue growth outpaced cost heavy investment information technology system stock have be scoop shallow consolidation early july wesson holding swhc dive mixed fiscal report earning beat expectation penny revenue miss wide mark more important management carved earning guidance cent vs cent consensus view put revenue guidance consensus expectation be management cite industry wide inventory glut peer sturm ruger rgr drop bell overseas china market tag mixed finish tokyo nikkei pull very thin advance stock europe be quiet sticking close start point midday
460,ISRG,stock end lower light volume monday concern federal reserve appear poise raise interest rate early next month nasdaq dow jone industrial average fall volume fall nasdaq nyse compare friday accord preliminary datum trader increase bet federal reserve soon raise interest rate follow friday strong job report saddle consumer higher borrow cost boost dollar slow economy leisure discretionary consumer stock be hit hardest stock market todayonline travel broker priceline com pcln plunge nearly weak outlook overshadowed better expect earning report stock sank buy point cup type base slice day move average meanwhile gamble stock fall expectation weakness chinese gamble enclave macau world top gaming destination wynn resort wynn fall more la vegas sand lvs sank mgm resort international mgm slip upside ibd stock linkedin lnkd rise continue climb right side deep cup type base buy point horton dhi luxoft lxft zebra technology zbra amdocs dox be company due report quarterly earning tuesday economic datum schedule tuesday include import export price october wholesale inventory september
461,ISRG,johnson johnson jnj kick medical industry earning season modest upside surprise tuesday send stock morning trading stock market today earning time item totale share year earlier quarter beating analyst consensus cent sale rise
462,ISRG,much century ask person most exciting technology future be robot probably have be right fly car decade ve appear movie tv show essentially slave often superhuman ability offensive moral implication wasn way robot have
463,ISRG,stock future be nose add early gain ahead wednesday open oil price gain european market higher
464,ISRG,dow future double early gain point fair market value nasdaq future show moderate point advance future add point
465,ISRG,volume be investor mind trading get underway stock market today tuesday gain weak trade be better sharp stick eye institutional investor need throw support upward motion become convince
466,ISRG,other matter weigh investor mind be new insight federal open market committee march meeting minute be due et
467,ISRG,early stock action be brisk
468,ISRG,alcoa aa step report mixed first quarter result late tuesday earning top expectation revenue didn management project growth business sector gas turbine world largest aluminum producer end tuesday oct low
469,ISRG,constellation brand stz jump more ahead open wine spirit purveyor report fourth quarter earning share better forecast gain revenue rumble line expectation management boost full year revenue guidance consensus estimate
470,ISRG,constellation share have be sizzling uptrend june stock drop strong trade monday test day move average
471,ISRG,intuitive surgical isrg cave bell maker robotic surgical instrument thursday close shave first quarter revenue guidance consensus view management say number include customer trade revenue defer preference company newly release da vinci xi system exclude trade revenue be year year consensus view
472,ISRG,stock have be climb december low work right side month consolidation
473,ISRG,pacific china market rise japan tumble second day hong kong hang seng index pop tokyo nikkei swoon putt index so far week
474,ISRG,europe stock be positive ground exit morning trade london ftse lead crowd gain
475,ISRG,dollar take back recent loss vs yen hold low week euro oil add few more penny rise barrel tuesday natural gas be also higher be so far week gold ease remain positive week be ounce
476,ISRG,later morning commerce department turn february wholesale inventory number et important weekly crude oil inventory estimate energy information administration be docket stock future be nose add early gain ahead wednesday open oil price gain european market higher dow future double early gain point fair market value nasdaq future show moderate point advance future add point volume be investor mind trading get underway stock market today tuesday gain weak trade be better sharp stick eye institutional investor need throw support upward motion become convince other matter weigh investor mind be new insight federal open market committee march meeting minute be due et early stock action be brisk alcoa aa step report mixed first quarter result late tuesday earning top expectation revenue didn management project growth business sector gas turbine world largest aluminum producer end tuesday oct low constellation brand stz jump more ahead open wine spirit purveyor report fourth quarter earning share better forecast gain revenue rumble line expectation management boost full year revenue guidance consensus estimate constellation share have be sizzling uptrend june stock drop strong trade monday test day move average intuitive surgical isrg cave bell maker robotic surgical instrument thursday close shave first quarter revenue guidance consensus view management say number include customer trade revenue defer preference company newly release da vinci xi system exclude trade revenue be year year consensus view stock have be climb december low work right side month consolidation pacific china market rise japan tumble second day hong kong hang seng index pop tokyo nikkei swoon putt index so far week europe stock be positive ground exit morning trade london ftse lead crowd gain dollar take back recent loss vs yen hold low week euro oil add few more penny rise barrel tuesday natural gas be also higher be so far week gold ease remain positive week be ounce later morning commerce department turn february wholesale inventory number et important weekly crude oil inventory estimate energy information administration be docket
477,ISRG,stock end modestly higher wednesday hit time high datum suggest economy be pick
478,ISRG,rise dow jone industrial average nasdaq rise volume be mixed nyse volume tracking lower tuesday nasdaq volume rise accord preliminary datum
479,ISRG,private employer add job march accord adp pretty much line consensus estimate figure prior month be revise sharply higher datum come ahead friday job report nonfarm payroll be expect increase unemployment rate tick lower
480,ISRG,order manufacture good rise better expect february biggest increase month
481,ISRG,stock market today office supply retailer staple spls lead term percentage gain jump heavy volume however stock remain depress well key support line week high
482,ISRG,meanwhile intuitive surgical isrg continue rebound sharply announce tuesday food drug administration have approve next generation da vinci robotic surgical system stock jump week high more double average daily volume week
483,ISRG,downside apollo education apol slump slice day move average operator profit university phoenix report revenue latest quarter fall greater expect
484,ISRG,company also say have receive subpoena education department seek information university phoenix operation northeast stock end modestly higher wednesday hit time high datum suggest economy be pick rise dow jone industrial average nasdaq rise volume be mixed nyse volume tracking lower tuesday nasdaq volume rise accord preliminary datum private employer add job march accord adp pretty much line consensus estimate figure prior month be revise sharply higher datum come ahead friday job report nonfarm payroll be expect increase unemployment rate tick lower order manufacture good rise better expect february biggest increase month stock market today office supply retailer staple spls lead term percentage gain jump heavy volume however stock remain depress well key support line week high meanwhile intuitive surgical isrg continue rebound sharply announce tuesday food drug administration have approve next generation da vinci robotic surgical system stock jump week high more double average daily volume week downside apollo education apol slump slice day move average operator profit university phoenix report revenue latest quarter fall greater expect company also say have receive subpoena education department seek information university phoenix operation northeast
485,ISRG,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
486,ISRG,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
487,ISRG,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
488,ISRG,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
489,ISRG,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
490,ISRG,share real estate zillow be hour follow result
491,ISRG,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
492,ISRG,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
493,ISRG,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
494,ISRG,stock tuesday keep recent habit post early gain time advance come rise trade
495,ISRG,nasdaq again lead jump increase volume dow jone industrial average climb trading nyse rise compare same monday
496,ISRG,stock market today again launch muddle economic news
497,ISRG,institute supply management manufacturing index rise march be february number expectation
498,ISRG,construction spending february rise be equal commerce department original estimate january better revise figure show decline line economist consensus estimate
499,ISRG,intuitive surgical isrg sew gain open company announce food drug administration have approve new da vinci xi surgical system design specialize abdominal surgery company say xi also have broader capability application previous da vinci system
500,ISRG,gain snap share highest mark july stock work way month consolidation
501,ISRG,lead stock casino operator wynn resort wynn la vegas sand lvs surge respectively gamble revenue china macau resort region reportedly jump march analyst expectation
502,ISRG,wynn share be back day move average stock be work climb right side deep consolidation begin march la vegas sand also retook day move average be work way right side deep consolidation
503,ISRG,qihoo qihu pop strong trade china base provider internet content mobile security software be climb right side deep consolidation stock tuesday keep recent habit post early gain time advance come rise trade nasdaq again lead jump increase volume dow jone industrial average climb trading nyse rise compare same monday stock market today again launch muddle economic news institute supply management manufacturing index rise march be february number expectation construction spending february rise be equal commerce department original estimate january better revise figure show decline line economist consensus estimate intuitive surgical isrg sew gain open company announce food drug administration have approve new da vinci xi surgical system design specialize abdominal surgery company say xi also have broader capability application previous da vinci system gain snap share highest mark july stock work way month consolidation lead stock casino operator wynn resort wynn la vegas sand lvs surge respectively gamble revenue china macau resort region reportedly jump march analyst expectation wynn share be back day move average stock be work climb right side deep consolidation begin march la vegas sand also retook day move average be work way right side deep consolidation qihoo qihu pop strong trade china base provider internet content mobile security software be climb right side deep consolidation
504,ISRG,stock remain black early afternoon trade wednesday be still well early morning high
505,ISRG,be dow jone industrial rally nasdaq be volume grow nyse be mildly nasdaq exchange compare same time tuesday
506,ISRG,stock market today heavily batter industry group pace advance ibd oil gas equipment agricultural operation oil gas royalty trust coal datum storage industry group gain more stock gain strong increase durable good order july follow bounce june
507,ISRG,few stock laggard group however be furnishing potential new market leader high growth investor buy
508,ISRG,datum storage group rank industry group month relative price performance wednesday ibd not single stock be trading least share show composite rating higher emc emc giant industry market cap have lowly composite grade stock have slump day move average early january fail hold key support level
509,ISRG,rise nearly wednesday fast turnover emc be year full year earning share be expect fall
510,ISRG,point stock index have not reach bear market territory re close
511,ISRG,monday intraday low nasdaq composite fall time high post july
512,ISRG,google googl grab headline thank strong upgrade goldman sachs company long term prospect stock more halter massive day slide institutional investor shore stock fast rise day move average
513,ISRG,july google clear early buy point long consolidation powerful volume breakout turnover rise more day average volume have higher rate success certainly case google day later stock gap time high
514,ISRG,investment bank note world premier search engine be early stage multus year cycle expand margin drive earning outperformance multiple expansion
515,ISRG,google post rise ep last month biggest jump quarters new cfo ruth porat help company control expense slow revenue increase revenue be just gain prior quarters net margin rise basis point vs year
516,ISRG,ibd_chung stock remain black early afternoon trade wednesday be still well early morning high be dow jone industrial rally nasdaq be volume grow nyse be mildly nasdaq exchange compare same time tuesday stock market today heavily batter industry group pace advance ibd oil gas equipment agricultural operation oil gas royalty trust coal datum storage industry group gain more stock gain strong increase durable good order july follow bounce june few stock laggard group however be furnishing potential new market leader high growth investor buy datum storage group rank industry group month relative price performance wednesday ibd not single stock be trading least share show composite rating higher emc emc giant industry market cap have lowly composite grade stock have slump day move average early january fail hold key support level rise nearly wednesday fast turnover emc be year full year earning share be expect fall point stock index have not reach bear market territory re close monday intraday low nasdaq composite fall time high post july google googl grab headline thank strong upgrade goldman sachs company long term prospect stock more halter massive day slide institutional investor shore stock fast rise day move average july google clear early buy point long consolidation powerful volume breakout turnover rise more day average volume have higher rate success certainly case google day later stock gap time investment bank note world premier search engine be early stage multus year cycle expand margin drive earning outperformance multiple expansion google post rise ep last month biggest jump quarters new cfo ruth porat help company control expense slow revenue increase revenue be just gain prior quarters net margin rise basis point vs year ibd_chung
517,ISRG,major average be trading intraday lows midday trade tech stock sell hard
518,ISRG,software maker biotechs weigh nasdaq be dow be volume be tracking lower board stock market today
519,ISRG,cree cree tumble year low massive turnover goldman sachs maintain buy rating company cut price target hour tuesday chipmaker earning beat view penny sale miss
520,ISRG,unisys uis vmware vmw be other tech stock sink heavy volume
521,ISRG,intuitive surgical isrg give earning sale fall respectively same year quarter stock be week high trading month low
522,ISRG,upside skecher skx gap leap highest level nearly year result sprint past view late tuesday be much early trade share be still buy point base clear feb shoe maker also make headline monday american meb keflezighi win first place boston marathon run sneaker skecher performance line
523,ISRG,super micro computer smci gap rise pop day move average first time march server maker late tuesday announce fiscal sale profit top forecast boost guidance view
524,ISRG,natus medical baby also reclaim day line jump busy trade stock be shape right side consolidation potential buy point open maker newborn infant medical gear report better expect result
525,ISRG,follow nancy gondo twitter major average be trading intraday lows midday trade tech stock sell hard software maker biotechs weigh nasdaq be dow be volume be tracking lower board stock market today cree cree tumble year low massive turnover goldman sachs maintain buy rating company cut price target hour tuesday chipmaker earning beat view penny sale miss unisys uis vmware vmw be other tech stock sink heavy volume intuitive surgical isrg give earning sale fall respectively same year quarter stock be week high trading month low upside skecher skx gap leap highest level nearly year result sprint past view late tuesday be much early trade share be still buy point base clear feb shoe maker also make headline monday american meb keflezighi win first place boston marathon run sneaker skecher performance line super micro computer smci gap rise pop day move average first time march server maker late tuesday announce fiscal sale profit top forecast boost guidance view natus medical baby also reclaim day line jump busy trade stock be shape right side consolidation potential buy point open maker newborn infant medical gear report better expect result follow nancy gondo twitter ibd_ngondo
526,ISRG,stock extend gain wednesday tuesday lower volume rally
527,ISRG,hour session nasdaq lead way dow jone industrial average add nyse nasdaq volume be tracking considerably lower tuesday stock market today
528,ISRG,earning front alcoa aa rise close week high late tuesday aluminum giant report profit cent share nicely expectation year sale come year slightly view
529,ISRG,day gainer actavis act bounce remain day move average institutional investor start selling stock late february decline so far have be relatively tame only high actavis be leaderboard stock
530,ISRG,ibd nq mobile nq be top performer rise ahead earning report thursday close growth prospect be bright china base security software firm fourth quarter earning be see rise cent share sale
531,ISRG,downside intuitive surgical isrg plunge company lower earning outlook late tuesday share gap april regulator approve medical device maker latest robotic surgical system
532,ISRG,close bed bath bbby be quarterly result home furnishing retailer plunge january cut full year earning forecast due lower sale expectation last month say fourth quarter result be hurt weather share fall ahead result stock remain technical downtrend stock extend gain wednesday tuesday lower volume rally hour session nasdaq lead way dow jone industrial average add nyse nasdaq volume be tracking considerably lower tuesday stock market today earning front alcoa aa rise close week high late tuesday aluminum giant report profit cent share nicely expectation year sale come year slightly view day gainer actavis act bounce remain day move average institutional investor start selling stock late february decline so far have be relatively tame only high actavis be leaderboard stock ibd nq mobile nq be top performer rise ahead earning report thursday close growth prospect be bright china base security software firm fourth quarter earning be see rise cent share sale downside intuitive surgical isrg plunge company lower earning outlook late tuesday share gap april regulator approve medical device maker latest robotic surgical system close bed bath bbby be quarterly result home furnishing retailer plunge january cut full year earning forecast due lower sale expectation last month say fourth quarter result be hurt weather share fall ahead result stock remain technical downtrend
533,ISRG,major average be little change friday weak post holiday trading nasdaq be edge dow jone industrial be flat volume friday half day session be run sharply lower same time wednesday last trading session thanksgiving universal display oled maker light emit flat panel display jump heavy volume new report product be used apple aapl iphone model due stock be approach buy point deep cup base fall oil price hurt energy stock help airline stock market today coal producer consol energy cnx oil stock southwestern energy swn longtime laggard drop weigh other hand american airline aal unite continental ual rise line decline oil price ibd stock hawaiian rise meanwhile walt disney drop heavy volume drag medium stock announce late wednesday espn sport network have lose subscriber past year stock drop cup handle buy point clear nov viacom viab fall time warner twx be
534,ISRG,share intuitive surgical isrg gap year low stock market friday cut sale forecast say fda have issue warning letter facility company already issue sale warning last week da vinci robotic surgery system didn move fast expect
535,ISRG,stock pop early gain weak trade tuesday aid progress federal budget not so terrible december retail sale report
536,ISRG,nasdaq jump dow jone industrial average stick gain
537,ISRG,volume be weak nasdaq lower nyse vs trade same time monday
538,ISRG,stock market today have receive lift congress hammer budget proposal ahead wednesday federal shutdown deadline house senate leader be work cobble together extension saturday accord washington post so lawmaker have time review complex bill fund government end september
539,ISRG,stock also feel mild boost december retail sale number holiday spending be weaker hope
540,ISRG,lead stock post strong start lead byambarella amba punch open search rebound straight decline maker video compression chip used digital motion camera be week high hold week move average
541,ISRG,downside printer maker stratasys ssys dive start block eden prairie minn base operation deliver revenue guidance expectation cut earning outlook consensus view statement also say expense expand significantly year due sale marketing initiative
542,ISRG,huge volume move send share test week support jan high
543,ISRG,intuitive surgical isrg carved gain massive trade maker robotic surgical instrument pre announce fourth quarter result raise revenue guidance well consensus expectation share have be climb floor month consolidation mid december tuesday gain lift stock back support week move average
544,ISRG,gamestop gme collapse powerful action video game retail chain lower already weak quarterly earning guidance analyst consensus range stock have be consolidate mid november be struggle hold support week line stock pop early gain weak trade tuesday aid progress federal budget not so terrible december retail sale report nasdaq jump dow jone industrial average stick gain volume be weak nasdaq lower nyse vs trade same time monday stock market today have receive lift congress hammer budget proposal ahead wednesday federal shutdown deadline house senate leader be work cobble together extension saturday accord washington post so lawmaker have time review complex bill fund government end september stock also feel mild boost december retail sale number holiday spending be weaker hope lead stock post strong start lead byambarella amba punch open search rebound straight decline maker video compression chip used digital motion camera be week high hold week move average downside printer maker stratasys ssys dive start block eden prairie minn base operation deliver revenue guidance expectation cut earning outlook consensus view statement also say expense expand significantly year due sale marketing initiative huge volume move send share test week support jan high intuitive surgical isrg carved gain massive trade maker robotic surgical instrument pre announce fourth quarter result raise revenue guidance well consensus expectation share have be climb floor month consolidation mid december tuesday gain lift stock back support week move average gamestop gme collapse powerful action video game retail chain lower already weak quarterly earning guidance analyst consensus range stock have be consolidate mid november be struggle hold support week line
545,ISRG,share intuitive surgical isrg be early trading friday company win first more dozen lawsuit file patient family late thursday bloomberg report intuitive wasn negligent training doctor use da vinci robotic surgery system doctor first attempt solo procedure result
546,ISRG,stock be well lows midday tuesday jump european bond yield point higher borrow cost
547,ISRG,just hour session nasdaq be slip dow jone industrial average ease volume nyse nasdaq be run higher compare same time monday
548,ISRG,major average be much early session yield year european bond rise highest level month monday yield year treasury note surge basis point
549,ISRG,stock market today gap gps fall heavy volume apparel retailer report weaker expect april same store sale
550,ISRG,commercial service outsource industry group be day worst perform weigh wagework wage plunge stifel nicolaus cut price target employee benefit provider wagework be week high sink day day move average
551,ISRG,upside manage health care stock humana hum be heavy turnover stock be hit resistance day move work flat base buy point stock be well lows midday tuesday jump european bond yield point higher borrow cost just hour session nasdaq be slip dow jone industrial average ease volume nyse nasdaq be run higher compare same time monday major average be much early session yield year european bond rise highest level month monday yield year treasury note surge basis point stock market today gap gps fall heavy volume apparel retailer report weaker expect april same store sale commercial service outsource industry group be day worst perform weigh wagework wage plunge stifel nicolaus cut price target employee benefit provider wagework be week high sink day day move average upside manage health care stock humana hum be heavy turnover stock be hit resistance day move work flat base buy point
552,ISRG,stock couldn come back early sell be spark drop china january manufacturing activity nasdaq boost netflix nflx strong show pare loss fall much intraday dow respectively close session lows higher volume nyse nasdaq stock market today result distribution day index few big name report close microsoft msft be late trading software maker fiscal earning sale top forecast starbucks sbux be trading higher hour coffee giant fiscal profit rise last year be cent view sale just miss synaptic syna be close touchpad maker fiscal ep fall cent short estimate intuitive surgical isrg fall hour report better expect earning sale key economic report be slate friday new home sale datum december be release monday morning
553,ISRG,do know time sell big winner be latest dip sign finally go collapse be pullback just blip way bigger gain best stock tend pull back numerous time long run make higher high higher lows nevertheless watch pullback carefully be sell kill rally high volume break trend line connect series higher lows usually tell time sell line start low first pullback week line extend lows subsequent pullback draw line weekly chart span least week line draw daily chart draw shorter period compel sell too early trend line method not trigger sell right top be repeatedly show work growth stock investor also consider overall market health stock fundamental other chart signal decide time sell intuitive surgical isrg maker da vinci robotic surgical system break buy point cup handle base july company turn year net loss strong profit year first major pullback come week end oct stock slice week line low yet stock didn undercut buy point soon rebound new high strong volume intuitive retreat second time april pierce week line plunge big volume hit low only investor have solid profit cushion have be able sit such decline stock didn fall further week line eventually form second point trend line low break again third retreat come october intuitive again slice week line low be milder drop trend line connect lows show stock have be sell february be additional sell signal yes month earlier make new high weak trade early february crash week move average massive trade intuitive fall january take nearly year half break again hit new high
554,ISRG,stock continue hold session high late tuesday nasdaq pace sixth straight gain
555,ISRG,nasdaq be dow jone industrial average rise volume be again run sharply higher board stock market today
556,ISRG,lead stock la vegas sand lvs jump nearly active trading putt just day move average casino operator report earning wednesday close sand recently find support week move average
557,ISRG,zillow bounce back earlier weakness rise time high fast trade be be downgrade fairly value buy crt capital upside reversal put stock past buy point handle accord report release today zillow home price more city be expect hit record high next year
558,ISRG,micron technology mu extend recent streak rise best level nearly year stock clear buy point late stage consolidation lose money past year analyst poll thomson reuter see turn profit share year
559,ISRG,downside allison transmission alsn drop appear find support day line late monday company announce sale share investment fund connect carlyle group cg onex corp last week stock briefly clear buy point flat base
560,ISRG,amgen amgn cree cree gilead science gild intuitive surgical isrg packaging corp america pkg skywork solution swks super micro computer smci vmware vmw yum brand yum be few notable company report earning close stock continue hold session high late tuesday nasdaq pace sixth straight gain nasdaq be dow jone industrial average rise volume be again run sharply higher board stock market today lead stock la vegas sand lvs jump nearly active trading putt just day move average casino operator report earning wednesday close sand recently find support week move average zillow bounce back earlier weakness rise time high fast trade be be downgrade fairly value buy crt capital upside reversal put stock past buy point handle accord report release today zillow home price more city be expect hit record high next year micron technology mu extend recent streak rise best level nearly year stock clear buy point late stage consolidation lose money past year analyst poll thomson reuter see turn profit share year downside allison transmission alsn drop appear find support day line late monday company announce sale share investment fund connect carlyle group cg onex corp last week stock briefly clear buy point flat base amgen amgn cree cree gilead science gild intuitive surgical isrg packaging corp america pkg skywork solution swks super micro computer smci vmware vmw yum brand yum be few notable company report earning close
561,ISRG,end year important take look past mistake also helpful go market best performer do help do better come year winner worth study be facebook fb be most highly anticipate new issue facebook quickly fizzle debut stock redeem year general market facebook start bang surge first week then get rocky stock slump late january peak still correction let facebook carve double bottom base buy point buy point double bottom pattern be cent high middle pattern sometimes be tough spot july facebook stage breakaway gap past buy point open nearly close prior session reaction solid second quarter earning announce night breakaway gap give impression once happen too late buy yet be sign powerful demand investor not shy away former leader such intuitive surgical isrg green mountain coffee roaster gmcr qualcomm qcom have breakaway gap course stellar run most case investor not buy once stock move past buy point base breakaway gap do so still cut loss short stock falter late october year stock have run settle become cup handle base stock clear alternative entry week end aug heavy trading jump october just stage breakaway gap facebook have mixed ibd rating have composite rating be not great earning share rating be good relative price strength rating be weak report change outlook facebook surge mobile ad sale show promising line business also deny facebook have breakthrough product change way person communicate keep touch friend family facebook give other company avenue promote product service facebook have mixed fundamental profit be flat quarters july sale grow same period
562,ISRG,stock hit fresh session high late thursday be track fourth straight gain
563,ISRG,help internet computer hardware stock nasdaq rally dow jone industrial average be volume be tracking modestly higher major exchange stock market today
564,ISRG,tata motor ttm stretched gain earlier stock clear buy point double bottom base heavy trading indian carmaker have composite rating highest auto manufacturer group tata be mentioned international leader earlier month
565,ISRG,armour ua rally regain day line fast trade stock be flat base larger pattern telsey advisory group upgrade share outperform market perform wednesday
566,ISRG,downside microsemi mscc reversed fall ahead fiscal earning close chipmaker be expect earn cent share year mark second straight quarter accelerate growth microsemi be work potential base
567,ISRG,intuitive surgical isrg kla tencor klac skywork solution swks starbucks sbux also be report earning close stock hit fresh session high late thursday be track fourth straight gain help internet computer hardware stock nasdaq rally dow jone industrial average be volume be tracking modestly higher major exchange stock market todaytata motor ttm stretched gain earlier stock clear buy point double bottom base heavy trading indian carmaker have composite rating highest auto manufacturer group tata be mentioned international leader earlier month armour ua rally regain day line fast trade stock be flat base larger pattern telsey advisory group upgrade share outperform market perform wednesday downside microsemi mscc reversed fall ahead fiscal earning close chipmaker be expect earn cent share year mark second straight quarter accelerate growth microsemi be work potential base intuitive surgical isrg kla tencor klac skywork solution swks starbucks sbux also be report earning close
568,ISRG,stock future stumble mixed terrain ahead friday open
569,ISRG,dow future be relatively steady point fair market value future keep narrow point gain nasdaq future backed early gain be fraction possibly hurt micron technology mu premarket slide follow weak fiscal third quarter report deliver late thursday
570,ISRG,clear stock market today have lot chew
571,ISRG,accord eurozone greece appear be table friday analyst project last ditch deal be reach weekend party start week resign greek default payment owe tuesday international monetary fund global market reflect investor position eventuality
572,ISRG,push europe lead index modest loss midday friday benchmark index paris frankfurt be still tracking gain range week euro edge dollar
573,ISRG,china mainland market dig serious correction shanghai composite diving tech heavy shenzhen composite friday market be hit liquidity concern trigger wave ipos last week lead fear frothy market be set unwind second week steep decline left index respectively june peak
574,ISRG,hong kong larger more internationally expose hang seng index fall friday end week effectively flat
575,ISRG,market have remain hold pattern week end thursday even day line nasdaq be drift day move average
576,ISRG,only real datum point friday economic front be university michigan final june consumer sentiment estimate due et
577,ISRG,stock nike nke muscle nearly ahead open report solid fiscal fourth quarter result late thursday earning jump fourth straight double digit gain revenue gain better expect analyst attribute surprise tight cost control stock have be lilting uptrend gain only buy point mid
578,ISRG,athletic shoe retailer finish line finl soar healthy result earning gain foiled consensus expectation decline revenue gain also top expectation stock have be steady uptrend december low rout month consolidation
579,ISRG,chipmaker micron slump ahead open report late thursday fiscal third quarter sale earning decline more expect stock have be decline correction december peak
580,ISRG,agricultural commodity be motion friday continue rain midwest raise concern lose production wheat future jump bushel be week corn rise more friday nearly last friday settle
581,ISRG,other commodity be mixed west texas intermediate crude oil brent crude fraction gold add few penny rise ounce week wti oil natural gas be essentially unchanged gold be stock future stumble mixed terrain ahead friday open dow future be relatively steady point fair market value future keep narrow point gain nasdaq future backed early gain be fraction possibly hurt micron technology mu premarket slide follow weak fiscal third quarter report deliver late thursday clear stock market today have lot chew accord eurozone greece appear be table friday analyst project last ditch deal be reach weekend party start week resign greek default payment owe tuesday international monetary fund global market reflect investor position eventuality push europe lead index modest loss midday friday benchmark index paris frankfurt be still tracking gain range week euro edge dollar china mainland market dig serious correction shanghai composite diving tech heavy shenzhen composite friday market be hit liquidity concern trigger wave ipos last week lead fear frothy market be set unwind second week steep decline left index respectively june peak hong kong larger more internationally expose hang seng index fall friday end week effectively flat market have remain hold pattern week end thursday even day line nasdaq be drift day move average only real datum point friday economic front be university michigan final june consumer sentiment estimate due et stock nike nke muscle nearly ahead open report solid fiscal fourth quarter result late thursday earning jump fourth straight double digit gain revenue gain better expect analyst attribute surprise tight cost control stock have be lilting uptrend gain only buy point mid athletic shoe retailer finish line finl soar healthy result earning gain foiled consensus expectation decline revenue gain also top expectation stock have be steady uptrend december low rout month consolidation chipmaker micron slump ahead open report late thursday fiscal third quarter sale earning decline more expect stock have be decline correction december peak agricultural commodity be motion friday continue rain midwest raise concern lose production wheat future jump bushel be week corn rise more friday nearly last friday settle other commodity be mixed west texas intermediate crude oil brent crude fraction gold add few penny rise ounce week wti oil natural gas be essentially unchanged gold be
582,ISRG,sell winner pro fifth series
583,ISRG,sell strength sell weakness
584,ISRG,even possible do little bit
585,ISRG,namely be good idea sell stock hit new high low turnover
586,ISRG,hand such action be display strength stock be touch fresh peak
587,ISRG,other hand be sign weakness type move come average daily volume prefer see convince turnover stock advance never see height
588,ISRG,lower trade suggest big investor be lose appetite stock
589,ISRG,intuitive surgical isrg action december provide good example handle stock touch fresh high weak volume
590,ISRG,time pioneer robotic surgical equipment have enjoy strong advance year have more triple level end hadn yet run wood chipper be stock market
591,ISRG,intuitive be rebound support week move average final week be vicinity prior high reach october strong quarterly earning report
592,ISRG,note october high have come big weekly turnover highest trade month
593,ISRG,wasn case december week end dec weekly volume be actually average
594,ISRG,anyone hold intuitive share time have interpreted sign take least profit
595,ISRG,look daily chart action also seem discourage new high come dec dec average turnover
596,ISRG,keep mind new high weak turnover isn always sign sell want take account overall action stock not just factor
597,ISRG,intuitive case have factor fact stock already have run considerably year execute several breakout week pullback way
598,ISRG,selling december have allow avoid steady decline sell winner pro fifth sell strength sell weakness even possible do little bit namely be good idea sell stock hit new high low turnover hand such action be display strength stock be touch fresh peak other hand be sign weakness type move come average daily volume prefer see convince turnover stock advance never see height lower trade suggest big investor be lose appetite stock intuitive surgical isrg action december provide good example handle stock touch fresh high weak volume time pioneer robotic surgical equipment have enjoy strong advance year have more triple level end hadn yet run wood chipper be stock market intuitive be rebound support week move average final week be vicinity prior high reach october strong quarterly earning report note october high have come big weekly turnover highest trade month wasn case december week end dec weekly volume be actually average anyone hold intuitive share time have interpreted sign take least profit look daily chart action also seem discourage new high come dec dec average turnover keep mind new high weak turnover isn always sign sell want take account overall action stock not just factor intuitive case have factor fact stock already have run considerably year execute several breakout week pullback way selling december have allow avoid steady decline
599,ISRG,share intuitive surgical isrg be midday trading wednesday robotic company late tuesday report financial result beat analyst estimate straight quarter maker robotic surgery system also raise outlook inspiring analyst raise price target share earlier wednesday rise much
600,ISRG,intuitive surgical report fourth quarter revenue vs year earlier earning share climb share wall street have expect revenue ep company sell da vinci surgical system year earlier intuitive share fall more early hour trading rise modestly record high regular session wasn immediately clear share be late company plan eastern conference call original story follow investor await intuitive surgical isrg result close thursday stock already orbit wonder company history beating view pull again stock reversed modestly lower morning hit record high mid afternoon trading rise eastern company sell da vinci robotic surgery system have turn consistent double digit profit sale growth nearly year keep ibd ranking top stock much time drive share more past month yet analyst follow company rate stock hold have wonder just many expensive system company sell big institution also have caution include thursday intuitive share have rise straight session mostly average sluggish volume suggest mutual fund other big player aren buy bulk follow straight day decline higher turnover still analyst expect continue growth fourth quarter average profit forecast call share year earlier quarter sale rise full year consensus call earning share sale be estimate fourth quarter didn see dramatic development company ibd report last month do regulatory nod single site set instrument further company goal minimize invasiveness surgery enable gall bladder removal only incision
601,ISRG,intuitive surgical isrg prepare earning report late tuesday analyst be wait see beat expectation quarter row company long history sale profit growth da vinci robotic surgery system have make habitue ibd ranking top stock
602,ISRG,intuitive surgical isrg prepare earning report late tuesday analyst be wait see beat expectation quarter row company long history sale profit growth da vinci robotic surgery system have make habitue ibd ranking top stock
603,ISRG,spread robotic assist surgery more medical procedure carry intuitive surgical isrg well past profit sale estimate send share sharply higher late trading tuesday medical robotic maker earning rise share revenue climb analyst poll thomson reuter expect intuitive surgical earn share sale
604,ISRG,blast cup handle base wednesday intuitive surgical isrg hold steady thursday stock be buy range past handle buy point wednesday intuitive surgical gap open past buy point gap up be intimidate new buyer rather think re late
605,ISRG,stock reversed higher close bell monday end session skid rout china stock market further drop oil price
606,ISRG,dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum
607,ISRG,energy mining biotech stock lag department store hospital tobacco stock lead upside
608,ISRG,aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session
609,ISRG,macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd
610,ISRG,sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman
611,ISRG,company due report quarterly result tuesday include csx csx ihs ihs
612,ISRG,labor department be due release closely watch job opening labor turnover survey jolt tuesday stock reversed higher close bell monday end session skid rout china stock market further drop oil price dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum energy mining biotech stock lag department store hospital tobacco stock lead upside aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman company due report quarterly result tuesday include csx csx ihs ihs labor department be due release closely watch job opening labor turnover survey jolt tuesday
613,ISRG,share intuitive surgical isrg jump early trading wednesday robotic surgical system maker earning beat analyst estimate intuitive surgical say profit rise share year earlier period analyst have estimate profit share medical device maker say revenue rise ahead
614,ISRG,intuitive surgical isrg cream expectation fourth quarter result thursday stock slip hour trading close new high maker da vinci robotic surgery system report profit share year quarter well thomson reuter estimate sale rise vs consensus
615,ISRG,intuitive surgical isrg stock be early trading stock market friday specialist robotic assist surgery late thursday report revenue miss view
616,ISRG,sunnyvale calif base intuitive say earn share year earlier revenue fall analyst estimate
617,ISRG,company say sell da vinci surgical robot year earlier quarter intuitive executive say new health care law be putt crimp hospital spending
618,ISRG,third quarter result be impact same pressure face first half year namely moderate growth benign gynecology combine change hospital capital spending priority associate implementation affordable care act intuitive ceo gary guthart say statement
619,ISRG,company say full year revenue be lower half earlier guidance unchanged growth growth
620,ISRG,intuitive surgical stock have plunge regulator have be review robotic procedure
621,ISRG,ibd medical system equipment group also include dexcom dxcm align technology algn cantel medical cmn rank industry group track
622,ISRG,related stryker bet robotic surgery mako surgical acquisition intuitive surgical isrg stock be early trading stock market friday specialist robotic assist surgery late thursday report revenue miss view sunnyvale calif base intuitive say earn share year earlier revenue fall analyst estimate company say sell da vinci surgical robot year earlier quarter intuitive executive say new health care law be putt crimp hospital spending third quarter result be impact same pressure face first half year namely moderate growth benign gynecology combine change hospital capital spending priority associate implementation affordable care act intuitive ceo gary guthart say statement company say full year revenue be lower half earlier guidance unchanged growth growth intuitive surgical stock have plunge regulator have be review robotic procedure ibd medical system equipment group also include dexcom dxcm align technology algn cantel medical cmn rank industry group track related stryker bet robotic surgery mako surgical acquisition
623,ISRG,robotic surgery hotshot intuitive surgical isrg like stay cut edge field so rather rest laurel maker da vinci robotic surgical system keep come new offering help propel growth expand base add new procedure lineup intuitive score nice front
624,ISRG,intuitive surgical isrg cream expectation fourth quarter result thursday stock slip hour trading close new high maker da vinci robotic surgery system report profit share year quarter well thomson reuter estimate sale rise vs consensus
625,ISRG,stock backed away early gain turn mixed first half hour friday session
626,ISRG,nasdaq backtrack narrow loss priceline pcln netflix nflx intuitive surgical isrg trade lower hold gain dow jone industrial average stand firm
627,ISRG,volume jump nasdaq nyse compare same time thursday
628,ISRG,stock market today jump early advance investor focuse positive side labor department march payroll report datum show payroll increase month better initial february number well new hire expect unemployment rate remain same vs expectation downtick
629,ISRG,anadarko petroleum apc climb putt ahead week woodland texas base oil gas producer agree pay settle toxic chemical claim related subsidiary spun kerr mcgee just prior acquisition anadarko
630,ISRG,week gain hoist anadarko month consolidation new high
631,ISRG,leader ibd stock moved start trade
632,ISRG,align technology algn bit gain early trade maker transparent dental brace announce international trade commission judge affirm earlier determination find patent have be infringe competitor clearcorrect judge issue cease desist order clearcorrect terminate investigation
633,ISRG,gain punch align back day move average continue rebound start monday stock day move average
634,ISRG,myriad genetic mygn jump add already healthy gain week salt lake city base provider genetic test be upgrade mizuho buy neutral stock have already soar week friday gap stock backed away early gain turn mixed first half hour friday session nasdaq backtrack narrow loss priceline pcln netflix nflx intuitive surgical isrg trade lower hold gain dow jone industrial average stand firm volume jump nasdaq nyse compare same time thursday stock market today jump early advance investor focuse positive side labor department march payroll report datum show payroll increase month better initial february number well new hire expect unemployment rate remain same vs expectation downtick anadarko petroleum apc climb putt ahead week woodland texas base oil gas producer agree pay settle toxic chemical claim related subsidiary spun kerr mcgee just prior acquisition anadarko week gain hoist anadarko month consolidation new high leader ibd stock moved start trade align technology algn bit gain early trade maker transparent dental brace announce international trade commission judge affirm earlier determination find patent have be infringe competitor clearcorrect judge issue cease desist order clearcorrect terminate investigation gain punch align back day move average continue rebound start monday stock day move average myriad genetic mygn jump add already healthy gain week salt lake city base provider genetic test be upgrade mizuho buy neutral stock have already soar week friday gap
635,ISRG,tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen
636,ISRG,nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today
637,ISRG,economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation
638,ISRG,day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session
639,ISRG,meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain
640,ISRG,several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar
641,ISRG,qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday
642,ISRG,monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn
643,ISRG,robotic surgery specialist intuitive surgical beat wall street estimate yet again late tuesday share trade hour firm procedure growth continue slow intuitive isrg earn share exclude time tax benefit still beat analyst consensus be year earlier sale rise
644,ISRG,robotic surgery specialist intuitive surgical isrg go straight quarterly earning beat report thursday market close face analyst expectation slow growth
645,ISRG,analyst poll thomson reuter expect company report profit share year quarter sale be expect rise full year analyst expect earning growth dip teen year profit jump last year post recession bounce
646,ISRG,expect slowdown reflect maturity company have be essentially ride product da vinci surgical system various add on last quarterly report april beat wall street estimate time row share hit time high have yet regain nonetheless stock remain high maintain ibd relative strength rating putt top stock
647,ISRG,stock action have track ibd medical system group overall now rank industry group follow intuitive be largest cap stock group highest rate composite rating
648,ISRG,intuitive stock be fraction early trading wednesday
649,ISRG,related intuitive other medical gear maker fall obamacare ruling robotic surgery specialist intuitive surgical isrg go straight quarterly earning beat report thursday market close face analyst expectation slow growth analyst poll thomson reuter expect company report profit share year quarter sale be expect rise full year analyst expect earning growth dip teen year profit jump last year post recession bounce expect slowdown reflect maturity company have be essentially ride product da vinci surgical system various add on last quarterly report april beat wall street estimate time row share hit time high have yet regain nonetheless stock remain high maintain ibd relative strength rating putt top stock stock action have track ibd medical system group overall now rank industry group follow intuitive be largest cap stock group highest rate composite rating intuitive stock be fraction early trading wednesday related intuitive other medical gear maker fall obamacare ruling
650,ISRG,intuitive surgical isrg break middle give investor opportunity enter stock little earlier traditional buy point
651,ISRG,maker robotic surgical system have set cup handle base buy point cent high handle most stock also offer earlier buy point allow investor lessen downside risk
652,ISRG,stock begin form cup march peak left side see daily chart fall build right side
653,ISRG,handle form just top base begin slope downward volume be most part quiet want see conventional buy point previously mentioned be
654,ISRG,earlier entry be establish draw trend line high handle peak price bar follow do so have reveal alternate buy point traditional buy point
655,ISRG,intuitive surge past early buy point traditional buy point july more time average daily turnover climb month have buy alternate buy point
656,ISRG,early buy point help reduce risk ll be kick stock due fluctuation soon
657,ISRG,intuitive pull back day move average line late july represent paper loss have buy traditional buy point loss have buy alternate entry
658,ISRG,such difference seem small give investor little extra cushion stock pull back ibd style investor be urge sell stock fall buy point preserve capital minimize downside risk
659,ISRG,minimize risk be especially important case intuitive surgical come nasdaq be still correction tech heavy index didn follow aug several week intuitive nasdaq rise day fourth day rally attempt volume be higher previous session
660,ISRG,advantage buy early buy point be purchase more share stock hit traditional entry point
661,ISRG,always make sure company fundamental be strong buy day intuitive surgical have accumulation distribution rating point moderate demand share rise day intuitive surgical isrg break middle give investor opportunity enter stock little earlier traditional buy point maker robotic surgical system have set cup handle base buy point cent high handle most stock also offer earlier buy point allow investor lessen downside risk stock begin form cup march peak left side see daily chart fall build right side handle form just top base begin slope downward volume be most part quiet want see conventional buy point previously mentioned be earlier entry be establish draw trend line high handle peak price bar follow do so have reveal alternate buy point traditional buy point intuitive surge past early buy point traditional buy point july more time average daily turnover climb month have buy alternate buy point early buy point help reduce risk ll be kick stock due fluctuation soon intuitive pull back day move average line late july represent paper loss have buy traditional buy point loss have buy alternate entry such difference seem small give investor little extra cushion stock pull back ibd style investor be urge sell stock fall buy point preserve capital minimize downside risk minimize risk be especially important case intuitive surgical come nasdaq be still correction tech heavy index didn follow aug several week intuitive nasdaq rise day fourth day rally attempt volume be higher previous session advantage buy early buy point be purchase more share stock hit traditional entry point always make sure company fundamental be strong buy day intuitive surgical have accumulation distribution rating point moderate demand share rise day
662,ISRG,major average lead growth stock get smack thursday hurt china manufacturing datum show contraction china purchasing manager index fall month low december read stock be session lows little more hour remain session dow jone industrial average fall respectively nasdaq lose distribution day be take shape preliminary datum show nyse nasdaq volume tracking higher wednesday stock market today china growth name be particularly hard hit baidu bidu slump day move average heavy volume fall other china name pressure include tal education group xrs new oriental education technology group edu yy yy netease nte elsewhere herbalife hlf plunge senate democrat edward markey call investigation company business practice new york time report earlier today hedge fund manager bill ackman be short stock meet member markey staff fall not markey accord markey spokesperson meanwhile starbucks sbux lose nearly ahead earning report close starbucks touch day move average re-cover be session high bright spot thursday be netflix nflx share soar time high company result easily top expectation sale growth accelerate fourth straight quarter rise left dead company stream business continue flourish close svb financial group sivb report quarterly result top rate name ibd bank super regional group watch other earning report intuitive surgical isrg synaptic syna microsoft msft
663,ISRG,earning update intuitive surgical isrg report earning rise share cent view revenue rev also comfortably forecast intuitive share jump nearly initial hour trading fall regular session original article follow intuitive surgical isrg be set report third quarter earning
664,ISRG,correction be gift top stock get chance form new basis bounce day move average market return uptrend such stock be buy intuitive surgical isrg monday ibd have backed recent high stock return day move average
665,ISRG,robotic surgery company intuitive surgical isrg beat analyst estimate yet again report third quarter result close tuesday drive share higher hour trading intuitive say profit climb year earlier share sale rise analyst poll thomson reuter expect earning share
666,ISRG,just look align technology algn have perfect tech invisible brace company find yet way improve early year san jose calif maker alternative metal brace introduce new material invisalign clear aligner system smarttrack highly elastic material better maintain
667,ISRG,give away razor charge blade basic model work variety industry work razor be cut edge surgical robot
668,ISRG,intuitive surgical isrg have be make go company da vinci surgical system isn exactly give away cost cool firm have be shift reliance product sale reliance various instrument accessory upgrade doctor already own machine
669,ISRG,basic da vinci box be console doctor sit look surgical site view screen surgeon move hand operate cause robotic arm machine move tandem smaller movement company say enable look feel open surgery cut big hole patient
670,ISRG,once hospital get system install intuitive start selling instrument make specially robot arm add extra steadiness revenue stream have kind plan obsolescence tool have microchip count number used so get be replace
671,ISRG,very clever say junaid husain senior medical technology analyst soleil security gift keep give
672,ISRG,first quarter result
673,ISRG,importance business be apparent intuitive first quarter result report april company beat analyst view quarter sale last year profit share affirm outlook rest year sale growth
674,ISRG,system sale rise just quarter vs growth instrument accessory intuitive place net new machine sequentially first quarter trim gross margin outlook year average selling price be low side goldman sachs promptly cut ep outlook cite decline margin
675,ISRG,husain say not so concern intuitive keep develop new extra new procedure december launch skill simulator enhance version training program surgeon deploy learn use da vinci system call official say demand simulator be so great delivery have be put next quarter
676,ISRG,february regulator approve fluorescence imaging system monitor blood flow tissue surface vessel sealer surgical stapler be await approval
677,ISRG,give company track success not just number product sell number procedure perform system intuitive report growth procedure quarter revenue procedure
678,ISRG,crucial way wrest more procedure install base be keep expand type surgery be do machine year market da vinci core procedure have be gynecology urology task remove prostate urinary obstruction uterine fibroid
679,ISRG,more recently intuitive have branch cardiothoracic colorectal head neck surgery official say last be growth driver first quarter
680,ISRG,system also have upgrade cycle much longer standard da vinci system be approve da vinci follow da vinci si
681,ISRG,da vinci si most notable change be dual monitor allow more surgeon work same time intuitive report surgeon be slowly surely upgrading new system first quarter customer trade standard da vincis si trade
682,ISRG,machine have be hit install base total system number be much smaller elsewhere europe rest world sale outside outpaced domestic sale first quarter gleacher analyst amit hazan say penetrating foreign market have long be challenge intuitive success depend relative power user bean counter
683,ISRG,model be very much patient drive physician drive hazan say term return investment system very debatable model doesn necessarily translate other country very well
684,ISRG,encourage research
685,ISRG,back case intuitive have be work conference circuit encourage study show robot surgery isn just cooler actually have better outcome conference call vice president alek cukic cite recent study compare robotic hysterectomy laparoscopic type robotic procedure show less blood loss shorter hospital stay fewer complication say
686,ISRG,acceptance medical community be slow pain staking process time hospital government budget be still tight
687,ISRG,japan represent potential market opportunity intuitive accord analyst tao levy collin stewart company have sell only handful machine lobby nationwide reimbursement purchase analyst expect decision next year assume post earthquake recovery go smoothly
688,ISRG,still levy be optimistic intuitive prospect abroad
689,ISRG,pretty much give quarter have ish percent system place internationally say continue place increase number system europe outside europe well
690,ISRG,analyst poll thomson reuter expect intuitive ep grow next year respectively give away razor charge blade basic model work variety industry work razor be cut edge surgical robot intuitive surgical isrg have be make go company da vinci surgical system isn exactly give away cost cool firm have be shift reliance product sale reliance various instrument accessory upgrade doctor already own machine basic da vinci box be console doctor sit look surgical site view screen surgeon move hand operate cause robotic arm machine move tandem smaller movement company say enable look feel open surgery cut big hole patient once hospital get system install intuitive start selling instrument make specially robot arm add extra steadiness revenue stream have kind plan obsolescence tool have microchip count number used so get be replace very clever say junaid husain senior medical technology analyst soleil security gift keep give first quarter importance business be apparent intuitive first quarter result report april company beat analyst view quarter sale last year profit share affirm outlook rest year sale growth system sale rise just quarter vs growth instrument accessory intuitive place net new machine sequentially first quarter trim gross margin outlook year average selling price be low side goldman sachs promptly cut ep outlook cite decline margin husain say not so concern intuitive keep develop new extra new procedure december launch skill simulator enhance version training program surgeon deploy learn use da vinci system call official say demand simulator be so great delivery have be put next quarter february regulator approve fluorescence imaging system monitor blood flow tissue surface vessel sealer surgical stapler be await approval give company track success not just number product sell number procedure perform system intuitive report growth procedure quarter revenue procedure crucial way wrest more procedure install base be keep expand type surgery be do machine year market da vinci core procedure have be gynecology urology task remove prostate urinary obstruction uterine fibroid more recently intuitive have branch cardiothoracic colorectal head neck surgery official say last be growth driver first quarter system also have upgrade cycle much longer standard da vinci system be approve da vinci follow da vinci si da vinci si most notable change be dual monitor allow more surgeon work same time intuitive report surgeon be slowly surely upgrading new system first quarter customer trade standard da vincis si trade machine have be hit install base total system number be much smaller elsewhere europe rest world sale outside outpaced domestic sale first quarter gleacher analyst amit hazan say penetrating foreign market have long be challenge intuitive success depend relative power user bean counter model be very much patient drive physician drive hazan say term return investment system very debatable model doesn necessarily translate other country very well encourage researchto back case intuitive have be work conference circuit encourage study show robot surgery isn just cooler actually have better outcome conference call vice president alek cukic cite recent study compare robotic hysterectomy laparoscopic type robotic procedure show less blood loss shorter hospital stay fewer complication say acceptance medical community be slow pain staking process time hospital government budget be still tight japan represent potential market opportunity intuitive accord analyst tao levy collin stewart company have sell only handful machine lobby nationwide reimbursement purchase analyst expect decision next year assume post earthquake recovery go smoothly still levy be optimistic intuitive prospect abroad pretty much give quarter have ish percent system place internationally say continue place increase number system europe outside europe well analyst poll thomson reuter expect intuitive ep grow next year respectively
691,ISRG,give away razor charge blade basic model work variety industry work razor be cut edge surgical robot
692,ISRG,intuitive surgical isrg have be make go company da vinci surgical system isn exactly give away cost cool firm have be shift reliance product sale reliance various instrument accessory upgrade doctor already own machine
693,ISRG,basic da vinci box be console doctor sit look surgical site view screen surgeon move hand operate cause robotic arm machine move tandem smaller movement company say enable look feel open surgery cut big hole patient
694,ISRG,once hospital get system install intuitive start selling instrument make specially robot arm add extra steadiness revenue stream have kind plan obsolescence tool have microchip count number used so get be replace
695,ISRG,very clever say junaid husain senior medical technology analyst soleil security gift keep give
696,ISRG,first quarter result
697,ISRG,importance business be apparent intuitive first quarter result report april company beat analyst view quarter sale last year profit share affirm outlook rest year sale growth
698,ISRG,system sale rise just quarter vs growth instrument accessory intuitive place net new machine sequentially first quarter trim gross margin outlook year average selling price be low side goldman sachs promptly cut ep outlook cite decline margin
699,ISRG,husain say not so concern intuitive keep develop new extra new procedure december launch skill simulator enhance version training program surgeon deploy learn use da vinci system call official say demand simulator be so great delivery have be put next quarter
700,ISRG,february regulator approve fluorescence imaging system monitor blood flow tissue surface vessel sealer surgical stapler be await approval
701,ISRG,give company track success not just number product sell number procedure perform system intuitive report growth procedure quarter revenue procedure
702,ISRG,crucial way wrest more procedure install base be keep expand type surgery be do machine year market da vinci core procedure have be gynecology urology task remove prostate urinary obstruction uterine fibroid
703,ISRG,more recently intuitive have branch cardiothoracic colorectal head neck surgery official say last be growth driver first quarter
704,ISRG,system also have upgrade cycle much longer standard da vinci system be approve da vinci follow da vinci si
705,ISRG,da vinci si most notable change be dual monitor allow more surgeon work same time intuitive report surgeon be slowly surely upgrading new system first quarter customer trade standard da vincis si trade
706,ISRG,machine have be hit install base total system number be much smaller elsewhere europe rest world sale outside outpaced domestic sale first quarter gleacher analyst amit hazan say penetrating foreign market have long be challenge intuitive success depend relative power user bean counter
707,ISRG,model be very much patient drive physician drive hazan say term return investment system very debatable model doesn necessarily translate other country very well
708,ISRG,encourage research
709,ISRG,back case intuitive have be work conference circuit encourage study show robot surgery isn just cooler actually have better outcome conference call vice president alek cukic cite recent study compare robotic hysterectomy laparoscopic type robotic procedure show less blood loss shorter hospital stay fewer complication say
710,ISRG,acceptance medical community be slow pain staking process time hospital government budget be still tight
711,ISRG,japan represent potential market opportunity intuitive accord analyst tao levy collin stewart company have sell only handful machine lobby nationwide reimbursement purchase analyst expect decision next year assume post earthquake recovery go smoothly
712,ISRG,still levy be optimistic intuitive prospect abroad
713,ISRG,pretty much give quarter have ish percent system place internationally say continue place increase number system europe outside europe well
714,ISRG,analyst poll thomson reuter expect intuitive ep grow next year respectively give away razor charge blade basic model work variety industry work razor be cut edge surgical robot intuitive surgical isrg have be make go company da vinci surgical system isn exactly give away cost cool firm have be shift reliance product sale reliance various instrument accessory upgrade doctor already own machine basic da vinci box be console doctor sit look surgical site view screen surgeon move hand operate cause robotic arm machine move tandem smaller movement company say enable look feel open surgery cut big hole patient once hospital get system install intuitive start selling instrument make specially robot arm add extra steadiness revenue stream have kind plan obsolescence tool have microchip count number used so get be replace very clever say junaid husain senior medical technology analyst soleil security gift keep give first quarter importance business be apparent intuitive first quarter result report april company beat analyst view quarter sale last year profit share affirm outlook rest year sale growth system sale rise just quarter vs growth instrument accessory intuitive place net new machine sequentially first quarter trim gross margin outlook year average selling price be low side goldman sachs promptly cut ep outlook cite decline margin husain say not so concern intuitive keep develop new extra new procedure december launch skill simulator enhance version training program surgeon deploy learn use da vinci system call official say demand simulator be so great delivery have be put next quarter february regulator approve fluorescence imaging system monitor blood flow tissue surface vessel sealer surgical stapler be await approval give company track success not just number product sell number procedure perform system intuitive report growth procedure quarter revenue procedure crucial way wrest more procedure install base be keep expand type surgery be do machine year market da vinci core procedure have be gynecology urology task remove prostate urinary obstruction uterine fibroid more recently intuitive have branch cardiothoracic colorectal head neck surgery official say last be growth driver first quarter system also have upgrade cycle much longer standard da vinci system be approve da vinci follow da vinci si da vinci si most notable change be dual monitor allow more surgeon work same time intuitive report surgeon be slowly surely upgrading new system first quarter customer trade standard da vincis si trade machine have be hit install base total system number be much smaller elsewhere europe rest world sale outside outpaced domestic sale first quarter gleacher analyst amit hazan say penetrating foreign market have long be challenge intuitive success depend relative power user bean counter model be very much patient drive physician drive hazan say term return investment system very debatable model doesn necessarily translate other country very well encourage researchto back case intuitive have be work conference circuit encourage study show robot surgery isn just cooler actually have better outcome conference call vice president alek cukic cite recent study compare robotic hysterectomy laparoscopic type robotic procedure show less blood loss shorter hospital stay fewer complication say acceptance medical community be slow pain staking process time hospital government budget be still tight japan represent potential market opportunity intuitive accord analyst tao levy collin stewart company have sell only handful machine lobby nationwide reimbursement purchase analyst expect decision next year assume post earthquake recovery go smoothly still levy be optimistic intuitive prospect abroad pretty much give quarter have ish percent system place internationally say continue place increase number system europe outside europe well analyst poll thomson reuter expect intuitive ep grow next year respectively
715,ISRG,return equity be important financial gauge commonly used value investing so do growth strategy ibd slim
716,ISRG,simple answer work indicator financial well be
717,ISRG,ibd founder chairman william neil study characteristic most successful stock high return equity emerge key factor
718,ISRG,thus return equity roe short be handful financial metric adherent slim consider stock research
719,ISRG,return equity be measure financial efficiency gauge much profit company be able generate company financial net worth be asset liability
720,ISRG,stock research look annual return equity least level tend set apart winning stock ordinary base finding neil research
721,ISRG,few example history
722,ISRG,intuitive surgical isrg have roe year march stock more triple peaked december
723,ISRG,southwestern energy swn roe be june lead surge week
724,ISRG,ctrip com ctrp have roe break february roar week
725,ISRG,brazil banco bradesco bbd register roe october lead rally week
726,ISRG,doesn always mean company smaller roe be poor investment big winner be shy return equity start major advance
727,ISRG,roe be strong give investor sense better poise continue solid earning performance
728,ISRG,be sure high roe be only part fundamental solid company have excellent earning sale growth superior profit margin big operate cash flow be other key element investor seek
729,ISRG,figure return equity ibd divide net income past fiscal year average shareholder equity past year
730,ISRG,be aware high amount long term debt indirectly inflate return equity debt reduce shareholder equity
731,ISRG,don want do math company return equity be find ibd stock checkup investor com be also show chart appear ibd weekly review stock spotlight big cap sector leader
732,ISRG,ibd smr rating combine sale growth profit margin return equity letter grade prefer stock return equity be important financial gauge commonly used value investing so do growth strategy ibd slim simple answer work indicator financial well be ibd founder chairman william neil study characteristic most successful stock high return equity emerge key factor thus return equity roe short be handful financial metric adherent slim consider stock research return equity be measure financial efficiency gauge much profit company be able generate company financial net worth be asset liability stock research look annual return equity least level tend set apart winning stock ordinary base finding neil research few example history intuitive surgical isrg have roe year march stock more triple peaked december southwestern energy swn roe be june lead surge week ctrip com ctrp have roe break february roar week brazil banco bradesco bbd register roe october lead rally week doesn always mean company smaller roe be poor investment big winner be shy return equity start major advance roe be strong give investor sense better poise continue solid earning performance be sure high roe be only part fundamental solid company have excellent earning sale growth superior profit margin big operate cash flow be other key element investor seek figure return equity ibd divide net income past fiscal year average shareholder equity past year be aware high amount long term debt indirectly inflate return equity debt reduce shareholder equity don want do math company return equity be find ibd stock checkup investor com be also show chart appear ibd weekly review stock spotlight big cap sector leader ibd smr rating combine sale growth profit margin return equity letter grade prefer stock
733,ISRG,stock end week sour note tech intensive nasdaq drag high profile loss distribution day add dow jone industrial average cede nano smidge nasdaq weigh loss google goog microsoft msft intuitive surgical isrg fall volume stock
734,ISRG,stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier
735,ISRG,nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline
736,ISRG,stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear
737,ISRG,friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week
738,ISRG,economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm
739,ISRG,half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer
740,ISRG,several late season earning report whip action bell
741,ISRG,carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june
742,ISRG,homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august
743,ISRG,handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss
744,ISRG,leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point
745,ISRG,qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction
746,ISRG,oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week
747,ISRG,overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain
748,ISRG,europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer several late season earning report whip action bell carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain
749,ISRG,share abbott laboratory be fraction midday trading wednesday medical product giant deliver mixed earning report seek reassure investor chinese nutritional business abbott say profit rise vs year earlier quarter cent share beating analyst consensus cent sale come bit expectation
750,ISRG,dividend hunter be find pleasant surprise base company offer fatter yield find economy flirt recession
751,ISRG,such company bt group bt pay dividend reflect annualize return london base bt group telecom mainstay have storied history former british telecom
752,ISRG,long british government act post office consolidated group fledgling telegraph company rename new entity british
753,ISRG,manage solution account bt group revenue fiscal year end march phone call line make
754,ISRG,other segment include convergence conveyance circuit carrier transit other account revenue last year
755,ISRG,bt group break flat base dec now stand buy point
756,ISRG,be mislead bt group be slow move stock solid slow growth company base slow growth economy flat base bt group not be significant say intuitive surgical isrg
757,ISRG,perhaps more importantly bt group be rise week line have touch twice flat base trading be attractively tight
758,ISRG,bt group end day just high date back july
759,ISRG,company ep gain have be low accelerate bt report earning gain march end ensue release show gain
760,ISRG,revenue rise september quarter end quarter streak sale shrinkage
761,ISRG,institution be leave fingerprint buy bt group include stock ratio accumulation distribution rating
762,ISRG,be concern bt group long term debt shareholder equity ratio stand lot even industry rely leverage
763,ISRG,bt group nyse list adr have average daily trading volume just
764,ISRG,primary list london stock exchange show average volume share adr reflect london share dividend hunter be find pleasant surprise base company offer fatter yield find economy flirt recession such company bt group bt pay dividend reflect annualize return london base bt group telecom mainstay have storied history former british telecom long british government act post office consolidated group fledgling telegraph company rename new entity british manage solution account bt group revenue fiscal year end march phone call line make other segment include convergence conveyance circuit carrier transit other account revenue last year bt group break flat base dec now stand buy point be mislead bt group be slow move stock solid slow growth company base slow growth economy flat base bt group not be significant say intuitive surgical isrg perhaps more importantly bt group be rise week line have touch twice flat base trading be attractively tight bt group end day just high date back july company ep gain have be low accelerate bt report earning gain march end ensue release show gain revenue rise september quarter end quarter streak sale shrinkage institution be leave fingerprint buy bt group include stock ratio accumulation distribution rating be concern bt group long term debt shareholder equity ratio stand lot even industry rely leverage bt group nyse list adr have average daily trading volume just primary list london stock exchange show average volume share adr reflect london share
765,ISRG,major average rise modestly tuesday climb fourth straight day earning season get better expect start
766,ISRG,lead gain follow nasdaq advance dow jone industrial average increase
767,ISRG,volume stock market today be nyse nasdaq compare monday accord preliminary figure turnover have be lackluster market streak
768,ISRG,footwear maker wolverine worldwide www jump new high strong volume quarterly profit easily beat expectation
769,ISRG,homeaway away online market vacation rental end more double average daily volume stock be buy point cup handle base putt upper end buy area
770,ISRG,company be due report second quarter earning july profit be expect rise cent share
771,ISRG,oceaneering international oii rise new week high heavy volume provider service product offshore oil natural gas industry report quarterly result july close street expect earning grow cent share year basis revenue be expect advance
772,ISRG,blue chip be mostly lead caterpillar cat maker construction mining equipment pop moderately higher volume retook slide day move average
773,ISRG,downside intuitive surgical isrg plunge massive volume maker davinci surgical robot slash second quarter sale guidance
774,ISRG,yum brand yum fastenal fast be company due report earning wednesday
775,ISRG,economic datum set release wednesday include mortgage banker association mortgage application index week july wholesale inventory crude oil inventory week july federal reserve also release minute june meeting major average rise modestly tuesday climb fourth straight day earning season get better expect start lead gain follow nasdaq advance dow jone industrial average increase volume stock market today be nyse nasdaq compare monday accord preliminary figure turnover have be lackluster market streak footwear maker wolverine worldwide www jump new high strong volume quarterly profit easily beat expectation homeaway away online market vacation rental end more double average daily volume stock be buy point cup handle base putt upper end buy area company be due report second quarter earning july profit be expect rise cent share oceaneering international oii rise new week high heavy volume provider service product offshore oil natural gas industry report quarterly result july close street expect earning grow cent share year basis revenue be expect advance blue chip be mostly lead caterpillar cat maker construction mining equipment pop moderately higher volume retook slide day move average downside intuitive surgical isrg plunge massive volume maker davinci surgical robot slash second quarter sale guidance yum brand yum fastenal fast be company due report earning wednesday economic datum set release wednesday include mortgage banker association mortgage application index week july wholesale inventory crude oil inventory week july federal reserve also release minute june meeting
776,ISRG,buyer remain control early tuesday optimism continue grow second quarter earning season lead way nasdaq dow jone industrial average add be just potential resistance level resistance nasdaq be dow nasdaq be
777,ISRG,head shoulder pattern late stage base failure stock etch third chart pattern give trader opportunity capture gold downside pattern do not necessarily show former market winner top make huge decline do appear not only get opportunity
778,ISRG,stock future point sharply higher ahead thursday open dollar fall overseas market show firm gain dow future be point slightly earlier high future hold point gain nasdaq future be point ahead large portion action stock market today be response
779,ISRG,mom have tell never judge person look do stock
780,ISRG,investor be discriminate basis be shape many case be bad bring other sell signal
781,ISRG,just stock strong fundamental shape base doesn mean automatic buy still have pore stock chart decipher good bad price volume action
782,ISRG,pitfall base be shape appearance look good action stock stage fast recovery selling sometimes type action be akin be too fast too furious be not healthy
783,ISRG,shape basis don allow stock go more natural correction sharp pullback good see stock consolidate week wear remain weak holder create better foundation result shape pattern
784,ISRG,cup cup handle base be short week respectively basis biggest stock market winner have take month more form qualcomm qcom clear month cup handle january stage astronomical run
785,ISRG,sunpower spwr blast month cup handle pattern more quadruple top
786,ISRG,sometimes shape base stock fall hard couple week then rally couple week gain new high ground fast recovery new high be sell signal mean stock be top
787,ISRG,time pullback send stock week move average typically heavy volume week week sell signal generally occur long uptrend
788,ISRG,keep watch variation sell signal sometimes be week follow week new high
789,ISRG,late october intuitive surgical isrg fall straight week find support week move average lead maker robotic surgical system then rise week row result faulty shape base
790,ISRG,good time didn last intuitive surgical soon reversed lower slump next few week get support week line mom have tell never judge person look do stock investor be discriminate basis be shape many case be bad bring other sell signal just stock strong fundamental shape base doesn mean automatic buy still have pore stock chart decipher good bad price volume action pitfall base be shape appearance look good action stock stage fast recovery selling sometimes type action be akin be too fast too furious be not healthy shape basis don allow stock go more natural correction sharp pullback good see stock consolidate week wear remain weak holder create better foundation result shape pattern cup cup handle base be short week respectively basis biggest stock market winner have take month more form qualcomm qcom clear month cup handle january stage astronomical run sunpower spwr blast month cup handle pattern more quadruple top sometimes shape base stock fall hard couple week then rally couple week gain new high ground fast recovery new high be sell signal mean stock be top time pullback send stock week move average typically heavy volume week week sell signal generally occur long uptrend keep watch variation sell signal sometimes be week follow week new high late october intuitive surgical isrg fall straight week find support week move average lead maker robotic surgical system then rise week row result faulty shape base good time didn last intuitive surgical soon reversed lower slump next few week get support week line
791,ISRG,orthodontic specialist align technology algn be selling hard wednesday ahead hour report afternoon trading
792,ISRG,be news company jmp security analyst haresco tell ibd email other medtech company have report week such intuitive surgical isrg tuesday have be report massive head wind europe
793,ISRG,quarter be typically soft investor fear demand aligner still expect be strong not be able fully offset sequential drop order europe haresco write
794,ISRG,align revenue come outside mostly europe
795,ISRG,related align tech profit sale growth see slow orthodontic specialist align technology algn be selling hard wednesday ahead hour report afternoon trading be news company jmp security analyst haresco tell ibd email other medtech company have report week such intuitive surgical isrg tuesday have be report massive head wind europe quarter be typically soft investor fear demand aligner still expect be strong not be able fully offset sequential drop order europe haresco write align revenue come outside mostly europe related align tech profit sale growth see slow
796,ISRG,buy thinly trade stock generally isn good idea lack liquidity make hard big player quickly unwind build significant position quality fund seldom buy such stock exception however happen penske automotive group pag trade share daily figure not be thin penske be high price stock intuitive surgical isrg example trade less share daily however share price intuitive be call thin penske share price neighborhood qualify thin yet least quality fund have be build position third quarter fidelity contrafund have add position past quarters penske own operate franchised car dealership puerto rico internationally collision repair center international dealership be primarily penske also have dealership germany italy sale be outside unite state penske doesn hedge currency fluctuation tuesday penske report acquire bmw mini dealership ontario calif move add annual revenue customer base be mostly upscale third revenue be tie premium brand such porsche audi bmw mercede benz penske grow earning last year revenue expand street expect ep pop year revenue growth result be report oct et analyst expect earning advance sale gain return equity be last year third year row minimum roe associate elite stock penske roe be penske pay quarterly dividend cent share represent annualize yield february company suspend dividend dividend be reinstate mid
797,ISRG,stock whittle away moderate earning loss late friday morning trade remain quiet sharply lower vs day level
798,ISRG,nasdaq be less apiece dow jone industrial average be camp loss
799,ISRG,decline be broad https www investor com stock market today industry track ibd post loss morning trade
800,ISRG,stock infoblox blox continue stake morning high ground deliver fiscal third quarter result
801,ISRG,retailer sear holding shld abercrombie fitch anf be morning hardest hit more respectively
802,ISRG,intuitive surgical isrg climb heavy trade washington state jury thursday clear company charge have be negligent training physician later link patient death company face additional suit tie injury allegedly link robotic surgical system
803,ISRG,stock have be trading bottom consolidation begin february friday move regain support stock week move average left share still face resistance week line
804,ISRG,titan machinery titn tank huge trade lower first quarter guidance robert baird downgrade stock neutral outperform share retailer farm construction equipment have be unravele february be now deep critical level support
805,ISRG,overseas europe market whittle away loss rolled close cac paris be frankfurt dax be ftse london have slip stock whittle away moderate earning loss late friday morning trade remain quiet sharply lower vs day level nasdaq be less apiece dow jone industrial average be camp loss decline be broad https www investor com stock market today industry track ibd post loss morning trade stock infoblox blox continue stake morning high ground deliver fiscal third quarter result retailer sear holding shld abercrombie fitch anf be morning hardest hit more respectively intuitive surgical isrg climb heavy trade washington state jury thursday clear company charge have be negligent training physician later link patient death company face additional suit tie injury allegedly link robotic surgical system stock have be trading bottom consolidation begin february friday move regain support stock week move average left share still face resistance week line titan machinery titn tank huge trade lower first quarter guidance robert baird downgrade stock neutral outperform share retailer farm construction equipment have be unravele february be now deep critical level support overseas europe market whittle away loss rolled close cac paris be frankfurt dax be ftse london have slip
806,ISRG,most new exchange trade fund introduce stock market year be just different version exist index handful be truly original number new etfs year be slightly less last year etfs debut here look most novel concept caveat
807,ISRG,stock hold slight loss early afternoon action friday have climb session lows hit latest consumer confidence report
808,ISRG,dow jone industrial average fall be pace end day winning streak nasdaq shed fall trade less time peak hit intraday oct
809,ISRG,week main index be pace deliver gain volume stock market today remain sharply higher board boost quadruple witching expiration option future contract
810,ISRG,raft economic report have come friday most notably weaker expect figure university michigan consumer sentiment index march read be well forecast accord econoday
811,ISRG,read new york state manufacturing also miss expectation industrial production datum beat forecast addition consumer price index rise more expect core price match forecast
812,ISRG,highly rate stock meritage home mth jump heavy turnover hit new multiyear high clear flat base buy point arizona base company have ibd composite rating best possible
813,ISRG,earning front hibbett sport hibb jump fourth quarter earning squeak forecast revenue meet analyst view sporting good chain provide full year guidance line expectation day gain have lift thinly trade stock day line support continue work consolidation begin august
814,ISRG,ulta beauty ulta dive deliver fourth quarter result late thursday earning revenue be better expect same store sale growth slow management give disappointing sale earning guidance ceo chuck rubin resign mid february send share tumble far key level support
815,ISRG,also downside intuitive surgical isrg tumble handful analyst have ramp rating stock same time company response thursday do little ease concern federal review intuitive robotic surgical equipment share have be correct hard week stock hold slight loss early afternoon action friday have climb session lows hit latest consumer confidence report dow jone industrial average fall be pace end day winning streak nasdaq shed fall trade less time peak hit intraday oct week main index be pace deliver gain volume stock market today remain sharply higher board boost quadruple witching expiration option future contract raft economic report have come friday most notably weaker expect figure university michigan consumer sentiment index march read be well forecast accord econoday read new york state manufacturing also miss expectation industrial production datum beat forecast addition consumer price index rise more expect core price match forecast highly rate stock meritage home mth jump heavy turnover hit new multiyear high clear flat base buy point arizona base company have ibd composite rating best possible earning front hibbett sport hibb jump fourth quarter earning squeak forecast revenue meet analyst view sporting good chain provide full year guidance line expectation day gain have lift thinly trade stock day line support continue work consolidation begin august ulta beauty ulta dive deliver fourth quarter result late thursday earning revenue be better expect same store sale growth slow management give disappointing sale earning guidance ceo chuck rubin resign mid february send share tumble far key level support also downside intuitive surgical isrg tumble handful analyst have ramp rating stock same time company response thursday do little ease concern federal review intuitive robotic surgical equipment share have be correct hard week
816,ISRG,stock be mixed little hour left go thursday session day confirm new uptrend gain higher volume
817,ISRG,dow jone industrial average fall weigh big sale miss ibm ibm late wednesday share slump heavy volume
818,ISRG,nasdaq add preliminary datum show nyse volume tracking lower wednesday nasdaq volume rise
819,ISRG,economic news weekly jobless claim fall less expect market didn seem mind claim fall economist expect bigger drop
820,ISRG,stock market today ebay ebay slump payment commerce giant report disappointing resultsand give weak guidance due uncertainty holiday sale
821,ISRG,elsewhere sandisk sndk jump chipmaker report strong earning give equally strong guidance company make flash memory product used cellphone tablet digital camera recent cup handle be sluggish first gain traction today
822,ISRG,new york mercantile exchange gold surge optimism fed delay taper recent government shutdown december contract surge settle ounce fed next meeting be schedule oct
823,ISRG,hour session be busy again earning avalanche continue close watch profit report chipotle grill cmg la vegas sand lvs google goog intuitive surgical isrg
824,ISRG,intuitive surgical have be rally mode ahead result ever william blair make positive comment oct share fall fractionally ahead result stock remain technical downtrend profit be see fall share sale stock be mixed little hour left go thursday session day confirm new uptrend gain higher volume dow jone industrial average fall weigh big sale miss ibm ibm late wednesday share slump heavy volume nasdaq add preliminary datum show nyse volume tracking lower wednesday nasdaq volume rise economic news weekly jobless claim fall less expect market didn seem mind claim fall economist expect bigger drop stock market today ebay ebay slump payment commerce giant report disappointing resultsand give weak guidance due uncertainty holiday sale elsewhere sandisk sndk jump chipmaker report strong earning give equally strong guidance company make flash memory product used cellphone tablet digital camera recent cup handle be sluggish first gain traction today new york mercantile exchange gold surge optimism fed delay taper recent government shutdown december contract surge settle ounce fed next meeting be schedule oct hour session be busy again earning avalanche continue close watch profit report chipotle grill cmg la vegas sand lvs google goog intuitive surgical isrg intuitive surgical have be rally mode ahead result ever william blair make positive comment oct share fall fractionally ahead result stock remain technical downtrend profit be see fall share sale
825,ISRG,stock turn impressive performance thursday undeterred smaller expect drop weekly jobless claim disappointing earning dow component ibm ibm ebay ebay dow jone industrial average fall fractionally close high session blue chip index be much rise nasdaq
826,ISRG,amazon com ceo jeff bezos audacious goal day deliver customer order automate drone have inspire investor rethink science fiction science possibility
827,ISRG,global marketplace be past tip point adopt robotic automation incorporation technology now be only begin kevin lane chief investment officer fusion analytic investment partner new york tell ibd
828,ISRG,help explain robo stox global robotic automation index etf robo rapid growth more asset just month debut stock market
829,ISRG,robo have return inception oct vs spdr spy market correction hasn be kind robo holding robo be year date spy have shed
830,ISRG,etf create dalla base robo stox llc contain foreign company engage develop industrial health care robotic printing system consumer robotic related software part
831,ISRG,many year only heavy industrial business car manufacturer used robot automation system day robotic machine be revolutionize wide variety industry lane write apple aapl plan invest robotic automation google goog have open robotic division acquire company build business
832,ISRG,robo have asset invest stock japan germany taiwan switzerland micro exposure other country portfolio weight asset bellwether stock primary player industry bellwether company get small amount sale robotic
833,ISRG,bellwether stock be weight rest be weight bellwether be system ddd aerovironment avav cognex cgnx faro technology faro intuitive surgical isrg irobot irbt lincoln electric leco mako surgical mako oceaneering international oii rockwell automation rok
834,ISRG,portfolio be rebalance reconstitute quarterly charge annual management fee vs etfs average
835,ISRG,holding most buzz
836,ISRG,much promise come much risk share system have tumble year date maker revolutionary printer spit dimensional object cut earning guidance fourth quarter owing heavy investment manufacturing marketing weak industrial consumer demand
837,ISRG,credit suisse analyst lower price target rating stock neutral earlier month silver line be system highlighted investment market share gain drive organic growth least next couple year credit suisse analyst shaffer colleague write client note feb
838,ISRG,faster clip rival stratasys ssys expect see organic revenue growth
839,ISRG,capital iq other hand maintain buy rating expectation system backlog nearly double come year thank higher consumer health care demand
840,ISRG,rockwell automation year date beat fiscal earning sale forecast raise guidance electrical equipment firm repurchase share still have buyback program
841,ISRG,capital iq issue strong sell rating intuitive surgical maker da vinci surgical system medical instrument feb note share have climb year date negative press hospital capital spending constraint health care reform law freed capacity exist robot continue pressure intuitive system sale capital iq analyst phillip seligman write amazon com ceo jeff bezos audacious goal day deliver customer order automate drone have inspire investor rethink science fiction science possibility global marketplace be past tip point adopt robotic automation incorporation technology now be only begin kevin lane chief investment officer fusion analytic investment partner new york tell ibd help explain robo stox global robotic automation index etf robo rapid growth more asset just month debut stock market robo have return inception oct vs spdr spy market correction hasn be kind robo holding robo be year date spy have shed etf create dalla base robo stox llc contain foreign company engage develop industrial health care robotic printing system consumer robotic related software part many year only heavy industrial business car manufacturer used robot automation system day robotic machine be revolutionize wide variety industry lane write apple aapl plan invest robotic automation google goog have open robotic division acquire company build business robo have asset invest stock japan germany taiwan switzerland micro exposure other country portfolio weight asset bellwether stock primary player industry bellwether company get small amount sale robotic bellwether stock be weight rest be weight bellwether be system ddd aerovironment avav cognex cgnx faro technology faro intuitive surgical isrg irobot irbt lincoln electric leco mako surgical mako oceaneering international oii rockwell automation rok portfolio be rebalance reconstitute quarterly charge annual management fee vs etfs average holding most much promise come much risk share system have tumble year date maker revolutionary printer spit dimensional object cut earning guidance fourth quarter owing heavy investment manufacturing marketing weak industrial consumer demand credit suisse analyst lower price target rating stock neutral earlier month silver line be system highlighted investment market share gain drive organic growth least next couple year credit suisse analyst shaffer colleague write client note feb faster clip rival stratasys ssys expect see organic revenue growth capital iq other hand maintain buy rating expectation system backlog nearly double come year thank higher consumer health care demand rockwell automation year date beat fiscal earning sale forecast raise guidance electrical equipment firm repurchase share still have buyback program capital iq issue strong sell rating intuitive surgical maker da vinci surgical system medical instrument feb note share have climb year date negative press hospital capital spending constraint health care reform law freed capacity exist robot continue pressure intuitive system sale capital iq analyst phillip seligman write
842,ISRG,strong earning google goog late thursday fuel big tech rally friday nasdaq hit multus year high extend gain thursday time high nasdaq jump add dow jone industrial average lag gain option expire today usually result higher volume preliminary datum
843,ISRG,be key frank caruso investment strategy
844,ISRG,first lead manager large cap growth direct team seek call dynamic gap
845,ISRG,gap be big difference fast caruso team expect stock earning grow wall street consensus expectation
846,ISRG,second key be caruso have team look gap year
847,ISRG,caruso be adamant avoid focus term
848,ISRG,approach have fund year nov top large cap growth peer averaged be
849,ISRG,past year fund average annual gain be vs peer group big cap bogey
850,ISRG,caruso age discuss investment process ibd office manhattan
851,ISRG,ibd do search lead stock differ other growth investor
852,ISRG,caruso think equity generally term combination growth capital return form dividend share buyback support valuation equity long period
853,ISRG,take long duration approach investment opportunity most growth investor be dangerously focuse moment growth short term try exploit phenomenon not lot analytical work be be do year
854,ISRG,ibd give example show tack work please
855,ISRG,caruso spring chipotle grill cmg miss couple month sale estimate stock be crushed go share research let be marginal buyer lurch be confident caliber management buy distressed stock great long term franchise july later begin execute sale improve add position begin october price
856,ISRG,ibd be cognizant technology solution ctsh example add big chunk stake few quarters
857,ISRG,caruso have great core competency technology be increasingly desire client cloud mobility be grow high teen low year have debt have excess cash
858,ISRG,putt strong quarter get catch immigration debate rely lot foreign visa conduct business stock go heartbeat
859,ISRG,be opportunity reload spring start initiate stock break high meet cognizant manager hour left convince still have great business plan stock moved higher immigration debate percolate buy now
860,ISRG,ibd be look investment opportunity create prospect federal reserve taper bond buy
861,ISRG,caruso don try overthink macro environment so march order analyst be focus company fundamental
862,ISRG,fed chairman ben bernanke start taper discussion have underperform broad market value particular prior month growth security start do well so market response taper seem have catalyze shift margin growth stock
863,ISRG,ibd be growth stock tend have more foreign exposure
864,ISRG,caruso yes growth stock generally have little more exposure foreign earning growth value stock have more exposure let say earning be fuel federal reserve stimulus step be speculation part discussion regard taper auger well future growth stock performance
865,ISRG,ibd computer service software system be largest category holding asset do expect good thing
866,ISRG,caruso cognizant be close weighting portfolio be build company google goog think priceline pcln service company person think technology company
867,ISRG,ansys anss be engineering simulation software company person think company benefit innovation
868,ISRG,old day have team engineer design new product build mockup then software run calculation test stress characteristic be tail end innovation take week run simulation
869,ISRG,today run million simulation even get real engineering side thing
870,ISRG,ibd biotech be second largest industry group asset be focuse
871,ISRG,caruso biotech come very long severe stock price now re see far greater pipeline productivity emerge couple leader ve center investment celgene celg biogen biib gilead gild be different area disease management
872,ISRG,biogen have be mostly multiple sclerosis story ve come market new oral medicine call tecfidera have experience most unbelievably successful product launch pharmacology history investor have be so focuse ms haven paid attention product be development
873,ISRG,be hemophilia product eloctate expect launch mid next year have opportunity take share baxter bax drive growth upside left tecfidera long time come
874,ISRG,gilead be basically hiv hepatitis story have new product launch horizon expect gilead remain dominant hiv midterm hepatitis portfolio be start contribute meaningfully corporate growth
875,ISRG,celgene be multiple myeloma story cancer story see expand use marketplace
876,ISRG,company be come pretty conservative valuation kind growth envision experience next couple year
877,ISRG,ibd do trim facebook fb stake recently not have foresee pullback begin mid october
878,ISRG,caruso stock have amazing run report earning demonstrated great acceleration mobility business person get excited stock double short time
879,ISRG,make meaningful reduction exposure euphoria have become close portfolio so cut position roughly half be roughly today
880,ISRG,fall stock have go day report earning then management talk need spend more investing person product lot highly value high growth company have see similar price correction
881,ISRG,comfortable own stock right price re get back
882,ISRG,ibd michael kor kor be relatively new be concern earning share growth have sharply decelerate recent quarters
883,ISRG,caruso re always concern decelerate growth rate kor decline be less extraordinary level still better lot company stock be reasonably value kind growth envision have opportunity europe elsewhere overseas kor be see differentiate here overseas
884,ISRG,ibd surprise starbucks sbux accelerate ep growth
885,ISRG,caruso re just unbelievable company re few have be able consistently reinvent ve do brilliant job expand product offering small footprint store be first market used new technology connect customer reward program be best class
886,ISRG,ibd precision castpart pcp be year ve do trimming be concern
887,ISRG,caruso be persistent acquire business let leverage own infrastructure re important supplier boee ba generate content boee ship part reduction be own company sell probably be boee precision have lag boee so precision have more upside
888,ISRG,ibd intuitive surgical isrg be way year yet ve add position recent quarters be still optimistic
889,ISRG,caruso have be most disappointing stock portfolio interest have be center uniqueness business be competitor scale robotic surgery be here stay continue grow
890,ISRG,procedure growth continue expand midteen clip year year issue execution relate installation sale have slow especially
891,ISRG,expect couple more tough quarters procedure growth continue area competition unbelievably high margin big share buyback debt hopefully be contrary growth stock recover
892,ISRG,ibd be concern linkedin lnkd ep growth have slow quarters
893,ISRG,caruso ve bring new advertising product mobile device market help growth rate re accelerate next year do facebook make decent sale summer market euphoria stock re more interested find price re engage linkedin facebook
894,ISRG,think core hold business tough replicate due network effect linkedin manager think business want be profitable good business be richly value grow so get entry trim point right be important
895,ISRG,ibd noble energy nbl ep growth have soar past quarters tumble crude oil price have douse energy producer stock spark lately stock have pull back oct stick
896,ISRG,caruso noble be best position energy company way frac inventory overseas israel africa have unbelievable reserve be really good operator really focuse create value
897,ISRG,energy firm be more volatile typically engage company asset be special
898,ISRG,ve see reduction underlie commodity price so welcome opportunity buy back make larger portfolio not quite point start buy back
899,ISRG,ibd biggest change ve make take fund helm february
900,ISRG,caruso basically perception growth be link company ability create long term value so focus be further forward many other investor focus be more economic business profitability hunt earning growth be sometimes very episodic re still look opportunity large cap growth re focuse longer term
901,ISRG,ibd be fund prior time horizon
902,ISRG,caruso say be probably more consistent most growth manager annual turnover growth portfolio be often re try do closer want great franchise have ability very long time tell analyst want understand company be competitively differentiate don want spending time try anticipate bad business be good stock be key frank caruso investment strategy first lead manager large cap growth direct team seek call dynamic gap gap be big difference fast caruso team expect stock earning grow wall street consensus expectation second key be caruso have team look gap year caruso be adamant avoid focus term approach have fund year nov top large cap growth peer averaged be past year fund average annual gain be vs peer group big cap bogey caruso age discuss investment process ibd office manhattan ibd do search lead stock differ other growth investor caruso think equity generally term combination growth capital return form dividend share buyback support valuation equity long period take long duration approach investment opportunity most growth investor be dangerously focuse moment growth short term try exploit phenomenon not lot analytical work be be do year ibd give example show tack work please caruso spring chipotle grill cmg miss couple month sale estimate stock be crushed go share research let be marginal buyer lurch be confident caliber management buy distressed stock great long term franchise july later begin execute sale improve add position begin october price ibd be cognizant technology solution ctsh example add big chunk stake few quarters caruso have great core competency technology be increasingly desire client cloud mobility be grow high teen low year have debt have excess cash putt strong quarter get catch immigration debate rely lot foreign visa conduct business stock go heartbeat be opportunity reload spring start initiate stock break high meet cognizant manager hour left convince still have great business plan stock moved higher immigration debate percolate buy now ibd be look investment opportunity create prospect federal reserve taper bond buy caruso don try overthink macro environment so march order analyst be focus company fundamental fed chairman ben bernanke start taper discussion have underperform broad market value particular prior month growth security start do well so market response taper seem have catalyze shift margin growth stock ibd be growth stock tend have more foreign exposure caruso yes growth stock generally have little more exposure foreign earning growth value stock have more exposure let say earning be fuel federal reserve stimulus step be speculation part discussion regard taper auger well future growth stock performance ibd computer service software system be largest category holding asset do expect good thing caruso cognizant be close weighting portfolio be build company google goog think priceline pcln service company person think technology company ansys anss be engineering simulation software company person think company benefit innovation old day have team engineer design new product build mockup then software run calculation test stress characteristic be tail end innovation take week run simulation today run million simulation even get real engineering side thing ibd biotech be second largest industry group asset be focuse caruso biotech come very long severe stock price now re see far greater pipeline productivity emerge couple leader ve center investment celgene celg biogen biib gilead gild be different area disease management biogen have be mostly multiple sclerosis story ve come market new oral medicine call tecfidera have experience most unbelievably successful product launch pharmacology history investor have be so focuse ms haven paid attention product be development be hemophilia product eloctate expect launch mid next year have opportunity take share baxter bax drive growth upside left tecfidera long time come gilead be basically hiv hepatitis story have new product launch horizon expect gilead remain dominant hiv midterm hepatitis portfolio be start contribute meaningfully corporate growth celgene be multiple myeloma story cancer story see expand use marketplace company be come pretty conservative valuation kind growth envision experience next couple year ibd do trim facebook fb stake recently not have foresee pullback begin mid october caruso stock have amazing run report earning demonstrated great acceleration mobility business person get excited stock double short time make meaningful reduction exposure euphoria have become close portfolio so cut position roughly half be roughly today fall stock have go day report earning then management talk need spend more investing person product lot highly value high growth company have see similar price correction comfortable own stock right price re get back ibd michael kor kor be relatively new be concern earning share growth have sharply decelerate recent quarters caruso re always concern decelerate growth rate kor decline be less extraordinary level still better lot company stock be reasonably value kind growth envision have opportunity europe elsewhere overseas kor be see differentiate here overseas ibd surprise starbucks sbux accelerate ep growth caruso re just unbelievable company re few have be able consistently reinvent ve do brilliant job expand product offering small footprint store be first market used new technology connect customer reward program be best class ibd precision castpart pcp be year ve do trimming be concern caruso be persistent acquire business let leverage own infrastructure re important supplier boee ba generate content boee ship part reduction be own company sell probably be boee precision have lag boee so precision have more upside ibd intuitive surgical isrg be way year yet ve add position recent quarters be still optimistic caruso have be most disappointing stock portfolio interest have be center uniqueness business be competitor scale robotic surgery be here stay continue grow procedure growth continue expand midteen clip year year issue execution relate installation sale have slow especially expect couple more tough quarters procedure growth continue area competition unbelievably high margin big share buyback debt hopefully be contrary growth stock recover ibd be concern linkedin lnkd ep growth have slow quarters caruso ve bring new advertising product mobile device market help growth rate re accelerate next year do facebook make decent sale summer market euphoria stock re more interested find price re engage linkedin facebook think core hold business tough replicate due network effect linkedin manager think business want be profitable good business be richly value grow so get entry trim point right be important ibd noble energy nbl ep growth have soar past quarters tumble crude oil price have douse energy producer stock spark lately stock have pull back oct stick caruso noble be best position energy company way frac inventory overseas israel africa have unbelievable reserve be really good operator really focuse create value energy firm be more volatile typically engage company asset be special ve see reduction underlie commodity price so welcome opportunity buy back make larger portfolio not quite point start buy back ibd biggest change ve make take fund helm february caruso basically perception growth be link company ability create long term value so focus be further forward many other investor focus be more economic business profitability hunt earning growth be sometimes very episodic re still look opportunity large cap growth re focuse longer term ibd be fund prior time horizon caruso say be probably more consistent most growth manager annual turnover growth portfolio be often re try do closer want great franchise have ability very long time tell analyst want understand company be competitively differentiate don want spending time try anticipate bad business be good stock
903,ISRG,stock end mixed wednesday investor mulled conflict earning report ahead key jobless claim housing datum due thursday nasdaq rise fresh year high edge dow jone industrial average lose lead ibm ibm drop follow mixed quarterly result volume be lower board stock market today accord preliminary datum online marketplace ebay ebay be sharply hour follow fourth quarter earning report stock have reversed higher heavy volume regular session ahead announcement close week high netflix nflx also soar hour session announce quarterly result show strong subscriber growth stock be try stem week slide have fall week line network ffiv jump post session trading maker network gear release quarterly result downside american eagle outfitter aeo fall modestly hour follow resignation ceo robert hanson company chairman jay schottenstein be name interim ceo mcdonald mcd intuitive surgical isrg starbucks sbux precision castpart pcp be company due announce quarterly earning thursday economic front labor department be schedule release jobless claim datum week jan government also release datum exist home sale december conference board release index lead economic indicator december
904,ISRG,medical giant johnson johnson jnj beat analyst expectation second quarter raise outlook company didn get much bump already elevated share price company early tuesday say sale rise year earlier quarter more analyst consensus accord thomson reuter
905,ISRG,orthopedic giant stryker say wednesday buy mako surgical mako make expensive bet nascent field robotic surgery stryker syk agree pay share mako nearly double tuesday close price company press release stryker ceo kevin lobo explain mako technology call rio system
906,ISRG,stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier
907,ISRG,nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline
908,ISRG,stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear
909,ISRG,friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week
910,ISRG,economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm
911,ISRG,half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer
912,ISRG,several late season earning report whip action bell
913,ISRG,carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june
914,ISRG,homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august
915,ISRG,handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss
916,ISRG,leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point
917,ISRG,qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction
918,ISRG,oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week
919,ISRG,overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain
920,ISRG,europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer several late season earning report whip action bell carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain
921,ISRG,major average continue trade tight range little more hour remain monday session nasdaq dow jone industrial average rise preliminary datum show nyse tracking lighter friday nasdaq volume be pace come close friday level stock market
922,ISRG,share intuitive surgical isrg gap tuesday morning month low analyst downgrade stock follow company warning
923,ISRG,late monday maker da vinci surgical system announce preliminary result include drop system revenue be partly offset grow revenue instrument accessory service overall sale fall woefully short analyst consensus number
924,ISRG,decline system sale be impact several factor include other thing increase economic pressure hospital turn cause defer da vinci system purchase moderate growth benign gynecologic procedure say company press release
925,ISRG,goldman sachs jmp security canaccord genuity downgrade stock neutral equivalent
926,ISRG,capital equipment business look be face material incremental head wind goldman analyst david roman write report tuesday addition management commentary payor be start encourage more conservative care well treatment outpatient setting be new dynamic have not previously contemplated thesis stock
927,ISRG,negative comment hospital spending have push several other stock ibd medical system group heavy volume stock market tuesday morning trading varian medical system var be more be hologic holx carefusion cfn sell mainly exclusively hospital share intuitive surgical isrg gap tuesday morning month low analyst downgrade stock follow company warning late monday maker da vinci surgical system announce preliminary result include drop system revenue be partly offset grow revenue instrument accessory service overall sale fall woefully short analyst consensus number decline system sale be impact several factor include other thing increase economic pressure hospital turn cause defer da vinci system purchase moderate growth benign gynecologic procedure say company press release goldman sachs jmp security canaccord genuity downgrade stock neutral equivalent capital equipment business look be face material incremental head wind goldman analyst david roman write report tuesday addition management commentary payor be start encourage more conservative care well treatment outpatient setting be new dynamic have not previously contemplated thesis stock negative comment hospital spending have push several other stock ibd medical system group heavy volume stock market tuesday morning trading varian medical system var be more be hologic holx carefusion cfn sell mainly exclusively hospital
928,ISRG,abbott free report recently announce result amplatzer amulet left atrial appendage laa occlusion device bid fortify core structural heart business datum be present europcr annual meeting european association percutaneous cardiovascular intervention eapci paris further result be publish be amplatzer amulet occlusion device amplatzer amulet occluder be advanced minimally invasive laa occlusion device design seal laa person suffering valvular atrial fibrillation time efficient manner device block laa open reduce chance blood clot reach bloodstream cause stroke amplatzer amulet device come several size cater several type complex patient anatomy moreover be claim be used patient blood thinner medication be not very safe option be contraindicate notably amplatzer amulet device be currently investigational device unite state study amplatzer amulet observational post market study have valvular af patient enrolled worldwide amulet device be effectively implanted enrolled patient follow period month post device implant assessment notably result year follow demonstrate treatment amplatzer amulet have lower risk ischemic stroke also reduce chance ischemic stroke transient ischemic attack systemic embolism glimpse structural heart structural heart business have maintain impressive top line performance last report quarter sale segment rise report basis notably structural heart business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mr company recently announce encourage result global study tendyne transcatheter mitral valve replacement tmvr system march company announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip ministry health labour welfare mhlw approve mitraclip system japan last november further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart market prospectsabbott strategy gain traction structural heart segment seem be align datum provide ally market research company report global atrial fibrillation market be estimate reach worth cagr company almost person suffer atrial fibrillation globally share price have be gain investor confidence consistently positive result past month stock have outperformed industry stock have gain comparison industry zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
929,ISRG,share merit medical system inc mmsi free report have gain release first quarter result apr rally be backed better expect earning share ep revenue growth product line strong performance geography past month company have gain significantly outperform industry decline let delve deep release company report adjust ep cent beat zack consensus estimate earning rise prior year quarter revenue detailin first quarter worldwide revenue totale report basis beating zack consensus estimate constant currency cc revenue come revenue inched cc meanwhile core revenue gross cc management organic growth be mainly drive catheter endoscopy inflation device sale moreover sale unite state china asia pacific europe middle east africa contribute overall growth merit medical system inc price consensus ep surprise merit medical system inc price consensus ep surprise merit medical system inc quotesegmental utah base manufacturer proprietary disposable device report revenue segment cardiovascular endoscopy revenue cardiovascular segment gross significant year year basis meanwhile endoscopy sale totale year marginsin report quarter gross profit come year year gross margin be basis point bps income operation gross notably operate margin expand bps however operate expense shot year year basis rise be mainly lead surge selling general administrative expense rise guidancemerit medical do not provide guidance however buoy solid first quarter management expect solid margin improvement quarters come takemerit medical exit first quarter solid note strong sale segment geography solid organic growth buoy optimism diversify product portfolio active product be major positive new biopsy device pipeline be also encourage additionally approval company distal access sync be promising management be optimistic acquisition complete fourth quarter asset purchase becton dickinson improvement operate margin be positive flip side company decline gross margin year year rise operate expense be discourage moreover management have not issue guidance quarters ahead zack rank key picksmerit medical currently carry zack rank hold few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus mark abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be surpass consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale surpass zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
930,ISRG,quality system inc qsii free report report fourth quarter fiscal adjust earning cent share beating zack consensus estimate however adjust earning decline year year basis meanwhile share quality system have rally industry decline past month quality system also know nextgen healthcare currently carry zack rank hold revenue detailrevenue fiscal fourth quarter totale also beat zack consensus estimate revenue rise year quarter management year year booking totale fourth quarter constant currency cc notably company flagship nextgen mobile platform see best quarter so far term booking secure large client base segment detailsquality system report fiscal fourth quarter revenue follow segment total software hardware related segment register revenue worth year year upside be attribute surge software related subscription service rise management growth be drive nextgen office solution formerly know meditouch contribution analytic mobile solution quality system inc price consensus ep surprise quality system inc price consensus ep surprise quality system inc quotesupport maintenance segment see soft quarter revenue decline year revenue cycle management rcm related service revenue segment come year year basis however management rcm pipeline have solid long term prospect electronic datum interchange datum service revenue segment fall marginal professional service segment gross revenue increase whopping prior year quarter transcription revenue entrada acquisition marginsgross profit report quarter decline year year gross margin contract basis point bps operate loss be quarter operate expense shot drive surge sg selling general administrative expense totale huge year year basis however research development expense contract quarter balance sheet company exit fiscal cash cash equivalent fiscal glanceon full year basis adjust earning share come cent beat zack consensus estimate cent however earning deteriorate year full year revenue totale also beat zack consensus estimate notably revenue rise prior year figure company provide initial view fiscal revenue be project range zack consensus estimate fiscal revenue be peg lie give range adjust earning be expect cent fiscal zack consensus estimate fiscal earning be pin cent again be range takequality system exit fiscal fourth quarter solid note management foresee solid growth prospect rcm pipeline acquisition entrada eagle dream have proven accretive moreover nextgen population health analytic suite nextgen mobile platform register significant growth fourth quarter company witness solid booking growth sequential year year basis solid guidance fiscal also hold promise flip side dull performance rcm electronic datum interchange segment be major headwind moment further contract gross margin surge operate expense raise concern company expense have contract indicate reduce focus innovation quality system also be broadly expose integration risk cutthroat competition niche space add wo key picksa few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be surpass consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale surpass zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus mark look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
931,ISRG,abbott free report have be spotlight late favorable development medical device business include core structural heart division company recently announce encourage result global study tendyne transcatheter mitral valve replacement tmvr system datum be present europcr annual meeting european association percutaneous cardiovascular intervention eapci paris global study tendyne device expect register adult patient early result be base successful implantation tendyne device first patient patient enrolled study suffer symptomatic mitral regurgitation mr be not eligible open heart surgery repair replace mitral valve notably result end day demonstrated patient treat tendyne witness major reduction mitral regurgitation symptom low mortality rate further improvement symptom be assessed base new york heart association nyha grade severity kansa city cardiomyopathy questionnaire kccq tendyne device completely retrievable minimally invasive replacement option tendyne device be used treat functional degenerative mixed cause mr be treat minimally invasive valve repair open heart surgery notably tendyne device be currently clinical investigation approval europe further company plan enroll first patient pivotal trial same term glimpse structural heart businessabbott structural heart business maintain impressive top line performance last report quarter segment sale rise report basis notably structural heart business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mr march company announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip ministry health labour welfare mhlw approve mitraclip system japan last november further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart business market prospectsabbott strategy gain traction structural heart segment seem be align datum provide ally market research datum provide company report tanscatheter mitral valve repair replacement market be estimate reach worth repair replacement valf cagr company almost person age suffer moderate severe mr share price have be gain investor confidence consistently positive result past month stock have outperformed industry stock have gain comparison industry gain zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
932,ISRG,veeva system inc veev free report report first quarter fiscal adjust earning cent share bottom line beat zack consensus estimate cent improve year quarter figure total revenue be first quarter year year moreover top line surpass zack consensus estimate veeva system strong growth subscription revenue segment drive metric veeva system outperformed industry year date basis company share have gain compare favorably industry rise current level be also higher index return just stock have zack rank hold segmental detailsfirst quarter subscription service revenue be year year upside be backed stronger expect booking quarter review subscription gross margin be expand roughly basis point bps year year company momentum product line especially veeva vault continue drive growth professional service revenue rise almost quarter review service gross margin be bps prior year quarter veeva system inc price consensus ep surprise veeva system inc price consensus ep surprise veeva system inc quotemargin profit report quarter increase year year gross margin veeva system contract bps report quarter operate income be report quarter year quarter level however operate margin contract bps year quarter figure rise operate expense have keep operate margin pressure quarter regard operate expense increase report quarter research development expense increase sale marketing expense rise general administrative expense increase company provide financial guidance second quarter fiscal total revenue be expect range zack consensus estimate be peg be guidance adjust operate income be expect adjust earning share be expect band cent zack consensus estimate be peg cent be guidance fiscal total revenue be anticipate band previous range zack consensus estimate be peg lie guidance adjust earning be project previous range zack consensus estimate metric be peg lie guidance conclusionveeva system exit first quarter fiscal solid note beating zack consensus estimate count solid performance subscription revenue have be key catalyst further bid replace simple custom make datum warehouse unique industry specific datum model veeva system recently introduce veeva nitro new model commercial datum warehouse life science be encourage veeva system consistent effort product innovation launch grow global demand cloud base vault application also boost opportunity flip side high expense operational side be cause drag company margin partially dampening revenue furthermore intense competition saturating life science market be key concern volatility foreign currency exchange rate be headwind earning medtech major glancea few better rank stock broader medical space report solid earning season be boston scientific corporation bsx free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here varian medical report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis stock have zack rank buy boston scientific post adjust earning share cent first quarter year quarter tally earning also surpass zack consensus estimate cent stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
933,ISRG,intuitive surgical inc isrg free report be top perform stock medtech space grow adoption company robot base da vinci surgical system increase procedure volume be key catalyst stock have rally year time industry decline index return stock have market cap let find company maintain positive trend robot base da vinci unit drive grow prevalence minimally invasive robot assist surgery self automate home base care use quick improve patient care shift payment system value base model indicate higher adoption artificial intelligence medtech space intuitive surgical flagship da vinci surgical system be power robotic technology platform have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery da vinci system have provide minimally invasive surgery more patient worldwide company launch upgrade flagship vinci xi technology notably xi suite be design seamlessly integrate future innovation such advanced instrumentation surgical skill simulation software upgrade other advancement dynamic platform company now ship xi single site xi millimeter stapler firefly several country minimally invasive surgery be become increasingly popular help patient recover faster thereby reduce hospitalization cost notably minimally invasive surgical instrument market be project reach worth cagr market market high price da vinci system hinder widespread adoption believe overwhelming benefit minimally invasive surgery compel surgeon patient use system drive company system sale improve top line growth long run first quarter da vinci procedure grow approximately year year intuitive surgical replace da vinci surgical system first quarter company install base grow year quarter company have strong opportunity general surgery market particularly drive procedure hernia repair colorectal surgery internationally company have significant opportunity japan south korea china zack rank estimate revisionin past day zack consensus estimate earning share increase current quarter intuitive surgical sport zack rank strong buy indicate possibility outperformance term see complete list today zack rank stock here company deliver average earning surprise trail quarters also expect long term earning growth look promising intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quote other key picksa few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term earning growth rate stock sport zack rank see complete list today zack rank stock here genomic health have expect earning growth rate zack rank varian medical have project long term earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
934,ISRG,baxter international inc bax free report have be healthy growth trajectory late strategic acquisition product development bullish outlook have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment past month share baxter have grow compare industry increase current level be also higher index rise stock have market cap company next year earning growth rate be also favorable compare industry rally company deliver positive earning surprise last quarters also have long term expect earning growth rate baxter have impressive growth score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine solid zack rank strong buy hold offer best investment opportunity let find recent positive trend be sustainable solid earningsbaxter end first quarter solid note beating consensus mark earning revenue adjust earning come cent share cent prior year quarter revenue be year year constant currency cc geographically sale inched year year meanwhile international sale increase year year company deliver strong result back solid performance core renaland pharmaceutical business renal unit sale increase year year basis pharmaceutical sale rise raise guidancebuoy solid first quarter earning result baxter lift financial outlook second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent also project sale growth cc anticipate adjust earning share continue operation range full year strategic buyout have be long help baxter gain market traction recently company complete consolidation thrombin topical preveleak surgical sealant product line mallinckrodt deal be expect widen baxter surgical portfolio hemostat sealant transaction have not be accretive first quarter earning company still estimate be so buyout india base claris injectable limit have provide baxter robust portfolio generic injectable molecule currently approve unite state upward estimate revision company estimate revision trend current year have be positive past couple month analyst moved north none opposite direction earning estimate have be raise same time frame other key picksother top rank stock broader medical sector include intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys project long term earning growth make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
935,ISRG,perkinelmer inc pki free report be currently top perform stock medtech space improve price performance strong fundamental instill confidence investor therefore haven take advantage stock price appreciation yet time add portfolio company have perform impressively first quarter be likely sustain momentum upcoming period past year share perkinelmer have rally significantly outperform industry growth just past day zack consensus estimate earning share rise cent company have zack rank buy indicate possibility outperformance term let find recent positive trend sustain stock impressive performance long run make attractive pick solid exit first quarter solid note earning cent share surpass zack consensus estimate revenue inched core discovery analytical solution da segment revenue totale quarter year year organic revenue increase year year revenue diagnostic segment gross reflect year year increase also show improvement organically raise perkinelmer expect adjust earning share be significantly higher previously issue guidance company project revenue earlier issue range unfavorable foreign exchange environment act deterrent quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion broad spectrum deliver comprehensive suite scientific informatic software solution aggregate datum actionable insight automate scalable way company product consist industry lead chemdraw software electronic lab notebook include cloud base element saas offer enterprise notebook solution tibco spotfire platform scientific datum analytic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
936,ISRG,investor interested medical stock always be look find best perform company group be intuitive surgical isrg free report stock right now take look stock year date performance comparison medical peer be able answer question intuitive surgical be member medical group include different company currently sit zack sector rank zack sector rank include different group be list order best worst term average zack rank individual company sector zack rank emphasize earning estimate estimate revision find stock improve earning outlook system have long record success stock tend be track beat market next month isrg be currently sporting zack rank strong buy zack consensus estimate isrg full year earning have moved higher past quarter mean analyst sentiment be stronger stock earning outlook be improve latest available datum show isrg have return start calendar year same time medical stock have lose average mean intuitive surgical be perform better sector term year date return look more specifically isrg belong medical instrument industry include individual stock currently sit zack industry rank average group have lose average so far year meaning isrg be perform better term year date return investor interest medical stock continue track isrg stock be look continue solid performance
937,ISRG,resm inc rmd free report recently announce definitive agreement buy healthcarefirst privately hold provider software solution service home health hospice agency meeting certain customary close condition receive regulatory approval deal be expect be finalize end first quarter fiscal resm calendar however financial detail deal have be keep wrapped further transaction be expect be immaterial resm consolidated financial result buyout integration synergiesper resm healthcarefirst solution comprise electronic health record ehr software bill coding service advanced analytic complement resm wholly own subsidiary line software solution integration healthcarefirst solution resm software service saas portfolio enhance latter efficacy manage grow population provide benefit patient family agency payer glimpse saas businessresm witness year year growth revenue saas business last report quarter notably company have be actively work chronic disease management algorithms include population health model health care analytic care co ordination saas model home health home nursing hospice area company introduce new offer oasis home health hospice market notably oasis stand outcome assessment information set resm be also expand range hospital software offering acquisition software service business home health home nursing other alternative care setting believe buyout help resm solidify saas portfolio market potential resm rapidly age population grow incidence chronic condition change trend higher inclination homecare other lower cost care setting continue provide impetus home health hospice segment go stratistic mrc report publish reuter global home healthcare market be expect reach worth cagr view state fact believe buyout be strategically align share price performanceover past month share resm have outperformed industry latest price movement stock have gain industry gain zack rank other stock considerresm currently carry zack rank buy other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys project long term earning growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
938,ISRG,president donald trump call summit north korean leader kim jong last thursday be quite shocker abandonement summit plan dealt blow underpenetrated emerge market asia be solid source revenue more base multinational company effect political mayhem cause msci broadest index asia pacific share outside japan south korea kospi japan nikkei plummet major wall street index dow jone industrial average lose ground well consider trend downward movement white house decide conduct meeting unite state announce plan send pre advance team singapore prepare trump kim summit jun medtech appear be very few sector shelter investor political tension shrug current volatility medical product industry have return call fall fact analyst believe medtech sector be able strengthen foothold faster rate meeting go plan be be number base medtech company operate asia post success summit company be able spread network north korea augment overall production research statista medtech market asia pacific region be estimate reach worth buoy encourage projection rather be interesting see medical product company be place political turmoil medtech stock gainmeanwhile medical product company have already be gain organic growth innovation higher consolidation tax abolition well focus emerge market include japan south korea china vietnam india philippine more fact stakeholder medical universe have be eyee market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space take look lead medtech player be gain prospect apac market becton dickinson company bdx free report popularly know bd particularly focus broader emerge market india china brazil turkey economic healthcare sector be grow rapidly particular safety engineer product continue drive growth emerge market believe exposure market boost top line turn accelerate ep growth zack rank hold company share have return year significantly higher index gain baxter international bax free report solid presence asia precisely india be worth mention company have research hub japan china recently baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost zack rank buy stock have outperformed index year time stock have return intuitive surgical inc isrg free report grow interest emerge market specifically apac region bode well past year company procedure performance asia project consistent strength company register solid growth china japan korea zack rank strong buy company share have return year see complete list today zack rank stock here boston scientific corporation bsx free report growth strategy comprise pursuit development opportunity outside unite station strengthen global presence inclusive emerge market backdrop flatten decline sale growth develop market unite state europe boston scientific be fortify foothold emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently project improvement performance china banking recent approval synergy zack rank stock have return year thing remember thing be not so easy appear be american never forget former president george bush refer north korea axis evil sponsored terrorism have solid access nuclear weapon further north korea multiple trial nuclear warhead have dampen country relationship analyst believe unforeseen summit not solve age old problem further guarantee kim jong tremendous anger open hostility not offend trump anymore do last week however trump team be expect reach agreement settle north korean nuclear other issue meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
939,ISRG,line product expansion strategy myriad genetic inc mygn free report have come new commercial coverage decision company market lead genomic test respect prostate cancer prolaris follow multiple reimbursement approval last few month molecular diagnostic personalize medicine major announce aggregate payer represent new cover life prolaris company payer include top commercial insurer unite state myriad note acceleration commercial insurer coverage prolaris have come close heel recently update national comprehensive cancer network nccn guideline support prolaris standard care make treatment decision patient suffering low favorable intermediate risk prostate cancer nccn guideline update nccn guideline release february revise medical rule prostate cancer treatment broadly include biomarker testing same indication state earlier change include new language back prolaris standard care take therapeutic decision patient low favorable intermediate risk prostate cancer rework nccn guideline accordingly instilled confidence myriad genetic receive expand reimbursement coverage certain test term company certain payer have already update policy base nccn rule include like medicaid state favorable prolaris medical policy decision several regional payer company first blue cross blue shield plan prospect development prolaris now provide insurance coverage prostate cancer patient unite state company grow prospect fast expand market prostate cancer test be also encourage report bcc research prostate cancer global market be estimate reach value worth cagr thus company clearly boast bountiful prospect market share price performanceover past day share myriad genetic have outperformed industry stock have rally compare industry increase zack rank key picksmyriad genetic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
940,ISRG,intuitive surgical inc isrg free report have announce start direct operation india distributor vattikuti technology pvt ltd post announcement intuitive surgical share price rise close iin past month share company have rally significantly outperform industry decline stock sport zack rank strong buy notably vattikuti provide high technology solution healthcare ally industry be authorize distributor da vinci surgical system india vattikuti management company plan install total da vinci robot year india courtesy robust demand country robot cost evidently drive intuitive surgical overseas revenue significantly silicon valley base pioneer field robotic assist minimally invasive surgery set sixth international headquarters bengaluru india employee sale marketing field service engineering business operation support customer country latest development not only ascertain wider collaboration opportunity intuitive surgical india surgical community also fortify company foothold asia da vinci international last report quarter intuitive surgical ous outside unite state system placement be include europe japan internationally company continue enjoy substantial opportunity japan south korea china flagship da vinci system witness continue growth urological procedure europe asia multispecialty growth china moreover additional procedure be grant reimbursement ministry health japan additionally da vinci surgical system receive regulatory clearance pmda pharmaceutical medical device agency japan be showcased large surgical society meeting shortly thereafter management intuitive surgical have install da vinci system so far india market prospectsper research business standard india surgical robotic market be estimate see cagr scale worth compare rise incidence chronic disease increase geriatric population grow demand minimally invasive surgery technological advancement field medical surgery be factor be fuel demand surgical robotic system hence be conclude intuitive surgical move have be timely strategic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report baxter international inc bax free report abiom have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here varian medical have project long term earning growth rate stock carry zack rank buy baxter have expect long term earning growth rate stock carry zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free intuitive surgical inc isrg free report have announce start direct operation india distributor vattikuti technology pvt ltd post announcement intuitive surgical share price rise close iin past month share company have rally significantly outperform industry decline stock sport zack rank strong buy notably vattikuti provide high technology solution healthcare ally industry be authorize distributor da vinci surgical system india vattikuti management company plan install total da vinci robot year india courtesy robust demand country robot cost evidently drive intuitive surgical overseas revenue significantly silicon valley base pioneer field robotic assist minimally invasive surgery set sixth international headquarters bengaluru india employee sale marketing field service engineering business operation support customer country latest development not only ascertain wider collaboration opportunity intuitive surgical india surgical community also fortify company foothold asia da vinci international last report quarter intuitive surgical ous outside unite state system placement be include europe japan internationally company continue enjoy substantial opportunity japan south korea china flagship da vinci system witness continue growth urological procedure europe asia multispecialty growth china moreover additional procedure be grant reimbursement ministry health japan additionally da vinci surgical system receive regulatory clearance pmda pharmaceutical medical device agency japan be showcased large surgical society meeting shortly thereafter management intuitive surgical have install da vinci system so far india market prospectsper research business standard india surgical robotic market be estimate see cagr scale worth compare rise incidence chronic disease increase geriatric population grow demand minimally invasive surgery technological advancement field medical surgery be factor be fuel demand surgical robotic system hence be conclude intuitive surgical move have be timely strategic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report baxter international inc bax free report abiom have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here varian medical have project long term earning growth rate stock carry zack rank buy baxter have expect long term earning growth rate stock carry zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free intuitive surgical inc isrg free report have announce start direct operation india distributor vattikuti technology pvt ltd post announcement intuitive surgical share price rise close past month share company have rally significantly outperform industry decline stock sport zack rank strong buy notably vattikuti provide high technology solution healthcare ally industry be authorize distributor da vinci surgical system india vattikuti management company plan install total da vinci robot year india courtesy robust demand country robot cost evidently drive intuitive surgical overseas revenue significantly silicon valley base pioneer field robotic assist minimally invasive surgery set sixth international headquarters bengaluru india employee sale marketing field service engineering business operation support customer country latest development not only ascertain wider collaboration opportunity intuitive surgical india surgical community also fortify company foothold asia da vinci international accomplishment last report quarter intuitive surgical ous outside unite state system placement be include europe japan internationally company continue enjoy substantial opportunity japan south korea china flagship da vinci system witness continue growth urological procedure europe asia multispecialty growth china moreover additional procedure be grant reimbursement ministry health japan additionally da vinci surgical system receive regulatory clearance pmda pharmaceutical medical device agency japan be showcased large surgical society meeting shortly thereafter management intuitive surgical have install da vinci system so far india market prospect research business standard india surgical robotic market be estimate see cagr scale worth compare rise incidence chronic disease increase geriatric population grow demand minimally invasive surgery technological advancement field medical surgery be factor be fuel demand surgical robotic system hence be conclude intuitive surgical move have be timely strategic other key pick other top rank medical stock be abiom inc abmd free report varian medical var free report baxter international inc bax free report abiom have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here varian medical have project long term earning growth rate stock carry zack rank buy baxter have expect long term earning growth rate stock carry zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
941,ISRG,resm inc rmd free report have be gain investor confidence consistently positive result stock have soar year compare rise industry increase company have market cap year historical growth rate be also favorable compare industry average consider solid prospect zack rank buy stock be attractive bet investor moment factor act favorlet take look possible growth propeller solid performanceresm exit fiscal third quarter promising note better expect earning revenue encouragingly note company achieve solid double digit revenue growth quarter lead sale software service business well new mask product device expand international businessin third quarter fiscal revenue unite state canada latin american country grow year year same europe asia other market rise year year cer growth be particularly strong france japan europe asia back connect health solution adoption include airsense aircurve airview myair notably company late receive reimbursement approval mandibular repositioning device france further accelerate uptake resm dental device help treat sleep apnea resm inc price resm inc price resm inc quote solid horizon growth strategyresm have identify growth horizon term progress first focus resm core sleep apnea franchise company have be make advanced technology combine digital health connect care solution second horizon be dedicate growth adjacent product geographic market include homecare ventilation chronic obstructive pulmonary disease amyotrophic lateral sclerosis other respiratory disorder regard company also recently introduce first self brand portable oxygen concentrator name mobi fiscal first quarter company re launch portable oxygen concentrator call activox be also target growth emerge market china india brazil third growth horizon incorporate portfolio opportunity new market include clinical adjacency such atrial fibrillation heart failure preserve ejection fraction asthma chronic disease management well sleep health wellness focus product developmentin order maintain leadership position sdb sleep disorder breathe market drive sale resm be concentrate product development innovation earlier company introduce world smallest cpap continious positive airway pressure call airmini launch airmini be achieve impressive early adoption product category small second use travel friendly cash pay cpap apap automatic positive airway pressure device company be well place fiscal work pipeline new product connect care solution sleep apnea copd chronic obstructive pulmonary disease neuromuscular disease other clinical adjacency other key picksother top rank stock broader medical sector include intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have project long term earning growth rate illumina expect long term earning growth amedisys expect long term earning growth rate stand more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
942,ISRG,steris plc ste free report have be gain investor confidence consistently positive result past year company have gain industry decline also company have outperformed gain developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have market cap company long term historical earning growth rate be higher solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction however earning estimate remain flat let find latest trend be sustainable solid quarterly exit fourth quarter fiscal better expect earning revenue be also encourage favorable underlie market trend new product service offering company strong organic growth specialty service life science apply sterilization segment also buoy optimism synergy health consolidation tracksteris acquisition base outsourced sterilization service provider synergy health plc have continue remain significant move company combine steris infection prevention service business synergy health hospital sterilization service earlier management say expect save least end fiscal balance divide evenly next fiscal company also anticipate cost synergy year synergy health transaction next fiscal strategic buyout recent past steris have be look expand adjacent market acquisition dilution follow synergy health buyout company sell synergy health healthcare consumable solution hcs business vernacare november apart company make acquisition fiscal company aim strengthen healthcare product healthcare specialty service apply sterilization technology business solid balance sheet positionsteris exit fiscal cash cash equivalent compare end fiscal company have long term debt end fourth quarter fiscal compare year other key picksa few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
943,ISRG,myriad genetic inc mygn free report recently announce definitive agreement buy counsyl leader expand carrier invasive prenatal screening notably buyout cost myriad genetic meeting certain customary close condition receive regulatory approval transaction be expect close first quarter fiscal financial detail dealmyriad genetic intend use combination cash hand exist revolve credit facility issuance common stock pay buyout buyout integration expect synergy benefitsmyriad genetic plan retain counsyl wholly own subsidiary post successful completion acquisition further integrate counsyl reproductive testing product hereditary cancer test myriad genetic plan solidify position lead woman health genetic testing company management acquisition deal help exist customer base counsyl reproductive test expand almost fold further encouragingly note counsyl reproductive genetic test be currently be cover commercial insurance unite state more room expand coverage foresight expand carrier screening prelude invasive prenatal screening test term market opportunity post buyoutper datum provide company believe myriad genetic decision foray high potential reproductive testing market be strategically align company roughly carrier screening test invasive prenatal screening test be estimate be carry unite state fiscal myriad genetic market be expect reach worth more fiscal reproductive genetic test perform unite state take dealmyriad genetic exit last report quarter promising note company observed strong revenue growth genesight vectra da prolaris test also hereditary cancer volume expansion be impressive be upbeat company witness growth new product volume success elevate program further raise fy guidance instill confidence stock consider myriad genetic strong fundamental business prospect buyout be expect help company cash bountiful opportunity high potential reproductive testing market share price performanceover past month share myriad genetic have outperformed industry latest price movement stock have gain industry decline zack rank stock considermyriad genetic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
944,ISRG,issue update research report idexx laboratory inc idxx free report company robust worldwide commercial capability best class product include next generation chemistry analyzer catalyst be key growth driver term stock carry zack rank hold lead molecular diagnostic company have outperformed industry stock have increase industry decrease notably idexx exit first quarter strong note better expect earning revenue improvement solid year year growth organic revenue raise ep guidance be also encourage stellar performance be drive robust sale companion animal group cag business fuel firm global catalyst uptake international revenue first quarter be organically drive organic gain international cag diagnostic recur revenue reflect continue consumable revenue gain support catalyst instrument base increase average testing utilization sturdy growth european lab revenue companion animal market fundamental remain safe sound tremendous global runway growth additionally be upbeat company expand premium instrument base unite state well international market include growth competitive instrument placement increase utilization consistent customer retention idexx innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth report quarter moreover company healthy top line growth be drive considerable contribution rest business segment additionally company boast strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue be be derive sale product international market thus strengthen dollar exchange rate relative other currency have negative impact revenue derive currency other money well profit draw product manufacture unite state sell internationally adverse currency translation affected adjust earning share tune cent also company heavy dependence third party distributor be drag key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
945,ISRG,home more half world population asia pacific apac have significant unmet healthcare need hold attractive growth potential medtech bigwig add further optimism corner healthcare be trump clear focus market article publish economic time asian healthcare market be expect grow more upside be attribute improve access healthcare facility increase government private investment china trade warmeanwhile investor be concern ongoing trade dispute severely hurt medtech company profit emerge market accuse china unfair trade practice president donald trump have impose tariff import china just day slap punitive duty chinese good be follow immediate retaliation china impose tariff export blow follow trump proposal implement tariff more worth chinese good article christian jone mondaq medtech firm unite state currently sell worth medical device annually china import total go jp morgan report trade war bring collateral damage country closely tie china supply chain include south korea taiwan malaysia singapore thailand india korea relation raise hopeamid trade war uproar trump latest stance rest apac have be breather investor last landmark asia trip trump reveal stronger reliance india strategic partner fact see india heart asia policy keep trump new policy lower drug price have positive impact india bilateral trade relation further help fix price certain exorbitant pharmaceutical medical device emergo article show indian medical device market be value expand moreover business standard article suggest india import medical device unite state grow inr inr meanwhile ty north korea seem be improve recent historic summit president kim jong trump put age old war tactic hold korea summit trump swear provide security guarantee dprk democratic person republic korea complete korean peninsula successful nuclear talk be likely pave way mutually beneficial trading relationship begin point future datum publish korea country commercial guide total import medical device korea gross unite state contribute more furthermore market share represent approximately korean import market choose right economy be gradually focuse lucrative asia pacific market be right time investor cash opportunity market have shortlist few medical device stock have carved niche asian market such stock be likely log massive gain give solid stand apac region present first pick be baxter international bax free report have solid presence asia research hub japan china company renal care team recently launch kaguya peritoneal dialysis technology japan baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost buyout bolster baxter foothold generic pharmaceutical space same year baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline zack rank buy stock have outperformed industry year time company share have rally compare industry rise see complete list today zack rank strong buy stock here next list be align technology algn free report zack rank company invisalign technology have be widely adopt apac region asia pacific region company witness first quarter volume growth lead china japan australia moreover align technology china stand second largest market unite state company also introduce clear aligner solution class ii correction invisalign technology mandibular advancement certain market apac fda approval same be expect second half past year share align technology have sky-rocket compare industry rise investor also consider intuitive surgical inc isrg free report zack rank hold company flagship da vinci general surgery urology procedure have be witness consistent growth asia intuitive surgical also see multispecialty growth china last report quarter recently additional procedure be grant reimbursement ministry health japan earlier year california base manufacturer surgical system announce start operation india distributor vattikuti technology pvt ltd read more intuitive surgical commence direct operation india past year share intuitive surgical have rally whopping industry decline medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
946,ISRG,market capitalization approximately intuitive surgical inc isrg free report continue benefit grow adoption company da vinci system increase procedure volume consistent innovation solid recur revenue base however unfavorable foreign exchange procedure adoption risk lower capital spending hospital increase regulatory headwind be major concern fiscal zack consensus estimate revenue be currently peg reflect increase further zack consensus estimate earning be peg show rise stock have zack rank hold here take quick look primary factor have be plague intuitive surgical discuss prospect ensure term recovery intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc mar surgical have be enjoy monopoly market robot used abdominal surgery launch flagship device call da vinci back post regulatory approval transenterix surgical robot abdominal surgery competition intuitive surgical have intensified report suggest news have negative impact company price movement even device be not expect compete directly da vinci medtech giant medtronic be major threat source company have be work surgical robot plan launch hold da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand gesture be translate smaller precise movement tiny instrument patient body da vinci have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery system have invasive surgery more patient worldwide recently da vinci surgical system have be observed cure patient diagnosed inguinal hernia company launch upgrade flagship vinci xi technology da vinci recently notably xi suite be design seamlessly integrate future innovation such advanced instrumentation surgical skill simulation software upgrade other advancement dynamic platform company now ship xi single site xi millimeter stapler firefly several country minimally invasive surgery be become increasingly popular help patient recover faster reduce hospital cost notably minimally invasive surgical instrument market be project reach worth cagr market market high price system hinder widespread adoption believe benefit minimally invasive surgery propelsurgeon patient use system drive company system sale improve top line growth long run favorable share price surgical have outperformed industry year time company share have surge almost industry decline current level be also higher index rise key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
947,ISRG,becton dickinson company bdx free report also know bd recently complete acquisition texas base tva medical financial term deal have be keep wrapped post announcement share bd inched management transaction be not expect be accretive bd financial result fiscal past year company share have rally compare industry rise stock carry zack rank hold come back news tva medical develop minimally invasive vascular access solution patient chronic kidney disease require hemodialysis recent integration be likely boost bd core medical segment additionally buyout enable bd provide tva flagship everlinq endoavf system everlinq endoavf receive marketing clearance fda be used hemodialysis rely open surgery acquisition allow bd serve physician patient provide minimally invasive procedure patient chronic kidney disease market opine be more patient end stage renal disease esrd depend hemodialysis unite state moreover research market minimally invasive surgical device be project reach cagr benefit minimally invasive surgery compare traditional open surgeriesa well asreduction healthcare cost growth market hence bd latest move be timely strategic medtech minimally invasive invasive surgery involve fewer incision reduce trauma patient late medtech space have be witness increase usage surgical procedure bd be major global medtech player have be rake huge profit minimally invasive procedure company flagship mueller snowden pencer laparoscopic instrument be most advanced surgical instrument available market intuitive surgical isrg free report coveted da vinci platform deserve special mention here system be power robotic technology enable surgeonsto make smaller precise movement also stryker corporation syk free report robotic arm assist mako surgery platform facilitate advanced joint replacement surgery solution want more industry better rank stock medical dental supply space be henry schein inc hsic free report henry schein gain unite state well overseas raise optimism stock carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
948,ISRG,intuitive surgical isrg free report recently announce fda approval sureform stapler company share climb follow announcement notably share intuitive surgical have rally industry decline year time stock carry zack rank hold back news latest clearance reflect california base manufacturer surgical system commitment minimally invasive innovation sureform be fully wrist mm stapler be first kind stapler offer degree fully wrist articulation new breed da vinci stapling be compatible da vinci xi surgical system sureform used smartfire technology optimize stapler staple line performance market prospectsper minimally invasive surgical instrument market be project reach worth cagr hence latest development have be timely strategic intuitive surgical minimally invasive surgery take medtech stormminimally invasive surgery involve less surgical incision reduce trauma patient late medtech space have be witness increase usage surgical procedure intuitive surgical coveted da vinci platform deserve special mention here system be power robotic technology help surgeon make smaller precise movement meanwhile stryker corporation syk free report robotic arm assist mako surgery platform facilitate advanced joint replacement surgery solution coveted mako platform recently record strong performance japan south pacific canada globally stryker install mako robot be unite state want more industry few better rank stock medical instrument space specialize minimally invasive surgical solution be masimo corporation masi free report steris plc ste free report masimo innovative noninvasive patient monitoring system have be drive top line stock carry zack rank buy see complete list today zack rank stock here steris harmony hybrid be design accommodate grow utilization demand minimally invasive surgery stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
949,ISRG,mckesson mck free report report fourth quarter fiscal earning share miss zack consensus estimate earning however improve year quarter figure mckesson post sale marginally miss zack consensus estimate constant currency cc quarter detailmckesson operate segment distribution solution technology solution however report quarter company do not report detail technology solution unit distribution segment report revenue quarter cc fact segment account whole company fourth quarter revenue mckesson corporation price consensus ep surprise mckesson corporation price consensus ep surprise mckesson corporation quotenorth america pharmaceutical distribution service revenue come prior year quarter full year revenue segment totale cc rise be attribute market growth acquisition have be partially offset brand generic conversion international pharmaceutical distribution service report revenue increase year quarter full year revenue segment be cc medical surgical distribution service rake revenue improve year year basis full year segment post revenue worth year marginsgross profit report quarter be year year basis gross margin be basis point bps operate expense rise year year basis fy glancefull year adjust earning share grow year include cent diluted share contribution create profit foundation report figure miss zack consensus estimate be peg revenue fiscal gross compare year figure marginally miss zack consensus estimate be pin fiscal cash flow operation totale mckesson end year cash cash equivalent fiscal mckesson repay approximately net long term debt share repurchase company board director authorize additional share repurchase program expect adjust earning share fiscal notably zack consensus estimate fiscal earning be peg give range free cash flow be expect fiscal guidance assume full year adjust tax rate approximately vary quarter quarter management fiscal outlook represent mid high single digit percentage growth year year reflect more stable market condition takemckesson wrapped fourth quarter fiscal mixed note adjust earning revenue miss estimate moreover solid growth distribution solution segment hold promise surge international sale be major positive however contract gross margin raise concern escalate operate expense be also headwind price fluctuation generic pharmaceutical stiff competition niche space add wo zack rank key picksmckesson currently carry zack rank hold few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be beating zack consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale surpass zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
950,ISRG,boston scientific corporation bsx free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain compare industry gain also company have outperformed gain developer manufacturer marketer medical device use interventional medical specialty have market cap company have earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable solid quarterly scientific exit first quarter solid note better expect earning revenue be upbeat company witness growth business line geography strategic buyout fortify ep businesswe be upbeat boston scientific recent acquisition apama medical deal boston scientific aim expand suite arrhythmia solution fall ep sub segment further gain traction ep market boston scientific announce plan acquire securus medical privately hold developer thermal monitoring system continuous measurement esophageal temperature geographic expansionan important part boston scientific growth strategy be continue pursue development opportunity outside unite state expand global presence inclusive emerge market boston scientific be gradually strengthen presence emerge market include brazil russia india china bric first quarter business emerge market register growth company be gain strong ground india well target emerge market additional emphasis boston scientific hope sustain strong overall international performance product launch be early stage rollout suspension medtech decision house senate suspend medical device tax year have come breather medical device bigwig boston scientific accord company temporary suspension allow continue plan invest innovative medical product company meanwhile have plan work full repeal medtech tax other stock considerother top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
951,ISRG,abbott free report provide impetus vascular business unite state recently announce receipt fda approval xience sierra notably xience sierra be latest family xience everolimus eluting coronary stent system xience sierra sierra be equip thinner profile enhance flexibility longer length small diameter further advanced stent delivery system effectively aids treat complex case involve multiple totally block vessel provide increase flexibility precision doctor management report case involve patient suffering complex blockage believe fda approval aid drive top line contribution abbott vascular business vascular business glancerecently abbott vascular business have continue deliver stable top line performance last report quarter segment sale improve report basis notably vascular business account total revenue broader medical device segment encouragingly note vascular business abbott have be slew development regard xience sierra coronary stent system company be award national reimbursement xience sierra japan ministry health labour welfare follow receipt regulatory approval april abbott have also be get positive response xience sierra coronary stent system post launch europe late last year market potentialper grand view research safely conclude development help abbott cash opportunity coronary stent market accord report global coronary stent market be expect witness cagr roughly share price movementover past month abbott have be outperform industry stock have gain compare industry increase zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
952,ISRG,issue update research report qiagen qgen free report be upbeat company progress testing menu expansion strategy however tough competitive landscape be concern stock carry zack rank hold netherlands base molecular diagnostic provider offer innovative technology product pre analytical sample preparation molecular diagnostic solution stock have be outperform industry past month latest stock movement have gain decline broader industry qiagen end first quarter solid note be impressed year year growth majority segment company have be proceed test menu expansion strategy regard april company announce receipt pre market approval fda partosure same month company launch qiastat dx europe follow closure recently announce stat dx acquisition completion defined development activity stat dx be also upbeat qiagen molecular diagnostic sale have be grow significantly first quarter company witness double digit cer growth revenue quantiferon latent tb test strength personalize healthcare follow rise sale infectious disease testing product also look forward implementation recently draw strategy boost top line contribution ngs portfolio meanwhile qiagen face stiff competition firm provide competitive pre analytical solution other product market company product be very competitive price sensitive add concern also strong reliance collaboration decline hpv sale unite state be other negative few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report cooper company inc coo free report intuitive surgical illumina sport zack rank strong buy cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate cooper company have long term expect earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
953,ISRG,medtronic plc mdt free report recently announce initiation clinical study bifurcation cohort evaluate efficiency safety standard drug eluting stent de treat bifurcation lesion study bifurcation cohort part resolute onyx post approval study cover patient bifurcation lesion site unite state europe be enrolling patient suffering coronary artery disease cad receive resolute onyx de diameter size vary mm notably resolute onyx de be not approve treat bifurcation lesion unite state further primary endpoint study be target vessel failure month medtronic datum study be submit fda expand indication approval include bifurcation lesion resolute onyx de further company state bifurcation lesion be responsible percutaneous coronary intervention thus believe positive datum provide impetus company effort achieve expand fda approval resolute onyx de accelerate business growth csh be consistently try enhance coronary structural heart csh segment be part cardiac vascular group cvg segment csh revenue third quarter fiscal be cer report low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk moreover continue uptake resolute onyx drug eluting stent unite state japan revive business encouragingly note medtronic recently receive fda nod launch resolute onyx mm drug eluting stent stent be smallest size market presently resolute onyx de be available use size unite state europe country recognize ce mark market strategy gain traction csh segment seem be align datum provide transparency market research report global coronary stent market be expect see cagr more specifically de market coronary stent market be expand fast be estimate witness cagr period market be likely expand unite state asia pacific europe well rest world stock performance past month medtronic have outperformed industry gain compare industry zack rank key picksmedtronic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report cooper company inc coo free report intuitive surgical illumina sport zack rank strong buy cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate cooper company have long term expect earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
954,ISRG,month have go last earning report intuitive surgical inc isrg free report share have add time frame recent positive trend continue lead next earning release be isrg due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent surgical report first quarter adjust earning share beat zack consensus estimate earning also improve year year basis revenue totale prior year quarter revenue also surpass zack consensus estimate solid performance be backed higher worldwide da vinci procedure lead growth general surgery procedure global urologic procedure management revenue also gain drop dollar segment come reflect year year increase management growth da vinci procedure volume primarily drive upside japan da vinci procedure specialty general surgery gynecology cardiothoracic surgery be grant national reimbursement status systemsin report quarter system revenue increase year year notably da vinci surgical system be ship company year year quarter review shipment include system operate lease arrangement compare year quarter servicesservice revenue come year international sale unite state revenue totale year year basis sequentially upside be attribute increase system revenue higher instrument accessory revenue ous procedure grow year year system placement report quarter compare year quarter first quarter placement include europe japan marginsgross margin be basis point bps year year first quarter operate income increase year year basis financial company end first quarter cash cash equivalent investment reflect increase quarter primarily drive cash generate operation company have not repurchase share quarter have approximately remain board buyback authorization company have not issue guidance however management feel revenue experience low single digit decline lackluster performance gynecology benign hysterectomy market management also feel margin fluctuate due mix newer product system accessory revenue have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quotevgm scoresat time isrg have nice growth score grade same score momentum front however stock be allocate grade value side putt lowest quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested zack style score indicate company stock be suitable growth momentum investor outlookestimate have be trend upward stock magnitude revision look promising come little surprise isrg have zack rank strong buy expect average return stock next few month
955,ISRG,illumina inc ilmn free report recently announce acquisition edico genome strengthen next generation sequence ngs platform company edico genome dragen bio dragen platform pair well illumina sequence portfolio help deliver rapid streamline output ngs customer edico genome be eminent provider datum analysis acceleration solution ngs dragen be build field programmable gate array fpga technology help proprietary software algorithms help deliver result timely manner decrease datum footprint illumina edico genome have establish strong ngs customer base lead solid adoption dragen standard part sequence believe acquisition help illumina provide enhance datum analysis experience ngs user expand customer base ngs platform focusillumina be consistently work enhance ngs platform illumina recently introduce second fda regulate ce ivd marked ngs system nextseq dx company have also receive product approval nextseq dx instrument ministry food drug safety mfds south korea april company collaborate bristol myer squibb company bmy free report field oncology alliance utilize illumina ngs technology develop globally commercialize diagnostic ivd assay support bristol myer squibb oncology portfolio illumina also announce global strategic partnership wih loxo oncology develop commercialize multus gene panel broad tumor profile result distributable ngs base companion diagnostic cdx pan cancer indication market potentialaccord market market global next generation sequence market be estimate reach worth cagr show acquisition be line company strategy share price performanceover past year illumina have be outperform industry company have gain industry decline zack rank other key picksillumina currently sport zack rank strong buy other top rank stock broader medical sector be intuitive surgical isrg free report cooper company inc coo free report intuitive surgical sport zack rank cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cooper company have long term expect earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
956,ISRG,unite state have hit rough water late few analyst label trouble self invite other foresee revolution rise trade war tension unite state china be show sign abatement issue have escalate point imposition tariff retaliatory tariff go side moreover president trump mull restriction chinese company come investing tech firm avert technology export be likely worsen scenario wasn enough unite state be urge country stop import oil iran november raise supply related trump decision impose tariff steel aluminum import china european union mexico canada threat higher tariff import car auto part have raise concern medtech stable groundin wake such rocky scenario investor be consistently lookout safer sector tailwind favorable consumer behavior grow demand liquid biopsy test defer implementation industry wide medical device tax back sector medical device space seem be safer territory emergo medical device industry be likely be worth minimally invasive surgical device market hog investor try pick sub industry boom prospect minimally invasive surgical device market be final stop reduce stay hospital lower healthcare cost pain scare tissue damage be certain benefit opt minimally invasive surgery traditional process persistence market research estimate global minimally invasive surgical device market value cagr report mordor intelligence minimally invasive surgery device market be project see cagr factor drive marketthe minimally invasive surgical device market be largely dependent age population census bureau report person age more be likely total almost double estimate population datum also show median age be increase most area country global scenario be pretty similar strengthen emerge market have be contribute largely rise demand minimally invasive surgical device geographically market be divide north america europe latin america asia pacific middle east africa wise guy report demand minimally invasive surgical device be solid asia pacific region expect cagr be grow dominance ai application healthcare technological revolution new avenue opportunity minimally invasive surgical device space robot assist surgery be vogue context first generation surgical robot be be install number operate room globally stock watch forwe have picked company believe help tap boom prospect minimally invasive surgical device market intuitive surgical inc isrg free report zack rank hold company design manufacture market da vinci surgical system advanced robot assist surgical platform mechatronic base platform enable minimally invasive surgery help avoid trauma associate open surgery see complete list today zack rank stock here company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair day come intuitive surgical have expect earning growth rate current year past month intuitive surgical have outperformed industry stock have gain industry fall medtronic plc mdt free report zack rank company have minimally invasive therapy group formerly refer covidien group follow completion covidien acquisition segment company offer ablation system acute care ventilation system brain capnography monitoring system host other product medtronic have expect earning growth rate current year stock have deliver positive earning surprise trail quarters average beat be past month medtronic have outperformed industry stock have rise compare industry nuvasive inc nuva free report zack rank company lead global medical device spine market focuse develop minimally disruptive surgical product procedurally integrate solution spine company principal product include minimally disruptive surgical platform call maximum access surgery mas recent past company have launch xlif crestline lateral alif lateral mis fixation nuvasive have expect earning growth rate current year past month nuvasive have outperformed industry stock have gain compare industry medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
957,ISRG,late medtronic plc mdt free report spine business have be register soft performance due challenge market scenario let see be possibility rebound time company be schedule report fourth quarter fiscal result open bell click here know company overall performance be likely be spine glancein last report quarter medtronic spine division be flat year year mid single digit growth bmp bone morphogenetic protein cer low single digit decline core spine hampered overall sale however company note growth be sluggish be line global spine market management combination advanced technology imaging navigation power instrument nerve monitoring have spur growth division company have also start demonstrate positive outcome related distribution relationship mazor robotic medtronic plc price ep surprise medtronic plc price ep surprise medtronic plc begin fiscal medtronic be suffering significant pricing pressure business offset strong procedural growth company believe price reduction basically stem consolidation hospital company state hospital be get more sophisticated buy pattern be consolidate vendor base result price decline medtronic expect competitive pricing pressure reduce next couple quarters lead net procedural growth company however look company outlook be uncertain term recovery company earlier note spine broader restorative therapy group rtg segment growth be mar impact slower spine market soon be report quarter zack rank stock currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate amedisys have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
958,ISRG,zimmer biomet holding inc zbh free report recently announce receipt clearance fda zyston strut open titanium interbody spacer system be expect revitalize spine division notably product be company first titanium spinal implant be build used printing technology zyston strut open titanium system zyston strut open titanium system be family lumbar cage be available various size meet patient requirement further system have be develop increase strength capacity graft visualization interbody spacer spinal fusion case also encompass surgical instrument enable insertion manipulation elimination implant be printing technology also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub further printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr zimmer biomet latest offer zyston strut open titanium system be build used printing process allow physician develop unique cage architecture maximize graft volume implantation zimmer biomet have announce receipt clearance unite bridge fixation system foot ankle business notably innovative product be result combination company osseoti porous metal technology printing process glimpse spine divisionzimmer biomet spine thoracic spine cmf segment revenue be cer first quarter company have be face revenue dissynergy related spine sale force integration meanwhile be upbeat recent fda nod be expect expand company lumbar spacer portfolio include peek optima trabecular metal technology allograft note zimmer biomet have be gain strong uptake mobi cervical disc also company recently launch product avenue tlif cage well vitality vital spinal fixation system unite state market potentialper report market research future safely conclude latest development help zimmer biomet cash opportunity spinal implant market accord report global spinal implant market be expect see cagr roughly price performanceover past month zimmer biomet have be observed underperform industry stock have decline compare rise industry believe latest fda approval boost investor faith stock zack rank stock considerzimmer biomet currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
959,ISRG,issue update research report bioscrip inc bio free report company struggle reimbursement challenge core business continue grow stock have zack rank hold bioscrip exit first quarter dismal note lower expect earning performance revenue be consensus mark huge year year decline be disappointment downside be due shift company strategy focus grow core revenue mix include contract change unite healthcare september also external challenge reimbursement cut pertain st century cure act hampered growth trend be expect persist well past month share bioscrip have underperform industry stock have lose gain broader industry positive note co base lead infusion service provider have continue progress multus faceted core plan improve finance scheme involve identify execute strategy accelerate core revenue growth build favorable product mix drive operational efficiency raise revenue collection well increase employee effectiveness bioscrip inc price bioscrip inc price bioscrip inc quote additionally company make significant advancement first quarter implement single repeatable model enforce operate cost reduction back solid synergy draw supply chain rationalization growth nursing productivity enhance shipping utilization improve patient board time rapidly change healthcare landscape company have late remain alert grow core infusion service platform clinically focuse customer orientated model apart bioscrip intent drive high growth core infusion service company be engage aggressive cost control currently company aim emerge smaller more focuse organization significant improve profitability better growth prospect improve operate cash flow performance key pickssome better rank stock broader medical sector be intuitive surgical isrg free report align technology inc algn free report baxter international inc bax free report intuitive surgical sport zack rank strong buy align technology baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate align technology have long term expect earning growth rate baxter international have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
960,ISRG,issue update research report gnc holding inc gnc free report be upbeat company strategy strengthen international presence however cut throat competition continue challenge stock currently carry zack rank hold lead global specialty retailer product health wellness include vitamin mineral herbal supplement sport nutrition diet have be underperform industry past year company have lose compare decline industry gnc holding exit first quarter dismal note year year decline adjust earning revenue additionally unite state gnc holding compete heavily advertised national brand large pharmaceutical food company well other retailer lead increase price competition company more participant be enter market positive note gnc holding international business have be key driver growth recent year management expect continue capitalize international revenue growth opportunity addition franchise store exist market expansion new high growth market growth product distribution exist new market regard gnc holding recently announce receipt hayao shareholder vote strategic partnership china joint venture agreement harbin pharmaceutical group hold hayao further company recently enter master franchise agreement rapid nutrition foray australia same time gnc holding have announce plan expand presence india operate collaboration master franchise partner guardian healthcare service pvt ltd development help boost investor faith stock also company have progressed significantly commerce business management commerce business continue grow higher expect moreover company be upbeat shift control third party cloud base company controlled platform key picksa few better rank stock broader medical sector be intuitive surgical isrg free report cooper company inc coo free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cooper company baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cooper company have long term expect earning growth rate baxter international have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
961,ISRG,share cryolife inc cry free report have gain past week company first quarter earning release stock rally post better expect earning share ep revenue reflectsgrowth product line strong performance geography release company gain significantly outperform industry let delve deeper cryolife earning detail company report adjust ep cent year year however figure better zack consensus estimate net loss cent revenue detailrevenue quarter increase year year revenue also trump consensus estimate primarily drive growth quarter also see strength bioglue tissue process moreover revenue include contribution recently complete acquisition jotec segmental basis product revenue increase year year first quarter segment revenue come bioglue biofoam follow cryolife inc price consensus ep surprise cryolife inc price consensus ep surprise cryolife inc quote preservation service revenue increase quarter review year segment company witness solid growth cardiac tissue business geographical basis company revenue unite state rise international revenue increase operational updatecryolife gross profit report quarter climb year year however gross margin contract basis point bps notably gross margin first quarter include charge associate step basis jotec inventory other distributor general administrative marketing expense first quarter rise year year research development expense shot year year operate expense totale first quarter year year operate loss quarter be compare unfavorably operate profit year quarter financial updatecryolife exit first quarter cash cash equivalent restrict security compare end guidance cryolife continue expect revenue band zack consensus estimate full year revenue stand guide range company also expect adjust ep range cent zack consensus estimate earning be peg cent company guide range takecryolife exit first quarter promising note be encourage note company have be witness growth product line strong geographic performance moreover company have be gain directly selling product end user be also optimistic company focus product innovation completion jotec buyout regard cryolife be highly upbeat continuously advance clinical development biogluechina perclot however escalate operate expense seem be discourage also tough competitive landscape act dampener zack rank other key pickscryolife have zack rank buy other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme release first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
962,ISRG,transenterix inc trxc free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session continue recent uptrend company stock be now past month time frame company have see positive estimate revision past few week zack consensus estimate current quarter have also moved higher past few week suggest more solid trading be ahead transenterix so make sure keep eye stock go forward see recent jump turn more strength road transenterix currently have zack rank hold earning esp be transenterix inc price transenterix inc price transenterix inc quoteinvestor interested medical instrument industry consider intuitive surgical inc isrg free report have zack rank strong buy see complete list today zack rank stock here be trxc go predict see other think stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
963,ISRG,bid strengthen oncology system segment varian medical system var free report recently announce plan demonstrate comprehensive portfolio advanced brachytherapy solution company exhibit product line american brachytherapy society annual meeting jun san francisco notably company demonstrate brachytherapy solution conference include brachyvision brachytherapy treatment plan system variseed ldr prostate treatment plan system vitesse real time plan hdr brachytherapy varian brachytherapy applicator accessory varian brachytherapy profile boost oncology announcement be likely boost varian oncology system segment apart various volumetric modulate arc therapy vmat stereotactic radiosurgery stereotactic radiotherapy brachytherapy unit be significant contributor oncology system salesin theoncology system business represent total revenue fiscal respectively first quarter fiscal oncology revenue totale cc year year basis brachytherapy company brachytherapy solution design manufacture sell serve advanced brachytherapy product varisource hdr afterloader gammame hdr pdr afterloader brachyvision brachytherapy treatment plan system other applicator well accessory company brachytherapy also develop market variseed ldr prostate treatment plan system vitesse software real time treatment plan hdr prostate brachytherapy aggressive rivalryhowever cutthroat competition niche brachytherapy space have be headwind varian company compete head head elekta ab mim software inc eckert ziegler bebig gmbh term brachytherapy solution varian manufacture high dose rate brachytherapy system crawley company brachytherapy treatment plan product be manufacture charlottesville virginia varian medical system inc price consensus varian medical system inc price consensus varian medical system inc market be alternative external beam radiotherapy process involve insertion radioactive seed wire ribbon directly tumor body cavity tumor brachytherapy be often used cancer head neck breast uterus cervix soft tissue well prostate recent research report grand view research global brachytherapy market be expect reach courtesy increase geriatric population lifestyle issue underpenetrated emerge economy consider solid prospect global market latest development be expect bolster varian foothold brachytherapy market medtech space favorable stock outperformed industry year time company share have return industry fall also current return be higher index rise zack rank other key picksvarian sport zack rank strong buy few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank see complete list today zack rank stock here genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
964,ISRG,jun issue update research report steris plc ste free report company have be actively try expand adjacent market strengthen core business acquisition dilution however company operate tough competitive landscape be concern stock carry zack rank buy share developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have outperformed industry past month stock have rally industry decline be encourage steris witness favorable underlie market trend new product service offering company strong organic growth specialty service life science apply sterilization segment also buoy optimism further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change expect better align operation recent past steris have be pursue growth footprint adjacent market acquisition dilution follow synergy health buyout company sell synergy health healthcare consumable solution hcs business vernacare november hcs business used generate roughly annual revenue apart company make consolidation fiscal transaction company aim strengthen healthcare product healthcare specialty service apply sterilization technology business believe steris chase back back acquisition long run order widen business customer base courtesy solid financial position meanwhile steris compete pharmaceutical research industrial customer several large company extensive product portfolio global reach well small entity limit product offering operation few country company worry face fierce competition new infection prevention sterile process contamination control surgical support product service enter market hamper steris growth considerably moreover multiple steris client be undergo consolidation partly due healthcare cost reduction measure initiate competitive pressure well legislator regulator third party payor think company fail check customer consolidation rate now adversely impact business well financial condition other key picksa few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report varian medical system inc var free report intuitive surgical illumina sport zack rank strong buy varian medical carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth varian medical expect earning growth rate be peg current year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
965,ISRG,bid strengthen medical management solution mms segment becton dickinson company bdx free report popularly know bd recently collaborate indiana base helmer scientific introduce refrigerate solution used bd new pyxis es refrigerator notably solution be first kind have be integrate automate dispense system post announcement new jersey base medical technology company share price drop marginal however past month bd rally impressive significantly outperform industry decline believe such favorable development provide cushion stock notably helmer scientific offer secure medical grade refrigerator freezer blood bank storage clinic lab pharmacy hospital research center university stock currently carry zack rank hold mms pyxis es system be significant contributor mms platform provide automate medication dispense system support decentralize medication management revenue last report quarter grow mms unit management upside be drive strong pyxis es adoption unite state well international growth come back news notification bd pyxis es be see bd healthsight viewer platform unique combination connective technology analytic expert service helmer access technology new bd pyxis es refrigerator provide storage refrigerate medication require temperature monitoring mms prospectsper research global medication management system market be expect reach value be poise see cagr period hence be conclude bd move have be timely strategic key picksa few better rank stock broader medical space be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
966,ISRG,medical device industry trend be reflective extensive discovery innovation life science industry past few year study publish cnbc medical device company have gain importance healthcare world improve research development technology far reach innovation gene therapy newer drug combination patient monitoring help big datum year shape medical fraternity unite state tax suspension fuel medical device market have further gain momentum owing recent year suspension controversial medical device tax excise tax be implement part obamacare medtech manufacturer significantly restrict activity accord article publish xtalk medical device tax be responsible reduction spending decline overall sale however be be see tax be fully eliminate resume year period now deferral encourage activity space bode well medtech company notably past month medical instrument industry have rally index return lead revolution medtechthe medtech space currently offer unprecedented opportunity growth market share expansion solid investment have help manufacturer use benefit big datum artificial intelligence ai medical mechatronic industry be also catch digital datum age enormous size datum be capture technology arrive business insight help healthcare sector provide better care reduce wastage latest trend adopt electronic health record ehr service medtech space have also be gain popularity major hcit healthcare bigwig have carved niche big datum domain be cerner corporation athenahealth inc company be make significant investment boost ehr platform meanwhile medical mechatronic be much await digital evolution global healthcare industry provide innovation healthcare industry reduction size age old medical device development low cost disposable device engineering concern einfochip believe mechatronic be future medical device benefit mechatronic have be see form printing cancer study development better medication deadly disease notably intuitive surgical isrg free report minimally invasive da vinci surgical system stryker corporation syk free report robotic arm assist surgery platform mako deserve mention here choose winning stocksgiven favorable scenario investment medical device stock strong potential seem be wise choice stock strong fundamental solid prospect make reward addition portfolio have take help zack stock screener select favorable stock shortlist stock vast universe medical product have picked one zack rank strong buy buy growth score notably growth score be comprehensive tool come handy screening winning stock broader sector research show stock growth score combine zack rank outperform most stock see complete list today zack rank stock here abiom inc abmd free report sport zack rank stock growth score be indicate outperformance term be underpin fact stock have impressive long term earning growth last day zack consensus estimate abiom current quarter earning share have increase cent abiom inc price consensus abiom inc price consensus abiom inc quotein past month share abiom have sky-rocket industry decline abiom flagship impella world smallest heart pump have continue be growth driver notably fourth quarter fiscal company spend year quarter integer holding corporation itgr free report carry zack rank have growth score long term earning growth be project last day zack consensus estimate integer hold current year earning share have increase integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quotein past month share integer holding have rally fare better industry integer holding have also be enhance profitability area advanced surgical orthopedic power solution focuse sale growth cost structure initiative company plan invest more area cardio vascular neuromodulation accelerate sale market penetration notably first quarter company spend year year basis varian medical system var free report stock have zack rank growth score company long term earning growth be project last day zack consensus estimate varian medical current year earning share have rise varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotein past month share varian medical have rally significantly beating industry varian medical ride solid growth prospect coveted halcyon radiotherapy treatment system hyperarc platform halcyon be design offer cost effective cancer care hyperarc be high definition radiotherapy technology second quarter fiscal company spend prior year quarter steris plc ste free report have zack rank growth score company current year earning growth be project last day zack consensus estimate steris fiscal earning share have increase steris plc price consensus steris plc price consensus steris plc quotein past month share company have rally considerably better industry company goal be provide infection prevention other procedural product service fourth quarter fiscal company invest year year basis idexx laboratory idxx free report carry zack rank growth score company long term earning growth be project last day zack consensus estimate idexx current year earning share have increase idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotein past month stock have rally significantly outperform industry company develop manufacture distribute product primarily companion animal veterinary livestock poultry first quarter company spend significant year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
967,ISRG,jun issue update research report walgreen boot alliance inc wba free report be currently look forward company modify rite aid contract expect benefit company long run stock carry zack rank hold be encourage company consistent sale increase retail pharmacy international business moreover walgreen boot have be gain traction slew strategic tie up bring more patient pharmacy be also upbeat company alliance express script company aim expand respective exist group purchasing effort latest pact be expect improve express script supply chain make medicine include biosimilar affordable accessible patient walgreen boot alliance inc price walgreen boot alliance inc price walgreen boot alliance inc quote positive apart walgreen boot decision buy stake china sinopharm hold guoda drugstore look promising provide strong impetus company worldwide retail pharmacy business limit number rite aid store acquisition also impress company have recently secure regulatory approval however walgreen boot face headwind form fierce competition tough industry condition even company continue reap benefit growth initiative major business tycoon be already advance pharmacy business fair market share notably slowdown generic introduction last few year have be affect walgreen boot margin also escalate reimbursement pressure generic drug cost inflation have be hamper walgreen boot margin significantly past month share walgreen boot have underperform industry stock have lose industry increase key pickssome better rank stock broader medical sector be illumina inc ilmn free report intuitive surgical isrg free report cheme corporation che free report illumina intuitive surgical sport zack rank strong buy cheme carry zack rank buy see complete list today zack rank stock here illumina expect long term earning growth intuitive surgical have expect long term earning growth rate cheme have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
968,ISRG,medtronic plc mdt free report have make encourage move respect aortic peripheral vascular apv business company recently announce receipt fda approval mm mm length pact admiral drug coat balloon dcb treat long superficial femoral artery sfa lesion patient peripheral artery disease pad company april medtronic receive approval treat sfa lesion mm length back support clinical datum complex lesion imaging cohort pact global study also cover long lesion stent restenosis chronic total occlusion group lesion length mm note pact admiral dcb receive fda approval december treat superficial femoral popliteal artery moreover be commercially available europe receipt ce mark approval so far more pad patient europe have be treat device glimpse apv medtronic revenue apv division improve year year constant exchange rate fourth quarter fiscal moreover peripheral vascular business grow low single digit latest development boost company performance segment market strategy gain traction peripheral vascular sub segment seem be align datum provide report interventional cardiology peripheral vascular device market be expect see cagr reach value believe high incidence peripheral artery disease due unhealthy lifestyle age population penetration company untapped market rise need minimally invasive angioplasty procedure technological advancement increase awareness person continue drive global acceptance technology view encourage factor believe company development regard pact admiral dcb be strategic be expect broaden customer base share price past month medtronic have be underperform broader industry stock have gain comparison industry increase nevertheless believe latest fda approval boost investor confidence stock zack rank key picksmedtronic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
969,ISRG,jun issue update research report haemonetic corporation hae free report company have be benefit continue momentum new business generation expand geography stock carry zack rank buy share lead provider hematology product solution have outperformed industry last month stock have rally compare industry rise haemonetic exit fourth quarter fiscal promising note earning revenue beating zack consensus estimate consistent momentum new business formation widening global footprint have also help company deliver strong result moreover gross operate margin growth buoy optimism investor stock additionally be upbeat haemonetic flourish plasma franchise solid end market demand plasma derive continue drive growth haemonetic be also confident maintain progress commercial plasma collection business further fiscal guidance look promising addition company strong cash position boost investor confidence flip side haemonetic operate fiercely competitive environment respect manual automate system include like mak system moreover company have be witness sluggish revenue growth blood center franchise significantly affect result past few quarters also management doesn expect quick recovery blood center outcome further add concern other key pickssome other top rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report abiom have project long term earning growth rate stock sport zack rank strong buy stryker have estimate long term earning growth rate stock hold zack rank intuitive surgical have expect long term earning growth rate zack rank see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
970,ISRG,rise agee population long track record chronic disease make unite state world largest medical device market furthermore market be currently ride recent suspension infamous medical device tax tax deferral year be likely prove beneficial company long haul significantly boost prospect research emergo medical device industry be project reach market value intuitive surgical inc isrg free report integer holding corporation itgr free report be close contender space notably intuitive surgical sport zack rank strong buy integer holding carry zack rank buy instill investor confidence stock intuitive surgical have growth score same integer holding be indicate latter better prospect long haul research show stock growth score combine zack rank be profitable pick see complete list today zack rank stock here here make detailed analysis company fundamental determine stock be currently position better medical instrument space market cap intuitive surgical engage design manufacturing coveted da vinci surgical system base texas integer holding manufacture develop medical device component primarily original equipment manufacturer company have market cap price performancein past month share integer holding have rally compare intuitive surgical gain industry decline stockshave also outperformed index return same time frame thus price performance be consider integer holding be advantageous position earning growth zack consensus estimate intuitive surgical current year earning be peg reflect project growth rate same integer holding stand indicate growth thus integer holding win round well sale growth zack consensus estimate intuitive surgical current year revenue be peg show anticipate growth same integer holding stand reflect growth here intuitive surgical score integer holding factor drive stocksintuitive surgicalca base intuitive surgical ride solid performance note da vinci surgical system notably system enable minimally invasive surgery help avoid trauma associate open surgery recent study be also find patient undergo robotic assist surgery used da vinci surgical system have lesser complication first quarter da vinci install base grow year year basis furthermore company recently begin direct operation india distributor vattikuti technology pvt ltd read more intuitive surgical commence direct operation india integer company recently sign agreement divest core advanced surgical orthopaedic unit medplast llc management expect deal unlock significant value long run notably first quarter segment generate revenue prior year quarter revenue witness organic growth year year furthermore company ride strong guidance expect adjust earning share reflect growth revenue be anticipate be indicate growth conclusionour comparative analysis indicate integer holding be position better intuitive surgical consider price performance style score earning growth projection other key picksa couple other top rank stock broader medical space be genomic health ghdx free report abiom inc abmd free report genomic health have expect earning growth rate current quarter stock flaunt zack rank abiom have expect long term earning growth rate sport zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free rise agee population long track record chronic disease make unite state world largest medical device market furthermore market be currently ride recent suspension infamous medical device tax tax deferral year be likely prove beneficial company long haul significantly boost prospect research emergo medical device industry be project reach market value intuitive surgical inc isrg free report integer holding corporation itgr free report be close contender space notably intuitive surgical sport zack rank strong buy integer holding carry zack rank buy instill investor confidence stock intuitive surgical have growth score same integer holding be indicate latter better prospect long haul research show stock growth score combine zack rank be profitable pick see complete list today zack rank stock here here make detailed analysis company fundamental determine stock be currently position better medical instrument space market cap intuitive surgical engage design manufacturing coveted da vinci surgical system base texas integer holding manufacture develop medical device component primarily original equipment manufacturer company have market cap price performance past month share integer holding have rally compare intuitive surgical gain industry decline stock have also outperformed index return same time frame thus price performance be consider integer holding be advantageous position earning growth projection zack consensus estimate intuitive surgical current year earning be peg reflect project growth rate same integer holding stand indicate growth thus integer holding win round well sale growth projection zack consensus estimate intuitive surgical current year revenue be peg show anticipate growth same integer holding stand reflect growth here intuitive surgical score integer holding factor drive stock intuitive surgical base intuitive surgical ride solid performance note da vinci surgical system notably system enable minimally invasive surgery help avoid trauma associate open surgery recent study be also find patient undergo robotic assist surgery used da vinci surgical system have lesser complication first quarter da vinci install base grow year year basis furthermore company recently begin direct operation india distributor vattikuti technology pvt ltd read more intuitive surgical commence direct operation india intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quoteinteger company recently sign agreement divest core advanced surgical orthopaedic unit medplast llc management expect deal unlock significant value long run notably first quarter segment generate revenue prior year quarter revenue witness organic growth year year furthermore company ride strong guidance expect adjust earning share reflect growth revenue be anticipate be indicate growth integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quote conclusion comparative analysis indicate integer holding be position better intuitive surgical consider price performance style score earning growth projection other key pick couple other top rank stock broader medical space be genomic health ghdx free report abiom inc abmd free report genomic health have expect earning growth rate current quarter stock flaunt zack rank abiom have expect long term earning growth rate sport zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
971,ISRG,express script hold company esrx free report have underperform broader industry last month company share have gain versus industry rally rapidly change healthcare environment unite state loss client stiff competition niche space be significant headwind company batter such challenge zack consensus estimate second quarter adjust earning be currently peg share last month same revenue be pin reflect year year decline stock have zack rank sell take sneak peek major issue plague express script loss patient mo base pharmacy benefit manager lose certain public sector client result year year decline adjust network claim last report quarter moreover adjust home delivery specialty claim totale quarter year year express script get script recently announce be get acquire cigna corporation global health insurance company acquisition be expect be conclude dec cigna take express script cash stock transaction worth competition rifeexpres script face intense competition patient benefit management industry independent pbms medimpact navitus health solution moreover pbm space be dominate bigwig cvs aetna cigna other guidance express script adjust earning share be estimate band significantly previous range key pickssome better rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank buy abiom have project long term earning growth rate stock hold zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
972,ISRG,cardinal health inc cah free report clayton dubilier rice cd recently announce joint investment plan navihealth notably tennessee base navihealth be acquire cardinal health deal value company have goal acquire entire business year navihealth currently serve more insure member manage care transition approximately acute hospital post acute care facility unite state meanwhile cd be oldest private equity firm world specialize buyout growth capital financing post announcement share cardinal health inched close however stock have decline industry increase past month stock currently carry zack rank strong sell come back news cd manage fund acquire approximately ownership stake navihealth cardinal health retain roughly interest business additionally cardinal health reserve call right reacquire business transaction be expect be complete third quarter latest strategic move enable ohio base distributor healthcare service deliver improve post acute care unite state market prospectsper frost sullivan post acute healthcare industry expect surge approximately revenue upside be attributable shift medically complex patient post acute care setting hence be conclude cardinal health decision have be timely strategic cardinal health acute patient health offer broad range acute patient care solution previously acquire navihealth coordinate care acute post acute set apart enable provider customize patient specific care plan company also analyze datum discover pattern optimize workflow furthermore cardinal health outpatient pharmacy solution enable healthcare provider boost patient population health management play critical role continue patient care discharge hospital home company have also launch line cardinal health hospital quality home consumer product allow patient caregiver buy same product used hospital support continuity care list include product related bath safety daily live aids key pickssome better rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report abiom have project long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank buy intuitive surgical have expect long term earning growth rate zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
973,ISRG,mechatronic high end technology incorporating electronic machine learn mechanical engineering have be vogue late grow prominence artificial intelligence ai robotic company organization significant exposure mechatronic have be rake huge profit research business wire decipher global mechatronic robotic market be project witness cagr period consider strong exposure mechatronic almost sphere technology automobile telecom more evolution medical mechatronic have be most fascinating grow prevalence minimally invasive robot assist surgery self automate home base care use information technology quick improve patient care well shift payment system value base model indicate predominance mechatronic medtech space so let delve detail medical mechatronic have be create new opportunity medtech raise investor confidence put money healthcare space long term gain be mechatronic shape healthcare paradigm medical mechatronic be much await digital evolution global healthcare industry medical mechatronic have provide innovation healthcare industry reduction size age old medical device development low cost disposable device portability device error free result hindawi renown healthcare engineering journal medical mechatronic revolution have be most important driver global knowledge base economy unite state here take look major aspect medical mechatronic have be do round global headline printing medical mechatronicsthe best example mechatronic healthcare industry be printing have change face medical device industry also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr major company stryker corporation syk free report have be early adopter printing technology company fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation robotic boost medical mechatronic rise mechatronic powerful compute improve sense molecular imaging have enabled new robotic solution mitigate age old problem medtech company solution be pain less error free inexpensive so medtech company be used mechatronic base robot cure disease have competitive edge strong customer base solid revenue handsome profit major company medtech giant intuitive surgical isrg free report be notable mention intuitive surgical design manufacture market da vinci surgical system advanced robot assist surgical platform mechatronic base platform enable minimally invasive surgery help avoid trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair day come let take look other medtech stock have be hog limelight base grow prevalence mechatronic artificial intelligence healthcare sector best medtech stock ride high mechatronicsin backdrop medtech stock be well position strong fundamental solid exposure mechatronic have used zack stock screener pick company have zack rank strong buy buy growth score research show stock growth score combine zack rank be better pick most abiom inc abmd free report stock sport zack rank growth score see complete list today zack rank stock here share abiom have surge year time compare favorably industry decline impella abiom flagship product line have continue be growth driver impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart expand flagship impella heart pump portfolio abiom recently announce receipt fda pre market approval pma impella cp heart pump smartassist april technology also feature optical sensor development have provide company significant exposure medical mechatronic company plan controlled roll technologically advanced heart pump hospital site develop heart recovery protocol next fiscal year varian medical system inc var free report stock have zack rank growth score share varian medical have gain year time varian medical have receive significant exposure medical mechatronic trend halcyon hyperarc platform halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt hyperarc platform be varian medical high definition radiotherapy technology apr varian medical launch halcyon kilovoltage imaging kv first human kv cone beam ct image halcyon be acquire washington university positive feedback image quality speed image acquisition process further varian medical hyperarc platform be design treat multiple metastase brain cancer case continue witness strong demand steris plc ste free report stock flaunt zack rank have growth score share steris have gain year time company manufacture market infection prevention decontamination microbial reduction surgical support product service steris acquisition base outsourced sterilization service provider synergy health plc be significant achievement buyout enabled combination steris infection prevention service business synergy hospital sterilization service today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
974,ISRG,jun issue update research report qiagen qgen free report company business be expect get boost flourishing molecular diagnostic market international expansion extend test menu growth drive strategic collaboration stock carry zack rank hold netherlands base molecular diagnostic provider offer innovative technology product pre analytical sample preparation molecular diagnostic solution share company have outperformed broader industry past month stock have rally versus decline industry qiagen end first quarter solid note be impressed year year growth most segment company also deliver strong performance respect operate margin meanwhile commitment return more shareholder increase repurchase reflect sturdy cash position expectation favorable currency movement ongoing year also buoy optimism investor be also upbeat qiagen progress test menu expansion strategy april company announce receipt fda pre market approval partosure same month launch qiastat dx europe follow closure recently announce stat dx acquisition completion defined development activity stat dx company be plan launch test unite state well other geography qiagen also launch novel liquid biopsy panel namely adnatest ar kit adnatest lungcancer kit first quarter qiagen announce receive approval japan ministry health labor welfare quantiferon tb gold qft diagnostic detect tuberculosis tb infection further recently change guideline issue world health organization center disease control international panel physician association add new impetus rise popularity proactive latent tb screening treatment also look forward implementation recently draw strategy boost top line contribution ngs next generation sequence portfolio meanwhile qiagen be expose stiff competition company be face severe rivalry firm provide competitive pre analytical solution other product used qiagen customer fact market company product be highly aggressive price sensitive further aggravate company wo also heavy reliance collaboration decline hpv human papillomavirus sale unite state be other negative industry player zack rank key picksqiagen currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
975,ISRG,issue update research report cardiovascular system inc csii free report notably number factor continue drive optimism stock instance company firm position coronary arterial disease cad peripheral arterial disease pad market space positive study result highlight effective technology impressive portfolio expansion well strong gross margin scenario player carry zack rank hold medical device manufacturer developer marketer innovative solution treat patient peripheral coronary arterial disease include arterial calcium see solid third quarter fiscal company witness year year rise revenue cad pad business also gross margin expansion be impressive past month share cardiovascular system have outperformed industry stock have surge compare increase industry company be putt effort innovate product investment market be also look forward recently launch coronary device japan reflect company focus widening international footprint cardiovascular system inc price cardiovascular system inc price cardiovascular system inc quote cardiovascular system have be broaden product portfolio enhance market reach be currently pursue product improvement evaluate new technology strengthen develop portfolio powerful micro invasive tool be also upbeat cardiovascular system new partnership have help extend portfolio company be now distributor orbusneich balloon product orbusneich pci balloon include sapphire ii pro have recently receive fda approval mm coronary balloon moreover company have sign original equipment manufacturer agreement integer holding corporation csi brand zilient guidewire additionally be optimistic favorable trend pad cad space american heart association many american suffer pad syndrome moreover age population couple rise incidence diabetes obesity be likely aggravate frequency pad complaint thus company growth area offer huge scope unique pad orbital atherectomy system oas cardiovascular system address hitherto unmet need market flip side company face cutthroat competition niche space oas product contend variety other product device treatment vascular disease include stent balloon angioplasty catheter atherectomy catheter well product used vascular surgery larger player contest stent balloon angioplasty market segment include bigwig abbott laboratory free report moreover profitability front cardiovascular system struggle long history net loss inception immediate recovery sight key pickssome better rank stock broader medical sector be intuitive surgical isrg free report amedisys inc am free report intuitive surgical sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate amedisys have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
976,ISRG,medtronic plc mdt free report diabetes group have be solid growth trajectory late encourage contribution majority sub segment expect strength reflect fourth quarter fiscal result be schedule release open bell click here know company overall performance be likely be diabetes focusmedtronic diabetes group presently comprise intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division diabetes segment develop manufacture market advanced integrate diabetes management solution include insulin pump therapy continuous glucose monitoring cgm system therapy management software note management expect double digit revenue growth diabetes group fourth quarter fiscal management consistently strong adoption minime system unite state enhance sensor supply capacity drive upside consequently zack consensus estimate diabetes group revenue indicate rise year quarter also estimate diabetes group revenue unite state reflect rise year medtronic plc price ep surprise medtronic plc price ep surprise medtronic plc quote last report quarter segment record improvement sale benefit increase uptake new sensor augment insulin pump system unite state well international market enhance production capacity same notably minime system have serve patient unite state apart management be optimistic uptick consumable revenue corporation johnson johnson diabetes care company user third quarter fiscal moreover have state company be progress well transition user expect trend continue yet be report quarter well fourth quarter fiscal medtronic proceed initiative boost performance minime portfolio february company expand product portfolio addition minime advance infusion set latest offer diabetes business be plan be make commercially available canada hong kong certain country europe fourth quarter fiscal same month company announce fda have approve new arm indication guardian sensor continuous glucose monitor cgm used minime insulin pump notably guardian sensor be company latest most accurate cgm medtronic be only sensor have receive fda nod control automate insulin delivery hybrid close loop system minime new arm indication guardian sensor offer more convenience flexibility patient be available unite state use minime system believe development be beneficial company diabetes group portfolio get reflect yet be report quarter result let see thing be shape sub segment fourth quarter release iim revenue rise high teen cer third quarter fiscal however company witness growth new patient count unite state growth be lead solid uptake minime system unite state guardian sensor cgm addition division deliver low digit constant currency growth international market account continue strength minime system give development regard minime system expect top line contribution continue uptake product rise get reflect soon be report quarter result dss grow mid single digit cer consumable benefit rise install base enhance patient utilization improvement business be expect continue zack rank stock currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate amedisys have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
977,ISRG,resm inc rmd free report recently demonstrated favorable outcome clinical analysis field chronic obstructive pulmonary disease copd study be conduct unite kingdom unite state highlight cost effectiveness combine home oxygen therapy home invasive ventilation niv therapy persistent hypercapnia patient suffer exacerbation copd combo regimen home oxygen therapy home mechanical ventilation home niv together know hot hmv have be present american thoracic society international conference be company sponsored health economic study go study hot hmv treatment reduce exacerbation frequency day hospital readmission datum analysis be used develop economic model national health service perspective study demonstrated reduction day readmission hot hmv patient compare home oxygen alone evidently indicated treatment be hugely cost effective resm analysis be base study study find be utilize build economic model payer perspective be optimistic entire development resm take consideration widely grow market copd treatment datum provide gbi research global copd market be currently worth be project reach value accord research report gape demand be meet numerous new efficient convenient product make inroad market undoubtedly resm hot hmv study related favorable outcome be step forward company intensify footprint niche market notably resm achieve strong global revenue growth past few quarters lead sale sleep device respiratory care device mask system well software solution believe resm product launch strategy gain traction sdb market be expect drive growth company term recent development company inform first self brand portable oxygen concentrator mobi subject fiscal third quarter launch have also introduce airmini world smallest pap positive airway pressure device past month resm have outperformed industry stock have gain compare rise industry zack rank key picksresm currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report cooper company inc coo free report intuitive surgical illumina sport zack rank strong buy cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate cooper company have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
978,ISRG,illumina inc ilmn free report have be gain investor confidence consistently positive result past year company share price have outperformed industry stock have gain industry fall also company have outperformed gain renown sequence array base genetic analysis solution provider have market cap company have earning growth rate next year solid prospect zack rank strong buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable solid quarterly exit first quarter solid note better expect earning revenue be also encourage significant year year growth count substantial upside be attribute strong consumable growth illumina sequence portfolio new product bode wellwe be upbeat illumina product launch continue contribute top line management be hopeful recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety mfds south korea last november illumina introduce nextseq dx instrument well be company second fda regulate ce ivd marked next generation sequence ngs system effort grow oncology spacellumina collaboration bristol myer squibb loxo oncology field clinical oncology application be expect garner positive result alliance bristol myer squibb utilize illumina ngs technology develop globally commercialize diagnostic ivd assay support bristol myer squibb oncology portfolio also look forward grail illumina recently develop company focuse cancer screening market believe grail be expect significantly expand illumina share multus dollar oncology market geographic expansionapart north america illumina market distribute product directly customer europe latin america asia pacific apac region direct selling force distributor specialize life science product first quarter illumina witness growth apac region propel shipment growth greater china obviously emerge market china be currently most favorable space illumina business recent time management have noticed considerable increase demand customer attempt set nipt operation china believe recent progress china open avenue illumina thereby enhance business growth other key picksother top rank stock broader medical sector be intuitive surgical isrg free report cheme corporation che free report amedisys inc am free report intuitive surgical cheme sport zack rank amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cheme have long term expect earning growth rate amedisys have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
979,ISRG,medtronic plc mdt free report restorative therapiesgroup rtg have be strong growth trajectory late encourage contribution majority sub segment expect strength reflect fourth quarter fiscal result be schedule release open bell click here know company overall performance be expect be rtg focusmedtronic rtg presently comprise spine brain therapy specialty therapy pain therapy division note management expect revenue growth rtg business fourth quarter fiscal management guidance balance ongoing strength pain brain therapy segment adverse impact weaken spine market consequently rtg zack consensus estimate revenue indicate rise year quarter medtronic plc price ep surprise medtronic plc price ep surprise medtronic plc quotein last report quarter segment record improvement sale drive low double digit growth brain therapy mid single digit growth specialty therapy high single digit growth pain therapy cer however revenue spine business remain flat cer year year basis let see thing be shape sub segment fourth quarter result brain therapy brain therapy now include neurovascular neurosurgery business company have be witness major development neurovascular business receive solid contribution stroke portfolio last report quarter medtronic announce receipt fda approval riptide aspiration system january add valuable tool company acute ischemic stroke ais product portfolio benefit get reflect yet be report quarter further april medtronic announce ce mark receipt launch visualase mri guide laser ablation system europe notably visualase system be used neurosurgery procedure provide advanced mri guide laser ablation technology development help company continue witness strength brain therapy business pain therapy pain therapy division now include pain spinal cord stimulation drug pump interventional spine business contribute encouragingly company top line third quarter fiscal pain therapy witness growth solid uptake intelli platform spinal cord stimulation well strength drug pump january company announce receipt fda approval new clinician programmer use synchrome ii intrathecal drug delivery system again april medtronic announce launch optisphere embolization sphere resorbable embolic platform develop embolization hypervascular tumor view company effort develop pain therapy division believe solid trend continue reflect be report quarter result well spine medtronic spine division include core spine bmp kanghui business last report quarter low single digit decline core spine be more offset mid single digit growth bmp cer management combination enable technology imaging navigation power instrument nerve monitoring mazor robotic spine implant have spur growth division expect encourage top line contribution business be report quarter zack rank stock currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate amedisys have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
980,ISRG,bid make quality radiotherapy treatment readily accessible varian medical system inc var free report recently announce software technology training education cooperation agreement brazil ministry health moh university science technology institution ict brazil enable company fight cancer treatment brazil latin america follow announcement varian medical share price inched close be likely provide further cushion company share have gain compare industry decline year time participate ict be select varian medical basis criterium candidate interview history successful project project management expertise propose team member experience company global engineering team switzerland finland unite state train researcher select ict june california base provider radiotherapy proton therapy thus be able fortify international position expand knowledge radiation therapy technology software meanwhile korea varian medical flagship hyperarc high definition radiotherapy hdrt be used treat patient brain cancer hyperarc be high definition radiotherapy technology provide intracranial radiosurgery solution capitalize unique capability varian medical truebeam edge treatment system be support company eclipse treatment plan software varian medical radiotherapy magnatevarian medical have make noteworthy progress radiotherapy niche notably company halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide coveted hyperarc platform be design treat multiple metastase brain cancer case continue witness strong demand last report quarter halcyon platform witness total order majority greenfield site inception halcyon have see more order emerge market furthermore europe middle east india africa geography company revenue grow constant currency respectively market prospectsper research market market global radiotherapy market be project reach cagr market be expand healthy pace account grow number cancer case rise sophistication novel treatment procedure zack rank other key picksvarian medical currently carry zack rank buy other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
981,ISRG,cerner corporation cern free report be underperform company medtech space stiff competition soft first quarter be major headwind moment past year cerner stock have lose industry rally last day estimate moved south versus upward revision indicate analyst pessimism regard stock zack consensus estimate earning share drop cent cerner have zack rank strong sell indicate possibility term therefore be time dump stock portfolio offload view second quarter cerner expect revenue zack consensus estimate second quarter revenue be peg give range cerner expect revenue range range notably current year zack consensus estimate revenue guide range cerner expect adjust earning share prior guidance decline resultsin first quarter cerner sale license software fall year year basis lower expect subscription booking impede growth segment notably subscription account revenue year year basis moreover operate margin last report quarter be basis point bps year year basis downside be attribute year year rise operate expense upside be lead personnel expense related revenue generate associate cash item company have long term debt end first quarter stiff competitionat present cerner face aggressive competition industry repute name allscript healthcare solution epic system ge healthcare technology mckesson corp quality system significant challenge apart dent pricing margin key picksa few better rank stock broader medical sector be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
982,ISRG,dentsply sirona xray free report have underperform industryin last month company share have lose compare unfavorably industry gain current level be also significantly lower index return rapidly change healthcare environment unite state sluggish first quarter decline margin foreign exchange headwind be significant obstacle company batter challenge zack consensus estimate second quarter adjust earning be currently peg cent last month also mark fall year year stock have zack rank strong sell take sneak peek major issue plague dentsply sirona company expect gross margin operate margin remain flat slightly year year basis come quarters be underlie margin rate improvement be expect be offset foreign exchange effect headwind target inventory equipment reduction further company be commit deliver operate cost saving fiscal expect more half amount saving result increase margin time same be likely be affected end first quarter dentsply sirona confirm expect full year operate margin be basis point bps bps year year basis regard dentsply sirona report adjust earning share ep cent first quarter year year metric beat zack consensus estimate net sale fall year year constant currency cc basis however figure surpass zack consensus estimate management expect adjust earning share range previous range revenue be project rise cc dentsply sirona have solid international presence therefore strong dollar especially euro well emerge market currency have negative impact result believe currency volatility remain headwind company face significant pricing pressure due intense competition dentsply sirona conduct operation domestic foreign highly competitive market condition size number company competitor vary product line regionally key picksa few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate stock flaunt zack rank intuitive surgical have expect long term growth rate sport zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
983,ISRG,luminex corporation lmnx free report report first quarter earning cent share beating zack consensus estimate cent further earning rise year year basis past month share luminex have gain industry decline luminex carry zack rank buy revenue detailrevenue come beating zack consensus estimate revenue also increase year quarter strength molecular diagnostic franchise notably first quarter luminex report revenue worth molecular diagnostic unit year year be drive sample answer molecular product revenue totale year quarter quarter review company place sample answer molecular system contract compare prior year quarter currently total active sample answer customer be just sample answer utilization customer grow customer verigene ary respectively particularly sale verigene platform grow same ary nearly triple year quarter luminex corporation price consensus ep surprise luminex corporation price consensus ep surprise luminex corporation quote segment analysissystem salesrevenue segment come year quarter consumable segment account revenue year year royalty revenuesroyalty revenue come year year basis assay revenuesthis segment post revenue worth increase year year basis be increase company automate product automate product see rise service revenuesrevenue segment totale nominal year quarter otherother revenue come year marginsgross profit report quarter be year year gross margin be contract basis point bps operate expense totale reflect drop year year basis operate profit be prior year quarter operate margin come bps balance sheet detailsluminex balance sheet remain strong debt free company exit quarter cash cash equivalent guidanceluminex expect second quarter revenue notably second quarter zack consensus estimate revenue be peg be slightly give range company expect revenue zack consensus estimate revenue be pin give range end first quarter solid note beating zack consensus estimate count molecular diagnostic revenue drive result company also ride solid ary verigene platform assay royalty revenue also witness upside new product pipeline be likely expand company portfolio furthermore solid revenue guidance buoy optimism fall operate expense expand operate margin be major positive flip side management first quarter see lowest system placement gross margin contract significantly system consumable service revenue decline year year basis highly competitive life science industry add wo other key pickssome other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
984,ISRG,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
985,ISRG,unite state be world largest medical device market be expect improve further aid long track record chronic disease also suspension controversial medical device tax year industry be currently ride high optimism research emergo medical device industry be project reach market value stryker corporation syk free report surmodic inc srdx free report be close contender space notably stock carry zack rank buy raise investor optimism stock also have vgm score research show stock vgm score combine zack rank strong buy be profitable pick here make detailed analysis company fundamental determine stock be currently position better medical product space market cap stryker be lead medical device company operate global orthopedic market other hand base minnesota surmodic be lead provider medical device diagnostic ivd technology company have market cap price performancein past year stryker share have gain compare industry rise stock have also surpass index increase meanwhile share surmodic have sky-rocket period price see complete list today zack rank stock here earning zack consensus estimate stryker current year earning be peg share reflect project growth same surmodic be peg cent indicate decline moreover stryker earning share have witness cagr surmodic earning project negative cagr totale cent hence stryker win round sale zack consensus estimate stryker current year revenue be peg show growth same surmodic be pin reflect growth stryker revenue witness cagr reach surmodic revenue depict negative cagr here too stryker win surmodic factor drive robotic arm assist mako surgery platform have be consistently drive top line last report quarter platform record new robot installation globally notably mako tka knee platform drive orthopaedic segment deliver organic growth recently company raise guidance second quarter buoy optimism stryker corporation price consensus stryker corporation price consensus stryker corporation have be acquisition spree recently company announce have reach agreement embolitech acquire innovative thrombectomy platform technology be likely enhance company focus develop highly differentiate whole product solution medical device customer recently company receive approval fda low profile percutaneous transluminal angioplasty pta balloon dilation catheter notably device be design broad range peripheral vascular application moreover partnership medtech bigwig abbott be also major positive surmodic inc price consensus surmodic inc price consensus surmodic inc quotein conclusionour comparative analysis indicate stryker be position better surmodic consider price performance well earning sale growth other key picksa few other top rank stock broader medical space be genomic health ghdx free report intuitive surgical inc isrg free report genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
986,ISRG,medical instrument industry broader medical universe have be gain innovation higher consolidation focus emerge market tax abolition industry increase month time higher index rise fundamentally industry have benefit massive change consumer behavior well be evident rise minimally invasive surgery higher demand liquid biopsy test well use quick improve patient care shift payment system value base model be interesting analyze best medical instrument stock be likely yield solid return day come first let glance latest headline space latest medical instrument headline glance stryker takeover plan boston medical instrument fraternity have be ride current merger acquisition trend recent report reuter stryker corporation syk free report be likely take boston scientific corporation bsx free report create market value more however possibility deal be uncertain thre be confirmatory statement press release company representative fact investor never forget stryker highly rumore acquisition plan nephew never materialize brighter side be not first time stryker have be tie boston scientific company acquire boston scientific neurovascular unit indicate probability second collaboration read more stryker likely acquire boston scientific stryker have zack rank buy deal materialize combine entity have medtech broadest spectrum product offering include cardiology orthopaedic surgical supply neuroscience reduce pricing pressure competition further company strong acquisition policy gain rapidly expand customer base moderate leverage enhance cash flow glance major acquisition recent past becton dickinson company takeover bard johnson johnson buyout covidien deserve mention abiom reserve slot lead medical instrument player abiom inc abmd free report replace wyndham worldwide corp enter global industry classification standard gic health care supply sub industry index research report globe mail abiom be follow trend medical device technology company reserve top slot index remind investor align technology inc algn free report top index abiom currently have market capitalization further company financial viability adequate liquidity reasonable price sector representation have lend competitive edge medical instrument industry read more abiom replace wyndham benchmark tax abolition boost da bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief tax take toll entire medical device industry enactment advanced medical technology association lobbying group tax have negative impact medical innovation result loss defer creation job now deferral encourage activity space repeal tax paradigm be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have invoked massive investment sector top medical instrument existence number player medical instrument industry choose right stock potential yield return be daunting task proprietary zack methodology make fairly simple have take help zack stock screener select favorable stock have select stock have favorable growth style score carry zack rank strong buy research show stock style score combine zack rank offer best investment opportunity see complete list today zack rank stock here varian medical system inc var free report outperformed industry month time stock have return have zack rank zack consensus estimate full year earning be currently peg year year june varian medical system demonstrated comprehensive portfolio advanced brachytherapy solution american brachytherapy society annual meeting development be likely boost varian oncology system segment apart various volumetric modulate arc therapy vmat stereotactic radiosurgery stereotactic radiotherapy brachytherapy unit be significant contributor oncology system company have be gain consistently coveted halcyon platform cost effective radiotherapy cancer treatment system notably company also launch halcyon kilovoltage imaging solid revenue oncology grow adoption particle therapy strong overseas presence particularly emerge country be positive varian have also be go global acquisition agreement recent buyout include sirtex australia coop taiwan partnership ministry health brazil solid guidance fiscal instill confidence intuitive surgical inc isrg free report outperformed industry month stock have rise almost sport zack rank zack consensus estimate full year earning be currently peg year year grow adoption company da vinci system increase procedure volume continuous innovation solid recur revenue base be key catalyst intuitive surgical da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand movement be translate smaller precise movement tiny instrument patient body da vinci have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery da vinci system have make available minimally invasive surgery more patient worldwide recently system have cure patient diagnosed inguinal hernia integer holding corporation itgr free report outperformed industry last month stock have return industry decline zack consensus estimate full year earning be currently peg year year company witness impressive start high organic year year growth earning revenue cardio vascular arm deserve special mention here other segment have also be deliver solid performance strategic divestment advanced surgical orthopedic portable medical wing medplast llc be expect prove profitable quarters ahead company have multus year plan long term development impressive guidance decline operate expense clear debt be other major positive hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
987,ISRG,abiom inc abmd free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock therefore time advantage stock price appreciation earning report abiom stock have rally further share have rise whopping significantly outperform industry decline year time current level be also higher index return last day zack consensus estimate earning rise cent company have zack rank strong buy indicate possibility outperformance term furthermore stock have growth score research show stock growth score combine zack rank buy be better pick most let find bullish trend sustain stock impressive performance long run make attractive benchmarkabiom recently joined coveted benchmark replace wyndham worldwide corp abiom currently have market capitalization cement position further company strong fundamental adequate liquidity reasonable price sector representation have lend competitive edge medtech industry read more abiom replace wyndham benchmark impella solid driverabiom flagship product line impella continue be growth driver last report quarter company witness increase adoption impella product unite state germany japan company flagship impella rp have see launch new site introduction recently impella be used treat year old cardiac patient mitsui memorial hospital lead cardiovascular center japan abiom recently announce receipt fda pre market approval smartassist moreover recent ce mark impella europe enhance product line significantly enabled company advance field heart recovery fy view fiscal company expect total revenue range reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range full year tax rate be expect other key pickssome other top rank medical stock be varian medical var free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
988,ISRG,varian medical var free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock past year varian medical share have rally versus industry decline current level be also better index gain last day zack consensus estimate current year earning have improve share california base provider radiotherapy solution carry zack rank buy indicate possibility outperformance term furthermore stock have growth score research show stock growth score combine zack rank strong buy be better pick most let find bullish trend sustain stock impressive performance long run make attractive pickdiverse product portfoliovarian medical boast highly diverse product spectrum have secure solid customer base year halcyon radiotherapy treatment system hyperarc platform deserve special mention regard notably halcyon platform have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt meanwhile hyperarc be high definition radiotherapy technology design treat multiple metastase brain cancer case furthermore varian medical recently announce plan demonstrate comprehensive portfolio advanced brachytherapy solution be expect boost company oncology system segment read more varian demonstrate brachytherapy solution portfolio strong international presencevarian medical foresee substantial opportunity cancer care emerge market company have expand reach strategic overseas buyout varian medical sign agreement acquire sirtex australian base company focuse interventional oncology therapy additionally cooperative cl enterprise lead distributor radiotherapy equipment taiwan have be acquire varian medical moreover varian medical recently announce software technology training education cooperation agreement brazil ministry health moh bid make quality radiotherapy treatment readily accessible latin america read more varian medical merge brazil moh fight cancer solid guidancevarian medical provide solid guidance fiscal revenue growth be expect range year year basis fiscal zack consensus estimate revenue be peg adjust earning share be project range zack consensus estimate same be pin guide range other key picksa few other top rank medical stock be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank abiom have project long term earning growth rate stock hold zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
989,ISRG,share medidata solution inc mdso free report have gain release first quarter result apr rally be backed better expect earning share ep revenue growth segment past month company have gain significantly outperform industry return zack rank hold company report adjust ep cent outpaced zack consensus estimate earning improve prior year quarter quarter first quarter gross year revenue beat zack consensus estimate management be optimistic broaden customer base owing significant enterprise agreement sign first quarter medidata solution inc price consensus ep surprise medidata solution inc price consensus ep surprise medidata solution inc quotesegment revenue come year year basis management total subscription backlog increase year year basis more revenue professional service gross prior year quarter marginsin first quarter gross profit come year year gross margin be impressive contract basis point bps adjust operate income totale year year basis adjust operate margin be bps company have retain guidance total revenue be expect represent year year growth notably zack consensus estimate be peg project range subscription revenue be anticipate professional service be expect garner approximately gaap operate income be expect gaap net income be project wrapped first quarter solid note strong growth record subscription segment be major positive improvement operate margin buoy optimism company also ride newly sign enterprise agreement quarter be likely broaden customer base furthermore medidata be gain momentum area payment etmf imaging mhealth company coveted rave genomic platform be also see slew development management foresee tremendous scope research development well flip side decline gross margin raise concern company also face stiff competition niche space key picksa few better rank stock report solid result earning season be intuitive surgical isrg free report abiom inc abmd free report varian medical system var free report intuitive surgical abiom sport zack rank strong buy varian medical carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent beat zack consensus estimate revenue be surpass consensus estimate varian medical report second quarter fiscal adjust earning share beat zack consensus estimate revenue totale beat consensus mark intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus mark more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
990,ISRG,jun issue update research report cvs health cvs free report increase demand pbm pharmacy benefit management specialty pharmacy be major growth driver stock dull retail performance last few quarters seem have disappoint investor company carry zack rank hold share company have outperformed industry past month stock have lose compare decrease broader industry cvs health end first quarter mixed note earning be ahead zack consensus estimate revenue lag same however top line year year growth be drive strong pharmacy service segment benefit upside specialty service strong pbm selling season be favorable factor notably company be already more halfway renewal retention rate be currently line rate have witness last few year tough pricing competition cvs health currently gain momentum high level service execution competitive pricing unique integrate model allow company provide differentiate product service generate saving better health outcome well convenience moreover solid year year retail ltc comparison be encourage company be presently move achieve completion aetna deal cvs health landmark acquisition health insurance giant introduce vast change healthcare landscape unite state investor be hopeful cvs health earn draw term synergy aetna transaction post closure meanwhile company commencement momentous healthcare consolidation be keep analyst upbeat successful culmination cvs health expect reap low mid single digit accretion second year post close buyout flip side company highly competitive retail pharmacy business be big concern face stiff rivalry pharmacy segment be availability low cost pharmacy option other retail business continue add pharmacy department portfolio particularly discount retailer have make substantial inroad gain major market share apart cvs health deliver sluggish number retail long term care business recent past company decision restrict participate tricare network many fully insure prime network be due negative impact pharmacy sale script comp key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
991,ISRG,share orthofix international ofix free report have lose past week company first quarter earning release apr better expect bottom line number share drop due lower earning outlook company period company have also significantly underperform industry belong stock have lose industry gain let delve deeper earning detail orthofix company report first quarter adjust earning share ep cent continue operation figure be ahead zack consensus estimate bottom line surge year year primarily strong sale growth company biostim extremity fixation spine fixation strategic business unit sbu exclude time item net income continue operation first quarter come cent share versus net loss continue operation cent thereby show remarkable year year improvement sale detailsorthofix first quarter sale improve constant exchange rate cer almost line zack consensus estimate result company adoption revenue recognition accounting change begin orthofix note convert consolidated revenue first quarter new standard growth have be cer report quarter sale be primarily drive strong performance company sbus namely biostim extremity fixation spine fixation partly offset year year decline biologic business sbu first quarter company post biostim sale reflect same cer growth prior year period extremity fixation sale be quarter review improvement cer first quarter company realize continue uptake new product commendable performance most company global market include unite state orthofix international price consensus ep surprise orthofix international price consensus ep surprise orthofix international quoteorthofix report spine fixation sbu sale reflect cer growth year earlier quarter uptick be attribute product launch adopt strategic initiative biologic sbu sale totale same cer year quarter decline result contractual reduction marketing service fee percentage orthofix receive mtf biologic marginsin first quarter gross margin contract basis point bps unfavorable sale mix impact quarterly gross margin sale marketing expense rise year year general administrative expense be company witness decrease research development expense overall adjust operate margin expand bps owing increase operate expense cash exit first quarter cash cash equivalent compare end first quarter net cash used operate activity be compare year have lower earning view expect biologic sale be flat less low single digit full year due contractual decrease marketing service fee company be go receive mtf biologic adjust ep continue operation be expect range fall earlier project band zack consensus estimate full year adjust ep stand company project range full year net sale projection have be increase band earlier prediction be zack consensus estimate full year revenue be peg lie upper end guide range takeorthofix exit first quarter mixed note earning exceed zack consensus estimate sale almost match consensus mark investor be upset poor biologic prospect continue be drag overall performance remainder year accordingly company have reduce full year earning expectation apart currency fluctuation competitive landscape macroeconomic headwind continue challenge company moreover higher cost operate expense be matter grave concern orthofix also heavy dependence third party final distribution product expose company heighten risk positive note top line be substantially drive strength extremity fixation well spine fixation business be expect continue term back sale force enhancement expand distributorship network introduction product zack rank key picksorthofix carry zack rank sell better rank stock broader medical space have post solid result earning season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beating zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep outshine zack consensus estimate revenue come outpace zack consensus estimate baxter post first quarter adjust bottom line cent exceed zack consensus estimate top line come edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
992,ISRG,amedisys inc am free report recently purchase back half kkr co holding common share more specifically company buy back more common stock global investment firm total transaction value deal also include aggregate outstanding share company common stock repurchase deal reflect price be yesterday close value transaction be immediately accretive company bottom line follow news share amedisys inched close trading monday jun amedisys be expect finance deal used available cash exist revolve credit facility company be left cash hand outstanding borrowing credit facility turn result net leverage ratio approximately home health hospice care provider amedisys be upbeat recent development remain line strategy deploy capital accretive manner maintain low leverage substantial borrow capacity future investment regard amedisys accretive acquisition continue be first priority capital deployment accordingly company consider transaction best utility capital give current buyout multiple company business prospect company also note kkr continue remain significant shareholder amedisys accordingly nathaniel zilkha member general partner kkr co still remain director amedisys board other recent acquisition amedisysover past year company make number strategic acquisition recent be east tennessee personal care service etpcs personal care provider headquarter knoxville tn amedisys buyout enlarge company personal care footprint outside massachusett florida apart company buy intercity home care personal care provider base malden notably intercity home care entire asset base have be take associate home care amedisys believe have wider presence massachusett other important acquisition late include home health center illinois massachusett texas hospice care center arizona massachusett tenet healthcare asset home staff earlier february last year share price performanceover past month share amedisys have outperformed industry belong stock have rally compare industry rise zack rank other key picksamedisys currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report varian medical system inc var free report intuitive surgical illumina sport zack rank strong buy varian medical carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth varian medical have expect earning growth rate current year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
993,ISRG,fresenius medical care fms free report post adjust earning cent american depositary share ad first quarter miss zack consensus estimate earning ad decline year year basis quarter review revenue inched year year miss zack consensus estimate constant currency cc revenue decline year year revenue first quarter witness negative impact result foreign currency translation stock have zack rank strong sell fresenius medical have outperformed industry past year company share have return compare favorably industry decline fresenius medical care price consensus ep surprise fresenius medical care price consensus ep surprise fresenius medical care quotesegmental detailshealth care service revenue decline cc year year basis segment witness organic growth year year health care product revenue increase cc organically dialysis treatment increase quarter review courtesy strong contribution same market treatment synergy acquisition geographical growthnorth america revenuesby geography north america revenue decline cc year year basis account total revenue health care product revenue inched cc higher sale renal pharmaceutical peritoneal dialysis product hemodialysis solution concentrate however be partially offset lower sale machine dialyzer end quarter company treat patient clinic north america year year be fuel higher dialysis treatment increase revenue treatment dialysis care business grow cc year year basis region meanwhile care coordination segment decline cc drive shift calcimimetic drug clinical environment unfavorable foreign exchange rate partially offset solid growth region emea revenuesrevenue region increase year year basis cc health care service health care product revenue emea segment increase cc year year basis dialysis product revenue grow cc courtesy higher sale product acute care treatment machine peritoneal dialysis product renal pharmaceutical health care service segment be primarily drive growth same market treatment however same be partially offset decline organic revenue treatment growth dialysis product revenue region be boost higher sale product acute care product peritoneal dialysis machine however be partially offset lower sale dialyzer end quarter company have patient be treat clinic emea region year year dialysis treatment increase year year basis region asia pacific revenuesrevenue asia pacific grow cc year year basis net health care service unit increase cc health care service segment asia pacific region be support acquisition cura group australia meanwhile health care product business increase cc year year basis growth segment be mainly drive higher sale chronic hemodialysis product product acute care treatment dialysis treatment region grow region latin america revenuesrevenue region increase cc year year basis notably health care product increase year year company treat patient clinic latin america year year dialysis treatment increase region solid sale machine well disposable dialysis treatment drive revenue latin america margin profit decline report quarter cc percentage revenue gross margin decline basis point bps revenue quarter fresenius medical estimate revenue growth band cc lower previous guidance cc zack consensus estimate revenue be currently peg reflect rise year year net income attributable shareholder be likely increase medical exit first quarter dull note miss zack consensus estimate count dull performance north america have be major dampener company continue face significant foreign exchange headwind further higher cost related dialysis service peritoneal dialysis product business china be likely put margin pressure fresenius medical face highly regulate environment almost country operate company have fulfill specific legal requirement include tough antitrust regulation company reconfirm mid term outlook growth strategy aim boost revenue corresponding average annual growth rate strong performance health care product segment hold promise wide range dialysis product be major catalyst company earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
994,ISRG,global week ahead keep eye trade war ball accord scotiabank watchful fx team market be gradually inform development china trade tension come week china trade war tension likely begin escalate week tuesday trade representative ustr hold public hearing address propose list tariff import china comment period end sometime first half june ustr revise list tariff send recommendation president trump then decide enact tariff mixed fray be ustr next list tariff chinese import more hearing similar process also friday bring treasury deadline proposal restrict chinese investment specifically related intellectual property seem liberally interpreted china potential retaliation move further inflame tension addition reuter london share world market theme operate global week ahead theme be trader investor be watch most closely fresh retail sale number come outeconomist poll reuter see april retail sale due tuesday grow just percent moderate march percent rise exclude automobile sector sale be expect increase percent percent march recent tax change be estimate have reduce annual personal taxe mean more money pocket consumer drive third economy now personal income tax season have come go bulk taxpayer refund have find way person pocket do consumer spend more economist reckon datum help shape debate many time federal reserve raise interest rate year bond market currently be bet least more increase combination extra spending tax cut frontload positive now see translate robust economic performance trader see fed track raise interest rate june consumer price rebound modestly april oil pricesoil price be highest surge show sign wane fact barrel be sight brent crude decision pull iran nuclear deal re impose sanction have push brent higher week biggest consecutive weekly rise be now past year iranian oil export start fall new sanction take hold even other opec country manage fill gap global oil market be still pretty finely balanced brent reach barrel second quarter next year bank america lynch predict add oil be rule question be now impact inflation central bank policy inflationary pressure develop world remain muted economic textbook suggest not long european be action have be heating europe april record highest value monthly deal year accord thomson reuter datum week ve have private equity firm agree buy zoopla owner zpg send share record high lift other online consumer focuse firm such auto trader rightmove japan takeda be buy shire cable giant comcast be seek approval bid buy british pay tv group sky uk particular be draw attention foreign buyer due still depress level pound fact stock trade discount long run average month forward pe basis credit suisse wealth management add uk equity most prefer market bank america lynch say be rotate europe uk euro stoxx index be close fully regain ground lose february volatility shock uk ftse be flat year be much percent week back deal make activity provide lift positive territory benchmark italy have new governmentafter week wrangling italy soon get new government make far right league establishment star movement market have so far take italian political risk stride league star tie be worst case scenario group be hostile eu budget restriction have make electoral pledge cost billion euro implement wonder cost insure italian debt default have bond yield have hit week high share be set biggest weekly fall week italian german bond yield gap key indicator relative risk have also widen remain level see march election clearly investor be still willing look politic week be long time politic party be yet agree be prime minister star member have even hint premier be independent figure not affiliated group watch happen malaysia big election winmalaysian market re open next week investor have day chew shock election result see incumbent prime minister najib razak lose year old mahathir mohamad end uninterrupted decade run ruling coalition offshore market be uneasy ringgit lose percent deliverable forwards market overseas malaysian equity fund show percent drop cost insure default malaysian debt rise more basis point election fear be mahathir be power year include late financial crisis fulfill pledge remove good service tax scrap toll fee reinstate fuel subsidy renegotiate chinese investment deal hit budget revenue mahathir have also vow corruption reform better governance be achieve remain be see now uncertainty take center stage top zack rank strong buy stock bp plc bp free report market cap oil stock have zack long term vgm score oil price rise fall story likely play here texas instrument txn free report market cap semiconductor stock be always news keep eye stock week trade tension intellectual property rise china intuitive surgical isrg free report medical device stock be front center represent key intellectual property available surgery technology day stock be richly price share type company be market be look growth key global macro light schedule week week ahead china report retail sale growth monday eurozone report gdp growth tuesday brazil address monetary policy wednesday report latest housing start permit wednesday too monday cpi india come have be tracking tuesday india export import growth datum come export have be weak import look strong peru proxy gdp look good look rise comparison chile gdp go china retail sale be beware be always steady number eurozone gdp seasonally adjust come have be be strong europe group wednesday brazil monetary policy rate selic rate fall japan gdp growth rate come have be annualize term germany key consumer inflation rate hicp come have be eurozone core hicp come have be housing start permit be stronger now be spring thursday malaysia gdp growth come have be initial claim be great again be last week overnight policy rate be flat friday russia gdp growth rise yes weak folk hong kong unemployment rate get revisit
995,ISRG,cheme corporation che free report have be gain investor confidence consistently strong performance upbeat result past month company share price have outperformed industry stock have gain compare industry also company have outperformed gain cheme have market cap moreover have deliver average earning beat trail quarters solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction magnitude estimate revision earning share increase zack style score system cheme sport growth score hint solid prospect research show stock growth style score combine zack rank strong buy offer best upside potential regard cheme have favorable net margin net income sale better industry project annual earning growth rate compare favorably industry moreover debt capital ratio bode well compare industry let find recent positive trend be sustainable cheme kick start solid note earning revenue beating zack consensus estimate stellar performance be drive steady year year revenue growth company subsidiary cheme vita business management note recent admission trend have be positive momentum be expect continue first quarter vita perform well financially operationally increase geographically weight average medicare reimbursement rate average daily census decline medicare cap also lend support revenue moreover be encourage vita median length stay recently report quarter turn be key indicator company penetration high acuity sector market roto rooter business also see consistent growth strong performance core plumbing drain clean service segment well solid growth water restoration further company see year year rise commercial residential revenue additionally cheme strong cash balance allow carry share repurchase program provide solid return investor moreover expansion gross operate margin buoy optimism flip side reimbursement related issue seasonality business competitive landscape dependence government mandate challenge moreover more vita revenue be payment medicare medicaid program raise concern other key picksother top rank stock broader medical sector be intuitive surgical isrg free report align technology inc algn free report baxter international inc bax free report intuitive surgical sport zack rank align technology baxter carry zack rank see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate align technology have long term expect earning growth rate baxter international have long term expect earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
996,ISRG,myriad genetic inc mygn free report report adjust earning share ep cent third quarter fiscal year year moreover adjust ep beat zack consensus estimate cent exceed company guide range cent report earning come cent compare cent year revenuestotal revenue be year year quarter review figure however outpaced zack consensus estimate be company guidance year year decline be however cause price reduction long term contract related hereditary cancer testing further company believe unfavorable weather condition unite state have adverse impact third quarter test volume however decline be partially offset grow new product volume better expect hereditary cancer volume success company elevate program moreover be fifth consecutive quarter company witness year year hereditary cancer volume growth lead encourage response newly launch riskscore test myrisk hereditary cancer testing portfolio myriad genetic inc price consensus ep surprise myriad genetic inc price consensus ep surprise myriad genetic inc quotequarter detailssegment wise molecular diagnostic test total revenue record total revenue year year account decline hereditary cancer testing revenue also hereditary cancer testing revenue decline due price reduction long term contract however volume growth exceed company growth target year year basis endopredict testing revenue remain flat year year report quarter vectra da testing revenue come year year other testing revenue decline further genesight testing revenue rise year year report quarter prolaris test rake revenue quarter year year pharmaceutical clinical service revenue accounting rest quarter totale reflect year year increase margin trendsgross margin quarter review contract basis point bps accord management gross margin performance be affected hereditary cancer test pricing issue partially offset improve efficiency production process result elevate program rise new product reimbursement vectra da prolaris test operate expense contract rise research development expense be offset fall selling general administrative sg expense report quarter financial positionmyriad genetic exit fiscal third quarter cash cash equivalent marketable security compare end precede quarter year date cash flow operation totale compare year year date company register free cash flow compare year period guidancemyriad genetic have raise guidance fiscal revenue zack consensus estimate lie guide range bottom line front company lift adjust ep range current zack consensus estimate be company guide range management have provide guidance fourth quarter fiscal company estimate adjust ep cent total revenue zack consensus estimate adjust ep be cent revenue be consensus estimate earning coincide low end company guide range revenue estimate lie project range viewmyriad genetic perform better expect third quarter fiscal however year year decline revenue be disappointing positive note company observed strong growth genesight vectra da prolaris testing revenue recent fda approval encourage test result buoy optimism flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation zack rank other key picksmyriad genetic have zack rank buy other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue edge past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
997,ISRG,henry schein inc hsic free report report adjust earning share ep cent first quarter year year adjust ep remain ahead zack consensus estimate year year upside earning be drive strong revenue growth business segment report basis ep come cent first quarter improvement year year revenue detailhenry schein report net sale first quarter year year ahead zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc quotein first quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service first quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit first quarter cash cash equivalent compare end first month net operate cash outflow be compare cash outflow year period result blackout period related spin merger company animal health business quarter review company do not repurchase share common stock close first quarter company have authorize repurchase common stock guidanceexclude cost related restructure spin merger henry schein global animal health business company have reiterate ep guidance company still expect ep range reflect growth adjust ep figure zack consensus estimate adjust ep be remain guide range takehenry schein exit first quarter strong note earning revenue steering past respective zack consensus estimate company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense currently await completion company global animal health business plan spin business contribute nearly company topline spin accordingly be expect bring major change henry schein overall operate result accord company follow spinoff animal health business merge privately hold vet first choice form new public company call vet first corp believe initiative remain part henry schein strategic plan focus more dental medical business zack rank key pickshenry schein have zack rank buy few other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
998,ISRG,amedisys inc am free report report earning share ep cent first quarter year adjust ep cent bottom line also remain well ahead zack consensus estimate cent first quarter net service revenue gross year year top line also beat zack consensus estimate quarter company home health division net service revenue totale first quarter reflect improvement year year medicare revenue rise year year medicare revenue improve year year amedisys inc price consensus ep surprise amedisys inc price consensus ep surprise amedisys inc quote hospice division net service revenue gross year year include medicare revenue medicare revenue recently company integrate additional operate segment business namely personal care corporate personal care net service revenue totale represent increase year number meanwhile corporate segment do not register revenue end first quarter company gross margin contract basis point bps quarter review climb gross profit expense salary benefit inched other expense rise adjust operate income report quarter reflect surge year tally adjust operate margin expand bps year figure amedisys exit first quarter cash cash equivalent compare end company long term obligation exclude current portion be end first quarter dec net cash provide operate activity first month be compare year period takeamedisys end first quarter promising note earning revenue exceed respective zack consensus estimate home health hospice division company witness encourage growth medicare medicare revenue amedisys be currently explore opportunity segment be also impressed company solid performance recently launch personal care segment favorable demographic trend strategic acquisition also bode well company however escalate operate expense decline gross margin continue raise concern also intense competitive landscape regulatory concern persistently challenge home health hospice industry zack rank key picksamedisys carry zack rank hold few better rank stock broader medical space have report robust earning figure report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep outpace zack consensus estimate revenue come higher zack consensus estimate baxter first quarter adjust ep cent better zack consensus estimate revenue also edge past consensus mark look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
999,ISRG,phibro animal health corporation pahc free report report adjust earning share ep cent third quarter fiscal year year adjust ep surpass zack consensus estimate cent accord company year year improvement be primarily drive higher gross profit reduce interest expense lower effective income tax rate report ep cent be year quarter lower net income net salesin report quarter net sale totale year year improvement be drive sale growth animal health mineral nutrition performance product segment sale segmentsnet sale animal health segment increase report quarter volume increase nutritional specialty vaccine product group segment nutritional specialty product grow principally volume growth product poultry dairy industry further sale vaccine increase majorly global volume growth phibro animal health corporation price consensus ep surprise phibro animal health corporation price consensus ep surprise phibro animal health corporation quote moreover sale medicated feed additive mfa other grow primarily strength international business domestic net sale mfa other rise volume growth certain product international net sale increase drive growth most region include benefit recent buyout additional penetration cattle sector net sale mineral nutrition segment increase higher average selling price result increase underlie raw material commodity price net sale performance product segment rise higher average selling price volume copper base product operational updatephibro third quarter gross profit increase year year gross margin expand basis point bps selling general administrative expense rise operate margin contract bps quarter financial update year date phibro generate cash flow operation compare year capital expenditure amount period reflect reduction year period fy view have reaffirm guidance fiscal company expect generate net sale current zack consensus estimate fall guide range phibro project adjust ep band current zack consensus estimate be also company guide range takephibro end third quarter fiscal solid note company witness considerable improvement segment moreover company believe continuous investment portfolio enhancement development organizational capability have start pay further improve gross margin favorable product mix buoy optimism moreover company be busy arrange fund third party invest development technology product be also upbeat phibro foraying companion animal space signing agreement develop innovative product canine lyme disease vaccine used novel delivery method zack rank key picksphibro have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1000,ISRG,corindus vascular robotic inc cvrs free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session reverse recent trend company stock be now past month time frame stock gain developer precision vascular robotic report have obtain pmda approval corpath grx system japan be largest percutaneous coronary intervention pci market world company have see change come estimate revision past few week zack consensus estimate current quarter have also remain unchanged recent price action be encourage so make sure keep close watch firm future corindus vascular robotic currently have zack rank hold earning esp be corindus vascular robotic inc price corindus vascular robotic inc price corindus vascular robotic inc quoteinvestor interested medical instrument industry consider intuitive surgical inc isrg free report have zack rank strong buy see complete list today zack rank stock here be cvrs go predict see other think hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1001,ISRG,jun issue update research report medtronic plc mdt free report be encourage global acceptance company advanced therapy escalate cost expense raise concern stock have zack rank hold past month share medtronic have outperformed industry stock have grow industry decline notably medtronic exit fiscal solid note better expect fourth quarter performance major business group contribute solid top line growth cer highlight sustainability group region addition display successful integration achievement synergy target also gradually stabilize cardiac rhythm heart failure crhf market buoy optimism medtronic plc price medtronic plc price medtronic plc quote receipt fda approval dbs deep brain stimulation therapy adjunctive treatment reduce partial onset seizure raise hope company target medical market medtronic be also focuse geographical diversification business company be highly positive foray standalone cgm continuous glucose monitoring market guardian connect be currently upbeat medtronic recently launch restructure initiative call enterprise excellence plan aim annual growth run rate saving end fiscal company new program have be design increase effectiveness growth related reinvestment ability provide consistent boost margin expansion drive ep leverage flip side company have be expose steep cost expense weigh heavily margin also guidance remain conservative apprehension lackluster cardiac vascular group cvg minimally invasive therapy group mitg performance turn dampen investor confidence stock key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1002,ISRG,look find strong medical stock be prudent search company group be outperform peer have intuitive surgical isrg free report be stock year let take closer look stock year date performance find intuitive surgical be member medical group include different company currently sit zack sector rank zack sector rank include different group be list order best worst term average zack rank individual company sector zack rank be successful stock pick model emphasize earning estimate estimate revision system highlight number different stock be poise outperform broader market next month isrg be currently sporting zack rank strong buy zack consensus estimate isrg full year earning have moved higher past quarter signal analyst sentiment be improve stock earning outlook be more positive base most recent datum isrg have return so far year meanwhile stock medical group have lose average see intuitive surgical be perform better sector calendar year look more specifically isrg belong medical instrument industry include individual stock currently sit zack industry rank average stock group have lose year meaning isrg be perform better term year date return investor interest medical stock continue track isrg stock be look continue solid performance
1003,ISRG,bioscrip inc bio free report report net loss continue operation cent share first quarter compare net loss cent year however net loss be wider zack consensus estimate penny revenueswith completion core pbm business divestment bioscrip now have simplified business structure focuse core infusion service net revenue quarter review totale reflect decline year year management temporary supply deficit shutdown company branch due severe winter weather condition lead downside further company shift strategy focus grow core revenue mix be major deterrent however top line surpass zack consensus estimate notably net revenue first quarter include core product mix show improvement prior year quarter gross profit first quarter be year year however gross margin expand basis point bps general administrative expense be reflect rise first quarter adjust operate income be mark year year decline however adjust operate margin expand bps year year bioscrip inc price consensus ep surprise bioscrip inc price consensus ep surprise bioscrip inc exit first quarter cash cash equivalent compare record end company have update revenue view previous company revenue guidance have be adjust implementation asc zack consensus estimate lie company guide range additionally bioscrip expect incur restructure expense primarily reflect cost related redesign optimize revenue cycle management process company continue expect net loss share band cent consensus estimate cent same fall company guide range takebioscrip exit first quarter mixed note revenue beat consensus mark massive year year decline be dampener nonetheless be encourage company progress first quarter courtesy new multus faceted core plan improve financial position company also expect core revenue home solution continue core growth prove accretive portfolio moreover be upbeat bioscrip completion contract transition projection growth core revenue company also take certain rigorous step revitalize sale force report quarter development drive business growth zack rank key picksbioscrip have zack rank sell few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme release first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1004,ISRG,jun issue update research report nuvasive inc nuva free report be upbeat company flourishing international business hold immense opportunity however highly competitive landscape be concern zack rank hold company lead global medical device company global spine market focuse develop minimally disruptive surgical product procedurally integrate solution spine have be outperform industry past month stock have gain compare industry rise be upbeat nuvasive international business record growth sixth consecutive quarter first quarter company see strong sale growth geography emerge market also perform well strong growth south africa saudi arabia asia pacific grow double digit strong result japan reintroduction xlif further nuvasive healthy cash balance support plan pursue acquisition develop product meanwhile presence large number player have make medical device market intensely competitive orthopedic industry particular be extremely competitive presence bellwether zimmer biomet holding zbh free report stryker corporation syk free report other also margin drag pricing pressure reimbursement issue continue be other major headwind key picka better rank stock broader medical sector be intuitive surgical isrg free report sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1005,ISRG,stryker corporation syk free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock therefore time advantage stock price appreciation past year stryker share have rally significantly outperform industry growth last day zack consensus estimate earning share rise company have zack rank buy indicate possibility outperformance term let find bullish trend sustain stock impressive performance long run make attractive pick focus inorganic growthstryker have be leverage bolt buyout drive inorganic growth stryker recently acquire entellus medical inc stryker also acquire vexim recent past specialize development sale vertebral compression fracture solution company close buyout novadaq net purchase price last report quarter buyout have proven accretive stryker mako propel growthmako be stryker robotic arm assist surgery platform first quarter see strong show mako total knee platform management primary growth driver include continue demand mako tka knee platform print product foot ankle portfolio report quarter company install total robot globally unite state reflect increase year year guidance solidbuoy stellar first quarter stryker expect second quarter earning share notably zack consensus estimate earning be peg be give range moreover organic net sale growth be expect adjust net earning diluted share range management be also confident basis point improvement operate margin other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1006,ISRG,issue update research report boston scientific corporation bsx free report company be gain traction emerge market particularly bric zone however product recall issue continue impede growth stock carry zack rank hold past month share boston scientific have outperformed industry several issue stock have gain versus industry decline notably boston scientific post impressive first quarter back growth business line geography view also paint bright picture term boston scientific be leave stone unturned strengthen core business well invest new technology company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum company growth first quarter boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus millipede structural heart inorganic expansion plan bode well stock operational efficiency also gradually improve foreign exchange scenario have start contribute company overall top line performance boston scientific be pull stop pump resource new technology global market accounting higher sale geographical region third quarter additionally be encourage company number approval gain product domestic well overseas market however be concern company recall prime product lotus range heart device fate lotus valve issue throw thro uncertainty more time boston scientific recently company announce delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state follow product voluntary recall february latest update company expect launch lotus edge unite state european market not currently fear indefinite future company fast grow transcatheter aortic valve replacement tavr business interventional cardiology lotus valve line be prime product key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1007,ISRG,keep line company product expansion strategy bruker corporation brkr free report recently introduce broad line mass spectrometry product workflow asm american society mass spectrometry conference company claim product act breakthrough life science research clinical research large cohort validation phenomic proteomic biopharma application apply toxicology forensic market launchesthe mass spectrometry product launch company be follow company have introduce scimaxtm magnetic resonance mass spectrometer mrm come phenomic proteomic innovation product be design enable high throughput phenomic extreme resolution mrm also company have unveil spoton lc maldi spotter automate wizard base workflow phenomic proteomic innovation category life science translational mass spectrometry imaging company introduce scil lab version key addition quantitation module mass spectrometry imaging msi workflow life science translational research company introduce fourth generation software metabolomic lipidomic research metaboscape power mrm axelerate version support handle large study sample phenomic research apart bruker introduce solution target metabolomic profile call rex lc qtof apply toxicology forensic company launch enhance version targetscreener hr include more compound field veterinary drug new psychoactive substance pesticide result database exceed compound mass spec glancenotably bruker mass spectrometry business fall bruker calid group have demonstrated strong sale performance recent time have be fuelled robust performance microbiology business healthy result life science research mass spectrometry believe newly expand mass spectrometry portfolio focuse execution company primary target market microbiology diagnostic life science research bruker be go sustain strong momentum mass spectrometry share price performance past month share bruker have outperformed industry stock have gain industry decline zack rank other stock considerbruker currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys hold zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1008,ISRG,unite state boast be biggest medtech market date be highly regard innovation technologically advanced product world kaloroma information article validate country dominance field thank more revenue generate world medical device tax medical device industry be boom possibility courtesy year suspension infamous medical device tax lift tax make scope solid research development be likely benefit company long run excise tax be implement obamacare significantly affect advanced medical technology association lobbying group tax impair medical innovation great extent result loss lower job creation address problem senate place temporary suspension taxe january december period taxe be impose again jan only be suspend jan year device tax suspension be very few amendment see landslide bipartisan house jan medical product industry have rally significantly outperform index decline account political cultural legal trouble plague market worldwide make right backdrop few medical device stock be well position strong fundamental solid prospect have used zack stock screener pick such stock have also take care include stock zack rank strong buy buy growth score research show stock growth score combine zack rank be better pick most intuitive surgical inc isrg free report have growth score past month share intuitive surgical have gain outperform industry decline california base company zack rank recently announce be commence direct operation india distributor vattikuti technology pvt ltd moreover company flagship da vinci sp surgical system urologic surgical procedure be recently approve fda last day zack consensus estimate intuitive surgical earning share rise abiom inc abmd free report have zack rank growth score see see complete list today zack rank stock here past month share abiom have gain outperform industry decline massachusett base company recently replace wyndham worldwide corp list last day zack consensus estimate abiom earning share rise cent varian medical system inc var free report have zack rank growth score past month share varian medical have rally fare better industry fall california base provider radiotherapy solution have late be target expansion africa company coveted halcyon system have be adopt different cancer center northern southern africa furthermore varian medical recently sign software technology training education cooperation agreement brazil ministry health moh university science technology institution ict brazil last day zack consensus estimate varian medical earning share remain stable surmodic inc srdx free report have zack rank growth score past month share surmodic have gain outperform industry growth minnesota base provider medical device recently sign agreement embolitech acquire innovative thrombectomy platform technology related intellectual property broad potential peripheral vascular application enhance company focus develop highly differentiate whole product solution more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1009,ISRG,intuitive surgical inc isrg free report be top perform stock medtech space company solid revenue base improve financial performance unwaver focus minimally invasive surgical method be key catalyst company have positive average earning surprise trail quarters moreover last day zack consensus estimate earning have improve reflect strong prospect company past year share intuitive surgical have rally industry decline current level be also higher gain want cash share price appreciation time add stock portfolio intuitive surgical sport zack rank strong buy favore stock solid surgical deliver strong first quarter result company flagship da vinci procedure see solid growth hold tremendous potential company also see expansion outside unite state buoy optimism earning revenue surpass consensus mark revenue totale prior year quarter meanwhile earning surge year year basis outside unite state revenue totale year year basis sequentially ous procedure rise da vinci surgical platform hold surgical have late be focuse minimally invasive surgical procedure order avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand movement be translate smaller precise movement notably first quarter da vinci procedure grow approximately year year basis management replace da vinci surgical system year quarter furthermore company install base grow year strong revenue basesince intuitive surgical have be deliver strong revenue revenue see cagr moreover company have solid recur revenue base first quarter total recur revenue be represent total revenue total recur revenue be represent total revenue other key picksother top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report exelixis inc exel free report abiom have long term growth rate stock sport zack rank see complete list today zack rank stock here genomic health have expect growth rate current quarter stock sport zack rank exelixis have project growth rate current quarter stock sport zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1010,ISRG,steris plc ste free report report fourth quarter fiscal adjust earning share ep year year ahead zack consensus estimate report ep come cent significant improvement cent year adjust ep figure full year be year period also zack consensus estimate couple cent steris generate revenue fiscal fourth quarter year year moreover top line exceed zack consensus estimate fiscal revenue come marginal improvement year period annual figure be line consensus mark quarter detailorganic revenue growth constant currency be year year fiscal fourth quarter mainly drive balanced growth segment company steris plc price consensus ep surprise steris plc price consensus ep surprise steris plc quote company operate segment healthcare product healthcare specialty service apply sterilization technology life science revenue healthcare product increase year year constant currency organic basis quarter review service revenue grow consumable revenue rise capital equipment revenue be flat year year revenue healthcare specialty service segment be constant currency organic basis fourth quarter register final impact linen business divestiture year year revenue apply sterilization technology rise backed increase demand core medical device customer revenue life science segment grow growth service revenue rise capital equipment revenue consumable revenue be flat year year marginsadjusted gross margin improve basis point bps year year report quarter steris gross margin expansion be fuel favorable product mix price basis point improvement divestiture currency have unfavorable impact basis point gross margin steris witness year year decline selling general administrative expense research development expense rise accordingly adjust operate margin expand bps year year basis report quarter financial detailssteris exit fiscal cash cash equivalent compare end fiscal company have long term debt end fiscal fourth quarter compare end fourth quarter fiscal full year company generate cash flow operation year period free cash flow be compare prior year guidancesteris expect constant currency organic revenue growth fiscal prior fiscal zack consensus estimate fiscal revenue be peg adjust ep outlook fiscal have be project range consensus estimate fiscal adjust ep lie guide range takesteris exit fourth quarter fiscal promising note earning revenue beating respective zack consensus estimate be also encourage favorable underlie market trend new product service offering further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change be expect better align operation zack rank key pickssteris have zack rank hold better rank stock broader medical space have report solid result earning season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come outpace zack consensus estimate baxter post first quarter adjust bottom line cent beat zack consensus estimate top line come edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1011,ISRG,medical group wmgi free report report first quarter adjust loss penny significantly narrower zack consensus estimate loss cent notably loss share year quarter be cent first quarter revenue come beat zack consensus estimate revenue also improve constant currency cc management represent estimate basis point bps increase year quarter past month share medical have gain industry decline medical carry zack rank hold medical group price consensus ep surprise medical group price consensus ep surprise medical group quotesegment detailslower segment post worldwide revenue year year sale unite state totale international sale come management lower extremity business witness improvement straight year flat sale upside be attribute growth total ankle return growth core lower extremity business furthermore have be continue progress ortholoc ankle small bone fracture product launch upper segment totale prior year quarter unite state sale totale internationally segment rake revenue worth management growth be drive growth company shoulder business quarter also see strong contribution flagship product simpliciti shoulder perform reversed glenoid management be positive blueprint acquisition be anticipate drive growth shoulder line product biologic sale be year international revenue segment rise sale drop sport med segment post worldwide sale year year basis however segment sale shot international sale sunk marginsin quarter review gross margin be bps year earlier quarter operate expense however rise increase sg selling general administrative research development expense ebitda margin expansion be bps pave way improvement balance sheet detailswright medical exit first quarter cash cash equivalent guidancewright medical reiterate revenue guidance band represent growth cc zack consensus estimate revenue be peg give range company expect adjust loss share cent zack consensus estimate same be pin cent again be project range full year adjust ebitda be anticipate range viewpointwright medical exit first quarter promising note year year loss have narrow revenue have tick solid performance upper lower extremity segment buoy optimism international sale segment be high be major positive acquisition blueprint have also proven beneficial consistent innovation be likely broaden company product portfolio moreover improvement gross margin be noteworthy flip side rise operate expense be concern decline sale biologic sport business be discourage distribution issue europe asia foreign currency volatility add wo key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1012,ISRG,haemonetic corporation hae free report report adjust earning share ep cent fourth quarter fiscal rise year year bottom line however be par zack consensus estimate report basis haemonetic post net earning cent share net loss cent year fiscal adjust ep come prior fiscal total revenuesrevenue be year year constant exchange rate cer report quarter top line also exceed zack consensus estimate year year growth be backed strong result north america improve international result fiscal revenue totale prior fiscal cer haemonetic corporation price consensus ep surprise haemonetic corporation price consensus ep surprise haemonetic corporation quoterevenue product report operate result business franchise plasma haemostasis management cell process blood center plasma report revenue total revenue be year year cer revenue bloodcenter total revenue decline cer hemostasis management franchise revenue total revenue rise cer revenue cell process be cer total revenue fourth quarter adjust gross margin be basis point bps year year favorable mix currency reduce cash inventory charge adjust operate income be quarter show decline year year adjust operate margin contract bps year year quarter review financial exit fiscal cash cash equivalent compare fiscal end company generate operate cash flow end fiscal compare fiscal end fiscal company report free cash flow transformation restructure cost vcc capital expenditure compare year capital expenditure have be record year lower fiscal issue fiscal revenue guidance company expect full year revenue growth plasma revenue growth be expect band hospital revenue be expect rise blood center revenue be likely decline zack consensus estimate revenue be peg company expect adjust ep band zack consensus estimate be guide range takehaemonetic exit fourth quarter fiscal mixed note continue momentum new business generation geographical expansion have help company deliver strong result however be disappoint company sluggish blood center business moderate overall growth encourage progress plasma hospital company also seem be upbeat receipt major regulatory clearance plasma business drive top line fiscal also company strong cash position boost investor confidence zack rank key pickshaemonetic have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1013,ISRG,davita inc dva free report report first quarter adjust operate earning share beating zack consensus estimate cent earning increase year year basis total revenue increase year year miss zack consensus estimate davita carry zack rank hold business detailsnet dialysis related lab patient service revenue first quarter be year year other revenue be year year basis davita see impressive result kidney care business net consolidated revenue segment be year year adjust kidney care operate income be year year operate division davita davita kidney care focus set worldwide standard clinical social operational practice kidney care adjust dialysis related lab service operate income first quarter be dialysis treatment first quarter be treatment day represent increase year year davita inc price consensus ep surprise davita inc price consensus ep surprise davita inc quote company patient care cost be approximately cent treatment compare last report quarter investor notice company major segment davita medical group dmg be track divestment optum subsidiary unitedhealth group inc transaction be subject regulatory approval other customary close condition result dmg business operation have be report discontinue quarter review share repurchase updatedure first quarter davita repurchase total share approximately average price share davita have repurchase share year date basis represent nearly company total share outstanding also include approximately stock repurchase guidancedavita reiterate guidance company project kidney care consolidated operate income range operate cash flow continue operation be estimate range effective tax rate be expect range end first quarter mixed note adjust earning beating zack consensus estimate revenue miss same company see impressive result kidney care business lately operate division davita davita kidney care focus clinical social operational practice worldwide company effort control expense hold promise compelling inorganic growth story be positive flip side sluggishness other business be major headwind davita company be face adverse effect pricing pressure medical industry rise medicare insurance cost company major segment davita medical group have be track divestment optum subsidiary unitedhealth group inc further high debt level adverse effect healthcare reform increase medicare advantage beneficiary be concern earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1014,ISRG,cooper company inc coo free report post second quarter fiscal adjust earning share beat zack consensus estimate earning also increase year year basis california base specialty medical device company report revenue worth surpass zack consensus estimate revenue improve prior year quarter pro basis defined constant exchange rate include acquisition period meanwhile cooper share have decline industry rise past month stock currently carry zack rank hold cooper company inc price consensus ep surprise cooper company inc price consensus ep surprise cooper company inc quotesegment detailscooper report revenue major segment coopervision cvi coopersurgical csi segment garner revenue worth year year basis cc management overall cvi sale have be drive strong performance silicone hydrogel portfolio clariti myday toric cvi revenue rake cc multifocal generate revenue worth cc single use sphere post revenue worth prior year quarter single use sphere revenue come year geographically segment see strong quarter revenue rise year year basis cc management expect growth momentum be strong second half fiscal growth expect upper single digit revenue rise year year basis emea asia pacific segment post revenue year cc management growth be lead strength paragard fertility solution product offering sub segment office surgical product csi account whopping year year fertility post sale worth year year margin analysisas percentage revenue adjust gross margin csi segment be report quarter basis point bps compare prior year quarter percentage revenue adjust gross margin cvi segment be report quarter higher revenue year quarter second quarter gross profit whole cooper company totale year quarter adjust gross margin be expand bps operate income quarter totale prior year figure adjust operate margin be bps guidance updatedcooper update revenue guidance fiscal company now expect fiscal revenue compare previous range notably zack consensus estimate same be peg lie project range revenue cvi segment be now estimate band compare state previously however csi revenue range have be keep intact fiscal adjust earning share be anticipate zack consensus estimate earning be pin project range wrapped fiscal second quarter solid note strong performance coopervision buoy optimism geographically well company put solid show acquisition paragard drive coopersurgical revenue management be optimistic recently complete acquisition lifeglobal be expect enhance cooper fertility business further continue improvement gross operate margin be promising flip side cooper long term debt have increase significantly raise concern moreover continue acquisition integration risk stiff competition niche space add wo key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1015,ISRG,jun initiate research report bio rad laboratory inc bio free report be upbeat company deliver robust performance overseas tough competitive landscape be concern stock carry zack rank hold california base manufacturer global supplier clinical diagnostic life science research product have be outperform industry past year stock have gain versus industry rise bio rad kick start solid note earning revenue rise year year first quarter company have be strongly progress effort strengthen hold other geography first quarter bio rad derive net sale globally company deliver robust performance primarily north america china asia pacific region further constant currency sale life science segment be particularly strong north america china europe currency neutral sale company clinical diagnostic segment see strength china asia pacific north america be encourage company active portfolio expansion blood typing market january bio rad announce receipt clearance fda ih incubator ih centrifuge instrument be used complete range bio rad ih system gel reagent manual blood typing method meanwhile bio rad operate highly competitive environment dominate firm vary large multinational corporation start up also competitive regulatory condition market company operate limit ability switch strategy price increase other driver cost increase life science segment bio rad primarily compete like becton dickinson thermo fisher scientific tmo free report other again prominent competitor clinical diagnostic segment be abbott laboratory free report diasorin further bio rad be expose risk associate weaker global economy lower reimbursement rate key picksa better rank stock broader medical sector be intuitive surgical isrg free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1016,ISRG,idexx laboratory inc idxx free report have be gain investor confidence consistently solid result stock have rally year ahead growth broader industry decline moreover company have market cap year expect growth rate be also favorable compare industry tally dwelling solid prospect zack rank buy player be attractive bet investor moment company estimate revision trend have also be positive last day analyst moved estimate northward movement opposite direction consensus mark current year earning have be raise share style score idexx laboratory sport favorable growth score reflective company strong fundamental research show stock impressive growth style score combine bullish zack rank strong buy offer best upside potential accordingly idexx laboratory have encourage net margin net income sale well industry negative also company sale asset ratio compare industry make sturdy growth pick let find be recent positive momentum be sustainable not company be lead manufacturer product service primarily companion animal veterinary livestock poultry exit first quarter commendable note better expect earning revenue performance stock stellar performance be drive robust sale cag companion animal group business first quarter cag revenue rise organically year year support cag diagnostic recur organic revenue growth moreover idexx vetlab consumable organic revenue growth be firm back expand premium instrument base unite state international market include growth competitive instrument placement increase utilization consistent customer retention notably january company make catalyst sdma test available north america idexx point care customer now be able add sdma essential element routine chemistry panel apart unite state canada idexx expect launch catalyst sdma test other part world next several month continue slew development idexx laboratory enter global agreement january diagnostic company call apply biocode deal idexx laboratory bring reference laboratory customer digital multiplex platform build apply biocode management aim commercially launch technology companion animal market fundamental remain consolidated global runway tremendous growth management innovation base multus modality global strategy accelerate recurrent cag diagnostic revenue growth report quarter moreover substantial top line rise be contribute considerable contribution other business segment furthermore raise guidance bottom line share instill confidence stock be also optimistic company witness double digit organic revenue growth international business upside indicated steady consumable revenue gain ride catalyst instrument base average testing utilization additionally company boast secure cash balance allow carry share repurchase meanwhile idexx laboratory heavy dependence third party distributor raise concern moreover rigid competitive landscape domestic overseas market weigh company margin other key picksa few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate stock have zack rank intuitive surgical have expect long term earning growth rate be zack rank stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1017,ISRG,genomic health inc ghdx free report have be gain investor confidence consistently positive result past year company share price have outperformed industry stock have gain industry fall also company have fared better gain developer marketer genomic base clinical test cancer diagnosis have market cap solid prospect zack rank strong buy stock be attractive pick now company estimate revision trend current year be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise cent let find recent positive trend be sustainable solid quarterly health exit first quarter promising note be encourage year year rise revenue drive solid performance unite state internationally breast cancer reimbursement prospect brightgenomic health be see healthy progress regard establish coverage oncotype dx breast cancer test company expect several key catalyst implementation pama reimbursement higher level invasive breast rate ajcc stage criterium drive growth further tailorx trial assign individualized option treatment study result have be select presentation plenary session american society clinical oncology annual meeting asco also provide impetus accord genomic health help invasive breast cancer test be available international region follow reimbursement approval solid prostate cancer test uptakegenomic health prostate cancer business have consistently accelerate last few quarters company have see increase adoption test private reimbursement first quarter revenue business rise year year basis lead rise test volume expand coverage payment private payer cms coverage intermediate risk patient geographical expansion health be make considerable expansion international arena so far company have deliver test result cancer patient nearly country first quarter international test increase high single digit back increase contribution exclude result germany france italy other key picksa few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1018,ISRG,unite state be largest medical world rake dollar revenue annually abiom inc abmd free report varian medical system inc var free report be solid contender space abiom flaunt zack rank strong buy varian medical carry zack rank buy stock have growth score research show stock growth score combine zack rank be better pick most here take detailed look fundamental company determine stock be currently position better medical instrument space market cap abiom be engage develop manufacturing marketing medical product design assist replace pump function heart failure varian medical be lead provider radiotherapy radiosurgery proton therapy brachytherapy world california base company currently have market cap price performancein past month share abiom have rally whopping significantly outperform industry decline comparison share varian medical have also outperformed industry gain same time frame notably bothmstock have also surpass index return same time frame consequently abiom win varian medical price performance be be consider meanwhile see complete list today zack rank stock here earning growth abiom zack consensus estimate current year earning be peg reflect year year growth stock have long term expect earning growth rate other hand same varian medical be peggedat indicate year year growth stock have long term expect earning growth rate abiom win round sale growth zack consensus estimate abiom current year revenue be show year year growth same varian medical be peg reflect year year growth here too abiom win varian medical drive stock abiomedabiom have consistently gain rise coronary heart disease unite state company diverse product line offer minimally invasive procedure help patient overcome stress open surgery moreover company impella product line have be solid growth driver last report quarter witness increase adoption impella product domestically internationally positive likely buoy company join coveted benchmark very recently notably abiom replace wyndham worldwide corp read more abiomedto replace wyndham benchmark varian medicalbeside be strong player oncology treatment market varian medical also have robust international presence particularly emerge economy notably varian medical recently complete major overseas buyout cooperative cl enterprise coop lead distributor radiotherapy equipment taiwan sirtex australia base company focuse interventional oncology therapy bid strengthen oncology system segment varian medical recently announce plan demonstrate company comprehensive portfolio advanced brachytherapy solution read more varian demonstrate brachytherapy solution portfolio conclusionour comparative analysis indicate abiom be well position compare varian medical consider price performance earning growth projection sale expectation other key pickssome other top rank stock broader medical space be genomic health ghdx free report intuitive surgical inc isrg free report genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free unite state be largest medical world rake dollar revenue annually abiom inc abmd free report varian medical system inc var free report be solid contender space abiom flaunt zack rank strong buy varian medical carry zack rank buy stock have growth score research show stock growth score combine zack rank be better pick most here take detailed look fundamental company determine stock be currently position better medical instrument space market cap abiom be engage develop manufacturing marketing medical product design assist replace pump function heart failure varian medical be lead provider radiotherapy radiosurgery proton therapy brachytherapy world california base company currently have market cap price performance past month share abiom have rally whopping significantly outperform industry decline comparison share varian medical have also outperformed industry gain same time frame notably bothmstock have also surpass index return same time frame consequently abiom win varian medical price performance be be consider meanwhile see complete list today zack rank stock here earning growth projection abiom zack consensus estimate current year earning be peg reflect year year growth stock have long term expect earning growth rate other hand same varian medical be peggedat indicate year year growth stock have long term expect earning growth rate abiom win round sale growth projection zack consensus estimate abiom current year revenue be show year year growth same varian medical be peg reflect year year growth here too abiom win varian medical drive stock abiom abiom have consistently gain rise coronary heart disease unite state company diverse product line offer minimally invasive procedure help patient overcome stress open surgery moreover company impella product line have be solid growth driver last report quarter witness increase adoption impella product domestically internationally positive likely buoy company join coveted benchmark very recently notably abiom replace wyndham worldwide corp read more abiom replace wyndham benchmark abiom inc price consensus abiom inc price consensus abiom inc quotevarian medical be strong player oncology treatment market varian medical also have robust international presence particularly emerge economy notably varian medical recently complete major overseas buyout cooperative cl enterprise coop lead distributor radiotherapy equipment taiwan sirtex australia base company focuse interventional oncology therapy bid strengthen oncology system segment varian medical recently announce plan demonstrate company comprehensive portfolio advanced brachytherapy solution read more varian demonstrate brachytherapy solution portfolio varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotein conclusion comparative analysis indicate abiom be well position compare varian medical consider price performance earning growth projection sale expectation other key pick other top rank stock broader medical space be genomic health ghdx free report intuitive surgical inc isrg free report genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1019,ISRG,resm inc rmd free report recently announce positive result company sponsored research support efficiency bilevel device result be present sleep annual joint meeting american academy sleep medicine sleep research society bilevel rescue study detailresm compare compliant patient medicare guideline switch bilevel therapy result demonstrated therapy compliance be achieve patient be shift positive airway pressure pap therapy first day treatment company bilevel device release distinct pressure inhalation other exhalation patient be pressure intolerant have persistent evidence apnea higher pressure be often prescribe advanced bilevel device believe positive result study be expect boost uptake company bilevel device glimpse companyresm achieve strong global revenue growth past few quarters lead sale sleep device respiratory care device mask system well software solution believe resm product launch strategy be anticipate gain traction sleep apnea market be expect drive growth company term recent development company inform first self brand portable oxygen concentrator mobi subject launch fiscal third quarter have also introduce airmini smallest pap positive airway pressure device world resm recently receive reimbursement approval mandibular repositioning device france further announce south korea start reimburse diagnosis therapeutic treatment sleep apnea term moreover company recently announce definitive agreement buy healthcarefirst privately hold provider software solution service home health hospice agency boost software service business market potentialper report sleep apnea device market be expect worth roughly cagr view datum conclude developmental step undertake company seem be progressive be strategically align share price performancein past month resm have outperformed industry stock have gain compare growth record industry zack rank other key picksresm currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1020,ISRG,petm express inc pet free report announce earning share ep cent fourth quarter fiscal year quarter cent also bottom line surpass zack consensus estimate cent year year upside be drive higher gross profit margin further tax cut owing recent tax reform provide impetus full year ep be reflect increase year ep figure also beat zack consensus estimate net sale report quarter rise year year however sale miss consensus estimate accord lead pet pharmacy americas sale upside be result increase reorder net sale totale full year year net sale however miss zack consensus estimate petm express inc price consensus ep surprise petm express inc price consensus ep surprise petm express inc quotein report quarter reorder sale increase year year basis new order sale decline average order value be approximately quarter compare year earlier quarter note variation average order value be mainly shift sale higher price item company seasonality business be mainly proportion flea tick heartworm medication product mix spring summer be consider peak season fall winter represent season quarter review petm acquire new customer year roughly order be generate compare prior year quarter gross margin expand basis point bps year year quarter review general administrative expense be year year however advertising expense decline adjust operate expense however rise depreciation expense nevertheless adjust operate margin quarter expand bps year quarter petm exit fiscal cash cash equivalent compare end fiscal company also declare quarterly dividend cent share payable shareholder record takepetm exit fiscal fourth quarter mixed note however be encourage growth reorder sale quarter further expand gross margin due shift higher margin product next generation medication buoy optimism company be also strive implement strategy revitalize top line include increase focus advertising efficiency boost new order sale well shift sale higher margin item also expand product line zack rank key pickspetm have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1021,ISRG,abbott free report recently announce launch latest generation afinion test system afinion analyzer unite state system deliver accurate hemoglobin hba result minute albumin creatinine ratio acr result minute therefore product enable healthcare provider adhere american diabetes association ada testing guideline efficiently promptly be afinion analyzer rapid test system afinion analyzer be rapid compact multus assay platform be capable streamline simplify delivery actionable accurate measurement hba acr result point care afinion platform also provide connectivity laboratory hospital information system li enable healthcare provider use various patient setting ada regular measure hba acr level be effective long term management patient diagnosed diabetes give host benefit offer be upbeat launch afinion analyzer system be expect boost top line contribution diagnostic division glimpse diagnostic businessabbott diagnostic division market diagnostic system well test business line core laboratory molecular point care rapid diagnostic reflect sale alere be acquire oct division account total sale first quarter last report quarter diagnostic revenue grow year year comparable operational basis drive better expect performance company rapid diagnostic business strength flu season unite state notably rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing further management project uptrend division continue back new product launch benefit alere acquisition strength alinity test platform market demographic be favor high incidence diabetes individual report mordor intelligence global market diabetes care device be expect attain value further abbott more person total population unite state be suffering diabetes thus such circumstance conclude developmental step undertake company seem be progressive be strategically align price have be gain investor optimism consistently positive result past month stock have outperformed industry share company have gain compare industry rise zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1022,ISRG,issue update research report illumina inc ilmn free report zack rank hold stock company market opportunity continue expand owing accelerate demand clinical translational customer recent strategic collaboration be also expect widen product portfolio share company have outperformed industry last month stock have rally industry decline notably illumina exit first quarter solid note better estimate earning well revenue moreover be encourage significant year year growth count huge upside be attribute strong rise consumable illumina sequence portfolio illumina inc price illumina inc price illumina inc quote additionally management be hopeful recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety south korea field oncology illumina collaboration bristol myer squibb loxo oncology be likely garner positive result line meanwhile company raise guidance indicate deliver impressive performance quarters come san diego base illumina be tool integrate system provider analysis genetic variation function company focus product innovation research development evident recent launch iseq sequence system post promising first quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio flip side company face stiff competition sequence snp single nucleotide polymorphism genotyp gene expression molecular diagnostic market several bigwig already enjoy significant market share intellectual property portfolio well regulatory expertise also national institutes health funding issue raise concern key pickssome better rank stock broader medical sector be intuitive surgical isrg free report resm inc rmd free report amedisys inc am free report intuitive surgical sport zack rank strong buy resm amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate resm have long term historical earning growth amedisys project long term earning growth more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1023,ISRG,penumbra inc pen free report report first quarter adjust earning share cent adjust loss cent year quarter moreover bottom line remain well ahead zack consensus estimate loss cent total revenue report quarter surge year year constant exchange rate cer exceed zack consensus estimate geographically first quarter revenue unite state represent total sale gross year period meanwhile international sale total sale improve year year cer penumbra inc price consensus ep surprise penumbra inc price consensus ep surprise penumbra inc quote product category revenue neuro product grow cer quarter review revenue peripheral vascular product business rise first quarter reflect increase cer year year operational updatepenumbra first quarter gross margin be represent basis point bps contraction year year however gross profit climb research development expense totale sale general administrative expense amount year year operate profit report quarter come versus operate loss prior year quarter financial update penumbra exit first quarter cash cash equivalent compare end outlookpenumbra have raise guidance revenue company now expect total revenue range compare earlier provide projection zack consensus estimate lag guide range takepenumbra exit first quarter better expect result year year comparison earning be favorable moreover company witness strong growth geography well product line company be focuse product innovation research development flip side escalate cost expense be weigh bottom line penumbra be active player fast grow interventional therapy space fact company product primarily cater unmet clinical need major market neuro peripheral vascular zack rank key pickspenumbra have zack rank hold few better rank stock broader medical space have report solid financial figure report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent outpaced zack consensus estimate revenue also edge past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1024,ISRG,align technology inc algn free report first quarter adjust earning share ep come year year earning be also higher company guide range cent figure comfortably beat zack consensus estimate cent well revenuesrevenue grow year year quarter surpass zack consensus estimate revenue be well ahead company guide range management top line be drive year year increase invisalign case shipment quarter upside be support growth north america international region expand customer base increase utilization solid worldwide case growth moreover increase revenue itero scanner contribute majorly segment detailrevenue clear aligner segment total revenue soar year year report quarter primarily drive continue strong invisalign case volume growth customer channel geographical region first quarter invisalign case shipment amount year year aid growth region well expansion customer base quarter align technology invisalign case be ship doctor worldwide be north america international region align technology inc price consensus ep surprise align technology inc price consensus ep surprise align technology inc quoterevenue scanner service improve significant marginsgross margin quarter review be basis point bps year year rise cost net revenue quarter align technology witness year year increase selling general administrative expense rise research development expense operate margin expand bps financial detailsalign technology exit first quarter cash cash equivalent short term marketable security compare end report quarter align technology repurchase share stock april stock repurchase program company currently have approximately left buy back program second quarter company project ep revenue company project invisalign case shipment band year meanwhile zack consensus estimate second quarter ep be revenue earning estimate be project range estimate revenue fall same takealign technology end first quarter solid note be upbeat continue strength invisalign volume north america company continue witness expand gp dentist customer base sustain strength invisalign utilization orthodontist be also encourage solid performance emea asia pacific market scanner service company witness rapid uptake itero scanner geography moreover company continue see increase adoption itero scanner invisalign case submission instead pvs impression thereby drive invisalign utilization further align technology recently announce receipt china food drug administration cfda approval commercial launch itero element intraoral scanner be also upbeat company expand itero element portfolio lauch itero element itero element flex scanner unite state majority european country cover france germany italy spain unite kingdom align technology have strong cash balance enable carry share repurchase turn provide solid return investor flip side company be expose foreign exchange fluctuation seasonal demand fluctuation higher operate expense pertain increase head count higher investment target expansion geographical presence portfolio zack rank key picksalign technology carry zack rank hold few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter adjust earning shareof beating zack consensus estimate revenue come exceed zack consensus estimate cheme post first quarter adjust earning share beating zack consensus estimate revenue come beating zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1025,ISRG,bruker corporation brkr free report report adjust earning share ep cent first quarter year figure also adjust ep beat zack consensus estimate couple cent report basis earning come cent share increase year year basis revenue detailbruker logged revenue first quarter year year moreover top line surpass zack consensus estimate exclude positive effect acquisition favorable impact change foreign currency rate bruker report year year organic revenue growth bruker corporation price consensus ep surprise bruker corporation price consensus ep surprise bruker corporation quote geographically european revenue improve high single digit year year report quarter north america revenue grow mid single digit asia pacific apac metric be low single digit due shipment acceptance delay related biospin apac customer management company register organic revenue growth drive strength nano best bruker biospin group revenue decline modestly first quarter level exclude impact currency translation biospin nmr have slow start year delay system shipment acceptance revenue nano group increase mid single digit constant exchange rate fuel strong uptick industrial research market calid revenue be high single digit organic basis strong performance daltonic mass spec business margin trenda percentage revenue gross margin quarter review expand basis point bps selling general administrative expense increase research development expense rise year year overall adjust operate margin improve bps financial positionbruker exit first quarter cash cash equivalent short term investment end mar net cash used operate activity be compare year period guidancebruker reiterate guidance full year company still expect revenue growth approximately include nearly organic revenue growth company project year year expansion bps adjust operate margin bruker still anticipate adjust ep range previous band zack consensus estimate remain ahead company guidance takebruker exit first quarter solid note strong year year increase revenue well earning additionally improvement gross operate margin buoy optimism company strategic acquisition activity have also be encourage further be upbeat company current focus product development higher flip side competitive landscape macroeconomic headwind continue challenge company zack rank key picksbruker carry zack rank hold few better rank stock broader medical space have report robust earning figure report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep exceed zack consensus estimate revenue come outpace zack consensus estimate baxter first quarter adjust ep cent better zack consensus estimate revenue also edge past consensus mark more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1026,ISRG,abiom inc abmd free report report fourth quarter fiscal earning share cent beat zack consensus estimate earning improve huge year quarter past month abiom share have gain industry decline abiom have zack rank buy revenue detail revenue report quarter come beating zack consensus estimate revenue also increase prior year quarter management upside be drive patient utilization growth year year basis reorder performance continue be strong quarter reorder increase prior year quarter translate reorder rate approximately average combine inventory hospital impella impella cp rise slightly unit site versus prior quarter last year abiom inc price consensus ep surprise abiom inc price consensus ep surprise abiom inc quoteimpella heart pump worldwide revenue quarter review totale year year unite state impella rake year quarter outside unite state fourth quarter revenue generate impella heart pump be whopping year year significant contribution come germany record revenue year year recently impella line clinch plethora regulatory approval fda margin quarter review gross margin be basis point bps year year operate income quarter gross year year basis operate margin be expand bps financial condition abiom balance sheet have be strong end fiscal company generate cash cash equivalent marketable security end fourth quarter company be currently debt free fy glance infiscal total revenue be fiscal fiscal worldwide impella heart pump revenue totale show increase year year unite state impella revenue totale outside unite state revenue impella heart pump totale year year revenue come germany year year basis full year gross margin be bps year year operate income full year come operate margin be operate margin expand bps cash cash equivalent totale fiscal fy outlook fiscal company expect total revenue range reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range full year tax rate be expect conclusion abiom end fiscal solid note flagship impella line continue drive growth string fda approval be encourage expansion operate margin be also major positive company also have solid global foothold buoy optimism however decline gross margin raise concern company continue face foreign exchange volatility intense competition niche space add wo other key pick other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past consensus markof more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1027,ISRG,maintain streak positive earning surprise corporation abc free report post adjust earning share second quarter fiscal beating zack consensus estimate improve year year upside be attribute strong growth pharmaceutical distribution segment world courier business revenue improve almost report quarter figure surpass zack consensus estimate stock have zack rank hold segmental distribution segmentrevenue segment be year year basis operate income be year year pharmaceutical distribution witness favorable result quarter courtesy ofsolid expansion revenue gross profit include acquisition however lower sale pharmedium operate loss profarma unit partially offset growth corporation price consensus ep surprise corporation price consensus ep surprise corporation quote other segment include consult service abcs world courier mwi veterinary supply revenue segment come year year growth segment be drive consolidation specialty joint venture brazil revenue mwi abcs growth canadian operation world courier business however operate income segment be quarter year year downside be primarily cause lackluster performance abcs lash group margin analysisin quarter review register gross profit year year basis percentage revenue gross margin be basis point bps prior year quarter increase gross profit pharmaceutical distribution service boost company margin second quarter operate expense be year year upside be cause buyout duplicate cost implementation new information technology system register operate income year year percentage revenue operate margin contract bps guidance fiscal expect revenue growth range year year basis notably zack consensus estimate revenue be currently peg year year company expect adjust earning share range notably zack consensus estimate earning be currently peg share fall guidance expect adjust operate expense increase range previous range adjust operate income growth be expect be flat year year end second quarter fiscal solid note strong growth pharmaceutical distribution segment strong guidance instill investor optimism stock further joint venture brazil strength mwi unit abcs growth canadian operation prospect world courier business be key positive moment further recent takeover largest independent wholesaler unite state be also positive flip side sluggishness abcs lash group be concern face headwind thank slowdown hepatitis revenue conversion brand drug lower price generic further temporary slowdown pharmedium growth be expect mar company bottom line regard company face lower expect production pharmedium facility earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1028,ISRG,nuvasive inc nuva free report report first quarter adjust earning share ep cent reflect rise year quarter figure however miss zack consensus estimate cent solid contribution international business strong case volume growth hardware businessle year year improvement earning include time item company report first quarter net loss cent share net income cent share year rise litigation liability associate company lawsuit former sale agent lead net loss revenue report quarter come constant exchange rate cer year figure be par zack consensus estimate report quarter revenue spinal hardware business increase lead rise case volume roughly contribution product launch xlif modulus tlx reline small stature cohere further continue growth reline posterior fixation system drive top line however rise pricing pressure product mix have offset case volume growth revenue growth surgical support business be roughly flat first quarter primarily due weakness biologic portfolio persistent slowdown service business case volume growth however international business record growth cer report basis sixth consecutive time solid contribution key geography nuvasive inc price consensus ep surprise nuvasive inc price consensus ep surprise nuvasive inc quotein report quarter be increase cost good sell exclude amortization intangible asset expense accordingly gross profit decline moreover company report basis point bps year year contraction gross margin sale marketing administrative expense go research development expense rise nuvasive record adjust operate income report quarter reflect decline year quarter adjust operate margin contract bps quarter company exit first quarter cash cash equivalent end outlooknuvasive reiterate guidance guidance have be adjust recent buyout safepassage full year benefit tax reform suspension medical device tax company expect revenue range reflect organic growth moreover report basis company expect revenue growth inclusive recently acquire safepassage zack consensus estimate be guide range foreign exchange rate be expect prove favorable nuvasive fact company expect foreign exchange rate have positive impact almost year compare state previously nuvasive continue expect full year adjust ep current zack consensus estimate fall guide range additionally adjust operate margin year be expect have disappointing first quarter thank softness business however solid show international business more growth sixth consecutive quarter buoy optimism further management believe addition lateral single position surgery expand lateral procedural solution offering enhancement advanced material science portfolio help company improve performance rest year moreover initial launch surgical intelligence platform help nuvasive strengthen position company also expect see bps improvement gross margin second half result focus house manufacturing facility regard company be also upbeat increase production ohio manufacturing expectation higher adjust operate profit margin reflect focus operational efficiency house manufacturing facility well moreover be upbeat recently complete buyout safepassage contribute revenue growth first quarter zack rank key picksnuvasive have zack rank sell few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep steering past zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1029,ISRG,ecolab inc ecl free report report first quarter adjust earning cent share beat zack consensus estimate earning also rise year year basis ecolab carry zack rank hold adjust quarterly net sale be year quarter also net sale beat zack consensus estimate segmental analysisglobal industrial sale segment grow year year almost upside be drive major gain water food beverage life science unit europe north america latin america lead global industrial regional growth however acquisition adjust fix currency operate income segment decrease year year basis due higher deliver product cost massive investment business ecolab inc price consensus ecolab inc price consensus ecolab inc quoteglobal increase lead strong growth specialty business line segment witness solid growth north america asia pacific acquisition adjust fix currency operate income rise year year global energy sale rise owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income remain flat year year other sale decline year year however sale segment witness robust growth north america notably other segment now have ecolab colloidal technology unit unit be previously part global industrial reportable segment acquisition adjust fix currency sale rise year year pest elimination unit segment register solid growth north america europe margin company margin quarter review remain pressure owing higher deliver product cost percentage revenue ecolab register adjust gross margin first quarter basis point bps year year basis adjust operate margin first quarter contract bps net revenue however ecolab remain hopeful latest pricing initiative have undertake management be expect boost margin come quarters view upecolab expect full year adjust earning range share previously issue range notably represent increase band year year notably zack consensus estimate be currently peg share percentage revenue adjust gross margin be expect be net revenue be significantly previously issue range second quarter ecolab expect adjust earning range share current outlook reflect increase year year adjust gross margin second quarter be expect be net revenue end first quarter favorable note beating zack consensus estimate count strength pest elimination business other segment decline year year report basis ecolab operate highly competitive market mar prospect long haul believe volatility foreign currency exchange rate remain significant headwind company ecolab face pricing pressure energy segment be likely hurt profit brighter side strong guidance instill optimism stock further europe north america latin america lead global industrial regional growth quarter strength global institutional segment lead growth specialty healthcare business line be also positive robust product portfolio expand customer base be likely drive organic sale long haul earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1030,ISRG,surmodic inc srdx free report report adjust earning cent share second quarter fiscal year year zack consensus estimate be loss penny revenue quarter increase beating zack consensus estimate stock have zack rank buy surmodic have outperformed industry year time stock have return compare industry rise return be also higher index return segmental report revenue segment medical device diagnostic ivd medical devicein report quarter sale improve due lower hydrophilic royalty revenue notably royalty license fee revenue totale year quarter uptick royalty license fee revenue reflect surmodic strength hydrophilic coating royalty further company gain license fee income recently announce collaboration abbott medical device product sale rise report quarter solid medical device sale medical device customer research development revenue decline year year basis unit generate operate income second quarter fiscal compare operate income year quarter ivdin quarter review sale increase upside come back strong growth stabilization biofx microarray antigen product sale operate income segment be report quarter compare second quarter fiscal surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quotemargin detailsproduct gross margin contract basis point bps second quarter product sale compare year period margin quarter suffer expense irish facility infrastructure lower medical device product gross margin second quarter fiscal expense be net sale higher net sale year quarter sg expense second quarter fiscal be revenue bps higher year year raise guidance fiscal surmodic expect fiscal revenue range previous band company expect fiscal earning share negative cent cent compare previous estimate negative cent cent zack conensus estimate be currently peg loss cent share exit second quarter fiscal solid note beating zack consensus estimate count further solid performance diagnostic segment gain strong growth stabilization biofx microarray antigen product sale hold promise surmodic issue solid guidance fiscal company solid initiative strengthen research development program bode well flip side company witness significantly high operate loss product sale decline due shipment issue particularly medical device segment further foreign exchange wo related creagh medical buyout have be major dampener surmodic drug coat balloon face stiff competition niche space company margin be expect stay pressure thank expense irish facility infrastructure lower medical device product gross margin earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1031,ISRG,dentsply sirona inc xray free report report adjust earning share ep cent first quarter beating zack consensus estimate however metric fall year year net sale increase year year also figure surpass zack consensus estimate however metric decline constant currency cc exchange rate stock carry zack rank hold dentsply price movement have be unfavorable past year stock have lose compare unfavorably industry rise net sale exclude precious metal impact net sale company precious metal dental alloy product be used third party construct crown bridge material be subject risk fluctuation precious metal price avoid impact fluctuate price dentsply report net sale precious metal content show actual performance independent precious metal price volatility net sale segment be year year dentsply sirona inc price consensus ep surprise dentsply sirona inc price consensus ep surprise dentsply sirona inc quotesegmental business be organized report segment dental healthcare consumable technology dental healthcare segment comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product net sale improve segment decline cc technology equipment consist dental implant cad cam system imaging system treatment center orthodontic product metric increase segment year year basis however revenue be cc geographic detailsin quarter sale unite state fall year year revenue area fall cc net sale europe increase cc net sale rest world climb cc margin profit report quarter be year year however percentage revenue gross margin contract basis point bps operate income fall quarter operate margin quarter contract bps net revenue guidance management expect adjust earning share range previous range notably zack consensus estimate earning be currently peg share significantly higher management expectation revenue be project rise cc zack consensus estimate revenue be currently peg exit first quarter solid note beating zack consensus estimate count robust performance company flagship dental implant cad cam system imaging system treatment center orthodontic product platform hold considerable promise long haul emerge market asia pacific middle east offer healthy growth opportunity long term basis remain vastly untapped low dental product penetration company agreement medtech bigwig patterson company canada be likely drive sale dentsply recently witness rebound sale asia particularly japan strong growth russia flip side lower guidance be indicative loom concern company higher capital expenditure product development tough competition be expect exert pressure margin unfavorable foreign exchange rate integration risk be major headwind term earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1032,ISRG,accuray incorporate aray free report report loss cent share third quarter fiscal cent wider zack consensus estimate cent wider year figure total revenue quarter increase year year beating zack consensus estimate segment detailsproduct revenue product revenue decline same japan decline roughly third quarter year year decline total product revenue company continue witness strength radixact service revenue service revenue amount report quarter year year courtesy increase upgrade purchase service contract gross order update gross order performance third quarter fiscal be last quarter order growth be primarily drive tomotherapy array product radixact system order accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quoteother platform drife sale radixact be company latest device contribute handsomely revenue radixact system account tomotherpay order quarter review further system be be accept true workhorse product market courtesy significantly improve product performance functional efficacy broad case mix versatility suite software upgradation series software upgradation have be growth driver accuray upgrade be primarily focuse improvise imaging faster plan capability well system connectivity further software enhancement involved improvisation cyberknife treatment plan efficiency regard accuray have introduce ctrue iterative reconstruction enhance ct imaging capability radixact annual estro meeting be hold barcelona geographical gain improve management revenue growth third quarter attribute european american apac region contribution order performance emea japan have also be strong margin detailsin quarter review total gross margin be roughly flat year year product gross margin increase report quarter compare year quarter be attribute increase revenue contribution cyberknife system radixact system service gross margin third quarter be compare year quarter operate expense totale versus year quarter increase be primarily lead investment research development sale marketing financial exit third quarter cash cash equivalent compare second quarter fiscal guidance company revise previous guidance company expect revenue previous range zack consensus estimate fiscal revenue be high end guide range guidance gross order growth have be maintain rise approximately year year basis company expect adjust ebitda previously provide range takeaccuray report mixed third quarter fiscal further company lower ebitda expectation largely due strategic investment lower expect gross margin however accuray continue ride market solid response radixact platform company revamp software flip side long sale implementation cycle cyberknife tomotherapy system majorly affect company top line increase operate expense result research development activity be also concern price have be outperform industry past month stock have gain industry decline zack rank key picksaccuray carry zack rank hold few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1033,ISRG,inogen inc ingn free report report adjust first quarter earning share cent beating zack consensus estimate whopping earning also rise same margin year figure cent total revenue report quarter come beating zack consensus estimate revenue surge prior year quarter notably total unit be sell reflect increase year year basis meanwhile past month inogen share have rally industry decline inogen inc price consensus ep surprise inogen inc price consensus ep surprise inogen inc quotesegmental analysissale revenue come year year rental revenue totale business business domestic sale be year upside be attribute company private label partner traditional home medical equipment provider international sale segment come year year basis primarily continue adoption company european partner favorable currency rate direct consumer sale rise year year management upside be attribute increase sale representative headcount associate consumer spending marginsgross profit report quarter be year year total gross margin be net revenue basis point bps year year contraction gross margin be primarily lead lower sale revenue unit rental gross margin partially offset reduce cost sale revenue unit quarter review operate expense increase operate margin percentage revenue contract bps be mainly impact upside research development expense totale quarter adjust ebitda come indicate year year growth financial conditioninogen exit quarter cash cash equivalent marketable security worth compare last report guidancebuoy solid first quarter result inogen raise outlook revenue guidance range be represent growth result notably zack consensus estimate full year revenue lie range direct consumer be expect be fastest grow channel company net income guidance full year be represent growth inogen also raise guidance adjust ebitda represent growth result company further expect net positive cash flow additional equity capital require meet current operate plan exit first quarter solid note beating consensus mark count strong sale unite state europe raise optimism raise guidance also paint bright picture flip side decline margin owing surge expense raise concern decline rental revenue add wo additionally management expect rental revenue decline zack rank key picksinogen carry zack rank hold few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1034,ISRG,maintain streak positive earning surprise perkinelmer inc pki free report report first quarter adjust earning cent share beating zack consensus estimate base waltham lead medtech company report adjust revenue approximately beat zack consensus estimate revenue also surpass year quarter figure stock carry zack rank buy perkinelmer have outperformed industry year time stock have return higher industry return almost segment analytical solution da robust growth end market revenue da totale first quarter year year organic revenue increase year year perkinelmer have be focuse finalize organizational change associate life science business da unit come profit da segment company report first quarter adjust operate income year quarter perkinelmer register high single digit organic revenue growth asia mid single digit organic revenue growth americas europe bric region perkinelmer report solid organic revenue growth drive continue strength brazil india end first quarter management perkinelmer confirm company be now offer product line china da segment perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote further company be also expect close acquisition china expand elemental analysis product da business solid growth life science apply market boost company business china diagnostic segmentrevenue be compare year reflect year year increase reflect improvement organically diagnostic business perkinelmer infectious disease business exclusively serve emerge market continue show strong growth increase mid digit year year basis reproductive health business diagnostic also grow mid single digit year year however apply genomic business be year year basis due lesser expect micro fluidic sale adjust operate income segment come compare first quarter margin analysisadjust gross profit quarter come year year adjust gross margin percentage revenue be quarter basis point bps year year company expect significant gross margin expansion next year adjust operate income perkinelmer come year year adjust operate margin percentage revenue be quarter basis point bps year year guidance full year perkinelmer expect adjust earning share be significantly higher previously issue guidance notably zack consensus estimate be currently peg share significantly company estimate company expect revenue previously issue range zack consensus estimate be currently peg lower company estimate unfavorable foreign exchange environment put solid pressure quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion exit first quarter solid note strong performance da segment growth da be bolster strength lifescience end market informatic profile onesource offer company experience healthy growth major geography asia americas europe bric nation solid prospect elemental analysis product line hold promise furthermore positive guidance solid long term outlook boost investor confidence stock flipside have diversify portfolio unfavorable foreign exchange be primary concern softness industrial end market due unfavorable timing instrument order have be major dampener perkinelmer further company continue acquire large number company increase integration risk also high debt level hinder company expansion plan earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1035,ISRG,idexx laboratory inc idxx free report report first quarter earning share ep year year report basis comparable constant exchange rate cer basis current zack consensus estimate adjust ep be peg cent company upside report ep be drive revenue growth solid operate margin gain impressive benefit tax reform revenue detailrevenue rise year year organic basis surpass zack consensus estimate upside be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system further steady overall growth contribute top line idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quotesegmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other first quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue grow organically revenue other segment rise organically marginsgross profit increase report quarter further gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense rise operate margin quarter improve bps financial positionidexx exit first quarter cash cash equivalent compare end net cash provide operate activity report quarter be compare year quarter guidanceidexx have reaffirm revenue outlook company have update revenue organic growth guidance previous however idexx continue expect revenue growth report basis zack consensus estimate revenue be peg guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis compare state previously zack consensus estimate adjust ep be peg takeidexx exit first quarter solid note moreover solid year year growth organic revenue raise ep guidance be encourage stellar performance be drive strong sale cag business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment zack rank other key picksidexx have zack rank buy few other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1036,ISRG,qiagen qgen free report first quarter adjust earning share ep come cent year year figure beat zack consensus estimate cent constant exchange rate cer company report adjust earning cent revenue detailnet sale actual rate first quarter grow year year basis cer also top line surpass zack consensus estimate region wise sale americas revenue grow cer revenue europe middle east africa increase further revenue asia pacific japan rise year year exclude business portfolio change sale top emerge market exhibit growth year year cer quarter review qiagen price consensus ep surprise qiagen price consensus ep surprise qiagen quotesegment detailqiagen primarily generate revenue molecular diagnostic apply testing pharma academia represent net sale respectively report quarter molecular diagnostic sale be cer sale derive apply testing remain flat cer pharma sale rise cer first quarter academia sale improve grow demand operational updateadjusted operate income exclude restructure charge increase year year first quarter also adjust operate margin expand basis point financial updateqiagen exit first quarter cash cash equivalent end net cash operate activity report quarter be year quarter moreover company report first quarter free cash flow compare year quarter qiagen announce new commitment january return shareholder open market repurchase return shareholder end notably share be repurchase frankfurt stock exchange guidanceqiagen have maintain guidance total net sale growth cer guidance also include decrease hpv test sale have adverse impact total net sale growth further sale second half acquisition stat dx be take account zack consensus estimate revenue be peg moreover adjust ep guidance have be reiterate cer consensus estimate earning be guide range further favorable currency movement be expect have positive impact net sale growth penny cent share adjust ep company also provide financial guidance second quarter net sale be expect grow cer adjust ep be expect cent cer underlie basis zack consensus estimate earning stand cent share coincide high end company guide range further favorable currency movement be expect have positive impact second quarter net sale growth penny adjust ep takeqiagen end first quarter solid note be impressed year year growth majority segment company also deliver strong performance respect operate margin meanwhile commitment return more shareholder increase repurchase reflect solid cash position expectation favorable currency movement also buoy optimism be also upbeat qiagen recent receipt fda pre market approval partosure notably test help assess risk spontaneous preterm birth patient symptom preterm labor further company plan market test unite state encouragingly note partosure test have already be successfully launch country europe middle east asia latin america flip side competitive landscape strong reliance collaboration remain major overhang zack rank key picksqiagen have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1037,ISRG,masimo corporation masi free report report adjust earning cent share first quarter outperform zack consensus estimate cent bottom line improve year quarter figure cent stock have zack rank buy revenue improve year quarter beat zack consensus estimate segmental analysisproduct revenue product revenue deliver strong quarter double digit growth product revenue be quarter year year product revenue also witness impressive growth overseas market new product include nomoline capnography rainbow noninvasive blood constituent monitoring sedline brain function monitoring organ oximetry contribute result company worldwide direct product revenue total product revenue increase first quarter oem sale total product revenue increase first quarter notably january masimo receive ce mark rd rainbow lite set sensor enable use oxygen reserve index rpvi management be improve rainbow base version pvi be less costly rainbow sensor masimo corporation price consensus ep surprise masimo corporation price consensus ep surprise masimo corporation quote royalty other revenuesfirst quarter royalty other revenue fall prior year quarter margin analysistotal gross profit first quarter be year year gross margin be net revenue basis point bps year year product gross margin expand bps net revenue revenue be estimate previous projection zack consensus estimate revenue be peg significantly lower guide figure total product revenue be estimate previously issue guidance royalty other revenue be estimate adjust earning share be expect previous guidance zack consensus estimate adjust earning significantly lower guide estimate exit first quarter strong note beating consensus mark count solid guidance raise investor optimism stock company have be gain strong segmental revenue improve product revenue margin expand product portfolio wider adoption invasive patient monitoring technology be major catalyst masimo set pulse oximetry business represent considerable growth opportunity international market moreover masimo receive noteworthy ce fda clearance quarter include clearance domestic use new rad telehealth monitor way audio video capability flip side lackluster performance royalty other revenue unit be concern furthermore company face fierce competition oem distributor medical device bigwig mar top line long haul earning medtech major glancea few other top rank stock broader medical space report solid earning season be intuitive surgical inc isrg free report varian medical system inc var free report baxter international inc bax free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1038,ISRG,maintain streak positive earning surprise athenahealth inc athn free report report adjust earning share first quarter beat zack consensus estimate notably adjust earning report year quarter be cent watertown base maker bill medical practice management software post revenue beating zack consensus estimate revenue increase year year athenahealth carry zack rank hold detailssegment detailsrevenue business service be year quarter however revenue implementation other segment be year year network expansionper management company expand network ambulatory hospital population health platform recently athenahealth surpass patient threshold currently serve more healthcare provider first quarter athenahealth add new hospital company end quarter hospital network company network have collector provider clinical provider communicator provider respectively year year basis athenaone hospital platform number discharge bed increase whopping year year population health platform number cover life increase year year buoy stellar network expansion company be expect fortify foothold revenue cycle management rcm space drive revenue earning long haul athenahealth inc price consensus athenahealth inc price consensus athenahealth inc quote margin analysisa strong client base have be major growth driver company adjust gross margin first quarter be compare year quarter athenahealth operate income increase year year drive top line growth cost save initiative company see operate margin total revenue basis point year year reiterate fiscal financial guidance company expect revenue range meanwhile zack consensus estimate revenue be peg company expect adjust operate income range adjust operate margin be expect band net revenue exit first quarter solid note earning revenue outpace zack consensus estimate believe application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system brand promise unbreak healthcare be fortify market position term exclusiveness service provide strong client base have be key catalyst business service revenue witness year year growth same implementation other segment decline major concern athenahealth ehr solution face significant competition like allscript healthcare solution other further athenahealth fall short booking goal quarter review deteriorate client retention rate also add company wo earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy baxter cheme carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent cheme post adjust earning share outpace zack consensus estimate revenue come beating zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1039,ISRG,hill holding inc hrc free report report second quarter fiscal adjust earning share ep reflect increase year quarter adjust earning surpass zack consensus estimate be well company project range strong bottom line performance be backed solid core revenue growth continue margin expansion strategic investment drive growth marked consecutive quarter double digit earning growth company revenue detailsrevenue second quarter increase year year cer top line also exceed zack consensus estimate momentum core business mortara acquisition value add new product geographically revenue grow revenue outside unite state increase cer core revenue growth be cer hill holding inc price consensus ep surprise hill holding inc price consensus ep surprise hill holding inc quotesegmental performancein second quarter patient support system revenue drop year year cer segment domestic revenue decline however adjust divestiture core revenue decrease prior year revenue front line care segment include welch allyn respiratory care mortara increase cer apart gain mortara performance be drive contribution new product strong growth thermometry blood pressure monitoring device physical assessment tool double digit growth respiratory care business surgical solution segment revenue increase cer international growth drive strong momentum middle east europe revenue increase growth be backed solid uptake integrate table motion contribution product iled new ts mobile operate table marginsreport gross margin fiscal second quarter be bps year year increase cost revenue company witness gross margin expansion account rise revenue adjust gross margin grow bps buoy company initiative portfolio diversification benefit cost sourcing efficiency product launch adjust operate margin improve bps outlookin view promising second quarter performance hill have update fiscal earning guidance have also provide third quarter estimate full year company continue expect revenue growth report basis cer exclude foreign currency mortara divestiture other strategic asset company continue expect core revenue growth zack consensus estimate fiscal revenue be peg hill now expect adjust earning share fiscal range compare previous range zack consensus estimate fiscal earning be peg company guide range third quarter hill expect revenue growth report basis approximately cer core revenue be expect increase year year company expect adjust earning share zack consensus estimate third quarter earning stand revenue consensus estimate earning be company guide range takehill exit fiscal second quarter strong note company see solid year year increase revenue strong international growth upside international growth be drive double digit growth canada middle east strength europe latin america company be also focuse product innovation research development regard company recently announce upgrading welch allyn spot vision screener latest version be capable quickly efficiently screening adult patient pupil size small mm diagnose vision related issue however decline revenue patient support system segment be quite disappointing also foreign exchange remain concern zack rank key pickshill romha zack rank sell few better rank stock broader medical space report solid earning season be resm inc rmd free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy resm cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass zack consensus estimate resm report third quarter fiscal adjust ep cent beating zack consensus estimate revenue come exceed consensus estimate cheme post first quarter adjust ep beating zack consensus estimate revenue come steering past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1040,ISRG,integer holding corporation itgr free report post first quarter adjust earning share cent share miss zack consensus estimate however earning rise year year revenue totale beating zack consensus estimate revenue also increase year year basis organically share integer holding have rally industry decline year time integer holding currently carry zack rank hold integer holding corporation price consensus ep surprise integer holding corporation price consensus ep surprise integer holding corporation quotesegment detailscardio segment continue see strong top line growth revenue come year year organically upside be drive continue strong demand integer own product rise demand contract manufacturing component advanced surgical orthopedic portable medicalin quarter review segment post revenue prior year quarter organically management growth be drive increase portable medical product spinal implant continue ramp new product well accelerate sale customer part inventory build program notably integer holding have plan divestiture segment product line medplast llc cardiac segment rake revenue worth year quarter organically management neuromodulation market remain key driver long term growth product line total medical sale account organic year year basis marginsgross profit quarter come year year gross margin be basis point bps company operate income totale year year basis operate margin be bps upside be attribute company reduction operate expense totale adjust ebitda increase financial holding exit quarter cash flow operation translate free cash flow notably report quarter company paid debt guidancebuoy stellar first quarter integer holding have post impressive guidance company expect adjust earning share reflect growth notably zack consensus estimate be peg range revenue be anticipate indicate growth zack consensus estimate be pin be give range company expect cash flow operation free cash flow company further expect pay debt adjust ebitda company have raise expect range approximately full year adjust effective tax rate be expect holding have strong start high organic year year growth earning revenue cardio vascular arm deserve special mention here strategic divestment advanced surgical orthopedic portable medical wing medplast llc be expect prove accretive quarters ahead company also have multus year plan long term development raise guidance contract operate expense clear debt be other major positive however recent loss major customer intense competition niche space raise concern key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1041,ISRG,allscript healthcare solution inc mdrx free report post first quarter adjust earning share cent share miss zack consensus estimate penny however earning improve year figure cent revenue report quarter come miss zack consensus estimate however revenue improve year year quarter review booking grow share allscript have lose compare industry decline past month allscript carry zack rank hold allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc quotesegment detailssoftware delivery support segment totale year year basis management recur software revenue consist subscription recur transaction support new maintenance increase year year large part growth be drive consolidation enterprise information solution eis business client servicesrevenue segment come recur service revenue increase year year drive addition eis revenue cycle service other multiyear service offering marginsgross margin first quarter be compare prior year quarter total operate expense be year year basis year year increase be attribute acquisition eis business mckesson corporation additionally company record legal transaction related other cost quarter review adjust ebitda totale first quarter financial exit quarter cash flow compare year quarter free cash flow totale year year basis latest have announce definitive agreement acquire healthgrid hold company healthgrid mobile enterprise patient engagement platform business management expect close deal second quarter stock repurchase updatestock repurchase totale first quarter allscript anticipate revenue notably zack consensus estimate revenue be peg lie expect range earning share be expect cent cent reflect increase year year zack consensus estimate earning share be pin cent lie guide range adjust ebitda be expect year year takeallscript have dull start first quarter earning revenue miss estimate however strong segmental revenue buoy optimism year year rise booking be also major positive company ride plethora strategic acquisition partnership be likely prove accretive earning quarters ahead flip side decline margin rise operate expense raise concern company be also expose integration risk intense competition niche space add wo key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1042,ISRG,dexcom inc dxcm free report report loss cent share first quarter line zack consensus estimate also figure be narrower loss cent report year quarter stock have zack rank hold total revenue grow year quarter revenue surpass zack consensus estimate segmental detailssensor revenue other revenue total revenue grow year year basis transmitter revenue increase prior year quarter tally receiver revenue grow year year dexcom inc price consensus ep surprise dexcom inc price consensus ep surprise dexcom inc detailsdexcom generate gross margin percentage revenue contract basis point bps year year margin be pressure due inventory change shift ous medicare international business display continue growth quarter year year basis research development expense totale quarter year year selling general administrative expense totale report quarter increase year year guidancedexcom raise full year guidance company expect revenue range previous range meanwhile zack consensus estimate revenue be currently peg be significantly lower guide estimate gross profit margin be project band report operate expense exclude investment intensive program be expect increase first quarter adjust earning meet zack consensus estimate solid contribution sensor revenue transmitter revenue receiver revenue be key catalyst moment glucose monitoring market represent significant commercial opportunity dexcom dexcom opportunity alternative market such intensive diabetes management space hospital gestational pre diabetes obesity be likely provide company competitive edge medtech space further company next generation fully disposable cgm system be also progresson flip side cutthroat competition market blood glucose monitoring device be headwind dexcom moment believe company margin continue be pressure come quarters owing high product development cost rise expenditure research development lower expect margin transmitter sale be also cause concern earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1043,ISRG,cardinal health inc cah free report report third quarter fiscal adjust earning share miss zack consensus estimate adjust earning fall year year revenue increase year year basis almost edge past zack consensus estimate cardinal health have zack rank hold last month share cardinal health have outperformed industry stock have return industry rise segmental revenue increase year year basis segment witness strong growth specialty business gain large number pharmaceutical distribution customer however segment witness expiration large mail order customer contract divestiture company china distribution business pharmaceutical witness decline profit thank generic pharmaceutical pricing medical segmentrevenue segment improve primarily higher contribution new exist customer acquisition patient recovery business medical segment profit increase cardinal health inc price consensus ep surprise cardinal health inc price consensus ep surprise cardinal health inc quotemargin profit increase year year percentage revenue gross margin expand basis point bps net revenue company slash guidance fiscal adjust earning share current range be significantly lower previous estimate downside be cause company effective tax rate associate cordis business zack consensus estimate revenue be peg takecardinal health exit quarter tepid note adjust earning miss consensus mark company witness encourage performance medical segment pharmaceutical segment register strong growth specialty business gain large number pharmaceutical distribution customer further company be banking strategic buyout joint venture supply agreement drive growth growth business profit pharmaceutical segment be hurt generic pharmaceutical pricing huge investment pharmaceutical platform lackluster generic performance be likely mar cardinal health operational efficiency upcoming quarters intense competition customer concentration be other bottleneck recently company close divestiture cardinal health china distribution earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1044,ISRG,abaxis inc abax free report report fourth quarter fiscal adjust earning share cent beating zack consensus estimate moreover adjust earning rise year cent full year adjust earning share come comparison fiscal figure also surpass zack consensus estimate total revenuesin fiscal fourth quarter abaxis record revenue reflect increase year top line also surpass zack consensus estimate foreign currency exchange fluctuation have favorable impact top line fiscal revenue be prior fiscal figure also beat zack consensus estimate segment detailrevenue north america accounting total revenue rise report quarter revenue international market accounting rest improve abaxis inc price consensus ep surprise abaxis inc price consensus ep surprise abaxis inc quoteabaxis operate main segment veterinary medical other report quarter veterinary sale contribute total sale medical add remain be generate other veterinary market revenue rise year year drive uptick veterinary consumable revenue veterinary instrument revenue be year year revenue medical market be same quarter last year lead strength medical rotor also revenue north american medical division totale year year global basis abaxis sell piccolos quarter compare year abaxis exhibit strong consumable growth year year quarter consumable product line total rotor revenue be year quarter global basis abaxis sell rotor unit quarter review year quarter hematology reagent rapid assay also drive growth consumable revenue solid contribution flex rapid assay heartworm feline parvo test canine specific lipase revenue rapid assay be major contributor top line moreover total instrument sale rise strong uptake recently launch urine sediment instrument operational updatesgross profit fourth quarter rise gross margin contract basis point bps research development expense increase year year sale marketing expense rise general administrative expense also rise however resultant operate income be quarter operate margin decline bps financial updateabaxis exit fiscal cash cash equivalent short term investment compare fiscal third quarter takeabaxis exit fiscal fourth quarter promising note however decline gross operate margin raise concern meanwhile year year increase revenue buoy optimism company be upbeat company solid consumable instrument sale growth strength medical veterinary market segment meanwhile be encourage company initiation new sale marketing strategy regard abaxis have receive encourage response recently launch product urine sediment analyzer flex rapid assay company plan additional launch fiscal be expect drive growth zack rank other key picksabaxis sport zack rank strong buy other top rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter adjust ep beating zack consensus estimate revenue come exceed consensus estimate cheme post first quarter adjust ep beating zack consensus estimate revenue come steering past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1045,ISRG,resm inc rmd free report announce third quarter fiscal adjust earning share ep cent prior year quarter earning beat zack consensus estimate cent include time item resm report ep cent quarter year year closer view top linerevenue report quarter increase year year constant exchange rate cer figure also beat zack consensus estimate geographic basis exclude revenue unite state canada latin america totale reflect increase prior year quarter moreover revenue quarter totale year year revenue combine emea apac region be highlight rise cer year adjust gross margin contract basis point bps year year report quarter fall average selling price lead gross margin contraction be however partially offset procurement production efficiency resm inc price consensus ep surprise resm inc price consensus ep surprise resm inc quotesel general administrative expense be year year be increase research development expense lead rise adjust operate expense amount however adjust operate margin quarter rise bps financial updatesresmed exit third quarter fiscal cash cash equivalent compare end second quarter fiscal year date company generate cash flow operation year figure third quarter earning release resm announce quarterly dividend cent share same prior payout dividend be paid jun shareholder record part company capital management plan resm repurchase share fiscal third quarter expect sg expense percentage revenue fourth quarter fiscal expense percentage revenue be project band fourth quarter reflect marketing expense associate product launch ongoing legal expense takeresm exit third quarter promising note company achieve solid double digit global revenue growth quarter lead sale software service business well new mask product device term recent development company recently receive reimbursement approval mandibular repositioning device france drive accelerate uptake resm dental device help treat sleep apnea further company announce south korea start reimburse diagnosis therapeutic treatment sleep apnea term factor boost investor faith stock however competitive bidding issue continue hurt stock company be also expose foreign exchange fluctuation zack rank other key picksresm carry zack rank buy other top rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter adjust ep beating zack consensus estimate revenue come exceed consensus estimate cheme post first quarter adjust ep beating zack consensus estimate revenue come steering past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1046,ISRG,genomic health inc ghdx free report report first quarter adjust earning cent share year adjust net loss cent thereby reflect significant improvement bottom line also exceed zack consensus estimate cent report net loss come cent share wider couple cent year revenue detailin report quarter company adopt new asc accounting standard calculate revenue used modify retrospective method accordingly metric be year pre adjust revenue new asc standard have be apply jan adjust constant currency basis top line improve year year quarterly number also surpass zack consensus estimate genomic health inc price consensus ep surprise genomic health inc price consensus ep surprise genomic health inc quote geographically first quarter product revenue unite state rise year pre adjust revenue product revenue growth be fuel rise inu invasive breast oncotype dx breast recurrence score test surge prostate test revenue oncotype dx genomic prostate score gps test international product revenue totale quarter review year year atadjust constant currency year pre adjust tally first quarter company deliver more oncotype dx test result year year margin trendgenomic health gross margin contract basis point bps year year first quarter company also witness rise operate expense escalation research development expense uptick general administrative expense increase selling marketing expense report quarter genomic health operate loss come wider year operate loss accordingly operate margin contract bps financial updategenomic health exit first quarter cash cash equivalent short term marketable security highlight improvement record end company have reaffirm earlier provide outlook genomic health expect full year revenue range reflect growth zack consensus estimate be guide range takegenomic health exit first quarter promising note adjust earning revenue outpace respective consensus mark be also encourage year year rise revenue drive solid performance unite state internationally company prostate cancer space strengthen nccn national comprehensive cancer network prostate cancer guideline additional new datum be increase private coverage oncotype dx gps test moreover company be upbeat commercial launch oncotype dx ar nucleus detect liquid biopsy test metastatic prostate cancer be expect contribute business growth company also witness series upside oncotype dx breast recurrence score test however genomic health sole reliance breast oncotype dx test be concern moreover company rise operate expense challenge zack rank key picksgenomic health carry zack rank hold few better rank stock broader medical sector solid result earning season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue also surpass consensus estimate cheme post first quarter adjust ep outshine zack consensus estimate revenue come beating zack consensus estimate baxter release first quarter adjust ep cent crossed consensus mark revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1047,ISRG,cardiovascular system inc csii free report report earning share penny third quarter fiscal year quarterly loss cent figure remain ahead earlier guide range loss cent breakeven moreover bottom line compare favorably zack consensus estimate loss cent net system record revenue fiscal third quarter mark year year increase also metric be guide range moreover top line match zack consensus estimate segment detailscoronary device revenue increase year year unite state coronary unit sell increase partially offset low single digit decline asp average selling price cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quote meanwhile peripheral device revenue rise year year basis improvement come back continue strength hospital set margingross margin report quarter be basis point bps year year meanwhile selling administrative sg expense inched research development expense be result adjust operate expense increase management operate expense be lower previous projection operate income be operate loss year quarter financial company exit third quarter fiscal cash cash equivalent compare end precede quarter positive note have long term debt company expect revenue range fourth quarter fiscal zack consensus estimate be peg fall company estimate range moreover company be likely earn gross profit accounting revenue operate expense be anticipate fiscal fourth quarter company project net income net earning share be predict cent cent consensus mark be peg couple cent lie company expect range system exit third quarter fiscal solid note year year increase coronary device peripheral device segment overall revenue grow back strength company segment year year also expansion gross margin buoy optimism company be putt effort product innovation investment flip side cardiovascular system face cut throat competition niche space zack rank key system have zack rank hold few better rank stock broader medical sector solid result report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue also surpass consensus estimate cheme post first quarter adjust ep outshine zack consensus estimate revenue come surpass zack consensus estimate baxter release first quarter adjust ep cent crossed consensus mark revenue also exceed zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1048,ISRG,abiom inc abmd free report be currently top perform stock medtech space improvement price performance strong fundamental signify stock bullish run therefore haven take advantage share price appreciation yet time add stock portfolio company have perform impressively last year have potential sustain momentum upcoming period long term expect earning growth rate hold promise stock attractive pick share shine brightover last month abiom have gain compare favorably index rally current level be also better industry gain company expand product portfolio be key catalyst regard also cost saving effort be encourage factor northward estimate revisionsone estimate current year moved north past day southward revision reflect analyst optimism company zack consensus estimate adjust earning increase current year positive trend signify analyst bullish sentiment company hold zack rank buy indicate robust fundamental expectation outperformance term see complete list today zack strong buy rank stock here strong growth company zack consensus estimate earning fiscal reflect year year growth moreover earning be expect register growth fiscal zack consensus estimate fiscal revenue reflect year year improvement moreover revenue be expect witness growth fiscal abiom forecast fiscal revenue range mark increase fiscal level operate margin be project band positive earning surprise historyabiom have impressive earning surprise history company outpaced zack consensus estimate trail quarters deliver positive average earning surprise abiom inc price consensus abiom inc price consensus abiom inc quoteimpella product lineabiom expand product portfolio strengthen company foothold prophylactic high risk pci cardiogenic shock patient market regard company impella line product deserve mention management impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart abiom impella impella cp impella be fda approve pump treat cardiogenic shock furthermore impella impella cp be approve treat urgent percutaneous coronary intervention pci such stent balloon angioplasty cure block coronary artery company right side heart pump impella rp device cure right heart failure company also have automate impella controller be primary user control interface impella platform feature highly exclusive inch high resolution display research report bcc research global market cardiac medical device be project reach cagr consider prospect niche space expect abiom gain solid market traction year come other picksother top rank stock market large be integer holding corporation itgr free report alibaba group hold limit baba free report intuitive surgical inc isrg free report alibaba group flaunt zack rank company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock carry zack rank zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1049,ISRG,dec issue update research report intuitive surgical inc isrg free report grow adoption company da vinci system increase procedure volume strategic acquisition continuous innovation solid recur revenue base be key catalyst stock have zack rank hold intuitive surgical be manufacturer da vinci surgical system advanced robot assist surgical system related instrument accessory system enable minimally invasive surgery help avoid trauma associate open surgery last quarter intuitive surgical launch additional instrument accessory da vinci xi platform country notably company initiate limit launch refine vessel sealer europe quarter management announce plan file first fda approval da vinci sp program submission additional indication thereafter intuitive surgical have strong opportunity general surgery market particularly drive procedure hernia repair colorectal surgery internationally company have significant opportunity japan south korea china flip side foreign exchange movement be affect company result intuitive surgical generate major portion revenue domestic market continue investment international business be widening company exposure international market hence unfavorable foreign exchange be major concern further medical product space have be precarious game republican day courtesy president trump repeat failure repeal replace obamacare however major medtech player intuitive surgical have be pin hope trump promise abolish infamous medical device sale tax elimination be far be achieve regard let not forget massive chaos medtech space trigger failure first republican healthcare bill be propose summer so call american health care act ahca fail garner support house owing solid opposition conservative moderate lawmaker persistent uncertainty have give rise concern regard sustainability medtech company include intuitive surgical investor optimism have be grow thank president trump promise enactment new tax reform however market have not benefit due lack favorable development regulatory front notably tax have be suspend year be likely be put effect again jan share shine surgical price movement have be robust last month company represent solid return almost compare favorably industry rally just current level be bit lower index gain key picksa few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report petm express flaunt zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex yielded return last year stock flaunt zack rank idexx laboratory have long term expect earning growth rate stock rise year time carry zack rank buy zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1050,ISRG,person call artificial intelligence reality be technology enhance ginni rometty chairman president ceo ibm ease threat robotic apocalypse global artificial intelligence ai market be evolve lightning pace germination early ai have be enhance life never fact stock ai space have be provide handsome return significantly higher broader market research firm tractica expect ai market revenue reach such optimistic forecast be be rely be quantum leap level only global ai trendsbe virtual assistant self drive car ai have gain prominence consumer enterprise government sector world robo global collective robotic market be anticipate increase tenfold month kingdom saudi arabia grant citizenship humanoid sophia develop hong kong base hanson robotic be not fascinating enough new base entrepreneur nick gerritsen recently develop world first ai politician sam address local issue related education housing immigration notice demand robotic product unite state have be shooting workplace well household report technavio suggest industrial robotic market country be expect see impressive cagr more so not be too wrong foresee future robot live cheek jowl human ai impact major apple inc siri microsoft cortana amazon alexa humanoid sophia impact ai have be incredible major sector be try utilize resource come best burgeon ai trend here have zero major sector be make most tech sector convergence ai big datait be actually amalgamation ai big datum analytic drive tech growth easier word big datum be huge amount unstructured datum big datum be integrate analyze simplified ai model originate various report suggest growth ai be directly proportional growth big datum space substantiate report bank america lynch suggest big datum market be set reach worth thereby boost ai drive tech expenditure day come medtech sector robot assist surgeriesai have be enhance healthcare space clinical application diagnostic support operational efficiency electronic health record system practice workflow supply chain management grow prevalence minimally invasive robot assist surgery self automate home base care use quick improve patient care shift payment system value base model indicate high prevalence ai medtech space medtech major intuitive surgical inc isrg free report design manufacture market da vinci surgical system advanced robot assist surgical platform ai platform enable minimally invasive surgery help avoid trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair day come auto sector ai drife driverless ai power car have not hit showroom yet february ford motor company free report make huge investment argo ai develop virtual driver system fact research report ignite suggest nearly car be connect internet globally smart sensor embed connectivity application big datum enhance geo analytical capability bigwig alphabet inc googl free report tesla tsla free report be expending million dollar ai infusion automobile stock bet onwe have select pure play ai company believe tap promising long term prospect fanuc corp fanuy free report offer state art factory automation product globally company have zack rank buy earning be estimate grow next year headquarter yamanashi prefecture japan fanuc be manufacturer factory automation robot last year company announce collaboration implement ai fanuc intelligent edge link drive field system nvidia corporation nvda free report field system be platform boost factory production efficiency advanced ai high end compute technology report fanuc leverage proven technology instead create new technology create level consumer reliability outpace competitor product market large fanuc corp price consensus fanuc corp price consensus fanuc corp quote irobot corporation irbt have be major player global service robotic market company manufacture design sell premium home robotic product global consumer market irobot carry zack rank hold earning be expect be next year see complete list today zack rank strong buy stock here irobot bring first self navigate fda approve remote presence robot hospital additionally company introduce first practical home robot roomba home clean company product line feature proprietary technology advanced concept clean mapping navigation irobot engineer be currently work ecosystem robot initiate home automation technology company recently close acquisition robopoli company largest european distributor irobot corporation price consensus irobot corporation price consensus irobot corporation quote rockwell automation inc rok offer premium industrial information automation solution various end market globe company have zack rank earning be project climb next year company bring together lead brand industrial automation include allen bradley control service dodge mechanical power transmission product reliance electric motor drife rockwell software factory management software recently report fourth quarter fiscal rockwell witness strong performance semiconductor automotive metal company continue make progress oem machine builder have strong semiconductor business asia heavy industry business latin america rockwell automation inc price consensus rockwell automation inc price consensus rockwell automation inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1051,ISRG,share price intuitive surgical inc isrg free report scale new week high nov eventually close bit lower company have gain last month much better rise broader industry gain take stock stable performance consideration expect intuitive surgical scale higher come quarters company long term growth also hold promise average volume share trade last month be remarkable approximately stock have market cap last day analyst have raise earning estimate current year have slash same net effect have take zack consensus estimate share period sunnyvale base company post impressive third quarter peformance earning revenue have register year year increase quarter company also witness growth segment international performance be encourage too more good news be market be upbeat intuitive surgical procedure performance asia show continue strength solid growth china japan korea company gain significantly ce mark approval da vinci europe stock receive further boost recent fda approval same believe increase adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key growth catalyst also grow procedural volume outside unite state open considerable opportunity company additionally solid outlook come quarters raise investor confidence stock further incremental spending product development higher investment international market be prudent move be likely drive long term growth company be also expect enhance organizational capability gain prominence market europe asia zack rank key picksintuitive surgical carry zack rank hold few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report sporting zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technologyha long term expect earning growth rate stock have soar year time myriad genetic have long term expect earning growth rate stock have surge year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1052,ISRG,have be month last earning report intuitive surgical inc isrg free report share have add time frame outperform market recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver intuitive surgical beat earning surgical post adjust earning share third quarter crush zack consensus estimate stellar revenue growth also figure improve year year basis interestingly past quarters company beat estimate average revenue increase year year drive growth instrument accessory service system revenue revenue also beat zack consensus estimate be important note company stockholder approve split issue outstanding common stock begin trading split adjust basis oct business highlightssolid procedure trend intuitive surgical post solid number quarter courtesy rise customer adoption procedure growth system placement company outperformed mature growth procedure especially general thoracic surgery precisely third quarter procedure increase approximately year year basis procedure grow approximately outside unite state ous procedure grow approximately year year procedure performance asia show continue strength solid growth china japan korea add solid growth prostatectomy procedure volume lend intuitive surgical competitive edge broader prostate surgery market third quarter launch bode well third quarter intuitive surgical expand launch additional instrument accessory da vinci xi platform country fact company initiate limit launch refine vessel sealer europe report quarter management announce plan file first fda approval da vinci sp program year end submission additional indication thereafter international sale globally intuitive surgical system placement include europe japan india new mexico china however ous market be early stage adoption sale be lower estimate region revenue accessory revenue segment grow quarter drive strong procedure growth increase sale stapling vessel sealing product revenue realize procedure be approximately compare year quarter system sale increase buoy higher system placement partially offset lower average selling price notably intuitive surgical generate approximately revenue associate operate lease report quarter compare third quarter come company flagship da vinci surgical platform company ship surgical system third quarter service company register revenue year year basis growth install base da vinci system surgical adjust gross margin report quarter contract basis point bps net revenue decrease margin be due medical device tax refund be receive notably management intuitive surgical expect margin fluctuate base company mix new product mix system instrument accessory revenue reduction product cost reinstatement medical device tax financial updateintuitive surgical end third quarter cash cash equivalent investment year year basis be primarily drive cash generate operation employee stock option exercise have estimate be move then turn fresh estimate have trend downward past month have be revision lower current quarter intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quotevgm scoresat time intuitive surgical stock have nice growth score momentum be do bit better however stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum investor growth investor outlookwhile estimate have be broadly trend downward stock magnitude revision have be net notably stock have zack rank hold expect line return stock next few month
1053,ISRG,asia pacific apac be home more half world population so demand healthcare be also exceptionally high region furthermore need cut edge medtech product service be significantly high world apac be exception fact research report mckinsey show apac be expect outpace european union world second largest medtech market pretty soon unite state almost person region be expect enter age group indicate emerge demand healthcare need also apac account third global disease burden further research report statista show medtech market asia pacific region be estimate reach nearly trump focus datum point huge unmet healthcare need apac market investor find president trump recent day long asia trip stop japan south korea china vietnam philippine be positive sign furthermore recent tweet great country be respect again asia see fruit long successful trip many year come be indicative favorable republican stance apac especially respect business trade here take sneak peek major postulate trump recent asia visit bilateral trade agreementtrump promise augment bilateral trade agreement indo pacific nation instill confidence apac policy however trump specifically mentioned agreement be bound follow principle fair reciprocal trade also voiced free open indo pacific trade emphasize increase focus nation japan australia india prospect china pacific be big enough accommodate china unite state say china president xi jinp trump visit china undoubtedly pose serious competitive threat unite state not just healthcare space also electronic semiconductor retail other area jinp statement clearly hint possibility country coexist peacefully political tension also be indicative strategic merger company nation order enhance trade practice medtech company eye apacconsider trump grow focus apac region seem be poise yield accretive return long term fact stakeholder medical universe have be eyee emerge market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space meanwhile health policy debacle unite state deteriorate economic condition europe conclude growth emerge market china india japan other bolster global foothold medtech company take look lead medtech player be tap also gain bountiful opportunity apac market baxter international bax free report baxter solid presence asia precisely india be worth mention company have research hub japan china just report third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space second quarter baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline further baxter strong presence peritoneal dialysis nutrition iv fluid anesthesia gase fortify footprint china zack rank buy stock have have impressive run bourse last year stock have return significantly higher broader industry gain corporation bsx free report important part boston scientific growth strategy be continue pursue development opportunity outside unite state just report third quarter business emerge market register organic growth rate remain company target reach sale business china be also remarkable year year company be currently look forward improve performance china banking recent approval synergy boston scientific be also optimistic core cardiology segment be gradually stabilize growth bric nation cardiology capacity china be expect double end india business be project grow more annually zack rank hold stock have yielded stellar return last year way ahead broader industry same time frame see complete list today zack rank stock here intuitive surgical inc isrg free report intuitive surgical grow interest emerge market specifically apac region bode well last couple year company procedure performance asia show continue strength solid growth china japan korea just report third quarter intuitive surgical system placement include japan india new mexico china zack rank hold company have return last year much higher broader industry same period becton dickinson company bdx free report becton dickinson company bd be focuse geographical expansion overseas market particular emerge nation note company be especially focuse broader emerge market india china be see rapid growth economic healthcare sector believe significant emerge market exposure boost company top line turn lead accelerate ep growth bd revenue grow just report fourth quarter fiscal emerge market revenue grow strong year year quarter constant currency drive strong performance greater asia china revenue see double digit growth lead player medtech space be zack rank hold stock have return last year much higher broader industry growth paradoxhowever trump americafirst pitch asia pacific economic cooperation summit apec be hold vietnam november have be serious threat multilateral trade have be clearly portray trump primary focus be be be betterment unite state zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1054,ISRG,omnicell inc omcl free report report adjust earning share cent first quarter beating zack consensus estimate cent earning improve year figure cent be company guide range cent revenue detailadjust revenue first quarter increase year year also zack consensus estimate omnicell inc price consensus ep surprise omnicell inc price consensus ep surprise omnicell inc quote segmental basis automation analytic revenue increase year year first quarter also revenue medication adherence segment rise year year operational updateomnicell gross profit report quarter increase gross margin expand basis point bps sg expense first quarter increase year year research development expense decrease year year operate expense be first quarter year year operate profit quarter totale compare year quarter financial updateomnicell exit first quarter cash cash equivalent compare end fourth quarter second quarter omnicell expect adjust revenue band include impact selling cost reduction revenue company expect second quarter adjust earning share band cent zack consensus estimate second quarter revenue be peg earning share cent estimate fall guide range omnicell reaffirm product booking range also company expect adjust revenue band include impact selling cost reduction revenue company also project adjust earning band share zack consensus estimate full year earning be peg company guide range zack consensus estimate full year revenue stand company guide range takeomnicell first quarter performance be impressive further company segment witness year year growth be encourage note company be work product innovation also omnicell be expect gain recent launch strategic partnership however tough competitive landscape act dampener zack rank key picksomnicell have zack rank hold few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter ep share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter ep beating zack consensus estimate revenue come steering past zack consensus estimate cheme post first quarter ep beating zack consensus estimate revenue come surpass zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1055,ISRG,gnc holding inc gnc free report report first quarter adjust earning share ep cent reflect year year decline adjust ep surpass zack consensus estimate cent revenuesrevenue now exclude lucky vitamin period report quarter drop year year drop be primarily sale lucky vitamin september termination gold card program same store sale increase domestic company own store include gnc com sale quarter review notably be third straight quarter growth domestic franchise location same store sale drop gnc holding inc price consensus ep surprise gnc holding inc price consensus ep surprise gnc holding inc quotesegment detailsgnc holding report operation segment canada include company own store unite state puerto rico canada franchise store unite state commerce international include franchise location approximately country health store china operation manufacturing wholesale comprise manufacture product sell other segment third party contract manufacturing sale wholesale partner report quarter gnc holding revenue canada segment decrease domestic franchise location revenue decline due decrease retail same store sale reduction number franchise store revenue international segment increase drive higher cross border commerce sale china revenue manufacturing wholesale segment exclude intersegment revenue decline segment third party contract manufacturing sale fall however intersegment sale increase company increase focus proprietary product margingross profit decline report quarter however gross margin expand basis point bps rise penetration company private label brand selling general administrative expense contract accordingly adjust operate margin drop bps financial positiongnc holding exit first quarter cash cash equivalent end long term debt be quarter review compare end net cash flow operate activity totale compare year further company generate free cash flow compare year quarter new gnc plan updateearlier management have announce plan revamp exist business model dub new gnc now more consumer have joined company loyalty program include approximately customer enrolled pro access membership store count updatea mar gnc holding have corporate store unite state canada domestic franchise location rite aid franchise store store location international location company currently have store location globally company intend shutter approximately store part ongoing optimization company store portfolio company have also announce plan open limit number new store take gnc holding exit first quarter mixed note year year fall adjust earning revenue be dampening company have be fire cylinder strengthen international presence regard gnc holding recently announce proposal enter strategic partnership china joint venture agreement harbin pharmaceutical group hold co ltd hayao have receive hayao shareholder vote further company have recently enter master franchise agreement rapid nutrition foray australia same time gnc holding have also announce plan expand presence india operate collaboration master franchise partner guardian healthcare service pvt ltd thus development help boost investor faith stock zack rank key picksgnc holding have zack rank hold few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter ep share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter ep beating zack consensus estimate revenue come steering past zack consensus estimate cheme post first quarter ep beating zack consensus estimate revenue come surpass zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1056,ISRG,stryker corporation syk free report report first quarter adjust earning share ep beating zack consensus estimate ep figure exceed high end guidance also increase year year michigan base medical device company report first quarter revenue beating zack consensus estimate narrow margin revenue also increase year year basis organic sale growth be impressive performance japan china australia emerge market be striking well meanwhile last month stock have rally compare industry gain stryker corporation price consensus ep surprise stryker corporation price consensus ep surprise stryker corporation quotesegment segment come cc upside be attribute knee division report sale worth cc moreover organic net sale segment rise management flagship mako total knee platform see significant uptick new robot installation year year segment register revenue cc organic net sale segment increase supply issue related company puerto rico facility ramp growth be mainly drive sub segment instrument endoscopy medical instrument see growth cc endoscopy grow medical rise management medical division witness organic growth drive strong performance core bed power cot product well physio business neurotechnology spinerevenue segment come cc organic net sale segment increase neurotechnology register revenue worth cc spine revenue come cc however report quarter spine business see softness well low double digit price decline core product line segment be also gain recent integration entellus medical geographical detailssale unite state come constant currency cc international sale totale cc management stryker have strong performance japan south pacific canada company also register double digit growth year year basis emerge market however company performance europe lack luster first quarter marginsin quarter review operate margin expand basis point bps adjust gross margin improve nominally prior year quarter management gross margin be favorably impact productivity efficiency foreign exchange gain offset business mix price financial continue maintain strong position cash marketable security approximately be hold outside unite state cash flow first quarter be approximately total debt balance sheet end quarter be guidancebuoy stellar first quarter performance stryker now expect second quarter earning share notably zack consensus estimate second quarter earning be peg be pretty encourage moreover organic net sale growth be expect adjust net earning diluted share range management be also confident bps improvement operate margin takestryker strong first quarter show be largely backed solid performance segment moreover company witness high domestic international growth revenue strong guidance current quarter full year buoy optimism company moreover surge operate margin reflect strength company prospect however supply issue puerto rico facility decline gross margin raise concern zack rank other key picksstryker carry zack rank buy few other top rank stock deliver solid result earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank see complete list today zack rank stock here labcorp report first quarter adjust ep beating zack consensus estimate revenue come steering past zack consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1057,ISRG,maintain streak positive earning surprise varian medical system inc var free report report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis revenue totale beat zack consensus estimate year year basis revenue rise cc company strengthen foothold radiation therapy market grow order basis trail month varian have zack rank buy company have outperformed industry year time stock have return compare favorably industry rise let delve deeper company quarterly result segment detailsoncology systemsin second quarter oncology revenue totale cc year year basis varian medical worldwide net install base be unit unit year year basis whole gross order be year quarter cc gross order americas inched year year basis cc emea gross order be flat year year apac gross order inched year year operate earning segment rise year year february varian medical acquire small privately hold quality assurance software company mobius medical system management mobius market lead software doselab be solid enhancement varian medical exist portfolio patient treatment plan qa machine qa technology strong performance software hardware service revenue boost varian medical oncology system second quarter particle therapyrevenue segment inched year year basis notably company do not book new probeam order quarter march varian medical announce first patient treatment st petersburg proton therapy center russia important step expand access proton therapy world varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quote halcyon drive revenuesin second quarter halcyon platform witness total order inception majority greenfield site reflect solid demand platform quarters ahead project growth be drive solid new scale configuration optimized different customer segment advanced capability marginstotal company gross profit report quarter be year year gross margin report quarter be expand basis point bps year year basis oncology gross margin report quarter be percentage revenue bps be primarily drive revenue growth hardware software service well margin rate expansion europe pricing discipline ongoing operational excellence financial company end quarter cash cash equivalent debt cash flow operation be year year drive operate income performance work capital efficiency guidance revenue growth be expect range year year basis fiscal zack consensus estimate revenue be peg moment adjust operate earning percentage revenue be expect range adjust earning share be expect range zack consensus estimate earning be peg moment cash flow operation be expect range medical end second quarter solid note halcyon platform drive top line solid revenue oncology grow adoption particle therapy strong overseas presence particularly emerge country be positive varian medical sign agreement acquire sirtex australian base company focuse interventional oncology therapy approximately aud varian oncology care management platform company acquire evinance innovation small privately hold montreal base company specialize clinical decision support software solid guidance fiscal instill confidence stock flip side company do not book new order proton therapy unit company compete large electronic company well smaller more specialize radiation therapy equipment manufacturer thus competition be likely mar revenue earning medtech major glancea few other top rank stock medical space report impressive result earning season be laboratory corporation america holding lh free report cheme corp che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here labcorp report first quarter adjust earning share beating zack consensus estimate revenue come exceed zack consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1058,ISRG,investor intuitive surgical inc isrg free report need pay close attention stock base move option market lately be nov put have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move intuitive surgical share be fundamental picture company currently intuitive surgical be zack rank hold medical instrument industry rank bottom zack industry rank last day analyst have increase earning estimate current quarter have drop estimate net effect have take zack consensus estimate current quarter share period give way analyst feel intuitive surgical right now huge imply volatility mean trade develop oftentimes option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
1059,ISRG,weight watcher international inc wtw free report recently announce offer senior note due note be unsecured be guarantee company subsidiary company intend enter new revolve credit facility refinance exist share price movementweight watcher share price movement past month have be impressive company share have return almost compare industry rally just current level be also higher return come back news interest rate conversion rate certain other term note be yet be determine company intend use net proceed offer expect borrowing propose new term loan facility worth cash hand repay amount outstanding exist credit facility weight watcher plan terminate such facility pay related fee expense believe company strong balance sheet help aid capitalize investment opportunity pursue strategic acquisition improve prospect moreover senior note offer reduce company cost capital thus strengthen balance sheet support growth weight watcher be largest provider weight control program world core business be weekly meeting demonstrate scientifically design program incorporate group support educate healthy eating pattern behavior modification physical activity zack rank key pickscurrently weight watcher carry zack rank hold few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report intuitive surgical isrg free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent stellar return last year stock flaunt zack rank intuitive surgical have long term expect earning growth rate stock have zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1060,ISRG,bio rad laboratory inc bio free report report third quarter earning cent share surge year figure bottom line also surpass zack consensus estimate cent wide margin notably net income quarter be favorably impact higher sale significantly improve gross margin net sale come year year constant exchange rate cer top line also beat zack consensus estimate year year improvement sale be largely drive strong performance europe asia pacific also bio rad register solid growth many key life science diagnostic product area quarter detailon segmental basis life science net sale come year year cer cer sale rise back strong performance droplet digital pcr ddpcr food safety gene expression product line well revenue generate recent acquisition raindance technology growth be however offset decrease process chromatography medium sale bio rad laboratory inc price consensus ep surprise bio rad laboratory inc price consensus ep surprise bio rad laboratory inc quotewithin clinical diagnostic company register sale year year cer upside result increase blood typing immunology quality control product line gross margin report quarter be basis point bps year year climb gross profit adjust operate margin same period expand basis point rise operate profit company exit third quarter cash cash equivalent short term investment compare end second quarter year date net cash provide operate activity be compare year period guidance fourth quarter bio rad expect net sale range include sale recently acquire raindance technology stock have see zack consensus estimate current quarter sale be peg project band fourth quarter gross margin be anticipate be line year date result operate margin fourth quarter be anticipate be band bottom linebio rad post strong quarterly show earning sale beating zack consensus estimate significant margin sale growth be majorly drive sale droplet digital pcr instrument consumable cell biology food safety product life science group also strong growth product blood typing quality control autoimmune testing diagnostic group contribute top line boost quarter review zack rank key picksbio rad have zack rank hold few better rankedmedical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue grow year year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1061,ISRG,express script hold company esrx free report post first quarter adjust earning share beat zack consensus estimate penny further adjust earning improve year year revenue edge past zack consensus estimate inched year year upside be drive operational cost improvement backed focus technology digital tool home delivery specialty service stock have zack rank sell express script have outperformed industry year time stock have gain period compare industry rise patient claim volume script first quarter witness year year decline patient claim adjust network claim be year year adjust home delivery specialty claim be report quarter year year result net adjust claim first quarter be year year basis decline be primarily drive loss certain public sector client express script hold company price consensus ep surprise express script hold company price consensus ep surprise express script hold company quote margin detailsadjust gross profit first quarter be year year percentage revenue adjust gross margin be flat year year adjust selling general administrative expense be prior year quarter express script get medical care pharmacy benefit roof express script recently announce be get acquire cigna corporation global health insurance company acquisition be expect be conclude dec cigna take express script cash stock transaction worth term deal cigna pay cash share stock newly combine company closure express script shareholder own approximately combine company transaction result total cost synergy guidanceadjust earning share second quarter be estimate range represent growth year year notably zack consensus estimate earning be currently peg be project range company expect total adjust claim second quarter range be attributable core business adjust earning be estimate band significantly previous range share be suspension share repurchase program notably zack consensus estimate earning be currently peged lie significantly guidance revenue be expect band zack consensus estimate revenue be currently peg lie guidance adjust ebitda be expect script end first quarter strong note beating consensus mark count however lackluster guidance be indicate concern stock moreover company face stiff competition raise concern buoy strong result quarter express script enterprise value initiative be estimate range notably management expect cumulative saving nearly earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1062,ISRG,pacific bioscience california pacb free report report first quarter adjust loss cent share be wider zack consensus estimate penny company report loss cent share year quarter meanwhile stock have lose compare industry decline year time pacific bioscience carry zack rank buy revenue menlo park base manufacturer sequence system post revenue miss zack consensus estimate revenue also drop year quarter primarily due lower instrument revenue quarter review product revenue totale deteriorate prior year quarter meanwhile service other revenue come year year pacific bioscience california inc price consensus ep surprise pacific bioscience california inc price consensus ep surprise pacific bioscience california inc quote furthermore instrument revenue come compare year consumable revenue come slightly year management sequel instrument booking be strong first quarter highest number instrument order introduction system order include instrument order bgi china growth sequel business have partially offset decline rs ii smart cell usage additionally alabama base hudsonalpha institute biotechnology have be used company flagship sequel system have be expand use human clinical research margin profit first quarter be year year basis gross margin be total revenue basis point bps year year operate expense totale slightly prior year quarter contraction be lead lower expense totale first quarter moreover sale general administrative expense quarter be slightly lower prior year quarter financial bioscience cash cash equivalent investment exclude restrict cash totale report quarter figure rise year year bioscience end first quarter dreary note product service revenue fall year year basis due lower instrument revenue however be partially offset strong sequel performance witness record booking quarter adoption system hudsonalpha be also major positive continue instrument order bgi china be encourage furthermore company be well poise expansion smrt sequence product development activity meanwhile highly competitive environment raise concern fall consumer revenue add wo other key pickssome other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1063,ISRG,becton dickinson company bdx free report post second quarter fiscal earning beat zack consensus estimate earning also improve constant currency cc becton dickinson also know bd post revenue worth surpass zack consensus estimate revenue rise cc year year basis revenue surge acquisition bard meanwhile bd share have gain compare industry bd currently carry zack rank hold becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company quotesegment detailsbd medicalthe segment post worldwide revenue cc management strong result be drive strength medication delivery solution diabetes care pharmaceutical system unit bd life revenue segment come reflect increase cc revenue growth reflect strong performance diagnostic system bioscience unit however growth preanalytical system unit be negatively impact production issue product line be resolve quarter segment growth be aid flu related revenue diagnostic system unit result stronger flu season comparison prior year bd report quarter segment post worldwide revenue cc segment result reflect strong performance peripheral intervention urology critical care unit solid growth surgery unit geographic resultsussale unite state come cc second quarter bd medical segment account revenue unite state bd life science account revenue bd interventional record unite state outside unite state come cc upside be drive strong performance bd medical bd life science bd interventional segment internationally bd medical post revenue worth bd life science rake international revenue bd interventional contribute margin analysisin report quarter gross profit totale year year bd post operate income year year basis guidancebuoy solid fiscal second quarter performance bd raise fiscal guidance company expect adjust earning share increase estimate benefit foreign currency represent growth approximately fiscal notably zack consensus estimate earning share lie range company raise revenue growth guidance fiscal be also high end previous guidance takebecton dickinson end fiscal second quarter promising note strong growth bd medical be primarily drive medication delivery solution diabetes care pharmaceutical system unit meanwhile acquisition bard have proven accretive fiscal second quarter result internationally bd post strong revenue have maintain global foothold however decline margin raise concern recent product recall foreign exchange volatility be also likely mar company prospect key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1064,ISRG,cerner corporation cern free report report adjust first quarter earning cent share year quarter figure be line zack consensus estimate revenue rise year year miss zack consensus estimate stock have zack rank hold cerner underperform industry year time stock have lose compare industry return booking year year upside revenue be primarily attribute increase booking first quarter booking be year year basis company register strong booking business office service however subscription booking be lower expect cerner corporation price consensus cerner corporation price consensus cerner corporation quotesegment detailsinstead report revenue category system sale support maintenance service cerner report segment first quarter license software first quarter fall year year basis lower expect subscription booking mar growth segment subscription account revenue worth year year basis professional service increase year year management strong performance segment be likely enhance revenue cycle position manage service segment revenue be year year support maintenance revenue be year year reimburse travel sale amount year quarter marginsgross margin first quarter be almost flat year year operate margin report quarter be contract basis point bps year year basis downside be cause surge operate expense rise year year growth be drive personnel expense related revenue generate associate cash item financial positioncerner exit first quarter free cash flow operate cash flow totale long term debt include capital lease obligation be slightly sequential basis view downbeatcerner expect second quarter revenue zack consensus estimate same be higher project range second quarter adjust earning share be project range cent range be lower zack consensus estimate cent revenue be project range range zack consensus estimate same be significantly higher projection full year adjust earning share be estimate range lag zack consensus estimate further company expect second quarter new business booking range exit first quarter tepid note miss consensus mark top line front revenue come expectation due software issue technology resale lesser expect subscription booking delay va contract downbeat guidance indicate concern stock further lower margin technology resale result higher mix device resale be concern additionally cerner have be face macroeconomic challenge cutthroat competition niche space surge operate expense also add wo international growth be likely boost company prospect australia canada middle east ireland germany cerner witness strong cash flow record booking believe company have growth opportunity revenue cycle management rcm population health ambulatory market base product strength enviable track record add new client solid growth healtheintent platform also hold promise further company recently report suite development ehr platform earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1065,ISRG,hologic inc holx free report report second quarter fiscal adjust earning share ep cent year year line low end company cent guidance adjust ep be also par zack consensus estimate report basis company record net loss share net income second quarter fiscal notably report figure include cash impairment charge goodwill process research development associate hologic cynosure business revenue detailrevenue gross quarter year year constant exchange rate cer top line surpass zack consensus estimate company guidance solid contribution breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline marginally international revenue be cer strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesegment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive new product revenue continue solid uptake aptima woman health product cytology perinatal revenue also show improvement cer revenue breast health segment inched cer revenue growth unite state be roughly flat report quarter upside be lead higher service new product revenue international revenue however climb year year mark third consecutive quarter growth exceed revenue gyn surgical business be cer medical aesthetic business quarter report revenue reflect total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal second quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business geographic mix revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit second quarter fiscal cash cash equivalent compare end first quarter fiscal total long term debt be end report quarter compare first quarter fiscal quarter company generate operate cash flow compare year guidancehologic have update fiscal financial guidance company currently expect adjust revenue compare previous range company expect revenue grow range compare previously provide range cer zack consensus estimate revenue be guide range adjust ep guidance remain unchanged call growth zack consensus estimate adjust ep be peg guide range third quarter fiscal hologic expect adjust revenue represent annualize decline cer zack consensus estimate revenue be peg project range adjust ep be estimate cent reflect annualize growth zack consensus estimate third quarter adjust ep be pin cent company guidance takehologic exit second quarter fiscal mixed note growth geographical region buoy optimism however be disappoint decline revenue diagnostic segment blood screening divestiture be also likely impede growth company further company lower revenue guidance fiscal reduce sale expectation cynosure business raise concern zack rank key pickshologic carry zack rank sell few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep steering past zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1066,ISRG,conm corporation cnmd free report report first quarter adjust earning share cent beating zack consensus estimate adjust earning also improve year year revenue come outpace zack consensus estimate revenue increase year year report constant currency cc conm domestic revenue report quarter represent total revenue rise year year basis courtesy growth general surgery orthopedic internationally revenue increase report cc represent total revenue meanwhile past month conm have rally outperform industry decline conm corporation price consensus ep surprise conm corporation price consensus ep surprise conm corporation quotesegment surgery account company revenue quarter segment register revenue worth year year basis drive robust growth capital sale domestically orthopedic revenue record growth consecutive quarters long time internationally orthopedic revenue increase year year mark eighth consecutive quarter growth general segment contribute quarter total revenue quarter review segment revenue come year year management growth be attribute strong performance product portfolio furthermore domestically first quarter general surgery sale increase internationally general surgery sale rise marginsadjusted gross margin increase basis point bps year year revenue gross profit rise year year basis adjust ebitda margin first quarter be compare year quarter ebitda grow year year basis financial company cash balance end first quarter be compare prior year quarter cash flow operation be first quarter compare prior year quarter long term debt end quarter be sequentially view raisedencourage solid first quarter performance conm raise financial guidance company now expect full year constant currency sale growth range higher previous range notably zack consensus estimate revenue be peg adjust net earning share be expect compare earlier show growth notably zack consensus estimate be guidance additionally management expect full year gross margin improve bps primarily drive company cost save initiative full year expense be expect range percentage total revenue takeconm exit first quarter strong top line growth margin expansion domestic international revenue witness solid year year growth company core segment orthopedic revenue outside unite state surge eighth consecutive quarter deserve special mention long term debt end quarter be also high raise concern zack rank key picksconm carry zack rank sell few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corp che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here labcorp report first quarter adjust earning share beating zack consensus estimate revenue come exceed zack consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1067,ISRG,baxter international inc bax free report report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent figure come company guidance cent last quarters company deliver positive earning surprise average be baxter post sale edge past zack consensus estimate constant currency cc revenue rise year year basis baxter have zack rank buy company have outperformed industry year time baxter share have return higher industry rally roughly geographical report operate result base reportable geographic segment americas north south america emea europe middle east africa apac asia pacific whole sale inched year year operational basis international sale increase almost operational basis strong demand company continuous renal replacement therapy crrt sale injectable pharmaceutical advanced surgery product iv solution peritoneal dialysis therapy boost sale worldwide americas baxter report sale cc year year basis emea baxter report sale cc year year basis apac baxter report sale cc year year basis baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quotesegmental detailsrenal productssale segment increase cc year year basis renal product sale be support improve performance major product line therapy globally notably solid performance chronic acute renal therapy drive sale segment medication deliverysale segment be remain constant year year cc notably segment include company iv therapy infusion pump administration set drug reconstitution device segment be year year cc notably pharmaceutical include company premixed oncology drug platform inhaled anesthesia well critical care product pharmacy compound service nutritionsale segment be line year year cc notably segment include sale company parenteral nutrition pn therapy advanced surgerysale segment be year year cc segment include company biological product medical device used surgical procedure hemostasis tissue sealing adhesion prevention march baxter complete acquisition hemostat sealant product mallinckrodt plc expand exist surgical portfolio especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt notably development be not accretive first quarter adjust earning however baxter expect deal be modestly accretive adjust earning acute therapiessale segment be year year cc sale crrt other organ support therapy focuse icu boost segmental revenue quarter review othersale segment be year year cc baxter pharmaceutical partner business be include segment margin register gross profit first quarter year year percentage revenue adjust gross margin contract basis point bps first quarter adjust operate income increase year year quarter percentage revenue operate margin contract bps first quarter guidancebaxter raise financial outlook company expect sale growth cc expect adjust earning continue operation range share full year second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent end first quarter solid note beating consensus mark count strong demand crrt sale injectable pharmaceutical advanced surgery product iv solution peritoneal dialysis therapy boost sale worldwide latest strategic buyout recothorm preveleak be noteworthy recently company get fda approval bivalirudin percent sodium chloride injection flip side baxter expect pharmaceutical business be flat year year basis due increase competition select product segment further foreign currency headwind intense competition have be dampening company performance long baxter performance last year lack luster lower sale threat integrate pharmacy solution franchise business earning medtech major glancea few other top rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank see complete list today zack rank stock here labcorp report adjust earning share beating zack consensus estimate revenue be exceed zack consensus estimate cheme post adjust earning share outpace zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale also surpass zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1068,ISRG,zimmer biomet holding inc zbh free report report first quarter adjust earning share year year ahead zack consensus estimate reportedly net earning come cent share compare year quarter revenue detailsfirst quarter net sale come mark increase constant exchange rate cer year year net sale also surpass zack consensus estimate quarter review sale generate americas totale year year cer same emea europe middle east africa gross asia pacific however register growth cer segmentssale knee be year year cer hip record drop cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf be cer dental decline other revenue fall zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc margin come reflect contraction bps first quarter selling general administrative expense be further research development expense rise adjust operate margin decline bps quarter cash positionzimmer biomet exit first quarter cash cash equivalent compare end total long term debt be compare end first quarter operate cash flow be compare year quarter company also paid dividend quarter company have issue full year guidance sale be project grow range management project sale growth figure include basis point impact favorable currency movement zack consensus estimate revenue be peg current year adjust ep be expect be band zack consensus estimate coincide high end guide range takezimmer biomet end quarter positive note be also encourage company consistent effort product renovation research development be optimistic synergy ldr hold acquisition broaden complement company musculoskeletal range be also impressed strong strategic financial goal combine entity expect reach however company decline sale knee hip other segment cer disappoint moreover supply headwind related major brand company knee hip segment affected first quarter performance extent zack rank key pickszimmer biomet have zack rank sell few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter adjust earning share beating zack consensus estimate revenue come exceed consensus estimate cheme post first quarter adjust earning share beating zack consensus estimate revenue come steering past zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1069,ISRG,cvs health corporation cvs free report first quarter adjust earning share ep surge year year exceed zack consensus estimate quarter adjust ep consider additional adjustment net interest expense propose aetna acquisition report ep continue operation come cent share surge year period net revenue first quarter increase year year however lag zack consensus estimate quarter detailspharmacy service revenue increase report quarter drive growth specialty claim volume higher pharmacy network volume well brand inflation be however partially offset increase generic dispense continue price compression cvs health corporation price consensus ep surprise cvs health corporation price consensus ep surprise cvs health corporation quotepharmacy network claim processed quarter climb day equivalent basis backed net new business growth also mail choice claim processed count be day equivalent basis continue adoption maintenance choice offering revenue cvs health retail ltc be year year accord company increase same store prescription day equivalent basis partnership pbm health plan inclusion number additional medicare part network year brand inflation be partially offset continue reimbursement pressure increase generic dispense rate front end same store sale increase year year drive basis pointsfavorable impactof shift sale associate easter holiday first quarter second quarter apart seasonal cough cold positively impact front store sale basis point approximately however be adversely affected soft customer traffic pharmacy same store sale increase report quarter increase pharmacy same store prescription volume be drive increase pharmacy same store prescription volume partially offset negative impact approximately basis point due recent generic introduction generic dispense rate proportion generic prescription total number prescription dispense increase approximately bps pharmacy service segment bps retail ltc segment gross profit improve accordingly gross margin expand bps total operate margin quarter expand bps cvs health exit first quarter cash cash equivalent short term investment compare end end first quarter net cash used operate activity be compare year outlookcvs health currently expect deliver full year adjust ep band also have reiterate adjust operate profit growth guidance range company have also provide guidance second quarter cvs health expect deliver adjust ep range apart adjust operate profit growth be expect range flat takecvs health end first quarter mixed note earning be ahead zack consensus estimate revenue remain consensus number however year year growth top line be drive strong pharmacy service segment benefit upside specialty service also strong year year retail ltc comparison be encourage company currently be move forward completion aetna deal zack rank key pickscvs health have zack rank hold few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1070,ISRG,nov issue update research report bruker corporation brkr free report stock carry zack rank hold bruker exit third quarter solid note better expect earning revenue performance scientific instrument segment perform well strong result drive growth nano calid group last quarters nano surface group business realize profitability owing prior restructure cost action report quarter high single digit growth be drive contribution hysitron nanoindenting product acquisition late january improve result axs business bruker corporation price bruker corporation price bruker corporation quotemove company strategic acquisition activity have also be encourage instance company recently announce completion germany base merlin buyout product company complement bruker maldi biotyper platform more good news be bruker maldi biotyper franchise have grow impressive system worth approximately annum be happy note demand maldi biotyper be increase apply market specifically food feed beverage category segment base recent development witness product portfolio management believe bruker be poise double microbiology business next year share company have be trading broader industry last month stock have return higher broader industry gain period company raise guidance be indicative brighter prospect flip side bruker conduct business international market result adverse currency fluctuation continue incur loss company also headwind unfavorable economic condition intense competition continue threat key picksa few better rank stock broader medical sector be petm express inc pet free report luminex corp lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month intuitive surgical have long term expect earning growth rate stock have surge last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1071,ISRG,transenterix inc trxc free report post loss cent share third quarter line zack consensus estimate company incur loss cent year quarter report quarter total revenue decline year quarter downside be attribute defer service revenue previous system sale operational detailsin report quarter total operate expense be compare year quarter research development expense decline year quarter be primarily due timing work conduct prepare fda submission sale marketing expense report quarter rise approximately prior year quarter be primarily related headcount growth other expense commercial expansion europe general administrative expense increase approximately prior year quarter be primarily due extend support european commercial investment overall net loss be wider prior year quarter transenterix inc price consensus ep surprise transenterix inc price consensus ep surprise transenterix inc quote financial conditiona sep transenterix have cash cash equivalent versus dec zack rank key pickscurrently transenterix carry zack rank hold few better rank medical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1072,ISRG,align technology inc algn free report first quarter adjust earning share ep come year year earning be also higher company guide range cent figure comfortably beat zack consensus estimate cent well revenuesrevenue grow year year quarter surpass zack consensus estimate revenue be well ahead company guide range management top line be drive year year increase invisalign case shipment quarter upside be support growth north america international region expand customer base increase utilization solid worldwide case growth moreover increase revenue itero scanner contribute majorly segment detailrevenue clear aligner segment total revenue soar year year report quarter primarily drive continue strong invisalign case volume growth customer channel geographical region first quarter invisalign case shipment amount year year aid growth region well expansion customer base quarter align technology invisalign case be ship doctor worldwide be north america international region align technology inc price consensus ep surprise align technology inc price consensus ep surprise align technology inc quoterevenue scanner service improve significant marginsgross margin quarter review be basis point bps year year rise cost net revenue quarter align technology witness year year increase selling general administrative expense rise research development expense operate margin expand bps financial detailsalign technology exit first quarter cash cash equivalent short term marketable security compare end report quarter align technology repurchase share stock april stock repurchase program company currently have approximately left buy back program second quarter company project ep revenue company project invisalign case shipment band year meanwhile zack consensus estimate second quarter ep be revenue earning estimate be project range estimate revenue fall same takealign technology end first quarter solid note be upbeat continue strength invisalign volume north america company continue witness expand gp dentist customer base sustain strength invisalign utilization orthodontist be also encourage solid performance emea asia pacific market scanner service company witness rapid uptake itero scanner geography moreover company continue see increase adoption itero scanner invisalign case submission instead pvs impression thereby drive invisalign utilization further align technology recently announce receipt china food drug administration cfda approval commercial launch itero element intraoral scanner be also upbeat company expand itero element portfolio lauch itero element itero element flex scanner unite state majority european country cover france germany italy spain unite kingdom align technology have strong cash balance enable carry share repurchase turn provide solid return investor flip side company be expose foreign exchange fluctuation seasonal demand fluctuation higher operate expense pertain increase head count higher investment target expansion geographical presence portfolio zack rank key picksalign technology currently carry zack rank hold few better rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical currently sport zack rank strong buy labcorp cheme carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass zack consensus estimate labcorp report first quarter adjust earning share beating zack consensus estimate revenue come exceed consensus estimate cheme post first quarter adjust earning share beating zack consensus estimate revenue come steering past zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1073,ISRG,investor interested medical stock always be look find best perform company group be intuitive surgical isrg free report stock right now take look stock year date performance comparison medical peer be able answer question intuitive surgical be member medical group include different company currently sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank be proven model highlight variety stock right characteristic outperform market next month system emphasize earning estimate revision favor company improve earning outlook isrg be currently sporting zack rank strong buy past quarter zack consensus estimate isrg full year earning have moved higher be sign improve analyst sentiment positive earning outlook trend latest available datum show isrg have return start calendar year meanwhile stock medical group have lose average mean intuitive surgical be perform better sector term year date return look more specifically isrg belong medical instrument industry include individual stock currently sit zack industry rank group have lose average so far year so isrg be perform better area investor interest medical stock continue track isrg stock be look continue solid performance
1074,ISRG,nov issue update research report intuitive surgical inc isrg free report manufacturer da vinci surgical system advanced robot assist surgical system related instrument accessory major positive sunnyvale base company have have impressive run bourse late glimpse recent price performance reveal favorable return past year compare industry rally company have solid track record characterize earning beat trail quarters recently intuitive surgical report stellar performance back higher adoption da vinci system physician overall growth global procedure system enable minimally invasive surgery help avoid trauma associate open surgery company performance be also drive grow volume courtesy general surgery oncology urology gynecology procedure intuitive surgical consistently introduce technology surgical system company plan launch upgrade da vinci flagship vinci xi technology management confirm submission document ce mark approval vinci further company expect availability device europe end long haul extensive expenditure product pipeline expansion international market europe drive growth company flipside company expect procedure growth rate slow outside unite state upcoming quarters lengthy sale purchase order cycle da vinci system have add company wo also expense research development increase significantly first half reflect high spending advanced imaging advanced instrumentation next generation robotic zack rank key picksintuitive surgical carry zack rank hold few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report stock sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last year align technology have long term expect earning growth rate stock have gain last year myriad genetic have long term expect earning growth rate stock have gain last year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1075,ISRG,corporation abc free report board director have approve hike cash dividend share revise dividend cent be paid dec shareholder record nov further believe benefit generic growth long run note company be well position ensure product reach market patient have access traditional complex new therapy strong organic growth rate pharmaceutical market improve patient access care improve economic condition population demographic introduction new innovative drug hepatitis drug persistent brand pricing environment drive growth moreover company focus specialty drug bode well flip side cutthroat competition niche space be additional concern operate highly competitive pharmaceutical distribution related health care service market company primary competitor be national generic regional distributor space be witness consolidation customer manufacturer globalization increase quality regulatory challenge company also face threat manufacturer chain drugstore specialty distributor packaging health care technology company company base chesterbrook pa be world largest pharmaceutical service company focus provide drug distribution related service reduce health care cost improve patient outcome zack rank key currently have zack rank hold few better rank medical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1076,ISRG,amedisys inc am free report report adjust earning continue operation cent share third quarter year year earning also surpass zack consensus estimate cent third quarter net service revenue gross year year top line however miss zack consensus estimate quarter company home health division net service revenue totale third quarter reflect marginal improvement year year medicare revenue decline year year medicare revenue improve year year amedisys inc price consensus ep surprise amedisys inc price consensus ep surprise amedisys inc quote hospice division net service revenue gross year year include medicare revenue medicare revenue recently company integrate additional operate segment business personal care corporate personal care net service revenue totale reflect increase year number meanwhile corporate do not register revenue end third quarter company gross margin contract basis point bps third quarter increase gross profit expense salary benefit inched other expense drop adjust operate income report quarter reflect increase year adjust operate margin expand bps year figure amedisys exit third quarter cash cash equivalent compare end precede quarter company long term obligation exclude current portion be report quarter previous quarter year date net cash provide operate activity be compare year period takeamedisys end third quarter mixed note home health division company witness decline medicare revenue be improvement medicare revenue hospice division company register strong growth segment amedisys be currently explore opportunity home health hospice segment favorable demographic trend strategic acquisition bode well company however escalate operate expense decline gross margin continue raise concern also intense competitive landscape regulatory concern continue challenge home health hospice industry zack rank other key picksamedisys carry zack rank buy other top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue rise year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1077,ISRG,nov issue update research report baxter international inc bax free report baxter recently exit third quarter favorable note beating zack consensus estimate count impressive performance hospital product renal segment hold promise stock carry zack rank buy headquarter deerfield il baxter be global medical technology company operate life sustain critical care product category be cushion economic downturn company product be not commodity nature provide strong recur revenue base baxter have be experience burgeon demand dialyzer globe more person be afflict end stage renal disease esrd due grow incidence diabetes blood pressure other kidney related disease come recently report third quarter baxter strong product portfolio plethora regulatory approval completion claris acquisition drive top line buoy solid performance management baxter lift full year guidance baxter estimate sale growth approximately cc adjust earning year be expect band share previous band year have be favorable baxter regulatory front so far third quarter management baxter confirm new fda approval temporary importation certain drug facility canada mexico further fda approval new premixed injectable be key catalyst come product portfolio baxter convenient kidney dialysis solution regenerative tissue product oxiris set continuous renal replacement therapy next generation sigma spectrum infusion pump be latest addition extensive product portfolio notably baxter home solution system be first technology design reduce storage weight handle requirement traditional pd therapy management claim have first patient therapy new system part clinical trial regulatory submission be expect ongoing political conundrum pertain repeal obamacare medtech space devastation cause hurricane marium believe solid foothold global market drive result medtech major large proportion sale come overseas market baxter benefit develop country incremental investment health care system share price movementover past year baxter have outperformed broader industry term price performance company represent solid return higher industry gain roughly current level be also higher return only earning medtech major glancewith most member have report number third quarter earning season be draw close medical broader sector zack sector have put impressive show so far positive revenue momentum favorable revision estimate current period be notable feature season petm express pet free report report earning share cent second quarter fiscal year year basis stock sport zack rank strong buy see complete list today zack rank stock here luminex lmnx free report report adjust earning share cent third quarter year year revenue increase almost year year stock flaunt zack rank intuitive surgical isrg free report post adjust earning share third quarter year year revenue increase year year stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1078,ISRG,surmodic inc srdx free report report earning cent share fourth quarter fiscal end sep compare favorably zack consensus estimate loss penny report earning be however lower year figure cent revenue be prior year quarter report revenue also surpass zack consensus estimate quarter detailsurmodic report revenue segment diagnostic ivd medical device medical devicein report quarter sale increase growth be attribute higher product sale royalty research development other revenue diagnostic ivd sale rise higher sale several product category surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quote balance sheet cash flowa sep company have cash cash equivalent compare sep surmodic generate cash operate activity fiscal capital expenditure totale fiscal outlooksurmodic expect fiscal revenue range look bottom line company expect adjust loss range cent share takewe be impressed surmodic fourth quarter fiscal result company beat earning revenue furthermore upbeat guidance raise investor faith stock regulatory approval surveil reflect surmodic solid foothold develop surface technology muscular device particularly drug delivery space surmodic be strive expedite surveil drug coat balloon development program be nascent stage flipside company expect ivd business grow mid single digit compare double digit gain realize fiscal owing anticipate top line headwind term further foreign exchange wo related creagh medical buyout be major dampener zack rank key pickssurmodic currently carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand basis point year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year revenue rise year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1079,ISRG,direxion launch leverage fund apr focuse provide exposure global robotic artificial intelligence ai space direxion daily robotic artificial intelligence automation index bull share ubot seek track fee expense performance indxx global robotic artificial intelligence thematic index fund characteristic market cap weight index look provide exposure exchange list company develop market be poise benefit adoption ai robotic fund charge fee basis point year provide triple leverage exposure underlie index index top holding include intuitive surgical inc isrg free report nvidia corp nvda free report yaskawa electric corp exposure respectively do fit portfolio global robotic market be experience robust growth demand automation be increase advancement technology drive more efficient business operation robotic sector have garner lot investor attention seek get share pie return sector offer owing increase attention sector have garner robotic etfs be great way gain diversify exposure space robotic artificial intelligence automation industry be rapidly grow evolve jablonski manage director direxion say launch ubot allow trader take bold position company be forefront technology add however investor note leverage etfs be complex instrument not suitable long term buy hold portfolio etfs employ strategy attain goal daily basis hence long term set performance fund significantly differ state objective other fund be other leverage fund offer exposure space discuss few other regular etfs seek provide exposure robotic sector see technology etfs here robo global robotic automation index etf robo free report fund seek provide diversify exposure robotic stock track robo stox global robotic automation index have aum charge fee basis point year fund be heavily incline compute process ai manufacturing industrial actuation exposure respectively fund top holding be hiwin technology corp fanuc corp krone ag allocation respectively geographical perspective fund top allocation be unite state japan germany exposure respectively fund have return year year date robotic artificial intelligence etf botz free report fund seek invest company have chance benefitting increase demand robotic ai track same index ubot fund have aum charge fee basis point year fund be heavily incline industrial machinery electronic component electronic equipment instrument exposure respectively fund top holding be intuitive surgical inc nvidia corp yaskawa electric corp exposure respectively geographical perspective fund top allocation be japan unite state switzerland exposure respectively fund have return year year date want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1080,ISRG,textron inc txt free report share increase report first quarter earning surpass zack consensus estimate bancorp usb free report decline announce first quarter revenue lag zack consensus estimate billionhancock hold co share decrease post first quarter revenue lag zack consensus estimate millionshare intuitive surgical inc isrg free report increase report first quarter earning outpace zack consensus estimate
1081,ISRG,triple digit gain regular day tuesday trading dow nasdaq be bolster number different thing strong housing start lack relative geopolitical tension early week nothing so influential very strong earning season be still early stage so far only week have pass delta air line beat estimate top bottom line overall result have be notably better expect bell earning report yesterday be better expect board company perform more impressively other intuitive surgical isrg free report post robust earning beat ibm ibm free report eke positive surprise new corporate tax benefit alone ibm watson enterprise have thus far fail inspire fresh investment big blue result ibm have shed more today pre market isrg share be morning new earning report be follow suit start morgan stanley ms free report left estimate dust morning investment banking major post share quarterly revenue outpace zack consensus estimate respectively net income grow sale trading rise more ms earning click here fellow financial institution bank usb free report beat earning estimate penny cent share miss revenue expectation bring opposed analyst be look still represent good year year growth pre market trading show usb share slip half percentage point hour more usb earning click here base chicago north shore abbott lab free report also top earning consensus penny cent share revenue also slightly surpass expectation report sale guidance full year have be post share zack consensus be roughly midpoint share be ahead today open bell more earning click here defense component major textron txt free report however perform much better morning cent share blow away expectation cent more double cent share year sale also impressed estimate year figure industrial sale perked company see gain arctic cat acquisition share be today pre market more txt earning click here
1082,ISRG,intuitive surgical inc isrg free report report first quarter adjust earning share beat zack consensus estimate earning also improve year year basis revenue totale prior year quarter revenue also surpass zack consensus estimate solid performance be backed higher worldwide da vinci procedure lead growth general surgery procedure global urologic procedure management revenue also gain drop dollar meanwhile last month stock have gain industry decline segment come reflect year year increase management growth da vinci procedure volume primarily drive upside japan da vinci procedure specialty general surgery gynecology cardiothoracic surgery be grant national reimbursement status intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quotesystemsin report quarter system revenue increase year year notably da vinci surgical system be ship company year year quarter review shipment include system operate lease arrangement compare year quarter servicesservice revenue come year international sale unite state revenue totale year year basis sequentially upside be attribute increase system revenue higher instrument accessory revenue ous procedure grow year year system placement report quarter compare year quarter first quarter placement include europe japan marginsgross margin be basis point bps year year first quarter operate income increase year year basis financial company end first quarter cash cash equivalent investment reflect increase quarter primarily drive cash generate operation company have not repurchase share quarter have approximately remain board buyback authorization company have not issue guidance however management feel revenue experience low single digit decline lackluster performance gynecology benign hysterectomy market management also feel margin fluctuate due mix newer product system accessory revenue surgical end first quarter solid note company flagship da vinci procedure record solid growth hold promise quarters ahead well company also see expansion outside unite state be encourage however company expect sale decline quarters ahead raise concern zack rank key picksintuitive surgical carry zack rank hold few better rank stock broader medical space be bio rad laboratory bio free report myriad genetic inc mygn free report abiom inc abmd free report bio rad laboratory sport zack rank strong buy have long term expect earning growth rate see complete list today zack rank stock here myriad genetic have long term expect earning growth rate stock carry zack rank buy abiom have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1083,ISRG,vwr corporation report third quarter adjust earning share ep cent reflect rise year figure bottom line also surpass zack consensus estimate cent strong top line performance include time item company report third quarter net ep cent year year revenue report quarter be year year figure also surpass zack consensus estimate organic basis revenue increase vwr corporation price consensus ep surprise vwr corporation price consensus ep surprise vwr corporation quoterevenue americas totale year year organically quarter review decline americas organic growth be due less bill day third quarter organic revenue growth further reduce result adverse weather condition puerto rico texas florida emea apac revenue quarter gross year year organic basis foreign exchange boost sale acquisition less disposition dent revenue vwr report third quarter gross margin expansion basis point year year sale general administrative expense rise company post operate income flat year year operate margin contract basis point merger updatepost first quarter earning release vwr have inked definitive agreement avantor inc get acquire latter enterprise value view vwr longer plan provide update financial guidance acquisition be expect complete fourth quarter takevwr third quarter report be quite impressive top bottom line beating zack consensus estimate geographically company record growth americas emea apac same period brighter note management look forward benefit propose merger avantor already process combine entity suite product service solution help company generate higher degree relevance biopharma industrial customer also buyout be expect generate significant synergy next year addition transaction be likely create robust product service portfolio production scale biopharma furthermore deal help strengthen vwr business asia pacific region zack rank key picksvwr currently have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue rise year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1084,ISRG,globus medical inc gmed free report report third quarter earning cent share line zack consensus estimate earning improve year figure penny upside be drive roughly growth revenue totale revenue also beat zack consensus estimate detailsin report quarter sale unite state increase year year rise be attribute structural improvement international sale increase year year continue market penetration japan gain key distributor market improve momentum core international business research development expense be year quarter selling general administrative expense be comparable quarter be due inclusion pre revenue robotic trauma commercial organization build increase investment domestic sale force globus medical inc price consensus ep surprise globus medical inc price consensus ep surprise globus medical inc quotefinancial updatetotal cash cash equivalent increase sep dec cash generate operation first month be compare year period company reaffirm guidance fiscal sale adjust earning zack rank key picksglobus medical currently carry zack rank sell few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand basis point year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year revenue rise year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1085,ISRG,haemonetic corporation hae free report report adjust earning share ep cent second quarter fiscal year year bottom line also beat zack consensus estimate cent report basis haemonetic post earning cent flat year year total revenuesrevenue be year year constant exchange rate cer report quarter top line also exceed zack consensus estimate haemonetic corporation price consensus ep surprise haemonetic corporation price consensus ep surprise haemonetic corporation haemonetic witness year year same cer rise revenue north america however international revenue decline cer revenue product report operate result business franchise plasma haemostasis management cell process blood center plasma report revenue total revenue be year year cer revenue bloodcenter total revenue decline cer hemostasis management franchise revenue total revenue rise cer revenue cell process dip cer total revenue second quarter gross margin be basis point bps year year operate income be second quarter fiscal slip year year operate margin contract bps year year quarter financial exit second quarter fiscal cash cash equivalent compare end precede year company long term obligation long term debt other long term liability be quarter review end first quarter fiscal haemonetic generate operate cash flow compare year period adjust free cash flow transformation restructure cost be quarter compare year fiscal reaffirm fiscal revenue guidance company still expect full year revenue be line fiscal revenue guidance plasma revenue growth remain unchanged range hospital revenue growth be expect unchanged band blood center revenue be expect decline range same previous guidance stock have see zack consensus estimate sale be peg however company raise adjust ep guidance new range earlier band zack consensus estimate remain guide range takehaemonetic exit second quarter fiscal promising note earning revenue beating zack consensus estimate continue momentum new business generation geographical expansion have help company deliver strong result recent past however be disappoint fact encourage growth noticed plasma hospital company sluggish blood center business moderate overall growth report cycle company strong cash position boost investor confidence be also optimistic strong market adoption nexsys pcs plasmapheresis system recently receive fda approval company increase fiscal adjust earning guidance be also impressive zack rank other key pickshaemonetic currently have zack rank buy few other top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue rise year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1086,ISRG,penumbra inc pen free report report third quarter earning share penny compare favorably loss cent year quarter figure be also better zack consensus estimate loss cent revenue report quarter rise year year constant exchange rate cer exceed zack consensus estimate geographic basis third quarter revenue unite state represent total sale gross year quarter same cer meanwhile international sale total sale advanced year year cer penumbra inc price consensus ep surprise penumbra inc price consensus ep surprise penumbra inc quotego product category revenue neuro product grow cer quarter review revenue peripheral vascular product business rise third quarter reflect increase cer year year operational updatepenumbra third quarter gross margin be reflect basis point bps expansion year year gross profit rise research development expense totale sale general administrative expense amount year year operate profit report quarter come compare favorably operate loss prior year quarter financial updatepenumbra exit third quarter cash cash equivalent compare end second quarter takepenumbra exit third quarter better expect result year year comparison earning be favorable moreover company witness strong growth geography product line company be focuse product innovation research development penumbra be active player fast grow interventional therapy space fact company product primarily cater unmet clinical need major market neuro peripheral vascular zack rank key pickspenumbra have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year revenue rise year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1087,ISRG,wednesday april triple digit gain regular day tuesday trading dow nasdaq be bolster number different thing strong housing start lack relative geopolitical tension early week nothing so influential very strong earning season be still early stage so far only week have pass delta air line beat estimate top bottom line overall result have be notably better expect bell earning report yesterday be better expect board company perform more impressively other intuitive surgical isrg free report post robust earning beat ibm ibm free report eke positive surprise new corporate tax benefit alone ibm watson enterprise have thus far fail inspire fresh investment big blue result ibm have shed more today pre market isrg share be morning new earning report be follow suit start morgan stanley ms free report left estimate dust morning investment banking major post share quarterly revenue outpace zack consensus estimate respectively net income grow sale trading rise more ms earning click here fellow financial institution bank usb free report beat earning estimate penny cent share miss revenue expectation bring opposed analyst be look still represent good year year growth pre market trading show usb share slip half percentage point hour more usb earning click here base chicago north shore abbott lab free report also top earning consensus penny cent share revenue also slightly surpass expectation report sale guidance full year have be post share zack consensus be roughly midpoint share be ahead today open bell more earning click here defense component major textron txt free report however perform much better morning cent share blow away expectation cent more double cent share year sale also impressed estimate year figure industrial sale perked company see gain arctic cat acquisition share be today pre market more txt earning click here mark vickerysenior editorquestion comment article author click here https www zack com bio mark vickery medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1088,ISRG,close bell tuesday fresh wave earning report have come wide swath sector big name post actual afternoon come exclusively better expect result ibm corp ibm free report first glance appear accomplish analyst have set cent earning beat share sale surpass analyst be look figure represent year year revenue growth first time year market trading be selling ibm share roughly virtually wipe company gain so far sell also provide drag dow index tomorrow morning have just finally dig hole past month ibm guidance full year be reaffirm share apparently investor be look something little stronger line unite continental ual free report top zack consensus earning estimate penny cent share revenue quarter also edge expectation mark upswing earning year quarter prasm metric full year guidance have tighten share company have beaten estimate bottom line straight quarters lam research lrcx free report also outperformed estimate not impressive margin company afternoon headline number share sale also mark fifth straight earning beat revenue growth year year be roughly yet late trading be selling news follow strong regular session result be post more lrcx earning click here csx corp csx free report easily better expectation bottom line cent share vs cent expect revenue better expect company have also outperformed past straight quarters trail quarter average late trading be push csx share finally intuitive surgical isrg free report post arguably most impressive report bunch share far outpace expect revenue solidly pass zack consensus share late trading be putt medtech company record high trading territory investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1089,ISRG,be first big week earning season mean ll get lot big cap company report include several dow component company various industry lead charge several have best chart not only week entire earning season not easy beat quarter year ve do mean survive various economic condition have management forward think vision keep winning streak best big cap earning chart johnson johnson jnj free report have keep earning beat streak alive hasn miss year share be stock market have pull back get boost earning unitedhealth group unh free report have best chart wall street share be recent time high be change growth stock be just pause big cap name move higher still ibm ibm free report have beat quarters row share have be stagnant several year worry revenue growth blockchain be ibm savior intuitive surgical isrg free report have be hottest medical stock last year have beat quarters row share have pause be buy opportunity lam research lrcx free report hasn miss year be great performer volatility have hit share earning report be just boost need investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1090,ISRG,intuitive surgical inc isrg free report first quarter result expect release apr market close be expect show steady growth instrument accessory segment revenue other segment be also expect help company generate solid result last quarter company post adjust earning share beating zack consensus estimate revenue totale also outpaced zack consensus estimate first quarter zack consensus estimate revenue be pin indicate year year increase consensus estimate earning be reflect year year rise intuitive surgical deliver positive earning surprise past quarters average be let delve deeper instrument accessory instrument accessory segment deliver solid result last quarter accounting total revenue company flagship da vinci surgical system continue be revenue driver segment first quarter zack consensus estimate revenue be peg show rise year year intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quotein company have introduce da vinci xi surgical system response customer need fourth quarter da vinci install base grow year year unit fact company ship da vinci system fourth quarter compare prior year period company also submit da vinci xi sp platform same quarter other factor intuitive surgical anticipate full year procedure growth solid forecast indicate company release encourage number first quarter well procedure growth be expect be drive general surgery procedure outside unite state management expect operate expense rise company continue invest emerge market new technology include computer assist surgery gross margin be expect net revenue global surgical gain significantly ce mark approval da vinci europe increase use da vinci general surgery unite state continue growth neurology europe japan multispecialty growth korea china also contribute rally additionally fourth quarter ministry health japan list reimbursement procedure quarter revenue outside unite state increase sequentially year year basis surgical be currently face stiff competition niche space regulatory approval transenterix surgical robot abdominal surgery last october competition intuitive surgical have intensified moreover medtech giant medtronic pose threat be possibly work launch surgical robot year here be quantitative model predict intuitive surgical carry zack rank hold do not have positive earning esp need increase odd earning beat zack esp earning esp intuitive surgical be uncover best stock buy sell re report earning esp filter zack rank intuitive surgical carry zack rank increase predictive power esp however also need positive esp be confident earning beat stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank strong buy see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank buy abbott laboratory free report have earning esp zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1091,ISRG,episode etf spotlight talk jeremie capron manage partner director research robo global robo global be creator first index track global robotic automation artificial intelligence industry index be benchmark robo global robotic automation index etf robo free report robot ai be improve become integral part life almost day learn new real life benefit innovative technology jeremie highlighted key growth area field investor not ignore rapidly evolve exponentially grow space then discuss index create robo global company have team expert look entire robotic automation landscape identify company be include index jeremie explain process selection constituent bellwether well bellwether also talk benefit equal weigh approach largely eliminate single stock risk etf asset be invest company rest international company japanese company get allocation make sense japan have be leader robotic so addition familiar name irobot irbt free report intuitive surgical isrg free report rockwell automation rok free report nvidia nvda free report see lot company etf jeremie talk foreign company be forefront technology finally discuss impressive earning growth company result index impressive return jeremie explain surge many company still look very attractive valuation perspective learn more world robotic automation ai robo etf please listen podcast visit https roboglobal com please visit etf section zack more information etf other etfs please make sure tune next podcast have comment question please email podcast zack comdisclosure own robo zack etf investor portfolio
1092,ISRG,collaboration machine artificial intelligence ai be take robotic new high human have hardly imagined few year back jeff bezos recent walk robot dog be example earlier week current richest man world stroll annual mar robotic conference hold palm spring robotic dog call spotmini build boston dynamic prominent robotic design company notably last month spotmini be see open unlock door extend arm attach structure ai drive robotic advancement robotic subsequent promotion same be probably bring closer day robot assist human household chore see sci fi movie believe ai have huge role play turn movie sequence reality aim incorporating cognitive think process machine have see virtual version intelligent machine form voice assistant apple aapl free report siri google microsoft msft free report cortana amazon amzn free report echo other seem now be time look lifelike realistic form machine have wider range application event grant citizenship world first humanoid robot sophia kingdom saudi arabia well development first artificially intelligent politician sam new indicate gap human world robotic be be bridge projection recent report idc project worldwide spending robotic be year also see spending allocate timeframe industrial robotic comprise discrete process manufacturing resource healthcare retail wholesale industry witness highest spending industrial segment be follow service consumer robot believe such huge growth prospect bode well robotic industry participant let take look stock be likely bring man machine closer rockwell automation inc rok free report be original equipment manufacturer oem industrial automation equipment application specific integrate software consult design service base milwaukee wi company be well position benefit attractive opportunity industrial automation information market notably rockwell beat zack consensus estimate trail quarters average positive surprise long term earning growth rate be currently peg rockwell carry zack rank buy see complete list today zack rank strong buy stock here rockwell automation inc revenue ttm rockwell automation inc revenue ttm rockwell automation inc quoteintuitive surgical inc isrg free report be prominent name minimally invasive robotic assist surgery domain intuitive surgical have gain significantly ce mark approval da vinci europe stock get further boost recent fda approval same company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair go forward notably intuitive surgical beat zack consensus estimate trail quarters average positive surprise long term earning growth rate zack rank stock be currently peg intuitive surgical inc revenue ttm intuitive surgical inc revenue ttm intuitive surgical inc quotewhile company be solely focuse manufacturing international business machine corp ibm free report be responsible provide ai run machine company advancement ai domain dedicate platform watson be huge positive view company have be showcase watson power robot believe watson have lot offer go forward notably ibm beat zack consensus estimate trail quarters average positive surprise long term earning growth rate be currently peg ibm carry zack rank hold international business machine corporation revenue ttm international business machine corporation revenue ttm international business machine corporation expert fear machine overpower human intelligence future now adequately able machine be great assistance increase productivity efficiency entire population look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1093,ISRG,era big datum portfolio be tune evolve digital trend make prudent investment choice prove be daunting task millennial have start recognize increase need emerge automation trend subsequently robotic iot printing be become part daily life latest buzzword be artificial intelligence ai siri google have make life easier latest version global position system help track almost anything everything intelligent route map also not be pro social network site facebook twitter snapchat be see primitive accord investment giant jim cramer ai big datum soon let company bat interestingly benefit same not remain restrict particular industry be feel business segment investment arena ai help medtech gain tractionnon healthcare bigwig apple aapl free report google amazon amzn free report ibm microsoft digital affluence be already eyee healthcare device market late courtesy solid prospect thing be note here health treatment cost have sky-rocket past few year surprisingly medical device pharmaceutical account only small portion healthcare expense josh makower md general partner venture capital firm new enterprise associate greater part healthcare cost go pay salary healthcare employee ai help curtail high labor cost go deloitte datum global health care spending be project increase annual rate significant escalation just report rise labor cost be act major spending growth driver also growth age population necessity ai have increase leap bound census bureau report be significant rise age population unite state population age older be project be almost double estimate population datum also show median age be increase most area country be global scenario well notably industry be bearing brunt explode population present world health organization latest available datum show more member state worldwide report have less physician population density physician patient unite state be strategic application ai sphere healthcare provide impetus productivity evidently company adopt ai technology have already witness reduction healthcare cost have also experience improve patient outcome more medtech stock go ai waymedtronic mdt free report be undoubtedly first medtech manufacturer forge ahead initiative bring ai technique manufacturing process back company partner ibm watson utilize latter machine learn algorithms incorporate ai diabetes app minime jointly launch first artificial pancreas system metronic have utilize sugar iq cognitive compute capability ibm watson detect important pattern trend diabetes ehr technology developer cerner cern free report be also adopt ai technique rapidly lately company have be headline courtesy effort digitize electronic health record system regard company recently enter collaboration salesforce renown player field customer relationship management other centrus health clinically integrate physician lead network latest development company be plan advance flagship big datum platform healtheintent intuitive surgical isrg free report design manufacture market da vinci surgical system advanced robot assist surgical platform ai platform enable minimally invasive surgery help negate trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair late boston scientific bsx free report have also be putt effort incorporate ai technique neuromodulation cardiac rhythm management cardiology peripheral intervention oncology endoscopy urology pelvic health conclusiona long debate be structure intelligent machine intensive technology make human capability outmoded gradually different story several adversity ai undoubtedly have emanate change behavioral pattern consumer medical device space other sector once again go jim cramer say love behavior change investing be incredibly lucrative have behavior change theme use selloff pick stock base change thus go say market hold ample promise proper execution ai definitely prove be trump card space zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1094,ISRG,month have go last earning report intuitive surgical inc isrg free report share have lose past month underperform market recent negative trend continue lead next earning release be isrg due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent surgical post adjust earning share fourth quarter beat zack consensus estimate improve year year revenue increase year year drive growth instrument accessory service system revenue also beat zack consensus estimate fy glanceintuitive surgical report revenue full year company have major revenue segment instrument accessory total revenue system total revenue service total revenue business highlightssolid procedure surgical post solid number quarter courtesy rise customer adoption procedure growth system placement company outperformed mature growth procedure especially general thoracic surgery precisely fourth quarter procedure increase approximately year year basis procedure performance asia reflect persistent strength backed solid growth china japan korea add growth prostatectomy procedure volume lend company competitive edge broader prostate surgery market fourth quarter favorable study resultsin november team investigator university southern california university michigan ann arbor penn state health intuitive surgical publish large scale study title robotic assist video assist thoracic open lobectomy propensity match analysis recent premiere datum annal thoracic surgery result study demonstrated increase number robotic assist lobectomy lobectomy be defined surgical excision lobe organ quarter review intuitive surgical submit application fda millimeter stapler da vinci xi platform international company have be gain solid prominence globally fact outside unite state company procedure improve approximately year year basis intuitive surgical system placement include europe japan notably system place europe be da vinci system however ous market be early stage adoption sale lag estimate region revenue segment rise quarter back strong procedure growth increase sale stapling vessel sealing product revenue realize procedure be approximately flat year year system sale segment increase buoy higher system placement partially offset lower average selling price come company flagship da vinci surgical platform intuitive surgical ship system compare prior year quarter company register revenue year year basis backed growth install base da vinci system gross surgical adjust gross margin report quarter expand basis point bps almost net revenue increase margin indicate company consistent effort lower manufacturing cost notably management expect margin fluctuate base company mix new product reduction product cost reinstatement medical device tax financial updateintuitive surgical end fourth quarter cash cash equivalent investment line third quarter figure management be offset final payment associate accelerate share repurchase agreement initiate company first quarter intuitive surgical anticipate full year procedure growth range procedure growth be expect be drive general surgery procedure outside unite state management expect operate expense rise range company continue invest emerge market new technology include computer assist surgery gross margin be expect range net revenue incorporating project impact newly enact tax law intuitive surgical expect income tax rate net pre tax income have estimate be move then fresh estimate follow upward path past month intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quote vgm scoresat time isrg have nice growth score be lag lot momentum front follow similar course stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested stock be suitable solely growth base style score outlookisrg have zack rank hold expect line return stock next few month
1095,ISRG,fourth quarter earning season have commence positive note most sector decent picture participant have report jan total earning company be year year higher revenue beating earning estimate surpass top line expectation notably company be report earning week latest earning preview overall earning fourth quarter be expect increase growth revenue indicate improve growth projection previous quarter drive corporate tax overhaul relatively healthy job datum factor have boost corporate earning stoke investment base pattern fourth quarter be expect register modest double digit percentage earning growth year year basis medtech earning so farmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be evident result medtech heavyweight abbott free report intuitive surgical isrg free report company exit fourth quarter solid note beating zack consensus estimate count upbeat fy guidance also instill confidence fourth quarter earning growth rate medical sector be peg revenue growth upcoming releaseslet take look major other medtech stock slate release quarterly report jan stryker corporation syk free report result be schedule release market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be year year basis stryker recently announce better expect preliminary net sale result fourth quarter full year net sale be estimate year quarter constant currency basis figure beat zack consensus estimate buoy prospect quantitative model indicate earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate stryker earning esp be uncover best stock buy sell re report earning esp filter stryker carry zack rank read more core segmental growth aid stryker earning stryker corporation price consensus stryker corporation price consensus stryker corporation quotezimmer biomet holding inc zbh free report be set report result market open notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be project year year basis solid prospect company surgical sport medicine foot ankle extremity trauma arm macroeconomic uncertainty unfavorable currency fluctuation have be dent sale past few quarters company have be deal pricing pressure regard zimmer biomet witness negative pricing pressure approximately last quarter absence favorable change line headwind reflect company fourth quarter result read more arm drive zimmer biomet earning result proven model do not conclusively show earning beat zimmer biomet quarter zimmer biomet have earning esp stock carry zack rank sell see complete list today zack rank strong buy stock here zimmer biomet holding inc price consensus zimmer biomet holding inc price consensus zimmer biomet holding inc quotealign technology inc algn free report be set report result market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be cent year year basis align technology achieve milestone patient undergo treatment flagship clear aligner system invisalign november company have be adopt several strategy drive adoption core invisalign product line company receive patent align technology smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align technology collaborate digital design recent past read more invisalign drive align technology earning positive development proven model do not conclusively show align technology be likely beat earning quarter align technology have earning esp stock carry zack rank align technology inc price consensus align technology inc price consensus align technology inc quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1096,ISRG,jan issue update research report intuitive surgical inc isrg free report stock have zack rank hold intuitive surgical share price movement have be compelling last month company represent solid return almost surpass broader industry gain current level be slightly lower return intuitive surgical exit fourth quarter solid note beating zack consensus estimate count company outperformed mature growth procedure especially general thoracic surgery procedure performance asia show continue strength solid growth china japan korea also expansion gross margin buoy optimism positive outlook come quarters raise confidence intuitive surgical have gain significantly ce mark approval da vinci europe stock have get further boost recent fda approval same fourth quarter intuitive surgical submit application fda millimeter stapler da vinci xi platform however surge operate expense reinstatement medical device tax be likely hurt bottom line further da vinci surgical system long sale purchase order cycle be drag cut throat competition niche space be also major concern key picksa few better rank stock broader medical sector be amedisys am free report bio rad laboratory bio free report resm rmd free report bio rad laboratory have zack rank buy company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank see complete list today zack rank strong buy stock here resm have long term expect earning growth rate stock hold zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1097,ISRG,inogen inc ingn free report report third quarter earning cent share comfortably beat zack consensus estimate cent improve year figure cent upside be drive roughly growth revenue totale surpass zack consensus estimate detailssale revenue surge rental revenue decline total gross margin be comparative period sale gross margin be compare prior year quarter improvement be primarily attributable increase mix direct consumer sale lower cost good sell unit be partially offset decline business business average selling price rental gross margin be versus year quarter downside result reimbursement rate reduction be partially offset reduce cost rental revenue primarily associate lower depreciation inogen inc price consensus ep surprise inogen inc price consensus ep surprise inogen inc quotegeneral administrative expense be comparative quarter be primarily due patent litigation settlement expense increase personnel related expense higher patent defense legal cost solid performance third quarter inogen raise guidance revenue range compare previous represent year year growth takeinogen report stellar third quarter result beating zack consensus estimate count company witness solid growth revenue adjust earning year year basis view solid domestic international business business sale have lead impressive quarterly performance upcoming quarters company expect direct consumer sale be fastest grow channel follow domestic business business sale context company recently sign lease expansion site ohio accelerate growth domestic direct consumer sale channel flip side decline rental mar company prospect company generate significant portion revenue international market volatile foreign exchange rate always concern zack rank key picksinogen currently carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank strong buy stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand basis point year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue rise year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1098,ISRG,phibro animal health corporation pahc free report report adjust earning share ep cent first quarter fiscal year year adjust ep also surpass zack consensus estimate penny accord company year year improvement be primarily drive higher gross profit ratio reduce interest expense lower effective income tax rate company report ep cent year quarter net salesin report quarter phibro net sale be year year improvement be drive sale growth animal health mineral nutrition segment performance product phibro animal health corporation price consensus ep surprise phibro animal health corporation price consensus ep surprise phibro animal health corporation quote sale segmentsnet sale animal health segment increase report quarter back volume increase nutritional specialty vaccine product group segment nutritional specialty product grow sale vaccine increase principally volume growth product poultry swine industry however sale medicated feed additive mfa other fall primarily due volume decline domestic net sale mfa other decline due reduce volume medically important antimicrobial unfavorable timing certain customer order international net sale increase drive growth most region include benefit improve economic condition brazil net sale mineral nutrition segment increase higher average selling price result increase underlie raw material commodity price however rise average selling price be partially offset lower volume trace mineral product net sale performance product segment increase higher average selling price volume copper base product operational updatephibro fiscal first quarter gross profit increase year year gross margin expand basis point bps selling general administrative expense rise operate margin be marginally flat year year quarter financial update year date phibro generate cash flow operation compare year period capital expenditure amount period reflect reduction year quarter fy outlookphibro have reiterate guidance fiscal company expect generate net sale current zack consensus estimate fall guide range phibro provide adjust ep guidance range current zack consensus estimate be also company guide range takephibro end fiscal first quarter solid note earning ahead zack consensus estimate company witness considerable improvement segment be also encourage expansion gross margin report quarter zack rank key picksphibro have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue rise year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1099,ISRG,intuitive surgical inc isrg free report post adjust earning share fourth quarter beat zack consensus estimate improve year year revenue increase year year drive growth instrument accessory service system segment revenue also beat zack consensus estimate stock have zack rank hold fy glanceintuitive surgical report revenue full year company have major revenue segment instrument accessory total revenue system total revenue service total revenue intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quote business highlightssolid procedure surgical post solid number quarter courtesy rise customer adoption procedure growth system placement company outperformed mature growth procedure especially general thoracic surgery precisely fourth quarter procedure increase approximately year year basis procedure performance asia reflect persistent strength backed solid growth china japan korea add growth prostatectomy procedure volume lend company competitive edge broader prostate surgery market fourth quarter favorable study resultsin november team investigator university southern california university michigan ann arbor penn state health intuitive surgical publish large scale study title robotic assist video assist thoracic open lobectomy propensity match analysis recent premiere datum annal thoracic surgery result study demonstrated increase number robotic assist lobectomy lobectomy be defined surgical excision lobe organ quarter review intuitive surgical submit application fda millimeter stapler da vinci xi platform international company have be gain solid prominence globally fact outside unite state company procedure improve approximately year year basis intuitive surgical system placement include europe japan notably system place europe be da vinci system however ous market be early stage adoption sale lag estimate region revenue segment rise quarter back strong procedure growth increase sale stapling vessel sealing product revenue realize procedure be approximately flat year year system sale segment increase buoy higher system placement partially offset lower average selling price come company flagship da vinci surgical platform intuitive surgical ship system compare prior year quarter company register revenue year year basis backed growth install base da vinci system gross surgical adjust gross margin report quarter expand basis point bps almost net revenue increase margin indicate company consistent effort lower manufacturing cost notably management expect margin fluctuate base company mix new product reduction product cost reinstatement medical device tax financial updateintuitive surgical end fourth quarter cash cash equivalent investment line third quarter figure management be offset final payment associate accelerate share repurchase agreement initiate company first quarter intuitive surgical anticipate full year procedure growth range procedure growth be expect be drive general surgery procedure outside unite state management expect operate expense rise range company continue invest emerge market new technology include computer assist surgery gross margin be expect range net revenue incorporating project impact newly enact tax law intuitive surgical expect income tax rate net pre tax income bottom lineintuitive surgical exit fourth quarter solid note beating zack consensus estimate count also company witness impressive procedure performance asia positive outlook upcoming quarters also raise optimism stock further incremental spending product development higher investment international market be likely boost long term growth however surge operate expense reinstatement medical device tax be likely dampen company bottom line upcoming day further da vinci surgical system have long sale purchase order cycle act deterrent add cutthroat competition niche space be concern key picksa few better rank stock broader medical sector be amedisys am free report bio rad laboratory bio free report abiom abmd free report amedisys have long term expect earning growth rate stock carry zack rank buy bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate abiom have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1100,ISRG,abbott free report report fourth quarter adjust earning continue operation cent share beating zack consensus estimate penny earning improve year year meet high end company guide range cent cent however report loss quarter come cent share year earning cent notably include anticipate net expense impact tax reform full year adjust earning come share line zack consensus estimate however figure beat year number fourth quarter worldwide sale come year year report basis figure also beat zack consensus estimate comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter worldwide sale full year come year year report basis figure also surpass zack consensus estimate abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise abbott laboratory quote quarter detailabbott operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis include positive impact currency fluctuation sale key emerge market increase drive double digit growth latin america india china medical device business sale rise report basis comparable operational basis sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis double digit growth structural heart heart failure neuromodulation vascular product sale however decline comparable operational basis rhythm management company see sale drop comparable operational basis however company receive fda approval magnetic resonance mr conditional labele quadra assura quadra assura mp cardiac therapy defibrillator crt device fortify assura implantable cardioverter defibrillator icd quarter review diabetes care sale improve comparable operational basis buoy double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis comparable operational basis foreign exchange drive sale pediatric nutrition sale increase comparable operational basis adult nutrition sale be comparable operational basis diagnostic sale rise year year report basis comparable operational basis core laboratory point care diagnostic sale grow respectively comparable operational basis molecular diagnostic sale be nominal strong growth infectious disease testing business be partially offset plan scale genetic business rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing guidanceabbott issue full year guidance adjust certain net specify item full year adjust earning share continue operation be expect band current zack consensus estimate be peg low end project range company also provide first quarter adjust earning share guidance expect report adjust earning continue operation range cent cent quarter current zack consensus estimate cent be project range takeabbott have steer past zack consensus estimate earning sale be optimistic company strong consistent epd medical device performance be upbeat contribution company other business well company continue benefit recently complete acquisition st jude medical offer industry lead pipeline cardiovascular neuromodulation diabetes vision care be also upbeat abbott successful closure alere acquisition synergy buyout form revenue rapid diagnostic have be benefit company meanwhile company emerge market performance have be extremely promising several strategic development zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report amedisys am free report notably bio rad sport zack rank strong buy amedisys intuitive surgical carry zack rank buy see complete list today zack rank stock here bio rad be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be revenue be amedisys be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be cent revenue be intuitive surgical be expect release fourth quarter result jan zack consensus estimate fourth quarter adjust ep be peg revenue be hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1101,ISRG,accuray incorporate aray free report report loss cent share second quarter fiscal cent narrower zack consensus estimate year figure total revenue second quarter increase year year beat zack consensus estimate segment detailsproduct revenue product revenue grow upside be primarily fuel radixact product launch also higher distributor revenue be major contributor service revenue service revenue amount report quarter year year basis courtesy increase upgrade purchase service contract gross order update gross order performance second quarter fiscal be improve last quarter order growth be primarily drive tomotherapy array product radixact system order accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quote other platform drife sale radixact be company latest device contribute revenue second quarter radixact system comprise tomotherpay order report quarter more radixact unit have be recognize product launch further system be be accept true workhorse product market significantly improve product performance functional efficacy broad case mix versatility suite software upgradation series software upgradation have be growth driver accuray upgrade include integrate datum management system idms accuray precision treatment plan software system preciseart module capture identify anatomical change take place patient course treatment have lead notable improvement company treatment plan capability oncology department geographical gain improve management revenue growth second quarter attribute european apac region contribution order performance emea japan region have also be strong margin detailsin quarter review total gross margin be basis point year year product gross margin increase report quarter compare year quarter increase be attributable increase revenue contribution cyberknife system radixact system service gross margin second quarter be compare year quarter operate expense totale compare year quarter increase be primarily due investment research development financial exit second quarter cash cash equivalent compare first quarter fiscal guidance company reaffirm previous guidance company expect revenue growth year year basis product revenue be expect grow year year gross order be expect rise approximately year year basis company expect adjust ebitda indicate growth year year takeaccuray report impressive second quarter fiscal result adjust loss share narrow year year revenue beat zack consensus estimate also company reiterate guidance fiscal accuray ride market solid response radixact platform company revamp software flip side long sale implementation cycle cyberknife tomotherapy system majorly affect company top line increase operate expense result research development activity be also concern price incorporate have be outperform industry month stock have gain compare industry rally zack rank key picksaccuray incorporate carry zack rank sell few better rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report amedisys am free report notably bio rad sport zack rank strong buy amedisys intuitive surgical carry zack rank buy see complete list today zack rank stock here bio rad be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be revenue be estimate amedisys be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be cent revenue be estimate intuitive surgical be expect release fourth quarter result jan zack consensus estimate fourth quarter adjust ep be revenue be estimate hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1102,ISRG,jan issue update research report angiodynamic inc ango free report stock have zack rank hold angiodynamic recently report dismal second quarter fiscal adjust earning revenue miss zack consensus estimate slash guidance fiscal sale be also discourage angiodynamic peripheral vascular segment have be weak late company also have high debt level end last quarter angiodynamic rise debt impose certain operate financial restriction limit company execution core business strategy company also recently recall acculis microwave tissue ablation system come stock price performance angiodynamic see negative return almost last year significantly underperform gain furthermore current level compare unfavorably broader industry gain flip side angiodynamic continue expand business back acquisition strategic alliance major buyout microsuli navilyst vortex medical nanoknife rita medical have significantly expand product pipeline angiodynamic have be make discipline investment business segment drive long term revenue growth angiodynamic have be offer broad spectrum product have help widen commercial opportunity company be also lead player thrombolytic catheter space have broad range unique catheter uni fuse speedlyser pulse spray thrombus portfolio angiodynamic be expect benefit ongoing market transition less invasive interventional procedure expect trend continue less invasive interventional procedure help reduce patient recovery time thereby save hospitalization cost key picksa few better rank stock broader medical sector be amedisys am free report bio rad laboratory bio free report intuitive surgical isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1103,ISRG,jan issue update research report walgreen boot alliance inc wba free report stock carry zack rank hold lead pharmacy lead health wellbeing company have be trading broader industry past month stock have gain comparison broader industry walgreen boot report impressive first quarter fiscal be encourage strength retail pharmacy usa division continue prescription growth account medicare part growth volume growth previously announce strategic pharmacy collaboration be particularly upbeat revise rite aid store deal company receive regulatory approval last september walgreen boot modify buyout contract help boost top line also gain operational benefit also help company expand optimize retail pharmacy network key market include northeast notably store be purchase be locate primarily northeast southern unite state distribution center be buy be locate dayville ct philadelphia pa spartanburg sc post transaction initial close synergy be expect be realize year moreover increase retail pharmacy international sale buoy optimism also be upbeat company decision acquire stake sinopharm hold guoda drugstore china provide strong impetus walgreen boot worldwide retail pharmacy business moreover company acceptance proposal sell part investment chinese wholesale partner guangzhou pharmaceutical corporation huge amount cash be major positive however walgreen boot face headwind form increase competition tough industry condition even company continue gain traction major mass merchant be expand pharmacy business enjoy fair market share moreover last few year slowdown generic introduction have be affect walgreen boot margin addition increase reimbursement pressure generic drug cost inflation have be hamper walgreen boot margin significantly key picksa few better rank stock broader medical sector be amedisys am free report bio rad laboratory bio free report intuitive surgical isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1104,ISRG,cvs health corporation cvs free report third quarter adjust earning share ep decline year figure however adjust ep beat zack consensus estimate penny year year decline earning be due disappointing retail ltc number well lower margin time adjustment ep continue operation third quarter come prior year quarter cvs health corporation price consensus ep surprise cvs health corporation price consensus ep surprise cvs health corporation quotenet revenue quarter increase year year almost line zack consensus estimate strong revenue growth pharmacy service segment be partially offset decline retail ltc revenue quarter quarter detailspharmacy service revenue increase report quarter drive growth specialty pharmacy volume higher pharmacy network claim volume well brand inflation be however partially offset increase generic dispense price compression pharmacy network claim processed quarter climb day equivalent basis backed net new business growth also mail choice processed claim count be day equivalent basis continue adoption maintenance choice offering rise specialty pharmacy claim revenue cvs health retail ltc drop year year primarily due decrease same store sale continue reimbursement pressure increase generic dispense rate front end same store sale be year year front store sale be affected soft customer traffic effort rationalize promotional strategy be partially offset increase basket size pharmacy same store sale also decline report quarter sale be affected approximately basis point bps due recent generic drug introduction also pharmacy same store prescription volume inched day equivalent basis apart marketplace change restrict cvs pharmacy participate certain network have bps negative impact same store prescription volume generic dispense rate proportion generic prescription total number prescription dispense increase approximately bps pharmacy service segment bps retail ltc segment gross profit drop gross margin contract bps total operate margin quarter decline bps cvs health exit third quarter cash cash equivalent short term investment compare end second quarter year date net cash provide operate activity be year period third quarter cvs health open new retail store shut retail location further company relocate retail store sep cvs health operated retail store include pharmacy target store state well district columbia puerto rico brazil outlookcvs health have narrow adjust ep guidance earlier band zack consensus estimate be guide range however full year operate cash flow guidance have be reiterate range free cash flow band fourth quarter company expect adjust ep zack consensus estimate fourth quarter be peg company projection takecvs health exit third quarter solid note however weak year year retail ltc comparison margin decline result dull earning performance nonetheless year year growth top line be drive strong pharmacy service segment benefit upside specialty service zack rank key pickscvs health have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corp lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1105,ISRG,conm corporation cnmd free report report third quarter adjust earning cent share beating zack consensus estimate penny moreover earning improve almost year year basis courtesy strong revenue revenue rise approximately surpass zack consensus estimate sale also rise constant currency basis cc revenue detailsin term product line orthopedic surgery net sale decline year year basis cc sale segment totale other hand general surgery segment net sale increase year year basis cc sale segment totale term product category sale single use product increase cc account net sale come capital product sale decline cc basis geography conm witness fall domestic revenue be almost net sale notably domestic revenue be negatively impact approximately thank occurrence hurricane harvey irma precisely conm operation region texas florida south carolina be hurt third quarter management company incur approximately loss domestic general surgery remain be domestic orthopedic unit result natural disaster however company witness organic growth international market come foreign currency exchange rate conm have favorable impact third quarter sale internationally conm corporation price consensus ep surprise conm corporation price consensus ep surprise conm corporation quote margin detailsadjust gross margin fourth quarter exclude restructure cost decline basis point bps year year same quarter last year management deterioration gross margin be primarily attributable unfavorable pricing be partially compensate favorable foreign exchange volatility benefit margin bps balance sheetconm have cash balance end third quarter long term debt inventory balance be end third quarter full year conm raise sale growth guidance band reflect raise prior guidance cc company now project adjust earning share range previously provide range management expect adjust gross margin exclude restructure cost band percentage revenue takeconm exit third quarter promising note strength general surgery business back strong performance advanced surgical endoscopic technology buoy optimism moreover raise revenue guidance be indicative brighter prospect ahead flip side decline sale orthopedic surgery be concern also conm operate highly competitive environment be likely mar top line growth zack rank key picksconm have zack rank sell few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1106,ISRG,petm express inc pet free report announce earning share ep cent third quarter fiscal year quarter cent also bottom line surpass zack consensus estimate year year rise earning be drive increase sale improve margin net sale report quarter rise year year outpace zack consensus estimate lead pet pharmacy americas upside sale be result increase new order reorder quarter report quarter reorder sale increase year year basis new order sale rise average order value be approximately quarter compare year quarter note variation average order value be mainly drive shift sale higher price item petm express inc price consensus ep surprise petm express inc price consensus ep surprise petm express inc quote company seasonality business be mainly proportion flea tick heartworm medication product mix spring summer be consider peak season fall winter represent season quarter review petm acquire new customer year roughly order be generate compare prior year quarter gross margin expand basis point bps year year quarter review general administrative expense be year year also advertising expense rise lead increase adjust operate expense depreciation expense amount nevertheless adjust operate margin quarter expand bps year quarter petm exit fiscal third quarter cash cash equivalent compare end second quarter fiscal company also announce hike quarterly dividend cent share payable shareholder record feb takepetm successfully deliver yet quarter solid result fiscal third quarter company once again top revenue earning be also encourage note stellar growth reorder new order sale quarter company be also strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale well shift sale higher margin item also expand product offering petm currently offer wide range product cater dog cat horse work upgrading exist portfolio zack rank other key pickspetm sport zack rank strong buy few other top rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report amedisys have long term expect earning growth rate stock carry zack rank buy bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate intuitive surgical have long term expect earning growth rate stock have zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1107,ISRG,resm inc rmd free report announce second quarter fiscal adjust earning share ep prior year quarter earning beat zack consensus estimate cent include time item resm report ep cent quarter year year company have face extra income tax expense quarter owing latest tax reform be time transition tax unremitted foreign earning lower corporate tax rate also result reduce net defer tax asset rise income tax expense closer view top linerevenue report quarter increase year year constant exchange rate cer figure also beat zack consensus estimate geographic basis exclude revenue americas totale reflect increase prior year quarter moreover revenue quarter totale year year revenue combine emea apac region be highlight rise cer year gross margin contract basis point bps year year report quarter selling general administrative expense be year year be increase research development expense lead rise adjust operate expense amount however adjust operate margin quarter rise bps resm inc price consensus ep surprise resm inc price consensus ep surprise resm inc quote financial updatesresmed exit second quarter fiscal cash cash equivalent compare end first quarter fiscal year date company generate cash flow operation year figure concurrent second quarter earning release resm announce quarterly dividend cent share same prior payout dividend be paid mar shareholder record feb part company capital management plan resm repurchase share fiscal second quarter expect sg expense percentage revenue band second half fiscal expense percentage revenue be project fiscal reflect marketing expense associate product launch ongoing legal expense takeresm exit second quarter promising note earning revenue beating zack consensus estimate bright side company achieve solid double digit revenue growth quarter lead sale software service business well new mask product device term recent development company also recently inform first self brand portable oxygen concentrator mobi subject fiscal third quarter launch factor boost investor faith stock however challenge competitive bidding reimbursement issue continue hurt stock company be also expose foreign exchange fluctuation zack rank other key picksresm carry zack rank buy other top rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report amedisys am free report notably bio rad sport zack rank strong buy amedisys intuitive surgical carry zack rank see complete list today zack rank stock here bio rad be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be revenue be amedisys be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be cent revenue be intuitive surgical be expect release fourth quarter result jan zack consensus estimate fourth quarter adjust ep be revenue be wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1108,ISRG,abiom inc abmd free report price scale new week high jan eventually close bit lower company share have gain last month compare broader industry gain headquarter danver abiom be engage develop manufacturing marketing medical product design assist replace pump function case heart failure stock have market cap be currently top perform stock medtech space improvement price performance strong fundamental indicate stock bullish run therefore haven take advantage price appreciation yet time add stock portfolio long term expect earning growth rate hold promise stock drive stock let take look major factor have be boost abiom lately strong preliminary resultsabiom recently report preliminary third quarter fiscal revenue approximately year year basis revenue impella product be likely be year year further preliminary fiscal guidance have be raise approximately prior year quarter impella product lineabiom expand product portfolio be expect strengthen company foothold prophylactic high risk pci cardiogenic shock patient market regard company impella line product deserve mention management impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart abiom impella impella cp impella be fda approve pump treat cardiogenic shock further impella impella cp be approve treat urgent percutaneous coronary intervention pci such stent balloon angioplasty cure block coronary artery company right side heart pump impella rp device cure right heart failure abiom inc price consensus abiom inc price consensus abiom inc quote company also have automate impella controller be primary user interface impella platform feature highly exclusive inch high resolution display bcc research global market cardiac medical device be project reach cagr consider prospect niche space expect abiom gain solid market traction year come northward estimate revisionone estimate current year moved north past day southward revision indicate analyst optimism company zack consensus estimate adjust earning increase current year positive trend signify analyst bullish sentiment company hold zack rank buy indicate robust fundamental expectation outperformance term see complete list today zack rank stock here zack consensus estimate fiscal revenue be peg year year moreover revenue be expect grow fiscal other key picksother top rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1109,ISRG,becton dickinson company bdx free report popularly know bd recently announce completion enrollment lutonix knee trial trial be prospective multicenter randomize controlled demonstrate superior efficacy lutonix drug coat balloon dcb compare standard angioplasty balloon catheter dcb platform glancedcb be special category balloon angioplasty be used treat coronary peripheral artery disease lutonix dcb platform treat severe claudication critical limb ischemia patient be suffering stenotic occlusive lesion knee artery reason lutonix dcb drive growth lutonix knee trial be only dcb trial knee artery unite state platform have enrolled more patient past year bd plan submit pre market approval application lutonix knee trial late fortify bd international lutonix dcb product have be make commercially available country europe canada australia treatment artery associate cli cli be detrimental arterial disease reduce blood flow lower leg artery estimate person nation have be suffering cli number be estimate grow nearly thus company customer base be expect expand course time lucrative marketsbd consistent focus expand emerge overseas market new product launch acquisition drive strategy be significant growth catalyst also latest development balloon angioplasty market be likely enhance company growth trajectory research report grand view research global angioplasty balloon market be expect reach worth further drug eluting balloon be expect be fastest grow segment forecast period courtesy favorable tiding regulatory front advantage standard normal balloon low cost effectiveness share shinein last year bd have outperformed industry term price performance company share have return compare favorably industry gain just fact current return be relatively higher index rally zack rank other key picksbd have zack rank buy other top rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1110,ISRG,medtronic plc mdt free report recently announce fda approval riptide aspiration system neurovascular unit broader restorative therapy group rtg add valuable tool company acute ischemic stroke ais product portfolio accord medtronic riptide aspiration system be design retrieve thrombus blood clot arc catheter restore blood flow patient experience blockage artery brain know ischemic stroke rtg rtg business currently include spine brain therapy specialty therapy pain therapy division notably last report second quarter fiscal revenue segment increase year year same cer improvement be drivenby low double digit growth brain therapy offset decline spine specialty therapy pain therapy rtg contribute total revenue last report quarter market prospectsper report transparency market research global ais diagnosis treatment market see cagr period market be expect reach worth end so latest development be strategic take bountiful opportunity niche space consideration stock performance estimate revisionover last month medtronic have outperformed broader industry stock have gain compare gain broader industry also estimate revision trend current year remain favorable estimate move north last month compare movement opposite direction estimate moved zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock have zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1111,ISRG,opko health inc opk free report report loss cent share third quarter compare loss cent year moreover loss be wider zack consensus estimate loss cent revenuesin third quarter opko health report total revenue year year report figure also miss zack consensus estimate gross profit third quarter be year year gross margin contract massive basis point bps research development expense totale year year selling general administrative expense amount consequently loss operation come highlight significant decline operate loss prior year quarter decline be attribute rise operate expense owing company significant investment associate commercial launch rayaldee consistent investment pharmaceutical pipeline opko health inc price consensus ep surprise opko health inc price consensus ep surprise opko health inc quote financialsopko health exit third quarter cash cash equivalent marketable security compare record end second quarter takeopko health exit third quarter disappointing note nonetheless be encourage company progress business include diagnostic business bio reference laboratory pharmaceutical business be also upbeat company revenue genedx bio reference genetic testing unit quarter reach highest level past quarters also opko health agreement japan tobacco develop market rayaldee japan buoy optimism however rise operate expense continue mar company financial zack rank key picksopko health currently have zack rank hold few better rankedmedical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1112,ISRG,solid third quarter inogen inc ingn free report be recently recognize fastest grow company north america deloitte technology fast acknowledgment be primarily base inogen solid fundamental growth story revenue improve almost notably be fourth consecutive year same recognition inogen company have zack rank hold deloitte technology fast recognize grow technology medium life science energy tech company north america award winner have be select basis revenue growth record factor drive inogenwe believe inogen direct customer business model have lend lead position oxygen therapy market direct consumer model give company opportunity build unique brand relationship customer earlier year company sign lease expansion site ohio accelerate growth domestic direct consumer sale channel grow direct customer sale marketing effort help drive awareness patient growth physician referral be also expect boost top line long term inogen raise guidance revenue previous represent year year growth inogen expand product portfolio be key catalyst company provide oxygen concentrator solution portable stationary use inogen flagship product be single solution portable oxygen concentrator poc furthermore inogen portable oxygen concentrator lend mobility independence oxygen therapy user platform be lightest continuous flow oxygen concentrator market consume much less power other device fortify company footprint long term oxygen therapy ltot market favorable market trendsa research report transparency market research suggest north america oxygen therapy device market be expect see cagr reach worth favorable market trend be indicative inogen grow manifold year come internationally inogen benefit develop country incremental investment health care system further underpenetrated oxygen therapy market favorable reimbursement scenario country germany france present significant growth opportunity inogen germany be estimate be second largest market europe medical oxygen system share price movementinogen share price movement past month have be favorable company represent return almost better broader industry gain just current level be also higher return stock considera few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report intuitive surgical isrg free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent stellar return last year stock have zack rank intuitive surgical have long term expect earning growth rate stock have zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1113,ISRG,nov issue update research report qiagen qgen free report stock currently carry zack rank sell netherlands base molecular diagnostic provideroffer innovative technology product pre analytical sample preparation molecular diagnostic solution stock have be trading broader industry last month latest share price have lose gain broader industry company end third quarter mixed note earning beating revenue miss zack consensus estimate note company have be face considerable negative impact timing national tender be lead decline hpv test sale rest world qiagen personalize healthcare business rely formation project pharmaceutical biotechnology company co develop companion diagnostic pair drug such company market currently be develop future use thus qiagen be expose risk not be able maintain relationship collaborative partner pursue develop competitive product technology own collaboration other moreover qiagen have be face intensify competition firm provide pre analytical solution other product also price sensitivity market pose threat be however impressed balanced growth company business segment profitability front qiagen perform well term operate margin be also upbeat company partnership co marketing agreement centogene ag boost bioinformatic portfolio moreover company focus drive growth sample insight offering buoy optimism key picksa few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month intuitive surgical have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1114,ISRG,nov issue update research report phibro animal health corporation pahc free report company have zack rank sell be new jersey base lead globally diversify animal health mineral nutrition company last month have be trading broader industry stock have decline compare gain broader industry notably phibro end second quarter fiscal mixed note bottom line exceed zack consensus estimate revenue decline marginally year year basis segment wise medicated feed additive mfa business be weak unite state business decline be due reduce sale medically important antimicrobial primarily change consumer preference less use certain antimicrobial market apart unfavorable timing certain customer order hampered business phibro animal health corporation price phibro animal health corporation price phibro animal health corporation quotealso persistent decline mineral nutrition segment sale be likely be drag business customer consolidation also affect phibro revenue unfavorable currency movement tough competitive scenario continue other headwind positive note animal health have continue remain key contributor deliver growth last few quarters phibro animal health product be excellent prevent control treat disease animal well increase nutrition improve health believe diverse product portfolio allow company address distinct grow condition livestock different region world phibro have extend reach unite state enter brazil other country south america china india asia pacific russia africa feel help company counter competition company continue invest far east asia poultry dairy industry be expect grow exponentially company currently expand dairy business market australia brazil mexico believe economic turmoil russia greece brazil china phibro have perform quite well have potential maintain momentum key picksa few better rank stock broader medical sector be petm express inc pet free report luminex corp lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have surge roughly last year luminex have long term expect earning growth rate stock have gain last year intuitive surgical have long term expect earning growth rate stock have surge last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1115,ISRG,hologic inc holx free report report fourth quarter fiscal adjust earning share ep cent year year however adjust ep beat zack consensus estimate penny remain upper end company guidance cent report basis company record earning cent share reflect year year decline revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company own estimation hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesolid double digit growth hologic molecular diagnostic international business drive upside top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue rise other hand international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer fourth quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system notably end hologic have ship panther diagnostic customer worldwide quarter marked sixth consecutive period double digit growth molecular diagnostic internationally cytology perinatal revenue also show decline cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal fourth quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit fiscal cash cash equivalent marginally report end fiscal total long term debt be end fiscal compare end last fiscal full year operate cash flow be compare year cash flow guidancehologic have provide fiscal financial guidance company currently expect adjust revenue grow range cer current zack consensus estimate stand guide rangeadjust ep be expect grow current zack consensus estimate adjust ep be peg fall just upper end guide range first quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg ahead project range adjust ep be project cent reflect annualize decline current zack consensus estimate first quarter adjust ep be peg cent company guidance takehologic post better expect fourth quarter fiscal result term earning revenue balanced growth geographical region buoy optimism however be disappoint decrease revenue company diagnostic segment blood screening divestiture be also likely mar company growth momentum day ahead zack rank key pickshologic carry zack rank hold few better rank medical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1116,ISRG,genomic health inc ghdx free report report third quarter adjust earning share ep cent reflect improvement year quarter loss cent earning also compare favorably zack consensus estimate loss cent report net loss come cent compare loss cent year quarter revenue detailtotal revenue quarter rise year year miss zack consensus estimate growth unite state international market drive top line however revenue be adversely impact roughly due hurricane certain region unite state geographically third quarter product revenue unite state improve product revenue growth be fuel rise prostate test revenue partially offset fall invasive breast cancer revenue international product revenue totale report quarter quarter company deliver more oncotype dx test result year year genomic health inc price consensus ep surprise genomic health inc price consensus ep surprise genomic health inc quote margin trendin quarter review genomic health gross margin expand basis point bps year year genomic health also witness rise operate expense owing rise research development expense however general administrative expense decline selling marketing expense contract report quarter genomic health report operate loss show year year improvement operate loss year financial updategenomic health exit third quarter cash cash equivalent short term marketable security include corporate equity investment reflect improvement record end second quarter company reiterate guidance genomic health expect meet low end full year revenue guidance exclude estimate hurricane impact revenue third quarter zack consensus estimate be guide range company also expect meet full year profit expectation exclude cost related biocartis transaction notably company expect full year profit meet end revenue guidance takegenomic health exit third quarter mixed note be concern company rise operate expense well nevertheless be encourage year year rise revenue drive solid performance unite state internationally management note strong demand genomic health oncotype test third quarter be partly account growth international prostate business specifically prostate cancer oncotype dx genomic prostate score test local coverage expand medicare coverage palmetto gba company also make positive development oncotype dx breast recurrence score test establish private coverage test germany context company sign exclusive agreement biocartis group develop diagnostic ivd version oncotype dx breast recurrence score test biocartis proprietary idylla platform be perform locally laboratory partner well hospital globally biocartis be innovative molecular diagnostic company provide next generation diagnostic solution flip side company sole reliance breast oncotype dx test be concern zack rank key picksgenomic health carry zack rank hold few better rank medical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1117,ISRG,cardinal health inc cah free report report first quarter fiscal adjust earning share beat zack consensus estimate however earning decline year year basis revenue increase year year basis almost miss zack consensus estimate stock have zack rank sell segmental segment pharmaceutical revenue inched year year basis segment witness strong growth specialty business also gain huge number pharmaceutical distribution customer segment witness drop profit thank generic pharmaceutical pricing company recent investment pharmaceutical platform however solid performance red oak sourcing platform have partially offset negative effect medical segment revenue segment increase primarily higher contribution new exist customer medical segment profit increase courtesy higher contribution new exist customer acquisition however lower contribution veteran affair contract partially affected sale segment cardinal health inc price consensus cardinal health inc price consensus cardinal health inc quote major highlightsin report quarter cardinal health close acquisition medtronic mdt free report patient recovery business cash further cardinal health launch connectsource new cloud base patient engagement platform first quarter cardinal health enter agreement first quarter distribute self manufacture surgeon glove directly certain international market company also announce agreement make cordis subsidiary exclusive distributor medinol coronary stent unite state marginsas percentage revenue gross margin expand basis point bps net revenue distribution selling general administrative sg expense increase year year basis report quarter company reaffirm fiscal guidance adjust earning share continue operation takecardinal health end first quarter fiscal solid note courtesy solid performance medical segment encourage fiscal guidance instill confidence stock meanwhile company be banking strategic buyout joint venture supply agreement drive growth deal medtech bigwig medtronic be likely boost company growth trajectory flipside pharmaceutical segment witness strong growth specialty business gain huge number pharmaceutical distribution customer profit segment be hurt generic pharmaceutical pricing increase generic pricing pressure be major headwind intensify competition customer concentration be other bottleneck sluggish macroeconomic scenario tough product pricing environment be likely impede growth peer surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1118,ISRG,intuitive surgical inc isrg free report recently announce better expect preliminary net sale result fourth quarter full year company be schedule report fourth quarter result jan follow announcement stock close value jan company expect net sale fourth quarter be approximately year year basis preliminary figure be higher zack consensus estimate full year revenue be expect be approximately year year basis company preliminary figure compare favorably zack consensus estimate intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quote preliminary fourth quarter revenue instrument accessory segment increase approximately year year basis management anticipate revenue growth instrument accessory segment be drive da vinci procedure growth revenue da vinci surgical system be expect be year year basis company ship da vinci surgical system quarter number da vinci surgery rise approximately year year basis fourth quarter upside be attribute surge general surgery procedure unite state worldwide urologic procedure service revenue increase approximately year year basis share price look upintuitive surgical have have outstanding performance bourse last year stock have gain outperform industry rally zack rank other picksintuitive surgical carry zack rank buy other top rank stock broader medical space be bio rad laboratory inc bio free report centene corporation cnc free report magellan health inc mgln free report sporting zack rank strong buy see complete list today zack rank stock here bio rad have long term growth rate last month stock have rally much industry gain centene have project long term growth rate stock have gain last month much industry gain magellan have impressive expect growth rate first quarter stock too gain last month surpass broader industry wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1119,ISRG,share abaxis inc abax free report rally follow company announcement strong preliminary figure third quarter fiscal jan close next day session prelim result market seem be pleased company expectation report revenue third quarter fiscal range reflect increase year year preliminary revenue figure be zack consensus estimate however abaxis expect operate income income tax provision fiscal third quarter lower report third quarter fiscal moreover company expect gross margin lower report year abaxis inc price ep surprise abaxis inc price ep surprise abaxis inc quote do latest tax reform mean latest tax legislation slash corporate tax rate be anticipate benefit company effective tax rate exclude time cash charge time cash charge approximately be result decrease defer tax asset due reduction federal tax rate company anticipate decline basis point bps effective tax rate fiscal drop bps fiscal fiscal share price movementover past month abaxis have be trading broader industry stock surge compare industry gain company have be perform well veterinary consumable contribution hematology reagent stat cartridge coagulation cartridge rapid assay be also upbeat increase sale hematology instrument worldwide moreover solid global sale piccolo instrument be encourage be also encourage abaxis expansion portfolio rapid test menu recent past company sign partnership american animal hospital association aaha develop wellness testing initiative improve veterinary blood work compliance implement preventive care believe successful expansion product portfolio boost top line help company foray new region zack rank key picksabaxis carry zack rank hold few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1120,ISRG,oct issue update research report align technology inc algn free report stock currently sport zack rank strong buy align technology manufacture market system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage have be trading industry past month stock have gain period compare growth industry company deliver encourage third quarter post better expect earning revenue be encourage company solid invisalign technology prospect growth north america internationally company receipt patent smarttrack aligner material also buoy optimism moreover align technology have be see strong international sale especially emea apac region third quarter marked milestone company china become second largest market globally unite state top number align technology witness balanced sale growth channel recent past primarily drive high invisalign technology case volume solid performance summer drive invisalign growth global market encourage development company recently sign distribution agreement patterson dental exclusive agreement effective september align technology itero element intraoral scanning system be available part patterson dental cad cam portfolio unite state canada flipside adverse foreign exchange translation continue raise concern align technology international operation also escalate cost expense be weigh margin moreover tough competitive landscape other macroeconomic headwind threat other key picksother top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last year luminexha long term expect earning growth rate stock have gain last year intuitive surgicalha long term expect earning growth rate stock have gain last year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1121,ISRG,hill holding inc hrc free report report preliminary unaudited revenue approximately first quarter fiscal year year constant exchange rate cer basis revenue figure be higher zack consensus estimate reflect improvement first quarter moreover core revenue rise surpass company year year expectation flat core revenue notably core revenue exclude foreign currency translation mortara divestiture other strategic asset company choose exit hill expect fiscal first quarter adjust earning share ep surpass high end cent band notably company have exclude benefit latest tax legislation other special item current ep expectation zack consensus estimate first quarter ep be peg cent meanwhile estimate revision trend have be favorable estimate moved north past month movement opposite direction fact current year estimate increase cent earning cent share stock have zack rank hold hill holding inc price ep surprise hill holding inc price ep surprise hill holding inc quotewhat do latest tax reform mean latest tax legislation slash corporate tax rate be anticipate benefit company time net gain roughly fiscal first quarter gain be majorly due revaluation net defer tax liability partially offset repatriation tax however company do not expect gain influence adjust gaap financial result moreover company anticipate decline basis point bps effective tax rate fiscal share price movementover past month hill have be trading broader industry stock have rally compare industry gain hill have be see increase revenue strong international growth company be focuse gain traction untapped international market successful execution strategy efficient international team organizational realignment hill merger acquisition activity be track company actively pursue acquisition accelerate growth key clinical area viz advance patient mobility wound care prevention surgical safety efficiency clinical solution respiratory help be also upbeat lead global medical device company focus expansion product development be reflect rise research development spending last november hill outlined impressive long term growth strategy key initiative company also state financial goal fiscal buoy optimism key picksa few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1122,ISRG,new year have be dominate cryptocurrency blockchain technology unlikely company such kodak jump bandwagon announce new kodakcoin kodakone platform just day retail power have also fared well many retailer report solid holiday shopping result help lift share major chain include sear macy free report kohl kss free report target tgt free report also read retail stock sear macy kohl be surge say other company outside trendy industry have also perform well let take look surge stock be worth consider right now ss technology holding inc ssnc free report investment financial management technology firm focus software related service see stock price soar wednesday hit new week high share ss technology climb come report surface company be advanced talk buy dst system inc share cash accord reuter potential deal be announce early week ss be currently zack rank buy firm be also currently trading respectable earning mark major discount compare computer software industry average top ss cash flow growth rate crush industry average help facilitate move such company current dst acquisition talk look ahead company full year earning be project jump hit share base current zack consensus estimate intuitive surgical inc isrg free report intuitive surgical stock hit new week high share company see stock price pop wednesday movement come robotic assist surgical equipment firm announce strong preliminary fourth quarter full year result intuitive now expect post revenue mark year year jump company be currently zack rank buy earn grade growth style score system current zack consensus estimate call intuitive earning hit share mark nearly climb year period top company current cash flow growth rate crush medical instrument industry average help intuitive continue innovate go forward brighthouse financial inc bhf free report provider annuity life insurance establish metlife meet see stock price jump brighthouse climb come just day metlife announce launch insurance base investment company start company metlife digital venture metlife digital accelerator brighthouse be currently zack rank buy rock overall vgm score support grade value grade growth momentum style score system company be currently trading earning be almost discount compare industry average top brighthouse ratio fall well insurance life insurance industry average look ahead company full year ep be project skyrocket reach share base current zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1123,ISRG,share becton dickinson company bdx free report rally new week high jan close tad lower indicate strong year date return approximately better index base franklin lake nj becton dickinson commonly know bd be medical technology company engage principally development manufacture sale medical device instrument system reagent last year bd outperformed industry term share price stock have return compare favorably industry gain just fact current return be relatively higher index rally notably bd have market cap consider stable performance expect bd scale higher come quarters company long term growth look promising becton dickinson company price becton dickinson company price becton dickinson company quote let take look major factor have be boost bd lately favorable tide regulatory frontbd collaboration check point health recently obtain ce mark molecular screening test antibiotic resistant carbapenemase produce organism cpos bd max system development be expect strengthen company foothold molecular diagnostic business globally abundant prospect global molecular diagnostic market be encourage accord research market be project reach cagr read more bd ce mark check point screening test fight cpo acquisition bard strategic acquisition have be key growth catalyst bd recently bd acquire bard management company be well place become biggest medical technology device company world approximately annualize revenue cash stock acquisition be value completion deal bd create third business segment bd interventional notably bard be integrate vertical come strategic advantage post deal closure bd generate high single digit growth adjust earning share fiscal transaction also lead pre tax annual saving fiscal bd be able expand new area bard operated fast grow vascular access segment piccs peripherally insert central catheter midline drug delivery port estimate revision trendmeanwhile company recent earning estimate have be favorable current year have see estimate go higher past day compare movement opposite direction have have significant impact zack consensus estimate earning inched becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quote zack rank key picksbd have zack rank hold few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1124,ISRG,now earning season be knock door be mystery investor hunt stock estimate beating potential be investor always try place ahead time look play stock be rich quality be positive earning surprise so important historically stock company solid quarterly earning nominal basis tank miss merely meet market expectation earning rise apparently look good doesn tell have be decelerate also seasonal fluctuation come play company be seasonally weak be strong be likely report sequential earning decline such case growth rate be mislead judge true health company other hand whole lot research analysis company financial initiative wall street analyst project earning also take company guidance consideration derive earning estimate thus outperform estimate be almost equivalent beating company own expectation well market perception margin earning surprise be big typically drife stock higher right release thus more anything else earning surprise push stock higher locate potential outperformer now find stock have potential beat bottom line be dream investor chase not always come true way fulfill be look earning surprise history company impressive track regard generally act driver send stock higher indicate company ability exceed estimate investor generally believe company have same trick sleeve deliver yet earn beat upcoming release winning strategyin order shortlist stock be likely come earning surprise choose follow primary screening parameter last ep surprise greater equal stock deliver positive surprise quarter tend surprise again average ep surprise last quarters greater lift bar outperformance slight higher set average earning surprise last quarters average ep surprise last quarters greater point more consistent surprise history make case surprise even stronger addition place few other criterium push chance positive surprise zack rank less equal only company zack rank strong buy buy get earning esp greater stock need have positive earning esp zack rank earning beat happen proven model order have long term growth potential high trading liquidity have add follow parameter too next year estimate ep growth year greater solid expect earning growth exhibit stock long term growth prospect average day volume greater high trading volume imply stock have adequate liquidity handful criterium have narrow universe stock here be stock caterpillar inc cat free report be manufacturer seller construction mining equipment zack industry rank stock be top time writing stock carry zack rank see complete list today zack rank stock here crocs inc crox free report company be retailer casual footwear man woman child have zack rank zack industry rank be top pioneer natural resource company pxd free report be independent exploration production company focuse help meet world energy need zack industry rank be top have zack rank legg mason inc lm free report be zack rank hold company subsidiary be principally engage provide asset management investment banking related financial service zack industry rank stock be top intuitive surgical inc isrg free report zack rank company be global technology leader minimally invasive robotic assist surgery get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available http www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1125,ISRG,bruker corporation brkr free report report adjust earning share ep cent third quarter year figure however adjust ep beat zack consensus estimate couple cent exclude time item bruker report net income cent share third quarter compare cent respectively year quarter revenue detailbruker report revenue third quarter year year top line surpass zack consensus estimate exclude positive effect acquisition favorable impact change foreign currency rate bruker report year year organic revenue growth quarter reveiw geographically currency adjust european revenue increase mid teen year year third quarter north america revenue increase low mid single digit asia pacific organic revenue decline marginally china revenue again rise double digit third quarter be offset steep decline japan soft performance other asia pacific region bruker corporation price consensus ep surprise bruker corporation price consensus ep surprise bruker corporation quote management expect continue organic revenue growth back multus year margin expansion initiative management company register organic revenue growth base nano calid group bruker biospin group report low single digit revenue growth year date basis revenue be however flat year year management upside be lead strong contribution aftermarket service sale be low double digit quarter year date period bruker nano report high single digit revenue growth year date basis back strong organic growth contribution january hysitron acquisition nanoindenting product also year date growth axs be drive higher industrial growth recovery european market organic basis nano group revenue rise low double digit calid revenue increase mid single digit year date organic basis third quarter calid gain invivo consumable acquisition make january year date daltonic mass spec revenue calid group increase optic product garner solid revenue growth strong execution improve apply industrial market demand best revenue rise organically year date basis backed higher mri oem consumer demand bruker ost acquisition make november margin trendgross margin report quarter contract basis point bps accord company adjust gross margin decline bps owing predict gross margin headwind acquisition negative currency effect well product geographic business mix selling general administrative expense increase research development expense rise year period other charge contract year year overall operate margin contract bps financial positionbruker exit third quarter cash cash equivalent short term investment end second quarter year date net cash provide operate activity be compare year period guidancebruker provide update guidance total revenue growth rate expectation year have be raise band earlier moreover organic revenue growth guidance have be lift continue acquisition growth expectation previously foreign currency tailwind current zack consensus estimate revenue be peg company expect adjust operate margin increase approximately bps year year previous guidance bps include approximate bps headwind fiscal recent acquisition bruker raise adjust ep projection range current zack consensus estimate ep be peg takebruker exit third quarter solid note company also raise guidance be indicative brighter prospect company strategic acquisition activity have be encourage be also upbeat company current focus product development increase flip side competitive landscape macroeconomic headwind continue challenge company also contraction gross operate margin be disappointing zack rank key picksbruker currently carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1126,ISRG,allscript healthcare solution inc mdrx free report report third quarter adjust earning cent share line zack consensus estimate figure surpass year earning cent adjust revenue exclude acquisition related defer revenue netsmart grow surpass zack consensus estimate further company complete acquisition mckesson corporation hospital health system business know enterprise information solution eis business oct allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc quote quarter detailskey highlight solid growth core solution service fuel sunrise electronic health record ehr platform allscript revenue cycle management service buoy optimism third quarter company also inked new partnership develop deploy solution medical procedure point care moreover company expand international client roster quarter booking booking third quarter be highest date year year basis notably net booking be generate software delivery unit remain come client service software delivery support maintenance revenue segment comprise software hardware subscription other transaction support maintenance revenue revenue segment increase quarter client service revenue segment take care recur manage service other project base client service client service revenue be year year basis recur revenue segment cover subscription recur transaction support maintenance recur manage service adjust recur revenue increase year year basis recur revenue segment comprise system sale other project base client service adjust recur revenue segment increase year year basis margin margin expand basis point bps third quarter percentage revenue allscript register adjust gross margin third quarter compare year quarter software gross margin percentage revenue increase bps year year basis however client service margin third quarter come revenue compare same period last year accord company adjust operate expense quarter totale reflect year year increase selling general administrative expense increase research development expense rise year company expect revenue high end earlier provide range adjust earning share growth guidance have be reaffirm band adjust ebitda be expect high end previously provide range management allscript guidance include month financial contribution eis acquisition fourth quarter moreover company anticipate incur nearly severance transaction cost related eis transaction start fourth quarter be expect be recognize quarterly later fourth quarter takeallscript exit third quarter favorable note solid guidance encourage long term outlook be key highlight quarter also expansion margin be encourage look forward takeover hospital health system business mckesson corporation allscript continue reliance merger acquisition activity pose substantial integration risk furthermore intensify competition be major dampener company product have long sale cycle involve intensive decision make different managerial level zack rank key picksallscript have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1127,ISRG,perkinelmer inc pki free report report third quarter adjust earning cent share beating zack consensus estimate cent company base waltham report adjust revenue approximately beat zack consensus estimate revenue also surpass year figure segment detailsrevenue discovery analytical solution da totale third quarter year quarter meanwhile operate profit margin percentage revenue be compare prior year quarter level diagnostic segment revenue be compare year quarter reflect increase organically meanwhile operate profit margin segment percentage revenue be compare year quarter perkinelmer inc price consensus ep surprise perkinelmer inc price consensus ep surprise perkinelmer inc quote margin detailsadjust gross margin percentage revenue be quarter basis point bps year year deterioration be result acquisition divestiture execute adjust selling general administrative sg expense percentage revenue be bps year quarter research development expense percentage revenue rise bps third quarter result company overall adjust operate margin continue operation be net revenue bps year year basis financial detailsin first month perkinelmer operate cash flow continue operation be company conclude quarter approximately debt cash guidance company revise adjust earning guidance full year perkinelmer now expect adjust earning share band compare previous range zack rank key have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report second quarter fiscal earning cent cent year quarter gross margin expand bps year year luminex report third quarter adjust earning cent year year company revenue quarter increase almost year year intuitive surgical post third quarter adjust earning year year basis revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1128,ISRG,pacific bioscience california inc pacb free report report loss cent share third quarter penny narrower zack consensus estimate loss be line year quarter strength china asia boost company bottom line quarter company have zack rank hold revenue miss zack consensus estimate decline year year basis notably dna sequence market be highly competitive owing presence several establish player cutthroat competition niche space be primary reason year year decline revenue segment detailsproduct revenue rise almost service revenue decline year quarter almost year date pacific bioscience generate product service revenue generate first quarters consumable revenue report quarter be year year basis consumable revenue growth be drive higher install base instrument growth sequel instrument utilization instrument revenue third quarter be year year basis end quarter review pacific bioscience install base sequel instrument totale instrument company didn record contractual revenue quarter pacific bioscience california inc price consensus pacific bioscience california inc price consensus pacific bioscience california inc quotemargin detailsin third quarter pacific bioscience generate gross profit percentage revenue gross margin quarter be substantially year operate expense third quarter totale compare year year basis year date operate expense be expense quarter totale year sale general administrative expense third quarter be compare third quarter financial updatecash investment end third quarter be compare end second quarter expect full year revenue improvement gross margin performance fourth quarter pacific bioscience expect gross margin range net revenue viewpointsolid contribution instrument consumable revenue platform act significant positive pacific bioscience third quarter improvement margin sale sequel system be encourage factor company also witness significant strength china notably place numerous system order region new exist customer major concern dna sequence market be highly competitive owing presence several establish player cutthroat competition niche space be headwind however problem related limit availability smrt cell single molecule real time sequel system higher cash operate expense be expect mar prospect company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here becton dickinson company bdx free report popularly know bd report fourth quarter fiscal earning share beat zack consensus estimate increase year year basis stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1129,ISRG,medtronic plc mdt free report announce fda approval new clinician programmer use synchrome ii intrathecal drug delivery system be implantable pump provide target drug delivery chronic pain severe spasticity notably target drug delivery be consider alternative oral treatment chronic pain help reduce systemic opioid accord company new synchrome ii clinician programmer be design make therapy management simple provide clinician visual tool intuitive workflow company also plan make synchrome ii available unite state soon new synchrome ii clinician programmer help simplify therapy management also enable physician reduce pain intrathecal delivery medication so systemic opioid be reduce eliminate entirely synchrome ii clinician programmer be application run tablet good quality screen display well simple guide workflow also company implement design change enhance performance synchrome ii pump keep patient safety mind market prospectsper transparency market research report global pain management therapeutic market be expect reach worth so latest development be strategic take bountiful opportunity niche space consideration development pain be consistently try boost pain therapy division be part restorative therapy group recently company announce study result show superiority medtronic itb intrathecal baclofen therapy conventional medical management cmm reduction severe post stroke spasticity pss adult september company announce fda approval launch intelli platform management certain type chronic intractable pain stock performance estimate revisionover last month medtronic have outperformed broader industry stock have gain versus gain broader industry also estimate revision trend current year remain favorable estimate move north last month compare movement opposite direction company current estimate moved same time frame zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock have zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1130,ISRG,medical group wmgi free report have be have dismal run bourse late last month stock have lose underperform broader industry gain current level also lag return company see negative earning share growth last year compare index broader industry company have unimpressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy hold offer best investment opportunity stock have vgm score here take look major issue plague medical moment guidance dullwright medical expect net sale band earlier include negative impact foreign currency exchange approximately negative estimate revision estimate revision trend medical have be dismal current quarter analyst moved south compare movement opposite direction last month result zack consensus estimate full year earning fall cent stock have zack rank sell signify probability term foreign currency headwindswright medical derive significant part total revenue international operation be affected fluctuation foreign currency exchange rate back order issuesproduct medical be usually market internationally combination subsidiary distributor europe asia africa latin america company primarily rely distributor sale however distribution product market have be troublesome due presence different distributor level problem be eventually result significant amount back order be major headwind pricing pressurewright medical continue face flat pricing due price discounting larger account limit product offering international price cut advent group purchasing organization be also keep price pressure key picksa few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock have zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1131,ISRG,market be not content nuvasive inc nuva free report unimpressive preliminary result fourth quarter result be announce jan stock lose close session next day prelim result glancewe believe dull revenue expectation fourth quarter have dampen investor spirit nuvasive announce preliminary revenue approximately quarter flat year year zack consensus estimate fourth quarter revenue be peg revenue be expect reflect year year growth estimate happen be line company guidance zack consensus estimate revenue stand view continue impact hurricane marium puerto rico fourth quarter well anticipate decline procedural volume nuvasive have issue update guidance third quarter earning call company have expect report revenue growth cer project revenue figure be approximately nuvasive also project adjust earning share ep be peg additionally adjust operate margin year be currently expect zack consensus estimate ep stand however company continue witness sequential growth international revenue notably back continue innovation nuvasive have witness more increase international sale fourth quarter fifth sequential quarter nuvasive inc price ep surprise nuvasive inc price ep surprise nuvasive inc quote preliminary outlook nuvasive have also provide initial guidance full year well company expect mid single digit revenue growth figure zack consensus estimate revenue be peg moreover company expect gaap operate margin expansion approximately basis point also adjust ebitda be expect range latest tax legislation slash corporate tax rate be expect result significant tax saving nuvasive tax rate cut company have face corporate tax rate gaap basis company also take synergy december acquisition privately hold intraoperative monitoring ionm service provider safepassage account issue guidance buyout be track be expect close january fulfillment certain customary close condition nuvasive acquisition strengthen company intraoperative neuromonitoring business line consolidated giant be expect deliver service more customer surgeon moreover follow acquisition safepassage ncs be likely aid more ionm case year unite state post closure deal transaction be expect prove accretive company ep be also expect support nuvasive long term target revenue growth expansion adjust operate ebitda margin zack rank key picksnuvasive carry zack rank hold few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1132,ISRG,dexcom inc dxcm free report report preliminary unaudited revenue approximately fourth quarter end dec revenue figure be higher zack consensus estimate reflect improvement fourth quarter fiscal total preliminary unaudited revenue be expect total level full year figure be well zack consensus estimate meanwhile estimate revision trend have be favorable estimate moved south past month movement opposite direction fact current year estimate narrow cent loss cent share stock have zack rank hold dexcom inc price consensus dexcom inc price consensus dexcom inc quote dexcom estimate total revenue range courtesy strong sensor volume international revenue expansion dexcom worldwide patient base meanwhile zack consensus estimate revenue be peg moment dexcom launch sensor platform expansionary move medicare international market be likely boost revenue however cutthroat competition niche space be likely mar top line share fallhowever market be not really happy dexcom preliminary result fourth quarter full year follow announcement stock tumble last trading session close company be likely report full financial result feb market close dexcom price movement past year have be unimpressive company report negative return compare unfavorably industry rally current level be also lower gain same time frame dexcom glucose monitoring device be more invasive better other self monitored glucose testing system moreover report suggest patient be unwilling realize benefit continuous glucose monitoring moment reluctance part physician patient adopt dexcom product make challenge company expand market share key pick few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1133,ISRG,january issue update research report bruker corporation brkr free report stock carry zack rank buy bruker have be trading broader industry past month stock have return higher gain broader industry period last quarters bruker nano surface group business realize profitability owing prior restructure cost action last report third quarter high single digit growth be drive contribution hysitron nanoindenting product acquisition january improve result axs business move company strategic acquisition activity have also be encourage instance company recently announce completion germany base merlin buyout product acquire company complement bruker maldi biotyper platform more good news be bruker maldi biotyper franchise have grow impressive system worth approximately annum be happy note demand maldi biotyper be increase apply market specifically food feed beverage category segment base recent development witness product portfolio management believe bruker be poise double microbiology business next year company raise guidance be also indicative brighter prospect flip side bruker conduct business international market result adverse currency fluctuation continue incur loss company also headwind unfavorable economic condition intense competition continue threat other key pickssome other top rank stock broader medical space be abiom inc abmd free report tactile system technology tcmd free report intuitive surgical inc isrg free report carry zack rank buy see complete list today zack rank stock here abiom have long term expect earning growth rate stock have rally last year tactile system have long term expect growth rate stock have soar last year intuitive surgical have long term expect growth rate last month stock have rally medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1134,ISRG,nov issue update research report batesville base hill holding inc hrc free report company currently have zack rank hold lead global medical device companyexite fiscal strong note fourth quarter earning revenue beating zack consensus estimate company see solid year year increase revenue strong international growth hill be currently focuse gain traction untapped international market successful execution company strategy courtesy efficient international team organizational realignment company be focuse product innovation research development slew product launch fourth quarter be encourage moreover improvement adjust gross operate margin buoy optimism november hill outlined impressive long term growth strategy key initiative company also state financial goal fiscal hill merger acquisition pipeline continue be robust company aggressively pursue acquisition accelerate growth key clinical focus area viz advance patient mobility wound care prevention surgical safety efficiency clinical solution respiratory help apart welch allyn trumpf several recent noteworthy acquisition include virtus aspen surgical however decline revenue patient support system segment be quite disappointing also foreign exchange tough competitive landscape remain headwind overall last month hill have be trading broader industry stock have gain compare industry rally key picksa few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last year luminexha long term expect earning growth rate stock have gain last year intuitive surgical have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1135,ISRG,davita inc dva free report report third quarter adjust operate earning cent share miss zack consensus estimate cent further earning decline year year basis total revenue increase year year beat zack consensus estimate year year improvement be mainly attributable rise patient service revenue increase capitated revenue year quarter davita carry zack rank sell davita healthcare partner inc price consensus davita healthcare partner inc price consensus davita healthcare partner inc quote segment updatedavita medical group dmg dmg nation largest operator medical group physician network provide integrate care management operate division davita focuse deliver healthcare broad range service third quarter dmg incur adjust operate loss exclude cash goodwill impairment other adjust item third quarter davita announce restructure dmg segment eliminate clinical position thus management davita expect annualize saving year start davita kidney carea operate division davita davita kidney care focus set worldwide standard clinical social operational practice kidney care davita see solid result kidney care business adjust operate income third quarter segment be year year primarily drive extra treatment day quarter notably company see negative financial impact hurricane harvey irma be estimate be approximately higher cost approximately lose contribution miss treatment uncollected revenue owing disruption company bill process natural disaster dialysis related lab servicesrevenue treatment dialysis lab business be essentially flat last quarter fact management davita expect revenue treatment essentially remain flat fourth quarter well company patient care cost be approximately treatment compare last quarter financial month end sep davita have operate cash flow free cash flow operate cash flow be third quarter year date share repurchase updatedavita buy back almost share company common stock approximately average price share october davita board director approve additional share repurchase authorization worth approximately nov davita repurchase total share company common stock total average price share guidancedavita expect adjust consolidated operate income range lower previously issue range company estimate adjust operate income kidney care segment band notably previously issue range be full year davita expect adjust consolidated operate income range significantly lower previous guidance takedavita end third quarter fiscal mixed note strong growth patient service be likely boost company growth trajectory come quarters davita continuous improvement kidney care be commendable well company effort control expense hold promise compelling inorganic growth story support strong financial position be positive however davita be challenged adverse effect healthcare reform rise medicare cost increase medicare advantage beneficiary also rate cut be likely hurt bottom line future lackluster performance company dmg segment slash guidance full year indicate loom concern ahead stock sluggishness dialysis lab business add concern earning medtech major earning season be draw close most member have report number medical broader sector zack sector be expect put impressive show quarter petm express pet free report report earning share cent second quarter fiscal year year basis also gross margin expand bps year year report quarter stock sport zack rank strong buy see complete list today zack rank stock here luminex lmnx free report report adjust earning share cent third quarter year year revenue quarter increase almost year year stock flaunt zack rank intuitive surgical isrg free report post adjust earning share third quarter year year revenue increase year year stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1136,ISRG,share price align technology inc algn free report scale new week high nov close nominally lower company have gain last month much higher gain align technology have also beat broader industry gain respect share price last month stock have market cap further align technology estimate revision trend current year be favorable past day estimate moved shift consequently estimate be share company also have trail quarter average positive earning surprise positive long term growth hold promise well company year historical growth rate be also favorable compare broader industry align technology sport zack rank strong buy company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank buy hold offer best investment opportunity align technology inc price consensus align technology inc price consensus align technology inc quote growth market be upbeat align technology recently report impressive third quarter performance year year growth earning revenue be encourage additionally company have strong cash balance enable carry share repurchase turn provide solid return investor expansion gross operate margin also buoy optimism company be also constantly investing product innovation recently company open first office canada support growth region accord company canada be second largest market base invisalign case volume align technology have also become part nasdaq index nasdaq equal weight index recently factor be expect boost company share price other key picksother top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank intuitive surgical carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last year luminexha long term expect earning growth rate stock have gain last year intuitive surgical have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1137,ISRG,myriad genetic inc mygn free report report adjust earning share ep cent first quarter fiscal year year moreover adjust ep beat zack consensus estimate surpass company guide range cent report net income come earning share quarter net loss loss cent share year quarter revenuestotal revenue rise year year first quarter figure also outpaced zack consensus estimate company guidance range year year rise top line be primarily account strong demand hereditary cancer genesight test myriad genetic inc price consensus ep surprise myriad genetic inc price consensus ep surprise myriad genetic inc quote quarter detailssegment wise molecular diagnostic test total revenue record total revenue year year mainly account rise genesight testing revenue endopredict testing revenue grow year year report quarter moreover vectra da testing revenue come year year other testing revenue rise prolaris testing space volume continue grow double digit fiscal first quarter however prolaris test register revenue quarter flat year year also hereditary cancer testing revenue drop year year volume grow year year third consecutive quarter pricing par expectation pharmaceutical clinical service revenue accounting rest quarter totale reflect year year decline margin trendsgross margin quarter review contract basis point bps accord management gross margin performance be adversely affected hereditary cancer test pricing issue partially offset byimprove efficiency hereditary cancer production process rise margin genesight business increase new product reimbursement operate expense rise owing rise selling general administrative sg expense research development expense however decline report quarter overall operate margin increase bps financial positionmyriad genetic exit fiscal first quarter cash cash equivalent marketable security compare end fiscal year date cash flow operation totale net cash used same year period also quarter company register free cash flow compare year period guidancemyriad genetic have reiterate guidance fiscal company continue expect revenue range zack consensus estimate lie guide range bottom line front company expect generate adjust ep range current zack consensus estimate be higher end company guidance range management have provide guidance second quarter fiscal company estimate adjust earning share cent total revenue zack consensus estimate adjust ep cent revenue exceed company guide range viewmyriad genetic kick start fiscal solid note first quarter number exceed zack consensus estimate company observed strong growth genesight endopredict testing revenue continue year year growth hereditary cancer volume pricing par expectation flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation additionally macroeconomic uncertainty higher expense owing extensive pipeline test impact company margin zack rank other key picksmyriad genetic have zack rank buy other top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1138,ISRG,nov issue update research report medical group wmgi free report company recently report third quarter result adjust earning be line zack consensus estimate exclusive platform technology perform reversed glenoid ortholoc di simpliciti shoulder system act key catalyst third quarter medical currently carry zack rank hold medical be focuse product innovation research development company recently launch invision total ankle revision system first system develop total ankle revision arthroplasty other major platform launch perform reversed be expect boost revenue medical solid guidance boost investor confidence company expect net sale band include negative impact foreign currency exchange approximately company forecast full year adjust ebitda continue operation however lackluster international performance lower extremity segment be matter concern sale segment decline year year basis third quarter lower extremity business sale fall third quarter internationally lower extremity sale decline year year basis medical group price medical group price medical group quote other concern pricing pressure continue trouble medical increase cost related product launch re build infrastructure be expect exert pressure margin problem associate distributor be major headwind past month medical have underperform broader industry respect price company have lose compare unfavorably broader industry gain almost earning medtech major glancemeanwhile earning season have take center stage most member have report number medical broader sector zack sector be expect put impressive show quarter petm express pet free report report earning share cent second quarter fiscal year year basis also gross margin expand bps year year report quarter stock sport zack rank strong buy see complete list today zack rank stock here luminex lmnx free report report adjust earning share cent third quarter year year revenue quarter increase almost year year stock flaunt zack rank intuitive surgical isrg free report post adjust earning share third quarter year year also revenue increase year year stock carry zack rank buy zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1139,ISRG,qiagen qgen free report report third quarter adjust earning share cent year year report figure be par zack consensus estimate constant exchange rate cer company report adjust earning share ep cent meet low end company guidance cent cer qiagen report ep quarter be cent year year revenue detailnet sale actual rate third quarter grow year year basis same cer however top line miss zack consensus estimate meanwhile consider acquisition omicsoft january revenue increase currency translation do not have material impact net sale also organic expansion contribute total cer growth region wise sale americas revenue grow cer revenue europe middle east africa asia pacific japan increase respectively cer sale top emerge market exhibit growth year year cer quarter review qiagen price consensus ep surprise qiagen price consensus ep surprise qiagen quote segment detailqiagen primarily generate revenue molecular diagnostic apply testing pharma academia represent net sale respectively report quarter molecular diagnostic sale be cer drive substantial growth quantiferon latent tb test qiasymphony automation system consumable portfolio solid performance companion diagnostic pharma collaboration sale derive apply testing rise cer increase uptake new product human id forensic pharma sale rise cer third quarter academia sale improve cer backed grow demand operational updateadjusted operate income third quarter increase year year also adjust operate margin expand basis point financial updateqiagen exit third quarter cash cash equivalent precede quarter year date net cash operate activity be year moreover company report year date free cash flow compare year period january qiagen complete synthetic share repurchase combine direct capital repayment reverse stock split part commitment return shareholder transaction be announce august involved approach used various large multinational dutch company boost shareholder return faster more efficient manner traditional open market purchase qiagen intend repay balance commitment open market share repurchase however qiagen have complete share repurchase goal ahead end open market repurchase share frankfurt stock exchange guidanceqiagen have maintain guidance adjust net sale growth cer moreover adjust ep guidance have be reiterate band cer be base operate financial leverage include benefit completion share repurchase plan efficiency action take however exclude expect cent share restructure cost plan zack consensus estimate earning be guide range zack consensus estimate revenue be peg company also provide financial guidance fourth quarter net sale be expect grow cer adjust ep be expect cent cer underlie basis zack consensus estimate fourth quarter revenue be peg consensus estimate earning stand cent takeqiagen end third quarter mixed note be impressed balanced growth company segment furthermore profitability front qiagen deliver strong performance respect operate margin be also upbeat company strategic focus drive growth sample insight offering meanwhile commitment return more shareholder increase share repurchase reflect solid cash position flip side decline hpv sale unite state continue be drag competitive landscape strong reliance collaboration also continue be concern zack rank key picksqiagenha zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand basis point year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1140,ISRG,hill holding inc hrc free report report fourth quarter fiscal adjust earning share ep increase year quarter adjust earning surpass zack consensus estimate remain company project range strong bottom line performance be back strong revenue growth continue margin expansion strategic investment drive future growth lower tax rate help offset modest impact recent hurricane include time adjustment hill report earning share compare cent year quarter hill holding inc price consensus ep surprise hill holding inc price consensus ep surprise hill holding inc quote full year adjust ep be year period revenue detailsrevenue fourth quarter fiscal increase year year cer top line also exceed zack consensus estimate fiscal revenue come report basis cer strong revenue growth report quarter be drive momentum core business acquisition mortara value add newly introduce product geographically revenue grow revenue outside increase cer core revenue growth be cer line company expectation segmental performancein fiscal fourth quarter patient support system revenue decrease year year cer segment domestic revenue decline however adjust divestiture core revenue increase product service revenue increase partially offset decline rental revenue revenue front line care segment include welch allyn respiratory care mortara increase same cer apart contribution mortara performance be drive contribution new product strong growth thermometry blood pressure monitoring device double digit growth respiratory care business surgical solution segment revenue increase cer upside be backed strong growth record placement integrate table motion contribution other product iled new ts mobile operate table marginsreport gross margin fiscal fourth quarter be unchanged year year account increase total cost revenue adjust gross margin grow bps back company consistent initiative portfolio diversification benefit cost sourcing efficiency new product launch accretive gain mortara adjust operate margin improve bps have initiate fiscal guidance have also provide fiscal first quarter view full year company expect revenue growth range report basis cer exclude foreign currency mortara divestiture other strategic asset company expect core revenue increase hill also expect adjust ep range stock have see zack consensus estimate fiscal earning be peg revenue first quarter hill expect revenue growth report basis approximately cer company core revenue be expect remain flat year year addition company expect adjust earning share cent stock have see zack consensus estimate first quarter earning be peg cent revenue takehill exit fiscal strong note fourth quarter earning revenue exceed respective zack consensus estimate company see solid year year increase revenue strong international growth hill be currently aim gain traction untapped international market successful execution courtesy efficient international team organizational realignment company be putt effort product innovation research development slew product launch fourth quarter be encourage however decline revenue patient support system segment be quite disappointing also foreign exchange remain headwind zack rank other key pickshill have zack rank buy few other top rank stock broader medical sector be petm express inc pet free report luminex corp lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1141,ISRG,dexcom inc dxcm free report report loss cent share third quarter narrower zack consensus estimate loss cent also figure improve loss cent report year quarter total revenue grow year quarter revenue meet zack consensus estimate segmental detailssensor revenue total revenue grow year year basis transmitter revenue increase prior year quarter receiver revenue grow year year other revenue include revenue service freight accessory etc accounting rest totale dexcom inc price consensus ep surprise dexcom inc price consensus ep surprise dexcom inc quote operational detailsdexcom generate gross margin percentage revenue compare same quarter prior year notably gross margin expand basis point bps year year international business display continue grow quarter generate revenue year year basis notably international business represent total revenue third quarter research development expense totale quarter contract year selling general administrative expense totale report quarter increase prior year quarter financial updatea sep dexcom have cash cash equivalent short term marketable security versus end second quarter company expect global revenue come low end previously issue guidance full year dexcom reaffirm low end gross margin guidance zack rank key picksdexcom have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1142,ISRG,nov issue update research report mountain view base omnicell inc omcl free report company develop market end end automation solution medication use process omnicell exit third quarter mixed note earning beating zack consensus estimate revenue miss same also weak gross margin scenario be matter concern believe company strategy include portfolio expansion acquisition penetration medication adherence market continue drive expense meanwhile expense related recently launch xt series have be exert pressure bottom line omnicell lower high end full year adjust revenue guidance be reflective fact overall weakness continue tough competitive landscape also act dampener last month omnicell share have be trading broader industry latest share price movement stock have lose significantly underperform broader industry addition positive note year year increase earning revenue be impressive company witness balanced growth business line quarter be encourage note company be work product innovation recent past omnicell have be observed gain consistently series product launch latest be xt series automate supply dispense system strategic partnership zack rank key picksomnicell have zack rank strong sell few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last year luminex have long term expect earning growth rate stock have gain last year intuitive surgical have long term expect earning growth rate stock have gain last year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1143,ISRG,oct issue update research report integra lifescience holding corporation iart free report stock currently have zack rank hold integra lifescience exit third quarter disappointing note earning revenue miss respective zack consensus estimate also contraction adjust operate margin adjust gross margin add wo positive note last month share integra lifescience have be trading slightly broader industry stock have gain loss broader industry same time frame consistently strong performance orthopedic tissue technology segment buoy optimism integra lifescience holding corporation price integra lifescience holding corporation price integra lifescience holding corporation quotewe believe company recent product diversification bolster investor confidence thereby boost stock price further late orthopedic tissue technology segment company launch several new regenerative product surgical reconstruction market third quarter company register mid single digit growth regenerative technology franchise primarily banking addition derma science strong growth patient skin portfolio tissue ablation global launch cusa clarity be get good response unite state abroad integra lifescience expect product drive growth be also optimistic fact integra lifescience have successfully witness certain key overseas development face foreign exchange fluctuation international business also company have adopt several term objective pillar strategy management also expect gain market traction strategic partnership acquisition flip side foreign exchange stiff competition potent headwind also many integra lifescience manufacturing development research facility be vulnerable natural disaster unprecedented event depend severity force company cease development manufacturing product be important note last quarter impact back back hurricane have grossly affected wound care orthopedic procedure particularly florida addition company be unable fulfill certain private label order disruption operation puerto rico lead double digit decrease private label sale third quarter key picksa few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar roughly last month luminex have long term expect earning growth rate stock have gain last month intuitive surgical have long term expect earning growth rate stock have surge last month zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1144,ISRG,becton dickinson company bdx free report popularly know bd report fourth quarter fiscal earning share beat zack consensus estimate increase year year basis company register revenue year period revenue however beat zack consensus estimate quarterly bd medical segment generate revenue decline prior year period segment result reflect adverse impact change dispense business model bd life science segment generate revenue year quarter segment performance reflect strong number bioscience diagnostic system preanalytical system unit revenue be roughly report basis comparable basis international revenue rise however comparable currency neutral basis revenue rise back solid growth company business becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company company expect fiscal revenue increase company expect adjust earning share stand alone basis represent growth approximately zack rank key picksbecton dickinson currently carry zack rank buy few other top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report third quarter adjust earning share cent year year company revenue quarter increase almost year year intuitive surgical post adjust earning share year year third quarter also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1145,ISRG,mckesson corporation mck free report be name reckon current medtech space top perform stock improvement price performance strong fundamental indicate bullish run investor haven yet take advantage stock share price appreciation time add portfolio good return company impressive performance account potential sustain momentum upcoming period long term expect earning growth rate reflect great promise stock attractive pick share price appreciationa glimpse company price trend reveal stock have have encourage trip bourse last month mckesson return whopping compare favorably index rally metric be also higher industry growth northbound estimate stock have see zack consensus estimate current year earning be revise upward analyst past day thus absence single southbound revision highlight analyst optimism company boost positive sentiment stock same time frame consensus mark adjust earning inched zack consensus estimate earning have be raise last couple month company sport zack rank buy indicate robust fundamental expectation outperformance term see complete list today zack strong buy rank stock here mckesson corporation price consensus mckesson corporation price consensus mckesson corporation quotestrong growth be major player pharmaceutical medical supply distribution market company distribution solution segment retain impressive performance fiscal weak pricing trend customer consolidation distribution solution segment cater wide range customer business segment benefit increase generic utilization inflation generic drive several patent expiration next few year celesio acquisition age population end fiscal distribution solution business revenue growth be expect increase mid single digit year year deal cvs healthmckesson recently announce have complete acquisition rxcrossroad cvs health corp cvs free report rxcrossroad be provider tailor service pharmaceutical biotechnology manufacturer transaction be value have be entirely funded cash hand buyout be expect enhance mckesson exist solution manufacturer brand specialty generic biosimilar drug include comprehensive patient support service custom pharmacy solution third party logistic enable company expand end end offering manufacturer read more mckesson buy rxcrossroad cvs health fiscal company strong guidance fiscal look impressive mckesson expect gaap earning share range fiscal year end mar adjust earning same be expect range other picksother top rank stock market large be integer holding corporation itgr free report intuitive surgical inc isrg free report integer holding have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1146,ISRG,intuitive surgical inc isrg free report fourth quarter result schedule release jan be expect show steady growth instrument accessory revenue major revenue component majorly drive earning quarter review expect improvement revenue other segment help company generate solid result season zack consensus estimate instrument accessory revenue be peg fourth quarter reflect increase year quarter be important note intuitive surgical deliver positive earning surprise past quarters average be prior quarter strong growth general surgery worldwide urology be say be suppose growth driver intuitive surgical inc price consensus intuitive surgical inc price consensus chart intuitive surgical inc quote upbeat preliminary result intuitive surgical have recently announce better expect preliminary net sale result fourth quarter company expect net sale fourth quarter be approximately year year basis da vinci procedure increase roughly fourth quarter preliminary fourth quarter revenue instrument accessory segment increase approximately year year basis read more intuitive surgical upbeat sale result other factor playwe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be catalyst fourth quarter zack consensus estimate revenue fourth quarter be grow year year further zack consensus estimate earning fourth quarter be peg grow year year be other factor influence intuitive surgical quarterly result earning season solid procedure trend solid revenue performance product instrument accessory be likely boost company top line add solid growth da vinci procedure be expect lend intuitive surgical competitive edge broader general surgery market december company file form fda da vinci single port surgical system certain urology procedure further intuitive surgical procedure trend be expect be solid globally courtesy stellar performance general surgery global urology segment da vinci service unit hold promise solid growth company da vinci service segment be expect drive company fourth quarter earning fact zack consensus estimate da vinci system unit segment be peg compare prior quarter increase be likely stem solid growth da vinci procedure come revenue service segment zack consensus estimate be year year basis growth system install base zack consensus estimate company total system install base be expect be unit drive higher system placement operate lease revenue be important note intuitive surgical generate approximately revenue operate lease last quarter compare third quarter approximately second quarter here be quantitative model predict intuitive surgical carry zack rank buy do not have positive earning esp increase odd earning beat zack esp earning esp intuitive surgical be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank intuitive surgical increase predictive power esp however also need positive esp be confident earning beat stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter centene corporation cnc free report have earning esp zack rank strong buy see complete list today zack rank stock here eiger inc eigr free report have earning esp zack rank blueprint medicine corporation bpmc free report have earning esp zack rank hold today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1147,ISRG,medtronic plc mdt free report announce study result show superiority medtronic itb intrathecal baclofen therapy conventional medical management cmm reduction severe post stroke spasticity pss adult notably result spasticity stroke randomise study sister trial be publish journal neurology neurosurgery psychiatry jnnp result demonstrate itb therapy lioresal intrathecal baclofen injection deliver synchrome ii infusion system be superior oral antispastic medication decrease muscle tone affected lower upper extremity go american association neurological surgeon datum more person suffer spasticity worldwide accord company severe spasticity patient have tight stiff muscle make everyday activity tire difficult proper treatment be not provide then excessive muscle tone significantly reduce quality life hence initiative provide effective treatment severe pss patient company demonstrated efficacy itb therapy oral medication sister be first randomize controlled open label multicentre study examine effectiveness safety itb therapy compare cmm oral medication treatment pss month active treatment development pain be consistently try boost pain therapy division be part restorative therapy group recently company announce fda approval new clinician programmer use synchrome ii intrathecal drug delivery system be implantable pump provide target drug delivery chronic pain severe spasticity september company announce fda approval launch intelli platform management certain type chronic intractable pain stock performance estimate revisionover last month medtronic have outperformed broader industry stock have gain versus gain broader industry also estimate revision trend current year remain favorable estimate move north last month compare movement opposite direction estimate moved zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock have zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1148,ISRG,myriad genetic inc mygn free report recently announce receipt fda approval bracanalysis cdx test usage companion diagnostic astrazeneca merck parp inhibitor lynparza olaparib patient negative metastatic breast cancer mbc germline brca mutation october company have announce fda acceptance supplementary premarket approval spma application bracanalysis cdx usage companion diagnostic astrazeneca parp inhibitor lynparza olaparib patient negative mbc management approval test be available patient be unaware brca status patient mbc unite state recent development bracanalysis cdxmyriad genetic have be leave stone unturned boost uptake bracanalysis cdx test december company present encourage datum embraca trial demonstrate bracanalysis cdx test ability effectively identify patient mbc respond pfizer investigational parp inhibitor talazoparib embraca trial cover roughly patient be test positive germline brca mutation determine bracanalysis cdx test also companion diagnostic olaparib treatment mbc cancer patient bracanalysis cdx have be submit japan review pharmaceutical medical device agency pmda marketing approval ministry health labor welfare company approval help cash market opportunity more patient year myriad genetic have also receive spma bracanalysis cdx march post approval bracanalysis cdx be be used complementary diagnostic test ovarian cancer patient associate improve progression free survival pfs used tesaro parp inhibitor zejula niraparib maintenance therapy market potentialmyriad genetic have be consistently try strengthen hold high potential breast cancer screening market report dpi research medium breast cancer screening market unite state be expect reach value roughly also encouragingly note myriad genetic have be consistently try expand high potential molecular diagnostic market be expect reach value cagr report share price genetic have be gain investor confidence consistently positive result past month company share price have outperformed broader industry stock have gain contrast broader industry fall zack rank key picksmyriad genetic carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1149,ISRG,medical group wmgi free report report adjust loss cent share third quarter line zack consensus estimate also figure be narrower cent year year basis net sale third quarter totale miss zack consensus estimate quarter detailwright medical report revenue total extremity biologic segment consolidated sale segment unite state increase year quarter almost internationally sale extremity biologic business be year year becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company quotetotal extremity biologic include sub segment lower extremity upper extremity biologic sport med other lower extremity sale segment decline year year basis quarter lower extremity business sale fall third quarter internationally lower extremity sale decline year year basis upper extremity sale segment increase year year basis quarter review upper extremity business grow year year basis also upper extremity sale increase year year basis internationally biologic sale segment rise year year basis quarter biologic business grow quarter sale segment grow internationally year year basis sport med other sale segment rise year quarter sport med other segment sale decline increase internationally third quarter guidancewright medical expect net sale full year band include negative impact foreign currency exchange approximately company forecast full year adjust ebitda continue operation range takewright medical be strive product innovation research development company recently launch invision total ankle revision system be first system develop total ankle revision arthroplasty management perform reversed launch boost revenue company deliver additional instrument set market however decrease lower extremity upper extremity sale internationally be matter concern zack rank key pickswright medical currently carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank strong buy stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand basis point year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1150,ISRG,zimmer biomet holding inc zbh free report report third quarter adjust earning share ep year year adjust earning also miss zack consensus estimate cent reportedly net earning come cent share mark slash year figure revenue detailszimmer biomet third quarter net revenue come mark drop constant exchange rate cer year year recently include ldr hold contribute basis point bps top line exclude contribution ldr hold quarter revenue decline cer year year revenue however remain line zack consensus estimate zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc quote revenue generate americas quarter be year year cer same emea europe middle east africa gross asia pacific however register growth cer reach segmentsrevenue derive knee be year year cer hip too record decline cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record marginal improvement cer dental be quarter other revenue drop marginsa dismal topline performance rise cost product sell result gross margin contraction third quarter zimmer biomet gross margin deteriorate bps quarter selling general administrative expense be research development expense also decline accordingly adjust operate margin expand bps quarter cash positionzimmer biomet exit third quarter cash cash equivalent compare second quarter end total long term debt be compare end second quarter year date operate cash flow be compare year period company also paid dividend third quarter outlook base dull topline show zimmer biomet have lower full year guidance company currently expect register revenue range represent growth cer range earlier prediction be growth include contribution approximately bps ldr transaction current zack consensus estimate revenue be peg guide range adjust ep expectation have be forecast range lower earlier range year current zack consensus estimate ep be peg much ahead current guidance fourth quarter company expect revenue range represent growth negative positive year year cer additionally adjust ep fourth quarter be expect be range takezimmer biomet end quarter dismal note earning remain zack consensus estimate revenue be marginally line same be disappoint company decline sale performance most core segment accord company challenge top line result be due pace supply recovery certain key brand softened domestic market condition slower anticipate sale recapture particularly unite state lower guidance also add concern indicate little chance recovery ahead however look forward ongoing synergy ldr hold acquisition broaden complement company musculoskeletal offer be also impressed strong strategic financial goal combine entity expect reach zack rank key pickszimmer biomet have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1151,ISRG,masimo corp masi free report report earning cent share third quarter outperform zack consensus estimate cent bottom line also improve year figure cent revenue improve year quarter beat zack consensus estimate quarter direct product revenue product revenue increase oem sale product revenue decline year quarter total product revenue increase year year basis company rainbow product revenue report quarter totale be year year basis quarter review masimo ship approximately set pulse oximeter rainbow set pulse co oximeter exclude handheld unit company estimation worldwide install base be unit sep unit oct financial conditiona sep masimo total cash cash investment be compare dec company generate cash operation masimo corporation price consensus ep surprise masimo corporation price consensus ep surprise masimo corporation quote guidancemasimo now expect fiscal revenue approximately previous guidance total fiscal product revenue be project approximately prior guidance royalty revenue projection be unchanged approximately fiscal earning diluted share be expect zack rank key picksmasimo have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1152,ISRG,qiagen qgen free report recently announce signing new collaboration agreement diasorin post collaboration qiagen quantiferon tb diagnostic test be available diasorin liaison portfolio fully automate analyzer be not first time qiagen be partner renown diagnostic ivd player earlier june have partner develop new test base review selection process involve qiagen assay technology test diasorin liaison family analyzer latest announcement qft stand be first assay qiagen quantiferon portfolio be available use liaison family system also company more liaison system have already be place globally thus believe deal help qiagen expand customer base moreover agreement company be work develop completely automate version quantiferon test read component use quantiferon tb test future quantiferon base test be adopt use liaison regard company plan launch ce marked new quantiferon read component use liaison xl third quarter moreover launch unite state launch china be plan same recent development quantiferon tb diagnostic test quantiferon tb diagnostic test kit fall qiagen molecular diagnostic segment be highest revenue grosser last report quarter notably segment contribute total revenue back substantial growth quantiferon latent tb test qiasymphony automation system consumable portfolio solid performance companion diagnostic pharma collaboration regard post receipt fda approval june qiagen have announce complete launch fourth generation blood test tuberculosis tb infection quantiferon tb gold qft unite state build quantiferon tb gold qft platform qft provide enhance analysis tb infection advanced kit make tb testing innovative antigen possible measure cell mediate immune response tb cd cd cell market prospectsqiagen have be witness substantial demand quantiferon tb diagnostic test kit notably company announce touch milestone conduct quantiferon tb test globally initial launch end also morbidity mortality weekly report mmwr publish center disease control prevention total new tb case be diagnosed unite state accord research market datum publish onbusiness wire tb market be expect see cagr regard latest partnership company be able cash opportunity tb market share price have be gain investor confidence consistently encourage result last month company share price have outperformed broader industry stock have lose compare broader industry decline zack rank key picksqiagen carry zack rank sell few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1153,ISRG,initiative reduce excessive opioid prescribe express script hold company esrx free report announce day analysis advanced opioid management program program be initiate last september address national opioid epidemic situation express script aim curb opioid opioid epidemic opioid crisis be rapid increase use prescription prescription opioid drug unite state canada notably opioid be diverse class strong painkiller often detrimental health fact report stat opioid more half person america next decade express script advanced opioid management program aim protect person used opioid medication mainly patient take opioid first time part advanced opioid management program express script therapeutic resource center pharmacist be also provide proactive counsele safe opioid use patient own home notably first day review nearly reduction be observed average day supply patient receive opioid prescription first time day supply prescription claim launch program day supply claim start program management company be proactively address national opioid epidemic reduce excessive improper opioid prescribe well promote greater compliance cdc guideline june express script announce new advanced opioid management solution address nation opioid addiction epidemic work comprehensively patient prescriber pharmacy aim be minimize early exposure prevent progression overuse abuse accord report persistence market research global opioid market have be estimate reach worth cagr stock performance estimate revisionexpres script stock have outperformed broader industry last month specifically stock have gain period compare industry gain moreover current rate be way higher also estimate revision trend current year remain favorable estimate move south last month compare movement opposite direction company current estimate moved past month zack rank key picksexpress script carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1154,ISRG,henry schein inc hsic free report recently announce purchase stake veterinary product distributor certain undisclosed financial term company deal drive earning notably sao paulo brazil base be family own distributor veterinary health care product begin henry schein have enter brazilian animal health market investment tecnew privately hold distributor animal health product latest acquisition company expect boost business brazil diversify relationship global supplier recent development animal healthhenry schein have be consistently try expand global animal health business segment witness rise revenue last report third quarter october company complete buyout merritt veterinary supply merritt become part veterinary business henry schein company offer comprehensive line product include pharmaceutical diagnostic equipment veterinary clinic eastern unite state strong presence southeastern part nation henry schein animal health also open new national distribution service center columbus brookhollow neighborhood expand presence central ohio market potentialaccord report grand view research global animal health market be expect reach value consider huge potential market believe latest development be strategic share price movementover past month henry schein have be underperform broader industry stock have lose contrast industry gain believe latest development help boost investor confidence stock reverse downtrend zack rank key pickshenry schein carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1155,ISRG,bid promote safe handle hazardous drug maintain medication sterility baxter international inc bax free report recently announce distribution agreement launch arisure close system transfer device unite state platform prevent contamination intravenous iv medication delivery system drug preparation management latest development baxter be able ensure safer drug preparation transportation administration disposal system reduce risk accidental exposure contamination patient caregiver arisure close system transfer device include close vial adapter intravenous dry spike close male luer valve arisure close male luer lower exposure risk healthcare professional sharp needle further arisure close male luer be compatible baxter link needle free iv connector clearlink luer activate valve pave way initiate mechanically close system broad product spectrumbaxter have impressive product portfolio convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump sigma spectrum infusion system minimize patient risk administer vital fluid medication recently company upgrade sigma spectrum infusion system launch devicevue advanced asset tracking system baxter international inc price baxter international inc price baxter international inc quote baxter be first only smart infusion pump manufacturer offer tagless end end acid tracking application design consultation potential customer drive operational efficiency maximize clinical value pump investment late baxter needle free connector product line have also be focus minimize hospital infection acute therapy baxter launch first oxiris continuous renal replacement therapy sepsis management protocol add baxter multus organ therapy offer utilize prismaflex system stock performance solidover past month baxter have gain compare favorably industry rally baxter be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long haul company long term expect earning growth rate hold promise regard zack rank key picksbaxter have zack rank hold few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1156,ISRG,abbott free report have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system company have be witness solid growth global diabetes care business primarily back solid contribution freestyle libre accordingly be leave stone unturned cash grow popularity cgm system eliminate need daily finger stick development freestyle librefollow fda approval september freestyle libre flash glucose monitoring system abbott recently achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage post approval freestyle libre have become only user calibration cgm device medicare coverage available person diabetes unite state meanwhile abbott have be steadily progress development diabetes care segment last september company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company announce receipt health canada license freestyle libre flash glucose monitoring system june drive diabetes care segment see revenue growth third quarter continue acceptance freestyle libre internationally believe latest cms reimbursement grant boost company performance domestic arena well expect freestyle libre contribute abbott top line japanese canadian development french health ministry approve national reimbursement device last market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth further diabetes market moreover report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe recent regulatory approval freestyle libre have come opportune moment however market be dominate well establish player johnson johnson jnj free report be most prominent space johnson johnson have tie base corporation successfully develop innovate insulin delivery system share price abbott have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain comparison broader industry gain zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate have gain year intuitive surgical have long term expect earning growth rate stock carry zack rank have surge year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1157,ISRG,integra lifescience holding corporation iart free report report preliminary unaudited revenue approximately fourth quarter year year preliminary revenue figure be zack consensus estimate management stellar quarterly performance come back strong organic growth specialty surgical solution well orthopedic tissue technology business moreover outperformance codman neurosurgery derma science acquisition rapid recovery hurricane hit puerto rico manufacturing facility enhance performance dural repair contribute top line integra lifescience expect fourth quarter adjust earning share ep surpass high end fourth quarter guidance zack consensus estimate fourth quarter ep be peg cent however estimate revision trend have be unfavorable estimate moved south past month movement opposite direction fact fourth quarter estimate decrease penny earning cent share stock have zack rank hold integra lifescience holding corporation price ep surprise integra lifescience holding corporation price ep surprise integra lifescience holding corporation quote share price movementover past year integra lifescience have be trading broader industry stock have rally compare industry gain believe company recent product diversification bolster investor confidence thereby boost stock price late orthopedic tissue technology segment company launch several regenerative product surgical reconstruction market third quarter company register mid single digit growth regenerative technology franchise primarily banking addition derma science strong growth patient skin portfolio tissue ablation global launch cusa clarity be get solid response unite state overseas integra lifescience expect product drive growth be also optimistic fact integra lifescience have successfully witness certain key overseas development face foreign exchange fluctuation international business also company have adopt several term objective pillar strategy management also expect gain market traction strategic partnership acquisition key picksa few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1158,ISRG,align technology inc algn free report report earning share ep third quarter substantially year year earning be also higher company guide range cent figure comfortably beat zack consensus estimate cent revenuesrevenue grow year year quarter surpass zack consensus estimate also remain well ahead company guide range management strong top line be drive robust invisalign case shipment year year third quarter upside be backed growth north america international region also year year surge teenage case board reflect very strong summer season contribute top line growth segment detailrevenue clear aligner segment total revenue soar year year report quarter primarily drive continue strong invisalign case volume growth customer channel geographical region third quarter invisalign case shipment amount year year aid growth region well expansion customer base quarter align technology invisalign case be ship doctor worldwide be north america be international region revenue scanner service improve significantly marginsgross margin third quarter be basis point bps year year rise cost net revenue quarter align technology witness year year increase selling general administrative expense rise research development expense operate margin however expand bps financial detailsalign technology exit third quarter cash cash equivalent short term marketable security marked rise precede quarter report quarter align technology close earlier announce accelerate stock repurchase program asr receive total share weight average share price management currently have available repurchase exist stock repurchase authorization fourth quarter company project ep cent revenue company also expect invisalign case shipment band same period year takealign technology end third quarter solid note earning revenue beating zack consensus estimate be upbeat continue strong invisalign volume extremely strong summer season drive company invisalign growth global market scanner service company witness nice uptake itero scanner gp dentist record contract come gp summit last september company expect bullish trend continue rest align be also look forward recently inked distribution agreement patterson dental align itero element intraoral scanning system additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side company be expose foreign exchange fluctuation seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio extension zack rank key pickscurrently align technology carry zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue rally year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1159,ISRG,henry schein inc hsic free report report adjust earning share ep cent third quarter year year however adjust ep miss zack consensus estimate cent year year upside earning be drive strong revenue growth revenue detailhenry schein report revenue third quarter year year also zack consensus estimate year year improvement come back growth local currency increase owing foreign currency exchange local currency internally generate sale increase acquisition growth be company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service third quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin decline basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year however adjust operate margin contract bps year year report quarter financial positionhenry schein exit third quarter cash cash equivalent compare end second quarter year date net cash provide operate activity be compare year period quarter review company buy back approximately share almost close third quarter company have authorize repurchase common stock ep guidancehenry schein update adjust ep guidance exclude litigation settlement expense fourth quarter loss related company divestiture equity ownership technology company now expect adjust ep range reflect growth adjust ep figure previous adjust ep guidance range be zack consensus estimate adjust ep be outside guide range company also provide guidance ep henry schein expect report ep band reflect annualize growth rate compare midpoint company adjust ep guidance range takehenry schein exit third quarter mixed note company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense zack rank key pickshenry schein have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corp lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1160,ISRG,rti surgical inc rtix free report recently execute deal acquire zyga technology inc privately hold medical device company base minnesota however successful close deal be subject filing state delaware currently delaware department state be close owing unfavorable weather condition financial term deal be still wrapped close deal rti surgical fund acquisition combination cash borrow exist credit facility zygazyga technology be dedicate research development surgical solution company provide economic value treatment underserved condition spine zyga be know primary medical device simmetry sacroiliac joint fusion system sijf glyder facet restoration device simmetry sacroiliac joint fusion system be minimally invasive spine surgery procedure design help stabilize si joint glyder facet restoration device be intend provide relief lumber facet pain restore facet joint function company generate approximately annual revenue rti surgical inc price consensus rti surgical inc price consensus rti surgical inc quotea strategic moverti surgical expect zyga technology simmetry sacroiliac joint fusion system leverage competency spine franchise acquisition be line company motto strategic transformation increase operational excellence lead reduce complexity surgical procedure market sijf market have see significant growth current year market be estimate be unite state sijf be expect exceed growth be attribute increase procedure volume technology adoption new surgeon idata research more population be likely suffer lower back pain point life share look upover last year rti surgical have have run bourse stock have rally compare industry gain zack rank key picksrti surgical have zack rank hold few better rank stock broader medical space be abiom inc abmd free report tactile system technology tcmd free report intuitive surgical inc isrg free report carry zack rank buy see complete list today zack rank stock here abiom long term growth rate be expect be impressive stock have rally be way industry gain last year tactile system have long term growth rate stock have rally have outperformed industry last year intuitive surgical have long term growth rate last month stock have rally surpass industry gain medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1161,ISRG,zimmer biomet holding inc zbh free report reach new milestone field total shoulder arthroplasty recent food drug administration fda approval sidusstem free shoulder system unite state follow approval sidus system be available country first quarter total shoulder arthroplasty solution claim benefit patient good bone stock also same time complain osteoarthritis post traumatic arthrosis focal avascular necrosis humeral head have undergo previous surgery shoulder do not compromise fixation zimmer biomet system be design restore patient anatomy preserve bone stock offer improve pre post operative patient outcome be encourage note sidus stem free shoulder system offer minimal bone resection total shoulder arthroplasty zimmer biomet claim advanced approach reduce pain restore range motion sidus system be first introduce europe company initiate clinical study unite state go strong clinical performance sidus stem free shoulder system have demonstrated time zimmer biomet seem highly optimistic show impression customer adoption article publish orthospinenews global shoulder arthroplasty market be value same be expect scale register cagr forecast period promising datum indicate timely strategic role latest fda approval be go play favor zimmer biomet solid stock performance last day zimmer biomet have be trading broader industry company have gain versus broader industry rise also company have outperformed gain same time frame zack rank key pickszimmer biomet carry zack rank sell better rank stock broader medical space be abiom inc abmd free report tactile system technology tcmd free report intuitive surgical inc isrg free report carry zack rank buy see complete list today zack strong buy rank stock here abiom have long term expect earning growth rate stock have rally last year tactile system have long term expect growth rate stock have soar last year intuitive surgical have long term expect growth rate last month stock have rally medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1162,ISRG,mckesson corp mck free report recently announce have complete acquisition rxcrossroad cvs health corp rxcrossroad be provider tailor service pharmaceutical biotechnology manufacturer transaction be value have be entirely funded cash hand rxcrossroad become part mckesson specialty health business mckesson expect transaction be accretive adjust earning share approximately cent third year follow close transaction mckesson specialty pharma business be strong growth driver next several year buyout be expect enhance mckesson exist solution manufacturer brand specialty generic biosimilar drug include comprehensive patient support service custom pharmacy solution third party logistic also allow company expand end end offering manufacturer rxcrossroad be founder medical distribution company be later acquire omnicare then acquire cvs health mckesson have be actively pursue deal divestiture acquisition drive growth recently mckesson divest enterprise information segment recently approximately cash indicate company focus core strength notably enterprise information solution portfolio include robust set clinical financial solution support full scope care delivery process include paragon ehr solution star healthquest revenue cycle solution lab analytic blood bank onecontent content management solution company also sign agreement acquire privately own company covermymed approximately however mckesson pharmaceutical distribution business contribute almost company top line be witness sluggish growth last few quarters due weak pricing trend customer consolidation distribution solution face stiff competition term price service various full line short line specialty wholesaler service merchandiser self warehousing chain manufacturer engage direct distribution third party logistic company large payer organization price performanceover last month mckesson have be trading industry company share have gain lower industry rally current level also be lower index return just mckesson corporation price mckesson corporation price mckesson corporation quotezack rank other picksmckesson have zack rank buy other top rank stock broader medical sector be integer holding corp itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock carry zack rank zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1163,ISRG,bioscrip inc bio free report report net loss continue operation cent share third quarter flat year year however report net loss share be wider zack consensus estimate loss cent revenueswith completion core pbm business divestment bioscrip currently have simplified business structure focuse core infusion service revenue continue operation third quarter decline year year miss zack consensus estimate year year decline be lead shift company strategy focus grow core revenue mix apart impact cure act contract modification impact hurricane harvey irma be major deterrent be partially offset synergy home solution acquisition bioscrip inc price consensus ep surprise bioscrip inc price consensus ep surprise bioscrip inc quote gross profit third quarter be year year gross margin also expand basis point bps adjust operate income be mark year year increase rise adjust operate expense adjust operate margin expand bps year year exit third quarter cash cash equivalent compare end second quarter update guidance bioscrip lower guidance adjust ebitda range earlier full year guidance incorporate estimate adverse effect cure act legislation company estimate regard contract company have reduce revenue outlook range previous include impact revise contract revenue damage incur due hurricane zack consensus estimate revenue lie company guide range takebioscrip exit third quarter dismal note lower expect top bottom line performance management slash guidance add concern nonetheless be encourage company progress third quarter courtesy new multus faceted core plan improve financial position company expect core revenue home solution continue core growth prove accretive be also upbeat company completion contract transition expectation core revenue growth zack rank key picksbioscrip have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1164,ISRG,dentsply sirona inc xray free report report third quarter adjust earning share ep cent beating zack consensus estimate cent earning also surpass year quarter figure cent quarter detailsdentsply net sale increase year period same also beat zack consensus estimate net sale exclude precious metal increase constant currency basis internal growth be third quarter quarter sale rise year quarter net sale europe increase net sale rest world decline dentsply sirona inc price consensus ep surprise dentsply sirona inc price consensus ep surprise dentsply sirona inc quote financial updatetotal cash cash equivalent company decline sep dec cash generate operation first month be compare year period sep company long term debt be versus year end company narrow adjust ep guidance range share earlier company project adjust ep range zack rank key pickscurrently dentsply carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report second quarter fiscal earning cent cent year quarter gross margin expand bps year year luminex report third quarter adjust earning cent year year company revenue quarter increase almost year year intuitive surgical post third quarter adjust earning year year basis revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1165,ISRG,steris plc ste free report report second quarter fiscal adjust earning share ep cent year quarter however earning miss zack consensus estimate cent report basis ep come cent year year revenue detailsteris generate revenue year year meanwhile top line beat zack consensus estimate year year decline be result sale loss owing divest business organic revenue growth constant currency be year year primarily drive balanced growth segment company operate segment healthcare product healthcare specialty service apply sterilization technology life science revenue healthcare product segment decline year year report quarter be largely due decline capital equipment revenue decrease consumable revenue result divestiture turn be partially offset increase service revenue steris plc price consensus ep surprise steris plc price consensus ep surprise steris plc quote revenue healthcare specialty service segment decline report basis due linen divestiture however organic revenue grow reflect growth im north america revenue apply sterilization technology rise organic revenue grow back increase demand segment core medical device customer revenue life science segment grow quarter growth service revenue increase consumable revenue rise capital equipment revenue organic basis revenue increase year year marginsadjusted gross margin improve basis point bps year year report quarter account synergy divest low margin business improvement operational efficiency favorable product mix pricing steris witness year year decline selling general administrative expense research development expense fall accordingly adjust operate margin expand bps year year basis report quarter financial detailssteris exit second quarter fiscal cash cash equivalent compare end first quarter fiscal company have long term debt end second quarter fiscal compare end first quarter fiscal year date company generate cash flow operation year period free cash flow period be compare prior year period guidancesteris continue expect organic revenue growth fiscal constant currency basis prior fiscal adjust ep be project range takesteris exit second quarter fiscal mixed note year year decline revenue be disappointment positive side organic growth performance be strong segment further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change be expect better align operation zack rank other key pickssteris have zack rank buy other top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1166,ISRG,walgreen boot alliance inc wba free report report adjust earning share ep first quarter fiscal year year constant exchange rate cer adjust ep surpass zack consensus estimate well report basis net earning come reflect decrease prior year quarter report earning come cent share show decline year year basis total saleswalgreen boot record total sale fiscal first quarter year year cer top line outpaced zack consensus estimate segment detailwalgreen boot currently report operate segment retail pharmacy usa retail pharmacy international pharmaceutical wholesale retail pharmacy usa division record sale first quarter highlight increase year year basis segment total sale comparable drugstore rise prescription filled comparable store grow account medicare part growth volume growth previously announce strategic pharmacy collaboration comparable retail sale drop due lower sale consumable general merchandise category personal care category partially offset increase sale health wellness well beauty category pharmacy sale account retail pharmacy usa division sale quarter increase year quarter pharmacy sale comparable store rise higher volume revenue retail pharmacy international division rise year year basis cer owing currency fluctuation cer comparable store sale first quarter decrease year year decline comparable pharmacy sale pharmaceutical wholesale division record quarterly sale year year cer walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc quote marginsgross profit report quarter increase year year however report gross margin contract basis point bps selling general administrative sg expense be year year however adjust operate income remain flat adjust operate margin contract bps financial boot exit first quarter cash cash equivalent compare end fiscal long term debt be compare end fiscal company generate operate cash flow first quarter fiscal compare year resultant free cash flow be quarter review boot have raise low end outlook fiscal cent share anticipate adjust ep compare previously provide range zack consensus estimate fiscal earning be peg company guide range however management adjust ep outlook fiscal do not include impact latest tax legislation slash corporate tax rate moreover guidance assume current exchange rate rest fiscal takewalgreen boot report impressive first quarter fiscal be also encourage increase sale retail pharmacy international segment moreover walgreen boot have be gain account company strategic tie up bring more patient pharmacy be also upbeat rite aid acquisition deal company get regulatory approval september walgreen boot modify merger contract be line growth strategy offer additional operational benefit also help company expand optimize retail pharmacy network key market include northeast also be upbeat company expand global footprint decision acquire stake sinopharm hold guoda drugstore co ltd guoda subsidiary china national accord medicine corporation ltd completion investment provide strong impetus walgreen boot worldwide retail pharmacy business notably shanghai base guoda be large national pharmacy chain china be retail pharmacy platform china national pharmaceutical group corporation cnpgc moreover company acceptance proposal sell part investment chinese wholesale partner guangzhou pharmaceutical corporation huge cash return buoy optimism zack rank key pickswalgreen boot carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report integer holding corporation itgr free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy company have long term expect earning growth rate have gain year see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate stock carry zack rank buy have gain year time integer holding have long term expect earning growth rate stock carry zack rank have gain year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1167,ISRG,neogen corporation neog free report report adjust earning cent share second quarter fiscal figure beat zack consensus estimate increase year quarter revenue increase year year basis lag zack consensus estimate slight margin revenue detailsfood safety segment revenue food safety segment totale revenue jump second quarter solid overall organic growth growth be majorly fuel strength number exist product line recent acquisition quarter company witness rise sale general sanitation product year quarter growth global culture medium business moreover sale rapid food safety diagnostic identify food bear pathogen include equalize salmonella rise notably include increase sale test detect also note sale segment be drive rise sale allergen test food such gluten peanut courtesy global food allergen regulator effort animal safety segment segment record revenue reflect increase year quarter growth segment be mainly drive increase sale genomic business rise rodent control product line rise sale animal care product increase sale veterinary instrument particularly detectable needle product line genomic business unit record increase year year basis management growth business unit be fuel expansion company testing facility scotland development new genomic testing product acquisition brazil base deoxi early neogen corporation price consensus ep surprise neogen corporation price consensus ep surprise neogen corporation quote margin detailsadjust gross margin expand basis point bps quarter largely due mixed impact acquisition quat rogama adjust operate income be sale second quarter compare year takewe believe neogen be steadily progress back prong strategy also be encourage accretive acquisition expand international footprint drive neogen overall result fiscal company have broad portfolio innovative disinfectant product more epa fda register product strengthen company global market position furthermore betastar advanced raptor integrate analysis platform be likely boost neogen food safety business year zack rank key picksneogen carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report integer holding corporation itgr free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy company have long term expect earning growth rate have gain year see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate stock carry zack rank buy have gain year integer holding have long term expect earning growth rate stock carry zack rank have gain year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius
1168,ISRG,jan issue update research report stryker corporation syk free report company solid international foothold be expect boost growth expand exist product offering business segment however company announce voluntary product recall oral care line stryker be focuse international growth significant turnaround company european business backed effective restructure measure indicate potential upside particular company medsurg product line have witness strong demand european australian market further favorable response medsurg product line china have enhance company international prospect stryker international organic sale growth third quarter be year year basis strong international performance come back solid performance europe asia latin america quarter internationally medsurg deliver organic sale growth indicate strong growth medical business primarily europe neurotechnology spine also witness robust organic growth performance be bolster high demand neurotech product europe asia country uk germany italy have be witness solid performance stryker long fact company physio unit launch automate external defibrillator aed europe recently flip side stryker announce voluntary product recall oral care lineup be offer company sage product unit add voluntary recall stryker have place temporary hold certain cloth base product stryker continue witness lower demand health care product company have be face challenge global economic condition particularly unite state western europe additionally lower reimbursement medical product service impose downward pressure price company product longer sale cycle slower adoption new technology dent top line stryker now expect full year organic sale growth lower end previous range adjust net earning band stryker price movement past year have be favorable company yielded return almost better industry rally current level be also higher index return same time frame stock have zack rank hold key picksa few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1169,ISRG,resm inc rmd free report announce first quarter fiscal adjust earning share ep cent prior year quarter earning also beat zack consensus estimate penny include time item resm report ep cent quarter year year revenue detailsrevenue report quarter increase year year constant exchange rate cer figure also beat zack consensus estimate geographic basis exclude revenue americas totale reflect increase prior year quarter moreover revenue report quarter totale year year revenue combine emea apac be highlight year year rise cer adjust gross margin contract basis point bps year year report quarter selling general administrative expense be year year be increase research development expense lead rise adjust operate expense amount accordingly adjust operate margin quarter contract bps financial updateresmed exit first quarter fiscal cash cash equivalent compare end fiscal year date company generate cash flow operation year figure concurrent first quarter earning release resm announce regular quarterly dividend cent share dividend be paid dec shareholder record nov previously declare resm temporarily suspend share repurchase program due recent acquisition however company still expect recommence buy back program sometime fiscal expect sg expense percentage revenue end fiscal expense percentage revenue be project fiscal reflect marketing expense associate product launch ongoing legal expense takeresm exit first quarter promising note brighter side company achieve solid double digit global revenue growth quarter lead sale software service business well new mask product device company also recently launch airfit classic nasal mask positive airway pressure pap treatment europe factor boost investor faith stock however challenge competitive bidding reimbursement issue continue plague stock company also remain expose foreign exchange fluctuation zack rank key picksresm currently carry zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1170,ISRG,varian medical system inc var free report report adjust earning share fourth quarter fiscal miss zack consensus estimate adjust earning also decline year year basis meanwhile revenue be year quarter revenue miss zack consensus estimate narrow margin varian medical end year backlog year year basis unfavorable performance company proton therapy unit be primary cause lackluster fourth quarter performance however solid guidance fiscal instill confidence stock palo alto base manufacturer medical device software carry zack rank hold varian medical system inc price consensus ep surprise varian medical system inc price consensus ep surprise varian medical system inc quotesegment detailsoncology system segment revenue totale year year constant currency cc oncology growth be drive double digit service growth newly issue upgrade hardware software notably varian medical register order hyperarc platform fourth quarter hyperarc be recently launch high definition radiotherapy technology gross order segment totale cc year quarter unite state gross order increase cc emea region gross order rise year year basis courtesy solid growth france germany poland india flipside gross order decline cc apac region thank weakness japan proton therapy fourth quarter revenue segment be year year basis quarter varian medical book order include concord medical proton center guangzhou china hcg india proton therapy order growth be year year basis halcyon drife growthvarian medical have be take initiative gain customer attention broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna last quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform have order fourth quarter order be emea order north africa apac marginsin fourth quarter gross margin contract basis point bps revenue oncology system gross margin contract nearly bps owing supply chain inefficiency percentage revenue expense research development remain flat year year basis meanwhile selling general administrative sg expense quarter be bps year year basis operate margin quarter review be net revenue bps year year notably fourth quarter last year include favorable bad debt release addition investment varian medical have spend capex buy back share company stock end fourth quarter varian medical have share remain exist repurchase authorization fy fiscal varian medical register adjust earning share revenue be cc year oncology revenue be cc full year revenue proton therapy unit totale year year company book proton therapy order fiscal fiscal be favorable varian medical term product launch well successful launch halcyon therapy system hyperarc technology deserve mention regard fy fiscal management estimate adjust earning share range cash flow operation be project fiscal revenue be estimate grow year year company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock carry zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1171,ISRG,cardiovascular system inc csii free report report adjust loss share cent first quarter fiscal flat year quarter adjust loss cent figure be narrower earlier provide guide range loss share cent figure compare favorably zack consensus estimate loss cent result system post revenue fiscal first quarter mark year year decline also figure be lower guide range first quarter fiscal figure also miss zack consensus estimate management procedure volume first quarter fiscal be impact hurricane moreover saline infusion pump recall quarter result lower estimate usage coronary device factor play significant role result revenue miss quarter cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quote date cardiovascular system have sell device lead institution unite state company add new peripheral account coronary account fiscal first quarter coronary device revenue decline year year peripheral device revenue inched margingross margin report quarter be basis point bps year year meanwhile selling administrative sg expense contract research development expense be resultantly adjust operate expense inched management operate expense be lower earlier provide guidance due lower incentive compensation result deterioration financial performance operate loss be compare loss year quarter financial company exit first quarter fiscal cash cash equivalent compare end fiscal system reaffirm fiscal revenue guidance range current zack consensus estimate fiscal revenue be peg be company guide range company expect revenue range second quarter fiscal current zack consensus estimate be peg company guide range moreover company expect gross profit account revenue operate expense be estimate second quarter fiscal company expect incur net loss loss share cent second quarter fiscal current zack consensus estimate be peg loss penny company guide range system exit first quarter fiscal mixed note decline year year revenue coronary device peripheral device be disappointing fiscal first quarter revenue decline year year basis owing impact hurricane positive note report loss quarter be narrower guide range company also expansion be gross margin be impressive company reaffirm revenue guidance fiscal buoy optimism moreover company be putt effort product innovation investment quarter company release year datum liberty clinical study late breaking presentation amputation prevention symposium amp chicago liberty show peripheral endovascular intervention help prevent amputation patient peripheral artery disease zack rank key pickscurrently cardiovascular system have zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1172,ISRG,baxter international inc bax free report report third quarter adjust earning share cent beat zack consensus estimate cent improve year figure cent baxter currently have zack rank buy figure be also company guide range cent cent interestingly last quarters company deliver positive earning surprise average be baxter post sale beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quote segmental detailssale hospital product segment climb cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand injectable pharmaceutical hospital pharmacy compound service meanwhile sale increase cc renal product segment renal product sale be support improve performance major product line therapy globally quarterly acquire claris third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space new patient enrolled third quarter baxter register patient new clinical trial unique expand hemodialysis therapy enabled theranova dialyzer treatment chronic acute renal failure fact baxter be expect launch hemodialysis enabled theranova australia new france germany switzerland belgium end year hurricane deal blow management baxter announce possibility shortfall supply certain product next quarter be company be still grapple limit production manufacturing site puerto rico hurricane marium however company have be grant regulatory approval fda special importation product facility ireland australia canada mexico maintain product supply balance market international foothold fortify baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa quarter notably oxiris leverage company flagship prismaflex system be expect lend baxter competitive edge global market guidance full year baxter estimate sale growth approximately cc adjust earning full year be expect band diluted share previous band baxter expect fourth quarter revenue face negative impact approximately thank operational disruption result hurricane marium adjust earning fourth quarter be expect band cent cent diluted share net sale fourth quarter be expect rise cc other company solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank petm express inc pet free report adjust announce earning share cent second quarter fiscal year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1173,ISRG,accuray incorporate aray free report report loss cent share first quarter fiscal line zack consensus estimate figure be narrower loss cent incur year quarter total revenue first quarter increase approximately year year beat estimate year year upside be drive product revenue growth segment analysisproduct revenue revenue segment increase back solid performance cyberknife tomotherapy system radixact platform segment increase product revenue be drive backlog conversion order revenue eimea japan region accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quote service revenue revenue segment see modest year year increase management growth segment be primarily drive continue install base expansion gross order update report quarter gross product order totale year year rise gross order be support company flagship radixact system tomotherapy other platform drife sale company new tomotherapy product platform also know radixact continue contribute top line radixact represent majority accuray tomotherapy order mix report quarter japan witness stellar performance radixact tomotherapy platform precision system accuray announce launch new precision treatment plan system recently system leverage company flagship radixact cyberknife system platform provide significantly improve treatment speed overall throughput cyberknife system ibms datum management system tomotherapy accuray also announce clearance new ibms datum management system tomotherapy be centralize database share make datum accessible multiple accurate system enhance flexibility improve efficiency radiation therapy department margin margin percentage net revenue expand basis point bps first quarter be primarily drive significant rise product service gross margin product gross margin improve back cyberknife system first quarter compare prior year quarter operate expense first quarter totale compare year period guidanceaccuray reaffirm guidance fiscal company maintain full year revenue projection band represent growth year year basis company also expect increase gross order fiscal adjust ebitda fiscal be anticipate range year year takeaccuray report loss first quarter fiscal however loss be narrower year figure company exit quarter solid note earning meeting consensus estimate revenue surpass same year year increase product service revenue be encourage reaffirm guidance also buoy optimism however fluctuation currency exchange rate particularly strong dollar continue affect company backlog top line zack rank key pickscurrently accuray have zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1174,ISRG,abaxis inc abax free report report second quarter fiscal adjust earning share cent line zack consensus estimate however adjust ep figure decline year figure cent total revenuein fiscal second quarter abaxis record revenue reflect increase year top line however miss zack consensus estimate accord company foreign currency exchange rate fluctuation have negligible impact abaxis top line segment detailon geographic basis revenue north america accounting total revenue decline report quarter revenue international market accounting rest improve abaxis operate main segment namely veterinary medical other report quarter veterinary sale account total sale medical contribute remain be generate other abaxis inc price consensus ep surprise abaxis inc price consensus ep surprise abaxis inc quote veterinary market revenue improve year year drive uptick veterinary consumable revenue veterinary instrument revenue be year year revenue medical market be same quarter last year strength piccolo instrument be offset decline medical rotor also revenue north american medical division totale year year global basis abaxis sell piccolos quarter compare year abaxis exhibit strong consumable growth year year quarter consumable product line total rotor revenue be almost line year quarter global basis abaxis sell rotor unit quarter review unit year quarter hematology reagent rapid assay drive growth consumable revenue report quarter however total instrument sale decrease due lower veterinary instrument sale operational updatesfiscal second quarter gross profit drop gross margin contract basis point bps research development expense increase year year sale marketing expense rise general administrative expense however decline however resultant operate income be quarter operate margin decline bps financial updateabaxis exit fiscal second quarter cash cash equivalent short term investment compare first quarter fiscal takeabaxis exit second quarter fiscal disappointing revenue lag zack consensus estimate also decline gross operate margin be matter concern however year year increase revenue buoy optimism be look forward improve consumable revenue boost veterinary sale performance abaxis quarter meanwhile be encourage note company be initiate new sale marketing strategy regard company recently start shipping vetscan ua hand hold urine chemistry analyzer september moreover latest launch vetscan phenobarbital profile vetscan canine pancreatic lipase rapid test buoy optimism abaxis plan additional product launch fiscal include vetscan fuse connectivity system accord company addition product drive growth long haul zack rank key pickscurrently abaxis have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year report basis intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1175,ISRG,mckesson corporation mck free report report second quarter fiscal end sep earning share beating zack consensus estimate earning also surpass year figure mckesson post sale beating zack consensus estimate be last year quarter detailmckesson operate segment distribution solution technology solution growth rate give be year year basis distribution solution revenue be quarter report constant currency basis however revenue technology solution business decline year quarter be due bifurcation technology solution business change healthcare joint venture mar segment reflect only number enterprise information solution business mckesson corporation price consensus ep surprise mckesson corporation price consensus ep surprise mckesson corporation quotefinancial conditiona sep mckesson have cash cash equivalent mar report quarter end sep company generate cash worth operation first half year mckesson repay long term debt paid acquisition repurchase common stock invest internally paid dividend fiscal outlookmckesson expect gaap earning diluted share range fiscal year end mar adjust earning same be expect range zack rankmckesson currently carry zack rank hold company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1176,ISRG,laboratory corporation america holding lh free report labcorp report third quarter adjust earning share ep year quarter quarter adjust ep also exceed zack consensus estimate simultaneous hurricane report quarter adversely affected adjust ep cent approximately report basis labcorp net earning come share increase year year net revenue third quarter increase year year increase net revenue be due growth acquisition organic growth net revenue growth less revenue acquisition first month close acquisition benefit foreign currency translation approximately basis point however be partially offset adverse impact multiple hurricane quarter laboratory corporation america holding price consensus ep surprise laboratory corporation america holding price consensus ep surprise laboratory corporation america holding quote quarter reviewcurrently labcorp report operate segment labcorp diagnostic covance drug development report quarter labcorp diagnostic report net revenue year year fuel price mix tuck acquisition organic volume measure requisition exclude requisition acquisition first month close acquisition benefit foreign currency translation approximately basis point company report increase total volume measure requisition increase revenue requisition quarter several quarters drag sale covance drug development report rise net revenue third quarter be primarily back acquisition chiltern organic growth benefit foreign currency translation approximately basis point gross margin expand bps quarter adjust operate income increase year year adjust operate margin contract bps year quarter rise selling general administrative expense labcorp exit quarter cash cash equivalent compare end second quarter year date operate cash flow be year period free cash flow come year period quarter company return shareholder share repurchase currently have authorization remain exist share repurchase plan outlookbased strong third quarter show consider gradually improve foreign exchange scenario company increase earlier provide outlook net revenue growth be now expect remain band year year ahead earlier range include bps impact unfavorable foreign exchange headwind current zack consensus estimate revenue be peg adjust ep guidance have be narrow range previous range current zack consensus estimate fall guide range free cash flow expectation have be raise new band previous range prior year takelabcorp third quarter earning top zack consensus estimate strong year year increase earning revenue be encourage too labcorp diagnostic business be strong improve price mix acquisition favorable foreign exchange scenario also several quarters dull performance covance drug development report strong growth be primarily back acquisition chiltern strong organic growth favorable foreign currency translation increase guidance boost investor confidence indicate chance bullish trend be maintain fourth quarter too believe integration newer acquisition labcorp be perfectly position drive long term profitable growth combination world class diagnostic drug development expertise knowledge service zack rank other key pickscurrently labcorp have zack rank buy few other top rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank see complete list today zack rank stock here petm report ep cent second quarter fiscal cent report year quarter also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1177,ISRG,walgreen boot alliance inc wba free report report adjust earning share ep fourth quarter fiscal year year adjust ep surpass zack consensus estimate report basis net earning come reflect decrease prior year quarter report earning come cent share show decline year year basis full year adjust ep come year quarter figure also surpass zack consensus estimate total saleswalgreen boot record total sale fiscal fourth quarter year year constant exchange rate cer top line outpaced zack consensus estimate fiscal sale totale year period moreover figure beat zack consensus estimate slight margin walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc quotesegment detailwalgreen boot currently report operate segment retail pharmacy usa retail pharmacy international pharmaceutical wholesale retail pharmacy usa division record sale fourth quarter highlight increase year year basis segment total sale comparable drugstore rise prescription filled comparable store grow account medicare part growth volume growth previously announce strategic pharmacy collaboration comparable retail sale drop due lower sale consumable general merchandise category personal care category partially offset increase sale health wellness well beauty category pharmacy sale account retail pharmacy usa division sale quarter increase year quarter pharmacy sale comparable store rise higher volume revenue retail pharmacy international division decline year year basis cer owing currency fluctuation cer comparable store sale fourth quarter decrease year year comparable pharmacy sale increase lead growth pharmaceutical wholesale division record quarterly sale year year cer marginsgross profit report quarter decline year year accordingly report gross margin contract basis point bps selling general administrative sg expense be year year however adjust operate income increase rise revenue outweighed increase operate expense contrast adjust operate margin contract bps financial boot exit fiscal cash cash equivalent compare end fiscal long term debt be compare end prior fiscal company generate operate cash flow fiscal compare year resultant free cash flow be fiscal boot have issue fiscal guidance company expect adjust ep range fiscal current zack consensus estimate fiscal earning be peg lower end company guide range takewalgreen boot report impressive fourth quarter fiscal earning sale surpass zack consensus estimate however decline sale retail pharmacy international be disappointment nevertheless walgreen boot have be gain account company strategic tie up bring more patient pharmacy september walgreen boot announce receipt federal trade commission ftc approval purchase store distribution center related inventory rite aid total synergy be expect be realize year initial close transaction achieve majorly procurement cost saving other operational area walgreen boot modify merger contract be line growth strategy offer additional operational benefit also help company expand optimize retail pharmacy network key market include northeast zack rank key pickscurrently walgreen boot have zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1178,ISRG,nuvasive inc nuva free report report third quarter adjust earning share ep cent reflect rise year quarter figure also surpass zack consensus estimate cent solid revenue growth primarily lead year year bottom line improvement include time item company report third quarter net income share cent significant improvement year figure cent share revenue report quarter increase year year constant exchange rate cer figure however miss zack consensus estimate upside revenue be drive robust performance international market strong growth geographical region unite state procedural volume be sluggish unable meet company expectation nuvasive inc price consensus ep surprise nuvasive inc price consensus ep surprise nuvasive inc quote however putt together impact hurricane harvey irma nuvasive result marium company international result less selling day revenue growth have be approximately year year report quarter company spinal hardware business register more growth backed introduction new product adjust impact hurricane offset effect less selling day spinal hardware business approximately grow year year surgical support business decline third quarter primarily continue softness biologic business new competitive product enter market company face challenge field also procedural issue be affect revenue volume however international business record growth cer continue strong demand company spine technology outside unite state particularly key market italy germany japan quarter review be increase cost good sell gross profit inched yet company report basis point bps year year contraction gross margin third quarter include bps year year impact low margin business sale marketing administrative expense go research development expense increase nuvasive post adjust operate income report quarter reflect rise year number adjust operate margin expand bps quarter review company exit third quarter cash cash equivalent short term investment end previously report quarter outlookin view continue impact marium puerto rico fourth quarter well anticipate lower procedural volume nuvasive have update full year guidance currently company expect report revenue growth lower earlier expect rate cer approximately earlier be figure also remain lower current zack consensus estimate nuvasive also lower guidance full year adjust earning share compare previous expectation share current zack consensus estimate remain significantly company guidance additionally adjust operate margin year be currently expect compare former projection exit third quarter better expect earning revenue number quarter company performance be significantly dependent stellar international growth company note report quarter marked fourth consecutive register more growth international business however overall sale quarter be grossly impact procedural volume related challenge unite state adverse impact harvey irma nuvasive result marium international front chance fourth quarter revenue be affected marium puerto rico due anticipate lower procedural volume continue same period nuvasive be pressed reduce full year guidance be disappointing zack rank key pickscurrently nuvasive have zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal cent report year quarter also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1179,ISRG,edward lifescience corporation ew free report report third quarter adjust earning share ep cent miss zack consensus estimate cent however adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business exclude time item net income third quarter come cent share year year respectively sale detailsedward lifescience third quarter sale improve however figure miss zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance surgical heart valve therapy critical care product line too region edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quote segment third quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt sale quarter totale year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system strong uptake core product outside unite state partially offset continue shift surgical aortic valf sapien valf unite state europe critical care sale be report quarter represent increase third quarter solid growth product category be drive strong growth company core product enhance surgical recovery program mainly unite state asia pacific marginsin third quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf well favorable comparison supply chain expenditure be however partially offset expense incur due flood hurricane marium puerto rico shutdown company manufacturing plant switzerland sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment expenditure increase year year owing continue investment company transcatheter aortic valve mitral valve program adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit third quarter cash cash equivalent short term investment compare end second quarter long term debt quarter totale compare report previous quarter cash flow operate activity be third quarter compare previous quarter exclude capital spending free cash flow be quarter average diluted share outstanding be guidance staysedward lifescience have reaffirm full year sale expectation high end previously project range zack consensus estimate full year revenue be coincide high end guide range adjust ep expectation have also be reinstate zack consensus estimate full year adjust ep stand company guide range fourth quarter company project sale adjust effect germany stocking sale zack consensus estimate revenue be company project range company estimate adjust ep cent cent meanwhile zack consensus estimate adjust ep be cent be also company forecast range takeedward lifescience exit third quarter disappointing note earning revenue lag respective zack consensus estimate company business be affected recent natural disaster caribbean unite state edward lifescience have principal manufacturing location critical care product puerto rico dominican republic puerto rico company have discontinue production due flood affected top line extent company also have postpone number procedure houston florida management natural disaster negatively impact third quarter sale tune nevertheless strong transcatheter valve sale domestic market well overseas be major positive company also perform well gross margin front raise optimism management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy however tough competition cardiac device market reimbursement issue continue challenge zack rank key pickscurrently edward lifescience have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1180,ISRG,idexx laboratory inc idxx free report record third quarter earning share ep cent same constant exchange rate cer year year report basis further report figure surpass zack consensus estimate cent strong top line growth third quarter drive earning revenue detailidexx third quarter revenue rise year year organic basis however miss zack consensus estimate year year increase be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quote segmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other third quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue meanwhile decline organically revenue other segment rise organically marginsgross profit increase report quarter gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense increase overall operate margin quarter improve bps financial positionidexx exit third quarter cash cash equivalent end second quarter year date net cash provide operate activity be compare year period guidanceidexx narrow revenue outlook previously provide range reflect organic revenue growth expectation zack consensus estimate revenue be peg peg lower end guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg guide range takeidexx exit third quarter mixed note earning beating revenue miss zack consensus estimate however solid year year growth organic revenue buoy optimism company raise ep guidance be also encourage stellar quarterly performance be drive strong sale company companion animal business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment however foreign currency fluctuation be expect continue hurt company operate result lower extent expect earlier zack rank other key picksidexx currently have zack rank buy other top rank stock broader medical sector be petm express inc pet free report thermo fisher scientific inc tmo free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy thermo fisher scientific intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter thermo fisher scientific report adjust earning share third quarter year year also company revenue grow year year intuitive surgical post adjust earning share third quarter year year basis further revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1181,ISRG,ecolab inc ecl free report report third quarter adjust earning exclude special gain charge tax item share beat zack consensus estimate penny earning improve year quarter ecolab carry zack rank sell adjust quarterly net sale be year quarter also net sale surpass zack consensus estimate business gain better pricing product innovation cost efficiency have more offset higher deliver product cost however ecolab expect impact hurricane fourth quarter sale cost be approximately cent share ecolab announce agreement divest equipment care business recently transaction be expect close end year read more ecolab divest equipment care segment share fall ecolab inc price consensus ep surprise ecolab inc price consensus ep surprise ecolab inc quotequarter detailsglobal industrial segment sale segment grow year year almost be drive major gain paper modest increase food beverage water north america latin america lead global industrial regional growth acquisition adjust fix currency operate income decline due higher deliver product cost however hurricane dent third quarter sale segment approximately operate income global institutional segment sale increase lead strong growth specialty healthcare business line acquisition adjust fix currency operate income increase pricing sale volume gain more offset innovation cum customer investment higher deliver product cost however hurricane affected third quarter sale segment less operate income approximately global energy segment sale increase owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income decline due higher deliver product cost lower pricing hurricane lower third quarter sale segment less operate income other segment sale climb year year account strong growth pest elimination business sale segment witness robust growth north america fix currency operate income rise pricing sale volume gain be offset higher field investment outlookecolab slash full year earning guidance owing impact hurricane divestiture equipment care business segment company expect adjust earning full year range much lower previously issue range notably ecolab expect impact hurricane full year sale cost be approximately cent share add divestiture equipment care be go hamper earning penny adjust margin full year be expect approximately net revenue come fourth quarter guidance ecolab expect adjust diluted earning share band compare year quarter adjust gross margin quarter be expect be net revenue company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here athenahealth athn free report exit third quarter fiscal solid note earning beating zack consensus estimate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1182,ISRG,headquarter austin tx luminex corporation lmnx free report report earning cent share third quarter surpass zack consensus estimate cent massive earning also increase year year revenue quarter increase almost year year almost line zack consensus estimate segment analysissystem sale revenue decline year year basis notably company ship multiplexing analyzer report quarter here note system include magpix lx flexmap assay revenue assay revenue grow year year royalty revenue come royalty revenue sale segment decline year year basis royalty revenue report quarter be affected reduction audit finding minimum royalty payment offset increase base royalty consumable sale revenue segment decline be owing effect timing order company large partner luminex corporation price consensus ep surprise luminex corporation price consensus ep surprise luminex corporation quotequarter tiding regulatory front luminex receive fda clearance ary assay report quarter also luminex announce receipt ce ivd mark ary norovirus assay luminex also announce japan central social insurance medical council have approve recommendation japanese ministry health labor welfare mhlw provide reimbursement proprietary verigene assay approval be verigene assay gram positive blood culture test gram negative blood culture test notably luminex be only company japan clear automate sample answer solution blood culture identification molecular diagnostic business solid molecular diagnostic group place more sample answer system report quarter company now have more molecular sample answer system contract total number active customer moreover average verigene customer now generate nearly assay revenue year ary generate more year reference margin detail gross margin be report quarter highlight contraction basis point bps year year company have also make standard cost adjustment related improvement labor utilization report quarter improve product margin necessary adjustment inventory current quarter affected gross margin operate expense decrease year year basis expense quarter be year year basis meanwhile sg cost inched year year result operate margin percentage revenue be expand bps third quarter financial condition company exit third quarter approximately cash investment second quarter guidanceluminex reiterate annual revenue guidance band depict growth year year basis luminex expect gross margin next few quarters mid meanwhile company project fourth quarter revenue range takeluminex exit third quarter solid note company third quarter see strong top line solid cash flow well profit company assay business be key growth driver long term company also witness favorable tiding regulatory front further expansion operate margin buoy optimism flipside low consumable revenue raise concern furthermore year year drop expense be discourage cutthroat competition niche space be headwind zack rank other key picksluminex sport zack rank strong buy other top rank stock broader medical sector be petm express inc pet free report thermo fisher scientific inc tmo free report intuitive surgical inc isrg free report notably petm sport zack rank thermo fisher scientific intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter thermo fisher scientific report adjust earning share third quarter year year company revenue grow year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1183,ISRG,omnicell inc omcl free report report earning share cent third quarter beating zack consensus estimate penny earning improve year figure cent welll revenue detailrevenue third quarter increase year year miss zack consensus estimate year year upside be drive product sensation related ramp xt series launch revenue also lag company guide range owing impact harvey irma hurricane segmental basis omnicell automation analytic revenue inched year year third quarter however revenue medication adherence segment rise year year omnicell inc price consensus ep surprise omnicell inc price consensus ep surprise omnicell inc quote operational updateomnicell gross profit report quarter increase gross margin contract basis point bps accord company adjust gross margin third quarter be reflect contraction bps year year sg expense third quarter decline year year research development expense rise year year operate expense be third quarter year year accord company adjust operate expense quarter totale year quarter financial updateomnicell exit third quarter cash cash equivalent compare end second quarter full year omnicell expect product booking range unchanged earlier forecast company have slash high end earlier guidance adjust revenue band moreover company now expect adjust earning band sharea compare project earlier zack consensus estimate full year earning share be peg zack consensus estimate full year revenue stand company also issue fourth quarter guidance management expect adjust revenue band omnicell project fourth quarter adjust earning cent cent zack consensus estimate fourth quarter revenue be peg earning share cent takeomnicell third quarter performance be impressive year year increase earning revenue further company segment witness year year growth be encourage note company be work product innovation also omnicell be expect gain recent launch strategic partnership third quarter company launch xt series automate supply dispense system be encourage development however weak margin be matter concern zack rank key picksomnicellha zack rank hold few better rank stock broader medical sector be petm express inc pet free report illumina inc ilmn free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy illumina intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter illumina report adjust earning share third quarter year year also illumina revenue grow year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1184,ISRG,quality system inc qsii free report report second quarter fiscal adjust earning cent share beating zack consensus estimate cent however adjust earning deteriorate year year basis revenue totale outpace zack consensus estimate revenue also increase year year basis quality system carry zack rank sell segment detailstotal software hardware related revenue increase primarily drive rise software related subscription service however growth segment be partially offset lower software license hardware sale decline almost quarter company expect software license hardware revenue remain pressure remainder fiscal support maintenance revenue quarter totale year year basis revenue segment be drive annual price increase professional service revenue increase almost year year increase be lead transfusion service however rise be offset decline sale software product come electronic datum interchange edi service revenue increase year year basis almost meanwhile company revenue cycle management rcm business revenue inched quarter review quality system recur revenue be drive contribution subscription support maintenance rcm edi second quarter recur revenue reach record level total revenue quality system inc price consensus ep surprise quality system inc price consensus ep surprise quality system inc quote quarter entrada hold promise august quality system complete acquisition eagledream health inc roughly cash eagledream health be cloud base analytic company optimize understand clinical financial administrative datum enhance practice performance follow acquisition nextgen healthcare wholly own subsidiary quality system gain facility provide enrich care experience accelerate patient engagement ambulatory clinic health system management further expect achieve capita cost efficiency well enhance work life balance clinician staff quarter come read more quality system complete eagledream health buyout entrada pipeline have be offer new deal quality system quite time now earlier year nextgen healthcare have acquire entrada second quarter fiscal result subscription revenue be significantly strength entrada believe acquisition prove accretive long haul booking decline quality system register booking worth year year basis management subscription booking continue be steady contributor second quarter booking however headwind perpetual license booking mar booking growth quarter margin detailsquality system gross margin remain flat year year basis net revenue report quarter come operate expense company record selling general administrative sg expense year percentage revenue sg expense second quarter be basis point bps year year basis meanwhile research development cost totale expand bps year year expense rise second quarter back incremental personnel cost offset increase software capitalization fiscal company project revenue band previously issue range adjust earning share be project range cent cent compare previous cent cent takequality system post stellar second quarter fiscal beating zack consensus estimate count be particularly upbeat company solid performance regard total software hardware related revenue quality system solid recur revenue base be key catalyst quarters come furthermore company new entrada eagle dream solution be likely drive growth flipside ongoing sluggishness rcm customer base intensify competition strict regulatory environment be likely mar top line furthermore management slash high end fiscal earning guidance signale loom concern company expect software license hardware revenue remain pressure remainder fiscal company solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here cerner corporation cern free report promise long term expect earning growth just report third quarter cerner register revenue year year basis stock carry zack rank zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1185,ISRG,abiom inc abmd free report report second quarter fiscal earning cent share come ahead zack consensus estimate cent figure be also higher cent year quarter report quarter revenue increase roughly year year approximately outpace zack consensus estimate year year upside be support robust performance impella heart pump product line quarter revenue manufacturer developer marketer medical product surge quarter impella revenue improve drive increase patient utilization outside unite state revenue surge germany account majority international revenue grow year year basis report quarter install base impella heart pump unite state grow hospital take install customer base total site install customer base impella cp heart pump grow hospital reach total overall operate income report quarter come operate margin percentage revenue compare prior year quarter abiom gross margin quarter be compare second quarter fiscal abiom inc price consensus ep surprise abiom inc price consensus ep surprise abiom inc quotefinancial conditionabiom cash cash equivalent be sep compare mar notably management announce company currently have debt guidanceabiom forecast fiscal revenue range mark increase fiscal level operate margin be project band takefurther believe robust demand impella product line continue drive abiom top line long term company expand product portfolio improve penetration prophylactic high risk pci cardiogenic shock patient market be evident fact impella cp continue add center unite state new publication regard device lead medical journal help promote utilization effectiveness abiom significant international presence help broaden customer base other positive fluctuation currency exchange rate adversely impact company international sale fluctuation currency exchange rate adversely impact abiom international sale company international presence broaden customer base zack rank key picksabiom hold zack rank buy see complete list today zack rank strong buy stock here few other top rank stock broader medical sector include petm express inc pet free report abbott free report intuitive surgical inc isrg free report petm sport zack rank abbott intuitive surgical carry zack rank petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale totale year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1186,ISRG,integra lifescience holding corporation iart free report report adjust earning share ep cent third quarter decline year figure adjust ep also miss zack consensus estimate cent include time item company report earning cent share year quarter revenue discussiontotal revenue report quarter increase year year lag zack consensus estimate exclude revenue acquisition discontinue product effect currency exchange rate organic revenue rise year year solid revenue growth third quarter be primarily drive strong contribution orthopedic tissue technology segment come product category revenue company specialty surgical solution segment increase orthopedic tissue technology revenue come third quarter year year margin trendgross margin contract basis point bps report quarter company adjust gross margin contract bps selling general administrative expense increase report quarter research development expense contract adjust operate margin see bps contraction third quarter financial positionintegra lifescience exit third quarter cash cash equivalent record end second quarter sep net cash flow operate activity be year quarter outlook have raise full year revenue guidance meanwhile full year organic revenue growth range be lower zack consensus estimate full year revenue be guide range company have revise full year adjust ep guidance previous range zack consensus estimate adjust earning be peg company guide range takeintegra lifescience exit third quarter disappointing note also contraction adjust operate margin adjust gross margin add wo moreover drop year year investment research development be discourage spite raise full year revenue guidance slash full year adjust earning range add wo however strong year year increase revenue back orthopedic tissue technology segment buoy optimism be also encourage note company segment see year year revenue growth quarter nonetheless believe company be try execute growth plan efficient management team zack rank key picksintegra lifescience have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1187,ISRG,cheme corp che free report third quarter adjust earning share ep be compare year figure figure also surpass zack consensus estimate quarter detailsrevenue quarter increase year year beating zack consensus estimate cheme currently operate wholly own subsidiary namely vita healthcare corporation major provider end life care roto rooter lead commercial residential plumbing drain clean service provider third quarter net revenue vita healthcare totale reflect increase year year revenue be drive increase average net medicare reimbursement rate rise average daily census however be offset acuity mix shift impact revenue roto rooter report sale third quarter be year year accord company revenue water restoration increase year year gross margin expand basis point bps year year adjust operate margin expand bps quarter rise selling general administrative expense cheme exit third quarter total cash cash equivalent end second quarter company have total debt end third quarter compare end precede quarter sep company have approximately undrawn borrow capacity exist year credit agreement third quarter company repurchase share worth march board have authorize additional cheme exist share repurchase plan sep company have remain share repurchase authorization plan company continue project vita healthcare revenue growth range prior medicare cap also admission average daily census be expect increase earlier be medicare cap bill limitation be expect be earlier project roto rooter business be estimate grow full year compare earlier range raise guidance be backed increase job pricing water restoration service growth full year adjust ep be expect grow range previously compare report takecheme exit third quarter solid note also company witness year year growth front moreover be encourage note company subsidiary see year year revenue growth quarter expansion gross operate margin strong bottom line projection also buoy optimism further reimbursement related issue seasonality business competitive landscape dependence government mandate continue challenge cheme zack rank key pickschemedha zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1188,ISRG,stryker corp syk free report report adjust earning share third quarter comfortably beat zack consensus estimate cent earning improve share year quarter company base kalamazoo mi have maintain streak positive earning surprise meanwhile trail quarters company post earning beat average currently stryker carry zack rank hold upside earning be primarily drive rise revenue beat zack consensus estimate constant currency cc net sale improve year quarter segment net sale increase year year report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume be partially offset due lower price medsurg net sale increase report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume neurotechnology spine net sale increase report quarter net sale quarter increase increase unit volume be partially offset due lower price fourth quarter stryker expect adjust earning range share full year company expect adjust earning band stryker expect organic sale growth full year takewe believe stryker innovative product pipeline be key catalyst term furthermore grow adoption mako drive sale orthopedic reconstructive surgery market flip side china prove be challenge market company come supply related headwind company have be grapple issue spine business long believe prove be major drawback quarters ahead nevertheless stryker effort sale force management bode well company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock hold zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy ou see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale amount year year abbott carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1189,ISRG,cerner corp cern free report report adjust third quarter earning cent share miss zack consensus estimate penny lackluster third quarter performance be primarily attribute year year decline booking have scale time high last quarter however earning rise year year basis company report net revenue fall short zack consensus estimate however revenue rise year year basis cerner hold zack rank buy booking disappointin third quarter cerner register booking worth year year basis fact booking be company previously issue guidance owing postponement several big contract quarter tentatively fourth quarter notably booking last quarter totale year year basis nonetheless cerner be well position strong full year performance base solid booking guidance fourth quarter next quarter booking be expect band midpoint reflect growth year year basis midpoint fourth quarter book guidance increase full year booking guidance year year basis segment detailssystem sale increase sale be buoy license software subscription partially offset decline technology resale total support maintenance service include professional manage service rise year quarter reflect solid execution company service organization revenue cycle have also be strong contributor courtesy strong sale contribution revwork service revenue management service population health service business also drive revenue third quarter solid growth flagship healtheintent solution company have be target broader shift fee service value base care long cerner also post impressive performance ambulatory small hospital market reimbursement travel revenue increase quarter slightly company full year expect growth rate geographically domestic revenue increase year quarter revenue increase margin balance sheet margin third quarter be revenue basis point bps year decline be due lower mix sublicens software lackluster performance technology resale business adjust operate margin third quarter be net sale bps year cerner end third quarter total cash investment total debt cerner include capital lease obligation be fy guidance fourth quarter cerner forecast revenue midpoint reflect growth year year basis adjust earning be expect band cent cent share midpoint be flat year year basis full year management expect revenue be low end previously issue range thank lower booking third quarter cerner currently forecast adjust earning lower previously issue range company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1190,ISRG,intuitive surgical inc isrg free report post adjust earning share third quarter crush zack consensus estimate stellar revenue growth also figure improve year year basis interestingly past quarters company beat estimate average revenue increase year year drive growth instrument accessory service system revenue revenue also beat zack consensus estimate be important note company stockholder approve split issue outstanding common stock begin trading split adjust basis oct stock currently have zack rank hold intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quotebusiness highlightssolid procedure trend intuitive surgical post solid number quarter courtesy rise customer adoption procedure growth system placement company outperformed mature growth procedure especially general thoracic surgery precisely third quarter procedure increase approximately year year basis procedure grow approximately outside unite state ous procedure grow approximately year year procedure performance asia show continue strength solid growth china japan korea add solid growth prostatectomy procedure volume lend intuitive surgical competitive edge broader prostate surgery market third quarter launch bode well third quarter intuitive surgical expand launch additional instrument accessory da vinci xi platform country fact company initiate limit launch refine vessel sealer europe report quarter management announce plan file first fda approval da vinci sp program year end submission additional indication thereafter international sale globally intuitive surgical system placement include europe japan india new mexico china however ous market be early stage adoption sale be lower estimate region revenue accessory revenue segment grow quarter drive strong procedure growth increase sale stapling vessel sealing product revenue realize procedure be approximately compare year quarter system sale increase buoy higher system placement partially offset lower average selling price notably intuitive surgical generate approximately revenue associate operate lease report quarter compare third quarter come company flagship da vinci surgical platform company ship surgical system third quarter service company register revenue year year basis growth install base da vinci system surgical adjust gross margin report quarter contract basis point bps net revenue decrease margin be due medical device tax refund be receive notably management intuitive surgical expect margin fluctuate base company mix new product mix system instrument accessory revenue reduction product cost reinstatement medical device tax financial updateintuitive surgical end third quarter cash cash equivalent investment year year basis be primarily drive cash generate operation employee stock option exercise bottom lineintuitive surgical exit third quarter solid note beating zack consensus estimate count procedure performance asia show continue strength solid growth china japan korea company gain significantly ce mark approval da vinci europe stock have get further boost recent fda approval same recent past positive outlook come quarters also raise confidence stock further incremental spending product development higher investment international market be likely drive long term growth however da vinci surgical system have long sale purchase order cycle act company fact stock look tad expensive add concern intuitive surgical expect sale be lower outside unite state key picksa few better rank stock broader medical sector be sonova hold sonvy free report enteromedic inc luminex corporation lmnx free report stock sport zack rank strong buy see complete list today zack rank stock here sonova represent solid return last month company have long term expect earning growth rate enteromedic have average earning beat trail quarters company have solid return past month luminex come positive earning surprise last quarter stock have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1191,ISRG,earning season kick high gear week company report include many big cap dow name have best earning track record name not easy beat nearly quarter row year company have manage do additionally share many have be breaking new high beat push share even higher week amazing earning chart taiwan semiconductor tsm free report have miss just once last year lot semis share be year high good time last snap sna free report hasn miss year share have stall last year get share move higher again ppg industry ppg free report have miss just once back share have be stick narrow trading range last year manufacturing pick again share finally make new high intuitive surgical isrg free report be hottest medical stock street have beat quarters row be anything stop share move higher paypal pypl free report hasn miss be spun ebay mobile payment take center stage stock have really sky-rocket be too much do fundamental justify big move want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1192,ISRG,intuitive surgical isrg free report third quarter result schedule release oct be expect show steady growth instrument accessory revenue major revenue component majorly drive third quarter earning expect improvement revenue other segment help company generate solid result season be important note intuitive surgical deliver positive earning surprise past quarters average be similar prior quarter strong procedure growth increase sale stapling vessel sealing product be expect be main factor drive surge instrument accessory revenue zack consensus estimate instrument accessory revenue stand third quarter reflect increase year quarter continue development european market solid access company product asia new platform imaging advanced instrument be likely drive revenue segment intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quoteother factor playwe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be catalyst third quarter overall revenue be expect prior year quarter be other factor influence intuitive surgical quarterly result earning season solid procedure trend expectation outperformance mature growth procedure especially general thoracic surgery be likely boost company top line add solid growth prostatectomy procedure volume be likely lend intuitive surgical competitive edge broader prostate surgery market third quarter geographically procedure growth third quarter be expect be lead china germany japan germany procedure growth be likely be support solid install base expansion furthermore procedure trend be expect be solid globally growth lead general surgery global urology segment system service unit hold promise solid growth company product system segment be expect drive company third quarter earning fact zack consensus estimate revenue segment stand year year basis increase reflect higher system placement operate lease revenue however be partially offset lower average selling price lease buyout revenue segment come revenue service segment zack consensus estimate stand year year basis growth system install base buoy higher system placement operate lease revenue expect company total system install base be unit unit last quarter be important note intuitive surgical generate approximately revenue operate lease last quarter compare second quarter here be quantitative model predict intuitive surgical do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp intuitive surgical be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank intuitive surgical carry zack rank increase predictive power esp however also need positive esp be confident earning beat fact zack consensus estimate earning reflect decline year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1193,ISRG,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report recently announce have initiate treatment recently introduce halcyon system treatment be provide penn medicine patient suffering head neck cancer notably treatment used halcyon platform be cost effective be short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon unit glancevarian medical have be take initiative gain customer broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna third quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide halcyon receive clearance ce mark european directive allow varian medical start selling system unite state management regulatory clearance china japan follow next year quarter varian medical book several order country australia belgium india morocco romania russia turkey market prospectsstrong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian medical datum market market reveal global radiotherapy market be project reach worth cagr meanwhile other important stock broader medical sector be zimmer biomet holding zbh free report abiom inc abmd free report intuitive surgical isrg free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1194,ISRG,gnc holding inc gnc free report report third quarter adjust earning share ep cent reflect massive year year deterioration adjust ep also miss zack consensus estimate penny management hurricane harvey irma marium have dent adjust ep figure tune cent year year decline be attribute dull revenue performance report quarter primarily canada manufacturing wholesale segment include time item company report earning cent share year year revenuesrevenue report quarter drop year year figure also miss zack consensus estimate lower sale canada manufacturing wholesale segment be cite major reason disappointing number same store sale increase domestic company own store include gnc com sale third quarter domestic franchise location same store sale decline gnc holding inc price consensus ep surprise gnc holding inc price consensus ep surprise gnc holding inc quote segment detailsgnc holding report operation segment canada include company own store unite state puerto rico canada franchise store unite state commerce international include franchise location approximately country health store china operation manufacturing wholesale comprise manufacture product sell other segment third party contract manufacturing sale wholesale partner report quarter gnc holding revenue canada segment drop primarily owing decrease due discontinuation gold card program unite state introduction company new loyalty program domestic franchise location well revenue decline nearly partially offset increase retail same store sale however gnc com sale be third quarter revenue international segment increase revenue international franchisee rise revenue china business increase report quarter revenue manufacturing wholesale segment exclude intersegment revenue decrease segment third party contract manufacturing sale fall owing lower demand related reduce sale customer sale wholesale partner decrease year year quarter however intersegment sale increase year company increase focus proprietary product margingross profit deteriorate report quarter consequently gross margin contract basis point bps selling general administrative expense rise accordingly adjust operate margin deteriorate bps financial positiongnc holding exit third quarter cash cash equivalent end second quarter long term debt be end quarter compare end second quarter year date net cash flow operate activity be compare year further company generate year date free cash flow compare year quarter new gnc plan updateearlier management have announce plan revamp exist business model dub new gnc company have be see change third quarter well transaction growth be third quarter oct consumer have joined company loyalty program include approximately customer enrolled pro access membership takegnc holding exit third quarter disappointing note revenue earning miss zack consensus estimate be attribute lower sale company canada manufacturing wholesale segment also decline gross adjust operate margin be matter concern positive note third quarter management witness positive response new gnc plan new consumer enrollment mygnc reward program company have also be witness improvement transaction commerce business buoy optimism zack rank key pickscurrently gnc holding have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1195,ISRG,boston scientific corporation bsx free report post adjust earning share ep cent third quarter year quarter figure remain line zack consensus estimate fall exactly upper end company adjust ep guidance range cent adjustment company report earning cent share year period revenue detailrevenue third quarter be year year report basis operational basis constant exchange rate cer figure top company guidance also exceed zack consensus estimate boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoteorganic revenue growth third quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically third quarter company achieve operational growth organically europe asia middle east africa region same emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively third quarter second largest contributor boston scientific top line be rhythm management include cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm decline defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin contract basis point bps year year rise cost product sell adjust operate margin improve marginal bps report quarter quarter selling general administrative expense go research development expense increase royalty expense reduce quarter balance sheetboston scientific exit third quarter cash cash equivalent end sequential last quarter end third quarter company have total long term debt marginal decline end second quarter guidanceboston scientific have provide update full year guidance banking solid third quarter show gradually improve foreign exchange scenario company raise revenue guidance range annualize growth report basis growth operational basis include contribution approximately bps endochoice symetis earlier band annualize growth report basis growth operational basis current zack consensus estimate revenue be guide range adjust ep guidance range have be slightly narrow earlier range zack consensus estimate be guide range company also provide fourth quarter financial guidance adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be takedespite back back natural disaster boston scientific manage register solid third quarter performance earning line zack consensus estimate revenue ahead mark gradually improve foreign exchange scenario have also start contribute company overall topline performance raise guidance be more impressive indicative overall bullish trend continue rest boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography third quarter be also encourage company gain number approval product domestic overseas market recent development worth mention be company recent acquisition apama medical developer single shot apama radiofrequency rf balloon catheter system treatment atrial fibrillation apart company receive fda approval formri labele announce launch resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system combine heartlogic heart failure diagnostic enduralife battery technology smartcrt technology apart company receive ce mark update direction use watchman laac device europe company acurate neo transapical aortic valve system have also gain ce mark company expect begin controlled launch europe fourth quarter zack rank other key pickscurrently boston scientific carry zack rank buy other top rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1196,ISRG,thermo fisher scientific inc tmo free report report better expect performance third quarter adjust ep come beating zack consensus estimate year quarter figure report basis second quarter ep marked year year rise revenue quarter come year year sale also exceed zack consensus estimate thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quote quarter detailorganic revenue third quarter grow year year acquisition increase revenue currency translation positively impact total revenue thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment total revenue improve year year analytical instrument segment sale rise reflect acquisition fei company revenue laboratory product service segment rally specialty diagnostic segment record increase gross margin third quarter be basis point bps year year rise gross profit adjust operate margin expand approximately bps rise selling general administrative expense increase research development expense company exit third quarter cash cash equivalent compare end previous quarter year date net cash provide operate activity be compare year period guidance raisedbacked solid third quarter performance favorable foreign exchange environment forecast also consider recently close acquisition patheon thermo fisher have raise full year financial guidance revenue guidance have be raise range growth previous year earlier band growth current zack consensus estimate fall guide range company have also raise adjust ep guidance range reflect growth previous year earlier prediction be range growth zack consensus estimate share remain guide band bottom linethermo fisher end third quarter promising note adjust earning revenue beating zack consensus estimate be encourage company series product launch major progress precision medicine initiative thermo fisher acquisition fei company have already start boost analytical instrument portfolio quarter company launch new electron microscopy system structural biology material science research also have release new iq series air quality monitoring platform enabled first fda approve gene therapy apart company have open precision medicine customer experience center guangzhou china be currently look forward recently complete acquisition patheon be go significantly enhance company value proposition biopharma customer add lead contract development manufacturing outsource service raise guidance be more impressive indicative overall bullish trend continue zack rank other key pickscurrently thermo fisher have zack rank buy few other stock worth consider broader medical sector be petm express inc pet free report abbott lab free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank well see complete list today zack rank stock here petm report ep cent second quarter fiscal cent report year quarter also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1197,ISRG,illumina inc ilmn free report report adjust earning share ep third quarter beat zack consensus estimate cent adjust earning also surpass year number include time item company report ep compare cent year revenuesin report quarter illumina revenue grow year year moreover top line beat zack consensus estimate illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc quote management top line growth third quarter be attribute strong uptake sequence consumable instrument well microarray portfolio moreover novaseq platform continue drive growth close novaseq system currently customer hand launch january management be also hopeful recent launch flow cell xp nextera dna flex library preparation kit drive novaseq demand product revenue total revenue increase year year service other revenue be year year operational updateillumina adjust gross margin come reflect contraction basis point bps year year owing novaseq introduction higher array service revenue product mix sequence consumable exclude amortization acquire intangible asset include stock base compensation expense adjust gross margin be highlight contraction bps year research development expense be year year selling general administrative expense rise consequently adjust operate margin reflect decline bps year period financial updateillumina exit third quarter cash cash equivalent short term investment third quarter year date net cash provide operate activity be compare year period guidancebanking solid third quarter performance illumina have raise full year revenue growth expectation earlier provide range meanwhile zack consensus estimate full year revenue be peg company raise adjust ep band earlier zack consensus estimate illumina bottom line stand far low end guide range takeillumina exit third quarter solid note be also encourage year year increase front company have also raise full year revenue guidance adjust ep range be look forward performance novaseq flow cell reagent kit novaseq xp novaseq system flip side weak margin owing lower instrument margin associate novaseq launch higher array service mix continue act deterrent also tough competitive landscape be concern zack rank key pickscurrently illumina have zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1198,ISRG,mazor robotic mzor free report recently announce receipt ce mark mazor surgical assurance platform allow company market mazor european union commercial partner medtronic mdt free report management medtronic be responsible marketing system europe platform be display eurospine conference dublin ireland launch mazor have receive encourage demand fact mazor robotic broad product spectrum have be key growth driver mazor last report quarter company receive purchase order surgical guidance system include mazor system renaissance system be mazor primarily major hospital corporation renaissance system order be distribution partner australia thailand mazor robotic system backlog end second quarter totale global basis company end second quarter system worldwide unite state mazor align software earlier year company have announce receipt fda clearance mazor align software software be design assist surgeon plan spinal deformity correction spinal alignment procedure perform mazor surgical assurance platform market prospectswe be encourage opportunity global spine surgery market research report market market suggest niche market reach worth cagr meanwhile company face stiff competition like zimmer biomet holding zbh free report intuitive surgical isrg free report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1199,ISRG,share price sunnyvale base intuitive surgical inc isrg free report scale new week high aug eventually close bit lower company have gain last month much better rise broader industry gain take stable performance stock consideration expect intuitive surgical scale higher come quarters company positive long term growth also hold promise average volume share trade last year be remarkable approximately stock have market cap last day analyst have raise earning estimate current year have slash estimate net effect have take zack consensus estimate current quarter share market be upbeat intuitive surgical licensing agreement justright surgical deal enable intuitive surgical global license justright surgical intellectual property energy base vessel sealing tissue stapling technology use robotic field joint product development equity financing arrangement be also part agreement intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quotealso company post impressive second quarter earning revenue register year year increase quarter company also witness growth segment international performance be also encourage believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key catalyst moreover increase procedural volume outside unite state open considerable opportunity company company be further putt effort product innovation research development regard recent fda approval da vinci instill confidence investor apart company be expect gain prominence europe asia enhance organizational capability further drive stock price zack rank key picksintuitive carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1200,ISRG,global week ahead pay attention catalyst summer trader regard event musketeer charge hill add confidence amount stooge give stumble thus create more ragged tone be writing stock market just couple mile old columbia picture studio lot larry moe curley get first biggest boost become partisan only time tell tale well first be biggest earning week season plenty room lousy report be so many get wash quickly second wednesday latest fomc statement hit tape watch market move comment recent weak inflation datum third finally trader close week friday st estimate gdp growth doesn beat be consider stumble here be roadmap come week earning play most significant role global equity market firm release earning be single heaviest report week season key name alphabet formerly google newmont mining mcdonald eli lilly caterpillar gm coca cola ford state street boee facebook procter gamble up mastercard intel amazon starbucks mattel merck xerox american airline wednesday consensus expect federal open market committee fomc not change fed fund target range rest july be statement only event press release show fomc member have big concern recent soft inflation figure majority reinforce belief be transitory friday week save best worst last first estimate gdp growth arrive be et record just growth bloomberg consensus expect consult fed nowcast forecasting business be get bit crowd day st loui fed have match atlanta fed latest estimate estimate be notch ny fed outside pay attention brazil wednesday consensus be firm banco central do brasil cut selic policy rate basis point bps agajn follow bps cut st brazilian cut happen bring cumulative ease last october full percentage point cycle peak top zack rank strong buy stock facebook fb free report be now incredible market cap stock long term zack vgm score be solid come mix lousy value growth long momentum trade last air liquide aiquy free report be big french diversify chemical firm market cap zack long term vgm score be mediocre chemical industry have be red hot year be european trading stock strong momentum trade year intuitive surgical isrg free report be darling medical instrument stock win get cheap stock price be shocking market cap stock be indeed accrue well deserve zack value score zack growth score be not good hope here maybe just watch hot momentum stock trade don buy global macro monday germany preliminary manufacturing pmi come service be solid expansion pmi number preliminary eurozone composite pmi come manufacturing pmi service pmi again pmis marked solid expansionary datum taiwan unemployment rate come have be get mexico weekly cpi be forecast prior tuesday finland unemployment rate come have be high germany important ifo index come business climate go current condition expectation poland unemployment rate come have be case shiller home price index come national index have be tracking wednesday brazil selic rate come look bps cut fed announce latest interest rate decision don expect change fed fund rate be thursday norway unemployment rate come be be much much better finland go figure sweden unemployment rate come be norway finland turkey release monetary policy decision week repo rate policy rate have be durable good order come prior month be initial claim also come prior be hot friday central bank russia give monetary policy decision key rate be now brazil national unemployment rate come be forecast go first estimate gdp quarter come prior be atlanta fed gdpnow tracker have quarter moment
1201,ISRG,intuitive surgical inc isrg free report post adjust earning share second quarter crush zack consensus estimate stellar revenue growth also figure improve year year basis interestingly last quarters company beat estimate average revenue increase year year drive growth recur instrument accessory service system revenue revenue also beat zack consensus estimate follow result share price be close also share intuitive surgical have return year date outperform industry gain business surgical post solid number quarter review courtesy rise customer adoption procedure growth system placement worldwide da vinci procedure volume grow approximately year year increase be attribute stellar performance general surgery worldwide urologic procedure notably company ship da vinci surgical system second quarter revenue accessory revenue segment grow quarter drive strong procedure growth increase sale stapling vessel sealing product revenue realize procedure be approximately compare year quarter system sale increase buoy higher revenue operate lease activity intuitive surgical place system order quarter year quarter management intuitive surgical note system be place operate lease transaction compare system year quarter service company register revenue year year basis due growth install base da vinci system international growthper management company post revenue outside second quarter company place system order compare year quarter first quarter include europe japan india australia china intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quotefinancial update intuitive surgical end report quarter cash cash equivalent investment year year basis takewe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key growth catalyst moreover increase procedural volume outside present significant growth opportunity company zack rank key company have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock boast impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1202,ISRG,intuitive surgical inc isrg free report be schedule report second quarter result close bell jul last quarter company earning exceed zack consensus estimate also company deliver average beat trail quarters let see thing be shape intuitive surgical prior announcement factor playwe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key catalyst earlier da vinci procedure increase approximately year year first quarter second quarter company expect procedure growth rate slow bit outside company anticipate full year procedure growth full year gross profit margin be expect upper end range net revenue moreover rise procedural volume outside particularly europe fortify company market position fact integrate table motion product line have gain significant traction short span time be likely boost company top line be report quarter meanwhile increase spending product development higher investment expand company footprint international market be prudent move drive long term growth view note intuitive surgical outperformed zack medical instrument sub industry last year stock have return sub industry have gain only intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quoteearning whisper proven model do not conclusively show intuitive surgical be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp intuitive surgical earning esp be most accurate estimate zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank intuitive surgical have zack rank favorable zack rank increase predictive power esp company esp make surprise prediction difficult also caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp hold zack rank telefex incorporate tfx free report have earning esp carry zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1203,ISRG,aug issue update research report sunnyvale base intuitive surgical inc isrg free report manufacturer da vinci surgical system advanced robot assist surgical system related instrument accessory company currently carry zack rank hold major positive intuitive surgical have have impressive run bourse late glimpse recent price performance reveal favorable return past year compare favorably industry increase company have solid track characterize consecutive earning beat trail quarters recent time intuitive surgical report stellar performance mainly due grow adoption da vinci system physician overall growth global procedure da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery performance be also aid grow volume courtesy general surgery oncology urology gynecology procedure intuitive surgical continuously introduce technology surgical system company also plan launch upgrade da vinci flagship vinci xi technology regard management confirm submission document ce mark approval vinci furthermore company expect availability device europe end long haul extensive expenditure product pipeline expansion international market europe drive growth company flipside company expect procedure growth rate slow bit outside unite state come quarters long sale purchase order cycle da vinci system have add wo also expense research development increase significantly first half reflect high spending advanced imaging advanced instrumentation next generation robotic key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1204,ISRG,second quarter earning season be nascent stage participant have report result jul accord latest earning preview earning cycle have witness encourage start courtesy stable bank result total earning member have go increase revenue uptrend be result reduce regulatory burden tax law change improve outlook domestic economy latest earning preview report second quarter earning company be expect be year quarter higher revenue majority earning yet be release next fortnight be crucial decide quarter turn be game changer irrespective outcome investor focuse medical sector expect good news medical sector broader zack sector be expect witness higher revenue quarter decline revenue investor be adopt watch space zack categorize medical product industry have register growth last month underperform index gain market remain jittery major part month due uncertainty surround future healthcare act let take sneak peek performance major medical product company be expect report earning early next week abbott laboratory free report be schedule report second quarter result open bell jul abbott have be healthy growth trajectory establish pharmaceutical division epd business company have deliver encourage operational sale growth trail few quarters however absence substantial advancement division recent past have compel company maintain low expectation high single digit growth yet be report quarter uncover best stock buy sell re report earning esp filter proven model do not conclusively show abbott be likely beat earning quarter be abbott laboratory have earning esp zack rank buy be most accurate estimate zack consensus estimate be cent abbott zack rank increase predictive power esp however company esp make surprise prediction difficult read more abbott laboratory pull surprise earning abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteintuitive surgical inc isrg free report be set report second quarter result close bell believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key growth catalyst company see complete list today zack rank strong buy stock here proven model do not conclusively show intuitive surgical be likely beat earning quarter be intuitive surgical currently have earning esp zack rank hold be most accurate estimate zack consensus estimate be peg read more intuitive surgical surprise earning intuitive surgical inc price ep surprise intuitive surgical inc price ep surprise intuitive surgical inc watertown athenahealth inc athn free report cloud base network provide service manage administrative duty medical provider company software platform handle bill management quality measurement report clinical documentation datum exchange patient communication referral many other related task company be schedule report second quarter earning believe company strong product portfolio expand physician base unique business model boost prospect company however proven model do not conclusively show company be likely beat earning give combination zack rank earning esp read more store athenahealth earning athenahealth inc price ep surprise athenahealth inc price ep surprise athenahealth inc quoteabaxis inc abax free report be schedule report second quarter be california base manufacturer portable medical human veterinary animal blood analysis system provide clinician rapid blood constituent measurement medical veterinarian market worldwide abaxis currently carry zack rank hold have earning esp be most accurate estimate zack consensus estimate stand cent abaxis inc price ep surprise abaxis inc price ep surprise abaxis inc earning beat miss investor focus company fundamental make investment decision therefore don forget check full earning release stock later trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
